<SEC-DOCUMENT>0001601830-21-000023.txt : 20211110
<SEC-HEADER>0001601830-21-000023.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211110075748
ACCESSION NUMBER:		0001601830-21-000023
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RECURSION PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001601830
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464099738
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40323
		FILM NUMBER:		211394467

	BUSINESS ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101
		BUSINESS PHONE:		(385) 269-0203

	MAIL ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Recursion Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20140305
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rxrx-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:bb127273-35b3-457d-ab21-bda4843992dc,g:487b784e-5d7c-455e-b63d-c9a591fced83,d:0bb060ddb7ef4084b0e9e9286fc531b1--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:rxrx="http://www.recursion.com/20210930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rxrx-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV8xLTEtMS0xLTA_3d8a0563-ac3b-4567-ba87-d3f12bbb20bb">0001601830</ix:nonNumeric><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV8yLTEtMS0xLTA_9efc6705-aadc-4d41-b5ce-44a359e9fa7c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV8zLTEtMS0xLTA_4f894f93-8577-4328-bc07-8ec65481a028">2021</ix:nonNumeric><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV80LTEtMS0xLTA_8524b89e-c0b4-47bd-9e02-649f19c0cede">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV81LTEtMS0xLTA_d0f1a6b6-e801-4063-b1f6-a1a62987ba0a">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rxrx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iec0cf3fd3c7f46d58081b8db6dd0a213_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014b7cc1c107456880d54adcaf72ca6c_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i227689ec41e7442c8fc5bdd888e16504_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81600d989114130b43235d442b1e71d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7ecc7deafb5e4f9c982501dc4510e260_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22f0a3e4f5d4143bce97be2c742375b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if98a6d661e4e47aab1f3971da19db8fa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cb24ed3206446e9ec9135d7c55c2b5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbae21d8d86e4d03b1dc645c4d773d58_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9367de1805594f3ea5232c87da29a431_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a193d7c195b410a9442788aa6400f38_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia091bf9e820244ad994cca02e9749f08_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc80a548fed40e799b5efc628f47c0f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0cf13b1f9d4529bf1fb83789fc572c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2f2c074b1e43afaf522e34126788a5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ff446e32064366bc8ac2fb705f08c7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28cbfc7f295d41798a3535412b1097ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b650a6bb07749f0a6edf5919d0a3161_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i285746a4957648a9b7d4042cbb79af11_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40cfd8df988f4d82810e987c2d28b259_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e44c4c74c4244ad9325ce8ee3d87c39_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43267d208dab4736ae222644e2d2c456_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f4b84aaf944dbe9a02fd4931d34296_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b3bdbb908941fe9dd8a36f77aa3125_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9cf913bc7c43ca9b2e069af2d8729b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40174ea8bb02463794d3b4d1c442fb95_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30420430e079491d8ed1cccc567ce1a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9e3fea7fdb4088a7ed864903989ab8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75c52a0d323d498e8014b63cf8a7850d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb56eae1b564d73804d37ddfe5ab0ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91d161d487e84f1f904d7fda0b4884fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776c6fde78c34963b7743761ab97c975_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9c4548723a94137977675db77d39056_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4482ced31be5421b8f43d4f1dbe206c4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5705097d3db6486b875714c0fdd8511f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e93eef6c0643958f8d3941866bed9b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1352bc1f243c4c93b8a1a85f705f61bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i881224a385cd4b5bb6c214cf65fbdc6f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b4fd7858ca4d1b8cbd0d11d1d96c2e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a9bdffe7f94be498dcc2410790c11f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872955c4fcdd4c5eaf64056f28e5f425_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a95d59cc58842588ef57ba5c32d5d71_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfdf3f6f12e4ce0ae4dfac0a5ed90d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28896c19aa0048d895dddd0ae8427e87_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e2b80f5d48496fa52384c883bedd9d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3209489bac6541a49f8dc6490492263d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5058a871b06b4ce2a3fa07e2e0a0bfb2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f381af37b384806826160a459ac1a6a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ff4d3f153a469d96516e024f93f1cc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8338d53d46ff438abc85d037a8e6da2f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869c72f28c2245f8b0f7ccc8daabd4fd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e11557b1837454f993cb507031865c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7ae49e496a4f9888670cd3e0d4b725_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77586c203c024828a9a78bdb39902891_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb73e0e9cb754e1bbe802d6ae2551e64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee0f1fd845e456095af44bb0a898324_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i182ec792f9954c3580432f8d5bb60d4c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16660690238a4cba84cc971aaa39f2bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i778df7726a034719acdc84318d53c893_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia31781556c024ff299dfa585947bf905_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e5e9f454354e0898d008f9b70e031f_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4cc970bf084e72a23bc5618284498a_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76fe27fdee64641b854285105025b00_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc1f03ee515432fa42136f5abffdeca_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664743a93bb344148d7136746fd74f72_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc65b757b0943af90388d031f257341_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d68dbe3edaa4b9280d1ffb236378a0b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817c708d2c01406eb506b6bb2d083fd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bf122307ee643a0845c0597e111bdfc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae7b4560de940f1ba648b0647540789_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac3d0f8815254b29b2f5393fc3e65f2c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7703b2a8b748759f610e861ada8589_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e32a03cb9fc49e4b252453d837334e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90fa6b131e76491793a97c75f8dfec99_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6feede82f4cb4ac49b0be949785d9497_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rxrx:CorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7296ea094e2d4b13917424c13cfba62e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5217d88f4c3e49a69c131211ccc0f740_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8495e49fee3844bab82f503ea301cd51_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd2a77b480e946b1a98b623504da657e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>rxrx:position</xbrli:measure></xbrli:unit><xbrli:context id="id524b0a380484a13b1423d25efdc9ce6_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e592cb3484481d8f3bdf27f4b46fb5_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:PacificWesternBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c469b1d47e4489abb014373df5e6a8_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712dde3d59e94dbba069d3ea10c0fb15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8000a9bf874bc2a077c5140c2c981d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2eb416e12e4f8a8c617e89412832c8_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:PacificWesternLetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38cdee8154a14b54b5c1a723df0dbb8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:PacificWesternLetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2921e91a9279497f81a20c55ba343d96_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d0e548c03ea4dd7b12d2c5350a4d3a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691d5ffc27f14a19a75ef556811825c4_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1a2671a54b4d92ac1029a3f54a040c_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50773bc073fb4acea17c712bc1126a6b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ccad45b4c84988b490de168ac87d85_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16333b91755459cbc141c348c781d1e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6e8d11e94a4bc8a66fa0b30b88119e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52b9725b29684ee8a41390d35b177c5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91f13a3891e14799978936761e6b66eb_I20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:KomasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ab0048367c48bcbdd713b807fbd5e6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:KomasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if53c3048ea9f49fdada4b25a94aa8898_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extensionperiod"><xbrli:measure>rxrx:extensionPeriod</xbrli:measure></xbrli:unit><xbrli:context id="ie9dfd0688b804a938bbb48c0edbe5056_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532e90ec1ce24d4395f470300c0303ad_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i570b1109d5a14f2cbffa015a78fae6ae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7019fd2b10448cf9b45ac7687f8df45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station41Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff20fde529149e6b553db40f2b4c2c5_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:MilpitasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ia41f6975e5dd422096f973c5f9c36e59_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station56Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21570e1162e44757bb2fe76c1778ed38_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station56Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a01ea1f999425489bb8e0b81240782_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station56Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44bce2b5c9264b77a056d1235fca4c45_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station56Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8e1278f8d04c5bb2a24c4705c97839_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254f679cd4904fd2ae4f87879e686402_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9aa8f9e434498bb2d91529de11b85c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie140edce6ab14151a2b4993eaf954127_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesA1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54664e6f89084434b268927edece521c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>rxrx:vote</xbrli:measure></xbrli:unit><xbrli:context id="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0bed1c8a884eb9b91557f3c6c8fbc6_I20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida225ec4cb3e47f0b2b397b7d9fc8ea1_D20210409-20210409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb46e3752d19457fb9b591d8ac77a4af_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rxrx:ChristopherGibsonAndAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="project"><xbrli:measure>rxrx:project</xbrli:measure></xbrli:unit><xbrli:context id="i579b43fe01ce4c56a9134274deed89c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ec7c8bf2994d2e9b1fab9c0703332a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236ba6571e724a009ebcfe23594fc46f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911deb0a783d45d48883d1a7b215ba7f_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic110f6aa94f44a0ea151f7f1d1355795_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac5bbd776f34c14905561c10878b1d4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6eea4fe55d0492db79350755e48b8b9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005b6369f9a04da2b37d8abb0937ccd6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c86ed481ac0466f814feccb1b0dfc44_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac787d8519de4fb7b4312d4d537327cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8946372da4bb412ebce1e7fbd111ba10_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe55087b940747989ca8778b35a30ba2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0aa783282d499eabe30b6edf7958f4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ce5ea44684646478e321a6f5da5f498_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4381c37b0f434d1292766458d6f33a83_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5509909b8164d1392214698e190db36_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12720851e14f4054b18ea160b3ae9c16_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ca49f352744d10969d369737887491_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaec16661eb85408985324c4bec4ce6bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1b4082185f4ff8b95aa9ccc5e14905_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0b13ec20ca48d586c285f56d52aaf7_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d027f3b69840d8bbb90d7865d8a14f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ab811b0acb4f168c59b520becd7a72_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8d774d0f354dffa104fb6ec49d31f5_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59ee14c284b45dfb5c8bbaae6df4885_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624cda05c6f442e482227cdcb651b01e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c8780804ec9494aa5a5c9fa23f6bcc6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd006ea4f4945efaeb183fc075f012d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:A2016WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i209f333c943b42e79aab9462added11c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:A2017WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33aa98d15eec4725a67ba5499bcbbc29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:A2018WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0015342eeae14a93b10cef24c0a7eb00_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:WarrantsIssuedInJanuary2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ead2550bf14c0893a228633bcb285d_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:WarrantsIssuedInJanuary2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2848f38457cf43dfb9f1a86a2619c3ec_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:WarrantsIssuedInJanuary2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd3ed16cc3a40d9b40309215a26d2d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3660f34156d445c9c45640b5093824c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb672f271cdc43bab7ca1eac36b7098e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7aac41dc2042ada5f77fd1aa3b0fbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if14c65e722904f9f939058b7366b4e72_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51a0fc21e8f4d418cb515efcc6a3eaf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c907d87561487794a79022d9299487_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3bd2b3f1de4ca2ab977e7dc5e21061_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25149b9a570440e894a302d56c3419d4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3102e5c386934e08baf3f55a99f19f8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e651de692a4311baff885fe1d206fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f6c3f9030e468f943ac8072eca5c43_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9f157f6cc14838be0480cbdd9ff968_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ff3b8c31df4b4b8a24cb74978eff8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a1c33e0c004ee7bcc3a113bfdbe90e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26eb528b81cf4adf8be643e9113fd19c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5628df5a4848456eb3ec9ada5263c011_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba0f31dd7d94a7aa2ea877325c0bb72_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia222d34dfedb42a989e65c18da7342b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied40c52ff827437a831df98fbdf2c99c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8b605c718747d2acbf2c3db10e6ec0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7afc904b0874b9c80f044ef16fb6c10_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d4ed7ff0ab424a9e1664b17448dcd5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c8d5736faa4c1983958144094f549c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1407ac7645fc47fa897329aea3c530a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i610ce8d6e6fb4af2aed56ad3de0f1a9f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe1a1be865947f4aa113d844800ea59_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec53fdf9f59440fb5fcf12d42df3d39_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab494b26364446fba34ae32a935dfc1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i190cd4db6d464d718e8e7930d9ca1083_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3214dd56bf64eedbbf429ee3a167178_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51038493a87f4438a225fa0f3eb3d1a8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a01352bcbd0418da5a4d83c3911cb35_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac2c0d34aa14f4b86eb9fb680095a93_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b0eacaa900484a97d3551758e92093_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6fec666dd574bdd860d28ccf54b11c1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d40bedd685247d78f2216e50d9a8eff_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie30ba9ac44034c578ac0d736845582c9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3de39547ef349e992ca21d173027833_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic04ee2989244405a8478ecdc58c1d93c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620b4c771b704d6bbc4945cbd1c5dc27_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida224670f66a4cd1b60d191c2e281cce_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief95da0bc6cf471e9f41eac09bb2d67b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf2d0d327cf84c748140d0325b4ebd61_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564180300205478f9ed895f99b4dfe03_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441ebff9e64d4bac86210ac2f3fe7cbe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie20600623f4948c3a5c474d9eecc9162_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0872f901a90f4c1abc3c5b8804f79732_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee4c5b8987c42068342ac8fe0f80772_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013dda72d65e48359f86e04e7a20b9e3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1296a5886a6f470cb0230592349be9eb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6b0ed534a640c5931de64b79a5225c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d9ff00f3094561b99abddcbbc1196c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d4a620cd1204890aa34ec28087d8251_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b15c90e4b864e4fac918da8be88c86f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a713b2042cb45f4baae40157f292534_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc102fb1bc82413aa69f0cd8e15bbcb7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i242c9fb9e9d34e39bc8bb5ea202c9f5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6914913f4c29445486a40ba822c76f9c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8622a762a34db69acf56d2140a8afe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4c24f5df41449c8a6537fb7c6f3dc2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7749db1c1872417f962d0cc10eb2a200_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9cf7bd8980049bea59d3c2a32ae4c09_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18aaa35da92e4cfcab63c485c3c4aaac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774ee2b9287545a0a57464dbab971920_I20171205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19aa404aca14cc6acdaf9338dfc7ff5_D20171205-20171205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-05</xbrli:startDate><xbrli:endDate>2017-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6893f1ac3dd94238a44159176b56e2aa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc41eefa45d46c3ad7b8fa3931ff65b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQ2_b2f45390-64b1-44d5-943f-cb4d523ed4c7">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzMx_b9020e71-f133-4b05-9381-fc4ae9c74db6">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMjg_7d750711-f0a6-460b-9797-cb42e25ce52e">September&#160;30, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzMy_2fff5b0a-f8f7-4b2e-8627-21e620840c03">&#9744;</ix:nonNumeric>   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">            </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">            </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">           </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzM0_21ac43f0-2d54-4f9b-a5d0-43a170de09bc">001-40323</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQ4_049c08be-a22f-4f62-941f-4a16d101167a">Recursion Pharmaceuticals, Inc.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6MjA1M2NmODZlNGViNDQ1MmFiY2QwZTlmMTkxYmI3YjMvdGFibGVyYW5nZToyMDUzY2Y4NmU0ZWI0NDUyYWJjZDBlOWYxOTFiYjdiM18wLTEtMS0xLTA_b07dd7c7-71ed-4464-98e6-d81b5ad21429">Delaware</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6MjA1M2NmODZlNGViNDQ1MmFiY2QwZTlmMTkxYmI3YjMvdGFibGVyYW5nZToyMDUzY2Y4NmU0ZWI0NDUyYWJjZDBlOWYxOTFiYjdiM18wLTQtMS0xLTA_0da10f05-f56c-41c0-9d1d-d93a9fc7ddc4">46-4099738</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQw_6db98f99-dd8a-4932-aab3-5b03c398941d">41 S Rio Grande Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzI3_310635fd-80ab-47b1-9327-a77511678b78">Salt Lake City</ix:nonNumeric>, <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQx_09fccbec-cf7c-4adb-9a83-ab94e0d348bf">UT</ix:nonNumeric> <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV81ODA_cad5c304-5898-4174-bf32-a6f8ce08789d">84101</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQz_702db905-b08a-4f57-87dd-1f4525468a62">385</ix:nonNumeric>) <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzM2_af9bf635-b972-4c15-92f3-04d2dfa5d419">269 - 0203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6Yzc3NDNlMzJlZjQyNGNjZTkxNTFhMmU3YmY2Nzk1MGEvdGFibGVyYW5nZTpjNzc0M2UzMmVmNDI0Y2NlOTE1MWEyZTdiZjY3OTUwYV8xLTAtMS0xLTA_1261f737-4ab3-4a24-b91d-697af51deda6">Class A Common Stock, par value $0.00001</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6Yzc3NDNlMzJlZjQyNGNjZTkxNTFhMmU3YmY2Nzk1MGEvdGFibGVyYW5nZTpjNzc0M2UzMmVmNDI0Y2NlOTE1MWEyZTdiZjY3OTUwYV8xLTEtMS0xLTA_e042e971-a03a-4185-96da-879c7abff31e">RXRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6Yzc3NDNlMzJlZjQyNGNjZTkxNTFhMmU3YmY2Nzk1MGEvdGFibGVyYW5nZTpjNzc0M2UzMmVmNDI0Y2NlOTE1MWEyZTdiZjY3OTUwYV8xLTItMS0xLTA_30bd5f98-9cee-4ebe-bd61-60d0b7522be9">Nasdaq Global Select Market</ix:nonNumeric> </span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzM3_1b77c91d-7570-4a1a-990c-9703a312127d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzI4_f1d83745-4fd1-4dba-8a97-36492b54424c">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6OTI2YzNlYmJlMzBjNDI2N2JjNzI3NzZjOTNlNGEyYzUvdGFibGVyYW5nZTo5MjZjM2ViYmUzMGM0MjY3YmM3Mjc3NmM5M2U0YTJjNV8wLTMtMS0xLTA_d9e64020-25fc-4b80-9391-10f97cc9ee0e">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-false" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6OTI2YzNlYmJlMzBjNDI2N2JjNzI3NzZjOTNlNGEyYzUvdGFibGVyYW5nZTo5MjZjM2ViYmUzMGM0MjY3YmM3Mjc3NmM5M2U0YTJjNV8xLTQtMS0xLTA_5cd03927-2ff3-47a9-9888-e2801c4f3067">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6OTI2YzNlYmJlMzBjNDI2N2JjNzI3NzZjOTNlNGEyYzUvdGFibGVyYW5nZTo5MjZjM2ViYmUzMGM0MjY3YmM3Mjc3NmM5M2U0YTJjNV8yLTQtMS0xLTA_276f4d6e-ba36-4736-8a7a-3ab52513f086">&#9746;</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzI5_9e0ee8ab-39db-46ad-95ab-1e9e6fd8a683">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV82MDQ3MzEzOTU1MTE3_835f5fb2-be22-40d8-b00f-5843775bb89f">&#9744;</ix:nonNumeric>   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="iec0cf3fd3c7f46d58081b8db6dd0a213_I20211031" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMjE0_b2f97709-3bfa-45a4-b0c8-cdbe276f669e">159,525,190</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i014b7cc1c107456880d54adcaf72ca6c_I20211031" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMjIx_c1ba1aa1-6656-4125-8ef6-7f445156128f">9,467,883</ix:nonFraction> of the registrant&#8217;s Class A and B common stock, par value $0.00001 per share, outstanding, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_13">Part I - Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_16">Item 1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_82">Item 2.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_82">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_82">24</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_106">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_106">33</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_109">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_109">33</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_112">Part II - Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_112">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_115">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_115">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_597">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_597">35</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_121">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_121">82</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_124">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_124">83</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_127">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.05pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0bb060ddb7ef4084b0e9e9286fc531b1_127">84</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_578"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in the common stock of Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us, or our) risky or speculative. This summary does not address all of the risks we face. Additional discussion of the risks summarized below, and other risks that we face, can be found in the section titled &#8220;Item 1A. Risk Factors&#8221; in this Quarterly Report on Form 10-Q.  </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product sales. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our drug candidates are in preclinical or clinical development, which are lengthy and expensive processes with uncertain outcomes and the potential for substantial delays.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since our inception, we expect to incur substantial and increasing operating losses for the foreseeable future, and we may not be able to achieve or maintain profitability.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our mission is broad and expensive to achieve and we will need to raise substantial additional funding, which may not be available on commercially reasonable terms or at all. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to finance our cash needs for the foreseeable future potentially through a combination of private and public equity offerings and debt financings, as well as strategic collaborations. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate at least some of our product development programs and other activities, and to possibly cease operations.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital entails risks, including that it may adversely affect the rights, or dilute the holdings, of our existing stockholders; increase our fixed payment obligations; require us to relinquish rights to our technologies or drug candidates; and/or divert management&#8217;s attention from our core business. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish additional strategic collaborations on commercially reasonable terms or at all, or if current or future collaborations are not successful, we may have to alter our drug development plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our current and future collaborators may never successfully develop and commercialize drug candidates, or the market for approved drug candidates may be less than anticipated, which in either case would materially and adversely affect our financial results and our ability to continue our business operations. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approach to drug discovery is unique and may not lead to successful drug products for various reasons, including potential challenges identifying mechanisms of action for our candidates. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although we intend to explore other therapeutic opportunities in addition to the drug candidates we are currently developing, we may fail to identify viable new candidates or we may need to prioritize candidates and, as a result, we may fail to capitalize on profitable market opportunities.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may experience delays in initiating and completing clinical trials, including due to difficulties in enrolling patients or maintaining compliance with trial protocols, or our trials may produce inconclusive or negative results.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain or there are delays in obtaining regulatory approvals for our drug candidates in the U.S. or other jurisdictions, or if approval is subject to limitations, we will be unable to commercialize, or delayed or limited in commercializing, the products in that jurisdiction and our ability to generate revenue may be materially impaired.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results may fluctuate significantly due to a variety of factors, a number of which are outside our control or may be difficult to predict, which could cause our stock price to fluctuate or decline. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to develop new solutions and enhancements to our drug discovery platform that keep pace with technological developments, or if we experience breaches or malfunctions affecting our platform, our ability to identify and validate viable drug candidates would be adversely impacted. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties that provide supplies or equipment, or that manufacture our drug products or drug substances, may not provide sufficient quantities at an acceptable cost or may otherwise fail to perform.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We or third parties on which we depend may experience system failures, cyber-attacks, and other disruptions to information technology or cloud-based infrastructure, which could harm our business and subject us to liability for disclosure of confidential information. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Force majeure events, such as the continuing COVID-19 pandemic or a natural disaster, could materially disrupt our business and the development of our drug candidates. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to adequately protect and enforce our intellectual property rights, including obtaining and maintaining patent protection for our key technology and products that is sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours and our ability to successfully commercialize our technology and products may be impaired. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive position may be harmed. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our obligations in the agreements under which we collaborate with and/or license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our partners, we could lose rights that are important to our business.  </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing, or commercializing competing products before we do.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to attract and retain key executives, experienced scientists, and other qualified personnel, our ability to discover and develop drug candidates and pursue our growth strategy could be impaired.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to comprehensive and ongoing statutory and&#160;regulatory&#160;requirements, noncompliance with which may delay or prevent our ability to market our products or result in fines or other liabilities. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; about us and our industry within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this report may include without limitation those regarding: </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development programs</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress, results, and cost of our current and future preclinical and clinical studies, including statements regarding the design of, and the timing of initiation and completion of, studies and related preparatory work, as well as the period during which the results of the studies will become available; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our clinical trials to demonstrate the safety and efficacy of our drug candidates, and other positive results; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our collaborators to continue research and development activities relating to our development candidates and investigational medicines; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our investigational medicines and any other approved product; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope, and likelihood of regulatory filings and approvals, including the timing of Investigational New Drug applications and final approval by the U.S. Food and Drug Administration, or FDA, of our current drug candidates and any other future drug candidates, as well as our ability to maintain any such approvals; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope, or likelihood of foreign regulatory filings and approvals, including our ability to maintain any such approvals; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the potential market opportunity for our drug candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify viable new drug candidates for clinical development and the rate at which we expect to identify such candidates, whether through an inferential approach or otherwise; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that the assets that will drive the most value for us are those that we will identify in the future using our datasets and tools; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and advance our current drug candidates and programs into, and successfully complete, clinical studies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to reduce the time or cost or increase the likelihood of success of our research and development relative to the traditional drug discovery paradigm; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to improve, and the rate of improvement in, our infrastructure, datasets, biology, technology tools, and drug discovery platform, and our ability to realize benefits from such improvements; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations related to the performance and benefits of our BioHive-1 supercomputer; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to realize a return on our investment of resources and cash in our drug discovery collaborations; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to scale like a technology company and to add more programs to our pipeline each year than in the prior; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully compete in a highly competitive market; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing, commercialization, and marketing capabilities and strategies; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our drug candidates, if approved, including the geographic areas of focus and sales strategy; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the approval and use of our drug candidates in combination with other drugs; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our current drug candidates, if approved, and other drug candidates we may develop; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing approaches that are or may become available; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients that we will enroll in our clinical trials and the timing of their enrollment; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety, efficacy, and therapeutic effects of our drug candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans for further development of our drug candidates, including additional indications we may pursue; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adequately protect and enforce our intellectual property and proprietary technology, including the scope of protection we are able to establish and maintain for intellectual property rights </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">covering our current drug candidates and other drug candidates we may develop, receipt of patent protection, the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, the protection of our trade secrets, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any intellectual property disputes and our ability to defend against claims of infringement, misappropriation, or other violations of intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to keep pace with new technological developments; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize third-party open source software and cloud-based infrastructure, on which we are dependent; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adequacy of our insurance policies and the scope of their coverage; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of a pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, or natural disaster, and the effect of such outbreak or natural disaster on our business and financial results; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our technical operations infrastructure to avoid errors, delays, or cybersecurity breaches; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our drug candidates, and for the manufacture of our drug candidates for preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to research, develop, manufacture, or commercialize our platform and drug candidates; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our current drug candidates and other drug candidates we may develop, if approved; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements, and need for additional financing;</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise substantial additional funding; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of current and future laws and regulations, and our ability to comply with all regulations that we are, or may become, subject to; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any current or future litigation, which may arise during the ordinary course of business and be costly to defend; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the net proceeds from our Initial Public Offering in April 2021; and </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those listed in the section titled &#8220;Risk Factors.&#8221; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate, and financial trends that we believe may affect our business, financial condition, results of operations, and prospects. These forward-looking statements are not guarantees of future performance or development. These statements speak only as of the date of this report and are subject to a number of risks, uncertainties and assumptions described in the section titled </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Risk Factors&#8221; and elsewhere in this report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we undertake no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report. While we believe such information forms a reasonable basis for such statements, the information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon them.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNC0xLTEtMS0w_36ab3738-69c7-4b41-b5dc-14b118dc7491">394,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNC0yLTEtMS0w_b42532f1-8b86-49da-88c6-98dcb98ef10c">262,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNS0xLTEtMS0w_789a902a-12ff-4c5c-9f85-2dd4c1c5b365">10,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNS0yLTEtMS0w_4873becc-66b7-4005-a8d4-028a18e49a6b">5,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNi0xLTEtMS0w_b1d6e9b6-5d52-4abe-9109-bdbfcfb29648">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNi0yLTEtMS0w_f301d7a8-f7d1-4e4b-8577-eed42fa29f99">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0xLTEtMS0xNDcwOQ_cdd46b20-8ded-4f16-9dc3-2cc652b4a99e">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0yLTEtMS0xNDcxNg_3c32ac8e-a7d2-44b4-8014-cc7939cae97e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0xLTEtMS0xNDY4NQ_d1b4bdb2-1156-4ebe-bd05-ec952a293ae8">184,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0yLTEtMS0xNDY5Mg_bc3dacaf-0178-4bf9-b7bb-9a2bc85487f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0xLTEtMS0w_847342c4-9ed4-4e38-a426-12d1988c588a">9,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0yLTEtMS0w_e6ddce38-8e99-43d7-868d-b11e45276639">2,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfOC0xLTEtMS0w_08220ab5-07fa-4c66-a47b-5c39fdf30bdf">600,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfOC0yLTEtMS0w_1f26be42-f2b9-4cea-971f-0e971053bdf0">269,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTAtMS0xLTEtMA_5db78f9a-9b60-4cde-9357-3bef3333545d">55,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTAtMi0xLTEtMA_4cb6b733-079f-4a94-a424-504759207faf">25,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTEtMS0xLTEtMA_781ccabb-3c1f-4b18-906a-20ca686bafd7">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTEtMi0xLTEtMA_69185d35-9b1e-4774-869a-1ac5e28c05b3">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTItMS0xLTEtMA_f3328892-f8e3-438d-a1e6-7f01eb83b975">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTItMi0xLTEtMA_e4b729e0-e96a-45f7-901e-7c9199a6e650">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTMtMS0xLTEtMA_f7c810f1-b913-4a80-949b-764ea07980ed">658,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTMtMi0xLTEtMA_f2b7276a-7c50-48de-bb13-57930ec6d57c">298,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTctMS0xLTEtMA_1c932d55-b734-4924-9ad4-5576a92fdcdc">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTctMi0xLTEtMA_27e8338e-6d31-4cde-8c78-173c919f9beb">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTgtMS0xLTEtMA_a9d69a16-dbe9-4563-81be-e91e304c438d">25,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTgtMi0xLTEtMA_b2b44f06-0fc6-4dff-99ac-57f46d076b11">10,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of unearned revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTktMS0xLTEtMA_3f33ba1a-99c0-4626-a350-c97fd154ca11">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTktMi0xLTEtMA_46ce3bf6-b0de-492d-90e2-c45e92a15d15">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjAtMS0xLTEtMA_b23097c4-4e64-4ca6-b466-74cf7b40ebd9">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjAtMi0xLTEtMA_a5164060-16c8-4356-a8ba-3bd8be2fba94">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease incentive obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncentivePayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjEtMS0xLTEtMA_764e75e5-2a99-48a5-82dd-6550c33a616b">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:LeaseIncentivePayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjEtMi0xLTEtMA_cc706071-8342-4a6a-a35d-bf83e6ab7f6a">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjItMS0xLTEtMA_db6a1131-aa14-4025-a3dd-cf37e857fe9a">42,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjItMi0xLTEtMA_871a883f-7a69-4325-b396-034b2e196ece">23,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjQtMS0xLTEtMA_eb1d6ac2-fbd3-42a5-b8a5-a789fcbc4975">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjQtMi0xLTEtMA_b7112c7c-e0ca-4346-b86f-ea34a1b2f0e0">2,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjUtMS0xLTEtMA_e79ec675-d85e-4620-82a9-dc15429dd1ef">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjUtMi0xLTEtMA_902ee95e-c6c7-432a-be39-16a760b3c4f1">16,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjYtMS0xLTEtMA_2800a2b9-deaf-48ab-84c8-9865e09b1523">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjYtMi0xLTEtMA_8ef99d6a-a834-4586-a56c-b0707f8e2c94">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease incentive obligation, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:LeaseIncentivePayableNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjctMS0xLTEtMA_54241f33-ac09-45dd-8454-81c44203c205">3,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:LeaseIncentivePayableNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjctMi0xLTEtMA_5263745f-bc80-4585-b1bb-52930968e52c">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjgtMS0xLTEtMA_e6670d44-a704-4e59-a3c4-8218d5752248">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjgtMi0xLTEtMA_1d1033b2-11a8-4e97-83b3-ee3404acea9f">56,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note&#160;8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzAtMS0xLTEtMA_686902be-6a6e-4bda-8f5f-1321864994c7"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzAtMi0xLTEtMA_f6838349-8d3c-4edd-9918-23405255b124"></ix:nonFraction></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock (series A, A-1, B, C and D), $<ix:nonFraction unitRef="usdPerShare" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzYz_aaf6305e-3ede-49ad-95d0-8d66765f6663"><ix:nonFraction unitRef="usdPerShare" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzYz_e93eac96-7f3c-4539-bff7-0730bb94a1bc">0.00001</ix:nonFraction></ix:nonFraction> par value;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0Xzc3_78c21a14-a802-4323-844a-370f2488344d">200,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0Xzg0_ef241c25-d2c7-4cbb-8196-558220194588">121,434,713</ix:nonFraction> shares authorized as of September&#160;30, 2021 and December&#160;31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzEzNg_2cfdb4b9-d308-4fdf-aca0-61d32fe40143"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzEzNg_dab78415-91da-4065-8ca6-2de7e114e715">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzE0Mw_8172cf5e-b1af-436d-9293-b490c3ba0790"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzE0Mw_b5b1686e-1bc8-4ca6-999a-a8ef722b5033">112,088,065</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively; liquidation preference of $<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzIzMw_68a04d48-c634-4498-af51-3ad22f852412">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzI0MA_bddd6bcc-5737-4dfe-9d6a-f612713f5a6d">450,850</ix:nonFraction> as of September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMS0xLTEtMA_52dc87d2-c1b0-45c7-9488-729cda548aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMi0xLTEtMA_abd5e789-1040-4a86-8e62-ec4de595e721">448,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock (Class A and B), $<ix:nonFraction unitRef="usdPerShare" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzM1_68f43972-646a-4cd5-ab11-f2c2cb5fc095"><ix:nonFraction unitRef="usdPerShare" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzM1_ee63c101-2fd4-431f-9612-a3a8a06addcc">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzQ5_ac0b9e63-8f69-4275-b7c0-d106d8c8bc55">2,000,000,000</ix:nonFraction> (Class A <ix:nonFraction unitRef="shares" contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzYx_45ccd4d0-b275-4e4b-8e2a-887703b5dc55">1,989,032,117</ix:nonFraction>, Class B <ix:nonFraction unitRef="shares" contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzcz_877f404c-53f9-4a6a-aaae-463c0ae6dfd9">10,967,883</ix:nonFraction>) and <ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzgx_a0dcf639-a9a0-479d-94ab-51095b49b586">188,400,000</ix:nonFraction> shares authorized as of September&#160;30, 2021 and December&#160;31, 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzEzMw_727f0a8b-55a0-4fba-8770-f4e2edf9ddc4"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzEzMw_ccee2ca5-9d44-4296-b5e0-e18872b37ff1">168,634,959</ix:nonFraction></ix:nonFraction> (Class A <ix:nonFraction unitRef="shares" contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE0NQ_7fa5c835-2809-4e6c-b87e-cf3c0adebee8"><ix:nonFraction unitRef="shares" contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE0NQ_a195cc7d-6af1-45b6-ae3b-57b5c8082613">159,167,076</ix:nonFraction></ix:nonFraction>, Class B <ix:nonFraction unitRef="shares" contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE1Nw_494e9d92-7fe5-40eb-a134-7cbb6d5ae913"><ix:nonFraction unitRef="shares" contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE1Nw_953f8813-8c9c-4c68-ac13-770168053030">9,467,883</ix:nonFraction></ix:nonFraction>) and <ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE2NQ_5b25efdb-3dd4-4a38-aecc-bb40317b5534"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE2NQ_80bad785-4d76-473b-b90a-4a0804de8996">22,314,685</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMS0xLTEtMA_fc30d4fd-1dbb-4cd7-aa0f-1d402a0a5d75">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMi0xLTEtMA_c1fe3a13-98d5-47d4-8441-422d06296ddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzUtMS0xLTEtMA_ab637cb4-3988-4038-a068-ba68c0aaff70">934,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzUtMi0xLTEtMA_93c2b79c-5edc-4eba-9f70-d1d8c837d901">7,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzYtMS0xLTEtMA_45252170-58e5-484b-b024-54a9093ed484">335,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzYtMi0xLTEtMA_6aa06103-9c89-4c33-b7ab-dced98e9420b">213,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMS0xLTEtNjA4Mg_f18afe37-47f4-4211-b72b-5d56420b3934">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMi0xLTEtNjEwMw_3cdb4cbc-9804-4768-ace9-c4031a3fc957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMS0xLTEtMA_e5f775c9-2758-40d4-ac62-e6395ee80f37">599,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMi0xLTEtMA_01fb8f07-7a26-4ad1-bfaa-5055c4418086">206,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzktMS0xLTEtMA_6c055924-8377-46c7-9317-837a4bae5eac">658,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzktMi0xLTEtMA_a34ca35e-0aad-4e3b-a633-e373480f9f25">298,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations (unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98a6d661e4e47aab1f3971da19db8fa_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC0xLTEtMS0w_09a741f0-2d0f-4810-80c3-7b637bd9a4ce">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3cb24ed3206446e9ec9135d7c55c2b5_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC0yLTEtMS0w_f12a26c2-0a48-42f4-9e49-c5c8bc015c4d">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbae21d8d86e4d03b1dc645c4d773d58_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC00LTEtMS0w_b417461e-c8ee-409b-8a7d-08cc94f16742">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9367de1805594f3ea5232c87da29a431_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC01LTEtMS0w_44bcdaf8-2129-44ba-bbbd-10952379a59b">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a193d7c195b410a9442788aa6400f38_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS0xLTEtMS0w_e6739fe6-14b8-4693-8130-abe229807d3b">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia091bf9e820244ad994cca02e9749f08_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS0yLTEtMS0w_f9f5199a-a5d0-4355-9563-84e822fd86a2">862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc80a548fed40e799b5efc628f47c0f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS00LTEtMS0w_fd3fbcbb-8c9b-4aaf-be5f-149db933f2ff">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0cf13b1f9d4529bf1fb83789fc572c_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS01LTEtMS0w_d7fd438e-2e1e-4364-9607-ee7b869e98f6">862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi0xLTEtMS0w_8c61cef8-adbc-485d-b896-f790b31805ee">2,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi0yLTEtMS0w_a177f220-25c7-4527-90fb-4e394657683c">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi00LTEtMS0w_351d2069-abf1-4565-8989-5072e0d90daa">7,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi01LTEtMS0w_335891c7-6e20-440e-9d48-e805a6cfd443">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS0xLTEtMS0w_387c5d8c-c9db-45fa-acc6-9488d7acedbf">33,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS0yLTEtMS0w_8d641bf1-34db-470a-82fc-d4a8e8251e21">16,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS00LTEtMS0w_e3558297-708b-411a-b43c-1b749d5b23ed">86,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS01LTEtMS0w_e50d99b6-ecbc-4e98-910b-62ad617795d0">42,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtMS0xLTEtMA_eb313dcb-ef7c-420a-9560-957190800590">15,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtMi0xLTEtMA_f13b0be2-2afa-4adb-ae99-1d12dcac6e03">6,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtNC0xLTEtMA_48ea6d26-49ad-4e64-b7f3-715db985255f">38,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtNS0xLTEtMA_febfa8f1-294e-4191-8272-ea716852633c">17,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtMS0xLTEtMA_4b31b682-59db-4812-97af-8ff35661e397">48,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtMi0xLTEtMA_6a1725c6-aa70-4410-a87e-9a7d1c28173d">23,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtNC0xLTEtMA_a71b199e-f988-4d74-8d53-b0a7781cc336">125,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtNS0xLTEtMA_606a0dbc-94cd-4c94-85aa-a61ab77396ea">60,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtMS0xLTEtMA_cd681856-d300-4b2b-92d1-99d2cb0150e5">46,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtMi0xLTEtMA_4f7e86c9-5fd5-49f5-a0ea-92a04c314e66">22,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtNC0xLTEtMA_3dde48db-8c3e-46a1-a262-b7fd0f07c648">117,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtNS0xLTEtMA_7e0ed0c6-e950-467a-ba4b-4be25132eb36">59,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtMS0xLTEtMA_984bfad8-9864-4723-b3b6-a298fbccff28">1,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtMi0xLTEtMA_968ef75f-6657-498b-87d0-d4d149b9e9b3">1,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtNC0xLTEtMA_f1fca121-9d21-4056-bde0-100a441cfd1b">3,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtNS0xLTEtMA_5633c84b-3f07-40b8-8e7d-a663c5ef24ef">2,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtMS0xLTEtMA_0ea56690-0b00-43c6-95d6-0207a10f0810">47,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtMi0xLTEtMA_c0043f6c-fa5b-45a2-a5e0-d8cb47b4d95f">23,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtNC0xLTEtMA_b30269c2-08e2-4b09-a896-362ffb221c4b">121,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtNS0xLTEtMA_0330aedf-267b-429b-bda3-c70a040a7dbe">61,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per share data</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share of Class A and B common stock, basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMS0xLTEtMA_e8eb82f7-dbe2-4deb-971c-6ff84cd642fe"><ix:nonFraction unitRef="usdPerShare" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMS0xLTEtMA_fb3bdc4d-e275-4800-8b23-303da26eb478">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMi0xLTEtMA_043b9a93-db50-432c-aa07-3681ac555d6c"><ix:nonFraction unitRef="usdPerShare" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMi0xLTEtMA_8ffed737-28a9-4087-ad02-13d5be56dd39">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNC0xLTEtMA_7f37ce18-0582-4a11-8093-b92338f8f43b"><ix:nonFraction unitRef="usdPerShare" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNC0xLTEtMA_9bc3dcf5-5066-453b-9b33-ec300f9821d8">1.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNS0xLTEtMA_991947eb-70f8-41a3-9391-ea474b0f6dc9"><ix:nonFraction unitRef="usdPerShare" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNS0xLTEtMA_df0ed233-36fc-49af-9474-f836573023bb">2.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average shares (Class A and B) outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMS0xLTEtMA_354eafaa-b1fe-43ec-9510-817cb4f4b071"><ix:nonFraction unitRef="shares" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMS0xLTEtMA_d54c7abe-c92f-44e4-a2e6-3c08591a9108">168,533,550</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMi0xLTEtMA_5ba4742a-ea85-4bdc-8943-ff2c1a2babc0"><ix:nonFraction unitRef="shares" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMi0xLTEtMA_73ff164d-4be7-4f32-a124-d07dc0be8f55">21,817,900</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNC0xLTEtMA_0646a43e-90eb-40db-b2e2-49fe35bdf21e"><ix:nonFraction unitRef="shares" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNC0xLTEtMA_5b753e4c-1225-4c75-912f-2b491fb60bce">110,513,231</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNS0xLTEtMA_930e80ff-f128-4de7-ae0a-cff978d3bc09"><ix:nonFraction unitRef="shares" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNS0xLTEtMA_c8f203d5-2cfb-4a89-b0a9-a7ca953c3003">21,704,008</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_474"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss (unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtMS0xLTEtNTMyNg_619e9600-eda9-4384-85a3-caf87fbcd010">47,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtMi0xLTEtNTMyNg_966ee677-ce13-4954-b8eb-aa1e34b5b699">23,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtNC0xLTEtNTMxMA_00f2a78e-5f8d-460b-a458-f3bac263f710">121,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtNS0xLTEtNTMxMA_a077b2d0-fd22-4751-88e8-aa28a3c2fa62">61,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtMS0xLTEtNTU3Mw_764a97a7-74f6-4983-b2ef-00698c4ab85b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtMi0xLTEtNTU3Mw_f3a39a16-a7c4-4429-ba65-d82dd8424557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtNC0xLTEtNTYwNw_25576a2a-05f1-43cd-8ff7-584fedee3cfa">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtNS0xLTEtNTYwNw_aac36e8f-ec6f-48b2-8d7a-27944cc1ea32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses (gains) on investments reclassified into net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtMS0xLTEtNTU3Mw_c61930d4-cfb3-4f93-a0df-880dab74e704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtMi0xLTEtNTU3Mw_39512ecd-052f-45b9-a072-d7141f1e5700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtNC0xLTEtNTYwNw_2bd091aa-a1dc-442c-9da7-e9574c5ee5ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtNS0xLTEtNTYwNw_3cb5268b-d0fd-4fd0-9b45-1b19762288dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctMS0xLTEtMTMxMDk_e336e560-e9e9-4707-92f8-45d0a75dd75f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctMi0xLTEtMTMxMDk_ed83cdfe-a2b2-493e-8b36-3424070e832f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctNC0xLTEtMTMxMTI_a8d78383-5f72-4fd7-874b-5a80b6c4a5a9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctNS0xLTEtMTMxMTI_9242d8f1-20c2-413e-a958-3f86c8776d06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtMS0xLTEtMTMxMDk_b6cad1b4-2ff6-4579-85fb-ead77b03651f">47,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtMi0xLTEtMTMxMDk_26978c4d-df0d-4f21-b726-998c950fd877">23,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtNC0xLTEtMTMxMTI_900e4586-3b0a-486c-bb4b-cb0bfadaca2e">121,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtNS0xLTEtMTMxMTI_d829f2af-ca62-4e20-a005-a4cce9fa5c8a">61,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Convertible Preferred Stock</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;(Class A and B)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630" decimals="INF" format="ixt:fixed-zero" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi0xLTEtMS0xODE4Ng_747d6a3b-4322-493b-9898-ad0a7bf0e4ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi0yLTEtMS0xODE4Ng_3b1633c6-5d37-4469-9e44-bd5ec87ca3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f2f2c074b1e43afaf522e34126788a5_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi0zLTEtMS0w_3ff64be2-92e9-4478-9a73-c9590d3cc6fe">168,425,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2f2c074b1e43afaf522e34126788a5_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi00LTEtMS0w_2888b386-9003-462b-982a-3242bd8fa545">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ff446e32064366bc8ac2fb705f08c7_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi01LTEtMS0w_7d7117fd-ec6b-471b-9931-5a99f6c50d1b">930,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28cbfc7f295d41798a3535412b1097ef_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi02LTEtMS0w_128d00dc-c651-4e16-b91b-6790f1d3a752">287,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b650a6bb07749f0a6edf5919d0a3161_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi03LTEtMS01OTI0_ac97d280-fd00-47ec-a226-84a3010033c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi03LTEtMS0w_b998513f-5253-4a51-a4ac-9e7e69bfe510">642,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285746a4957648a9b7d4042cbb79af11_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMy02LTEtMS0w_bf3a2678-d3aa-4f25-9521-e94d77b1ee89">47,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMy03LTEtMS0w_bd98a177-37a4-4768-892f-89f686341809">47,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40cfd8df988f4d82810e987c2d28b259_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNC03LTEtMS01ODA2_c844fa7b-c37c-4184-819d-5d7e991f1832">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNC04LTEtMS0xODE3OQ_912dbaf7-984b-46ac-9d83-54922b00abd2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e44c4c74c4244ad9325ce8ee3d87c39_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy0zLTEtMS0w_2bc9e656-17be-4fad-84e8-8b76c69b9f51">209,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43267d208dab4736ae222644e2d2c456_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy01LTEtMS0w_eb69fb25-d8eb-4298-aa6c-bb53046b8588">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy03LTEtMS0w_562ccb5d-5441-4f3f-bd0d-b4c56559e0c1">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43267d208dab4736ae222644e2d2c456_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOC01LTEtMS0w_6a90f70b-c2c9-4993-be0f-476ac2028af7">3,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOC03LTEtMS0w_92553d70-13f9-48da-8253-dbce003276ef">3,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy0xLTEtMS0xODE4Ng_a9687855-ff60-4746-b78a-672cc293336a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy0yLTEtMS0xODE4Ng_707edfd5-5c17-4044-8bc3-ec55f4fc406b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS0zLTEtMS0w_2856e969-60d0-4c56-abe2-69fd4c313ae9">168,634,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS00LTEtMS0w_41410097-48bf-4b27-bd70-27e702cb7bd5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b3bdbb908941fe9dd8a36f77aa3125_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS01LTEtMS0w_75407563-8453-4d11-9d8f-82a42ad67e61">934,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b9cf913bc7c43ca9b2e069af2d8729b_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS02LTEtMS0w_a3574b93-5530-4aab-b2c4-85f7c303f39b">335,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40174ea8bb02463794d3b4d1c442fb95_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy03LTEtMS0xODE4NA_8dfe8210-ad0a-4120-a928-7972a3e8414c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS03LTEtMS0w_8e1c305e-ff21-41b5-acd2-57788dc0220b">599,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Preferred&#160;Stock</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Class A and B)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deficit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated other comprehensive income</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity (Deficit) </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi0xLTEtMS0w_b77e5520-0f43-4ee0-872e-d714e8ae82e0">112,088,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi0yLTEtMS0w_1d04b2b3-2b88-417a-b282-4c9996258921">448,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30420430e079491d8ed1cccc567ce1a4_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi0zLTEtMS0w_59a3e899-17d5-408d-bb76-75c2c0fabf34">22,314,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30420430e079491d8ed1cccc567ce1a4_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi00LTEtMS0w_949709fc-e9f7-4211-b9c6-b37f34249840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9e3fea7fdb4088a7ed864903989ab8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi01LTEtMS0w_b2b0e74b-d4f7-473c-80af-cc1264a8e10d">7,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75c52a0d323d498e8014b63cf8a7850d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi02LTEtMS0w_af9d70af-cede-469c-b13c-e57e18d88063">213,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb56eae1b564d73804d37ddfe5ab0ba_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi03LTEtMS01OTM4_a553f2eb-d0f4-415f-9bbe-c5ff17678b4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi03LTEtMS0w_0e620aee-7caf-49c5-af7c-507c3b498377">206,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91d161d487e84f1f904d7fda0b4884fd_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMy02LTEtMS0w_dea507b3-93fc-4489-b2bc-f3aab3a7fcec">121,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMy03LTEtMS0w_93e4ef58-8bc0-431f-8dfa-c41ec31df4e1">121,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776c6fde78c34963b7743761ab97c975_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC03LTEtMS01ODQw_e5742b2f-3e33-448f-87a3-e2150c876659">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC04LTEtMS0xODE3NA_d84a63f6-5556-49b0-a100-d5d6244bff12">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuance for initial public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC0zLTEtMS0w_d9135068-a7af-4775-b765-3e5c8ef84da4">27,878,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC00LTEtMS0w_c044e022-c49b-4d07-9c8d-40bde881994d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c4548723a94137977675db77d39056_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC01LTEtMS0w_8dd2ade8-5b6d-4019-9cc5-3a809e0f942b">462,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC03LTEtMS0w_f1ddd6a7-fc97-491d-bf2b-f1d62894f31e">462,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="rxrx:TemporaryEquitySharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS0xLTEtMS0w_7639a316-1705-47c5-896d-7597316482d2">112,088,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:TemporaryEquityValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS0yLTEtMS0w_399c8488-6209-4eb5-9b4c-850473d0ec60">448,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4482ced31be5421b8f43d4f1dbe206c4_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS0zLTEtMS0w_9e59e09b-1682-4fbd-b691-ba432673e4ef">115,598,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4482ced31be5421b8f43d4f1dbe206c4_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS00LTEtMS0w_063d08f9-4074-409c-9747-9e88ed0cd0bd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5705097d3db6486b875714c0fdd8511f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS01LTEtMS0w_0042e0e9-2dd5-41e5-a82c-70dabf6d97a1">448,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e93eef6c0643958f8d3941866bed9b_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS03LTEtMS0w_facf7812-f208-464f-87c0-bf91be82e3e8">448,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock warrant exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1352bc1f243c4c93b8a1a85f705f61bd_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNi0zLTEtMS0w_697596ec-a338-46b6-8a00-3dfa935c4037">129,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881224a385cd4b5bb6c214cf65fbdc6f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNi01LTEtMS0w_26cc102f-61af-4409-863c-1ddd8e71efba">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b4fd7858ca4d1b8cbd0d11d1d96c2e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNi03LTEtMS0w_6e77d905-3d05-4aeb-a4d1-003c5e206ab9">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNy0zLTEtMS0w_e21ded27-af72-40f3-a6f0-e14038d16409">2,713,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c4548723a94137977675db77d39056_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNy01LTEtMS0w_b2303509-fb23-47d0-886d-8cd4fc027d05">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNy03LTEtMS0w_b7eddf62-9917-4ef6-b8ef-4fc32fc65e43">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c4548723a94137977675db77d39056_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOC01LTEtMS0w_b8058f3f-dabe-4868-9b0c-f7cffa7d5a78">10,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOC03LTEtMS0w_249f5c3c-3784-4da3-87bd-b18a89c1166e">10,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS0xLTEtMS0w_4f34f5fa-873d-4e82-9136-e0600033e87d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS0yLTEtMS0w_8a2777ca-c758-4e4c-84f9-fff6bc052138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS0zLTEtMS0w_b0442f96-c0bd-48e6-acd1-77c2f10cc3c6">168,634,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS00LTEtMS0w_f27a0a98-e896-4c79-8d52-95a7b4a274c5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b3bdbb908941fe9dd8a36f77aa3125_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS01LTEtMS0w_695c81df-3fd6-4947-9822-5352699d1681">934,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b9cf913bc7c43ca9b2e069af2d8729b_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS02LTEtMS0w_bb4147b9-5e00-4a7d-bac0-74107ba942e2">335,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40174ea8bb02463794d3b4d1c442fb95_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMTAtNy0xLTEtMTgxNzc_f6938c87-6940-46ea-8a4a-f5c7a39ecd48">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS03LTEtMS0w_88a90553-8cbe-4ffb-a07b-c166a0abae13">599,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit (unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Preferred Stock</span></td><td colspan="6" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; Deficit</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a9bdffe7f94be498dcc2410790c11f_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi0xLTEtMS0w_390d9d1e-5876-432d-8389-a90323ab5a23">75,189,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a9bdffe7f94be498dcc2410790c11f_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi0yLTEtMS0w_fd388c6b-fffa-4890-b5a2-b6a954e70a15">201,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872955c4fcdd4c5eaf64056f28e5f425_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi0zLTEtMS0w_d695778a-c669-4f1c-9101-02a863157a0a">21,652,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872955c4fcdd4c5eaf64056f28e5f425_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi00LTEtMS0w_4f442a2c-96ee-43c2-aecd-f7d3bd7cd211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a95d59cc58842588ef57ba5c32d5d71_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi01LTEtMS0w_9d9a2711-ac8f-4d76-9268-7d81fecd769c">4,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cfdf3f6f12e4ce0ae4dfac0a5ed90d2_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi02LTEtMS0w_93405808-0ecd-448e-89e0-931b6bb33e13">163,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a9bdffe7f94be498dcc2410790c11f_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi03LTEtMS0w_fd1087b9-9b63-4f51-9637-a1739be162ff">159,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28896c19aa0048d895dddd0ae8427e87_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMy02LTEtMS0w_39313815-2157-4e52-8be6-03f34e71e405">23,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMy03LTEtMS0w_029316d7-238c-4b35-8a3c-dbceef0c6398">23,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0e2b80f5d48496fa52384c883bedd9d_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC0zLTEtMS00OTI5_0862dba9-ab81-40d2-a048-aa0ebbe7bd29">282,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3209489bac6541a49f8dc6490492263d_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC01LTEtMS00OTI5_b79e528a-0498-4afb-849e-8d7a452f2309">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC03LTEtMS00OTI5_4642f23f-1879-4a2e-8c8a-399c70779105">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Series D convertible preferred stock inclusive of the convertible notes, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" name="rxrx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0wLTEtMS0xMzQxMy90ZXh0cmVnaW9uOmUzYjQxYWYwYjhmOTQzMzY5OTE1YWE1NTU1N2ZmZDRmXzY1OTcwNjk3NjY3Nzg_315960ef-2ce3-4ffe-8bcf-80d7d3d48f19">228</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5058a871b06b4ce2a3fa07e2e0a0bfb2_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0xLTEtMS03MDg2_33f5fd97-a626-42f6-966c-ecbd025c7af1">35,349,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0yLTEtMS03MTEw_f911142f-1c2a-4e50-997f-2da505e12b11">236,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3209489bac6541a49f8dc6490492263d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC01LTEtMS0w_0cacfe01-5c6c-40a9-8b04-f843b4f32320">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC03LTEtMS0w_3a555d39-b6a3-4077-a088-ee2148d6f48d">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0xLTEtMS0w_1bae6939-532b-485f-8803-6a10971bc212">110,539,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0yLTEtMS0w_53b709f7-fe71-4303-9b02-caed3ac2117d">437,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0zLTEtMS0w_738aba03-11ad-42fb-8483-ef75657830ef">21,934,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS00LTEtMS0w_61a3c7bb-01bb-4bb4-a294-2c53b513997e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8338d53d46ff438abc85d037a8e6da2f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS01LTEtMS0w_4ceb39bb-ac30-4f63-8e2f-edfd5eaa6e43">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i869c72f28c2245f8b0f7ccc8daabd4fd_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS02LTEtMS0w_857f1c72-6474-4b3d-a86b-3b9e4afe4764">187,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS03LTEtMS0w_0781aa51-5b67-42ae-ae0e-8df701d6ced1">182,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Preferred Stock</span></td><td colspan="6" style="border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; Deficit</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e11557b1837454f993cb507031865c5_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi0xLTEtMS0w_57a7b905-518f-40ec-b191-53af011461b4">75,189,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e11557b1837454f993cb507031865c5_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi0yLTEtMS0w_6086aefa-f14a-4036-bff5-41225411c2a9">201,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b7ae49e496a4f9888670cd3e0d4b725_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi0zLTEtMS0w_cbc5cfef-5e6f-4cce-9e96-a2fa49307dbe">21,637,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7ae49e496a4f9888670cd3e0d4b725_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi00LTEtMS0w_d2841943-d0dd-4f95-9968-453f3272764b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77586c203c024828a9a78bdb39902891_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi01LTEtMS0w_58d003e6-bcee-4914-8b89-23e19449b6a4">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb73e0e9cb754e1bbe802d6ae2551e64_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi02LTEtMS0w_258dfb85-fb69-4d16-ac44-eef0a962260f">126,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e11557b1837454f993cb507031865c5_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi03LTEtMS0w_7116fe7b-1a3d-4bb4-9a0e-e50abe254cc1">124,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icee0f1fd845e456095af44bb0a898324_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMy02LTEtMS0w_95f87f38-5a27-4098-8d29-7166fbbe9c54">61,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMy03LTEtMS0w_475af47b-4f9f-447f-85ed-0ddb00262725">61,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i182ec792f9954c3580432f8d5bb60d4c_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNC0zLTEtMS0w_099788b4-736b-44a0-b603-84b21b1b0ca7">296,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16660690238a4cba84cc971aaa39f2bc_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNC01LTEtMS0w_160ba0a9-e03d-45b0-a54d-5d856caad7f6">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNC03LTEtMS0w_18d504ea-06e6-4352-8271-70defc65d097">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Series D convertible preferred stock inclusive of the convertible notes, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="rxrx:TemporaryEquityIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS0wLTEtMS0xODQ5NS90ZXh0cmVnaW9uOmNkMzVjODliNWE3MDQ0YzBiZTgyODE5NjQyOTE1MzNmXzY1OTcwNjk3NjY3Nzg_de6e8a81-1b56-40d5-be3d-9ccf8f74661e">228</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS0xLTEtMS03MTc3_42f91446-74cf-4044-bc13-264d61f5c8d9">35,349,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS0yLTEtMS03MTc3_f9892f46-3410-447a-8d6a-dd8a9c8e439e">236,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16660690238a4cba84cc971aaa39f2bc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS01LTEtMS0w_3262a41a-adb6-4a97-947b-4443709c1e19">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS03LTEtMS0w_b24aa5f5-421c-449d-80ac-c2793d3ba892">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi0xLTEtMS0w_4cb2ee84-96d3-41fc-a59a-66793f399002">110,539,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi0yLTEtMS0w_1df3b8fb-723c-4185-85f2-5df77dad332d">437,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi0zLTEtMS0w_11867643-9baf-47d7-bff4-c4e8a2c112cb">21,934,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi00LTEtMS0w_9309de6e-0aae-4169-8dd9-fb58f93686e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8338d53d46ff438abc85d037a8e6da2f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi01LTEtMS0w_a5e80c51-7f10-4ca6-b1d8-ddc12fccc891">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i869c72f28c2245f8b0f7ccc8daabd4fd_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi02LTEtMS0w_327824b5-f7f5-479d-ae05-0ed75138b48e">187,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi03LTEtMS0w_87a4e129-6db0-4250-9491-c78d53fc7519">182,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNC0xLTEtMS0w_db61c954-474d-4d16-8be0-e61c45a5bd10">121,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNC0yLTEtMS0w_a96b1b66-710d-4b1a-bd90-e9c5f724d238">61,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNi0xLTEtMS0w_7ef911b4-47f5-4bb0-b41c-a578d6f0b18b">6,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNi0yLTEtMS0w_3c09dc5e-6f9d-4845-9d87-004b8ec06ad4">2,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNy0xLTEtMS0w_f08d9e1b-86e8-47ff-b0a1-19fe5e96fdf3">10,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNy0yLTEtMS0w_1525c3ce-711a-4f4a-b39a-f4d5e7a51238">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0xLTEtMS0xMjY5MA_9b1ed40e-abd3-418c-a1d7-0d2e0629c8c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0yLTEtMS0xMjY3Ng_5c4029c9-300e-4d94-9877-6a148e0ffb06">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOS0xLTEtMS0xMjY5MA_8144d013-b53f-4a0c-bd60-2caf61e83345">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOS0yLTEtMS0xMjY4Mw_ed56d041-b02c-4fea-96dc-796895037d7c">883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0xLTEtMS0w_efa54568-fff0-4aa5-b6ec-af319e82b5ea">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0yLTEtMS0w_19f082f9-491a-407d-ba35-703ac80db205">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTAtMS0xLTEtMA_5c752a1e-28a6-4039-a926-966fdefe0897">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTAtMi0xLTEtMA_0f0d7840-aa73-4461-8b5f-be1a35d1e2de">30,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables and assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTEtMS0xLTEtMA_8f10b722-4b2f-4f39-a8b0-b60d3316c21b">6,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTEtMi0xLTEtMA_1a85a19d-a845-427c-97d1-1fbe2e8d2217">677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTItMS0xLTEtMA_12ee21bd-be21-4177-9d8a-7da903f6d3ec">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTItMi0xLTEtMA_979581c6-46bb-4dc0-8cbe-32ff715174ea">29,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTMtMS0xLTEtMA_4f455f2e-77ea-4e0a-8e3d-fc8583d086a2">5,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTMtMi0xLTEtMA_bc6f841e-b5b6-44f8-b6d9-f41a519cb1dc">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:IncreaseDecreaseInAccruedDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTQtMS0xLTEtMA_24164a27-1da5-4414-a7cd-2ba4d1724c1c">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" name="rxrx:IncreaseDecreaseInAccruedDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTQtMi0xLTEtMA_e6997e9a-c13b-40a9-9d53-38963ffad274">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses, deferred rent and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTUtMS0xLTEtMA_b643a27d-694f-4907-af8d-bf0ad967e86f">11,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTUtMi0xLTEtMA_11ef7605-3515-4221-bad0-f417eebb2595">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTYtMS0xLTEtMA_c3140d87-6936-4907-bc5e-9174d977d2cb">97,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTYtMi0xLTEtMA_dfb349cc-0ae4-45a4-8a1b-62a27f6105f5">53,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTktMS0xLTEtMA_788333fd-2422-47c6-93a7-c423c8ff0388">35,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTktMi0xLTEtMA_76566b77-8a2c-40b5-bfc7-a0c2a5a9656f">2,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of a business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMS0xLTEtMTk3OA_de0b5e9e-b844-4259-8f2a-ca35733c8b25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMi0xLTEtMjAwMg_8bac9ab7-b952-49f5-86de-12749dc37158">2,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMS0xLTEtMTkwOQ_608a5473-13d7-45ce-8ea0-90df84d99047">184,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMi0xLTEtMTkzNA_b729ba1d-924a-4462-a1c6-13a067ccecfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMS0xLTEtMA_67dfe49a-16e5-4f3f-b29a-103f17b650ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMi0xLTEtMA_02c53528-cbcc-49d7-9902-4f180528fac9">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjEtMS0xLTEtMA_a07ef781-5983-4458-881f-379f179677d4">219,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjEtMi0xLTEtMA_74a3e210-65fb-488b-ad64-f0b5ae7bac2f">4,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from initial public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjQtMS0xLTEtMA_8ad264a8-d538-4b4d-badc-94368ae94641">462,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjQtMi0xLTEtMA_85e6dd87-e2d2-41d7-8814-21751dd8d7e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjktMS0xLTEtMTI1OTY_21a54a75-2478-4752-90cf-7e536882219c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjktMi0xLTEtMTI1ODk_4f7e0b7d-00be-4f01-8dce-c74b838ad5de">229,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjUtMS0xLTEtMA_326db931-ac6b-4642-8fde-92a50c89c17b">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjUtMi0xLTEtMA_829fa462-676d-478a-a4ea-e92132eb9657">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjYtMS0xLTEtMA_5ce8cbca-ccaa-4a31-940a-5f62e6e6f383">12,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjYtMi0xLTEtMA_c0312a90-9f21-42f0-b41c-729c4aba41e5">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjctMS0xLTEtMA_e8c7de8d-eb6c-4941-9819-306512a6788f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjctMi0xLTEtMA_bf7dc222-aee8-4095-b160-74fa87764ab6">6,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjgtMS0xLTEtMA_8280201c-7a09-4829-968e-95823a256c98">454,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjgtMi0xLTEtMA_d0d0676d-2f09-451c-96e1-d52c1a9289c2">236,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzAtMS0xLTEtMA_e39cacfa-1c51-4834-aea9-fabee4a270b0">137,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzAtMi0xLTEtMA_b742899a-1389-487d-922b-c217bd679187">177,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzEtMS0xLTEtMA_c19a8dbf-badc-444a-93e8-b9603d6e452a">267,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e11557b1837454f993cb507031865c5_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzEtMi0xLTEtMA_153aca46-f934-4a8a-b091-c802299f5e57">75,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzItMS0xLTEtMA_19c9cfef-ae4c-4b7e-9617-e0e37d827c8f">404,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzItMi0xLTEtMA_388b7ab0-b624-4038-b7ee-9316053eb571">253,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non&#8212;cash investing and financing information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzUtMS0xLTEtMA_65c077e9-c06c-48fd-bb94-969a6cce26ad">448,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzUtMi0xLTEtMA_1365c7a3-266b-4543-b9e8-6d9ec7165120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible notes to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDItMS0xLTEtMTY5MzQ_209cb22c-99b0-4b73-9cf7-da5d536eb917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDItMi0xLTEtMTY5MzQ_f82d6123-eba3-4fd7-965f-c7026c06a2b1">8,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs recorded in equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="rxrx:StockIssuanceCostsNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzYtMS0xLTEtMA_6b224dfe-6b5b-46e7-a772-b01b042bd32d">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="rxrx:StockIssuanceCostsNoncash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzYtMi0xLTEtMA_5abe33cb-004b-4c4e-b4a6-570b181b2694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzctMS0xLTEtMA_f81f898d-8777-420c-818d-5a99368bf571">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzctMi0xLTEtMA_04f007cb-c6ec-4a55-b938-63d23d877d50">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDAtMS0xLTEtMA_9ae892cd-b544-4200-8065-43e2bb96215a">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDAtMi0xLTEtMA_036f5c95-0f60-43c0-9d55-281d7edd5861">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying notes to these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recursion Pharmaceuticals, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_34"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNC9mcmFnOjQ0YzI0MGI1MDhkZDRlNzNiNmMzMjMyMTU2NThiYzYyL3RleHRyZWdpb246NDRjMjQwYjUwOGRkNGU3M2I2YzMyMzIxNTY1OGJjNjJfMzA2NQ_6a35878a-cbc9-4a2c-b706-6ac3b36b7a0b" continuedAt="i3ca658fd1f41420d9c255056337b6c7f" escape="true">Description of the Business </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3ca658fd1f41420d9c255056337b6c7f"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us or our) was originally formed as a limited liability</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and changed our name to Recursion Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is a biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. Recursion&#8217;s rich, relatable database of biological images generated in-house on the Company&#8217;s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people&#8217;s lives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNC9mcmFnOjQ0YzI0MGI1MDhkZDRlNzNiNmMzMjMyMTU2NThiYzYyL3RleHRyZWdpb246NDRjMjQwYjUwOGRkNGU3M2I2YzMyMzIxNTY1OGJjNjJfMTAxMg_91ff49c0-c573-479a-bcd5-b3e8159cb570">335.1</ix:nonFraction> million. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration&#160;with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has funded its operations to date through the issuance of convertible preferred stock (see Note 9, &#8220;Convertible Preferred Stock&#8221; for additional details) and the issuance of Class A common stock in an Initial Public Offering (IPO), which was completed in April 2021 (see Note 10, &#8220;Common Stock&#8221; for additional details). Recursion will likely be required to raise additional capital. As of September&#160;30, 2021, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company&#8217;s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the net proceeds from the IPO, together with the Company&#8217;s existing cash and cash equivalents and borrowings available to it, will be sufficient to fund the Company&#8217;s operating expenses and capital expenditures for at least the next 12 months.</span></div></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_37"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfNDE4NA_b0a06aac-ff60-4aac-9b77-8773983c5033" continuedAt="i9d57287ebf764edebd6a109d4a9a8e95" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9d57287ebf764edebd6a109d4a9a8e95" continuedAt="i81be363dc76f41f4aeda0c54fd168c52"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfNDE4NQ_519dcaa6-bd71-47d8-9d18-ac7ba8121772" continuedAt="ib71ba26b0dc14f87b4109b664e33c7a3" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes for the year ended December&#160;31, 2020 included in the Company&#8217;s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company completed a <ix:nonFraction unitRef="number" contextRef="i778df7726a034719acdc84318d53c893_D20210401-20210430" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfODU1_ef6d1ef5-bdde-414d-8fd9-28987c47c050">1.5</ix:nonFraction>-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 10, &#8220;Common Stock&#8221; for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company&#8217;s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a <ix:nonFraction unitRef="number" contextRef="ia31781556c024ff299dfa585947bf905_D20210401-20210430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfMTI5Mw_e8698712-a2e7-47da-86d7-193cebccf3ba">one</ix:nonFraction>-for-one basis. The creation and issuance of the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i81be363dc76f41f4aeda0c54fd168c52" continuedAt="if01f49da95b94673bb9ee7c560566af7"><ix:continuation id="ib71ba26b0dc14f87b4109b664e33c7a3"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 10, &#8220;Common Stock&#8221; for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#8217;s financial statements. Revenues and net loss for any interim period are not necessarily indicative of future or annual results.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards, although the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company&#8217;s financial statements with other public companies difficult because of the potential differences in accounting standards used. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion may remain an EGC until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#8220;large accelerated filer;&#8221; or (b) have annual gross revenues of $1.07&#160;billion or more; or (3) the date on which we have issued more than $1.0&#160;billion of non-convertible debt over a three-year period.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfNDE4Ng_a25a7f6e-9159-43f5-a7fc-80e059cb2568" continuedAt="i5e87c7e270464f9799022e5e8fec6d9b" escape="true">Recent Accounting Pronouncements </ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if01f49da95b94673bb9ee7c560566af7"><ix:continuation id="i5e87c7e270464f9799022e5e8fec6d9b">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02). Under ASC (Accounting Standards Codification) 842 - Leases, the Company will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) on its Condensed Consolidated Balance Sheet at the commencement date of each lease. ASC 842 is effective for annual and interim periods beginning on or after December 15, 2021 and early adoption is permitted. The Company must adopt the standard using the modified retrospective approach either: (1) as of the earliest period presented and through the comparative periods in the entity&#8217;s financial statements or (2) as of the effective date of ASC 842, with a cumulative-effect adjustment to equity. The Company expects the adoption to materially increase assets and liabilities on the Condensed Consolidated Balance Sheets related to those leases classified as operating and not recognized on the Condensed Consolidated Balance Sheets under current GAAP. The Company is continuing to evaluate the effect that ASC 842 will have on its consolidated financial statements and related disclosures. The Company will adopt the new standard on January 1, 2022.</ix:continuation></ix:continuation>  </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_447"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTcwMjE_16d68b65-8c20-4319-8b10-593286da8212" continuedAt="i76f94caa3298417198aadee2eff25b04" escape="true">Acquisitions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i76f94caa3298417198aadee2eff25b04" continuedAt="i0f16b705eed042aba8a1e4d09aa41fb4"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an asset purchase agreement to purchase <ix:nonFraction unitRef="number" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTcwMjQ_00c604fa-1c37-4d9b-8102-a7ff61cf1248">100</ix:nonFraction>% of the assets of Vium, Inc. (Vium) for a total cash consideration of $<ix:nonFraction unitRef="usd" contextRef="idd4cc970bf084e72a23bc5618284498a_D20200701-20200731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzcxNDY4MjU1ODQ4MzA_4958b9a0-3b39-475b-9e44-73ec3edb66f9">2.6</ix:nonFraction> million. The primary purpose of the acquisition was to obtain Vium&#8217;s technology. This was a related party transaction, see Note 16, &#8220;Related Party Transactions&#8221; for additional details. The acquisition of Vium has been accounted for as a business combination using the acquisition method of accounting.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTcwMjI_15588352-a5c5-4963-ada0-3d239b52e594" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired as of the July 2020 acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzEtMS0xLTEtMjU5OA_94be0819-039f-4d76-a44d-7f1a80f633c9">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzItMS0xLTEtMjU5OA_bfb1c2f6-5955-4d21-b98d-48889447a5a6">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76fe27fdee64641b854285105025b00_I20200731" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzMtMS0xLTEtMjU5OA_f5b59c09-ed40-4847-8db4-c3d0ab6bb393">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzQtMS0xLTEtMjU5OA_625fc871-1257-4766-a4c9-96ef1fa8d42a">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzUtMS0xLTEtMTMxNzY_2020d916-c239-4bea-878c-4e129302e73a">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzYtMS0xLTEtMjY0Ng_db8fe8d2-325c-4c21-8e88-62b428757b80">801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzctMS0xLTEtMTMxNzY_056a28b4-ff2e-4068-89c3-b604980200c5">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0f16b705eed042aba8a1e4d09aa41fb4"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Vium have been included in our Condensed Consolidated Statements of Operations  since the date the business was acquired and were not significant. The technology intangible asset is being amortized on a straight-line basis over its <ix:nonNumeric contextRef="i1fc1f03ee515432fa42136f5abffdeca_D20200701-20200731" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTc2ODQ_49667a98-63f0-43c7-b730-cde69fcc0885">three-year</ix:nonNumeric> useful life. The inventory and other intangible assets were fully impaired at the time they were acquired as the Company did not intend to use them. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill includes the value of potential future technologies as well as the overall strategic benefits provided to the business.</span></div></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_40"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA1_0d8a5da5-c2b4-4330-832b-dce24677d3ab" continuedAt="iba026d9684e6489496deac8d517e0245" escape="true">Supplemental Financial Information </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iba026d9684e6489496deac8d517e0245" continuedAt="i3d146c9f367941d6b11138a8c14de5ac"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA2_c57fc696-5751-40b8-98e0-d116caecbc35" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:69.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i664743a93bb344148d7136746fd74f72_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMi0xLTEtMS0w_0637e80f-4494-46d6-a8b4-a736a964148b">29,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc65b757b0943af90388d031f257341_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMi0yLTEtMS0w_4f63bd82-641f-4e6b-a469-06bf688873b1">19,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d68dbe3edaa4b9280d1ffb236378a0b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMy0xLTEtMS0w_4ee3fbd2-7563-4ce0-912b-29edd762b30f">13,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817c708d2c01406eb506b6bb2d083fd0_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMy0yLTEtMS0w_1a9d3ccb-ebe6-4014-9339-ee4a9f346bc9">13,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf122307ee643a0845c0597e111bdfc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNC0xLTEtMS0w_788c57b9-cf4f-40a0-b51e-0f4d617380c3">20,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae7b4560de940f1ba648b0647540789_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNC0yLTEtMS0w_6bfdaf16-22f6-46f9-acea-3841afc93d0d">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3d0f8815254b29b2f5393fc3e65f2c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNS0xLTEtMS0w_5a14d55f-d440-4926-9ddc-b99230c6c50d">8,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc7703b2a8b748759f610e861ada8589_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNS0yLTEtMS0w_b987ded4-4897-41b0-a6db-b85558482b11">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNi0xLTEtMS0w_25543477-bc86-47df-8f46-4ce98d55311c">71,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNi0yLTEtMS0w_768836ea-7af7-4e43-a172-1b2e774b7062">35,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNy0xLTEtMS0w_3ff4c7eb-d0ff-40ec-a8db-1fd20aecc704">16,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNy0yLTEtMS0w_03cc7801-c04d-48c6-8fb4-192ac692e0db">9,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfOC0xLTEtMS0w_99e307ff-24f5-45eb-b98f-c7155b94891b">55,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfOC0yLTEtMS0w_b6a80f6c-d277-4320-bf04-e151ec80c580">25,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense on property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTI4_763c6ed3-05b3-4b38-a34f-d5226846e749">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTM1_66458910-2c43-4a80-9c40-90f222cac8a1">6.3</ix:nonFraction> million during the three and nine months ended September 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTgx_cae97fc7-054f-45f6-9915-af7dd11c892e">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTg4_b6377caa-4d7c-4d82-8d5e-db07aec0112e">3.1</ix:nonFraction> million during the three and nine months ended September 30, 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the nine months ended September 30, 2021, the Company purchased a Dell EMC supercomputer for $<ix:nonFraction unitRef="usd" contextRef="i4e32a03cb9fc49e4b252453d837334e6_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMjk1_a07ebfd0-38e3-480b-ade4-bcf536adf492">17.9</ix:nonFraction> million. The purchase was classified as office equipment in the above table. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA3_f848ac29-0320-4e7e-aa1a-b708ff2ab36c" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:69.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMi0xLTEtMS0w_ff0ac1d3-21c2-45de-ad3a-f4c669c465f9">7,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMi0yLTEtMS0w_1a1653ef-a0cf-406d-9627-094d2b4852ea">3,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:AccruedDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMy0xLTEtMS0w_c36c3f1b-904e-45b3-95bb-c9b95e6c4312">3,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:AccruedDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMy0yLTEtMS0w_3c7d4d27-c8cf-4d0e-86bf-cbf69ae1039a">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued early discovery expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:AccruedEarlyDiscoveryExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNC0xLTEtMS0w_561555a5-c766-435c-83a2-99ef6ce5e3f2">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="rxrx:AccruedEarlyDiscoveryExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNC0yLTEtMS0w_a616c58f-fc7e-4c60-93ef-7eb168a06b1a">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued investment purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:AccruedInvestmentPurchasesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0xLTEtMS0xNTIxNQ_7c932a58-2df9-464e-9bc8-3f5a363d616d">5,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:fixed-zero" name="rxrx:AccruedInvestmentPurchasesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0yLTEtMS0xNTIzMQ_8b70e1bc-56fe-420f-8d1a-09978f85bedb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:ConstructionPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0xLTEtMS0xNTUwNg_7e60e7d3-ccc3-40ce-9468-ace4e0d65216">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ConstructionPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0yLTEtMS0xNTUxMQ_c89436ed-bf1a-4743-9f81-c54c59561877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0xLTEtMS0w_70f0ff18-e3cf-4ffc-bd97-49d6983b1bd8">5,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0yLTEtMS0w_fe74cd73-399f-464b-824b-70f33874e835">4,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0xLTEtMS0w_6ca158a1-3027-4c47-81ae-97105879bcc1">25,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0yLTEtMS0w_ba69c50b-eb43-4200-8a72-8371a784dfb5">10,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3d146c9f367941d6b11138a8c14de5ac"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA4_5c3a5762-315f-4b23-91dd-4eea54a2e9da" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi0xLTEtMS0w_ffbc150a-1dd2-4c3a-898b-dbd3f42b789e">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi0yLTEtMS0w_e05a512f-f605-43f4-a4f8-29fd0f4fe3ac">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi00LTEtMS0w_5334139b-059d-4436-aec5-4aa873c34208">2,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi01LTEtMS0w_59da03a9-8b4c-4f61-baec-0039aa9eee88">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy0xLTEtMS0w_b828b366-3ca4-4b04-a5ed-25bc44522700">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy0yLTEtMS0w_cf393d30-a029-48f4-823f-183287ee130f">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy00LTEtMS0w_a6a21ca6-d429-4381-a05a-a25bbb5d29aa">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy01LTEtMS0w_9017b295-e0a4-4daf-8bb2-c05a5b642375">290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC0xLTEtMS0w_bb06600b-7112-4101-a4ce-c18803d7fad3">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC0yLTEtMS0w_03a99082-3290-4f63-8579-b38f37842d88">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:InterestRevenueExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC00LTEtMS0w_f57f22cb-9613-40dc-ae63-fbcdb0eda25c">2,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC01LTEtMS0w_399bd634-b92a-4ee5-96e2-e24271c1d4b8">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the nine months ended September 30, 2021, interest expense primarily related to changes in fair value of the Series A and B warrants (see Note 12, &#8220;Stock-based Compensation&#8221; for additional details on the warrants). The Company also had expenses for the Midcap loan and tenant improvement allowance notes (see Note 7, &#8220;Notes Payable&#8221; for additional details.) For the nine months ended September 30, 2020, interest expense included expenses on the Midcap loan, convertible notes and tenant improvement allowance notes (see Note 7, &#8220;Notes Payable&#8221; for additional details). Interest expense was included in &#8220;Other loss, net&#8221; on the Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_428"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzYwNDczMTM5NTc5NDU_17d15e2f-41f9-48d8-a99e-d99745dda96e" continuedAt="i2358963ff2d34dd8a146d79e32beae3d" escape="true">Investments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2358963ff2d34dd8a146d79e32beae3d" continuedAt="i889984e9822341f39be83ac75e0b30b7"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company invested cash in an investment portfolio. The primary objectives of the investment portfolio are to preserve principal, maintain prudent levels of liquidity and obtain investment returns. Recursion&#8217;s investment policy limits investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the investments for declines in fair value below their cost basis each quarter or whenever circumstances indicate that the cost basis of an asset may not be recoverable and assesses whether the decline was due to credit-related factors or other factors. The evaluation is based on a number of factors, including the extent to which the fair value is below the cost basis; adverse conditions related specifically to the security, such as any changes to the credit rating of the security; and the intent to sell, or whether Recursion will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is impaired could change in the future based on new developments or changes in assumptions related to that particular security.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzYwNDczMTM5NTc5NDY_0749158f-b7bc-44f5-bdd2-74baf2a4fe62" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s available-for-sale investments by type of security: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItMS0xLTEtMjA3Nw_1bf9af3c-de56-4b41-96ab-f9245b67f434">187,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItMi0xLTEtMjA3Nw_3073cc30-aaaf-423a-a8da-e38760bc2c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItMy0xLTEtMjA3Nw_c31dbe35-b72e-427c-a3c6-196cd86a7d54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItNC0xLTEtMjA3Nw_c2f350d9-74dd-47db-b689-bfb1ed2e3fcf">187,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtMS0xLTEtMjA5Mg_8871a2fd-e2dd-4569-b306-c50bf686c75e">5,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtMi0xLTEtMjA5Mg_4ed7443f-6e00-4683-ada3-90186a4c1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtMy0xLTEtMjA5Mg_525cab9b-3701-40e1-90a8-5917af8a829f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtNC0xLTEtMjA5Mg_20f1485c-ac29-4fd3-bb69-98d9e5400519">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtMS0xLTEtMjA5Mg_560b5c70-4818-4de6-8538-6765ca1acfbc">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtMi0xLTEtMjA5Mg_1f031cb7-b102-4c3b-bc8f-961618af090c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtMy0xLTEtMjA5Mg_81477564-7e5e-41c6-87f6-4e358b0acb6e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtNC0xLTEtMjA5Mg_263a482b-a2ff-40d8-a3c9-19459ac37a63">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctMS0xLTEtMjA5Mg_257b04eb-cac3-411c-98b1-48df25ebfa36">191,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctMi0xLTEtMjA5Mg_4c5091ec-5961-45cd-b384-194037b66ebd">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctMy0xLTEtMjA5Mg_868e4a49-1f03-4fb7-b3bc-0008b5407794">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctNC0xLTEtMjA5Mg_0e31be97-7c27-41f8-8830-567e0f13f51d">191,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtMS0xLTEtMTM0MTk_70e09cc7-2a41-4ad1-af5b-a890b1bbdf9a">405,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtMi0xLTEtMTM0MTk_8bce10f2-c29b-418e-939d-25dafa12073f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtMy0xLTEtMTM0MTk_6ada445d-8c4c-4214-a280-695ad85a4cde">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtNC0xLTEtMTM0MTk_e5180391-592e-4f3a-a33f-f11ff5c6ff9b">405,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzYwNDczMTM5NTc5NDc_fcfbeee7-bc59-421c-a412-dad1419d6d84" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of the Company&#8217;s available-for-sale investments on the Condensed Consolidated Balance Sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8495e49fee3844bab82f503ea301cd51_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTo5NzQwODk0Zjk2Zjg0ZDFjOGJjNmI3MzFkNmMyMTRkNy90YWJsZXJhbmdlOjk3NDA4OTRmOTZmODRkMWM4YmM2YjczMWQ2YzIxNGQ3XzEtMS0xLTEtMjIwMw_1d78a610-281e-476a-ace9-e2675ba17841">221,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2a77b480e946b1a98b623504da657e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTo5NzQwODk0Zjk2Zjg0ZDFjOGJjNmI3MzFkNmMyMTRkNy90YWJsZXJhbmdlOjk3NDA4OTRmOTZmODRkMWM4YmM2YjczMWQ2YzIxNGQ3XzItMS0xLTEtMjIwMw_06612074-7deb-44b8-8cd0-721f4f85b96f">184,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTo5NzQwODk0Zjk2Zjg0ZDFjOGJjNmI3MzFkNmMyMTRkNy90YWJsZXJhbmdlOjk3NDA4OTRmOTZmODRkMWM4YmM2YjczMWQ2YzIxNGQ3XzQtMS0xLTEtMTM0MjU_f7d2d5ff-dfa6-4f6a-ba3a-1a7349efc134">405,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i889984e9822341f39be83ac75e0b30b7" continuedAt="i49cbc15b189a4eb185df6a215e398b37">As of September&#160;30, 2021, all of the Company&#8217;s available-for-sale investments mature in one year or less. </ix:continuation></span></div><div><span><br/></span></div><div><ix:continuation id="i49cbc15b189a4eb185df6a215e398b37" continuedAt="i0127f974e7a54c80baa0da020f18656e"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company held a total of <ix:nonFraction unitRef="position" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzY1OTcwNjk3Njg4MjU_96cdb105-20ee-4577-b2a1-fb8daefdc69f">16</ix:nonFraction> positions, which were in an unrealized loss position as of September&#160;30, 2021. The unrealized losses were primarily due to changes in interest rates. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">here were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> significant unrealized losses as of September&#160;30, 2021. </span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i0127f974e7a54c80baa0da020f18656e">Realized gains and losses on the Company&#8217;s investments were insignificant during the three and nine months ended September 30, 2021. <ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzY1OTcwNjk3Njg4NTE_7f26e297-38f3-46e4-969d-3a9b06135d46"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzY1OTcwNjk3Njg4NTE_b67543ca-0d6b-4dbf-88f2-9868db4af48d">No</ix:nonFraction></ix:nonFraction> impairments were recorded during the three and nine months ended September 30, 2021. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Condensed Consolidated Statements of Income.</ix:continuation> </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_43"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMTA1Ng_371135cf-74f1-422a-b323-ac0351c3af94" continuedAt="ice65d9a1e4084d3cac35af2eb8e11745" escape="true">Goodwill and Intangible Assets </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ice65d9a1e4084d3cac35af2eb8e11745"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of goodwill was $<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfOTI_8bdace92-881e-4651-be13-41becf30f22a">801</ix:nonFraction> thousand as of September&#160;30, 2021. There were <ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjA0NzMxMzk1NjE1Mw_24b3d6ed-d9b7-4bdf-bf2c-caa303e27292"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillPeriodIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjA0NzMxMzk1NjE1Mw_b99e673f-ca3d-4b8f-864d-58fd3298643f">no</ix:nonFraction></ix:nonFraction> changes to the carrying amount of goodwill during the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2020, the goodwill addition related to the purchase of Vium (see Note 3, &#8220;Acquisitions&#8221; for additional details on the acquisition). <ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_5e5378a7-7eb2-412b-a3bb-10e48ad13dc8"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_af02938e-1f78-4977-9cd5-150370653c30"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_de5df63c-bd7c-44b5-9b10-70f5f72ad4a0"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_f9103484-92fc-4bd9-b099-0913cab48198">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> goodwill impairment was recorded during the three and nine months ended September 30, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMTA1OQ_3e6f96f5-758d-4812-a278-9284d676ffb8" continuedAt="ia60ebd94386d47129836ff00eb3770b2" escape="true"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMTA1OQ_5d1c2801-c4d6-4abe-8808-209b26cba0f6" continuedAt="i90d3610eed2f4ac5ab0200e46e8e6e07" escape="true">The following table summarizes intangible assets:</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="ia60ebd94386d47129836ff00eb3770b2"><ix:continuation id="i90d3610eed2f4ac5ab0200e46e8e6e07"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi0xLTEtMS0w_57934f42-bede-421e-852f-cc716c88b742">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi0yLTEtMS0w_843edcff-e11c-46ba-ad4c-62199272fdbe">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi0zLTEtMS0w_2cd1ba8d-aa8b-43da-819a-03c523e94e3a">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi01LTEtMS0w_db08ba1f-cd78-4cd0-a18d-10dabf027f9a">911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi02LTEtMS0w_bab28fa2-ba36-413e-94f6-aefbc3a9bc19">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi03LTEtMS0w_a645dbe1-8d8b-4a9a-801a-f83bdfbcac40">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible asset </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy0xLTEtMS0w_543797b0-176e-4fb5-aea4-503b726d2df9">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy0zLTEtMS0w_485df7d4-b1e3-428c-a4f2-24042ae2cdaf">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy01LTEtMS0w_644a38ae-1a4e-4c4d-9bba-cf8760eb132d">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy03LTEtMS0w_20c5667a-243e-41b1-bafe-f1bdccf28683">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC0xLTEtMS0w_5ed7894e-d847-42bc-a162-6051b825e494">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC0yLTEtMS0w_da622b89-f88c-46ea-a905-67f71a36b281">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC0zLTEtMS0w_f45dcab4-6d01-4b21-be15-e0e039fa677b">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC01LTEtMS0w_be8b4165-fda6-4b5f-972d-a2b876817a0a">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC02LTEtMS0w_f97f0b4c-5ecf-4892-944a-c981ac17c4e3">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC03LTEtMS0w_f17b5c81-c40c-4db8-8722-e647890a925d">1,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNDM2_e32a1e9a-ee96-4a4e-8ba5-3c5f291678b8">76</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNDQz_e2937e53-772f-4c9b-b946-d624d5d647cf">228</ix:nonFraction> thousand during the three and nine months ended September 30, 2021, respectively. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjU5NzA2OTc2NzkzMA_46a27453-aca9-47fe-82bc-81f449a95219"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjU5NzA2OTc2NzkzMA_dab6ebf8-9b43-4880-90db-126d67fcf836">51</ix:nonFraction></ix:nonFraction> thousand during the three and nine months ended September 30, 2020. Amortization expense was included in research and development in the Condensed Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The indefinite-lived intangible asset represents the Recursion domain name that the Company purchased. <ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfOTYw_9b187234-97fe-4be3-b960-0d5d07b0b345"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfOTYw_d29c8d13-5a4a-4ed2-bf9b-02d9abba42a7">No</ix:nonFraction></ix:nonFraction> indefinite-lived intangible asset impairment charges were recorded during the three and nine months ended September 30, 2021. There were <ix:nonFraction unitRef="usd" contextRef="i3f381af37b384806826160a459ac1a6a_I20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjA0NzMxMzk1NTM4OA_95b3c04e-e793-4cef-801e-8781280a10b8">no</ix:nonFraction> indefinite-lived intangible assets on the Condensed Consolidated Balance Sheet as of September&#160;30, 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDcyMA_6c439e33-8450-45ef-8949-07ffe2d40c1f" continuedAt="ia1af1461b8844a138ce3e5bfba0d0b3a" escape="true">Notes Payable </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia1af1461b8844a138ce3e5bfba0d0b3a" continuedAt="ia7bc41aa6b8440d685b9f1c7f27f428d"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Midcap Financial </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a new Credit and Security Agreement with Midcap Financial Trust (Midcap) and the other lenders party thereto (the Midcap loan agreement). The Midcap loan agreement provided for a term loan facility that included&#160;an initial tranche of $<ix:nonFraction unitRef="usd" contextRef="id524b0a380484a13b1423d25efdc9ce6_I20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzE4_6296bcb0-d6b1-443d-b95c-7b9afe30add6">11.9</ix:nonFraction> million. The Company used $<ix:nonFraction unitRef="usd" contextRef="i17e592cb3484481d8f3bdf27f4b46fb5_D20190901-20190930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDQ0_f2cd659b-7442-458b-9bf4-18a9f82ea5c7">11.2</ix:nonFraction> million of the proceeds from the initial tranche to fully repay a previously outstanding term loan with Pacific Western Bank (Pacific). In July 2021, the Company paid the balance due under the Midcap loan agreement. The total amount paid was $<ix:nonFraction unitRef="usd" contextRef="i61c469b1d47e4489abb014373df5e6a8_D20210701-20210731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MjM5Ng_d0509485-fc8a-46fe-8b3a-374f332e7977">12.7</ix:nonFraction> million. The Company recorded an early extinguishment loss of $<ix:nonFraction unitRef="usd" contextRef="i61c469b1d47e4489abb014373df5e6a8_D20210701-20210731" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3NDc3NQ_dbe8df62-2ecc-4331-91bc-ec7261c07a1f">996</ix:nonFraction> thousand, which was included in &#8220;Other expense, net&#8221; on the Condensed Consolidated Statements of Operations. As of December&#160;31, 2020, the outstanding principal balance under the Midcap loan agreement was $<ix:nonFraction unitRef="usd" contextRef="i712dde3d59e94dbba069d3ea10c0fb15_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNzM1_c2e56adc-9e36-4b0d-b036-06ed71185362">11.9</ix:nonFraction> million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company paid fees of approximately $<ix:nonFraction unitRef="usd" contextRef="ice8000a9bf874bc2a077c5140c2c981d_D20190101-20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMjU5Mg_c33fc4ec-a8f6-4633-b6ff-78d927dbba22">298</ix:nonFraction> thousand in connection with the origination of the Midcap Loan Agreement. These fees were deferred and recorded as a direct deduction from the carrying value of the loan payable and were amortized to interest expense over the expected remaining term of the agreement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ia7bc41aa6b8440d685b9f1c7f27f428d"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pacific Western </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, Pacific issued a standby letter of credit of $<ix:nonFraction unitRef="usd" contextRef="ibc2eb416e12e4f8a8c617e89412832c8_I20180531" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMjkyMg_6c4200da-f587-47a2-b5d5-4ea7f02cb30a">3.8</ix:nonFraction> million for the benefit of the Company&#8217;s landlord, securing certain Company obligations relating to tenant improvements. This letter of credit was transferred to J.P. Morgan during the nine months ended September 30, 2021. See Note 15, &#8220;Fair Value Measurements&#8221; for additional details. As of December&#160;31, 2020, the outstanding letter of credit was $<ix:nonFraction unitRef="usd" contextRef="i38cdee8154a14b54b5c1a723df0dbb8b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzIyNg_730edf27-e558-4548-b8be-19543e028acf">3.8</ix:nonFraction> million, for which the Company held $<ix:nonFraction unitRef="usd" contextRef="i38cdee8154a14b54b5c1a723df0dbb8b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzI1Nw_dc246607-d647-43f2-af1e-51549f745b84">4.0</ix:nonFraction> million of restricted cash as collateral.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April of 2020, the Company issued convertible promissory notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i2921e91a9279497f81a20c55ba343d96_I20200430" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTUzNA_d79ac09b-7f30-43fc-ae68-2a1360b1331b"><ix:nonFraction unitRef="usd" contextRef="i1d0e548c03ea4dd7b12d2c5350a4d3a3_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTUzNA_ed7557dd-43a6-4019-98ca-3d9d00d8a291">6.4</ix:nonFraction></ix:nonFraction> million. Under certain conditions, the principal was convertible into an amount of equity with a fair value that exceeded the amount of the notes&#8217; principal on the conversion date. This feature of the notes was accounted for separately at fair value as a derivative liability. These notes converted to <ix:nonFraction unitRef="shares" contextRef="i691d5ffc27f14a19a75ef556811825c4_D20200901-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTY2MQ_40422235-3213-4566-bff9-45fc83a52be8">1,203,231</ix:nonFraction> shares of Series D Preferred Stock in September 2020. Upon conversion of the notes, the Company recorded the $<ix:nonFraction unitRef="usd" contextRef="i4c1a2671a54b4d92ac1029a3f54a040c_D20200901-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNzE0NjgyNTU4ODkxMQ_481de8ac-ffbc-4bb2-b214-4279dbb8383b">1.6</ix:nonFraction> million fair value of the derivative liability as equity on the Condensed Consolidated Balance Sheet. Changes in the fair value of the derivative were recorded in &#8220;Other loss, net&#8221; in the Condensed Consolidated Statements of Operations and were $<ix:nonFraction unitRef="usd" contextRef="i50773bc073fb4acea17c712bc1126a6b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzg1MA_9e0621af-128c-49b6-8046-629a1d9a2110">161</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="id3ccad45b4c84988b490de168ac87d85_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTg0NA_bbaae9c3-9cdb-4017-af40-eff870281bfb">484</ix:nonFraction> thousand during the three and nine months ended September 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Notes Payable for Tenant Improvement Allowance </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="ie16333b91755459cbc141c348c781d1e_D20180101-20181231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDE4MQ_bae1e94a-3a2c-4e2a-b60a-2e8f18163a3f">992</ix:nonFraction> thousand, which was available as part of the Station 41 lease from its landlord for use on tenant improvements (see Note 8, &#8220;Commitments and Contingencies&#8221; for additional details). Under the terms of the lease, the note will be repaid over a <ix:nonNumeric contextRef="ie16333b91755459cbc141c348c781d1e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDQxOA_8daf122a-8659-4899-b15e-8ffa3cf468c0">10</ix:nonNumeric>-year period at an <ix:nonFraction unitRef="number" contextRef="i6b6e8d11e94a4bc8a66fa0b30b88119e_I20181231" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDQzOQ_6b00266e-713b-4492-91a2-6b7c29ea0b99">8</ix:nonFraction>% interest rate.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDcyMQ_7ec897ad-1496-4d23-933b-fcdf2851fbff" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable consisted of the following: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:67.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMi0xLTEtMS0w_3c0aecbb-a47a-4c4f-8c1f-d5fd5869e0ee">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMi0yLTEtMS0w_cc6805a5-3c13-4542-8877-61f2bf35d428">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMy0xLTEtMS0w_e5ee7e31-e9d5-4e19-b618-c9728fa35356">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMy0yLTEtMS0w_d07e3c33-c53d-4287-a5ff-a6f08da3d0db">11,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNC0xLTEtMS0w_9e0ef981-2c93-4ffb-a28c-fe6fdacdafd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNC0yLTEtMS0w_8755044a-5f1b-4066-858d-7b45141eb3a7">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNS0xLTEtMS0w_376790e6-96d2-4248-9267-8b7e523773b1">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNS0yLTEtMS0w_901216fe-3582-4301-bf23-d87e419be1b3">12,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDcyMg_d9a4447c-44f9-4079-8aef-930f06cc32fe" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding the Company&#8217;s debt principal repayment obligations as of September&#160;30, 2021: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfMS0xLTEtMS0w_14bdf124-4ef1-4cbf-adc7-9c9d8a54afa9">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfMi0xLTEtMS0w_e148cecc-adc5-416c-9c66-a0b227119685">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfMy0xLTEtMS0w_99b6ccfc-21a9-465a-a3f1-76db78bb416a">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNC0xLTEtMS0w_bb4619e2-7917-48c6-9ff2-24720d5b2222">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNS0xLTEtMS0w_5ff295fc-5433-4ec0-962d-a1d615c367ff">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="rxrx:LongTermDebtMaturityAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNi0xLTEtMS0w_918ae752-8987-46e4-bf6a-9952a2c0e86a">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNy0xLTEtMS0w_239f85da-62ac-428d-9523-6d48676b794a">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_49"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTM5MQ_7ff638fc-e031-4005-b075-8bc3381e62bc" continuedAt="if0a7f0113d33435284904fc61613040a" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if0a7f0113d33435284904fc61613040a" continuedAt="i077e648607b14da78bd41b8c466a2d92"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various long-term real estate leases primarily related to office, research and development (R&amp;D) and operating activities. For the three and nine months ended September 30, 2021, total rent </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i077e648607b14da78bd41b8c466a2d92" continuedAt="i14d6b48d760548328fc60cbac7a5f72a"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense was $<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjYy_aaa76984-4e8d-4b09-8519-9514785e3e31">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjY5_243121be-4b47-4543-b6c8-90d979238f2d">4.4</ix:nonFraction> million, respectively. For the three and nine months ended September 30, 2020, total rent expense was $<ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMzMy_1164baee-7c20-43d8-8153-a521a1b1a654">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMzM5_95c874fb-6b01-4639-a910-f5a347f866a5">3.2</ix:nonFraction> million, respectively. The leases described below are classified as operating leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Komas Lease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company entered into a new facilities lease, with the right of use and payments beginning in January 2017. The term of the lease is <ix:nonNumeric contextRef="i91f13a3891e14799978936761e6b66eb_I20160831" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTk4_f2f31a94-4430-41b9-a647-c9d835b0f88d">7</ix:nonNumeric> years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. This lease included an allowance for tenant improvements. Tenant improvements were recorded as property and equipment and are being depreciated over the term of the lease. In conjunction with the allowance for tenant improvements, the Company recorded a lease incentive obligation of $<ix:nonFraction unitRef="usd" contextRef="i91f13a3891e14799978936761e6b66eb_I20160831" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncentiveFromLessor" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTAyNw_6ef845fa-98c5-42bc-965a-c9b50f95fa15">847</ix:nonFraction> thousand which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $<ix:nonFraction unitRef="usd" contextRef="i97ab0048367c48bcbdd713b807fbd5e6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncentivePayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTE3OQ_71a29ce8-9842-4b63-ab82-fc8bf619d320">282</ix:nonFraction> thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Station 41 Lease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a new facilities lease, with the right of use beginning in December 2017 and payments beginning in June 2018. The term of the lease is <ix:nonNumeric contextRef="if53c3048ea9f49fdada4b25a94aa8898_I20170831" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTM1Mg_245957d1-f073-4975-9cc7-f652b1d7d3da">10</ix:nonNumeric> years, with <ix:nonFraction unitRef="extensionperiod" contextRef="ie9dfd0688b804a938bbb48c0edbe5056_D20170801-20170831" decimals="0" format="ixt-sec:numwordsen" name="rxrx:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTM2MQ_ebcdc7c6-4d9b-4507-b77b-183f568f5e13">one</ix:nonFraction> <ix:nonNumeric contextRef="if53c3048ea9f49fdada4b25a94aa8898_I20170831" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTM5Mw_301c643b-8df1-4919-b077-5bba9f752516">five-year</ix:nonNumeric> renewal option. This lease includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. This lease included an allowance for tenant improvements of $<ix:nonFraction unitRef="usd" contextRef="i532e90ec1ce24d4395f470300c0303ad_I20171231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncentiveFromLessor" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTYwNQ_8a0b9b87-1902-4bc1-97c7-b2e9521f47e5">4.0</ix:nonFraction>&#160;million, the full amount of which was drawn in 2017. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. The Company recorded a leasehold obligation for tenant improvements, which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $<ix:nonFraction unitRef="usd" contextRef="i570b1109d5a14f2cbffa015a78fae6ae_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncentivePayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjAyOA_c0c919e5-211f-4774-a1c5-6a5590cf3065">2.5</ix:nonFraction> million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company elected to draw an additional tenant improvement loan of $<ix:nonFraction unitRef="usd" contextRef="ie16333b91755459cbc141c348c781d1e_D20180101-20181231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjExMA_bae1e94a-3a2c-4e2a-b60a-2e8f18163a3f">992</ix:nonFraction>&#160;thousand available under the Station 41 lease. This loan is incorporated into and acts to increase the base rent over the remaining life of the lease. The increase in rent includes a charge for interest, which accrues on the principal amount outstanding at a rate equal to <ix:nonFraction unitRef="number" contextRef="i6b6e8d11e94a4bc8a66fa0b30b88119e_I20181231" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjM3Nw_6b00266e-713b-4492-91a2-6b7c29ea0b99">8</ix:nonFraction>%. The Company accounts for this additional tenant improvement loan as a note payable on the Condensed Consolidated Balance Sheets with the current portion included in the Current Portion of Notes Payable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company amended the Station 41 lease to include additional space in the conjoining unit with the right to use the new space beginning in June 2020 for an additional <ix:nonNumeric contextRef="ib7019fd2b10448cf9b45ac7687f8df45_I20191231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjc1NQ_960fbf5a-4a33-4069-b680-ec0388c812cf">seven years</ix:nonNumeric>. This amendment for the extra space includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Milpitas Lease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a new facilities lease, with the right of use and payments beginning in August 2019. The term of the lease is <ix:nonNumeric contextRef="ifff20fde529149e6b553db40f2b4c2c5_I20190831" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMzM4Mw_45f4f86a-4773-4945-8cb6-106895827f66">9</ix:nonNumeric> years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Station 56 Lease</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a new facilities lease with <ix:nonFraction unitRef="sqft" contextRef="ia41f6975e5dd422096f973c5f9c36e59_D20210101-20210131" decimals="0" format="ixt:num-dot-decimal" name="rxrx:LesseeOperatingLeaseSizeOfLeasedAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjA0NzMxMzk1OTg3NQ_24601ba7-d1c4-4df7-a121-8b1987c461f0">91,478</ix:nonFraction> square feet adjacent to the Station 41 lease. The right of use began in August 2021 and the term of the lease is approximately <ix:nonNumeric contextRef="i21570e1162e44757bb2fe76c1778ed38_I20210131" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjA0NzMxMzk1OTg0OQ_2aae3017-edf5-4e70-bdb3-c5ad9c1711a9">11</ix:nonNumeric> years with a <ix:nonNumeric contextRef="i54a01ea1f999425489bb8e0b81240782_I20210131" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjA0NzMxMzk1OTg2Ng_eed6e627-8277-4baf-a2d7-1d850bf2404e">five-year</ix:nonNumeric> renewal option. The lease includes provisions for escalating rent payments, with total minimum payments of $<ix:nonFraction unitRef="usd" contextRef="i21570e1162e44757bb2fe76c1778ed38_I20210131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTA5OTUxMTYzMzYzOA_5e80dfbb-ad6d-4f68-9353-1dd68737866f">32.0</ix:nonFraction> million. Rent expense is recognized straight-line over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease includes a tenant improvement allowance of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i21570e1162e44757bb2fe76c1778ed38_I20210131" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:LesseeOperatingLeaseTenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjU5NzA2OTc3NDQ4Mg_33748d29-1304-42df-a38c-bf19a9cc8daa">10.1</ix:nonFraction> million. As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i44bce2b5c9264b77a056d1235fca4c45_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncentiveFromLessor" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjU5NzA2OTc3Mzc4OA_b707bbf3-e727-4007-86c3-be35a28b47af">2.2</ix:nonFraction> million of the tenant improvement allowance has been utilized. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. The Company recorded a leasehold obligation for the tenant improvements, which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $<ix:nonFraction unitRef="usd" contextRef="i44bce2b5c9264b77a056d1235fca4c45_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncentivePayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjU5NzA2OTc3NDQ5MA_c8cc79c1-a569-4fc5-a2bf-3de941654958">2.1</ix:nonFraction> million.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i14d6b48d760548328fc60cbac7a5f72a" continuedAt="i6a0893289afd4f088fb289ae2ae95420"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Future Minimum Lease Payments</span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTM5NQ_9178bbc6-6c58-456f-b17b-b5b2f4a7ab73" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum commitments as of September&#160;30, 2021 under the Company&#8217;s lease agreements are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfMS0xLTEtMS0w_af33609c-9de6-434d-9c14-47d730d10b31">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfMi0xLTEtMS0w_3d8c8812-883d-4292-af83-8acb53e86de8">3,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfMy0xLTEtMS0w_4187d10d-7c80-4405-bf45-2aedb9e5ed86">7,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNC0xLTEtMS0w_c175efd6-e824-4cce-9833-049d73365c7d">7,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNS0xLTEtMS0w_fbe23264-7946-480d-9fdf-eaf1a61c0910">7,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNi0xLTEtMS0w_bc553583-563e-433d-aefb-f42a723207d9">34,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Minimum Payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNy0xLTEtMS0w_f5b78c46-f1b9-4eb3-8604-445401f5db38">61,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Obligations</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors&#160;for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#8217;s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company&#8217;s exposure and enable it to recover a portion of any amounts it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of September&#160;30, 2021 and December&#160;31, 2020, as no amounts in excess of insurance coverage are probable or estimable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Agreements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a0893289afd4f088fb289ae2ae95420">The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#8217;s future financial position, results of operations or cash flows.</ix:continuation>  </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_52"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="rxrx:TemporaryEquityTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMTE1Mg_1924cf5b-1fe4-4845-b6ad-2b8a2d520af1" continuedAt="i34a597eadeb74095bcc32098ad348f4f" escape="true">Convertible Preferred Stock </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i34a597eadeb74095bcc32098ad348f4f" continuedAt="i586dcff8b352465dada6ca4277601aa1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has issued preferred stock as part of various financing events. In April 2021, all outstanding shares of convertible preferred stock converted into <ix:nonFraction unitRef="shares" contextRef="i6b8e1278f8d04c5bb2a24c4705c97839_D20210401-20210430" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMTk1_df104106-8ac6-4463-88e7-8480d868b00d">115,598,018</ix:nonFraction> shares of Class A common stock as part of the IPO (see Note 10, &#8220;Common Stock&#8221; for additional details on the IPO). There was <ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMzIy_3f774fc4-2b4b-41af-a4a4-2c8393f7e37d">no</ix:nonFraction> convertible preferred stock outstanding as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No convertible preferred stock was issued during the three and nine months ended September 30, 2021. The Company issued <ix:nonFraction unitRef="shares" contextRef="i254f679cd4904fd2ae4f87879e686402_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMxMw_33e8247f-bcd1-44d5-8c67-a9a94d676621"><ix:nonFraction unitRef="shares" contextRef="iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMxMw_eee16585-7cdd-444b-ae07-febea8fe928a">35,349,630</ix:nonFraction></ix:nonFraction> shares of Series D convertible preferred stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i254f679cd4904fd2ae4f87879e686402_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMwMA_1df1e336-9a03-4568-9c1d-37eca6432357"><ix:nonFraction unitRef="usd" contextRef="iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMwMA_876673aa-ed47-4354-ab99-b88bffc2b20e">235.2</ix:nonFraction></ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usdPerShare" contextRef="iea9aa8f9e434498bb2d91529de11b85c_I20200930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODM5Ng_031c87c6-65cd-4760-898c-6c435f1ed01c">6.70</ix:nonFraction> per purchased share and $<ix:nonFraction unitRef="usdPerShare" contextRef="iea9aa8f9e434498bb2d91529de11b85c_I20200930" decimals="2" name="rxrx:SaleOfStockConvertedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODQwOA_50a372cc-7995-4111-be79-6dfc708d7740">5.37</ix:nonFraction> per converted share) during the three and nine months ended September 30, 2020. As part of the Series D issuance, outstanding convertible notes were converted into Series D shares. As of September&#160;30, 2020, there were no cumulative dividends owed or in arrears on the preferred stock.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i586dcff8b352465dada6ca4277601aa1" continuedAt="i6635c533e9964c62a01dc057c82f2fa5"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMTE1Mw_755fbaef-9fc5-4c7e-9935-ca0c85a04a09" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible preferred stock consisted of the following as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands except share data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferences </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Issuable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Upon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0xLTEtMS0w_8ada96db-b9c2-4533-8b39-1a56ea64227b">30,078,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0yLTEtMS0w_38c37cd7-0fcb-4ba3-b251-2b4ff2c931d1"><ix:nonFraction unitRef="shares" contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0yLTEtMS0w_48430d39-6791-4c87-802b-e0880f0bd749">29,965,754</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0zLTEtMS0w_f996029e-6bfd-4d2d-ae36-664f3dd3d74a">21,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi00LTEtMS0w_839705ca-88e5-41c8-879d-894447da1426">21,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi01LTEtMS0w_b4b5cb5b-d1b2-40de-bd98-9b06fac1e3f7">29,965,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0xLTEtMS0w_ba5e9f2e-0da3-4df8-9561-5b247735d991">4,975,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0yLTEtMS0w_17a03e20-b1d7-4594-902f-acb2362a028b"><ix:nonFraction unitRef="shares" contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0yLTEtMS0w_d7c1d9bf-aa80-4d0b-aa8b-cef98417ad96">4,975,520</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0zLTEtMS0w_eb68d182-5da8-40cc-a11d-d3d2333e871e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy00LTEtMS0w_80a8cf3f-8e00-4d93-88d8-6cf4b2b3dabc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy01LTEtMS0w_ede275a5-2fc0-455f-b709-06560314dccb">4,975,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54664e6f89084434b268927edece521c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0xLTEtMS0w_cbf7c929-0744-4a5c-b4a3-feb2fbbd507b">21,497,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54664e6f89084434b268927edece521c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0yLTEtMS0w_53f43264-b1bb-41dd-95c0-55215646131b"><ix:nonFraction unitRef="shares" contextRef="i54664e6f89084434b268927edece521c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0yLTEtMS0w_7e7131fa-e22a-47f0-8e92-08ff0cead99c">21,471,898</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54664e6f89084434b268927edece521c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0zLTEtMS0w_5ec1f2a2-9313-45b3-8eba-76157572eb5d">59,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54664e6f89084434b268927edece521c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC00LTEtMS0w_d8818324-9d7b-45aa-bf28-6c5a000948d7">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54664e6f89084434b268927edece521c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC01LTEtMS0w_b1664213-942a-44e5-a8a9-ff6c0be3f742">21,471,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0xLTEtMS0w_7e501915-df5a-4b5e-b2a4-4f0bb74315af">18,956,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0yLTEtMS0w_57ed85a0-bad5-4c1f-9880-f7b4784f56c4"><ix:nonFraction unitRef="shares" contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0yLTEtMS0w_f122307e-0d49-414c-8a39-6a150abf0c1f">18,776,345</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0zLTEtMS0w_ea0f1f61-9c5a-4920-a74f-8cbb8df2ad0e">119,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS00LTEtMS0w_43806c8c-d704-469a-8c03-c348d2d5b81e">122,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS01LTEtMS0w_4ea806f3-9b95-48aa-b899-9dc067bb9e44">22,286,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0xLTEtMS0w_fc3e0ef7-03ab-49dc-8ef3-9e4370be21d8">45,926,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0yLTEtMS0w_064ed59a-ac45-4c49-8529-6fc1539fa10c"><ix:nonFraction unitRef="shares" contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0yLTEtMS0w_fbe45b32-dbaa-4124-80f6-69afe1c3c3ef">36,898,548</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0zLTEtMS0w_885a0097-2649-4d08-9093-10f8071b1e63">247,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi00LTEtMS0w_0b43589a-4018-4b55-9f43-02e05914f21e">247,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi01LTEtMS0w_aa44ba01-85ee-487f-9145-2ffdfe3984fa">36,898,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0xLTEtMS0w_18fdbb6d-0c00-4961-b535-fd25cd30b5c1">121,434,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0yLTEtMS0w_4ed48cb6-df98-4e6e-bf5a-73cd174f5d81"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0yLTEtMS0w_cfad05b6-d456-4ccb-ba45-cd413ef9f3b1">112,088,065</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0zLTEtMS0w_179ab814-4919-4fea-bc33-fd446c1f7a60">448,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy00LTEtMS0w_34efdc31-d8af-4647-b969-93617504efdb">450,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy01LTEtMS0w_a1384664-bca1-4670-a6d7-8ac3825ea767">115,598,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Classification </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6635c533e9964c62a01dc057c82f2fa5">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; equity (deficit) on the Condensed Consolidated Balance Sheets because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event.</ix:continuation> </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_55"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfMjk4Mw_6be7c4a7-b931-4f24-afc7-e799da8d5cda" continuedAt="ibb781e2e38cd432e80a676453de05d4b" escape="true">Common Stock </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibb781e2e38cd432e80a676453de05d4b" continuedAt="i85f5ae5705eb4d9c80fde1cc5a7889e1"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Class A common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="rxrx:CommonStockVotePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfODY_5ba13917-0567-4e91-b921-e9354fce811c">one</ix:nonFraction> vote per share and each share of Class B common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930" decimals="INF" name="rxrx:CommonStockVotePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfMTY2_4a1f6eea-061e-4532-8d70-418abaa37ec4">10</ix:nonFraction> votes per share on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#8217;s board of directors. As of September&#160;30, 2021 and December&#160;31, 2020, no dividends had been declared. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;20, 2021, the Company closed its IPO and issued <ix:nonFraction unitRef="shares" contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNDg0_2ff370cb-51a4-4005-b94b-8a359c1613ea">27,878,787</ix:nonFraction> shares of its Class A common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ice0bed1c8a884eb9b91557f3c6c8fbc6_I20210420" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNTI4_af750a17-0d66-4976-9fa4-f0f41901244b">18.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNTYx_f2f7a961-c2aa-4488-9a5f-77eb313f64c2">462.4</ix:nonFraction> million, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjIz_cd24e8c3-c5ce-4e4e-a47d-287239d7d704">35.1</ix:nonFraction> million and other offering costs of $<ix:nonFraction unitRef="usd" contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:PaymentsOfStockIssuanceExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjU0_90d120d4-6353-4406-9083-0a509dadf74f">4.3</ix:nonFraction> million. In connection with the IPO, all shares of convertible preferred stock converted into <ix:nonFraction unitRef="shares" contextRef="i6b8e1278f8d04c5bb2a24c4705c97839_D20210401-20210430" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNzY5_df104106-8ac6-4463-88e7-8480d868b00d">115,598,018</ix:nonFraction> shares of Class A common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Split</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors approved a <ix:nonFraction unitRef="number" contextRef="i778df7726a034719acdc84318d53c893_D20210401-20210430" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfODU5_ce1353bd-ffd7-493b-9898-7f95a9ac4197">1.5</ix:nonFraction>-for-1 forward stock split of the Company&#8217;s common and convertible preferred stock. Each shareholder of record on April&#160;9, 2021 received <ix:nonFraction unitRef="number" contextRef="ida225ec4cb3e47f0b2b397b7d9fc8ea1_D20210409-20210409" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfOTg3_e882bb92-f005-485b-bfe9-9622a4660f22">1.5</ix:nonFraction> shares for each then-held share. The split proportionally increased the authorized shares and did not change the par values of the Company&#8217;s stock. The split affected all stockholders uniformly and did not affect any stockholder's ownership percentage of the Company's shares of common stock. All shares and per share amounts presented within these Condensed Consolidated Financial Statements were adjusted to reflect the forward stock split for all periods presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A and B Common Shares Authorization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company&#8217;s Board of Directors authorized two classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930" decimals="INF" name="rxrx:CommonStockVotePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfMTg0Mg_4a1f6eea-061e-4532-8d70-418abaa37ec4">10</ix:nonFraction> votes per share and is convertible at any time into one share of Class A common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Class B common stock is held by Christopher Gibson, Ph.D., our Chief Executive Officer (CEO), or his affiliate. As of September&#160;30, 2021, Dr. Gibson and his affiliate held outstanding shares of Class B common stock representing approximately <ix:nonFraction unitRef="number" contextRef="ifb46e3752d19457fb9b591d8ac77a4af_I20210930" decimals="2" name="rxrx:AffiliatedHoldersOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjU5NzA2OTc2OTY4MA_e91895eb-e7da-42e0-87d7-61b6be22455d">37</ix:nonFraction>% of the voting power of the Company&#8217;s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the equity awards held by </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85f5ae5705eb4d9c80fde1cc5a7889e1">Dr. Gibson had been fully vested and exercised and exchanged for shares of Class B common stock as of September&#160;30, 2021, Dr. Gibson and his affiliate would hold approximately <ix:nonFraction unitRef="number" contextRef="ifb46e3752d19457fb9b591d8ac77a4af_I20210930" decimals="2" name="rxrx:AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjU5NzA2OTc2OTY4Nw_f96d4266-9920-4abe-83e1-413d1737bdcc">41</ix:nonFraction>% of the voting power of the Company&#8217;s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the board of directors; the adoption of amendments to the Company&#8217;s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company&#8217;s assets, or other major corporate transaction.</ix:continuation></span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_58"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;11. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMzExNQ_66e63931-f6b2-49d8-aa55-2e716ae006f4" continuedAt="i2d320bd57c8d4886ba79c1b527974556" escape="true">Collaborative Development Contracts </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2d320bd57c8d4886ba79c1b527974556" continuedAt="i84dceddb5da6410c843cae94df320c82"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer AG</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the Company entered into a Research Collaboration and Option Agreement (the Bayer Agreement) with Bayer AG (Bayer) for a <ix:nonNumeric contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831" format="ixt-sec:durwordsen" name="rxrx:CollaborativeAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMzExNg_dab4ee17-edcd-4c9d-8bbd-6962e754f094">five-year</ix:nonNumeric> term pursuant to which the Company and Bayer may initiate approximately <ix:nonFraction unitRef="project" contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831" decimals="INF" name="rxrx:CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMzExNw_e5cd2db2-63d2-448f-ae36-8c4d2480120d">10</ix:nonFraction> research projects related to fibrosis across multiple organ systems, including the lung, liver and heart. Under the agreement, the Company contributed compounds from our proprietary library and Bayer contributed compounds from its proprietary library and will contribute scientific expertise throughout the collaboration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, the Company received a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:CollaborativeAgreementNonRefundableUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfNzEw_ce01c25f-f8d9-426d-8c59-33eabbbb6bf6">30.0</ix:nonFraction> million, which was recorded as unearned revenue on the Condensed Consolidated Balance Sheet. The Company determined that it has one performance obligation under the agreement, which is to perform research and development services for Bayer. Recursion determined the transaction price to be the $<ix:nonFraction unitRef="usd" contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:CollaborativeAgreementNonRefundableUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfOTk5_ce01c25f-f8d9-426d-8c59-33eabbbb6bf6">30.0</ix:nonFraction> million upfront payment received and allocated the amount to the single performance obligation. The Company is recognizing the revenue over time using a cost-based input method, based on labor costs incurred to perform the research and development services. This method of recognizing revenue requires the Company to make estimates of the total costs to provide the services required under the performance obligation. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September 30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i579b43fe01ce4c56a9134274deed89c9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTU5NA_c9f564b5-09f3-4dd6-986f-18bcb69d221d">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i87ec7c8bf2994d2e9b1fab9c0703332a_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTYwMQ_1cdb9a61-b208-481b-ae02-93daed40eb53">7.5</ix:nonFraction> million, respectively, of revenue resulting from the collaboration. There was $<ix:nonFraction unitRef="usd" contextRef="i236ba6571e724a009ebcfe23594fc46f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTY3NA_38a68075-be77-4c4c-8991-89ce61345abc">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i236ba6571e724a009ebcfe23594fc46f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTY4MQ_30f23f33-0733-45b0-8489-f19b0ab5c846">9.2</ix:nonFraction> million of current and non-current unearned revenue, respectively, remaining as of September&#160;30, 2021. The allocation of unearned revenue between current and non-current is based on Recursion&#8217;s estimates of when the Company expects to incur the related costs. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i84dceddb5da6410c843cae94df320c82">Under each research project, the Company will work with Bayer to identify potential candidates for development. Under the agreement, Bayer has the first option for licenses to potential candidates. Each such license could potentially result in option exercise fees and development and commercial milestone payments payable to the Company, with an aggregate value of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMjMwOA_915d42a7-b6ab-4de4-9c14-df07c8a3610e">100.0</ix:nonFraction> million (for an option on a lead series) or up to approximately $<ix:nonFraction unitRef="usd" contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMjM2Nw_44aa38cc-26f7-40b0-b86c-827db41c279d">120.0</ix:nonFraction> million (for an option on a development candidate), as well as tiered royalties for each such license, ranging from low- to mid-single digit percentages of sales, depending on commercial success.</ix:continuation> </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_61"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4NQ_421b01df-d05b-491e-8712-3779edcb0bda" continuedAt="ie8788297312f4f61a5cd91718d2608a3" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie8788297312f4f61a5cd91718d2608a3" continuedAt="i42e4ff78777e49c9878edb3433607fcc"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). Under the 2021 Plan, <ix:nonFraction unitRef="shares" contextRef="i911deb0a783d45d48883d1a7b215ba7f_I20210430" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3NzcxOA_a7c329eb-f531-417c-8fc7-cb05634300ad">16,186,000</ix:nonFraction> shares of Class A common stock were reserved. Additionally, shares were reserved for all outstanding awards under the previous 2016 Plan. The Company may grant stock options, restricted stock units (RSUs), stock appreciation rights, restricted stock awards and other forms of stock-based compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="ic110f6aa94f44a0ea151f7f1d1355795_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3ODAxMQ_0c7096e7-67ec-42b7-b7a5-5c939c40e11d">15,580,505</ix:nonFraction> shares of Class A common stock were available for grant.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4MQ_03788d12-b6f8-472b-ab25-460a86cc9dcc" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for stock options and RSUs for employees and non-employees within the Condensed Consolidated Statements of Operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac5bbd776f34c14905561c10878b1d4_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi0xLTEtMS0w_bfd68ee1-d2f1-436f-9833-9c5190e709d1">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6eea4fe55d0492db79350755e48b8b9_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi0yLTEtMS0w_f2d0dfd1-4636-4604-827c-e9c0eda81113">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005b6369f9a04da2b37d8abb0937ccd6_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi00LTEtMS0w_1b277f53-32a9-4df4-b3f9-0d43348ea892">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c86ed481ac0466f814feccb1b0dfc44_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi01LTEtMS0w_4a27218e-d924-4ff2-bc08-c419e3b61d6c">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac787d8519de4fb7b4312d4d537327cd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy0xLTEtMS0w_d47e15e5-41e1-4ed4-8c7e-c02f8b2c2799">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8946372da4bb412ebce1e7fbd111ba10_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy0yLTEtMS0w_4b71e37e-b993-4e5d-b82b-41be8307e450">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe55087b940747989ca8778b35a30ba2_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy00LTEtMS0w_dc8da729-78ac-4c24-93e9-33d18f878a6a">6,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a0aa783282d499eabe30b6edf7958f4_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy01LTEtMS0w_06e8a5fc-8a87-465b-9ce9-d57c6eea9ba8">1,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC0xLTEtMS0w_cc9eec55-57e9-4d67-8740-7389c7c37ac8">3,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC0yLTEtMS0w_24b75245-d5d5-4aa4-8e1b-63889ecaf53c">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC00LTEtMS0w_da1c630f-398d-477c-8ba1-3381080e3902">9,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC01LTEtMS0w_109fd1a3-2d53-40b5-955a-0e67b0999702">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i42e4ff78777e49c9878edb3433607fcc" continuedAt="i86a33b1d1ace442db293644b6317f34c"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options generally vest over <ix:nonNumeric contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTUxNQ_ac406a21-3205-4bfd-9c02-1e0c120b76c6">four years</ix:nonNumeric> and expire no later than <ix:nonNumeric contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTU0Mw_daa25a2e-7dca-4043-b9a1-4b7cec81ebfc">10</ix:nonNumeric> years from the date of grant. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4OA_2c14f085-f0dc-4a7b-af42-d94943b78a99" continuedAt="i89998f0d973942e6945374a4b57589d5" escape="true">Stock option activity during the nine months ended September 30, 2021 was as follows: </ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i89998f0d973942e6945374a4b57589d5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands except share data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining&#160;Contractual Life (In Years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS0xLTEtMS0w_f39d5c35-3ae6-414d-bf54-c743386dfa4c">20,937,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS0yLTEtMS0w_02ee372d-7f7a-4a18-aef6-0e75118c433c">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ce5ea44684646478e321a6f5da5f498_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS0zLTEtMS0w_1b5e7782-3ae1-4e82-8f42-cb4a17a73995">8.5</ix:nonNumeric></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81600d989114130b43235d442b1e71d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS00LTEtMS0w_541e3805-4768-4892-8da6-7ce00bd08f3c">12,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMi0xLTEtMS0w_880979d9-60fa-44e9-91b3-b6414dcb94ec">2,840,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMi0yLTEtMS0w_57bf05e9-e5db-4854-80ee-e3117dba7432">10.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMy0xLTEtMS0w_e0f1559e-0c41-49c2-9e46-c98a64ea1a4d">1,203,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMy0yLTEtMS0w_35fa1f72-edbc-4cf6-8e41-acf2215c2164">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNC0xLTEtMS0w_5f167a05-eabc-498b-873e-9ae6193e01e5">2,711,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNC0yLTEtMS0w_c359e781-1da4-4486-a864-a8adbb424570">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNC00LTEtMS0w_de677fbb-9da4-4fc5-93e4-c17c14b2d1a7">14,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS0xLTEtMS0w_f0aabc5b-ab2b-4e88-820b-af52c3d39e15">19,863,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS0yLTEtMS0w_f6a3f3a8-d554-4a1c-9443-6a3a994dc248">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS0zLTEtMS0w_fb00896f-52e4-4be8-99cb-1c8cfa69440b">8.2</ix:nonNumeric></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS00LTEtMS0w_fdbfd464-ae5a-4b32-8e2e-3ec89968ce2b">396,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi0xLTEtMS0w_e73a18a0-40db-4b54-80f5-4872f79abfc3">7,963,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi0yLTEtMS0w_17addf5c-b7f5-4cb9-96c2-e42e91b9e37d">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi0zLTEtMS0w_57f6f83d-4217-48c1-a314-5934034fcd2f">7.2</ix:nonNumeric></span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi00LTEtMS0w_b2f0a6c0-5c11-452c-a1e2-495996143215">169,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the nine months ended September 30, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTg0OQ_0c4f2e4d-46fe-46cc-8d42-ee9db2198937">6.41</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTg1Ng_6f2a5303-837c-4774-ade4-e9e0c1427c93">1.49</ix:nonFraction>, respectively. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ3Ng_8ad609b1-cd7e-44dc-aed4-9a2235e6fbee" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMi0xLTEtMS0w_9bcf4c65-151a-4adb-bc46-632f41c505e4">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMi0yLTEtMS0w_b2879bbf-9735-4d6e-b5f0-ce1a721b12dc">6.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMy0xLTEtMS0w_30e02373-4e58-45f6-b87a-f8e06315b70e">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMy0yLTEtMS0w_8eb1a725-fec4-4be5-b3ca-9797793cbb9e">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNC0xLTEtMS0w_ed81b8fb-9c0f-428a-936d-54b0503a8d28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNC0yLTEtMS0w_e233948d-6fb9-4005-8723-6f4c3fe65d52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNS0xLTEtMS0w_497530c9-e527-4013-8206-6d332fd114f2">0.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNS0yLTEtMS0w_94a7c2b1-8edf-44fa-b734-21dfb62aac76">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="i4381c37b0f434d1292766458d6f33a83_D20210201-20210228" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjAzOA_f3cf609a-66f4-4035-b85e-96d9dcfd1c7d">150,000</ix:nonFraction> shares of stock options with a performance and service condition that had a fair value of $<ix:nonFraction unitRef="usd" contextRef="i4381c37b0f434d1292766458d6f33a83_D20210201-20210228" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjEzMQ_4f783fd1-080a-4e81-910c-884d7ccf9d13">358</ix:nonFraction> thousand. The grant was fully expensed during the three months ended June 30, 2021 as the performance and service conditions were met.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ia5509909b8164d1392214698e190db36_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjI2Ng_7df3e76a-ff55-4664-bbb7-61be05806d45">1,500,000</ix:nonFraction> shares of stock options with performance, market and service conditions. At grant date, the Company estimated that the fair value of the options was approximately $<ix:nonFraction unitRef="usd" contextRef="ia5509909b8164d1392214698e190db36_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjQzMg_735f92c0-a679-42a7-8d47-0b11b647c605">2.0</ix:nonFraction> million. For the three and nine months ended September 30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i12720851e14f4054b18ea160b3ae9c16_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3ODgxNg_dfd4aa96-922b-4323-827f-affccf194ccb">41</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i84ca49f352744d10969d369737887491_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTA5OTUxMTYzNjY5Ng_2a291fca-015f-495d-8431-f313312bf881">1.6</ix:nonFraction> million of expense was recorded, respectively, as several of the conditions were met during the three months ended June 30, 2021. For the three and nine months ended September 30, 2020, <ix:nonFraction unitRef="usd" contextRef="iaec16661eb85408985324c4bec4ce6bc_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjU0Ng_2209eadc-1de4-4f39-95f1-1c7d9ae2f443"><ix:nonFraction unitRef="usd" contextRef="idd1b4082185f4ff8b95aa9ccc5e14905_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjU0Ng_d8820a77-6294-4233-b078-e065ec2f7de8">no</ix:nonFraction></ix:nonFraction> expense was recorded as the performance conditions were not considered probable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMzQxOQ_18b778e8-9db9-43c1-b2fb-fff373ca88c4">27.9</ix:nonFraction> million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMzU0OQ_432d0b8d-aaf4-413d-8765-46c201a9a129">three years</ix:nonNumeric>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RSUs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Recursion redesigned certain aspects of its long-term incentive program. As a result, equity awards granted to employees since the redesign generally consist of a combination of stock options and RSUs. RSUs awarded to employees pursuant to the 2021 Plan generally vest over <ix:nonNumeric contextRef="i6a0b13ec20ca48d586c285f56d52aaf7_D20210401-20210430" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4NA_90dadcd9-04fa-4088-b050-bec60d4de8b1">four years</ix:nonNumeric>. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion&#8217;s common stock on the date of grant.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4OQ_c296cdc5-9169-4ed9-abdc-ab38f1a4ebc5" continuedAt="i196de5c92d894e8eb68c2a9357bab394" escape="true">The following table summarizes Recursion&#8217;s RSU activity during the nine months ended September 30, 2021: </ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i86a33b1d1ace442db293644b6317f34c" continuedAt="ia4232289f0e849c29ae6d288cf46ed32"><div><ix:continuation id="i196de5c92d894e8eb68c2a9357bab394"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6d027f3b69840d8bbb90d7865d8a14f_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMS0xLTEtMS0w_6be04d8d-4f32-479f-8da4-ee7c688b7759">&#8212;</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6d027f3b69840d8bbb90d7865d8a14f_I20201231" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMS0yLTEtMS0w_53742752-a83c-4d6b-baa9-d0456967e3e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMi0xLTEtMS0w_17ef6dd9-6a51-4801-b09b-1958ba941510">143,723</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMi0yLTEtMS0w_2977d549-bd17-4f8f-a663-d725707f9d13">29.46</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMy0xLTEtMS0w_528605e6-d03f-4eee-9700-379b714536fe">2,528</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMy0yLTEtMS0w_6adc78e6-faa8-43e9-8814-ac829c289a42">34.82</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNC0xLTEtMS0w_cf54cab5-4ff9-4b8e-b0fc-1dd73644f9f6">673</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNC0yLTEtMS0w_4cda9564-ab6d-4606-ad45-5d44684eb5c2">29.42</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23ab811b0acb4f168c59b520becd7a72_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNS0xLTEtMS0w_0e5adb8a-96c4-4d6d-950f-1019104ea64a">140,522</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23ab811b0acb4f168c59b520becd7a72_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNS0yLTEtMS0w_564de6cf-038d-4806-a61d-16fac15c0e04">29.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i23ab811b0acb4f168c59b520becd7a72_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDEzMg_3d91e585-9cc4-4109-995c-e6ae90c67171">3.6</ix:nonFraction> million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDI1Mw_507cc34b-4e48-4ca9-a068-ecec1d426719">three years</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Share Purchase Plan (ESPP)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors and stockholders of the Company adopted the 2021 Employee Stock Purchase Plan (the 2021 ESPP). Under the 2021 ESPP, <ix:nonFraction unitRef="shares" contextRef="ibc8d774d0f354dffa104fb6ec49d31f5_I20210430" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDQ0OQ_2bb9d726-8591-4421-b0f5-ea56231900e3">3,238,000</ix:nonFraction> shares of Class A common stock were reserved. The 2021 ESPP has consecutive <ix:nonNumeric contextRef="ia59ee14c284b45dfb5c8bbaae6df4885_D20210401-20210430" format="ixt-sec:durwordsen" name="rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ3OQ_6f1f5436-d621-4762-92d6-ee0234321fde">six-month</ix:nonNumeric> offering periods. The offering periods are scheduled to start on the first trading day on or after May 20 and November 20 of each year, except the first offering period, which commenced on the Plan Effectiveness Date and will end on the first trading day on or after November 20, 2021. The second offering period will commence on the first trading day on or after November 20, 2021. The per share purchase price will be <ix:nonFraction unitRef="number" contextRef="ia59ee14c284b45dfb5c8bbaae6df4885_D20210401-20210430" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDk2MA_322d28f9-672a-4f4d-85a8-6fde20858ae0">85</ix:nonFraction>% of the lower of the fair market value on (1) the first trading day of the offering period or (2) the exercise date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP grants is measured at grant date. The fair value is determined considering the purchase discount and the fair value of the look-back feature. Black-Scholes pricing models are used to calculate the fair value of the look-back feature. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ5MA_73891a70-9800-4ca7-a202-92f21d171307" continuedAt="ibc2bbf7555814b6ea4831af406747f91" escape="true">The weighted-average assumptions used in the Black-Scholes models were as follows:</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="ibc2bbf7555814b6ea4831af406747f91"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfMi0yLTEtMS0w_849455b4-005f-4503-a29d-fc45529ad0c3">0.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfMy0yLTEtMS0w_45cb2126-649c-43a8-885e-3905e723b40e">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfNC0yLTEtMS0w_1547b7ab-1c52-47c2-9830-59cfd7095fb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfNS0yLTEtMS0w_ef7ecbe2-5a9f-403f-a565-21665f0b695f">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTQzNA_85cb3b33-d3ea-4e68-8e54-2020f43d6e0f">no</ix:nonFraction> shares were issued under the 2021 ESPP. For the three and nine months ended September 30, 2021, Recursion recognized expense of $<ix:nonFraction unitRef="usd" contextRef="i624cda05c6f442e482227cdcb651b01e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTA5OTUxMTYzNjU3Nw_2ce82efd-65bb-4e8e-ae94-799ded061bf6">233</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3OTAwMQ_e0827309-34db-41db-b00d-60ae683e5646">450</ix:nonFraction> thousand, respectively. As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i0c8780804ec9494aa5a5c9fa23f6bcc6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTU2OA_1d38948b-d784-4420-ad97-915c1bd51038">136</ix:nonFraction> thousand of unrecognized compensation cost related to the 2021 ESPP is expected to be recognized as expense over approximately the next <ix:nonNumeric contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTY5OA_41ae53f3-31fb-4692-91fc-963b2d4a5257">two months</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Pacific loan agreement (see Note&#160;7, &#8220;Notes Payable&#8221; for additional details), the Company issued to Pacific fully vested warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ibfd006ea4f4945efaeb183fc075f012d_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTg5NQ_77831024-6153-4d19-9427-545286fdd365">84,486</ix:nonFraction> shares of Series A Preferred Stock (Series A warrants) at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibfd006ea4f4945efaeb183fc075f012d_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTk2Ng_fb34bc87-4e9a-4011-948d-c9d2ceead4d6">0.71</ix:nonFraction> per share. In May 2017, the Company drew on additional borrowing capacity under the Pacific loan agreement, which required the Company to issue additional fully vested warrants for <ix:nonFraction unitRef="shares" contextRef="i209f333c943b42e79aab9462added11c_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjE1MA_879a4920-b7af-4aa3-a527-1a425e609cb1">28,161</ix:nonFraction> shares of Series A Preferred Stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i209f333c943b42e79aab9462added11c_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjIwMQ_f8bcfe21-ba84-4351-8ee2-f6a055b37b8f">0.71</ix:nonFraction> per share. These Series A warrants were exercised in April 2021. As of December&#160;31, 2020, their fair value was $<ix:nonFraction unitRef="usd" contextRef="i209f333c943b42e79aab9462added11c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:ClassOfWarrantOrRightFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjMwMA_d9827342-c431-4f17-b2ff-b9c153581b92">77</ix:nonFraction> thousand.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company drew on additional borrowing capacity under an amended agreement. This required the Company to issue fully vested warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i33aa98d15eec4725a67ba5499bcbbc29_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjQ2Mw_036e9350-df5f-4406-9f2a-6e0349eed156">25,762</ix:nonFraction> shares of Series B Preferred Stock (Series B warrants) at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i33aa98d15eec4725a67ba5499bcbbc29_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjUzNA_0f95da71-8f8e-4cba-ae92-1dd6aeb7a3db">2.79</ix:nonFraction> per share. These Series B warrants were exercised in April 2021. As of December&#160;31, 2020, their fair value was $<ix:nonFraction unitRef="usd" contextRef="i33aa98d15eec4725a67ba5499bcbbc29_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:ClassOfWarrantOrRightFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjYzMw_3c60c8c6-d300-4aec-bb4b-d432d563feef">48</ix:nonFraction> thousand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i0015342eeae14a93b10cef24c0a7eb00_D20200101-20200131" decimals="INF" format="ixt:num-dot-decimal" name="rxrx:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjY4NQ_48f7bb6e-067e-4377-93b5-f0643f4df160">180,000</ix:nonFraction> shares of Series&#160;C Preferred Stock (Series C warrants) at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic1ead2550bf14c0893a228633bcb285d_I20200131" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjc2Ng_6f321bcc-a78b-4a01-a98b-5b7756631f73">6.51</ix:nonFraction> per share as part of a services agreement. The warrants vest ratably over <ix:nonNumeric contextRef="ic1ead2550bf14c0893a228633bcb285d_I20200131" format="ixt-sec:durmonth" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjg0Mw_0183fa3a-3803-4163-9eef-36e94d9c7212">18</ix:nonNumeric> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia4232289f0e849c29ae6d288cf46ed32"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">months. The Series C warrants remained outstanding and were fully vested and exercisable as of September&#160;30, 2021. The grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2848f38457cf43dfb9f1a86a2619c3ec_I20210930" decimals="2" name="rxrx:ClassOfWarrantOrRightGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjk2NQ_1bf185c3-4c24-4df6-9c39-d19314e74351">4.10</ix:nonFraction> per share. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FASB has issued accounting guidance on the classification of freestanding warrants and other similar instruments for shares that are redeemable (either puttable or mandatorily redeemable). The guidance requires liability classification for certain warrants that are exercisable into convertible preferred stock. The initial fair values of the Series A and B warrants were recorded as debt issuance costs, which resulted in a reduction in the carrying value of the debt and subsequent accretion. The Company remeasured the Series A and B warrants on each Condensed Consolidated Balance Sheet date. The change in valuation was recorded in the Condensed Consolidated Statements of Operations in &#8220;Other loss, net.&#8221; The liability was recorded to equity upon the exercise of the Series A and B warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Series C warrants&#8217; compensation expense was recorded in general and administrative expense ratably over the requisite service period based on the award&#8217;s fair value at the date of grant. These warrants were classified as equity as they were issued to non-employees for services and the convertible preferred stock was not redeemable, except in the event of a deemed liquidation event, which was not considered probable. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4Nw_c59a6caf-3a58-4f8f-a400-cbf82e975bab" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a summary of the changes in the Company&#8217;s Series A and B warrant liability balance during the nine months ended September 30, 2021 and 2020: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd3ed16cc3a40d9b40309215a26d2d3_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfMS0xLTEtMS0w_d574dbb7-c4e5-4e5c-9ca5-ae2ee1474e5f">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in fair value of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3660f34156d445c9c45640b5093824c_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfMi0xLTEtMS0w_5cded4db-5619-4d78-8da0-a337c69c68bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb672f271cdc43bab7ca1eac36b7098e_I20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfMy0xLTEtMS0w_0e479348-5541-433a-8480-bb22032d5fa5">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7aac41dc2042ada5f77fd1aa3b0fbe_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfNS0xLTEtMS0w_fda0e392-78fb-4f94-9db5-23cecae3e9ec">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if14c65e722904f9f939058b7366b4e72_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfNi0xLTEtMS0w_b6c5335e-f7ba-44ac-b998-8093aa04fc59">2,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recorded in equity upon exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if14c65e722904f9f939058b7366b4e72_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfNy0xLTEtMS0w_4f577a1a-d682-4194-b9b1-e305b4e13291">2,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51a0fc21e8f4d418cb515efcc6a3eaf_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfOC0xLTEtMS0w_80b83a35-ad35-442e-994d-f05c990db841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_67"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfMTYwNw_c0e022d0-f2a8-45e3-b686-de36b7ac7691" continuedAt="ic48fb256ff32494998bcbe19cf5b5a81" escape="true">Income Taxes </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic48fb256ff32494998bcbe19cf5b5a81"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_8ce99c65-9c5b-4891-9930-f3ddc1b77792"><ix:nonFraction unitRef="usd" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_ae46c046-501e-4f53-8635-dcc4f132d760"><ix:nonFraction unitRef="usd" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_dbbd4429-6174-4d59-a83d-9d0e54c1f8c9"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_e7a14926-70f2-4ade-b07a-35e9c027018a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record any income tax expense during the three and nine months ended September 30, 2021 and 2020. The Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. Valuation allowances are recorded when the expected realization of the deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. Realization of the Company&#8217;s deferred tax assets are dependent upon the generation of future taxable income, the amount and timing of which are uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards (NOLs) and tax credit carry-forwards are subject to review by the Internal Revenue Service (IRS) and may become subject to annual limitations due to ownership changes that have occurred previously or that could occur in the future under Section&#160;382 of the Internal Revenue Code. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. Any limitation may result in expiration of a portion of the NOLs or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, Utah and California. The Company is not currently under examination in any of these jurisdictions. The Company is subject to income tax examinations on all federal returns since the 2018 tax return.</span></div></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RleHRyZWdpb246OGQxOGE0NDA2OWJmNDQwNTljY2RlNmYyZThkZWIzYjlfMzI0Mg_96816a54-a07d-44a7-a904-e3043851c39d" continuedAt="i52094c43084b487abef00f71393748e6" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i52094c43084b487abef00f71393748e6" continuedAt="i4f5f1ecd2dfb4fee8c807471a400eb9b"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, Recursion calculated net loss per share of Class A and Class B common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. For the three and nine months ended September 30, 2021, the Company reported a net loss and therefore basic and diluted loss per share are the same.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights, including the liquidation and dividend rights, of the holders of the Company&#8217;s Class A and Class B common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A and Class B common shares as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A and Class B common stock was the same during the three and nine months ended September 30, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion issued certain shares of convertible preferred stock that were outstanding until April 2021 and were concluded to be participating securities. For the three and nine months ended September 30, 2020, there was only one class of common stock outstanding. Due to the presence of participating securities, Recursion calculated net loss per share for the three and nine months ended September 30, 2020 using the more dilutive of the treasury stock or the two-class method. For periods presented in which the Company reports a net loss, the losses are not allocated to the participating securities. As the Company reported a net loss during the three and nine months ended September 30, 2020, diluted net loss per share was the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The preferred stock converted to common stock in April 2021 as part of the Company&#8217;s IPO. See Note 10, &#8220;Common stock&#8221; for additional details.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RleHRyZWdpb246OGQxOGE0NDA2OWJmNDQwNTljY2RlNmYyZThkZWIzYjlfMzI0Mw_17897279-391a-4513-ad7b-96a061d820af" continuedAt="ia46688b84b104821aa537ff88549dbf5" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amount)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarningsDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0xLTEtMS0w_0573fcc8-f2ab-4db2-86e9-34d57f2064b5"><ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0xLTEtMS0w_635417c9-c8e3-451c-81bd-ed7225929dd0">44,763</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarningsDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0yLTEtMS0w_94f8ec77-1168-44e6-bfe7-2f3985773d56"><ix:nonFraction unitRef="usd" contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0yLTEtMS0w_bc046644-7825-44fd-a171-7a3812698d77">2,664</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC00LTEtMS0w_a6162b1e-d377-454d-af91-de4cc2cf2010"><ix:nonFraction unitRef="usd" contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarningsDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC00LTEtMS0w_c2ec7687-2a66-46a2-a35c-997f720df570">111,133</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC01LTEtMS0w_e4fd0674-56d5-400c-9102-2cb87c4811d4"><ix:nonFraction unitRef="usd" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:UndistributedEarningsDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC01LTEtMS0w_f44b1184-9847-4017-890f-f0bd832d2f47">10,413</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0xLTEtMS0w_1704a993-e3cb-456f-93b4-b328c42ed268"><ix:nonFraction unitRef="shares" contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0xLTEtMS0w_5f3c7583-fc25-4141-8c52-12e2d97b6cca">159,065,667</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0yLTEtMS0w_ca4ee1de-4109-494e-8d33-2c1e932be89e"><ix:nonFraction unitRef="shares" contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0yLTEtMS0w_d017da3f-6dcf-430f-90ad-4241e2ab4cd7">9,467,883</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi00LTEtMS0w_c0ecd5ee-388f-44f3-90c7-ddc2f82dedc5"><ix:nonFraction unitRef="shares" contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi00LTEtMS0w_efe108e4-617a-4dca-b982-d8e72ff177ee">101,045,348</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi01LTEtMS0w_224e3cf4-ce9d-49a7-a093-6c7c5b8b90c5"><ix:nonFraction unitRef="shares" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi01LTEtMS0w_bd78ce90-b434-4629-a065-856cae274e33">9,467,883</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0xLTEtMS0w_51864beb-e354-4965-9d2c-211f11116058"><ix:nonFraction unitRef="usdPerShare" contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0xLTEtMS0w_5878acf9-a784-4ed9-bcef-9924e4b1e0f7">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0yLTEtMS0w_6e2be9b3-eadc-4a41-95be-0a2c63af5f0f"><ix:nonFraction unitRef="usdPerShare" contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0yLTEtMS0w_b1c84710-8145-4f13-ae4f-6f480ed68b63">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy00LTEtMS0w_2c5866a3-6a5a-40c8-a04f-007e945617ce"><ix:nonFraction unitRef="usdPerShare" contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy00LTEtMS0w_335d7c77-089f-432e-bd18-e1f43c4e88a5">1.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy01LTEtMS0w_87e4bb6e-b944-43dc-af45-7237dbde13ef"><ix:nonFraction unitRef="usdPerShare" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy01LTEtMS0w_f5b9cd70-feb5-47c7-a511-960eb27ccf56">1.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RleHRyZWdpb246OGQxOGE0NDA2OWJmNDQwNTljY2RlNmYyZThkZWIzYjlfMzI0NA_95cf1f3d-79d2-4ddf-bdb4-b894e3eeeda9" continuedAt="ib5968b3f9e584534898b89e229f63b0a" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf3bd2b3f1de4ca2ab977e7dc5e21061_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy0xLTEtMS0w_43769199-43c0-4042-8025-688c4c5dc31a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i25149b9a570440e894a302d56c3419d4_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy0yLTEtMS0w_3e5916f8-6e62-4104-928e-0c2505adfc22">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3102e5c386934e08baf3f55a99f19f8f_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy00LTEtMS0w_e3cc65d5-0096-4b6f-8ffa-05fb6cdf67af">46,324,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53e651de692a4311baff885fe1d206fd_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy01LTEtMS0w_1def27f6-00a1-4552-9f8d-b622f737233a">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70f6c3f9030e468f943ac8072eca5c43_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC0xLTEtMS0w_d941c6af-ccfd-4dac-ae2d-0499b0b1f6f5">16,764,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b9f157f6cc14838be0480cbdd9ff968_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC0yLTEtMS0w_1d52e8e6-0af5-4945-bfb2-cd2cd69d93e1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66ff3b8c31df4b4b8a24cb74978eff8f_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC00LTEtMS0w_6e5a756d-8021-4ec8-9748-508e3c78f518">15,506,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3a1c33e0c004ee7bcc3a113bfdbe90e_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC01LTEtMS0w_9c7fec35-0386-4b27-bbcf-519fc10321f4">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26eb528b81cf4adf8be643e9113fd19c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS0xLTEtMS0w_b061083c-03aa-400e-8f57-cede72cc3e27">163,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5628df5a4848456eb3ec9ada5263c011_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS0yLTEtMS0w_eaca3bcf-cf23-480d-a667-447d5a7313cc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ba0f31dd7d94a7aa2ea877325c0bb72_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS00LTEtMS0w_9cdc9e98-1458-40c0-8285-f10087449aec">180,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia222d34dfedb42a989e65c18da7342b2_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS01LTEtMS0w_39dc77dd-b10d-4376-bf3e-4a7fb38a20d5">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied40c52ff827437a831df98fbdf2c99c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi0xLTEtMS0w_add0ab22-bdfc-47c1-aa0e-ebbac45d22fd">37,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice8b605c718747d2acbf2c3db10e6ec0_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi0yLTEtMS0w_3867a538-f6b5-46b7-931b-33a7df8e8aac">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7afc904b0874b9c80f044ef16fb6c10_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi00LTEtMS0w_bcc27b48-6cde-455e-be21-c2e4e19152f1">5,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29d4ed7ff0ab424a9e1664b17448dcd5_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi01LTEtMS0w_03fac065-994c-4544-afc3-cbc89cfd8208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy0xLTEtMS0w_227b8e8f-af7c-49fb-890d-0a256d90a4dd">16,965,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy0yLTEtMS0w_a8a1f1cf-eaec-45d3-89d3-3d7cec66c0bb">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy00LTEtMS0w_cf8b6d52-d464-4ec9-acca-f78eef36be83">62,016,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy01LTEtMS0w_3796b188-45c0-4ebc-9cc4-791a7e6af676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="ia46688b84b104821aa537ff88549dbf5" continuedAt="i88a8ee454e61498f87d0d5162b7b34e2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share during 2020:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4f5f1ecd2dfb4fee8c807471a400eb9b"><div><ix:continuation id="i88a8ee454e61498f87d0d5162b7b34e2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amounts)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28896c19aa0048d895dddd0ae8427e87_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfMy0xLTEtMS0w_39313815-2157-4e52-8be6-03f34e71e405">23,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icee0f1fd845e456095af44bb0a898324_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfMy0yLTEtMS0w_18e4222e-6488-44ae-8eeb-00ddc7127969">61,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0xLTEtMS0w_3cadf291-fc9f-434e-a552-7d4425d408af"><ix:nonFraction unitRef="shares" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0xLTEtMS0w_d1b94fd2-1e52-4c11-8066-50596dd7fc51">21,817,900</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0yLTEtMS0w_6bfa7fc2-546e-4356-9991-7a2672b652aa"><ix:nonFraction unitRef="shares" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0yLTEtMS0w_ecd91a91-4323-41fb-af65-5486e1c00860">21,704,008</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0xLTEtMS0w_17f844da-22de-4ef2-816b-63c0eed64922"><ix:nonFraction unitRef="usdPerShare" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0xLTEtMS0w_ac48f523-b7c0-4271-ab59-798f5067558d">1.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0yLTEtMS0w_3dcb9ec4-1c13-4d4f-9461-258cdd70b276"><ix:nonFraction unitRef="usdPerShare" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0yLTEtMS0w_84661191-605b-499b-9780-7d07b50497de">2.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:continuation id="ib5968b3f9e584534898b89e229f63b0a"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43c8d5736faa4c1983958144094f549c_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMi0xLTEtMS0w_7433f0ab-3c7e-49e2-8954-b813bd29e9f1">89,839,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1407ac7645fc47fa897329aea3c530a8_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMi0yLTEtMS0w_42f0bb90-e9a8-4959-801a-8c32bb6b3304">82,453,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i610ce8d6e6fb4af2aed56ad3de0f1a9f_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMy0xLTEtMS0w_efa4280e-5b7e-4f8d-893f-006603e15157">3,576,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebe1a1be865947f4aa113d844800ea59_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMy0yLTEtMS0w_2b5be312-777b-40ef-a962-c340d55c6e9c">3,589,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibec53fdf9f59440fb5fcf12d42df3d39_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNC0xLTEtMS0w_67e42ba7-6e9a-408a-adbb-4d98fbf9f8a5">115,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaab494b26364446fba34ae32a935dfc1_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNC0yLTEtMS0w_498ac237-d6c7-41b2-a450-7b487d7c8d26">115,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNS0xLTEtMS0w_92a2bdc6-20e9-4475-b7c3-f855e25931f2">93,531,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNS0yLTEtMS0w_22ae6c62-41ee-4ad3-bc2d-6ae0daeedc7c">86,158,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_73"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RleHRyZWdpb246MjI0ZjA0MDMxMjNmNDhmOThjNmJkMjQ4ZTA2NmFiYTRfMjA0Nw_72ccea86-bfca-4bf6-99d8-59744013f02c" continuedAt="iee26ae8ff43c46de9fa78ada1b9e5f51" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iee26ae8ff43c46de9fa78ada1b9e5f51" continuedAt="ia07cf21731a3447da2b8e799f3d0cb42"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value hierarchy consists of the following three levels:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2 &#8212; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3 &#8212; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain a cash balance in a collateralized account to secure the Company&#8217;s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measured the Series A and B preferred stock warrant liabilities at fair value using a Black-Scholes option-pricing model. See Note 12, &#8220;Stock-based Compensation&#8221; for details on the valuation of the warrant liabilities and a reconciliation of the balance. </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia07cf21731a3447da2b8e799f3d0cb42"><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RleHRyZWdpb246MjI0ZjA0MDMxMjNmNDhmOThjNmJkMjQ4ZTA2NmFiYTRfMjA0OA_a40f30fb-653b-48f7-9d26-834911ae2236" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190cd4db6d464d718e8e7930d9ca1083_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0xLTEtMS0xODIyOQ_fe1feb49-5519-481a-8131-2a96f31dca23">187,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3214dd56bf64eedbbf429ee3a167178_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0yLTEtMS0xNjMxNQ_ee0f8ce7-c301-43dd-9930-af5adffc03e1">187,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51038493a87f4438a225fa0f3eb3d1a8_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0zLTEtMS0xNjMxNQ_a90350e4-209c-4c63-ae87-ae695739b6d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a01352bcbd0418da5a4d83c3911cb35_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS00LTEtMS0xNjMxNQ_79bd0844-6c7c-43b5-892e-59b92d7509e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac2c0d34aa14f4b86eb9fb680095a93_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNi0xLTEtMS0xODIyOQ_50820a15-4e7f-4f80-a075-78f328e8fcf1">34,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b0eacaa900484a97d3551758e92093_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNi0yLTEtMS0xNjIyNA_54a59010-c639-4f68-8652-ca38f37a22d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6fec666dd574bdd860d28ccf54b11c1_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0zLTEtMS0xNjE2NA_67d851fe-4040-466e-8b71-2c4502bcb921">34,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d40bedd685247d78f2216e50d9a8eff_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNi00LTEtMS0xNjIyNA_2dc07249-e91b-4c41-95fc-784b99d08be0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30ba9ac44034c578ac0d736845582c9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy0xLTEtMS0xODIyOQ_7a614377-9778-4574-aee7-3412cb941051">10,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3de39547ef349e992ca21d173027833_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy0yLTEtMS0xNjI2NQ_af82bc09-a681-41e2-9ebb-e0c5c4be0608">10,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04ee2989244405a8478ecdc58c1d93c_I20210930" decimals="-3" format="ixt:fixed-zero" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy0zLTEtMS0xNjI2NQ_f5ec6804-bf58-4165-a57e-2fbb8453afcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620b4c771b704d6bbc4945cbd1c5dc27_I20210930" decimals="-3" format="ixt:fixed-zero" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy00LTEtMS0xNjI2NQ_315f1cb0-b317-404a-a7c6-45a5b7ccf30c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida224670f66a4cd1b60d191c2e281cce_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS0xLTEtMS0xMzAxMA_ece04ba8-972a-453a-a323-149a671120c9">5,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief95da0bc6cf471e9f41eac09bb2d67b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS0yLTEtMS0xMzAxMA_5b064bad-4ecb-47f8-96ef-a8d00c097c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf2d0d327cf84c748140d0325b4ebd61_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS0zLTEtMS0xMzAxMA_97e3378e-e805-46cc-bd61-e7efc713293f">5,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564180300205478f9ed895f99b4dfe03_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS00LTEtMS0xMzAxMA_1d2b248c-ea2c-450d-8b67-cfcc778e945a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441ebff9e64d4bac86210ac2f3fe7cbe_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtMS0xLTEtMTMwMTA_b8f8bc78-b0de-433c-bc98-8d0fcacf8938">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie20600623f4948c3a5c474d9eecc9162_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtMi0xLTEtMTMwMTA_280d3af1-76fd-4995-b3ce-4c26de1d849c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0872f901a90f4c1abc3c5b8804f79732_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtMy0xLTEtMTMwMTA_6c88644d-a166-4e41-a7eb-f381e3630fc4">21,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee4c5b8987c42068342ac8fe0f80772_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtNC0xLTEtMTMwMTA_6bc1e231-2a12-4a5a-9cdb-4db8dfee6944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013dda72d65e48359f86e04e7a20b9e3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItMS0xLTEtMTMwMTA_dcbb3e8f-e024-42ab-a25b-14faf66ab722">156,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1296a5886a6f470cb0230592349be9eb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItMi0xLTEtMTMwMTA_7ead7da0-edc1-4bc3-8a81-5de21629b134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6b0ed534a640c5931de64b79a5225c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItMy0xLTEtMTMwMTA_ff133076-9804-4851-9744-2ddf5753792d">156,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d9ff00f3094561b99abddcbbc1196c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItNC0xLTEtMTMwMTA_146745ae-ab15-4aec-99a8-69472f060dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30ba9ac44034c578ac0d736845582c9_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0xLTEtMS0w_e4dca323-b0fc-4715-bddc-4cf05a500c25">416,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3de39547ef349e992ca21d173027833_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0yLTEtMS0w_32dc0bc2-305c-4945-b7a1-e85e44e72871">197,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04ee2989244405a8478ecdc58c1d93c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0zLTEtMS0w_beba590d-51b2-4f82-9fdf-d5e9f1a94f71">218,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620b4c771b704d6bbc4945cbd1c5dc27_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS00LTEtMS0w_409b7cb1-a573-433c-9dae-8cf79259fa99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC0xLTEtMS0w_0b64858e-e5cf-4d8c-bc88-0be68e4e1eb3">5,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC0yLTEtMS0w_8ce287b8-275c-48cd-9de1-c30cc1a2cbbe">5,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231" decimals="-3" format="ixt:fixed-zero" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC0zLTEtMS0w_3020ff06-d27a-4d57-9868-bb2b4f4fb7f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a713b2042cb45f4baae40157f292534_I20201231" decimals="-3" format="ixt:fixed-zero" name="rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC00LTEtMS0w_7c40f88e-ca6a-4744-b753-afe80ac790c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS0xLTEtMS0w_27c54d89-4002-4e8e-ac8d-e68f9de5efd0">5,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS0yLTEtMS0w_5377a716-f3e7-4aa4-b13f-1eec1bef1b75">5,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS0zLTEtMS0w_4f37ec4b-36fa-440e-be33-d10e98d8c5f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a713b2042cb45f4baae40157f292534_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS00LTEtMS0w_68d8c4ff-f5e5-43e2-a8e0-78c882723f72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy0xLTEtMS0w_0cd9ddb6-270c-46aa-abe0-3f42c8c60862">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy0yLTEtMS0w_6f9b9cd5-ec3b-4eb1-bf4a-590e78015031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy0zLTEtMS0w_8381bd94-539a-43e9-9283-34b9b0274822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a713b2042cb45f4baae40157f292534_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy00LTEtMS0w_11b20eb0-b6ad-4414-bdd4-f8ace458a087">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC0xLTEtMS0w_80e17168-e7d1-4870-a0ec-238adcd4f457">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC0yLTEtMS0w_e5540255-e354-40c6-be11-876160a6435d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC0zLTEtMS0w_831fbd15-c6d2-4a86-a427-15e56ecd5cca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a713b2042cb45f4baae40157f292534_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC00LTEtMS0w_4be2965f-e855-46db-b9d7-a308cdb8d705">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheets, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RleHRyZWdpb246MjI0ZjA0MDMxMjNmNDhmOThjNmJkMjQ4ZTA2NmFiYTRfMjA0Ng_8472d96f-dd9e-4401-90cc-d07d51c7ffac" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments that are not measured at fair value: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc102fb1bc82413aa69f0cd8e15bbcb7_I20210930" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy0xLTEtMS0w_9eb7c568-ae89-4417-b8e2-b86f1b365258">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242c9fb9e9d34e39bc8bb5ea202c9f5c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy0yLTEtMS0w_7232c794-08c3-4e23-b892-abb4bc4491c5">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6914913f4c29445486a40ba822c76f9c_I20210930" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy00LTEtMS0w_fcbc5a5c-b5da-466b-a0ab-7ea3446bfad2">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8622a762a34db69acf56d2140a8afe_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy01LTEtMS0w_1468fada-805c-4986-b027-301cebee394e">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc102fb1bc82413aa69f0cd8e15bbcb7_I20210930" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC0xLTEtMS0w_ba561d4e-dd74-43f4-b89d-9756f985665e">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242c9fb9e9d34e39bc8bb5ea202c9f5c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC0yLTEtMS0w_ef9dc1e6-c4cc-4165-a62b-e4a3cbf12d4f">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6914913f4c29445486a40ba822c76f9c_I20210930" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC00LTEtMS0w_ffa02ee3-0c9a-4f99-8e5e-25437c56b9eb">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8622a762a34db69acf56d2140a8afe_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC01LTEtMS0w_5a8fab6d-6b63-43b5-900f-8e274b7f8cab">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4c24f5df41449c8a6537fb7c6f3dc2_I20210930" decimals="-3" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS0xLTEtMS0w_5f05b91f-494a-4c1b-bed3-af0a3f7e0f09">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7749db1c1872417f962d0cc10eb2a200_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS0yLTEtMS0w_dc46f016-7c75-4407-b908-6961fbece49f">12,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cf7bd8980049bea59d3c2a32ae4c09_I20210930" decimals="-3" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS00LTEtMS0w_25adef53-d016-4f6c-a1aa-81b7949ab5be">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18aaa35da92e4cfcab63c485c3c4aaac_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS01LTEtMS0w_1c5177ca-8944-47f7-8dd2-b0b4393d311c">12,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_76"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16. <ix:nonNumeric contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMjc5_ca2715bc-c361-4fdd-a267-da7d960483b7" continuedAt="i62faa02bd257431ab2e6d9d273c6ef05" escape="true">Related Party Transactions </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i62faa02bd257431ab2e6d9d273c6ef05" continuedAt="i2d5d43503dd94039afa1483eb4b35d56">On December&#160;5, 2017, the Company entered into a loan agreement with its CEO to provide a loan of $<ix:nonFraction unitRef="usd" contextRef="i774ee2b9287545a0a57464dbab971920_I20171205" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LoansAndLeasesReceivableRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMTQw_ab4faeb2-85b4-4ad8-8866-80a3a397e743">595</ix:nonFraction> thousand. The loan had a <ix:nonNumeric contextRef="ia19aa404aca14cc6acdaf9338dfc7ff5_D20171205-20171205" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMjgx_ccd6b959-8274-4d7b-a8e4-5d2d4caaf02c">seven-year</ix:nonNumeric> term. As of September&#160;30, 2021 and 2020, <ix:nonFraction unitRef="usd" contextRef="i6893f1ac3dd94238a44159176b56e2aa_I20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:LoansAndLeasesReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMTkw_585e4f4a-b7bc-4c71-bd34-817e6f02ec2e"><ix:nonFraction unitRef="usd" contextRef="i5fc41eefa45d46c3ad7b8fa3931ff65b_I20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:LoansAndLeasesReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMTkw_84726900-ff2a-4b66-89cb-9f869f7e8fbb">no</ix:nonFraction></ix:nonFraction> amount remained outstanding on the loan as the balance was fully paid during the nine months ended September 30, 2020. </ix:continuation></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2d5d43503dd94039afa1483eb4b35d56">The acquisition of Vium was a related party transaction due to the fact that Vium was affiliated with certain investors of the Company. See Note 3, &#8220;Acquisitions&#8221; for additional details on the acquisition.</ix:continuation></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following is a discussion and analysis of the financial condition of Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us or our) as of September&#160;30, 2021 and December&#160;31, 2020 and the results of operations during the three and nine months ended September 30, 2021 and 2020. This commentary should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, &#8220;Financial Statements&#8221; and the Company&#8217;s audited consolidated financial statements and accompanying notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the final prospectus for our initial public offering (IPO), which was filed with the Securities and Exchange Commission (SEC), pursuant to Rule 424(b)(4) on April 16, 2021 (the Final Prospectus). This discussion, particularly information with respect to our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, includes forward-looking statements that involve risks and uncertainties as described under the heading "Note About Forward-Looking Statements" in this Quarterly Report on Form 10-Q. You should review the disclosure under the heading "Risk Factors" in this Quarterly Report on Form 10-Q for a discussion of important factors that could cause our actual results to differ materially from those anticipated in these forward-looking statements. </span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or the Recursion OS, that combines an advanced infrastructure layer to generate what we believe is one of the world&#8217;s largest and fastest-growing proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We believe that the combination of wet-lab biology and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tools in our closed-loop system differentiates us from others within the industry. Similarly, our balanced team of life scientists and computational and technical experts creates an environment where empirical data, statistical rigor, and creative thinking are brought to bear on our decisions. To date, we have leveraged our Recursion OS, which is depicted below, to create three value drivers: i) advancement of our internally-developed programs, including four clinical-stage assets, focused on areas of significant unmet need, several of which have market opportunities in excess of $1.0&#160;billion in annual sales, ii) strategic partnerships with leading biopharmaceutical companies, and iii) Induction Labs, a growth engine created to explore new extensions of the Recursion OS both within and beyond therapeutics. The number of programs we are advancing in research and development has more than doubled since 2019. Although we cannot provide any guarantee that we will achieve similar timelines with future product candidates, we believe we will be able to continue accelerating the pace of program additions in the future. As such, we are a biotechnology company scaling more like a technology company.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><img src="rxrx-20210930_g1.jpg" alt="rxrx-20210930_g1.jpg" style="height:543px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recursion finished the third quarter of 2021 with a portfolio of 4 clinical stage programs, 4 preclinical programs, 7 late discovery programs, and 41 early discovery programs. Additionally, Recursion continued scaling the total number of executed phenomic experiments to approximately 95 million, the size of its proprietary data universe to over 11 petabytes, and the number of biological inferences to approximately 200 billion. Data have been generated on the Recursion OS across 38 human cell types, an in-house chemical library of over 717 thousand compounds, and an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in silico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> library of 12 billion small molecules, by a growing team of more than 330 Recursionauts that is balanced between life scientists and computational and technical experts.  </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><img src="rxrx-20210930_g2.jpg" alt="rxrx-20210930_g2.jpg" style="height:384px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Business Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Neurofibromatosis type 2 (NF2) (REC-2282): </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early October, we received Fast Track Designation for REC-2282 from the FDA for the potential treatment of NF2 meningiomas. We plan to initiate a parallel group, two stage, Phase 2/3, randomized, multicenter study in early 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt">Cerebral cavernous malformation (CCM) (REC-994):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We plan to initiate a Phase 2, double-blind, placebo-controlled safety, tolerability and exploratory efficacy study of this candidate in early 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.15pt">Familial adenomatous polyposis (FAP) (REC-4881):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In September we received Orphan Drug Designation for REC-4881 from the FDA for the potential treatment of Familial Adenomatous Polyposis. We plan to initiate a Phase 2, randomized, double-blind, placebo-controlled study to evaluate safety, pharmacokinetics, and efficacy in the first half of 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.15pt">GM2 gangliosidosis (REC-3599):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We plan to initiate a Phase 2 study of this candidate in the first half of 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.15pt">Clostridium difficile colitis (REC-3964):</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We expanded our medicinal chemistry team and digital chemistry tools and made progress in IND-enabling studies for REC-3964, which is the most advanced New Chemical Entity developed by the Recursion OS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer AG Partnership</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continue to advance our collaboration with Bayer to discover small molecule drug candidates with the potential to treat fibrotic diseases. We have multiple programs progressing simultaneously with our partner. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recursion OS</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.15pt">Biological Contexts: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We advanced our capabilities to model diseases in multiple biological contexts, including new types of biological perturbations beyond CRISPR-based knockouts, complex cell type </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">onboarding, and organoid model systems. Moreover, we made progress on multiple maps in iPSC-derived neural cell types. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.15pt">Mechanisms of Action: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We improved our computational methods to identify mechanisms of action and used this technology to increase our ability to screen out compounds with potentially toxic effects for multiple programs earlier than is possible with traditional approaches. We believe that such methods will better enable us to advance the most promising novel chemical compounds through discovery. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.15pt">Transcriptomics Validation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We made significant improvements to our transcriptomics protocols to enable increases in throughput. Additionally, we have been optimizing our ability to use transcriptomics signatures for compound characterization. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facilities and Manufacturing</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We continued to make progress in expanding our current headquarters and creating a chemistry, manufacturing and controls (CMC) site in Salt Lake City. These spaces are designed with flexibility in mind to enable next generation automated workflows and instruments for compound, tissue culture, and biobank management to further industrialize the drug discovery and development process.</span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_482"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in November 2013. On April&#160;20, 2021, we closed our IPO and issued 27,878,787 shares of Class A common stock at a price of $18.00 per share, raising gross and net proceeds of $501.8 million and $462.4 million, respectively. Prior to our IPO, we had raised approximately $448.9 million in equity financing from investors in addition to $30.0 million in an upfront payment from our strategic partnership with Bayer AG (Bayer).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the capital we have raised to fund operations and investing activities across platform research operations, drug discovery, clinical development, digital and other infrastructure, creation of our portfolio of intellectual property and administrative support. We do not have any products approved for commercial sale and have not generated any revenues from product sales. We had cash, cash equivalents and investments of $578.9 million as of September&#160;30, 2021. Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to meet our working capital and capital expenditure needs at least into 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, we have incurred significant operating losses. Our net losses were $47.4 million and $121.5 million during the three and nine months ended September 30, 2021, respectively. Our net losses were $23.9 million and $61.2 million during the three and nine months ended September 30, 2020, respectively. As of September&#160;30, 2021, our accumulated deficit was $335.1 million. We anticipate that our expenses and operating losses will increase substantially over the foreseeable future. The expected increase in expenses will be driven in large part by our ongoing activities, if and as we: continue to advance our platform; continue preclinical development of our current and future product candidates and initiate additional preclinical studies; commence clinical studies of our current and future product candidates; establish our manufacturing capability, including developing our contract development and manufacturing relationships and building our internal manufacturing facilities; acquire and license technologies aligned with our platform; seek regulatory approval of our current and future product candidates; expand our operational, financial and management systems and increase personnel, including personnel to support our preclinical and clinical development, manufacturing and commercialization efforts; continue to develop, grow, perfect and defend our intellectual property portfolio; and incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in new technologies to expand our platform and plan to build world class capabilities in key areas of manufacturing sciences and operations, including small molecule production, novel chemical entity development, product characterization and process analytics. Our investments may also include scaled research solutions, scaled infrastructure, as well as novel technologies to improve efficiency, characterization and scalability of manufacturing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will need to raise additional financing in the future to fund our operations, including the commercialization of any approved product candidates. Until such time, if ever, as we can generate significant product revenue, we expect to finance our operations with our existing cash and cash equivalents, any future equity or debt financings and upfront, milestone and royalty payments, if any, received under current or future license or collaboration agreements. We may not be able to raise additional capital on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, results of operations and financial condition may be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our business has generated revenue from two sources: (i)&#160;grant revenue and (ii)&#160;operating revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize grant revenue in the period in which the revenue is earned in accordance with the associated grant agreement, which is the period in which corresponding reimbursable expenses under the grant agreement are incurred. Grant revenue was generated from grants awarded by the National Institute of Health. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Operating revenue is primarily generated through funded research and development agreements derived from strategic alliances, such as our strategic partnership with Bayer. We are entitled to receive variable consideration as certain milestones are achieved. The timing of revenue recognition is not directly correlated to the timing of cash receipts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses account for a significant portion of our operating expenses. We recognize research and development expenses as they are incurred. Research and development expenses consist of costs incurred in performing research and development activities, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs to develop and operate our platform; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs of discovery efforts which may lead to development candidates, including research materials and external research; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs for clinical development of our investigational products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs for materials and supplies associated with the manufacture of active pharmaceutical ingredients investigational products for preclinical testing and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">personnel-related expenses, including salaries, benefits, bonuses and stock-based compensation for employees engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">costs associated with operating our digital infrastructure; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other direct and allocated expenses incurred as a result of research and development activities, including those for facilities, depreciation, amortization and insurance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor research and development expenses directly associated with our clinical assets at the program level to some degree, however, indirect costs associated with clinical development and the balance of our research and development expenses are not tracked at the program or candidate level. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expenses associated with third-party contracted services as they are incurred. Upon termination of contracts with third parties, our financial obligations are generally limited to costs incurred or committed to date. Any advance payments for goods or services to be used or rendered in future research and product development activities pursuant to a contractual arrangement are classified as prepaid expenses until such goods or services are rendered. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses general and administrative costs as incurred. General and administrative expenses consist primarily of salaries; employee benefits; stock-based compensation; and outsourced labor for personnel in executive, finance, human resources, legal and other corporate administrative functions. General and administrative expenses also include legal fees for corporate and patent matters; professional fees for accounting, auditing, tax and administrative consulting services, insurance costs, facilities and depreciation expenses. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future to support personnel in research and development and to support our operations as we increase our research and development activities and activities related to the potential commercialization of our drug candidates. We also expect to incur increased expenses associated with operating as a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs and investor and public relations costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Loss, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss, net consists of interest earned on our cash and cash equivalents, interest expense incurred under our loan agreements, changes in the fair value of warrant liabilities and debt extinguishment costs.  </span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s results of operations: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.506%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(79.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,499&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,402)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,928)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,815)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,782)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,428)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,873)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,555)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121,546)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,240)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60,306)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s components of revenue: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased by $1.5 million and $6.4 million during the three and nine months ended September 30, 2021, respectively, compared to the prior year. The increase in revenue was due to revenue recognized from our strategic partnership with Bayer entered into in August 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s components of research and development expense: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.506%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,535&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,358&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of research and development expense include the following allocated by development phase: Platform, which refers primarily to expenses related to screening of product candidates through hit identification; Discovery, which refers primarily to expenses related to hit identification through development of candidates; and Clinical, which refers primarily to expenses related to development of candidates and beyond. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $16.7 million and $44.4 million during the three and nine months ended September 30, 2021, respectively, compared to the prior year. The increase in research and development expenses was due to an increased number of experiments screened on our platform, an increased number of pre-clinical assets being validated and increased clinical costs as studies progressed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s general and administrative expense: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.506%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative expenses</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,690&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,964&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,726&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,481&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,684&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,797&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $8.7 million and $20.8 million during the three and nine months ended September 30, 2021, respectively, compared to the prior year. The increase in general and administrative expenses was due to the growth in size of the Company&#8217;s operations including an increase in salaries and wages of $3.7 million and $10.6 million during the three and nine months ended September 30, 2021, respectively, equipment costs, human resources costs, facilities costs and other administrative costs associated with operating a growth-stage company. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other loss, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Recursion&#8217;s components of other loss, net: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.238%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands, except percentages)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended<br/>September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&gt;100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative fair value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/m</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other loss, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n/m = Not meaningful</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss, net decreased by $373 thousand during the three months ended September 30, 2021 compared to the prior year. The decrease in Other loss, net during the three months ended September 30, 2021 was due to the fair value adjustment on the derivative liability for the convertible notes during the three months ended September 30, 2020 and a decrease in interest expense due to the payment in July 2021 of the balance due on the Midcap loan. See Note 7, &#8220;Notes Payable&#8221; to the Condensed Consolidated Financial Statements for additional details on the Midcap loan payment and the derivative.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss, net increased by $1.5 million during the nine months ended September 30, 2021 compared to the prior year. The increase in Other loss, net during the nine months ended September 30, 2021 was primarily due to an increase in the fair value of the Series A and B warrants. See Note 12, &#8220;Stock-Based Compensation&#8221; to the Condensed Consolidated Financial Statements for additional details on the warrants. This increase was partially offset by the fair value adjustment on the derivative liability for the convertible notes. See Note 7, &#8220;Notes Payable&#8221; to the Condensed Consolidated Financial Statements for additional details on the derivative. </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_94"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet commercialized any products and does not expect to generate revenue from the sales of any product candidates for at least several years. Cash and cash equivalents totaled $394.7 million as of September&#160;30, 2021 and $262.1 million as of December&#160;31, 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and experienced negative operating cash flows and we anticipate that the Company will continue to incur losses for at least the foreseeable future. Our net loss was $47.4 million and $121.5 million during the three and nine months ended September 30, 2021, respectively. The Company&#8217;s net loss was $23.9 million and $61.2 million during the three and nine months ended September 30, 2020, respectively. As of September&#160;30, 2021 and December&#160;31, 2020, Recursion had an accumulated deficit of $335.1 million and $213.6 million, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion has financed its operations through the private placements of preferred stock and an IPO. As of September&#160;30, 2021, the Company had received proceeds of $448.9 million from the sale of its preferred stock. The Company received net proceeds of $462.4 million from the IPO. See Note 10, &#8220;Common Stock&#8221; to the Condensed Consolidated Financial Statements for additional details on the IPO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received a $30.0 million upfront payment from the Company&#8217;s strategic partnership with Bayer. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Midcap Credit and Security Agreement </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Credit and Security Agreement with Midcap Financial Trust (Midcap) and the other lenders party thereto (the Midcap loan agreement). The Midcap loan agreement provided for a term loan facility that included an initial tranche of $11.9 million. In July 2021, the Company paid the balance due on the loan outstanding with Midcap. See Note 7, &#8220;Notes Payable&#8221; to the Condensed Consolidated Financial Statements for additional details.     </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the Condensed Consolidated Statements of Cash Flows for each of the periods presented below: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,456)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities was $97.5 million during the nine months ended September 30, 2021. Cash used in operating activities increased from the nine months ended September 30, 2020 as a result of higher costs incurred for research and development and general and administrative due to the Company&#8217;s growth. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities was $54.0 million during the nine months ended September 30, 2020. Cash used in operating activities increased from the nine months ended September 30, 2019 due to higher costs incurred for research and development and general and administrative due to the Company&#8217;s growth.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $219.5 million during the nine months ended September 30, 2021. Cash used in investing activities primarily consisted of investment purchases of $184.2 million and property and equipment purchases of $35.3 million, which included $17.9 million for the purchase of a Dell EMC supercomputer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $4.1 million during the nine months ended September 30, 2020. Cash used in investing activities included $2.6 million for the Acquisition of Vium, Inc (Vium) and $2.1 million of capital expenditures primarily for the purchase of lab equipment and leasehold improvements. The cash outflows were partially offset by the proceeds from the note receivable. See Note 3, &#8220;Acquisitions&#8221; to the Condensed Consolidated Financial Statements for additional details on the Vium acquisition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was $454.7 million during the nine months ended September 30, 2021. Cash provided by financing activities primarily included $462.4 million of net proceeds from the IPO. Financing cash flows also included an outflow of $12.7 million for the repayment of long-term debt on the Midcap loan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was $236.1 million during the nine months ended September 30, 2020, which consisted primarily of proceeds from the sale of preferred stock of $229.5 million. Financing cash flows also included $6.4 million of proceeds from the issuance of convertible notes. See Note 7, &#8220;Notes Payable&#8221; to the Condensed Consolidated Financial Statements for additional detail on the convertible notes. </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_97"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates and Policies </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A summary of the Company&#8217;s significant accounting estimates and policies is included in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in our Final Prospectus filed with the SEC on April 16, 2021 in connection with our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IPO. There were no significant changes in the Company&#8217;s application of its critical accounting policies during the nine months ended September 30, 2021.</span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_100"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2 in Item 1 of this Quarterly Report on Form 10-Q for information regarding recently issued and adopted accounting pronouncements. </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_103"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act, amount other things, exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion as elected to use the extended transition period for new or revised financial accounting standards during the period in which we remain an EGC. However, the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company&#8217;s financial statements with other public companies difficult because of the potential differences in accounting standards used. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion may remain an EGC until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#8220;large accelerated filer;&#8221; or (b) have annual gross revenues of $1.07&#160;billion or more; or (3) the date on which we have issued more than $1.0&#160;billion of non-convertible debt over a three-year period. </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_106"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, Recursion had an investment portfolio with a fair value of $405.9&#160;million which included cash, cash equivalents and available-for-sale investments. See Note 5, &#8220;Investments&#8221; to the Condensed Consolidated Financial Statements for additional details on the portfolio. Recursion&#8217;s investment portfolio is subject to interest rate risk and will fall in value if market interest rates increase. The Company does not believe it is materially exposed to changes in interest rates related to the investments and Recursion does not currently use interest rate derivative instruments to manage exposure to interest rate changes of the investments. A hypothetical 100 basis point increase in interest rates relative to interest rates as of September&#160;30, 2021, would have resulted in a reduction in fair value of approximately $5.7&#160;million of the investment portfolio. In addition, a hypothetical 100 basis point decrease in interest rates as of September&#160;30, 2021 would have an insignificant effect on net loss in the ensuing year.    </span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_109"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act) designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives as management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Officer and Chief Financial Officer have concluded that, as of September&#160;30, 2021, our disclosure controls and procedures were effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, many of the Company&#8217;s employees are working remotely. We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment, in part because our internal control over financial reporting was designed to operate in a remote working environment. The Company is continually monitoring and assessing the COVID-19 situation to determine any potential impacts on the design and operating effectiveness of our internal controls over financial reporting.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_115"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are not currently a party to any material litigation or other material legal proceedings. We may, from time to time, become involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect our future financial position, results of operations or cash flows.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_597"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:-0.47pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:143%">RISK FACTORS</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:5.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q and our other public filings with the SEC, before making investment decisions regarding Recursion common stock. The risks described below are not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating results, and financial condition to be materially and adversely affected.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR LIMITED OPERATING HISTORY, FINANCIAL POSITION, AND NEED FOR ADDITIONAL CAPITAL</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale, which may make it difficult to evaluate our current and future business prospects.</span></div><div style="padding-right:18.7pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in November 2013, we have focused substantially all of our efforts and financial resources on building our drug discovery platform and developing our initial drug candidates. All of our drug candidates are still in the discovery, preclinical development, or clinical stages. Before we can commercialize our drug candidates, they require, among other steps, clinical success; development of internal or external manufacturing capacity and marketing expertise; and regulatory approval by the U.S. Food and Drug Administration (FDA) and other applicable jurisdictions. We have no products approved for commercial sale and we can provide no assurance that we will obtain regulatory approvals to market and sell any drug products in the future. We therefore have never generated any revenue from drug product sales, and we do not expect to generate any revenue from drug product sales in the foreseeable future. Until we successfully develop and commercialize drug candidates, which may never occur, we expect to finance our operations through a combination of equity offerings, debt financings, and strategic collaborations or similar arrangements. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. For these and other reasons discussed elsewhere in this Risk Factors section, it may be difficult to evaluate our current business and our future prospects. </span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="padding-right:18.7pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses in each year since our inception. Our net losses were $47.4 million and $23.9 million for the three months ended September 30, 2021 and 2020, respectively, and $121.5 million and $61.2 million for the nine months ended September 30, 2021 and 2020, respectively. We had an accumulated deficit of $335.1 million as of September 30, 2021. Substantially all of our operating losses have resulted from costs incurred in connection with research and development efforts, including clinical studies, and from general and administrative costs associated with our operations. We expect our operating expenses to significantly increase as we continue to invest in research and development efforts and the commencement and continuation of clinical trials of our existing and future drug candidates. We also continue to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur substantial and increasing operating losses for the foreseeable future. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses, combined with expected future losses, have had, and will continue to have, an adverse effect on our stockholders&#8217; deficit and working capital. Because of the numerous risks and uncertainties associated with developing pharmaceutical products and new technologies, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:27.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate at least some of our product development programs, business development plans, strategic investments, and potential commercialization efforts, and to possibly cease operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission to decode biology and deliver new drugs to the patients who need them is broad, expensive to achieve, and will require substantial additional capital in the future. We have four clinical stage programs and 52 additional programs in various stages of preclinical development. We expect our expenses to increase in connection with our ongoing activities as we continue the research and development of, initiate clinical trials of, and potentially seek marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval for, our current drug candidates, and as we add to our pipeline what we believe will be an accelerating number of additional programs. Preclinical and clinical testing is expensive and can take many years, so we will need supplemental funding to complete these undertakings. If our drug candidates are eventually approved by regulators, we will require significant additional funding in order to launch and commercialize our products. </span></div><div style="padding-right:5.75pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-right:12.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including:</span></div><div style="padding-right:12.25pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the number of drug candidates that we pursue and their development requirements;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the scope, progress, results, and costs of our current and future preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the costs, timing, and outcome of regulatory review of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">if we obtain marketing approval for any current or future drug candidates, expenses related to product sales, marketing, manufacturing, and distribution;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">our ability to establish and maintain collaborations, licensing, and other strategic arrangements on favorable terms, and the success of such collaborations, licensing, and strategic arrangements;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:31pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the impact of any business interruptions to our operations or to the operations of our manufacturers, suppliers, or other vendors, including the timing and enrollment of participants in our planned clinical trials, resulting from the COVID-19 pandemic or other force majeure event;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:6pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the costs of preparing, filing, and prosecuting patent and other applications covering our intellectual property; maintaining, protecting, and enforcing our intellectual property rights; and defending intellectual property-related claims of third parties;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">our headcount growth and associated costs as we expand our business operations and our research and development activities, including into new geographies; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the costs of operating as a public company.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically have financed our operations primarily through private placements of our convertible preferred stock and, more recently, through the net proceeds from our initial public offering completed on April 20, 2021. As of September 30, 2021, we had cash and cash equivalents of $394.7 million. We expect that our existing cash position and short-term investments as of the date of this Quarterly Report on Form 10-Q will be sufficient to fund our operating expenses and capital expenditures for at least the next 12 months. However, identifying potential drug candidates and conducting preclinical development testing and clinical trials is a time-consuming and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our drug candidates, even if approved, may not achieve commercial success. We do not anticipate that our commercial revenues, if any, will be derived from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of products for at least several years. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives, and we may need to raise substantial additional funds sooner than expected.</span></div><div style="padding-right:15.1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:0.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenues, we expect to finance our cash needs potentially through a combination of private and public equity offerings and debt financings, as well as strategic collaborations, partnerships, and licensing arrangements. We do not have any committed external source of funds other than amounts payable by Takeda Pharmaceutical Company Limited (Takeda) and by Bayer AG (Bayer) under collaboration agreements. Disruptions in the financial markets in general, and more recently due to the COVID-19 pandemic and U.S. debt ceiling and budget deficit concerns, may make equity and debt financing more difficult to obtain. We cannot be certain that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional funds through equity or debt financings, or strategic collaborations or similar arrangements, on a timely basis and satisfactory terms, we may be required to significantly curtail, delay, or discontinue one or more of our research and development programs or the future commercialization of any drug candidate, or we may be unable to expand our operations or otherwise capitalize on our business opportunities as desired. Any of these circumstances could materially and adversely affect our business and results of operations</span><span style="background-color:#f4f4f5;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and may cause us to cease operations.</span></div><div style="padding-right:0.7pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:0.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations, require us to relinquish rights to our technologies or drug candidates, and divert management&#8217;s attention from our core business.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of any financing we obtain may adversely affect the holdings or rights of our stockholders, and the issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our shares to decline. To the extent that we raise additional capital through the sale of Class A common stock or securities convertible or exchangeable into Class A common stock, our stockholders&#8217; ownership interests will be diluted. Moreover, the terms of those securities may include liquidation or other preferences that materially and adversely affect our stockholders&#8217; rights as a common stockholder. Debt financing, if available, would</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in increased fixed payment obligations. In addition, we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, which could adversely impact our ability to make capital expenditures, declare dividends, or otherwise conduct our business. We also may need to raise funds through additional strategic collaborations, partnerships, or licensing arrangements with third parties at an earlier stage than would be desirable. Such arrangements could require us to relinquish rights to some of our technologies or drug candidates, future revenue streams, or research programs, or otherwise agree to terms unfavorable to us. Fundraising efforts have the potential to divert our management&#8217;s attention from our core business or create competing priorities, which may adversely affect our ability to develop and commercialize our drug candidates and technologies. </span></div><div style="padding-right:9.35pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:9.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are engaged in strategic collaborations and we intend to seek to establish additional collaborations, including for the clinical development or commercialization of our drug candidates. If we are unable to establish collaborations on commercially reasonable terms or at all, or if current and future collaborations are not successful, we may have to alter our development and commercialization plans.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development programs and the potential commercialization of our drug candidates will require substantial additional cash to fund expenses. To date our operating revenue has primarily been generated through funded research and development agreements with Takeda and Bayer. For example, in August 2020, we entered into a Research Collaboration and Option Agreement with Bayer (the Bayer Agreement) for discovery of small molecule drug candidates with the potential to treat fibrotic diseases, and we received a non-refundable upfront payment of $30.0 million that is recognized over time. We intend to seek additional strategic collaborations, partnerships, and licensing arrangements with pharmaceutical and biotechnology companies, including for the development and potential commercialization of one or more</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug candidates. In the near term, the value of our company will depend in part on the number and quality of the collaborations and similar arrangements that we create. Whether we reach a definitive agreement for a collaboration will depend, among other things, on our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the potential collaborator&#8217;s evaluation of a number of factors. Those factors may include, among others, (i) our technologies and capabilities; (ii) our intellectual property position with respect to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the subject drug candidate; (iii) the design or results of clinical trials; (iv) the likelihood of approval by the FDA and similar regulatory authorities outside the U.S.; (v) the potential market for the subject drug candidate; (vi) potential competing products; and (vii) industry and market conditions generally. In addition, the significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future collaborators.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations and similar arrangements are complex and time-consuming to negotiate and document. We may have to relinquish valuable rights to our product candidates, intellectual property, or future revenue streams, or grant licenses on terms that are not favorable to us or in instances where it would have been more advantageous for us to retain sole development and commercialization rights. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e may be restricted under collaboration agreements from entering into future agreements on certain terms with other potential collaborators. In addition, management of our relationships with collaborators will require (i) significant time and effort from our management team; (ii) coordination of our marketing and research and development programs with the marketing and research and development priorities of our collaborators; and (iii) effective allocation of our resources to multiple projects.</span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations and similar arrangements may never result in the successful development or commercialization of drug candidates or the generation of sales revenue. The success of these arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations, and they may not pursue or prioritize the development and commercialization of partnered drug candidates in a manner that is in our best interests. Product revenues arising from collaborations are likely to be lower than if we directly marketed and sold products. Disagreements with collaborators regarding clinical development or commercialization matters can lead to delays in the development process or commercialization of the applicable drug candidate and, in some cases, the termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies or other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. If we were to become involved in arbitration or litigation with any of our collaborators, it would consume time and divert management resources away from operations, damage our reputation, and impact our ability to enter into future collaboration agreements, and may further result in substantial payments from us to our collaborators to settle any disputes. </span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to establish additional strategic collaborations and similar arrangements on a timely basis, on acceptable terms, or at all, and to maintain and successfully conclude them. Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return. If we are unable to establish or maintain strategic collaborations and similar arrangements on terms favorable to us and realize the intended benefits, our research and development efforts and potential to generate revenue may be limited and our business and operating results could be materially and adversely impacted.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We or our current and future collaborators may never successfully develop and commercialize our drug candidates, which would negatively affect our results of operation and our ability to continue our business operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become profitable depends upon our ability to generate substantial revenue in an amount necessary to offset our expenses. To date, we have not generated any revenue from our drug candidates or technologies, other than limited grant revenues, as well as payments under collaboration agreements, including the Bayer agreement. We expect to continue to derive most of our revenue in the near future from collaboration relationships. We do not expect to generate significant revenue unless and until we progress our drug candidates through clinical trials and obtain marketing approval of, and begin to sell, one or more of our drug candidates, or we otherwise receive substantial licensing or other payments under our collaborations. Even if we obtain market approval for our drug candidates, one or more of them may not achieve commercial success.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization of our drug candidates depends on a number of factors, including but not limited to our ability to:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">successfully complete preclinical studies;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:7pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">obtain approval of Investigational New Drug (IND) applications by the FDA and similar regulatory approvals outside the U.S., allowing us to commence clinical trials;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">successfully enroll subjects in, and complete, clinical trials;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">receive regulatory approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">obtain patent and trade secret protection or regulatory exclusivity for our drug candidates, and maintain, protect, defend, and enforce such intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">launch commercial sales of our drug products, whether alone or in collaboration with other parties;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">obtain and maintain acceptance of our drug products by patients, the medical community, and third-party payors, and effectively compete with other therapies;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">obtain and maintain coverage of and adequate reimbursement for our drug products, if and when approved, by medical insurance providers; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">demonstrate a continued acceptable safety profile of drug products following marketing approval.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:33.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates, which would materially harm our business. </span></div><div style="padding-right:33.1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:33.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current or future collaborators would similarly need to be effective in the above activities as they pertain to the collaborators in order to successfully develop drug candidates. We and they may never succeed in developing and commercializing drug candidates. And even if we do, we may never generate revenues that are significant enough to achieve profitability; or even if our collaborators do, we may not receive option fees, milestone payments, or royalties from them that are significant enough for us to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would eventually depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, develop a pipeline of drug candidates, enter into collaborations, or even continue our operations.</span></div><div style="padding-right:16pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:15.85pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results may fluctuate significantly due to a variety of factors and could fall below our expectations or the expectations of investors or securities analysts, which may cause our stock price to fluctuate or decline.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of our future losses, and when we might achieve profitability, is uncertain, and our quarterly and annual operating results may fluctuate significantly for various reasons, including the following:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the timing of, and our levels of investment in, research and development activities relating to our drug candidates;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the timing of, and status of staffing and enrollment for, clinical trials;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the  results of clinical trials for our drug candidates, including whether there are any unexpected health or safety concerns with our drug candidates and whether we receive marketing approval for them;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">commercialization of competing drug candidates or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:27pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the timing and cost of manufacturing our drug candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">additions and departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the level of demand for our drug candidates should they receive approval, which may vary significantly; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">changes in the regulatory environment or market or general economic conditions. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of one or more of these or other factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet any forecasts we provide to the market, or the expectations of industry or financial analysts or investors, for any period. If one or more of these events occur, the price of our Class A common stock could decline substantially. </span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:15.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders&#8217; equity, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may engage in acquisitions and strategic partnerships in the future, including by licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition or strategic partnership may entail numerous risks, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">increased operating expenses and cash requirements;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the assumption of indebtedness or contingent liabilities;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the issuance of our equity securities, which would result in dilution to our stockholders&#8217; equity;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">difficulties in assimilating operations, intellectual property, products, and drug candidates of an acquired company, and with integrating new personnel;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives, even if we are unable to complete such proposed transaction;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to retain key employees and maintain key business relationships;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:9pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or drug candidates and ability to obtain regulatory approvals; and</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:37pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">our inability to generate revenue from acquired intellectual property, technology, and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:35.3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake such a transaction, we may assume or incur debt obligations, incur a large one-time expense, or acquire intangible assets, which could result in significant future amortization expense and adversely impact our results of operations.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF DRUG CANDIDATES</span></div><div style="padding-right:23.05pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:23.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to drug discovery is unique and may not lead to successful drug products for various reasons, including but not limited to challenges identifying mechanisms of action for our candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We image cells and use cell morphology to understand how a diseased cell responds to drugs and if or when it appears normal. Biology is complex. If studying the shape, structure, form, and size of cells does not prove to be an accurate way to better understand diseases or does not lead to the biological insights or viable drug candidates we anticipate, our drug discovery platform may not be useful or may not lead to successful drug products, or we may have to move to a new business model, any of which could have an adverse effect on our reputation and results of operations. If the mechanism of action of a drug candidate is unknown, it may be more difficult to choose the best lead to optimize from an efficacy standpoint and to avoid potential off-target side effects that could affect safety. Such uncertainty could make it more difficult to form partnerships with larger pharmaceutical companies, as the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses involved in late-phase clinical trials increase the level of risk related to potential efficacy and/or safety concerns and may pose challenges to IND and/or New Drug Application (NDA) approval by the FDA or other regulatory agencies.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:45.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our drug candidates are in preclinical or clinical development, which are lengthy and expensive processes with uncertain outcomes and the potential for substantial delays.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current drug candidates are in preclinical or clinical development. Before we can bring any drug candidate to market, we must, among other things, complete preclinical studies, have the candidate manufactured to appropriate specifications, conduct extensive clinical trials to demonstrate safety and efficacy in humans, and obtain marketing approval from the FDA and other appropriate regulatory authorities, which we have not yet demonstrated our ability to do. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of a clinical trial can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.  We may accelerate development from cell models in our drug discovery platform directly to patients without validating results through animal studies or validate results in animal studies at the same time as we conduct Phase 1 clinical trials. This approach could pose additional risks to our success if the effect of certain of our drug candidates on diseases has not been tested in animals prior to testing in humans.</span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four clinical-stage drug candidates focused on rare, monogenic diseases, and we anticipate filing IND applications with the FDA or other regulators for Phase 2 studies for all four drug candidates. We may not be able to file such INDs, or INDs for any other drug candidates, on the timelines we expect, if at all, and any such delays could impact any additional product development timelines. Moreover, we cannot be sure that submission of an IND will result in the FDA or other regulators allowing further clinical trials to begin or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. These regulatory authorities could change their guidance at any time, including their positions on the acceptability of our trial designs or the clinical endpoints or populations selected, which may require us to complete additional or longer clinical trials, or they may impose stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting an NDA to the FDA, as well as a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for each drug candidate and, consequently, to the ultimate approval and commercial marketing of each drug candidate. We do not know whether any of our future clinical trials will begin on time or be completed on schedule, if at all.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in completing our preclinical studies and initiating or completing clinical trials, or numerous unforeseen events during, or as a result of, any clinical trials, that could require us to incur additional costs or delay or prevent our ability to receive marketing approval or to commercialize our drug candidates, including those related to one or more of the following:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:15pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">regulators, Institutional Review Boards (IRBs), or ethics committees may not authorize us or our investigators to commence a clinical trial or to conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:17pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">we may have difficulty reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective Contract Research Organizations (CROs), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:26pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">the number of participants required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:25pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">our third-party contractors may fail to comply with regulatory requirements, fail to meet their contractual obligations to us in a timely manner or at all, deviate from the clinical trial protocol, or drop out of a trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22pt;text-indent:-10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">the supply or quality of our drug candidates or the other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate;</span></div><div style="margin-top:6pt;padding-left:22pt;text-indent:-10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">the occurrence of delays in the manufacturing of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:22pt;text-indent:-10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">reports may arise from preclinical or clinical testing of other therapies that raise safety, efficacy, or other concerns about our drug candidates; and</span></div><div style="margin-top:6pt;padding-left:22pt;text-indent:-10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">clinical trials may produce inconclusive or negative results about our drug candidates, including that candidates have undesirable side effects or other unexpected characteristics, in which event, we may decide &#8211; or our investigators or regulators, IRBs, or ethics committees may require us &#8212; to suspend the trials in order to conduct additional studies or to terminate the trials.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time as we move through the stages of development, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as enrollment of participants continues and more data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:28pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. If we decide or are required to suspend or terminate a clinical trial, we may elect to abandon product development for that program. Significant preclinical study or clinical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial delays, including those caused by the COVID-19 pandemic, also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates. Any delays in or unfavorable outcomes from our preclinical or clinical development programs may significantly harm our business, operating results, and prospects.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate, continue, and complete clinical trials for current or future drug candidates if we are unable to locate and timely enroll a sufficient number of eligible participants in these trials as required by the FDA or similar regulatory authorities outside the United States. The process of finding potential participants may prove costly and our ability to enroll eligible participants may be limited or may result in slower enrollment than we anticipate due to a number of factors, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the eligibility criteria for the clinical trial in question, including that participants have specific characteristics or diseases;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the availability of an appropriate genomic screening test;</span></div><div style="margin-top:6pt;padding-left:21.6pt;text-indent:-9.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.85pt">the perceived risks and benefits of the drug candidate under study;</span></div><div style="margin-top:6pt;padding-left:21.6pt;text-indent:-9.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.85pt">difficulties in identifying, recruiting, and enrolling a sufficient number of participants to complete our clinical studies;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the referral practices of physicians;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">whether competitors are conducting clinical trials for drug candidates that treat the same indications as ours, and the availability and efficacy of competing therapies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to monitor participants adequately during and after the trial and to maintain participant informed consent and privacy;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the proximity and availability of clinical trial sites for prospective participants;</span></div><div style="margin-top:6pt;padding-left:21pt;padding-right:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">pandemics such as the COVID-19 pandemic, natural disasters, or other external events that may limit the availability of participants, principal investigators, study staff, or clinical sites; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that enrolled participants will not complete a clinical trial.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If individuals are unwilling to participate in or complete our studies for any reason, or we experience other difficulties with enrollment or participation, the timeline for recruiting participants, conducting studies, and obtaining regulatory approval of potential products may be delayed.</span></div><div style="padding-right:11pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our planned clinical trials, or those of our current and potential future collaborators, may not be successful or may reveal significant adverse events not seen in our preclinical or nonclinical studies, which may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our drug candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through preclinical studies and clinical trials that our drug candidates are both safe and effective for use in each target indication. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials, and initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of drug candidates proceeding through clinical trials. Drug candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most drug</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates that commence clinical trials are never approved as products, and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our drug candidates.</span></div><div style="padding-right:22pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with many treatments for rare diseases and other conditions, there have been, and it is likely that in the future there may be, side effects associated with the use of our drug candidates. Moreover, if we develop drug candidates in combination with one or more disease therapies, it may be more difficult to accurately predict side effects.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our current or future drug candidates, we may have difficulty recruiting participants in our clinical trials, they may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more drug candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a drug candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials were later found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, operating results, and prospects.</span></div><div style="padding-right:37pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:36.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future conduct clinical trials for our drug candidates outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future choose to conduct additional clinical trials outside the United States, including in Australia, Europe, Asia, or other jurisdictions. FDA acceptance of trial data from clinical trials conducted outside the United States may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; (ii) the trials are performed by clinical investigators of recognized competence; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including a sufficiently large size of trial populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our drug candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the United Kingdom&#8217;s departure from the EU (referred to as Brexit) on January 31, 2020, and the end of the &#8220;transition period&#8221; on December 31, 2020, the EU and the United Kingdom entered into a trade and cooperation agreement that governs certain aspects of their future relationship, including the assurance of tariff-free trade for certain goods and services. As the regulatory framework for pharmaceutical products in the United Kingdom relating to the quality, safety, and efficacy of pharmaceutical products; clinical trials; marketing authorization; and commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit will materially impact the future regulatory regime that applies to products and the approval of drug candidates in the United Kingdom. Longer term, the United Kingdom is likely to develop its own legislation that diverges from that in the EU.</span></div><div style="padding-right:7pt"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult to establish with precision the incidence and prevalence for target patient populations of our drug candidates. If the market opportunities for our drug candidates are smaller than we estimate, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if approved for commercial sale, the total addressable market for our drug candidates will ultimately depend upon, among other things, (i) the diagnosis criteria included in the final label and whether our drug candidates are approved for these indications; (ii) acceptance by the medical community; and (iii) patient access, product pricing, and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement by third-party payors. The number of patients targeted by our drug candidates may turn out to be lower than expected, patients may not be amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Due to our limited resources and access to capital or for other reasons, we must prioritize development of certain drug candidates, which may prove to be the wrong choice and may adversely affect our business.</span></div><div style="padding-right:3pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we intend to explore other therapeutic opportunities in addition to the drug candidates that we are currently developing, we may fail to identify viable new drug candidates for clinical development for a number of reasons.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:17.3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to pursue the development of our existing and planned drug candidates for additional indications, and to identify new drug candidates and disease targets, require substantial technical, financial, and human resources whether or not they are ultimately successful. For example, under the Bayer agreement, we are collaborating with Bayer to develop various projects related to fibrosis. There can be no assurance that we will find potential targets using this approach, that any such targets will be tractable, or that clinical validations will be successful. Our research programs may initially show promise in identifying potential indications and/or drug candidates, yet fail to yield results for clinical development for a number of reasons, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the research methodology used may not be successful in identifying potential indications and/or drug candidates, including as a result of the limited patient sample represented in our databases and the validity of extrapolating based on insights from a particular cellular context that may not apply to other, more relevant cellular contexts;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22pt;text-indent:-10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">potential drug candidates may, after further study, be shown to have harmful side effects or other characteristics that indicate they are unlikely to be effective products; or</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:30pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">it may take greater human and financial resources than we can allocate to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, thereby limiting our ability to develop, diversify, and expand our product portfolio.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and human resources, we will have to prioritize and focus on certain research programs, drug candidates, and target indications while forgoing others. As a result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:29pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially adversely affect our future growth and prospects.</span></div><div style="padding-right:29pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:12.95pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or there are delays in obtaining required regulatory approvals for our drug candidates in the U.S. or other jurisdictions, or if approval is subject to limitations, we will be unable to commercialize, or will be delayed or limited in commercializing, the drug candidates in such jurisdiction and our ability to generate revenue may be materially impaired.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates and the activities associated with their development and commercialization &#8212; including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export &#8212; are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize any of our drug candidates, we must obtain marketing approval. Currently, all of our drug candidates are in development and we have not received approval to market any of our drug candidates from regulatory authorities in any jurisdiction. It is possible that our current and future drug candidates will never obtain regulatory approval. </span></div><div style="padding-right:2.15pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:2.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only limited experience in filing and supporting applications to regulatory authorities and expect to rely on CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#8217;s safety and efficacy. It also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Given our novel approach to drug discovery that uses our platform to generate data, regulatory authorities may not approve any of our drug candidates derived from our platform or they may elect to inspect our platform.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical or clinical trials, approval, if obtained at all, may be delayed. The length of such a delay may vary substantially based upon a variety of factors, including the type, complexity, and novelty of the drug candidates involved. Delays in the approval or rejection of an application may also be caused by (i) changes in marketing approval policies during the development period; (ii) changes in or the enactment of additional statutes or regulations; or (iii) changes in regulatory review for each submitted NDA, 510(k), Premarket Approval Application, or equivalent application types. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application, or they may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. Our drug candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may not be able to enroll a sufficient number of patients in our clinical studies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:23pt;padding-right:18pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication or that a related companion diagnostic is suitable to identify appropriate patient populations;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:18pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">a drug candidate may be only moderately effective or may have undesirable or unintended side effects, toxicities, or other characteristics;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:18pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">we may be unable to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:22pt;text-indent:-10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:24pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">the data collected from clinical trials of our drug candidates may not be sufficient or of sufficient quality to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:17pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">the FDA or comparable foreign regulatory authorities may find deficiencies with, or fail to approve, our  manufacturing processes or facilities, or those of third-party manufacturers with which we contract, for clinical and commercial supplies; and</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:28pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical or manufacturing data are insufficient for approval.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the drug candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a drug candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. </span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If are unable to obtain or experience delays in obtaining approval of our current and future drug candidates in the U.S. or other jurisdictions, or if approval is subject to limitations, the commercial prospects for the drug candidates may be harmed, and our reputation and ability to generate revenues may be materially impaired.</span></div><div style="padding-right:18pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never realize a return on our investment of resources and cash in our drug discovery collaborations.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct drug discovery activities for or with collaborators who are also engaged in drug discovery and development, which include pre-commercial biotechnology companies and large pharmaceutical companies. Under these collaborations, we typically provide the benefit of our drug discovery platform and platform experts who identify molecules that have activity against one or more specified targets, among other resources. In consideration, we have received, and expect to receive in the future, (i) equity investments; (ii) upfront fees; and/or (iii) the right to receive option fees, cash milestone payments upon the achievement of specified development, regulatory, or commercial sales milestones for the drug discovery targets, and potential royalties. Our ability to receive fees and payments and realize returns from our drug discovery collaborations in a timely manner, or at all, is subject to a number of risks, including but not limited to the following:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">our collaborators may incur unanticipated costs or experience delays in completing, or may be unable to complete, the development and commercialization of any drug candidates;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:12pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to our collaborations and may not perform their obligations as expected;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:12pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">collaborators may decide not to pursue development or commercialization of drug candidates for various reasons, including results of clinical trials or other studies, changes in the collaborator&#8217;s strategic focus or available funding, their desire to develop products that compete directly or indirectly with our drug candidates, or external factors (such as an acquisition or industry slowdown) that divert resources or create competing priorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">existing collaborators and potential future collaborators may begin to perceive us to be a competitor more generally, particularly as we advance our internal drug discovery programs, and therefore may be unwilling to continue existing collaborations, or enter into new collaborations, with us;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution, or marketing of a drug candidate or product;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation, or the preferred course of development, might cause delays or terminations of the research, development, or commercialization of drug candidates, or might result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:19pt;text-align:justify;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">collaborators may not properly obtain, maintain, enforce, defend, or protect our intellectual property or proprietary rights, or they may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our or their intellectual property or proprietary rights;</span></div><div style="margin-top:6pt;padding-left:23pt;padding-right:7pt;text-indent:-11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">collaborators may infringe, misappropriate, or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">drug discovery collaborations may be terminated prior to our receipt of any significant value.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be over-reliant on our partners to provide information for molecules that we in-license, or such molecules may not be well-protected because the composition of matter patents that once protected them have expired. Moreover, we may have difficulty obtaining the quality and quantity of active pharmaceutical ingredients (API) for use in drug candidates, or we may be unable to ensure the stability of the molecule, all of which is needed to conduct clinical trials or bring a drug candidate to market. For those molecules that we are attempting to repurpose for other indications, our partners may not have sufficient data, may have poor quality data, or may not be able to help us interpret data, any of which could cause our collaboration to fail.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:20pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any drug discovery collaborations that we enter into do not result in the successful development and commercialization of drug products that result in option fees, milestone payments, royalties, or other payments to us, we may not receive an adequate return on the resources we have invested in such collaborations, which would have an adverse effect on our business and results of operations. Further, we may not have access to, or may be restricted from disclosing, certain information regarding our collaborators&#8217; drug candidates being developed or commercialized and, consequently, may have limited ability to inform our stockholders about the status of, and likelihood of achieving, milestone payments or royalties under such collaborations.</span></div><div style="padding-right:20pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing, or commercializing products before, or more successfully than, we do.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. There are other companies focusing on technology-enabled drug discovery to identify and develop new chemical entities that have not previously been investigated in clinical trials (NCEs) and/or known chemical entities that have been previously investigated (KCEs). Some of these competitive companies are employing scientific approaches that are the same as or similar to our approach, and others are using entirely different approaches. These companies include large pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies of various sizes worldwide. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Potential competitors also include academic institutions, government agencies, and other public and private research organizations. Many of the companies that we compete against, or which we may compete against in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. They may also compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient recruitment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the field of tech-enabled drug discovery, we believe that our approach utilizing a combination of wet-lab biology to generate our proprietary dataset, and the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tools in our closed-loop system, sets us apart and affords us a competitive advantage in initiating and advancing drug development programs. We further believe that the principal competitive factors to our business include (i) the accuracy of our computations and predictions; (ii) the ability to integrate experimental and computational capabilities; (iii) the ability to successfully transition research programs into clinical development; (iv) the ability to raise capital; and (v) the scalability of our platform, pipeline, and business.</span></div><div style="padding-right:12pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any drug candidates that we successfully develop and commercialize will compete with currently-approved therapies, and new therapies that may become available in the future, from segments of the pharmaceutical, biotechnology, and other related industries. The key competitive factors affecting the success of all of our drug candidates, if approved, are likely to be (i) their efficacy, safety, convenience, and price; (ii) the level of non-generic and generic competition; and (iii) the availability and amount of reimbursement from government healthcare programs, commercial insurance plans, and other third-party payors. Our commercial opportunity could be reduced or eliminated if competing products are more effective, have fewer or less severe side effects, are more convenient, or are less expensive than products that we or our collaborators may develop, or if competitors obtain FDA or other regulatory approval more rapidly than us and are able to establish a strong market position before we or our collaborators are able to enter the market. </span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary tools and technology and other competitive advantages do not remain in place and evolve appropriately as barriers to entry in the future, or if we and our collaboration partners are not otherwise able to effectively compete against existing and potential competitors, our business and results of operations may be materially and adversely affected.</span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:15.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we have multiple programs and drug candidates in our development pipeline and are pursuing a variety of target indications and treatment modalities, we may expend our limited resources to pursue a particular drug candidate and fail to capitalize on development opportunities or drug candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently focus on the development of drug candidates regardless of the treatment modality or the particular target indication. Because we have limited financial and personnel resources, we may forgo or delay pursuit of opportunities with potential target indications or drug candidates that later prove to have greater commercial potential than our current and planned development programs and drug candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future drug candidates for specific indications may not yield any commercially viable future drug candidates.</span></div><div style="padding-right:6pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:27.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we have made, and in the future are likely to make, public statements regarding the expected timing of certain milestones and key events, such as the commencement and completion of preclinical and clinical studies in our internal drug discovery programs as well as developments and milestones under our collaborations. Our collaborators, such as Bayer, have also made public statements regarding expectations for the development of programs under collaborations with us and may in the future make additional statements about their goals and expectations for collaborations with us. The actual timing of these events can vary dramatically due to a number of factors, such as (i) delays or failures in our or our current and future collaborators&#8217; drug discovery and development programs; (ii) the amount of time, effort, and resources committed by us and our current and future collaborators; and (iii) the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that our or our current and future collaborators&#8217; programs will advance or be completed in the time frames we or they announce or expect. If we or any collaborators fail to achieve one or more of these milestones or other key events as planned, our business and reputation could be materially adversely affected.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR PLATFORM AND DATA</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have invested, and expect to continue to invest, in research and development efforts to further enhance our drug discovery platform, which is central to our mission. If the return on these investments is lower or develops more slowly than we expect, our business and operating results may suffer.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug discovery platform is central to our mission to decode biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering. The platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. Our platform depends upon the continuous, effective, and reliable operation of our software, hardware, databases, and related tools and functions, as well as the integrity of our data. Our ability to develop drug candidates and increase revenue depends in large part on our ability to enhance and improve our platform. The success of any enhancement depends on several factors, including (i) innovation in hardware solutions; (ii) increased computational storage and processing capacity; (iii) development of more advanced algorithms; and (iv)  generation of additional biological and chemical data, such as that necessary to our ability to identify important and emerging use cases and quickly develop new and effective innovations to address those use cases. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested, and expect to continue to invest, in research and development efforts that further enhance our platform. These investments may involve significant time, risks, and uncertainties, including the risks that any new software or hardware enhancement may not be introduced in a timely or cost-effective manner; may not keep pace with technological developments; or may not achieve the functionality necessary to generate significant revenues.  </span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:4.3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary software tools, hardware, and data sets are inherently complex. We have from time to time found defects, vulnerabilities, or other errors in our software and hardware that produce the data sets we use to discover new drug candidates, and new errors with our software and hardware may be detected in the future. The risk of errors is particularly significant when new software or hardware is first introduced or when new versions or enhancements of existing software or hardware are implemented. Errors may also result from the interface of our proprietary software and hardware tools with our data or with third-party systems and data. </span></div><div style="padding-right:4.3pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully enhance our drug discovery platform, or if there are any defects or disruptions in our platform that are not timely resolved, our ability to develop new innovations and ultimately gain market acceptance of our products and discoveries could be materially and adversely impacted, and our reputation, business, and operating results could be materially harmed.</span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems and infrastructure may fail or experience security breaches that could adversely impact our business and operations and subject us to liability.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant growth in the complexity of our data and the software tools that our hardware infrastructure supports. We rely significantly upon information technology systems and infrastructure owned and maintained by us or by third party providers to generate, collect, store, and transmit confidential information and data (including but not limited to intellectual property, proprietary business information, and personal information) and to operate our business. We also outsource elements of our operations to, and obtain products and services from, third parties and engage in collaborations for drug discovery with third parties, each of which has or could have access to our confidential information. </span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deploy and operate an array of technical and procedural controls to reduce the risks to our information technology systems and infrastructure and to maintain the confidentiality and integrity of our data, and we expect to continue to incur significant costs on detection and prevention efforts.  Despite these measures, our information technology and other internal infrastructure systems face the risk of failures, security breaches, or other harm from various causes or sources, and third parties with whom we share confidential information may also experience similar events that materially impact us. These causes or sources include:</span></div><div style="margin-top:6pt;padding-right:4pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">service interruptions;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">system malfunctions;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">computer viruses; </span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">natural disasters; </span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">telecommunication and electrical failures; </span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">inadvertent or intentional actions by our employees or third-party providers; and </span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:4pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">cyber-attacks by malicious third parties, including the deployment of malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information.</span></div><div style="padding-right:10.8pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to cyber-attacks, the techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups and individuals with a range of motives (including industrial espionage) and expertise, such as organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies. The costs to us to investigate and mitigate cybersecurity incidents in particular could be significant. We may not be able to anticipate all types of security threats and implement preventive measures effective against all such threats. In addition, in response to the ongoing COVID-19 pandemic, an increased amount of work is occurring remotely, including through the use of mobile devices. This could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced, and may continue to experience, cyber-attacks, security breaches, and other system failures, although to our knowledge we have not experienced any material interruption or incident to date. If we do not accurately predict and identify our infrastructure requirements and failures and timely enhance our infrastructure, or if our remediation efforts are not successful, it could result in a material disruption of our business operations and development programs, including the loss or unauthorized disclosure of our trade secrets, individuals&#8217; personal information, or other proprietary or sensitive data. For example, we use a set of proprietary tools to generate, analyze, and derive novel insights from our biological and chemical data. The loss, corruption, unavailability of, or damage to our data would interfere with and undermine the insights we draw from our platform, which could result in the waste of resources on insights based on flawed premises or other adverse consequences. In addition, the loss or corruption of, or other damage to, clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts, as well as significant costs to recover or reproduce the data. A security breach that leads to unauthorized disclosure of our intellectual property or other proprietary information could also affect our intellectual property rights and enable competitors to compete with us more effectively. Likewise, as we rely on third parties for the manufacture of our drug candidates and to conduct clinical trials, similar events relating to their systems and operations could also have a material adverse effect on our business and lead to regulatory agency actions. </span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, any security breach or other event that leads to loss, unauthorized access to, or disclosure of personal information, including personal information regarding clinical trial subjects, contractors, directors, or employees, could harm our reputation, compel us to comply with federal and/or state notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. For more information see &#8220;Risk Factors&#8212; We are subject to U.S. and foreign laws regarding privacy and data security that could entail substantial compliance costs, while the failure to comply could subject us to significant liability&#8221; set forth below.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that failures, disruptions, security breaches, cyber-attacks, or other harmful events result in a loss of or damage to our information technology systems or infrastructure &#8211;  or the inappropriate acquisition or disclosure of confidential, proprietary, or personal information &#8211; we could be exposed to a risk of loss, enforcement measures, regulatory agency actions, penalties, fines, indemnification claims, litigation, potential civil or criminal liability, collaborators&#8217; loss of confidence, damage to our reputation, and other consequences, which could materially adversely affect our business and results of operations. While we maintain insurance coverage for certain expenses and liabilities related to failures or breaches of our information technology systems, it may not be adequate to cover all losses associated with such events. In addition, such insurance may not be available to us in the future on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfactory terms or at all. Furthermore, if the information technology systems of third parties with whom we do business become subject to disruptions or security breaches, we may have insufficient recourse against them.</span></div><div style="padding-right:4.3pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:9.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruptions in the availability of server systems or communications with internet or cloud-based services, or failure to maintain the security, confidentiality, accessibility, or integrity of data stored on such systems, could harm our business.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party data centers and telecommunications solutions, including cloud infrastructure services such as Google Cloud and Amazon Web Services, to host substantial portions of our technology platforms and to support our business operations. We have no control over these cloud-based service or other third-party providers, although we attempt to reduce risk by minimizing reliance on any single third party or its operations. We have experienced, and expect we may in the future again experience, system interruptions, outages, or delays due to a variety of factors, including infrastructure changes, human or software errors, website hosting disruptions, and capacity constraints. A prolonged service disruption affecting our cloud-based solutions could damage our reputation or otherwise materially harm our business. </span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if the security measures of our third-party data center or cloud infrastructure providers are breached by cyber-attacks or other means and unauthorized access to our information technology systems or data occurs, it could result in interruptions to our operations and the loss of proprietary or confidential information, which could damage our reputation, cause us to incur substantial costs, divert our resources from other tasks, and subject us to significant legal and financial exposure and liabilities, any one of which could&#160;materially adversely affect our business, results of operations, and prospects. Such third-party providers may also be subject to natural disasters, power losses, telecommunications failures, or other disruptive events that could negatively affect our business and require us to incur significant costs to secure alternate cloud-based solutions. In addition, any changes in our providers&#8217; service levels or features that we utilize or a termination of our agreements could also adversely affect our business.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:37pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our solutions utilize third-party open source software (OSS), which presents risks that could adversely affect our business and subject us to possible litigation.</span></div><div style="padding-right:3pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our solutions include software that is licensed from third parties under open source licenses, and we expect to continue to incorporate such OSS in our solutions in the future. We cannot ensure that we have effectively monitored our use of OSS, validated the quality or source of such software, or are in compliance with the terms of the applicable open source licenses or our policies and procedures. Use of OSS may entail greater risks than use of third-party commercial software as open source licensors generally do not provide support, updates, or warranties or other contractual protections regarding infringement claims or the quality of the code. OSS may also be more susceptible to security vulnerabilities. Third-party OSS providers could experience service outages, data loss, privacy breaches, cyber-attacks, and other events relating to the applications and services they provide, which could diminish the utility of these services and harm our business. We also could be subject to lawsuits by third parties claiming that what we believe to be licensed OSS infringes such parties&#8217; intellectual property rights, which could be costly for us to defend and require us to devote additional research and development resources to change our solutions. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR OPERATIONS/COMMERCIALIZATION</span></div><div style="padding-right:8pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may materially and adversely affect our business and operating results and could disrupt the development of our drug candidates.</span></div><div style="padding-right:8pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;COVID-19 pandemic, which has continued to spread, and the related adverse public health developments, have disrupted the normal operations of businesses across industries, including the biotechnology and pharmaceutical industries. National, state, and local governments in regions affected by the&#160;COVID-19 pandemic have implemented, or may implement or reinstitute, measures such as quarantines, shelter-in-place policies, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">travel restrictions, and other public safety protocols. The health effects of the pandemic, along with these initiatives, have adversely affected workforces, organizations, government entities, healthcare communities, regional and national economies, and financial markets, leading to economic slowdowns and increased market volatility from time to time. </span></div><div style="padding-right:8pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor applicable government recommendations and have made some modifications to our normal operations. For example, we have instituted a temporary work from home policy for certain personnel and suspended all non-essential business travel. Although we believe that these and the other safety measures we have taken have not substantially impacted our productivity or business activities, it is not certain that this will continue to be the case. Moreover, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of the increased number of personnel working remotely, which may be less secure and lead to the release of confidential or proprietary information that could adversely affect our business. And notwithstanding governmental precautionary measures or those implemented by us, the COVID-19 pandemic or other similar outbreak could affect the health and availability of our workforce, as well as that of the third parties from whom we obtain goods and services. </span></div><div style="padding-right:8pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the continued global spread of COVID-19 &#8212; including any variants that are more contagious, have more severe effects, or are resistant to treatments or vaccinations &#8212; could adversely impact our preclinical or clinical trial operations in the U.S. and other countries, including our ability to recruit and retain trial participants as well as principal investigators and site staff. As may be the case with other biopharmaceutical companies, we could experience protocol deviations, difficulties in enrolling participants, and delays in activating new trial sites and in initiating and concluding preclinical and clinical studies. Also, the&#160;COVID-19 pandemic could make it more difficult or costly to source products needed for the trials, or to engage with CROs and regulators regarding our drug candidates. Any negative impact COVID-19 has on enrollment in or the execution of our drug trials, or our interactions with CROs or regulators, could cause costly delays, adversely affect our ability to obtain regulatory approval for and to commercialize our drug candidates, increase our operating expenses, and have a material adverse effect on our business and operating results.</span></div><div style="padding-right:8pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate direct and indirect impacts of COVID-19 on our operations, including our research and development activities and preclinical and clinical trials, or the operations of our third-party partners, will depend on future developments that are highly uncertain and difficult to predict, including (i) the duration and severity of the pandemic; (ii) the  availability and acceptance rates of vaccines; (iii) the availability and effectiveness of treatments; and (iv) the success of containment and protective measures. If these impacts are more severe than we anticipate or our countermeasures are insufficient, it could disrupt our ability to develop, obtain regulatory approvals for, and commercialize drug candidates, and have a material adverse effect on our business and results of operation. Further, uncertainty around these and related issues could lead to adverse effects on the economies of the U.S. and other countries, which could impact our ability to raise the capital needed to develop and commercialize our drug candidates.</span></div><div style="padding-right:22.3pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:22.3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any drug candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our drug candidates that receive marketing approval will depend upon their degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. The degree of market acceptance will depend on a number of factors, including:</span></div><div style="padding-right:11pt"><span><br/></span></div><div style="padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">their efficacy and safety as demonstrated in pivotal clinical trials and published in peer-reviewed journals;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">their potential and perceived advantages compared to alternative treatments, including any similar generic treatments;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the prevalence and severity of any side effects or adverse events;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to offer these products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:21pt;padding-right:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to offer appropriate patient access programs, such as co-pay assistance;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:21pt;padding-right:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">their convenience and ease of dosing and administration compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the clinical indications for which the drug candidate is approved by the FDA or comparable regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">product labeling or product insert requirements of the FDA or other comparable foreign regulatory authorities, including any limitations, contraindications, or warnings;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">restrictions on how the product is distributed;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of market introduction of competitive products;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">publicity concerning these products or competing products and treatments;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the strength of marketing and distribution support; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">favorable third-party coverage and sufficient reimbursement.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:12.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically-effective, and cost-effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups, as well as the viewpoints of influential physicians, can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies, or private insurers will determine that any product we may develop is safe, therapeutically effective and cost-effective as compared with competing treatments. If any drug candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:12.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any drug candidates we may develop, we may not be successful in commercializing those drug candidates, if and when they are approved.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have little experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, develop sales and marketing software solutions, or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to market and sell our drug candidates, if and when they are approved. We may also elect to enter into collaborations or strategic partnerships with third parties to engage in commercialization activities with respect to selected drug candidates, indications, or geographic territories, including territories outside the United States, although there is no guarantee we will be able to enter into these arrangements.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time-consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition commercialization personnel. Factors that may inhibit our efforts to commercialize any approved product on our own include:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the inability of sales personnel or software tools to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the inability to price products at a sufficient price point to enable an adequate and attractive level of profitability;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></div><div style="margin-top:6pt;padding-left:21pt;padding-right:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, they may also experience many of the above challenges. In addition, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop internally. We may not be successful in entering into such arrangements, or we may be unable to do so on terms that are favorable to us or them. We also may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively, or they may expose us to legal and regulatory risk by not adhering to regulatory requirements and restrictions governing the sale and promotion of prescription drug products, including those restricting off-label promotion. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing any future approved drug candidates.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:29pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal facilities and those of our external service providers.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in Salt Lake City, Utah have not been reviewed or pre-approved by any regulatory agency, such as the FDA. An inspection by the FDA could disrupt our ability to generate data and develop drug candidates. Our laboratory facilities are designed to incorporate a significant level of automation of equipment, with integration of several digital systems to improve efficiency of research operations. We have attempted to achieve a high level of digitization for a research operation relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of equipment malfunction and even overall system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility, or potential cybersecurity breaches. This may lead to delay in potential drug candidate identification or a shutdown of our facility. Any disruption in our data generation capabilities could cause delays in advancing new drug candidates into our pipeline, advancing existing programs, or enhancing the capabilities of our platform, including expanding our data, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the future, we may manufacture drug substances or products at our facilities for preclinical and clinical use, and we may face risks arising from our limited prior manufacturing capability and experience.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or capability internally to manufacture drug substances or products for preclinical, clinical, or commercial use. If, in the future, we decide to produce drug substances or products for preclinical and clinical use, the costs of developing suitable facilities and infrastructure and implementing appropriate manufacturing processes may be greater than expected. We may also have difficulty implementing the full operational state of the facility, causing delays to preclinical or clinical supply or the need to rely on third-party service providers, resulting in unplanned expenses.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our development and commercial capacity, we may establish manufacturing capabilities inside the Salt Lake City area or in other locations or geographies, which may lead to regulatory delays or prove costly. If we fail to select the correct location, complete construction in an efficient manner, recruit the appropriate personnel, and generally manage our growth effectively, the development and production of our investigational medicines could be delayed or curtailed.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:27pt"><span><br/></span></div><div style="padding-right:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recursion, or the third parties upon whom we depend, may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not be adequate.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:19pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in Salt Lake City, Utah; Milpitas, California; and Canada. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics (including any potential effects from the current global spread of COVID-19), power shortages, telecommunications failure, or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our drug candidates, and interruption of our business operations. Natural disasters or pandemics, such as the COVID-19 outbreak, could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations, and prospects. Our wet lab houses the robots used to produce our dataset that builds the Recursion Data Universe, which is a key means by which we conduct drug candidate discovery. If a natural disaster, power outage, or other event occurred that (i) prevented us from using all or a significant portion of our headquarters or the datacenter where we collocate our graphics processing unit cluster; (ii) damaged critical infrastructure or our robots, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers; or (iii) otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we do not have a disaster recovery and business continuity plan for systems related to chemistry. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, the amounts of insurance may not be sufficient to satisfy all damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our facilities in Salt Lake City, Utah are located in a busy downtown area. Although we believe we have taken the necessary steps to ensure our operations are safe to the surrounding area, there could be a risk to the public if we were to conduct hazardous material research, including use of flammable chemicals and materials, at our facilities. If the surrounding community  perceives our facility as unsafe, it could have a material and adverse effect on our reputation and operations.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:46pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety, or other laws and regulations, we could become subject to fines, penalties, or personal injury or property damages.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety, and other laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for significant damages for harm to persons or property, as well as civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover costs and expenses arising from injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</span></div><div style="padding-right:12pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter and insurance coverage is becoming increasingly expensive. For example, we can only obtain insurance for the loss of our data that would partially compensate us for its loss. We do not know if we will be able to maintain existing insurance with adequate levels of coverage in the future, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. If we obtain marketing approval for any drug candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. The coverage or coverage limits currently maintained under our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected. Clinical trials or regulatory approvals for any of our drug candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any drug candidates that we or our collaborators may identify. Additionally, operating as a public company will make it more expensive for us to obtain directors and officers liability insurance. If we do not have adequate levels of directors and officers liability insurance, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors.</span></div><div style="padding-right:12pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial federal net operating loss (NOL) carryforwards. To the extent that we continue to generate taxable losses as expected, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except under certain circumstances. Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use pre-change NOL carryforwards and certain other pre-change tax attributes (such as research tax credits) to offset its post-change income could be subject to an annual limitation. An &#8220;ownership change&#8221; is generally defined as a greater than 50%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">change by value in the ownership of the corporation&#8217;s equity by over a three-year period. Such annual limitation could result in the expiration of a portion of our NOL carryforwards before utilization. If not utilized, the carryforwards will begin to expire in 2036. We may have experienced ownership changes within the meaning of Section 382 in the past and we may experience some ownership changes in the future as a result of subsequent shifts in our stock ownership, such as a result of our initial public offering in April 2021, follow-on offerings, or subsequent shifts in our stock ownership (some of which shifts are outside our control. We have not conducted a study to assess whether an ownership change for the purposes of Section 382 has occurred due to the significant complexity and cost associated with such a study. Future legislative or regulatory changes could also negatively impact our ability to utilize our NOL carryforwards or other tax attributes. Similar provisions of state tax law may also suspend or otherwise limit the ability to use NOLs and accumulated state tax attributes. As a result, if we attain profitability, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes for federal and state tax purposes, which could result in increased tax liability and adversely affect our future cash flows.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our estimates or judgments relating to our critical accounting policies prove to be incorrect, or financial reporting standards or interpretations change, our results of operations could be adversely affected.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Use of Estimates.&#8221; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our consolidated financial statements include stock-based compensation and valuation of our equity investments in early-stage biotechnology companies. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards, or changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhanced systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements, which may have an adverse effect on our financial position and reputation.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits could cause us to incur substantial liabilities and could limit commercialization of any drug candidates that we may develop.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of drug candidates in human clinical trials, and we will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our drug candidates or medicines caused injuries, we could incur substantial damages or settlement liability. Regardless of merit or eventual outcome, liability claims may also result in:</span></div><div style="padding-right:5pt;text-align:justify"><span><br/></span></div><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">decreased demand for any drug candidates or therapeutics that we may develop;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">significant costs to defend the litigation;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">loss of revenue; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the inability to commercialize our drug candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance, including coverage for clinical trials that we sponsor, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we commence additional clinical trials and if we successfully commercialize any drug candidates. The market for insurance coverage can be challenging, and the costs of insurance coverage will increase as our clinical programs increase in size. We may not be able to maintain insurance coverage at a reasonable cost and with adequate limits to satisfy any and all liability that may arise.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES</span></div><div style="padding-right:32pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:32pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties that perform some of our research and preclinical testing or conduct our clinical trials may not perform satisfactorily or their agreements may be terminated.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties to conduct some aspects of research and preclinical testing and clinical trials. The third parties include clinical research organizations, clinical data management organizations, medical institutions, and principal investigators. Any of these third parties may fail to fulfill their contractual obligations, including by not meeting deadlines for the completion of research, testing, or trials, or we or they may terminate their engagements with us. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. If we need to enter into alternative arrangements, it could delay product development activities.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for research and development activities reduces our control over these activities, but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our respective clinical trials is conducted in accordance with the general investigational plan and protocols for the trial, as well as applicable legal, regulatory, and scientific standards. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timeframes. In addition, the FDA and comparable foreign regulatory authorities require compliance with good clinical practices (GCP) guidelines for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate, and that the rights, integrity, and confidentiality of trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participants are protected. Regulatory authorities enforce GCP compliance through periodic inspections of trial sponsors, principal investigators, and trial sites. </span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of the third parties fail to comply with applicable GCP regulations, some or all of the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional nonclinical or clinical trials or to enroll additional patients before approving our marketing applications. In addition, if we or the third parties fail to comply with our stated protocols or applicable laws and regulations during the conduct of clinical trials, we could be subject to warning letters or enforcement actions by the FDA and comparable foreign regulatory authorities, which could result in civil penalties or criminal prosecution, as well as adverse publicity that harms our business. </span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also will not be able to obtain, or may be delayed in obtaining, marketing approvals for any drug candidates we may develop if these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct clinical trials in accordance with our stated protocols or regulatory requirements. As a result, we may be delayed or unable to successfully commercialize our medicines.</span></div><div style="padding-right:17pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties that manufacture our drug candidates for preclinical development, clinical testing, and future commercialization may not provide sufficient quantities of our drug candidates or products at an acceptable cost, which could delay, impair, or prevent our development or commercialization efforts.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate any manufacturing facilities and have no manufacturing personnel, although we are in the process of securing a facility to establish production capabilities for preclinical animal studies and early human clinical trials. We rely, and expect to continue to rely, on third parties for drug supplies for our clinical trials, the manufacture of many of our drug candidates for preclinical development and clinical testing, as well as the commercial manufacture of our products if any of our drug candidates receive marketing approval. We may be unable to establish necessary agreements with third-party manufacturers or to do so on acceptable terms. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or products, or have sufficient quantities at an acceptable cost or quality, which could delay, impair, or prevent our development or commercialization efforts.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the facilities used by our contract manufacturers to manufacture our drug candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not expect to control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with current good manufacturing practice guidelines (cGMP) in connection with the manufacture of our drug candidates in the near to intermediate term, or possibly the long term. If our contract manufacturers cannot maintain adequate quality control and qualified personnel to successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority finds deficiencies with, does not approve, or withdraws approval of these facilities for the manufacture of our drug candidates, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or market our drug candidates, if approved. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Our drug candidates and any other products that we may develop may compete with the drug candidates and approved products of other companies for access to manufacturing facilities or capacity, which may further restrict our ability to secure manufacturing sites.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or products that may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our drug candidates.</span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. If it is necessary to replace any such manufacturer, we may incur added costs and delays in identifying and qualifying any a replacement. In addition, any performance failure on the part of our distributors could delay clinical development or marketing approval of any drug candidates we may develop or seek to commercialize, producing additional losses and depriving us of product revenue.</span></div><div style="padding-right:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture and distribution of our drug candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:18.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately source clinical and commercial supplies, equipment, and active pharmaceutical ingredients (API) from third party vendors as our drug development pipeline matures, it could significantly harm our business.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We procure raw materials, components, parts, consumables, reagents, and equipment used in the development and operation of our platform and the development of our drug candidates from third party vendors. We also rely on third party vendors to perform quality testing. Particular risks to our platform include reliance on third-party equipment and instrument suppliers and consumable and reagent suppliers. As we increase development of drug products and commence clinical testing and commercialization, we will require expanded capacity across our supply chain. We face risks regarding our sourcing of products and quality-testing services, including:</span></div><div style="padding-right:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability of suppliers and service providers to grow their capacity to meet demand, whether from us or other drug manufacturers, particularly if the field of technology-   enabled drug discovery continues to expand;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">termination or non-renewal of supply and service agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:7pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">disruptions to the operations of these suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the supplier or service provider or force majeure events, such as the COVID-19 pandemic; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:46pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inspections of third-party facilities by regulatory authorities that could have a negative outcome and result in delays in, or termination of, their ability to meet our requirements.</span></div><div style="padding-right:46pt;text-indent:4.5pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, certain of our specialized equipment, as well as the API used in our drug candidates, are obtained from single-source suppliers. Our ability to successfully develop our drug candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain equipment and the API for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization. We do not currently have arrangements in place for a redundant or second-source supply of any such equipment or ingredients in the event any of our current suppliers fails or is unable to meet our requirements. While our single-source suppliers have generally met our demand for their products on a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timely basis in the past, we are not certain that they will be able to meet our future demand, whether due to any of the above factors, the nature of our agreements with those suppliers, our limited experience with those suppliers, our relative importance as a customer, or any other reason. For all of our drug candidates, we intend to identify and qualify additional vendors and manufacturers, as available, to provide such equipment and API prior to our submission of an NDA to the FDA and/or an MAA to the EMA, which may require additional regulatory inspection or approval and result in further delay.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:11pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interruption or delay in the supply of components, materials, specialized equipment, API, and quality-testing sources at acceptable prices and in a timely manner could impede, delay, limit, or prevent our development efforts, which could harm our business, results of operations, and prospects. </span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success significantly depends on our ability to obtain patents of adequate scope covering our proprietary technology and products. Obtaining and maintaining patent assets is inherently challenging, and our pending and future patent applications may not issue with the scope we need, if at all.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We protect our products, product candidates, and platform technologies, in both the U.S, and internationally, with patents and patent applications owned by or licensed to us, and we plan to file additional patent applications in the future. Our commercial success will depend in significant part on our ability to obtain, maintain, protect, and enforce our patents and other intellectual property rights in the U.S. and other countries for our drug candidates and our core technologies important to the development and implementation of our business, including our phenomics platform, preclinical and clinical assets, and related know-how. </span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent prosecution is a complex, expensive, and lengthy process, with no guarantee that a patent will issue in a timely fashion or at all, or with sufficiently broad claims to protect our drug candidates and core technologies. Further, the laws and regulations for obtaining and maintaining patents are subject to change by legislative or judicial action in the relevant jurisdictions. The patent positions of pharmaceutical, biotechnology, and other life sciences companies in particular can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date in the U.S., and tests used for determining the patentability of patent claims in all technologies are in flux. The pharmaceutical, biotechnology, and other life sciences patent situation outside the U.S. can be even more uncertain. The U.S. Patent and Trademark Office (USPTO) and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges.</span></div><div style="padding-right:4pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and licensed patents may be challenged in the patent offices and courts in the United States and abroad. Third parties may invent, publish, or file patents of their own in ways which overlap or conflict with our patent rights. Moreover, even if unchallenged, our owned patent portfolio and any patent portfolio we license may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our drug candidates, but that has a different composition that falls outside the scope of our patent protection. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective, non-provisional filing date, and patents protecting drug candidates might expire before or shortly after the candidates are commercialized given the amount of time required for development, testing, and regulatory review. The various governmental patent agencies also require compliance with extensive rules and fee obligations. Failure to do so can, under certain circumstances, result in the abandonment of a patent application or the termination of patent rights. Non-compliance events that could result in abandonment or lapse of a patent or patent application include a failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have patent applications pending before the USPTO and other patent offices, and we plan to file new applications in the future. Patent offices may require us to significantly narrow our claims based upon prior art discovered by the USPTO or through third-party submissions. Moreover, we do not always have the right to control the preparation, filing, prosecution, and maintenance of licensed patents and applications under arrangements with collaborators or licensors. We may become involved in procedural challenges, including inter parties review, which could result in the narrowing or elimination of our patent rights or those of our licensors. This could limit our ability to stop others from freely using or commercializing similar or identical technology and products, or limit the duration of the patent protection covering our technology and drug candidates. Such challenges may also result in our inability to manufacture or commercialize our drug candidates without infringing third-party patent rights. Further, inadvertent or intentional public disclosures of our inventions prior to the filing of a patent application have precluded us, and in the future may preclude us, from obtaining patent protection in certain jurisdictions. We also could fail to identify patentable aspects of our technology and research and development output in time to obtain patent protection.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also currently own a number of U.S. provisional patent applications. These provisional applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of filing one or more of our related provisional patent applications. If we do not timely file any non-provisional patent applications, we may lose our priority dates with respect to our provisional patent applications and any patent protection on the inventions disclosed in such applications.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presently do not own or in-license any issued patents with respect to certain of our programs, including our product candidate for the treatment of GM2 gangliosidosis (REC-3599); lead molecules for the treatment of C. difficile colitis (REC-163964, REC-164014, and REC-164067); lead molecules for the treatment of neuroinflammation (REC-648455, REC-648597, and REC-648677); lead molecules for the treatment of Batten disease (REC-648190, REC-259618, and REC-648647); lead molecules for the treatment of CMT2A (REC-64810, REC-648458, REC-1262, and REC-150357); lead molecules for the treatment of STK11-mutant immune checkpoint resistance in non-small cell lung cancer (REC-64151); and MYC inhibitory molecules for the treatment of solid and hematological malignancies.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot provide any assurances that any of our or our licensors&#8217; pending or future patent applications will issue, or that any pending or future patent applications that mature into issued patents will include claims with a scope sufficient to protect our drug candidates from competition. If we fail to obtain and maintain adequate intellectual property protection covering any technology, invention, or improvement that is important to our business, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to prevent third parties from launching generic versions of our products, from using our proprietary technologies, or from marketing products that are very similar or identical to ours. If the breadth or strength of protection provided by our patents and patent applications are threatened, it could also dissuade companies from collaborating with us to license, develop, or commercialize current or future drug candidates. This could have a material, adverse effect on our ability to successfully commercialize our technology and products, and on our business and results of operations.</span></div><div style="padding-right:22pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-right:22pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current proprietary position for certain drug candidates depends upon our owned or in-licensed patent filings covering components of such drug candidates, manufacturing-related methods, formulations, and/or methods of use, which may not adequately prevent a competitor or other third party from using the same drug candidate for the same or a different use.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patent protection is generally considered to be desirable for drug products because it provides protection without regard to any particular method of use or manufacturing, or formulation. For some of the molecules that we in-license from our collaboration partners, we cannot rely on composition of matter patent protection as the term on those patents has expired or is close to expiring.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. While we file applications covering method of use for our programs at appropriate times in the development process, we cannot be certain that claims in any future patents issuing from these applications will cover all commercially-relevant applications of molecules in competing uses. These types of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents do not prevent a competitor or other third party from developing, marketing, or commercializing a similar or identical product for an indication that is outside the scope of the patented method, or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Additionally, some commercially-relevant jurisdictions do not allow for patents covering a new method of use of an otherwise-known molecule. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or abroad, which may have a material adverse effect on our business.</span></div><div style="padding-right:22pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any drug candidates we may develop, our business may be materially harmed.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and specifics of any FDA marketing approval of any drug candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval. Only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:49.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, when we explore repurposing molecules owned by our collaboration partners or other third parties, we in-license the rights to use those molecules for our use. If we are not able to obtain a license, or to obtain one on commercially reasonable terms and with sufficient breadth to cover the intended use of third-party intellectual property, our business could be materially harmed.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights, and particularly those arising from patents, is uncertain because these rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. Examples where our intellectual property rights may not further our competitive advantage include the following:</span></div><div style="margin-top:12pt;padding-left:22pt;padding-right:39pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">others may be able to duplicate or utilize similar technology in a manner that infringes our patents but is undetectable or done in a jurisdiction where we have not secured, or cannot secure or enforce, patent rights;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22pt;padding-right:25pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:31pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material, adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive position may be harmed.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and contractual arrangements to protect proprietary know-how, information, and technology that is not covered by our patents. With respect to curating our data and our library of small molecules generally, we consider trade secrets and know-how to be our primary intellectual property. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees, and consultants. Our agreements with our employees and consultants also require them to acknowledge ownership by us of inventions they may conceive as a result of their work for us and to perfect such ownership by assignment. However, we may not be able to prevent the unauthorized disclosure or use of our trade secrets or other confidential information through these agreements or other preventative measures. In addition, third parties, including our competitors, could independently develop and lawfully use the same or substantially equivalent trade secrets and know-how.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if their secrecy is lost or they are independently developed by a third party. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations, and financial condition.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:40pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of third parties or are in breach of their non-competition or non-solicitation agreements with third parties.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take efforts intended to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how, or trade secrets of others in their work for us, or breach any applicable non-competition or non-solicitation agreement. However, we may in the future be subject to claims that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a third party, including a former employer or competitor, or that we caused an employee or contractor to breach the terms of their non-competition or non-solicitation agreement with a third party. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in obtaining such agreements or an assignment of rights to us.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to defend against or enforce these claims, which may be costly, a distraction to management, and of uncertain outcome. If we are found liable for disclosure or misuse of a third party&#8217;s proprietary information, or are unable to secure rights to intellectual property developed by an employee or contractor, in addition to requiring us to pay damages, a court could prohibit us from using technologies or features that may be essential to our drug candidates that incorporate or are derived from such proprietary information, in addition to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">awarding damages. Moreover, any such litigation could also adversely affect our ability to hire or retain employees or contractors. If we are unable to establish our rights to valuable intellectual property or retain key personnel, it may prevent us from successfully commercializing our drug candidates and have an adverse effect on our business, financial condition, and results of operation.</span></div><div style="margin-top:6pt;padding-right:47pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation to defend against third party claims that we are infringing their intellectual property rights, or to enforce our intellectual property rights, presents numerous risks.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. Intellectual property litigation or other legal proceedings, with or without merit, is generally expensive and time consuming, potentially distracting to technical and management personnel, and subject to uncertain outcomes. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and that of our collaborators, to develop, manufacture, market, and sell our drug candidates, and to use our proprietary technologies, without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties. Given the vast and continually increasing number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents granted in the future. We may in the future become party to, or threatened with, litigation or adversarial proceedings initiated by our competitors or other third parties alleging that our products or technologies are covered by their patents.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have obtained patents or filed patent applications in areas important to our business, including artificial intelligence and deep learning, technology-aided drug discovery, CRISPR, high-throughput screening, and combinations of any or all of these fields. For example, we sublicense CRISPR-Cas9 gene editing technology from a licensed vendor, which provides critical tools upon which portions of our drug discovery process relies. CRISPR-Cas9 gene editing is a field that is highly active for patent filings and there are ongoing disputes between third parties, which we are not party to, regarding the ownership of and licensing rights related to the technology. The extensive patent filings related to CRISPR and Cas make it difficult for us to assess the full extent of relevant patents and pending applications that may cover this technology, and there may be third-party patents, or pending patent applications with claims that may issue in the future, covering our use of CRISPR-Cas9.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators are found to infringe a third party&#8217;s patent or other intellectual property rights, it could result in significant damages and costs. In addition, we could be required to obtain a license from such third party to continue developing and marketing our drug candidates and technology, which may not be available on commercially reasonable terms or at all, or to cease developing and commercializing the infringing technology or drug candidates. If we are prevented from commercializing our drug candidates or forced to cease some of our business operations, it could materially harm our reputation and have a significant adverse impact on our business and results of operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:28pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, we may initiate litigation, or file counterclaims, to protect or enforce our patents and other intellectual property rights if we believe competitors or other third parties have infringed, misappropriated, or otherwise violated our rights. Our ability to enforce our intellectual property rights is subject to litigation risks, including that the opposing party may seek counterclaims against us, as well as uncertainty as to the protection and enforceability of those rights in some countries. If we seek to enforce our intellectual property rights, we may be subject to findings that our patents should be interpreted narrowly and do not cover the technology at issue, or that they are invalid or unenforceable. If we are unable to enforce and protect our intellectual property rights, or if they are circumvented, invalidated, or rendered obsolete by the rapid pace of technological change, it could have an adverse impact on our competitive position, business, and financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position. </span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong. The legal systems of some countries do not favor the enforcement of patents and other intellectual property rights, while other jurisdictions may have limited enforcement rights for patent holders. This could make it difficult for us to stop the infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. Consequently, we and our licensors may have limited remedies in those foreign countries if patents are infringed, or we or our licensors may be compelled to grant a license to a third party, which could materially diminish the value of those patents and could limit our potential revenue opportunities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may use our technologies to develop their own products that compete with ours in jurisdictions where we have not obtained patent protection or where we have patent protection but limited enforcement rights. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span></div><div style="padding-right:24pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we collaborate with or license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we could lose rights that are important to our business.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license certain intellectual property that is important to our business and in the future we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. Our current license agreements impose, and we expect our future license agreements will impose, various development, diligence, commercialization, and other obligations on us in order to maintain the licenses. In spite of our efforts, a licensor might conclude that we have materially breached our obligations under a license agreement and seek to terminate the agreement, thereby removing or limiting our ability to develop and commercialize products and technology covered by the agreement. If these in-licenses are terminated, or if the underlying patent rights licensed thereunder fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our drug candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">the priority of invention of patented technology.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements under which we license intellectual property or technology from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or it could increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and similar issues may arise with respect to our collaboration agreements, such as the Bayer Agreement. Our collaboration with Bayer is one of our key collaborations, and there can be no assurance that this collaboration will continue past the current term, on favorable terms or at all, or that at any time while the collaboration is in effect the parties will operate under the agreement without disputes. Possible disputes may involve ownership or control of intellectual property rights, negotiations of licensing agreements resulting from the collaboration, exclusivity obligations, diligence and payment obligations, for example.</span></div><div style="margin-top:6pt;padding-right:47pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our intellectual property has been, and in the future may be, discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights and our ability to contract with non-U.S. manufacturers.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property rights may be subject to a reservation of rights by one or more third parties. For example, certain intellectual property rights that we have licensed, or may in the future license, have been generated through the use of U.S. government funding. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future processes and related products and services pursuant to the Bayh-Dole Act of 1980 (the Bayh-Dole Act). These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that (1) adequate steps have not been taken to commercialize the invention and achieve practical application of the government-funded technology, (2) government action is necessary to meet public health or safety needs, (3) government action is necessary to meet requirements for public use under federal regulations or (4) we fail to meet requirements of federal regulations (also referred to as &#8220;march-in rights&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government also has the right to take title to these inventions if we or our licensors fail to disclose the invention to the government or fail to file an application to register the intellectual property within specified time limits. These rights may permit the government to disclose our confidential information to third parties. In addition, our rights in such inventions may be subject to requirements to manufacture products embodying such inventions in the United States. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any exercise by the government of such rights could have a material adverse effect on our competitive position, business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic, or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO GOVERNMENT REGULATION</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive FDA or other regulatory approval for any of our drug candidates, we will be subject to ongoing regulatory obligations and other conditions that may result in significant additional expense, as well as the potential recall or market withdrawal of an approved product if unanticipated safety issues are discovered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or a comparable foreign regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also include submission of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or they may contain requirements for potentially costly post-marketing studies and surveillance to monitor the safety and efficacy of the product. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to comply with regulatory requirements, or any discovery of previously unknown problems with a product &#8212; including adverse events of unanticipated severity or frequency &#8212; or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">clinical trial holds;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">fines, warning letters or other regulatory enforcement action;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the foregoing actions could materially and adversely affect our reputation, business, results of operation, and prospects.</span></div><div style="padding-right:47pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:47pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug designation for certain of our drug candidates, and we may be unsuccessful or unable to maintain the benefits associated with such a designation, including the potential for market exclusivity.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may seek orphan drug designation for certain of our drug candidates. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the U.S. Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. We have received orphan drug designation from the FDA for REC-4881 for the potential treatment of familial adenomatous polyposis, but we may be unsuccessful with respect to other drug candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly in Europe, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of drugs that are intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. </span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective, or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition or if another drug with the same active part of the molecule is determined to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for our drug candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our drug candidates in other jurisdictions.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may submit marketing applications in countries other than the United States. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of drug candidates with which we must comply prior to marketing in those jurisdictions. For example, our trials to date have consisted of small patient populations and some international regulatory filings may require larger patient populations or additional nonclinical studies or clinical trials.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our drug candidates will be harmed.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our drug candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, although a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a drug candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States. These may include additional nonclinical studies and clinical trials, since clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As we expand our operations outside the United States, we will be exposed to various risks related to the global regulatory environment.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expanded our operations into Canada, and we expect our non-U.S. activities to increase in the future, including the conduct of clinical trials in other countries. If we expand our operations outside of the United States, we must dedicate additional resources to comply with U.S. laws governing activities in other countries, as well as numerous laws and regulations in each jurisdiction in which we plan to operate. </span></div><div style="margin-top:6pt;padding-right:1pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or business from paying, offering, authorizing payment, or offering anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates U.S. publicly-traded companies to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="padding-right:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, U.S. and foreign anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws) prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, and soliciting or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial consequences. We have direct or indirect interactions with officials and employees of governmental agencies or government-affiliated hospitals, universities or other organizations.  We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing, inconsistent, or conflicting laws, rules and regulations governing international business practices, and ambiguities in their interpretation and application, create uncertainty and challenges. The failure to comply with any such laws or regulations may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:44pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek priority review designation for one or more of our other drug candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that a drug candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the drug candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of 10 months. We may request priority review for our drug candidates from time to time. The FDA has broad discretion with respect to whether or not to grant priority review status to a drug candidate, so even if we believe a particular drug candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></div><div style="padding-right:44pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our drug candidates, may not lead to a faster development, regulatory review, or approval process, and each designation does not increase the likelihood that any of our drug candidates will receive marketing approval in the United States.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy designation for some of our drug candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our drug candidates qualify as breakthrough therapies, the FDA may later decide that such drug candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek fast track designation for some of our drug candidates from time to time. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular drug candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-right:22.3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA, and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our drug candidates.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:7.9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, EMA, and regulatory authorities in other countries have each expressed interest in further regulating small molecule pharmaceuticals. Agencies at both the federal and state level in the United States, as well as U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the small molecule pharmaceutical industry. Such action may delay or prevent commercialization of some or all of our drug candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our drug candidates. These regulatory review agencies and committees, and any new requirements or guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our drug candidates, or lead to significant post-approval limitations or restrictions. As we advance our drug candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such drug candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process, or further restrictions on the development of our drug candidates, can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future drug candidates in a timely manner, if at all.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current or future drug candidates or any future drug candidates, restrict or regulate post-approval activities, and/or affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations and statutes, or their interpretation, could impact our business in the future by requiring, for example, (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; and (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act, or the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, (i) subjects biological products to potential competition by lower-cost biosimilars; (ii) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (iii) increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iv) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and (v) creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (as increased pursuant to the Bipartisan Budget Act of 2018) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Since then, the ACA risk adjustment program payment parameters have been updated annually. Members of the U.S. Congress have expressed intent to pass legislation to fundamentally change or repeal parts of the ACA. While Congress has not passed repeal legislation to date, the Tax Cuts and Jobs Act of 2017 repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year,commonly referred to as the &#8220;individual mandate.&#8221;</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There additionally has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional state and federal healthcare reform measures will be adopted in the future that could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future drug candidates or additional pricing pressures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue prospects could be affected by changes in healthcare spending and policy in the U.S. and abroad.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry and new laws, regulations, or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery of, or payment for healthcare products and services could negatively impact our business and results of operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement, or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the demand for our current or future drug candidates, if we obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to set a price that we believe is fair for our products;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to obtain coverage and reimbursement approval for a product;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the level of taxes that we are required to pay; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the availability of capital.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, other customers, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm, and diminished profits and future earnings.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our drug candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our drug candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="padding-right:8pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:8pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:14pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act;</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;text-align:justify;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:2pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">the federal physician payment transparency provisions, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Department of Health and Human Services information related to transfers of value made to licensed physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners;</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:14pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH Act) and its implementing regulations, imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:14pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:22pt;padding-right:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Further, many state laws governing the privacy and security of health information in certain circumstances differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs and may require us to undertake or implement additional policies or measures. We may face claims and proceedings by private parties, and claims, investigations and other proceedings by governmental authorities, relating to allegations that our business practices do not comply with statutes, regulations or case law involving applicable fraud and abuse, privacy or data protection, or other healthcare laws and regulations, and it is possible that courts or governmental authorities may conclude that we have not complied with them, or that we may find it necessary or appropriate to settle any such claims or other proceedings. In connection with any such claims, proceedings, or settlements, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, other damages, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="padding-right:1pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and foreign laws regarding privacy, data protection, and data security that could entail substantial compliance costs, while the failure to comply could subject us to significant liability.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy, data protection, and data security have become significant issues in the U.S., Europe, and other jurisdictions where we conduct or may in the future conduct our operations. The regulatory framework for the collection, use, safeguarding, sharing, and transfer of health and other personal information is rapidly evolving worldwide and is likely to remain in flux for the foreseeable future.&#160;The scope and interpretation of the laws that are or may be applicable to us are often uncertain, subject to differing interpretations, and may be inconsistent among different jurisdictions.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., HIPAA, as amended by the HITECH Act, imposes on covered entities certain requirements relating to the privacy, security, and transmission of individually identifiable health information. The legislation also increased the civil and criminal penalties that may be assessed for violations and gave state attorneys general the authority to file civil actions in federal courts to enforce the HIPAA rules. In addition, for clinical trials conducted in the U.S., any personal information that is collected is further regulated by the Federal Policy for the Protection of Human Subjects. Privacy laws are also being enacted or considered at the state level. These include the California Consumer Privacy Act (CCPA), which creates individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households, as well as a new California privacy law passed by voters known as the California Privacy Rights Act (CPRA). While there is currently an exception for protected health information subject to HIPAA and clinical trial regulations, the CCPA and/or CPRA may impact our business activities, and there continues to be uncertainty about how these laws will be interpreted and enforced. Other states have passed general privacy legislation that also may impact our business activities, in the future and additional states are evaluating similar legislation. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we enroll subjects in clinical trials in the European Union (EU) or other jurisdictions, or otherwise acquire or process personal data of individuals in those jurisdictions, we may be subject to additional restrictions relating to the collection, use, storage, transfer, and other processing of this data. Clinical trial activities in the European Economic Area (EEA), for example, are governed by the EU General Data Protection Regulation (GDPR). The GDPR, among other things, (i) imposes requirements on companies that process personal data (including consent provisions); (ii) imposes strict rules on the transfer of personal data to countries outside the EU (including the U.S.); (iii) includes significant penalties for non-compliance, including fines of up to 4% of global revenues or 20 million Euros, whichever is greater; (iv) confers a private right of action on data subjects and consumer associations to seek compensation for damages in some situations; and (v) provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biometric, and health data. The exit of the United Kingdom (UK) from the EU, often referred to as Brexit, has created uncertainty concerning data protection regulation in the UK. The European Commission in June 2021 announced a decision of &#8220;adequacy&#8221; concluding that the UK ensures an equivalent level of data protection to the GDPR. The effect of the decision is that personal data flows from the EEA to the UK are permitted. However, the GDPR and UK data protection laws impose restrictions on cross-border personal data transfers to other jurisdictions determined not to maintain adequate protections for personal data, including the U.S. We may need to take additional steps, such as new contractual negotiations or modifications to our policies or practices relating to cross-border transfers of personal data, to comply with these restrictions. More generally, laws and regulations governing privacy and data protection exist in many other countries around the world, and these laws (which are evolving and expanding) create complicated and potentially inconsistent obligations that may impact our business. </span></div><div style="padding-right:11pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increasing number, complexity, and potential inconsistency of current and future laws and regulations relating to privacy, data protection, and data security in the U.S. and other countries make our compliance obligations more difficult and costly. This is particularly true with respect to healthcare data or other personal information acquired as a result of our research activities and clinical trials. If we fail to comply with applicable laws and regulations or experience a breach of security that results in unauthorized disclosure of personal information &#8211; or if a third party with whom we share personal information or who processes such information for us fails to comply with applicable requirements or experiences a leak &#8211; it could lead to government investigations and enforcement actions, as well as civil claims and litigation against us. We could incur substantial costs to defend against any such claims or proceedings and may also be held liable for significant fines, penalties, and monetary judgments. Any of the foregoing could have a material adverse effect on our business, results of operations, and reputation.</span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:9pt;padding-right:40pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:143%">Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, CROs, consultants, and vendors. Misconduct by these parties could include intentional, reckless, and/or negligent conduct that causes us to fail to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately, or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us, including inadvertent violations such as a sale of pledged shares by a lender when the pledgor is in possession of material nonpublic information.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance, or codes of conduct. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred and our employees may, from time to time, bring lawsuits against us for employment issues, including injury, discrimination, wage and hour disputes, sexual harassment, hostile work environment, or other employment issues. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO EMPLOYEE MATTERS AND MANAGING GROWTH</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and experienced scientists, and to attract, retain, and motivate qualified personnel.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical, and business development expertise of Christopher Gibson, our Chief Executive Officer; Tina Marriott Larson, our Chief Operating Officer and President; Michael Secora, our Chief Financial Officer; Shafique Virani, our Chief Corporate Development Officer; and Ramona Doyle, our Chief Medical Officer; as well as the other principal members of our management, scientific, technological, and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time or may not be able to perform the services we need in the future. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, and sales and marketing personnel is also critical to our success. For example, we rely on our employees to help operate and repair our robots, and on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of the services of our executive officers or other key employees or consultants could impede our ability to successfully implement our business strategy. Replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the breadth of skills and experience required to successfully develop, gain regulatory approval of, and commercialize drug products, and the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. We may also experience difficulties recruiting scientific and clinical personnel from universities and research institutions. If one or more of our clinical trials are unsuccessful, it may become more challenging to recruit and retain qualified scientific personnel.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are headquartered in Salt Lake City, Utah and also have operations in several other areas. Some of the employees we may want to hire in the future may not reside in any of these areas and may not want to relocate. In addition, many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to hire, retain, and motivate highly qualified senior executives and personnel, the rate and success with which we can discover and develop drug candidates, our ability to pursue our growth strategy, and our business may be adversely impacted.</span></div><div style="padding-right:20pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-right:15.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of employees and the scope of our operations, particularly in the areas of product development, regulatory affairs and, if any of our drug candidates receive marketing approval, in sales, marketing, and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems; expand our facilities; and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO THE SECURITIES MARKETS AND OWNERSHIP OF OUR CLASS A COMMON STOCK</span></div><div style="margin-top:6pt;padding-right:20pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-right:20pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The dual-class structure of our common stock affects the concentration of voting power, which limits our Class A common stockholders&#8217; ability to influence the outcome of matters submitted to our stockholders for approval, including the election of our board of directors, the adoption of amendments to our certificate of incorporation and bylaws, and the approval of any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transaction.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A common stock offered in our initial public offering has one vote per share, and our Class B common stock has 10 votes per share. As of September 30, 2021, there were 159,167,076 shares of our Class A common stock and 9,467,883  shares of our Class B common stock outstanding. As of that date, Dr. Gibson, our CEO and a member of our board of directors, and his affiliate held no shares of our Class A common stock and all of the issued and outstanding shares of our Class B common stock, representing approximately 37% of the voting power of our outstanding capital stock, which voting power may increase over time as Dr. Gibson exercises or vests in equity awards outstanding as of September 30, 2021. If all such equity awards held by Dr. Gibson had been exercised or vested and exchanged for shares of Class B common stock as of September 30, 2021, Dr. Gibson and his affiliate would hold 41% of the voting power of our outstanding capital stock.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of our stockholders, including the election of our board of directors, the adoption of amendments to our certificate of incorporation and bylaws, and the approval of any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transaction. Dr. Gibson may have interests that differ from our Class A common stockholders and may vote in a way with which our Class A stockholders disagree with and which may be adverse to our Class A stockholders&#8217; interests. The concentrated control may have the effect of delaying, preventing, or deterring a change in control of our company, could deprive our stockholders of an opportunity to receive a premium for their capital stock as part of a sale in our company, and, thus, may affect the market price of our Class A common stock.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future transfers by the holders of Class B common stock will generally result in those shares automatically converting into shares of Class A common stock, subject to limited exceptions, such as certain transfers for estate planning. Transfers or exchanges of shares of Class B common stock may result in the issuance of additional shares of Class A common stock and such issuances will be dilutive to holders of our Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon the earliest of (i) April 16, 2028; (ii) the date specified by written consent or agreement of the holders of 66 2&#8260;3% of our then outstanding shares of Class B common Stock; (iii) nine months after Dr. Gibson ceases to hold any positions as an officer or director of the Company; or (iv) nine months after the death or disability of Dr. Gibson. We refer to the date on which such final conversion of all outstanding shares of Class B common stock pursuant to the terms of amended and restated certificate of incorporation occurs as the Final Conversion Date.</span></div><div style="padding-right:13pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Dr. Gibson established personal stock trading plans in accordance with Securities Exchange Act Rule 10b5-1 and Recursion&#8217;s Insider Trading Policy. Under the plans, all </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding stock options may be exercised and we anticipate shares representing up to approximately</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4% of Dr. Gibson&#8217;s holdings may be sold or transferred to donor-advised philanthropic funds. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate the Rule 10b5-1 transactions may take place over the next 13 months. Any such transactions will be disclosed through public filings as required by the SEC.</span></div><div style="padding-right:20pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-right:0.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, our executive officers, directors, holders of 5% or more of our capital stock, and their respective affiliates, including Dr. Gibson and his affiliate, beneficially owned shares representing approximately 62% of our voting power. These stockholders, acting together, may be able to impact matters requiring stockholder approval, including the elections of directors; amendments of our organizational documents; and approval of any merger, sale of all or substantially all of our assets, or other major corporate transaction. This concentrated control may also have the effect of deterring, delaying, or preventing unsolicited acquisition proposals or offers for our capital stock that other stockholders may feel are in their best interest. The interests of this group of stockholders may not always coincide with each other&#8217;s interests or the interests of other stockholders, and they</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the market price for our common stock.</span></div><div style="padding-right:20pt;text-align:justify"><span><br/></span></div><div style="margin-top:9pt;padding-right:10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and eligible for exemptions from certain disclosure requirements, which could make our Class A common stock less attractive to investors.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). We will remain an emerging growth company until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#8220;large accelerated filer&#8221; as defined under SEC rules; or (b) have total annual gross revenues of $1.07 billion or more; or (3) the date on which we have issued more than $1 billion in nonconvertible debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies. These exemptions include:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (Section 404);</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:16pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:15pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">reduced disclosure obligations regarding executive compensation; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">not being required to hold a nonbinding stockholder advisory vote on executive compensation or on approval of any golden parachute payments not previously approved.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Likewise, we may elect not to provide certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. </span></div><div style="padding-left:5.75pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The JOBS Act further provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised U.S. generally accepted accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. As a result, changes in rules of U.S. GAAP or their interpretation, the adoption of new guidance, or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. If some of our Class A common stockholders find our common stock less attractive because we may rely on these exemptions, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline. </span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:27.35pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our Class A common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Class A common stock has been volatile since our initial public offering and it is likely that the price will fluctuate substantially in the future. The stock price may be influenced by many factors, a number of which are beyond our control, which factors include:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">results of clinical trials of our drug candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the level of expenses related to any of our drug candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the results of our efforts to discover, develop, acquire, or in-license additional drug candidates or products;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">performance of the overall stock market and shares of biotechnology companies in particular, as well as general economic conditions; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this volatility, holders of our Class A common stock may not be able to sell their stock at or above the price they originally paid for it, which could result in the loss of a part or all of their investment.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our Class A common stock in the public market could cause our stock price to fall.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our Class A common stock in the public market could occur at any time. These sales, or the perception in the market that one or more holders of a large number of shares intend to sell their shares, could cause the market price of our Class A common stock to decline.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had 159,167,076 shares of our Class A common stock and 9,467,883 shares of our Class B common stock outstanding. As of the date of this Quarterly Report on Form 10-Q, all of these shares could be freely sold in the public market, except that 39.4% of these shares are held by directors, executive officers, and other affiliates and therefore are subject to certain limitations under Rule 144 under the Securities Act of 1933, as amended (the Securities Act). </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 1,626,250 shares of our Class B common stock that are beneficially owned by Dr. Gibson have been pledged to secure his obligations under a line of credit with UBS Credit Corp. (UBS). If he defaults on his repayment obligations under the line of credit, UBS or any designee of UBS may exercise its rights to sell shares pledged to cover the amount due thereunder.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, 39,818,210 shares of Class A common stock that are either subject to outstanding options and warrants or reserved for future issuance under our equity compensation plans are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as of September 30, 2021, the holders of approximately 135,870,793 shares of our Class A common stock issued and issuable upon conversion of Class B common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future we may also issue our securities in connection with any financings, investments, or acquisitions, and the number of shares issued could constitute a material portion of our then-outstanding common stock.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of a significant number of shares of our Class A common stock under any of the above circumstances, or otherwise, in the public market at any time, or the perception that they may be sold, could have a material adverse effect on the market price of our Class A common stock. In that event, holders of our Class A common stock may not be able to sell their stock at or above the price they originally paid for it, which could result in the loss of part or all of their investment.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we will incur significant legal, accounting, and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and the Nasdaq Stock Market have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Stock Market.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-right:32pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the market prices of our Class A common stock.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market prices of our Class A common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">establish a classified board of directors so that not all members of our board are elected at one time;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">prohibit cumulative voting;</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">authorize our board of directors to amend the bylaws;</span></div><div style="margin-top:6pt;padding-left:22pt;padding-right:23pt;text-indent:-10.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.55pt">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and</span></div><div style="margin-top:6pt;padding-left:21pt;text-indent:-9.05pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.55pt">require a super-majority vote of stockholders to amend some provisions described above.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the General Corporation Law of the State of Delaware prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of Class A common stock and could also affect the price that some investors are willing to pay for our stock.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our actual operating results may differ significantly from any guidance that we provide.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may provide guidance in our quarterly earnings releases, or otherwise, regarding our future performance that represents our management&#8217;s estimates as of the date of release. This guidance, which would include forward-looking statements, would be based on projections prepared by our management. Neither our registered public accountants nor any other independent expert or outside party would compile or examine the projections. Accordingly, no such person would express any opinion or any other form of assurance with respect to the projections.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. The principal reason that we would release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying any guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance would be only an estimate of what management believes is realizable as of the date of release. Actual results may vary from our guidance and the variations may be material.</span></div><div><span><br/></span></div><div style="margin-top:9pt;padding-right:7.2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting. Any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our Class A common stock.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief financial officer has only been the chief financial officer of a publicly traded company since our initial public offering and our chief executive officer has only been the chief executive officer of a publicly traded company since our initial public offering. Neither has been involved in the long term operations of a public company. Pursuant to Section 404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form 10-K with the SEC. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. However, our independent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting until our first annual report required to be filed with the SEC following the date we are no longer an emerging growth company. At such time as we are required to obtain auditor attestation, if we then have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. During our evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of shares of our Class A common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISKS</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the ongoing COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets. Uncertainty in the U.S. regarding the federal government&#8217;s debt ceiling and related budgetary matters may also cause volatility and uncertainty in the global markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our drug candidates and impaired ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers or result in supply disruption. Any of the foregoing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-right:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the risks of litigation that may arise in the ordinary course of our business, which could be costly and time-consuming to pursue or defend.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically are, and in the future may be, involved in legal proceedings or claims that arise in the ordinary course of business, such as those regarding commercial or contractual disputes, intellectual property rights, employment matters, product liability, or data privacy. </span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we and our directors and officers are also subject to potential securities class action litigation, particularly if the market price of our Class A common stock is volatile. The stock market in general, and Nasdaq-listed and biotechnology companies in particular, experience significant price and volume fluctuations from time to time that often are unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action lawsuits, and we may be the target of such litigation in the future.</span></div><div style="padding-right:2pt"><span><br/></span></div><div style="margin-top:6pt;padding-right:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation, whether with or without merit, may be expensive to pursue or defend; divert management&#8217;s attention; result in adverse judgments for damages, injunctive relief, penalties, and fines; and harm our business and reputation.</span><span style="background-color:#f4f4f5;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> S</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ome third parties may be able to sustain the costs of litigation more effectively than we can because they have substantially greater resources. Insurance may not cover all claims or may cover only a portion of our expenses and losses, and may not continue to be available on terms acceptable to us. </span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our Class A common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. If only a small number of analysts maintain coverage of us, the trading price of our stock would likely decrease. If an analyst covering our stock downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div><span><br/></span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_121"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Sales of Unregistered Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Use of Proceeds from Public Offering of Class A Common Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2021, the Registration Statements on Form S-1 (File No. 333-254576) for the initial public offering of our Class A common stock was declared effective by the SEC. Shares of our Class A common stock began trading on the Nasdaq Global Market on April 16, 2021. The offering closed on April 20, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters of our IPO were Goldman Sachs &amp; Co. LLC, J.P. Morgan, BofA Securities, SVB Leerink, Allen &amp; Company LLC and KeyBanc Capital Markets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid the underwriters of our IPO an underwriting discount totaling approximately $35.1 million. In addition, we incurred expenses of approximately $4.3 million which, when added to the underwriting discount, amount to total expenses of approximately $39.5 million. Thus, the net offering proceeds, after deducting underwriting discounts and offering expenses, were approximately $462.4 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are holding a significant portion of the balance of the net proceeds in bank deposits held in checking accounts and an investment portfolio. There has been no material change in the planned use of proceeds from our IPO from those that were described in the final prospectus filed pursuant to Rule 424(b) under the Securities Act and other periodic reports previously filed with the SEC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Issuer Purchases of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_124"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No. </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed / Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521123764/d149444dex31.htm">Amended and Restated Certificate of Incorporation of Recursion Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40323</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 21, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521123764/d149444dex32.htm">Amended and Restated Bylaws of Recursion Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40323</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 21, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521089610/d89478dex41.htm">Amended and Restated Investors&#8217; Rights Agreement by and among the Registrant and certain of its stockholders, dated September 1, 2020.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-254576</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001601830/000119312521089610/d89478dex42.htm">Specimen Class A common stock certificate of the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-254576</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-q0321.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-q0321.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-q0321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i0bb060ddb7ef4084b0e9e9286fc531b1_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on November&#160;10, 2021. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:49.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RECURSION PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Gibson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Gibson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Secora</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Secora</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-q0321.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i17885378382e40dfae136cdfbdbf6d68_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Gibson, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Recursion Pharmaceuticals, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Gibson, Chief Executive Officer (principal executive officer)&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;10, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-q0321.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7a2c895b80544282ad83f15f0275921c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Secora, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Recursion Pharmaceuticals, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael Secora</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Secora, Chief Financial Officer (principal financial officer)&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;10, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-q0321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2a70b427837b4520b8359087d4078cfa_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Recursion Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), The undersigned certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher Gibson</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Gibson, Chief Executive Officer (principal executive officer)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael Secora</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Secora, Chief Financial Officer (principal financial officer)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;10, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rxrx-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bb127273-35b3-457d-ab21-bda4843992dc,g:487b784e-5d7c-455e-b63d-c9a591fced83-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rxrx="http://www.recursion.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.recursion.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rxrx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.recursion.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.recursion.com/role/DescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessDetails" roleURI="http://www.recursion.com/role/DescriptionoftheBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.recursion.com/role/BasisofPresentation">
        <link:definition>2103102 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.recursion.com/role/BasisofPresentationPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationDetails" roleURI="http://www.recursion.com/role/BasisofPresentationDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.recursion.com/role/Acquisitions">
        <link:definition>2106103 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.recursion.com/role/AcquisitionsTables">
        <link:definition>2307301 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetails" roleURI="http://www.recursion.com/role/AcquisitionsDetails">
        <link:definition>2408403 - Disclosure - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformation" roleURI="http://www.recursion.com/role/SupplementalFinancialInformation">
        <link:definition>2109104 - Disclosure - Supplemental Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationTables" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationTables">
        <link:definition>2310302 - Disclosure - Supplemental Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationPPEDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails">
        <link:definition>2411404 - Disclosure - Supplemental Financial Information - PPE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationAccrualsDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails">
        <link:definition>2412405 - Disclosure - Supplemental Financial Information - Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalFinancialInformationInterestDetails" roleURI="http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails">
        <link:definition>2413406 - Disclosure - Supplemental Financial Information - Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.recursion.com/role/Investments">
        <link:definition>2114105 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.recursion.com/role/InvestmentsTables">
        <link:definition>2315303 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTypeofSecurityDetails" roleURI="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails">
        <link:definition>2416407 - Disclosure - Investments - Type of Security (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBalanceSheetClassificationDetails" roleURI="http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails">
        <link:definition>2417408 - Disclosure - Investments - Balance Sheet Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.recursion.com/role/InvestmentsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssets">
        <link:definition>2119106 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2320304 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsDetails" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails">
        <link:definition>2421410 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsDetails_1" roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1">
        <link:definition>2421410 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.recursion.com/role/NotesPayable">
        <link:definition>2122107 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableTables" roleURI="http://www.recursion.com/role/NotesPayableTables">
        <link:definition>2323305 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableMidcapFinancialDetails" roleURI="http://www.recursion.com/role/NotesPayableMidcapFinancialDetails">
        <link:definition>2424411 - Disclosure - Notes Payable - Midcap Financial (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayablePacificWesternDetails" roleURI="http://www.recursion.com/role/NotesPayablePacificWesternDetails">
        <link:definition>2425412 - Disclosure - Notes Payable - Pacific Western (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableConvertibleNotesDetails" roleURI="http://www.recursion.com/role/NotesPayableConvertibleNotesDetails">
        <link:definition>2426413 - Disclosure - Notes Payable - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableNotesPayableforTenantImprovementAllowanceDetails" roleURI="http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails">
        <link:definition>2427414 - Disclosure - Notes Payable - Notes Payable for Tenant Improvement Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableCurrentNoncurrentDetails" roleURI="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails">
        <link:definition>2428415 - Disclosure - Notes Payable - Current/Noncurrent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayablePrincipalRepaymentsDetails" roleURI="http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails">
        <link:definition>2429416 - Disclosure - Notes Payable - Principal Repayments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.recursion.com/role/CommitmentsandContingencies">
        <link:definition>2130108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.recursion.com/role/CommitmentsandContingenciesTables">
        <link:definition>2331306 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2432417 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMinimumpaymentsDetails" roleURI="http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails">
        <link:definition>2433418 - Disclosure - Commitments and Contingencies - Minimum payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStock" roleURI="http://www.recursion.com/role/ConvertiblePreferredStock">
        <link:definition>2134109 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockTables" roleURI="http://www.recursion.com/role/ConvertiblePreferredStockTables">
        <link:definition>2335307 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockNarrativeDetails" roleURI="http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails">
        <link:definition>2436419 - Disclosure - Convertible Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockSummaryDetails" roleURI="http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails">
        <link:definition>2437420 - Disclosure - Convertible Preferred Stock - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.recursion.com/role/CommonStock">
        <link:definition>2138110 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockNarrativeDetails" roleURI="http://www.recursion.com/role/CommonStockNarrativeDetails">
        <link:definition>2439421 - Disclosure - Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeDevelopmentContracts" roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContracts">
        <link:definition>2140111 - Disclosure - Collaborative Development Contracts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeDevelopmentContractsBayerAGDetails" roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails">
        <link:definition>2441422 - Disclosure - Collaborative Development Contracts - Bayer AG (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.recursion.com/role/StockBasedCompensation">
        <link:definition>2142112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.recursion.com/role/StockBasedCompensationTables">
        <link:definition>2343308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2444423 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails">
        <link:definition>2445424 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails">
        <link:definition>2446425 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails">
        <link:definition>2447426 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRSUActivityDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails">
        <link:definition>2448427 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails">
        <link:definition>2449428 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWarrantsDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationWarrantsDetails">
        <link:definition>2450429 - Disclosure - Stock-Based Compensation - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails" roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails">
        <link:definition>2451430 - Disclosure - Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.recursion.com/role/IncomeTaxes">
        <link:definition>2152113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.recursion.com/role/IncomeTaxesDetails">
        <link:definition>2453431 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.recursion.com/role/NetLossPerShare">
        <link:definition>2154114 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.recursion.com/role/NetLossPerShareTables">
        <link:definition>2355309 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails">
        <link:definition>2456432 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails">
        <link:definition>2457433 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.recursion.com/role/FairValueMeasurements">
        <link:definition>2158115 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.recursion.com/role/FairValueMeasurementsTables">
        <link:definition>2359310 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>2460434 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails">
        <link:definition>2461435 - Disclosure - Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.recursion.com/role/RelatedPartyTransactions">
        <link:definition>2162116 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.recursion.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2463436 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rxrx_LesseeOperatingLeaseTenantImprovementAllowance" abstract="false" name="LesseeOperatingLeaseTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rxrx_SupplementalFinancialInformationAbstract" abstract="true" name="SupplementalFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_ChristopherGibsonAndAffiliatesMember" abstract="true" name="ChristopherGibsonAndAffiliatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_WarrantsArrangementsLineItems" abstract="true" name="WarrantsArrangementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" abstract="false" name="CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_ViumIncMember" abstract="true" name="ViumIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_WarrantsArrangementsTable" abstract="true" name="WarrantsArrangementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_A2016WarrantsMember" abstract="true" name="A2016WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_MilpitasMember" abstract="true" name="MilpitasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_Station41Member" abstract="true" name="Station41Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_LeaseArrangementNameAxis" abstract="true" name="LeaseArrangementNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" abstract="true" name="MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_PacificWesternLetterOfCreditMember" abstract="true" name="PacificWesternLetterOfCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_ConvertibleSeriesDPreferredStockMember" abstract="true" name="ConvertibleSeriesDPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_ConvertibleSeriesA1PreferredStockMember" abstract="true" name="ConvertibleSeriesA1PreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LeaseIncentivePayableNoncurrent" abstract="false" name="LeaseIncentivePayableNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_TemporaryEquityIssuanceCosts" abstract="false" name="TemporaryEquityIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" abstract="false" name="CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityValueConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" abstract="false" name="AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rxrx_ConvertibleSeriesAPreferredStockMember" abstract="true" name="ConvertibleSeriesAPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_PacificWesternBankLoanMember" abstract="true" name="PacificWesternBankLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_ClassOfWarrantOrRightGrantDateFairValue" abstract="false" name="ClassOfWarrantOrRightGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rxrx_Station41LeaseMember" abstract="true" name="Station41LeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_Station56Member" abstract="true" name="Station56Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" abstract="false" name="CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_A2017WarrantsMember" abstract="true" name="A2017WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_CommonStockVotePerShare" abstract="false" name="CommonStockVotePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rxrx_StockIssuanceCostsNoncash" abstract="false" name="StockIssuanceCostsNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_KomasMember" abstract="true" name="KomasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_A2021EquityIncentivePlanMember" abstract="true" name="A2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" abstract="false" name="IncreaseDecreaseInAccruedDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_SeriesAAndSeriesBWarrantsMember" abstract="true" name="SeriesAAndSeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_AccruedEarlyDiscoveryExpensesCurrent" abstract="false" name="AccruedEarlyDiscoveryExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_PaymentsOfStockIssuanceExpenses" abstract="false" name="PaymentsOfStockIssuanceExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_WarrantsIssuedInJanuary2020Member" abstract="true" name="WarrantsIssuedInJanuary2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_AccruedDevelopmentCostsCurrent" abstract="false" name="AccruedDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" abstract="false" name="LesseeOperatingLeaseSizeOfLeasedAsset" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="rxrx_CorporateBondsMember" abstract="true" name="CorporateBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementNonRefundableUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_AffiliatedHoldersOwnershipPercentage" abstract="false" name="AffiliatedHoldersOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rxrx_CollaborativeAgreementTerm" abstract="false" name="CollaborativeAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rxrx_TemporaryEquityTextBlock" abstract="false" name="TemporaryEquityTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rxrx_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_ConvertibleSeriesCPreferredStockMember" abstract="true" name="ConvertibleSeriesCPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_SaleOfStockConvertedPricePerShare" abstract="false" name="SaleOfStockConvertedPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" abstract="false" name="SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rxrx_A2018WarrantsMember" abstract="true" name="A2018WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_ClassOfWarrantOrRightFairValue" abstract="false" name="ClassOfWarrantOrRightFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_ConvertibleSeriesBPreferredStockMember" abstract="true" name="ConvertibleSeriesBPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_MidcapLoanAgreementMember" abstract="true" name="MidcapLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rxrx_AccruedInvestmentPurchasesCurrent" abstract="false" name="AccruedInvestmentPurchasesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rxrx_LeaseArrangementNameDomain" abstract="true" name="LeaseArrangementNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rxrx_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>rxrx-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bb127273-35b3-457d-ab21-bda4843992dc,g:487b784e-5d7c-455e-b63d-c9a591fced83-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40c6797f-8ba2-4cb6-8528-d25d3b325e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8957b79-b0c1-4d73-967b-5855389cbef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6797f-8ba2-4cb6-8528-d25d3b325e2a" xlink:to="loc_us-gaap_AssetsCurrent_e8957b79-b0c1-4d73-967b-5855389cbef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5d5a368-a4e4-4539-beeb-03cae3fe25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6797f-8ba2-4cb6-8528-d25d3b325e2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5d5a368-a4e4-4539-beeb-03cae3fe25bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_dc946d10-a2a5-40bd-8e3c-3b2c25724cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6797f-8ba2-4cb6-8528-d25d3b325e2a" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_dc946d10-a2a5-40bd-8e3c-3b2c25724cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3d981f68-0b3a-48d3-abe0-3d3e4adfef4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6797f-8ba2-4cb6-8528-d25d3b325e2a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3d981f68-0b3a-48d3-abe0-3d3e4adfef4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6bd2ca1b-8fef-4944-b306-cb79cfa66b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ebdc5ca0-1e69-416b-8c10-2a038c7b976a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6bd2ca1b-8fef-4944-b306-cb79cfa66b39" xlink:to="loc_us-gaap_Liabilities_ebdc5ca0-1e69-416b-8c10-2a038c7b976a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1b37c17b-cbe1-45db-a2cd-cf81b8842ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6bd2ca1b-8fef-4944-b306-cb79cfa66b39" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1b37c17b-cbe1-45db-a2cd-cf81b8842ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9780a00f-76e5-4c0e-afcd-d7f456955716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6bd2ca1b-8fef-4944-b306-cb79cfa66b39" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9780a00f-76e5-4c0e-afcd-d7f456955716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fcf51163-f1dc-4910-816b-91d1e4428c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6bd2ca1b-8fef-4944-b306-cb79cfa66b39" xlink:to="loc_us-gaap_StockholdersEquity_fcf51163-f1dc-4910-816b-91d1e4428c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81ffe6ec-8f36-40f1-8cbc-fdd2695810c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81ffe6ec-8f36-40f1-8cbc-fdd2695810c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_881fd878-39ce-4d5d-b49f-d0566092048c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:to="loc_us-gaap_RestrictedCashCurrent_881fd878-39ce-4d5d-b49f-d0566092048c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3eb7f08d-7589-4dd2-bd34-53c090e4eab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3eb7f08d-7589-4dd2-bd34-53c090e4eab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c65a55e3-40e8-4d3d-a1e8-1069c89c4c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:to="loc_us-gaap_OtherAssetsCurrent_c65a55e3-40e8-4d3d-a1e8-1069c89c4c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_b92fb07f-c96c-4e69-8ba7-4e75b95201ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_b92fb07f-c96c-4e69-8ba7-4e75b95201ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c91ea494-08d8-4266-a1bc-d796bf9278d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_323d2951-17b2-4516-8ad8-198f9c03275f" xlink:to="loc_us-gaap_ShortTermInvestments_c91ea494-08d8-4266-a1bc-d796bf9278d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_549ec131-7056-4226-8143-fc5820a51d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d61724e4-b5ba-4b35-b768-a5e2cfb1fd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_549ec131-7056-4226-8143-fc5820a51d1e" xlink:to="loc_us-gaap_AccountsPayableCurrent_d61724e4-b5ba-4b35-b768-a5e2cfb1fd41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_173c24b3-d64b-455d-8c16-18d9669b6c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_549ec131-7056-4226-8143-fc5820a51d1e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_173c24b3-d64b-455d-8c16-18d9669b6c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a679f17-841c-47a1-b32d-c84eed3942a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_549ec131-7056-4226-8143-fc5820a51d1e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1a679f17-841c-47a1-b32d-c84eed3942a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_1988868f-087b-4708-88ec-b43f8b0cad61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_549ec131-7056-4226-8143-fc5820a51d1e" xlink:to="loc_us-gaap_NotesPayableCurrent_1988868f-087b-4708-88ec-b43f8b0cad61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_aa528bb4-953a-42be-a2d5-859c5ef08153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_549ec131-7056-4226-8143-fc5820a51d1e" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_aa528bb4-953a-42be-a2d5-859c5ef08153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7bee0aa6-b96a-4bc6-8374-edb4fc7aa8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fd7e006a-6c52-4cf8-ab20-b99c80dd8f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7bee0aa6-b96a-4bc6-8374-edb4fc7aa8a5" xlink:to="loc_us-gaap_CommonStockValue_fd7e006a-6c52-4cf8-ab20-b99c80dd8f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4af35208-ef33-4800-b5a6-136e0711c0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7bee0aa6-b96a-4bc6-8374-edb4fc7aa8a5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4af35208-ef33-4800-b5a6-136e0711c0f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5666a1c-377c-496d-b709-0851e4f0209a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7bee0aa6-b96a-4bc6-8374-edb4fc7aa8a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5666a1c-377c-496d-b709-0851e4f0209a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f204399d-7922-40ce-87d9-d86a17d5ba02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7bee0aa6-b96a-4bc6-8374-edb4fc7aa8a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f204399d-7922-40ce-87d9-d86a17d5ba02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ed37c9cf-aeb5-4aa8-a87b-182e37e1717d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c8e2f82-cc95-4859-a6cb-25b9c35fb4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed37c9cf-aeb5-4aa8-a87b-182e37e1717d" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c8e2f82-cc95-4859-a6cb-25b9c35fb4d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_1931d9b4-df36-4d30-b080-907ebbf9306e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed37c9cf-aeb5-4aa8-a87b-182e37e1717d" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_1931d9b4-df36-4d30-b080-907ebbf9306e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92c734df-4856-4b67-b36b-404199f5fb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed37c9cf-aeb5-4aa8-a87b-182e37e1717d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_92c734df-4856-4b67-b36b-404199f5fb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_0df6d85a-c31d-4faa-8a44-13013b79ed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed37c9cf-aeb5-4aa8-a87b-182e37e1717d" xlink:to="loc_us-gaap_LongTermNotesPayable_0df6d85a-c31d-4faa-8a44-13013b79ed1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseIncentivePayableNoncurrent_16a08bd5-789d-42c3-8981-140095540617" xlink:href="rxrx-20210930.xsd#rxrx_LeaseIncentivePayableNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ed37c9cf-aeb5-4aa8-a87b-182e37e1717d" xlink:to="loc_rxrx_LeaseIncentivePayableNoncurrent_16a08bd5-789d-42c3-8981-140095540617" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f44828d7-ad6a-4cdd-a7d1-d6a626b8d739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_00ca6ec7-0205-42c3-b767-e56cf9032b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f44828d7-ad6a-4cdd-a7d1-d6a626b8d739" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_00ca6ec7-0205-42c3-b767-e56cf9032b73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_205cf024-647d-4e09-a90a-e1eb4be87ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f44828d7-ad6a-4cdd-a7d1-d6a626b8d739" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_205cf024-647d-4e09-a90a-e1eb4be87ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_52e0c910-d039-4400-bd7d-04d1d86edff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_58ade303-467a-49c5-a0ac-10fc33202729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_52e0c910-d039-4400-bd7d-04d1d86edff6" xlink:to="loc_us-gaap_OperatingIncomeLoss_58ade303-467a-49c5-a0ac-10fc33202729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6a617705-27f8-4aba-9514-5b2bd7fbbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_52e0c910-d039-4400-bd7d-04d1d86edff6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6a617705-27f8-4aba-9514-5b2bd7fbbc76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cecae2e3-f9af-41c8-a8ec-de0b82b9500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e01914b-1309-462d-aa59-25a5e4ccfb51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cecae2e3-f9af-41c8-a8ec-de0b82b9500e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5e01914b-1309-462d-aa59-25a5e4ccfb51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3cbf4e8d-c7c5-4ab6-8fbb-f458a35c8107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cecae2e3-f9af-41c8-a8ec-de0b82b9500e" xlink:to="loc_us-gaap_OperatingExpenses_3cbf4e8d-c7c5-4ab6-8fbb-f458a35c8107" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f4b692b5-6fad-45f2-9efc-9694854ac4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4d69d876-9a15-43f8-9ad3-34a2b39a3306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f4b692b5-6fad-45f2-9efc-9694854ac4d5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4d69d876-9a15-43f8-9ad3-34a2b39a3306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4fe613ff-2cba-49ca-8763-2fa90614ea74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f4b692b5-6fad-45f2-9efc-9694854ac4d5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4fe613ff-2cba-49ca-8763-2fa90614ea74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea7a915a-e24b-41c6-a716-07bd1ecbc3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99e821be-7b29-4231-9c32-eca8e3fbf953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea7a915a-e24b-41c6-a716-07bd1ecbc3e5" xlink:to="loc_us-gaap_NetIncomeLoss_99e821be-7b29-4231-9c32-eca8e3fbf953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aae24e1c-c5cd-44e0-9d11-4e32f3bd6426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea7a915a-e24b-41c6-a716-07bd1ecbc3e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_aae24e1c-c5cd-44e0-9d11-4e32f3bd6426" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f3de551-f700-4695-a2dd-5d849fab84ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67932e25-73b7-4efb-841e-32a13d387bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f3de551-f700-4695-a2dd-5d849fab84ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67932e25-73b7-4efb-841e-32a13d387bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b717ff75-631d-4692-8e2c-42745b6276b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f3de551-f700-4695-a2dd-5d849fab84ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b717ff75-631d-4692-8e2c-42745b6276b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e4cfac8-5b9f-4a5c-8700-747a4a88291c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f3de551-f700-4695-a2dd-5d849fab84ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e4cfac8-5b9f-4a5c-8700-747a4a88291c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49058482-57dd-4d56-9293-15f26ae92074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_de087653-c5c3-4de3-8927-877d37eadbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49058482-57dd-4d56-9293-15f26ae92074" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_de087653-c5c3-4de3-8927-877d37eadbb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9303db33-7a0f-4a33-8e40-b4423fef9744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49058482-57dd-4d56-9293-15f26ae92074" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9303db33-7a0f-4a33-8e40-b4423fef9744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ea02ee18-a6dc-4c46-912c-4941cbee66bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49058482-57dd-4d56-9293-15f26ae92074" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ea02ee18-a6dc-4c46-912c-4941cbee66bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_4c88c35e-7451-4a88-bb56-d2e0aedfcca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49058482-57dd-4d56-9293-15f26ae92074" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_4c88c35e-7451-4a88-bb56-d2e0aedfcca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db33b9ab-fdbd-4507-be94-5ee52bc84cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_398ab895-46b8-4f7c-a94a-889ead5eb222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db33b9ab-fdbd-4507-be94-5ee52bc84cca" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_398ab895-46b8-4f7c-a94a-889ead5eb222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_009cc818-5dc0-40d5-be6d-3009da8e5802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db33b9ab-fdbd-4507-be94-5ee52bc84cca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_009cc818-5dc0-40d5-be6d-3009da8e5802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9161b032-b44f-4eac-89fe-6a040e3ab8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db33b9ab-fdbd-4507-be94-5ee52bc84cca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_9161b032-b44f-4eac-89fe-6a040e3ab8ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d5ff1dd2-d307-4ca4-82ee-b3b7ed9bfbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db33b9ab-fdbd-4507-be94-5ee52bc84cca" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d5ff1dd2-d307-4ca4-82ee-b3b7ed9bfbe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_e7f911f5-1c7d-4296-92c9-c4a914801b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db33b9ab-fdbd-4507-be94-5ee52bc84cca" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_e7f911f5-1c7d-4296-92c9-c4a914801b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f960625-303d-4bee-b150-7e6c9e7ae37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_NetIncomeLoss_5f960625-303d-4bee-b150-7e6c9e7ae37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c387a4e3-9f93-4286-b193-307ceb8547e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c387a4e3-9f93-4286-b193-307ceb8547e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_df2cd9e1-3be7-4467-ba5b-9b16c68b4c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_ShareBasedCompensation_df2cd9e1-3be7-4467-ba5b-9b16c68b4c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8469995e-9992-4cb0-ac9c-16c3496b3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_AssetImpairmentCharges_8469995e-9992-4cb0-ac9c-16c3496b3be4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b3bab10f-a6ef-492c-8bca-e40b5834b689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b3bab10f-a6ef-492c-8bca-e40b5834b689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f1260101-7171-43eb-8a0c-928c0fee35bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f1260101-7171-43eb-8a0c-928c0fee35bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9d644ca3-4ab2-4818-a44f-4e497786f98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9d644ca3-4ab2-4818-a44f-4e497786f98b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef00d77e-2688-4bfa-b9a1-84ab75735207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef00d77e-2688-4bfa-b9a1-84ab75735207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bb072431-57f6-4541-8c96-a37e1ca74c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bb072431-57f6-4541-8c96-a37e1ca74c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c94117bf-0a5c-4bb0-b17b-6397cbd78218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c94117bf-0a5c-4bb0-b17b-6397cbd78218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_e55c0d05-8689-4b1b-ae53-b3283a2de6b9" xlink:href="rxrx-20210930.xsd#rxrx_IncreaseDecreaseInAccruedDevelopmentExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_e55c0d05-8689-4b1b-ae53-b3283a2de6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d83ac389-0c54-4b3f-8cc0-aef06f0e5174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e34a084a-54f5-4fb5-8d8f-d7fbfc0f27b5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d83ac389-0c54-4b3f-8cc0-aef06f0e5174" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#AcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_15671eee-f2d5-4dd9-93c4-af2c82d1a819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9935b370-274e-432b-b2b1-92801ba4cd72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_15671eee-f2d5-4dd9-93c4-af2c82d1a819" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9935b370-274e-432b-b2b1-92801ba4cd72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_27b9eb9c-cc1b-43a0-9c40-d18480d0cff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_15671eee-f2d5-4dd9-93c4-af2c82d1a819" xlink:to="loc_us-gaap_Goodwill_27b9eb9c-cc1b-43a0-9c40-d18480d0cff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b75ecdc3-1e26-4572-ac6c-11dba4895697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_29b59b00-35c0-4dbe-8db4-96468df13062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b75ecdc3-1e26-4572-ac6c-11dba4895697" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_29b59b00-35c0-4dbe-8db4-96468df13062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_8122a792-5ad7-4157-9eae-92f8b31a117e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b75ecdc3-1e26-4572-ac6c-11dba4895697" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_8122a792-5ad7-4157-9eae-92f8b31a117e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8ffb3087-1645-4175-8236-fde997453fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b75ecdc3-1e26-4572-ac6c-11dba4895697" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8ffb3087-1645-4175-8236-fde997453fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_46f7782a-b288-4788-81ae-90a0147a9310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b75ecdc3-1e26-4572-ac6c-11dba4895697" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_46f7782a-b288-4788-81ae-90a0147a9310" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationPPEDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb30b754-4f18-4cb1-a7f9-d09eb7cd3f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7e08313a-f0d7-44b6-b221-19ee8f2718ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fb30b754-4f18-4cb1-a7f9-d09eb7cd3f74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7e08313a-f0d7-44b6-b221-19ee8f2718ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85e51769-1648-4f21-904c-5921b1c6502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fb30b754-4f18-4cb1-a7f9-d09eb7cd3f74" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_85e51769-1648-4f21-904c-5921b1c6502a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationAccrualsDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5d010eb9-e265-49c7-b1a7-383d6305a960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5d010eb9-e265-49c7-b1a7-383d6305a960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedDevelopmentCostsCurrent_270d54ee-9f3b-4d6f-99a0-579e6e9a625c" xlink:href="rxrx-20210930.xsd#rxrx_AccruedDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:to="loc_rxrx_AccruedDevelopmentCostsCurrent_270d54ee-9f3b-4d6f-99a0-579e6e9a625c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_1da37a79-ac2d-4bcf-822d-c5535f188878" xlink:href="rxrx-20210930.xsd#rxrx_AccruedEarlyDiscoveryExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:to="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_1da37a79-ac2d-4bcf-822d-c5535f188878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedInvestmentPurchasesCurrent_1a74e347-a891-427a-a306-909f2d8b9b0c" xlink:href="rxrx-20210930.xsd#rxrx_AccruedInvestmentPurchasesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:to="loc_rxrx_AccruedInvestmentPurchasesCurrent_1a74e347-a891-427a-a306-909f2d8b9b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_2c0549cb-4687-4667-83d7-b06d2c4773d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:to="loc_us-gaap_ConstructionPayableCurrent_2c0549cb-4687-4667-83d7-b06d2c4773d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd08ec8b-5180-46bf-9ba6-d740b7ec8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7224ed86-94a2-4285-9c5b-ff58ec080538" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bd08ec8b-5180-46bf-9ba6-d740b7ec8f07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationInterestDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_76abfe14-4047-4377-aaaf-7498b9aabd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_24c07308-ee3a-4105-a11a-0e336ffabdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_76abfe14-4047-4377-aaaf-7498b9aabd6e" xlink:to="loc_us-gaap_InterestExpense_24c07308-ee3a-4105-a11a-0e336ffabdb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_6844c912-edde-45ae-9da7-939b5a66e695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_76abfe14-4047-4377-aaaf-7498b9aabd6e" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_6844c912-edde-45ae-9da7-939b5a66e695" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsTypeofSecurityDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0be76b2a-404f-4c73-b15e-d2b214110a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_813a915e-6b2f-4a21-a225-a821c1a57f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0be76b2a-404f-4c73-b15e-d2b214110a8f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_813a915e-6b2f-4a21-a225-a821c1a57f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b82b8249-3a1c-4144-a997-58c3b0dbf6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0be76b2a-404f-4c73-b15e-d2b214110a8f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b82b8249-3a1c-4144-a997-58c3b0dbf6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38b5187f-3aea-4225-b46e-0147cc895bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0be76b2a-404f-4c73-b15e-d2b214110a8f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_38b5187f-3aea-4225-b46e-0147cc895bee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#GoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02e710-5fa9-4510-a50e-e575273c8a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4c8ce77b-b03d-4888-94bb-9b0f651515bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02e710-5fa9-4510-a50e-e575273c8a22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4c8ce77b-b03d-4888-94bb-9b0f651515bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_412c31d4-2396-4364-9193-688e2150c405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0a02e710-5fa9-4510-a50e-e575273c8a22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_412c31d4-2396-4364-9193-688e2150c405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e4e48f4-62a9-4fa9-862c-786f28efdf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_24c21f53-2d49-413d-848a-2ecef0d96dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e4e48f4-62a9-4fa9-862c-786f28efdf65" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_24c21f53-2d49-413d-848a-2ecef0d96dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf48db5c-06af-406a-bcd1-1f3018808386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8e4e48f4-62a9-4fa9-862c-786f28efdf65" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf48db5c-06af-406a-bcd1-1f3018808386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e6e04ea3-f54c-4e3d-8d5a-3b2df329fda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fe626e5a-d126-4e87-9929-443289ce35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e6e04ea3-f54c-4e3d-8d5a-3b2df329fda8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_fe626e5a-d126-4e87-9929-443289ce35c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0aa6c228-5dc7-4f85-8d72-49624a371d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e6e04ea3-f54c-4e3d-8d5a-3b2df329fda8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0aa6c228-5dc7-4f85-8d72-49624a371d83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="rxrx-20210930.xsd#GoodwillandIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc23e046-96cf-485c-98c6-11acdeaaa4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_135bcfad-84e6-4f0a-bb58-f67ed7ddb678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc23e046-96cf-485c-98c6-11acdeaaa4b5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_135bcfad-84e6-4f0a-bb58-f67ed7ddb678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_93082e73-727c-4a6b-8bc9-8dd6cae62e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc23e046-96cf-485c-98c6-11acdeaaa4b5" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_93082e73-727c-4a6b-8bc9-8dd6cae62e6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableCurrentNoncurrentDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_91e0b3f4-de99-4c2a-82ad-1aee84085139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_67877adf-662f-4c17-a936-f078a8320e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_91e0b3f4-de99-4c2a-82ad-1aee84085139" xlink:to="loc_us-gaap_LongTermDebtCurrent_67877adf-662f-4c17-a936-f078a8320e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4cfb4947-3f5a-4e2f-a7cd-70613ceb2c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_91e0b3f4-de99-4c2a-82ad-1aee84085139" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4cfb4947-3f5a-4e2f-a7cd-70613ceb2c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0e5f86b6-8fe4-42ab-b0ef-4fbd50e33f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_91e0b3f4-de99-4c2a-82ad-1aee84085139" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0e5f86b6-8fe4-42ab-b0ef-4fbd50e33f3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayablePrincipalRepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a2fb54db-278a-4841-b4ec-5ac6891f3f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a2fb54db-278a-4841-b4ec-5ac6891f3f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d50cf3c3-3329-412e-964b-fe5df3ff485a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d50cf3c3-3329-412e-964b-fe5df3ff485a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2103592f-2adf-4bd8-b36c-43a1fc4c729d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2103592f-2adf-4bd8-b36c-43a1fc4c729d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2a376dda-9293-4aef-b790-4666afcad7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2a376dda-9293-4aef-b790-4666afcad7b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_396b7512-20e5-4555-83e5-1cf24b2438cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_396b7512-20e5-4555-83e5-1cf24b2438cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LongTermDebtMaturityAfterYearFour_98a5dbc2-3e08-40f4-87bc-0e7564deddbb" xlink:href="rxrx-20210930.xsd#rxrx_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cebb6d56-d80c-42d4-a06f-760292ace6e6" xlink:to="loc_rxrx_LongTermDebtMaturityAfterYearFour_98a5dbc2-3e08-40f4-87bc-0e7564deddbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommitmentsandContingenciesMinimumpaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_5ab4f9fb-1533-4dcd-a350-d7859001aea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_5ab4f9fb-1533-4dcd-a350-d7859001aea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_ef7bd27e-aae9-4326-b67a-f7dce7e6fec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_ef7bd27e-aae9-4326-b67a-f7dce7e6fec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2381cd13-01b2-4408-92f8-d0e3ddf6fe0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2381cd13-01b2-4408-92f8-d0e3ddf6fe0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5dc8febc-c02f-4c68-83ac-9a4f765e3512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_5dc8febc-c02f-4c68-83ac-9a4f765e3512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3fb3bb8a-41f3-440c-b708-d7096dd13f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3fb3bb8a-41f3-440c-b708-d7096dd13f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_02037166-ae0c-45ad-860a-f3bc9ffa8826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bb0007c0-826e-442a-8c56-0e685267cd5c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_02037166-ae0c-45ad-860a-f3bc9ffa8826" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_365c63dc-e511-491f-8c3e-e8ec5fce5bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_20fde2bb-57e5-4d08-9fd8-ade4a2de37d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_365c63dc-e511-491f-8c3e-e8ec5fce5bfd" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_20fde2bb-57e5-4d08-9fd8-ade4a2de37d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9375371c-8dc4-4744-82f6-75c2e630cc37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7c7da8ee-b5bc-4343-b8a9-0ba06074e29c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9375371c-8dc4-4744-82f6-75c2e630cc37" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7c7da8ee-b5bc-4343-b8a9-0ba06074e29c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_158db119-86bc-49e1-aef4-089f1b40fc2d" xlink:href="rxrx-20210930.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9375371c-8dc4-4744-82f6-75c2e630cc37" xlink:to="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_158db119-86bc-49e1-aef4-089f1b40fc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e48a12d1-f493-434f-8332-565e9edac095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9375371c-8dc4-4744-82f6-75c2e630cc37" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e48a12d1-f493-434f-8332-565e9edac095" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>rxrx-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bb127273-35b3-457d-ab21-bda4843992dc,g:487b784e-5d7c-455e-b63d-c9a591fced83-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.recursion.com/role/CoverPage" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CoverPage" xlink:type="extended" id="i915bddbef69847efb4a6566491d60fae_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7d6627d0-dde3-4332-b957-a18c8ea40f29" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentType_7d6627d0-dde3-4332-b957-a18c8ea40f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_50dd4693-b7ec-4bbe-b583-e59d4cd014b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentQuarterlyReport_50dd4693-b7ec-4bbe-b583-e59d4cd014b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc77f3d5-2b19-46a1-ae13-c094b22227ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentPeriodEndDate_fc77f3d5-2b19-46a1-ae13-c094b22227ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3529df05-0afd-47da-b8ef-06623be5e4ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentTransitionReport_3529df05-0afd-47da-b8ef-06623be5e4ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7961c051-1346-4d05-89a3-e32eaa5d04b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityFileNumber_7961c051-1346-4d05-89a3-e32eaa5d04b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b4b3f3e7-42ad-4790-808d-dbbac1415ce6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityRegistrantName_b4b3f3e7-42ad-4790-808d-dbbac1415ce6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5bcfd748-ab02-4bb4-b77f-42683610debf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5bcfd748-ab02-4bb4-b77f-42683610debf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3468128d-4dee-419a-930c-54604bda5f3f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityTaxIdentificationNumber_3468128d-4dee-419a-930c-54604bda5f3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_57f514eb-f4fd-4c53-9081-eb9253d38dc5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressAddressLine1_57f514eb-f4fd-4c53-9081-eb9253d38dc5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_91ea46c1-c8ac-4fa5-9eba-bddb3e7df17f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressCityOrTown_91ea46c1-c8ac-4fa5-9eba-bddb3e7df17f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_912b6a36-df7f-4eb7-aa74-ac8260ae732c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressStateOrProvince_912b6a36-df7f-4eb7-aa74-ac8260ae732c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6ac9f6ab-7b7e-4a08-86ee-b7020d7f5646" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressPostalZipCode_6ac9f6ab-7b7e-4a08-86ee-b7020d7f5646" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ea6dbed-6699-4ed9-afee-97c7f566f8ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_CityAreaCode_8ea6dbed-6699-4ed9-afee-97c7f566f8ec" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cdc6e65d-ad60-4289-8d47-edcc56ea0d0a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_LocalPhoneNumber_cdc6e65d-ad60-4289-8d47-edcc56ea0d0a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_63ef779c-3572-465f-9877-a0461719819c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_Security12bTitle_63ef779c-3572-465f-9877-a0461719819c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ff69e661-4fd6-4d99-97c2-c6e42061c008" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_TradingSymbol_ff69e661-4fd6-4d99-97c2-c6e42061c008" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e96c02e7-8afc-44b2-b092-c8d1d0a55156" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_SecurityExchangeName_e96c02e7-8afc-44b2-b092-c8d1d0a55156" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7e0170a8-b2b6-498a-a0ad-ed0a19236bb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityCurrentReportingStatus_7e0170a8-b2b6-498a-a0ad-ed0a19236bb1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_63ea4aad-fdd1-485f-a974-85fe5780c7f9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityInteractiveDataCurrent_63ea4aad-fdd1-485f-a974-85fe5780c7f9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_342bf806-7d11-4f24-bf2a-7cc7563f0cc5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityFilerCategory_342bf806-7d11-4f24-bf2a-7cc7563f0cc5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9fef2fb9-07e7-4822-a034-ce41bcd80d95" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntitySmallBusiness_9fef2fb9-07e7-4822-a034-ce41bcd80d95" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_13258345-7adf-4b06-b36f-8f577a4ae74b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityEmergingGrowthCompany_13258345-7adf-4b06-b36f-8f577a4ae74b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_d044bad9-d81b-4379-8f30-6f4f189957cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityExTransitionPeriod_d044bad9-d81b-4379-8f30-6f4f189957cf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cfa036ba-2f60-40d2-bb35-6cb188df9d19" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityShellCompany_cfa036ba-2f60-40d2-bb35-6cb188df9d19" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5f0169dd-d38b-424f-b1fc-24984d9f3071" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5f0169dd-d38b-424f-b1fc-24984d9f3071" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b8604bc5-0f36-4e96-8695-567142eb0d36" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityCentralIndexKey_b8604bc5-0f36-4e96-8695-567142eb0d36" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1c95b2da-8612-45a9-82ea-68ef834d15b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_AmendmentFlag_1c95b2da-8612-45a9-82ea-68ef834d15b5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a2b55972-61c4-48aa-a35a-44c49b6da9b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentFiscalYearFocus_a2b55972-61c4-48aa-a35a-44c49b6da9b3" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fe7cbc09-eae3-4eb2-9103-02b38195f301" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fe7cbc09-eae3-4eb2-9103-02b38195f301" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4e45d1d4-a268-43bb-9f96-87f1c5451347" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_CurrentFiscalYearEndDate_4e45d1d4-a268-43bb-9f96-87f1c5451347" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c8761540-67fa-44a8-bb91-5b219ad8aa4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:to="loc_us-gaap_ClassOfStockDomain_c8761540-67fa-44a8-bb91-5b219ad8aa4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:to="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_44634aae-fa2e-425b-a698-52e0d789d849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:to="loc_us-gaap_CommonClassAMember_44634aae-fa2e-425b-a698-52e0d789d849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_948e7472-cab9-4382-9aa1-b0cf011d0e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:to="loc_us-gaap_CommonClassBMember_948e7472-cab9-4382-9aa1-b0cf011d0e7a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended" id="i6b434fd67c804e19bc2ddb1490cfde46_CondensedConsolidatedBalanceSheetsunauditedParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e53cbfb-dd4b-42ad-8a94-358329f0aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e53cbfb-dd4b-42ad-8a94-358329f0aeb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_52e135a4-256a-47d3-9e0b-522ffc318fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_52e135a4-256a-47d3-9e0b-522ffc318fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_16f8a238-29e0-431a-9cf5-8628ca12e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockSharesIssued_16f8a238-29e0-431a-9cf5-8628ca12e6c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6b0b4d96-3ba8-4009-96b9-5f73ae021f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6b0b4d96-3ba8-4009-96b9-5f73ae021f78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f3c3244a-67a8-430c-952b-39fdb163179a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:to="loc_us-gaap_ClassOfStockDomain_f3c3244a-67a8-430c-952b-39fdb163179a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:to="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3637cdf6-5035-4031-9d97-e32faeb7db0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:to="loc_us-gaap_CommonClassAMember_3637cdf6-5035-4031-9d97-e32faeb7db0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0cf5dd4c-60cf-42f1-bbf5-4c23b9a6a19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:to="loc_us-gaap_CommonClassBMember_0cf5dd4c-60cf-42f1-bbf5-4c23b9a6a19d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended" id="i2d693830a7144de696973c82269400fc_CondensedConsolidatedStatementsofOperationsunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d8f7f77d-230b-42ca-9ee0-8475a37a084e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_RevenuesAbstract_d8f7f77d-230b-42ca-9ee0-8475a37a084e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9af5a6-a716-4e78-9517-da0996fbb704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d8f7f77d-230b-42ca-9ee0-8475a37a084e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9af5a6-a716-4e78-9517-da0996fbb704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_183fc040-cfa9-4605-bd04-a38e562340b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_183fc040-cfa9-4605-bd04-a38e562340b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1ef6dbc6-ff57-4925-ab47-cbee8e7fbef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1ef6dbc6-ff57-4925-ab47-cbee8e7fbef6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d5cbf547-66ef-4e68-bef2-d9cec528c007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:to="loc_us-gaap_OperatingExpenses_d5cbf547-66ef-4e68-bef2-d9cec528c007" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96d2c3d2-7081-4bf0-a4b7-4bceaabfbab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_OperatingIncomeLoss_96d2c3d2-7081-4bf0-a4b7-4bceaabfbab5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4e75d5e7-1634-4340-9a78-f7ee8c938445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4e75d5e7-1634-4340-9a78-f7ee8c938445" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_707ab1e8-7c2f-4e47-a448-e743371f3328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_NetIncomeLoss_707ab1e8-7c2f-4e47-a448-e743371f3328" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d7e9d89d-9e30-4a2b-8bcd-5db81be09e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_EarningsPerShareBasic_d7e9d89d-9e30-4a2b-8bcd-5db81be09e4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_60552a70-5c46-45ba-9d02-8c77a0458084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_60552a70-5c46-45ba-9d02-8c77a0458084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31313ba0-9149-4f29-9546-c9968cd0edeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31313ba0-9149-4f29-9546-c9968cd0edeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4bb673d-7a3a-448b-82a4-2cc3a4ed0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4bb673d-7a3a-448b-82a4-2cc3a4ed0ac8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:to="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_94d158d7-1d28-4342-a57f-243bfd2e41e0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:to="loc_srt_ProductsAndServicesDomain_94d158d7-1d28-4342-a57f-243bfd2e41e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:to="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e7d1ad5a-e236-4b81-908f-27befc642656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:to="loc_us-gaap_GrantMember_e7d1ad5a-e236-4b81-908f-27befc642656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_2c6a5f70-6af2-4463-8ae8-e808750c2fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:to="loc_us-gaap_LicenseAndServiceMember_2c6a5f70-6af2-4463-8ae8-e808750c2fe4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="extended" id="i4ecb915800de41a8a6ffb001c1a7de25_CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_89cbeebe-901e-46ed-8d75-2144da66c2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_89cbeebe-901e-46ed-8d75-2144da66c2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6b79edc4-35c0-4ee0-9ecc-53811a1bd814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6b79edc4-35c0-4ee0-9ecc-53811a1bd814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_81ce9594-74c0-47c8-86bd-2208fb40d079" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_81ce9594-74c0-47c8-86bd-2208fb40d079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_9be820ba-e2df-446e-80cd-0654cfcf5a32" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_9be820ba-e2df-446e-80cd-0654cfcf5a32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4a2b96b3-e45e-48f0-a965-81ac6719db9d" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4a2b96b3-e45e-48f0-a965-81ac6719db9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d3c8d9c1-cb03-4f2b-9364-d8b34a8aa1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d3c8d9c1-cb03-4f2b-9364-d8b34a8aa1c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b520f0c5-33c6-4557-8b7a-29296d546c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_59c2d449-5f91-469f-8150-9c3a0896cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f81d53c-6061-4cb8-86de-ee5f066fa0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f81d53c-6061-4cb8-86de-ee5f066fa0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_72ec2936-1695-464c-8457-e2f739882e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockholdersEquity_72ec2936-1695-464c-8457-e2f739882e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b89561be-144f-465e-9f2c-d6451901ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_NetIncomeLoss_b89561be-144f-465e-9f2c-d6451901ef6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c834d7-a7e3-45ad-93be-5122de46e984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c834d7-a7e3-45ad-93be-5122de46e984" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c07092d-d052-458a-b0d7-55fc44ff096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c07092d-d052-458a-b0d7-55fc44ff096d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c6bf818b-d508-49b5-bca9-95ed7e4f4be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c6bf818b-d508-49b5-bca9-95ed7e4f4be0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_82b96184-0726-401f-b90c-c50cbf8897d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_82b96184-0726-401f-b90c-c50cbf8897d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_681310b3-1a14-4500-af4a-f8e861b10535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_681310b3-1a14-4500-af4a-f8e861b10535" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f372f6f-dcac-429e-8d1b-fef9ecf2d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f372f6f-dcac-429e-8d1b-fef9ecf2d3a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2443f4a-2147-4fdd-8740-d301c3d4deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2443f4a-2147-4fdd-8740-d301c3d4deb4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b4315abe-4b7c-4bff-802f-d04b3577b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b4315abe-4b7c-4bff-802f-d04b3577b6d1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3bbd8fc3-41c7-4e33-8793-3cdbbceffac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4c926a1-f808-4a1b-ac78-80ca2566992b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:to="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d8ef121-e2f4-42ca-b6de-886312d1fbdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:to="loc_us-gaap_EquityComponentDomain_3d8ef121-e2f4-42ca-b6de-886312d1fbdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:to="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c1c7c275-591e-4242-b38d-39f6273bdb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_CommonStockMember_c1c7c275-591e-4242-b38d-39f6273bdb7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_98993835-0cf3-4edc-a4b9-4308fe56096c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_98993835-0cf3-4edc-a4b9-4308fe56096c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_33bd722a-7484-486b-8ca8-ef68bb73aba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_RetainedEarningsMember_33bd722a-7484-486b-8ca8-ef68bb73aba6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b4e1b8a0-83e4-4fbe-9613-f152dc6e1a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b4e1b8a0-83e4-4fbe-9613-f152dc6e1a49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dcf45b7f-c2bd-4dd2-890c-a113d672aff4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:to="loc_us-gaap_ClassOfStockDomain_dcf45b7f-c2bd-4dd2-890c-a113d672aff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_24a99793-e33f-4277-9a96-89604db1d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:to="loc_us-gaap_ClassOfStockDomain_24a99793-e33f-4277-9a96-89604db1d24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b06bc6d1-4d0e-4361-ad98-47b709cb288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_24a99793-e33f-4277-9a96-89604db1d24c" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b06bc6d1-4d0e-4361-ad98-47b709cb288d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_04848990-33e4-4135-bbe6-66884e0e6369_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_04848990-33e4-4135-bbe6-66884e0e6369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_92424210-ed07-41ba-a8ad-666ddc368d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_92424210-ed07-41ba-a8ad-666ddc368d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SeriesAAndSeriesBWarrantsMember_ec7830ad-59bf-43d0-8d94-032c23a8a30e" xlink:href="rxrx-20210930.xsd#rxrx_SeriesAAndSeriesBWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92424210-ed07-41ba-a8ad-666ddc368d7c" xlink:to="loc_rxrx_SeriesAAndSeriesBWarrantsMember_ec7830ad-59bf-43d0-8d94-032c23a8a30e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#BasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/BasisofPresentationDetails" xlink:type="extended" id="i3a4b03d619f044cc83746adc8f2b97f9_BasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0ee95bd-f47a-4143-bb16-eb04928a8c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2204c9c3-ea3b-4f57-b61b-adc30fa076a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ee95bd-f47a-4143-bb16-eb04928a8c9f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2204c9c3-ea3b-4f57-b61b-adc30fa076a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ee95bd-f47a-4143-bb16-eb04928a8c9f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4c8dbf1f-7854-4a01-b157-9168e3d46ceb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:to="loc_us-gaap_EquityComponentDomain_4c8dbf1f-7854-4a01-b157-9168e3d46ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46834675-e3c2-4619-a1b3-b0a754bf4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:to="loc_us-gaap_EquityComponentDomain_46834675-e3c2-4619-a1b3-b0a754bf4cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_705f1e63-ebc9-48c8-bea2-e967d47876cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_46834675-e3c2-4619-a1b3-b0a754bf4cf0" xlink:to="loc_us-gaap_CommonStockMember_705f1e63-ebc9-48c8-bea2-e967d47876cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#AcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/AcquisitionsDetails" xlink:type="extended" id="i0e119a86b4b34889899958a109b33b1c_AcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bd1d13b3-c67f-46b2-b4b7-d59cd2cadbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bd1d13b3-c67f-46b2-b4b7-d59cd2cadbd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_798583e7-c7b2-40f7-b0f7-399feaffacb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_798583e7-c7b2-40f7-b0f7-399feaffacb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_53e716b1-28e4-4c4c-addf-acaf78e89224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_53e716b1-28e4-4c4c-addf-acaf78e89224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a29fcd54-dfa8-4fff-b8b6-d15451903199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a29fcd54-dfa8-4fff-b8b6-d15451903199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3f24be0c-a3b3-4943-84e5-bedf0e2e8cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3f24be0c-a3b3-4943-84e5-bedf0e2e8cca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ae64d515-d112-4b99-87f6-0ac5d027d053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ae64d515-d112-4b99-87f6-0ac5d027d053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_86d5b569-47dc-4cbe-a63f-2a8710862f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_86d5b569-47dc-4cbe-a63f-2a8710862f49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_576c55d3-1cbd-41cb-b901-8476b183516c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_Goodwill_576c55d3-1cbd-41cb-b901-8476b183516c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2276cb55-b237-4278-9d41-f5ce6ba8d772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2276cb55-b237-4278-9d41-f5ce6ba8d772" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_956ff3c8-2986-4707-a0a0-884fba9f93cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_956ff3c8-2986-4707-a0a0-884fba9f93cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a167d3f-c851-4943-877c-c0281657aee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a167d3f-c851-4943-877c-c0281657aee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ViumIncMember_3c51f2b8-abd3-4b7a-9136-9ba1757c23fb" xlink:href="rxrx-20210930.xsd#rxrx_ViumIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a167d3f-c851-4943-877c-c0281657aee3" xlink:to="loc_rxrx_ViumIncMember_3c51f2b8-abd3-4b7a-9136-9ba1757c23fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0cbfbad-2b11-48d3-a284-481f777ca452_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0cbfbad-2b11-48d3-a284-481f777ca452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf9f9481-3029-47d2-8495-b97fd1b627fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf9f9481-3029-47d2-8495-b97fd1b627fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fde43839-2407-43fd-8a39-c4ab0fbd7522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf9f9481-3029-47d2-8495-b97fd1b627fc" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fde43839-2407-43fd-8a39-c4ab0fbd7522" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationPPEDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails" xlink:type="extended" id="i79ddd92e451146e0a730f37f1b28ed11_SupplementalFinancialInformationPPEDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8443b35f-e38b-4338-b42b-1e094cdf3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8443b35f-e38b-4338-b42b-1e094cdf3c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d0b6adb-2e8a-4c89-b012-7ad468717589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d0b6adb-2e8a-4c89-b012-7ad468717589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f335b805-c04b-4c6c-9281-914584df3309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f335b805-c04b-4c6c-9281-914584df3309" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e62bc4b0-19c6-4de4-9ee5-5320d0ae7a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_Depreciation_e62bc4b0-19c6-4de4-9ee5-5320d0ae7a25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_bc32fdca-364e-499e-8f2f-6b791485cdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_bc32fdca-364e-499e-8f2f-6b791485cdb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2849e318-1db9-41a9-ac57-7aa2278b7084_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2849e318-1db9-41a9-ac57-7aa2278b7084_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LaboratoryEquipmentMember_690f02ae-c6a4-42ef-9356-7b33962fdd09" xlink:href="rxrx-20210930.xsd#rxrx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_rxrx_LaboratoryEquipmentMember_690f02ae-c6a4-42ef-9356-7b33962fdd09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e67b5156-e824-4d05-900c-f86cabb127d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e67b5156-e824-4d05-900c-f86cabb127d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_d3c425a2-273a-4a27-95a3-46989749ca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_us-gaap_OfficeEquipmentMember_d3c425a2-273a-4a27-95a3-46989749ca18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_8c289dd2-db30-480d-92e7-e15030ccc20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_us-gaap_AssetUnderConstructionMember_8c289dd2-db30-480d-92e7-e15030ccc20d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsTypeofSecurityDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails" xlink:type="extended" id="i3c1ca4d31b3142c9931b473a79541148_InvestmentsTypeofSecurityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7502a600-3e04-4995-9df7-6ee8379a8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7502a600-3e04-4995-9df7-6ee8379a8ec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2245ce0c-cc98-4e81-91bf-a5c94e9ed0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2245ce0c-cc98-4e81-91bf-a5c94e9ed0c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fb2c746f-b8dc-4ba6-9736-606af4bb9204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fb2c746f-b8dc-4ba6-9736-606af4bb9204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16cec1e-c481-43ed-aba5-1e2e2efd6559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16cec1e-c481-43ed-aba5-1e2e2efd6559" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ef6ae13-70dc-4353-b2f1-ef39df3e6139_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ef6ae13-70dc-4353-b2f1-ef39df3e6139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_434e474c-9b36-4575-95ab-9793a099401c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_us-gaap_MoneyMarketFundsMember_434e474c-9b36-4575-95ab-9793a099401c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CorporateBondsMember_22371a4d-e088-4493-8371-d41211dcee4b" xlink:href="rxrx-20210930.xsd#rxrx_CorporateBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_rxrx_CorporateBondsMember_22371a4d-e088-4493-8371-d41211dcee4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_33d8e2b2-3659-4b47-9854-26178e031cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_us-gaap_CertificatesOfDepositMember_33d8e2b2-3659-4b47-9854-26178e031cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_432a3b72-347f-4047-92f4-9b86b5e2360d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_us-gaap_CommercialPaperMember_432a3b72-347f-4047-92f4-9b86b5e2360d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsBalanceSheetClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails" xlink:type="extended" id="i5e37ca5525894ff7bed4c7feeeaff1b9_InvestmentsBalanceSheetClassificationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1256b73d-3952-41bf-903d-eeb379bf7ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d35ff08a-132d-4b9d-8c9d-fea473e3e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1256b73d-3952-41bf-903d-eeb379bf7ffb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d35ff08a-132d-4b9d-8c9d-fea473e3e9fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1256b73d-3952-41bf-903d-eeb379bf7ffb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_409c967f-dd5a-4266-97f8-09549509c587_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_409c967f-dd5a-4266-97f8-09549509c587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_41ec88c3-f066-4c4f-a669-ce34e262b5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_41ec88c3-f066-4c4f-a669-ce34e262b5fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9892cb96-18a4-4b57-bdc9-12e5440abf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_9892cb96-18a4-4b57-bdc9-12e5440abf0e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableMidcapFinancialDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableMidcapFinancialDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NotesPayableMidcapFinancialDetails" xlink:type="extended" id="idc524a101528461592bd748ba865e283_NotesPayableMidcapFinancialDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3f4efa2c-577d-4658-b2a3-917925bc77a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3f4efa2c-577d-4658-b2a3-917925bc77a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0182928e-fd7c-4971-a2f8-7f51f4ec1546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_RepaymentsOfDebt_0182928e-fd7c-4971-a2f8-7f51f4ec1546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09b82149-99f9-4102-aaca-db8d29edae76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09b82149-99f9-4102-aaca-db8d29edae76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d6de0e79-e1c7-4f3c-9d6a-fc46c213264c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_LineOfCredit_d6de0e79-e1c7-4f3c-9d6a-fc46c213264c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ac81ac0-175e-4a63-a3e7-3ed6ced7f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ac81ac0-175e-4a63-a3e7-3ed6ced7f60b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a69e408-04e8-4474-b907-fc469880159c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a69e408-04e8-4474-b907-fc469880159c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_96396b26-1c9c-4fb0-8622-41af507c605f" xlink:href="rxrx-20210930.xsd#rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:to="loc_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_96396b26-1c9c-4fb0-8622-41af507c605f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PacificWesternBankLoanMember_8e0b8ef7-1357-4fce-8d5e-1e44f5af507a" xlink:href="rxrx-20210930.xsd#rxrx_PacificWesternBankLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:to="loc_rxrx_PacificWesternBankLoanMember_8e0b8ef7-1357-4fce-8d5e-1e44f5af507a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MidcapLoanAgreementMember_e85e615b-b115-441a-b49e-92eb825696a8" xlink:href="rxrx-20210930.xsd#rxrx_MidcapLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:to="loc_rxrx_MidcapLoanAgreementMember_e85e615b-b115-441a-b49e-92eb825696a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5822cd3a-9419-4d1f-a37f-f517a5f0e394_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5822cd3a-9419-4d1f-a37f-f517a5f0e394_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_7b962cdb-474b-461f-88f8-8f1ba64ed620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:to="loc_us-gaap_LineOfCreditMember_7b962cdb-474b-461f-88f8-8f1ba64ed620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8764eef7-cb96-4dda-9792-ab0d34f43dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:to="loc_us-gaap_LoansPayableMember_8764eef7-cb96-4dda-9792-ab0d34f43dce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayablePacificWesternDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayablePacificWesternDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NotesPayablePacificWesternDetails" xlink:type="extended" id="i5917f60901e34844b1330bc1c4d36b9d_NotesPayablePacificWesternDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2aee5909-34cb-4650-9c19-0cfa8ee583ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2aee5909-34cb-4650-9c19-0cfa8ee583ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_226d602e-ca4c-48e4-9649-250b6135fb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_LineOfCredit_226d602e-ca4c-48e4-9649-250b6135fb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3f6f1b18-950c-4519-834f-3790335c3df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_RestrictedCash_3f6f1b18-950c-4519-834f-3790335c3df1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:to="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2aed8616-20ab-46eb-a59f-deedd77b14e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:to="loc_us-gaap_CreditFacilityDomain_2aed8616-20ab-46eb-a59f-deedd77b14e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d3a9e50-32d3-4272-9d8c-f915ca8247b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:to="loc_us-gaap_CreditFacilityDomain_1d3a9e50-32d3-4272-9d8c-f915ca8247b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_103593f7-31af-4267-b738-c5ce2289d025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1d3a9e50-32d3-4272-9d8c-f915ca8247b8" xlink:to="loc_us-gaap_LetterOfCreditMember_103593f7-31af-4267-b738-c5ce2289d025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:to="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_781bbae5-4504-4138-b26f-bb3ccd9a03a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_781bbae5-4504-4138-b26f-bb3ccd9a03a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PacificWesternLetterOfCreditMember_5b6cdcdc-6901-4754-8d11-9e9a180ff9ce" xlink:href="rxrx-20210930.xsd#rxrx_PacificWesternLetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_781bbae5-4504-4138-b26f-bb3ccd9a03a6" xlink:to="loc_rxrx_PacificWesternLetterOfCreditMember_5b6cdcdc-6901-4754-8d11-9e9a180ff9ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableConvertibleNotesDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NotesPayableConvertibleNotesDetails" xlink:type="extended" id="if49cc1e3b02649c2859bd52046f52a3e_NotesPayableConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6dbd795d-4c6c-4989-81bf-95ecb80efe30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6dbd795d-4c6c-4989-81bf-95ecb80efe30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78465ce8-c951-4ce1-9b5c-f9e67f867b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78465ce8-c951-4ce1-9b5c-f9e67f867b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3327d9b1-588d-4a01-8c21-35095dd17feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3327d9b1-588d-4a01-8c21-35095dd17feb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c7f460ed-cb40-4078-81ce-cc282c142706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c7f460ed-cb40-4078-81ce-cc282c142706" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c1ee13fc-8430-41e0-a82b-314af8e3dbba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c1ee13fc-8430-41e0-a82b-314af8e3dbba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2042b0bb-f85a-461e-b9ea-7237a5e80513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2042b0bb-f85a-461e-b9ea-7237a5e80513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_de2c082a-f0e6-4f5e-92fb-e0506e46027f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2042b0bb-f85a-461e-b9ea-7237a5e80513" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_de2c082a-f0e6-4f5e-92fb-e0506e46027f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableNotesPayableforTenantImprovementAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails" xlink:type="extended" id="i578d5128486a41bdadedc2d8ef15c9a5_NotesPayableNotesPayableforTenantImprovementAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0a1d9ce9-b38a-417e-bd3c-42ba5bff0828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0a1d9ce9-b38a-417e-bd3c-42ba5bff0828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3bd29f0d-e353-4240-a44f-ea364366b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_DebtInstrumentTerm_3bd29f0d-e353-4240-a44f-ea364366b4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91e5f75-5d67-4015-ba3c-a4ee817fc712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91e5f75-5d67-4015-ba3c-a4ee817fc712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e0f57e7-5686-476b-829d-d62a7560fbe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e0f57e7-5686-476b-829d-d62a7560fbe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_480498b8-b86b-4b32-9db7-d0241b1d2ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_480498b8-b86b-4b32-9db7-d0241b1d2ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_7586b079-8078-4451-af5b-0170fa8552ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_480498b8-b86b-4b32-9db7-d0241b1d2ab6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_7586b079-8078-4451-af5b-0170fa8552ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0fad8bc-1f2d-4eaa-8998-63c034dc3821_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0fad8bc-1f2d-4eaa-8998-63c034dc3821_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c1212c0-0a36-42fe-b0ee-9781eb4d0989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c1212c0-0a36-42fe-b0ee-9781eb4d0989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember_63a5dc69-d258-4fa8-b9a7-5ce18070fe5b" xlink:href="rxrx-20210930.xsd#rxrx_Station41LeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c1212c0-0a36-42fe-b0ee-9781eb4d0989" xlink:to="loc_rxrx_Station41LeaseMember_63a5dc69-d258-4fa8-b9a7-5ce18070fe5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableCurrentNoncurrentDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails" xlink:type="extended" id="id326860d752f43bbaab77c4b930f5bb0_NotesPayableCurrentNoncurrentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9fadaef2-2b6a-44ef-b889-933077912a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_LongTermDebtCurrent_9fadaef2-2b6a-44ef-b889-933077912a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ccc9fe01-562d-4463-84f9-63d344b9d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ccc9fe01-562d-4463-84f9-63d344b9d8ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1ec97c42-a915-42c5-8dbc-433b8ecaa0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1ec97c42-a915-42c5-8dbc-433b8ecaa0b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eae93a71-0404-49eb-b1ff-4de94b7ac60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_LongTermDebt_eae93a71-0404-49eb-b1ff-4de94b7ac60f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3cb9194a-63ea-4e69-b032-b78c8f6df5e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3cb9194a-63ea-4e69-b032-b78c8f6df5e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af39c1bc-a156-4d98-a57f-bf94b7359404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af39c1bc-a156-4d98-a57f-bf94b7359404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f5622b23-fcb1-49f4-b527-a8ec2eea7ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af39c1bc-a156-4d98-a57f-bf94b7359404" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f5622b23-fcb1-49f4-b527-a8ec2eea7ff2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i3780598acc0247b7a921284ec04d0519_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_41744428-4c83-4ba6-8eca-741590cc3b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LeaseAndRentalExpense_41744428-4c83-4ba6-8eca-741590cc3b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f4009c1b-2890-4992-aa4a-d069ffdd8d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f4009c1b-2890-4992-aa4a-d069ffdd8d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_f6e25ed7-b3ba-423c-99bf-d4dbc56c1b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveFromLessor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_IncentiveFromLessor_f6e25ed7-b3ba-423c-99bf-d4dbc56c1b69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_7e8b7ae2-4657-4442-8cdc-daa1d77e4c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseIncentivePayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_7e8b7ae2-4657-4442-8cdc-daa1d77e4c37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_1ef5b0f9-9cda-4b82-a79d-5d433a926804" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_1ef5b0f9-9cda-4b82-a79d-5d433a926804" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_40a4eead-0573-466e-929f-d4a13c9b1a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_40a4eead-0573-466e-929f-d4a13c9b1a0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7e6a924-6ca2-47f5-b2a2-497f71e3f965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7e6a924-6ca2-47f5-b2a2-497f71e3f965" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9eb9275e-d669-43bd-a63c-5ba91ef0a1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9eb9275e-d669-43bd-a63c-5ba91ef0a1fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_d9990883-77a5-4d42-bfdc-b4a8cd3d19da" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseSizeOfLeasedAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_d9990883-77a5-4d42-bfdc-b4a8cd3d19da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650d1356-7687-435a-863c-93baf8013a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650d1356-7687-435a-863c-93baf8013a81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_ae635d1b-d520-4e46-b688-34d037893834" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_ae635d1b-d520-4e46-b688-34d037893834" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameDomain_499e7c77-25de-427a-af83-2861904c6c93_default" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:to="loc_rxrx_LeaseArrangementNameDomain_499e7c77-25de-427a-af83-2861904c6c93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:to="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_KomasMember_89775382-c5c9-4ad2-8ca4-9584f98751e6" xlink:href="rxrx-20210930.xsd#rxrx_KomasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:to="loc_rxrx_KomasMember_89775382-c5c9-4ad2-8ca4-9584f98751e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41Member_5c735a48-cdee-46a2-b593-b381cfe2a725" xlink:href="rxrx-20210930.xsd#rxrx_Station41Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:to="loc_rxrx_Station41Member_5c735a48-cdee-46a2-b593-b381cfe2a725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station56Member_77b6716d-ba38-4215-9627-079e36cda571" xlink:href="rxrx-20210930.xsd#rxrx_Station56Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:to="loc_rxrx_Station56Member_77b6716d-ba38-4215-9627-079e36cda571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f0de6e57-e1ca-441b-b948-b1fc7033d52b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f0de6e57-e1ca-441b-b948-b1fc7033d52b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88e93317-5e6f-4360-9910-a2276fab254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88e93317-5e6f-4360-9910-a2276fab254d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember_d138845d-4dfc-4fef-8e5d-1856388a604d" xlink:href="rxrx-20210930.xsd#rxrx_Station41LeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88e93317-5e6f-4360-9910-a2276fab254d" xlink:to="loc_rxrx_Station41LeaseMember_d138845d-4dfc-4fef-8e5d-1856388a604d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3fde2b6f-deb0-4e14-86d6-1664f1cb1676_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3fde2b6f-deb0-4e14-86d6-1664f1cb1676_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3276d307-c0b8-4db9-8caa-2be63d37eb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3276d307-c0b8-4db9-8caa-2be63d37eb05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_52f88777-73c2-49f6-9218-f2255eb283e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3276d307-c0b8-4db9-8caa-2be63d37eb05" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_52f88777-73c2-49f6-9218-f2255eb283e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_211dd375-7b79-4927-a48a-d8bf42fa2b17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_211dd375-7b79-4927-a48a-d8bf42fa2b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41Member_f1a4ca6e-d228-4bcb-b716-122e7d56a0b2" xlink:href="rxrx-20210930.xsd#rxrx_Station41Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:to="loc_rxrx_Station41Member_f1a4ca6e-d228-4bcb-b716-122e7d56a0b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MilpitasMember_24762930-bc72-4b0e-9634-926de696329e" xlink:href="rxrx-20210930.xsd#rxrx_MilpitasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:to="loc_rxrx_MilpitasMember_24762930-bc72-4b0e-9634-926de696329e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station56Member_71bb64fb-95c2-4904-95f1-30761fac9dd7" xlink:href="rxrx-20210930.xsd#rxrx_Station56Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:to="loc_rxrx_Station56Member_71bb64fb-95c2-4904-95f1-30761fac9dd7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#ConvertiblePreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails" xlink:type="extended" id="i94327e80a70e48828d36690cb523597e_ConvertiblePreferredStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5742068f-d9fd-4bb2-b8d5-85cd71caa4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5742068f-d9fd-4bb2-b8d5-85cd71caa4cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b4d6fbbb-622c-4e23-bf67-1c820e55edf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_b4d6fbbb-622c-4e23-bf67-1c820e55edf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51821ba1-48ef-41c2-9fba-0dc410b95e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51821ba1-48ef-41c2-9fba-0dc410b95e48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06a2c418-5cb3-4e71-b9c6-b950c7085005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06a2c418-5cb3-4e71-b9c6-b950c7085005" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52f41f92-4dc9-4696-abc0-27382528bf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_52f41f92-4dc9-4696-abc0-27382528bf09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockConvertedPricePerShare_5ecb963b-e1c8-4278-b2b0-e71daa5e7c2c" xlink:href="rxrx-20210930.xsd#rxrx_SaleOfStockConvertedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_rxrx_SaleOfStockConvertedPricePerShare_5ecb963b-e1c8-4278-b2b0-e71daa5e7c2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecb39128-2ee1-408c-ab55-b27cc30e17b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecb39128-2ee1-408c-ab55-b27cc30e17b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_0cf604e5-8eab-46a3-a618-2b42cfc38eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecb39128-2ee1-408c-ab55-b27cc30e17b2" xlink:to="loc_us-gaap_IPOMember_0cf604e5-8eab-46a3-a618-2b42cfc38eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_846f5a25-559c-4af3-8278-2f8cd3c4a68d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:to="loc_us-gaap_ClassOfStockDomain_846f5a25-559c-4af3-8278-2f8cd3c4a68d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ffac770-e323-41bb-a082-b42dacd0cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:to="loc_us-gaap_ClassOfStockDomain_1ffac770-e323-41bb-a082-b42dacd0cd4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesDPreferredStockMember_3d1a55e9-5641-4e6a-89cb-73c853731914" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ffac770-e323-41bb-a082-b42dacd0cd4d" xlink:to="loc_rxrx_ConvertibleSeriesDPreferredStockMember_3d1a55e9-5641-4e6a-89cb-73c853731914" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#ConvertiblePreferredStockSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails" xlink:type="extended" id="iff4f7b5179de4579a62c6f14afc9f1c5_ConvertiblePreferredStockSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bc91b517-2fd2-43d0-9fe0-e5be9702fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bc91b517-2fd2-43d0-9fe0-e5be9702fec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_85b88073-3705-4193-8536-742dcff6d446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_85b88073-3705-4193-8536-742dcff6d446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d9a24c33-951b-4148-ad62-4d8a0839e10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_d9a24c33-951b-4148-ad62-4d8a0839e10a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5a7b47e5-a565-4b5d-80b3-923cf9c8b760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5a7b47e5-a565-4b5d-80b3-923cf9c8b760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_97e0793f-fabb-4ec4-8365-184914c2e679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_97e0793f-fabb-4ec4-8365-184914c2e679" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissued_3d40dbf8-7798-4efc-9a5b-575bbde64537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissued_3d40dbf8-7798-4efc-9a5b-575bbde64537" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dcff7899-d325-4d74-a73d-0772238ba7ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:to="loc_us-gaap_ClassOfStockDomain_dcff7899-d325-4d74-a73d-0772238ba7ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:to="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesAPreferredStockMember_5162dc67-c05f-4889-bd79-42753ef3e2bf" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesAPreferredStockMember_5162dc67-c05f-4889-bd79-42753ef3e2bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesA1PreferredStockMember_da845993-fa84-4dbd-b8de-91fae47f1f2b" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesA1PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesA1PreferredStockMember_da845993-fa84-4dbd-b8de-91fae47f1f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesBPreferredStockMember_e52c7ded-f252-4042-ae97-dca30ea84f3b" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesBPreferredStockMember_e52c7ded-f252-4042-ae97-dca30ea84f3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesCPreferredStockMember_069969c5-c2ac-4106-9b7e-e1038d6add26" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesCPreferredStockMember_069969c5-c2ac-4106-9b7e-e1038d6add26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesDPreferredStockMember_59a87a46-ba49-4d86-bdeb-96969a5864fc" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesDPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesDPreferredStockMember_59a87a46-ba49-4d86-bdeb-96969a5864fc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommonStockNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CommonStockNarrativeDetails" xlink:type="extended" id="if67936d6b58f4b3e968d1aed14ffccad_CommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockVotePerShare_aa5e039c-fb08-4904-b57b-145cbea8b43c" xlink:href="rxrx-20210930.xsd#rxrx_CommonStockVotePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_CommonStockVotePerShare_aa5e039c-fb08-4904-b57b-145cbea8b43c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84e4d3e2-ecfc-4741-b5ae-30d70a649f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84e4d3e2-ecfc-4741-b5ae-30d70a649f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dc32ce57-b2d7-45d1-ab5c-d395da57b31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dc32ce57-b2d7-45d1-ab5c-d395da57b31b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_43eaa61e-868b-4383-a77f-8665c9ce90ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_43eaa61e-868b-4383-a77f-8665c9ce90ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_829a2756-e185-49b9-a75e-9290231e48a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_829a2756-e185-49b9-a75e-9290231e48a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PaymentsOfStockIssuanceExpenses_c05f549a-e17a-4045-8bc1-104a3722452b" xlink:href="rxrx-20210930.xsd#rxrx_PaymentsOfStockIssuanceExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_PaymentsOfStockIssuanceExpenses_c05f549a-e17a-4045-8bc1-104a3722452b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b1f9c003-6b84-44d4-b872-c23dcdafa86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b1f9c003-6b84-44d4-b872-c23dcdafa86a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e5c4e6fd-27ee-4e66-8545-c52ba2e9f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e5c4e6fd-27ee-4e66-8545-c52ba2e9f196" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersOwnershipPercentage_c5bcd3f3-7acf-4108-9e4a-0d6561181f13" xlink:href="rxrx-20210930.xsd#rxrx_AffiliatedHoldersOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_AffiliatedHoldersOwnershipPercentage_c5bcd3f3-7acf-4108-9e4a-0d6561181f13" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_196985a3-9261-47a9-ace9-7bb623a41a68" xlink:href="rxrx-20210930.xsd#rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_196985a3-9261-47a9-ace9-7bb623a41a68" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_feb98036-4187-43e6-9417-09485cdf8f85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_feb98036-4187-43e6-9417-09485cdf8f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f1a460-f39a-404f-bc25-56afd3dbef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f1a460-f39a-404f-bc25-56afd3dbef3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_815c4fb2-82e3-4720-b4c5-e339b39a2cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f1a460-f39a-404f-bc25-56afd3dbef3f" xlink:to="loc_us-gaap_IPOMember_815c4fb2-82e3-4720-b4c5-e339b39a2cf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_410cd4af-5b95-499a-a8d6-ad5b64426097_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:to="loc_us-gaap_RelatedPartyDomain_410cd4af-5b95-499a-a8d6-ad5b64426097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f205c21b-e509-4572-9372-5f032042c1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:to="loc_us-gaap_RelatedPartyDomain_f205c21b-e509-4572-9372-5f032042c1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ChristopherGibsonAndAffiliatesMember_e60ec38c-9fb0-4ab0-a28f-bc9df0ada2d6" xlink:href="rxrx-20210930.xsd#rxrx_ChristopherGibsonAndAffiliatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f205c21b-e509-4572-9372-5f032042c1a2" xlink:to="loc_rxrx_ChristopherGibsonAndAffiliatesMember_e60ec38c-9fb0-4ab0-a28f-bc9df0ada2d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3f1d777e-0c94-447a-88ce-9b8b5d260738_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:to="loc_us-gaap_ClassOfStockDomain_3f1d777e-0c94-447a-88ce-9b8b5d260738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:to="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_93977176-1bb4-45a1-8e1a-b2fa92779f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:to="loc_us-gaap_CommonClassAMember_93977176-1bb4-45a1-8e1a-b2fa92779f27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0abdf9de-d4ad-48c0-babf-ee8399661e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:to="loc_us-gaap_CommonClassBMember_0abdf9de-d4ad-48c0-babf-ee8399661e5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CollaborativeDevelopmentContractsBayerAGDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails" xlink:type="extended" id="i30bc3c7f489649dc9d536a62fb75464f_CollaborativeDevelopmentContractsBayerAGDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementTerm_553561aa-54db-4694-a242-56a6020db037" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementTerm_553561aa-54db-4694-a242-56a6020db037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_a477e99d-eca0-497c-b30e-abd55d9d2000" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_a477e99d-eca0-497c-b30e-abd55d9d2000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_5d9017bc-25c3-4299-854e-e93fe972ab25" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_5d9017bc-25c3-4299-854e-e93fe972ab25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1b185377-cd7c-43e2-aa4b-9e94c89a8915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1b185377-cd7c-43e2-aa4b-9e94c89a8915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc111f32-8d79-4744-9b34-2679d6809ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc111f32-8d79-4744-9b34-2679d6809ec2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_024586ec-be8e-451e-81dd-ff40db86f7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_024586ec-be8e-451e-81dd-ff40db86f7f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_79b11d4c-3908-4992-8afd-21e812873771" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_79b11d4c-3908-4992-8afd-21e812873771" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_b1ef5e3d-eb12-42ec-9175-6253451c27f1" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_b1ef5e3d-eb12-42ec-9175-6253451c27f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:to="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_857a6f2e-2024-4657-9c3e-7117238d20e2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_857a6f2e-2024-4657-9c3e-7117238d20e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f64c8d1b-a12b-4c24-a359-f7b78d97701c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f64c8d1b-a12b-4c24-a359-f7b78d97701c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BayerAGMember_b0f8165e-9bdf-4fbd-b356-6c1152b00cf1" xlink:href="rxrx-20210930.xsd#rxrx_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f64c8d1b-a12b-4c24-a359-f7b78d97701c" xlink:to="loc_rxrx_BayerAGMember_b0f8165e-9bdf-4fbd-b356-6c1152b00cf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dede07d-abc8-4a99-b012-340e8e488c29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dede07d-abc8-4a99-b012-340e8e488c29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b39009a-4fb1-4c77-821e-af26c80ef836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b39009a-4fb1-4c77-821e-af26c80ef836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e70b8db9-7d31-4e25-8d7b-adc3854c502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b39009a-4fb1-4c77-821e-af26c80ef836" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e70b8db9-7d31-4e25-8d7b-adc3854c502a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i84b1dd19b339402ca3409cc265982a22_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_531471c8-5912-47c5-9695-e33239998dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_531471c8-5912-47c5-9695-e33239998dd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b280d94-5921-4678-a263-e20513887ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b280d94-5921-4678-a263-e20513887ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1ccf8a8a-c5c1-4394-9164-56c53ad35b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1ccf8a8a-c5c1-4394-9164-56c53ad35b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49c6747c-7161-4a01-8e32-50136147874f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49c6747c-7161-4a01-8e32-50136147874f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c57b73b-8fcd-4c31-84ce-9f24b8f280ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c57b73b-8fcd-4c31-84ce-9f24b8f280ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6fff6aa6-5df6-46ea-8788-a9d4d6525503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6fff6aa6-5df6-46ea-8788-a9d4d6525503" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_0b957e47-12c9-43cb-b908-9618e2c6b07e" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_0b957e47-12c9-43cb-b908-9618e2c6b07e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ebcebf8-3101-4d49-9fbb-4ce855ae1aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ebcebf8-3101-4d49-9fbb-4ce855ae1aaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_80b627f2-7333-42bf-b87f-450929ec361b" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_80b627f2-7333-42bf-b87f-450929ec361b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a308b081-88b9-42b4-82d8-e86d400284d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a308b081-88b9-42b4-82d8-e86d400284d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d5106665-b85f-4030-ad97-56d4a41f95a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d5106665-b85f-4030-ad97-56d4a41f95a1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dda96482-a620-4daf-bc31-9afc608a11d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dda96482-a620-4daf-bc31-9afc608a11d0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c1cea792-c7df-44fa-b4f2-01c81fb3c45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c1cea792-c7df-44fa-b4f2-01c81fb3c45e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_ed5048bd-78b4-45b2-ace1-5d3e4073a7d5" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_ed5048bd-78b4-45b2-ace1-5d3e4073a7d5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7e4548f0-692e-48ec-ba18-102c43979461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7e4548f0-692e-48ec-ba18-102c43979461" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_652ecc95-9e80-4a7c-bce8-7236911f1442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_652ecc95-9e80-4a7c-bce8-7236911f1442" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99c7e6ff-2eff-474f-b4d0-f3b3c91a986c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99c7e6ff-2eff-474f-b4d0-f3b3c91a986c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:to="loc_us-gaap_PlanNameDomain_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:to="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EquityIncentivePlanMember_653c573d-7c01-42eb-90fa-364bc7a1faca" xlink:href="rxrx-20210930.xsd#rxrx_A2021EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:to="loc_rxrx_A2021EquityIncentivePlanMember_653c573d-7c01-42eb-90fa-364bc7a1faca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EmployeeStockPurchasePlanMember_2b1c8bd7-9f3c-4e17-8358-f978fc61a7a9" xlink:href="rxrx-20210930.xsd#rxrx_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:to="loc_rxrx_A2021EmployeeStockPurchasePlanMember_2b1c8bd7-9f3c-4e17-8358-f978fc61a7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_90bc9bcc-2eaf-409e-a78f-c515dbc0d115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_PerformanceSharesMember_90bc9bcc-2eaf-409e-a78f-c515dbc0d115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3bd42af6-13a0-4899-a57c-81a334bcaa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_RestrictedStockMember_3bd42af6-13a0-4899-a57c-81a334bcaa2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8bea6cab-0df6-476a-b246-605f321d4e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8bea6cab-0df6-476a-b246-605f321d4e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_592c0c56-94f7-475e-8763-ca0ade4e192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_EmployeeStockMember_592c0c56-94f7-475e-8763-ca0ade4e192c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_236da44b-98d5-41c3-8112-11cc3335a22b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:to="loc_us-gaap_GranteeStatusDomain_236da44b-98d5-41c3-8112-11cc3335a22b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e4c40699-01b3-45b7-a8bf-c8db3668a111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:to="loc_us-gaap_GranteeStatusDomain_e4c40699-01b3-45b7-a8bf-c8db3668a111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4b67dbd2-a2e3-430a-9baf-4692fc164aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_e4c40699-01b3-45b7-a8bf-c8db3668a111" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4b67dbd2-a2e3-430a-9baf-4692fc164aa3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="extended" id="i818a686942a94c16909e05b03ceef535_StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e58173c-d6ac-47ab-a9b2-e813c169b5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_559c33fb-fbc7-400e-b446-b0c0a4dc4276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e58173c-d6ac-47ab-a9b2-e813c169b5cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_559c33fb-fbc7-400e-b446-b0c0a4dc4276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e58173c-d6ac-47ab-a9b2-e813c169b5cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c6e7bec-deea-4230-a1ad-878ed28c3742_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c6e7bec-deea-4230-a1ad-878ed28c3742_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_962df8e1-50ec-4799-8858-8bbcc3c8918e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_962df8e1-50ec-4799-8858-8bbcc3c8918e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbcd23ee-d008-4b3f-993d-7a556bad7693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbcd23ee-d008-4b3f-993d-7a556bad7693" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="extended" id="i49e09879505d42708977ffe5d7fc5af4_StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c4a51939-48ab-496c-a310-366d8212ea31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c4a51939-48ab-496c-a310-366d8212ea31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a765275-5ba6-4edc-bca0-24fef9c05a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a765275-5ba6-4edc-bca0-24fef9c05a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c969a17-a7b9-44b5-99f9-c0b9a9c8ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c969a17-a7b9-44b5-99f9-c0b9a9c8ea54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9ff36136-8395-4ef6-9bee-c93277e18049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9ff36136-8395-4ef6-9bee-c93277e18049" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:to="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8fb6571-8245-45ad-b03e-ab0eedd6ee72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8fb6571-8245-45ad-b03e-ab0eedd6ee72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d812ba6-106d-4e27-8c10-584bcd97238f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d812ba6-106d-4e27-8c10-584bcd97238f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_84c365d1-b132-4e84-9c64-ebd5c33e9acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d812ba6-106d-4e27-8c10-584bcd97238f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_84c365d1-b132-4e84-9c64-ebd5c33e9acf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="extended" id="i612d23591f5a4455b2b6d9ce08977f2d_StockBasedCompensationScheduleofRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b5e6084-c607-495f-92e1-5064ec4d076c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b5e6084-c607-495f-92e1-5064ec4d076c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11c47f0a-0927-4afc-a550-587809e8f1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11c47f0a-0927-4afc-a550-587809e8f1c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc4cf276-553e-4488-abaf-c0d17570932a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc4cf276-553e-4488-abaf-c0d17570932a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b2d82e15-9b59-45a9-aad5-6860d32836e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b2d82e15-9b59-45a9-aad5-6860d32836e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d56c264-304c-4e6d-b34f-bb9176637637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_338585bc-06f5-406a-800f-cb48d2464613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_338585bc-06f5-406a-800f-cb48d2464613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536c9ade-19ce-452e-90a6-b559fc2eb2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536c9ade-19ce-452e-90a6-b559fc2eb2a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90b52001-3bcf-4797-a01d-81648bfa5eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90b52001-3bcf-4797-a01d-81648bfa5eaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_541dd342-ea6d-4ddf-8304-7a9980f462e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_541dd342-ea6d-4ddf-8304-7a9980f462e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71d77ead-594b-4c6a-b0ff-b333544afabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:to="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2f29a39-1884-4e75-b2af-34f7db8f32c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2f29a39-1884-4e75-b2af-34f7db8f32c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abf44462-ba64-45dc-bd8d-6962bbba8c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abf44462-ba64-45dc-bd8d-6962bbba8c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3dfbdc7e-46e1-4387-9ac0-0345b66071b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abf44462-ba64-45dc-bd8d-6962bbba8c09" xlink:to="loc_us-gaap_RestrictedStockMember_3dfbdc7e-46e1-4387-9ac0-0345b66071b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails" xlink:type="extended" id="if0059347e29f4625adb6b710c60c3822_StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80f5e827-4c2b-4866-a3d4-0a3aa68b0976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80f5e827-4c2b-4866-a3d4-0a3aa68b0976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a21be2c8-e539-422e-be8d-1772e4ce1f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a21be2c8-e539-422e-be8d-1772e4ce1f19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80204d-57bb-44d1-b251-6a4eda050ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80204d-57bb-44d1-b251-6a4eda050ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f1c031d-f65d-40e1-b5b2-13e7f2d35bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f1c031d-f65d-40e1-b5b2-13e7f2d35bb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:to="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e58c9b4c-f085-4d70-8195-93fadd283a07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e58c9b4c-f085-4d70-8195-93fadd283a07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fee6dc6-48b7-466f-8daa-3b8b5757dbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fee6dc6-48b7-466f-8daa-3b8b5757dbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b2be7fe4-780d-4524-949c-0259ca4ba056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fee6dc6-48b7-466f-8daa-3b8b5757dbee" xlink:to="loc_us-gaap_EmployeeStockMember_b2be7fe4-780d-4524-949c-0259ca4ba056" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationWarrantsDetails" xlink:type="extended" id="ia9ba4cb26286448e97153eff8b9e0c9b_StockBasedCompensationWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_90511a0c-b2bc-4593-96ae-22d57de8358d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_90511a0c-b2bc-4593-96ae-22d57de8358d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65461cfb-a9ab-4eb8-a966-dd062c23500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65461cfb-a9ab-4eb8-a966-dd062c23500e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightFairValue_ed263360-b587-46cd-beb8-93d2f14d7bcc" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_ClassOfWarrantOrRightFairValue_ed263360-b587-46cd-beb8-93d2f14d7bcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightIssued_79ee88ff-7b65-45ba-9770-11b3ce8392b9" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_ClassOfWarrantOrRightIssued_79ee88ff-7b65-45ba-9770-11b3ce8392b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_22b2a078-081a-40fe-81b9-5b09f9ca247a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_22b2a078-081a-40fe-81b9-5b09f9ca247a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightGrantDateFairValue_cfaa74e6-49e0-4f72-9f31-cb0cee42cb31" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_ClassOfWarrantOrRightGrantDateFairValue_cfaa74e6-49e0-4f72-9f31-cb0cee42cb31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9883fb8e-8817-4aa6-9649-8c5fea27b955_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9883fb8e-8817-4aa6-9649-8c5fea27b955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2016WarrantsMember_2a587f94-cefb-4106-a0e4-a0364319fffd" xlink:href="rxrx-20210930.xsd#rxrx_A2016WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_A2016WarrantsMember_2a587f94-cefb-4106-a0e4-a0364319fffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2017WarrantsMember_5f9e5616-dd91-4efe-a531-e6b911c4bc1a" xlink:href="rxrx-20210930.xsd#rxrx_A2017WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_A2017WarrantsMember_5f9e5616-dd91-4efe-a531-e6b911c4bc1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2018WarrantsMember_93ff2181-bc0f-4101-ab5f-26062ee35fc5" xlink:href="rxrx-20210930.xsd#rxrx_A2018WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_A2018WarrantsMember_93ff2181-bc0f-4101-ab5f-26062ee35fc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsIssuedInJanuary2020Member_ecd0e63b-dcf1-49f1-9db1-88b9ddbd8528" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsIssuedInJanuary2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_WarrantsIssuedInJanuary2020Member_ecd0e63b-dcf1-49f1-9db1-88b9ddbd8528" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c5b905df-2d05-44ac-930a-418787459cac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:to="loc_us-gaap_ClassOfStockDomain_c5b905df-2d05-44ac-930a-418787459cac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58fe850b-ae0d-44da-9ffd-f01262b0d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:to="loc_us-gaap_ClassOfStockDomain_58fe850b-ae0d-44da-9ffd-f01262b0d1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesCPreferredStockMember_00285683-a279-4daf-b813-5b04efcc5392" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_58fe850b-ae0d-44da-9ffd-f01262b0d1fd" xlink:to="loc_rxrx_ConvertibleSeriesCPreferredStockMember_00285683-a279-4daf-b813-5b04efcc5392" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails" xlink:type="extended" id="i635fcbbefc3c4f1291fd783a3dd6f4b1_StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_82d0fa92-70bc-4e83-823c-351df969bf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_82d0fa92-70bc-4e83-823c-351df969bf54" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ad1f4469-dfa2-4995-9569-1e6fe202ea28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ad1f4469-dfa2-4995-9569-1e6fe202ea28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39210876-0db9-4127-a88b-2928d9ab1959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39210876-0db9-4127-a88b-2928d9ab1959" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e48560dc-7b60-4bc3-8ee8-0c1379827c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e48560dc-7b60-4bc3-8ee8-0c1379827c34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a592fbb8-fa06-43c4-952f-2f8ebce908bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_82d0fa92-70bc-4e83-823c-351df969bf54" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_abe05418-a2c9-4aa0-a5bf-53a207f2e97a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_abe05418-a2c9-4aa0-a5bf-53a207f2e97a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dde7b5b8-6f34-423a-a60f-345367030332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dde7b5b8-6f34-423a-a60f-345367030332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_32344ebc-84e2-4e4b-9149-2aeb8ffcdbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dde7b5b8-6f34-423a-a60f-345367030332" xlink:to="loc_us-gaap_WarrantMember_32344ebc-84e2-4e4b-9149-2aeb8ffcdbd2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="extended" id="i996c60a8bbaa40689640bad2f24d557f_NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings_08d74e50-2c46-4419-b62e-da76da1f4935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:to="loc_us-gaap_UndistributedEarnings_08d74e50-2c46-4419-b62e-da76da1f4935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsDiluted_6346fb8d-b68c-43c4-b144-929e2c94f998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:to="loc_us-gaap_UndistributedEarningsDiluted_6346fb8d-b68c-43c4-b144-929e2c94f998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0fad93b2-4a90-40d7-ae07-f4a38fd83f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0fad93b2-4a90-40d7-ae07-f4a38fd83f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3156e862-1e5c-4ac7-817a-bb0852f24613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3156e862-1e5c-4ac7-817a-bb0852f24613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_34733818-6bc9-47f3-a930-417856620e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_EarningsPerShareBasic_34733818-6bc9-47f3-a930-417856620e1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_873e652f-bc52-4cd6-80ac-47a6f1f20e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_873e652f-bc52-4cd6-80ac-47a6f1f20e69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5afdc5e6-1b78-4a47-90c7-73bae28e5480_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:to="loc_us-gaap_ClassOfStockDomain_5afdc5e6-1b78-4a47-90c7-73bae28e5480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:to="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e29c8478-1da3-4ce1-9e9a-4e3b576c41e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:to="loc_us-gaap_CommonClassAMember_e29c8478-1da3-4ce1-9e9a-4e3b576c41e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_be3165a8-357e-4f6d-8f5a-34a35b2afe89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:to="loc_us-gaap_CommonClassBMember_be3165a8-357e-4f6d-8f5a-34a35b2afe89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="extended" id="i781b44685d6c4442aa972a0d6a9508ab_NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6393be5c-6fff-4ad4-91d2-c4f706b70622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74a19ae9-9b81-4c15-8bae-58c28b6f12c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6393be5c-6fff-4ad4-91d2-c4f706b70622" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74a19ae9-9b81-4c15-8bae-58c28b6f12c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6393be5c-6fff-4ad4-91d2-c4f706b70622" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_405b64be-fe19-49f7-9cc6-86c67b41fd3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_405b64be-fe19-49f7-9cc6-86c67b41fd3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_954c22d5-83fc-4479-b8b8-a46c081cb2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_954c22d5-83fc-4479-b8b8-a46c081cb2ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_409001ac-7270-461f-9d5b-7134cda20deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_StockCompensationPlanMember_409001ac-7270-461f-9d5b-7134cda20deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d3da4cd2-1560-42c1-963a-7a8b08f0db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_WarrantMember_d3da4cd2-1560-42c1-963a-7a8b08f0db5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_51ec2e61-a0aa-4fdf-9c37-2819d0028904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_EmployeeStockMember_51ec2e61-a0aa-4fdf-9c37-2819d0028904" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_868281cc-22a9-4424-abd2-f211f487c345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_868281cc-22a9-4424-abd2-f211f487c345" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b248ece2-c0c9-4b0d-998f-807964acfe4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:to="loc_us-gaap_ClassOfStockDomain_b248ece2-c0c9-4b0d-998f-807964acfe4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:to="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_15f9a535-7b24-4493-95fe-6ff0b3686353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:to="loc_us-gaap_CommonClassAMember_15f9a535-7b24-4493-95fe-6ff0b3686353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ebbf57b3-5ad9-44e1-9b9e-b6ee07043914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:to="loc_us-gaap_CommonClassBMember_ebbf57b3-5ad9-44e1-9b9e-b6ee07043914" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="ib5b0cacd3298431983618146664f31b4_FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8b439a4-fb91-4f21-b368-5ca43bb20cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8b439a4-fb91-4f21-b368-5ca43bb20cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_675b26b6-fa85-4b60-8078-1b36e178158d" xlink:href="rxrx-20210930.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_675b26b6-fa85-4b60-8078-1b36e178158d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8f629a5b-eb27-4a36-8f7b-d5e8626d87e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8f629a5b-eb27-4a36-8f7b-d5e8626d87e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5323b4a1-3c38-4e7f-b4d0-e5557905ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5323b4a1-3c38-4e7f-b4d0-e5557905ec88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_330a6bc2-f820-4e14-97e1-846da821306a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_330a6bc2-f820-4e14-97e1-846da821306a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0d843ced-503c-40d3-bb57-05d472ed2e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0d843ced-503c-40d3-bb57-05d472ed2e00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bda99059-0cb5-458a-8c4b-403c7d35d31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bda99059-0cb5-458a-8c4b-403c7d35d31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_326fbc21-5155-4227-837d-527b80942c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bda99059-0cb5-458a-8c4b-403c7d35d31b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_326fbc21-5155-4227-837d-527b80942c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8440c30b-2437-484c-a95e-4fd115546acd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8440c30b-2437-484c-a95e-4fd115546acd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1001cb8a-18d9-4fe1-9a1b-fbdea0110eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1001cb8a-18d9-4fe1-9a1b-fbdea0110eda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b88cff28-9fc4-4a28-8413-4f28a7b909e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b88cff28-9fc4-4a28-8413-4f28a7b909e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_502f23fa-cb3e-4879-ad8e-a2ded13e03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_502f23fa-cb3e-4879-ad8e-a2ded13e03a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_413d1235-a419-410b-a1df-60ca10881f33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_413d1235-a419-410b-a1df-60ca10881f33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_910ec788-44db-42f7-9378-5ef774765f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_910ec788-44db-42f7-9378-5ef774765f91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fe7f4743-a142-4743-816c-2ca85351a7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:to="loc_us-gaap_CommercialPaperMember_fe7f4743-a142-4743-816c-2ca85351a7d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec254759-fdd4-42cd-b0df-e68a2c9891ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ec254759-fdd4-42cd-b0df-e68a2c9891ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6ee77a39-ec5b-46d6-8da5-8c6351dbf9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6ee77a39-ec5b-46d6-8da5-8c6351dbf9d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e88961cc-4efd-4bb3-9b87-aebfe5cb42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e88961cc-4efd-4bb3-9b87-aebfe5cb42f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_cc065bd8-0f90-49f4-a8eb-db825bb58d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_cc065bd8-0f90-49f4-a8eb-db825bb58d65" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="extended" id="i070062e48d1b402c8feb1ac4acf77602_FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a288add8-3b05-423b-9744-634c7307d124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_LongTermDebtCurrent_a288add8-3b05-423b-9744-634c7307d124" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5335c3d9-ff75-4e35-b002-be014b533189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5335c3d9-ff75-4e35-b002-be014b533189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_3fefea97-d362-4128-8283-111ff304358f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_LongTermDebtFairValue_3fefea97-d362-4128-8283-111ff304358f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ee58bcab-cd7f-4951-8ab3-05311ce6f71a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_ee58bcab-cd7f-4951-8ab3-05311ce6f71a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_292d565c-fdfc-4df2-abfd-017caac32d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_292d565c-fdfc-4df2-abfd-017caac32d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_292d565c-fdfc-4df2-abfd-017caac32d55" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_beae14d2-afc4-41a4-8140-a25f390bf078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_beae14d2-afc4-41a4-8140-a25f390bf078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_055c33f2-b960-4028-b5ed-aa0a50d3a5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_055c33f2-b960-4028-b5ed-aa0a50d3a5c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c2688b83-dcaa-4715-b197-178c43ba0bb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c2688b83-dcaa-4715-b197-178c43ba0bb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6ec4debe-8ee8-4144-9cc8-60fd130ab2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6ec4debe-8ee8-4144-9cc8-60fd130ab2a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f2490b56-f733-4121-a9c3-b5f6eeeb397f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6ec4debe-8ee8-4144-9cc8-60fd130ab2a1" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f2490b56-f733-4121-a9c3-b5f6eeeb397f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.recursion.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.recursion.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i3b93089d39114dcfa1f6c07188e54589_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansAndLeasesReceivableRelatedParties_a90f9e34-4b31-4984-bf16-129f08125731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:to="loc_us-gaap_LoansAndLeasesReceivableRelatedParties_a90f9e34-4b31-4984-bf16-129f08125731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a5d15cb2-58a8-4256-93b0-51cfe952a1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:to="loc_us-gaap_DebtInstrumentTerm_a5d15cb2-58a8-4256-93b0-51cfe952a1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0595fe6c-a947-4511-9322-95ede8911544_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:to="loc_us-gaap_RelatedPartyDomain_0595fe6c-a947-4511-9322-95ede8911544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4b336a38-f153-49a6-927e-5d1aa356ade1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:to="loc_us-gaap_RelatedPartyDomain_4b336a38-f153-49a6-927e-5d1aa356ade1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_2b93d276-001a-4d40-8e75-7e9d4d61b27e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4b336a38-f153-49a6-927e-5d1aa356ade1" xlink:to="loc_srt_ChiefExecutiveOfficerMember_2b93d276-001a-4d40-8e75-7e9d4d61b27e" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rxrx-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bb127273-35b3-457d-ab21-bda4843992dc,g:487b784e-5d7c-455e-b63d-c9a591fced83-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_eb04c53d-8707-4f6e-99c8-4418a80dd3f8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AffiliatedHoldersOwnershipPercentage_51b75125-aca2-48ed-8b65-d735474bad81_terseLabel_en-US" xlink:label="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated holders, ownership percentage</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersOwnershipPercentage_label_en-US" xlink:label="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Holders, Ownership Percentage</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersOwnershipPercentage_documentation_en-US" xlink:label="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Holders, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:href="rxrx-20210930.xsd#rxrx_AffiliatedHoldersOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:to="lab_rxrx_AffiliatedHoldersOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_c81270ed-5d5c-4ac2-847b-24bad7ac3416_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fd76955c-a052-4087-ac31-ff6e548dbe7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d5e8dc83-3737-4dd0-85c8-9b4cf0a0c6d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_e89c28f8-a8c5-4bd9-8b91-694454f88e0e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d9d92703-7996-4bf8-9eca-dce1054f7ff0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f9ce3c96-c5cb-4cf0-ba0e-abaf179aae0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8e10b316-0dc7-4a11-9c63-45b173795505_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a50c020d-5e3c-4ef5-b075-0dc67eb291a6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4ad81431-6c79-4d98-8e46-f389cd7d368b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Fair Value of Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TemporaryEquityIssuanceCosts_65d87c4a-8e0d-46ae-87ba-e3e0b8e70f99_terseLabel_en-US" xlink:label="lab_rxrx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_rxrx_TemporaryEquityIssuanceCosts_label_en-US" xlink:label="lab_rxrx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:label id="lab_rxrx_TemporaryEquityIssuanceCosts_documentation_en-US" xlink:label="lab_rxrx_TemporaryEquityIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityIssuanceCosts" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TemporaryEquityIssuanceCosts" xlink:to="lab_rxrx_TemporaryEquityIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_56eab526-3bd4-47c7-9747-0f192490821a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9561834b-a1dd-44d7-9d6d-93a18632bbed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_a529daa1-d412-4846-98ca-e3ca6b55428e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f2ea1bc8-0a52-47c4-bc2d-a205d936e33e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cfee1cfb-c20d-4a9d-8c9c-7e34046e9dc6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d55f2bbc-a213-4ebc-b093-ea666d98dd18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d380ff99-74fd-44ac-be42-beeaa9fe8b60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarnings_a5f16204-9742-49fa-bc1b-1b2f012c7647_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed earnings, basic</link:label>
    <link:label id="lab_us-gaap_UndistributedEarnings_label_en-US" xlink:label="lab_us-gaap_UndistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarnings" xlink:to="lab_us-gaap_UndistributedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0e26a93a-24f3-448d-bfa8-4ea56df3668e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0eef28e8-6982-4aa1-aeac-b745f4350d17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, cancelled in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_17646470-620e-4e68-bf0f-469f0e0696c2_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_a6a3a57e-cbaa-4543-be6b-f35134601500_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_f797f2b3-b96b-4a9e-a6e3-e6da3b80c495_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, shares outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_e0dc7d41-ca4e-44aa-8f79-7b4a399e9d29_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_fec1c1cb-412d-4a29-98b1-4ca07b1c2bb5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8f7318a7-6266-4d51-ae1e-917f284079a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_87a160cc-b988-4343-bc78-60b55d4b1882_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24dfe78a-2e4a-43be-8bbc-fa7cdb43ccf1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5e8cfb78-04c6-4db1-b007-5f5a433e24c3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f8e0005a-6d26-4edd-a657-08b79d76e04a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e146de35-eb2d-4e29-94c6-17298252de90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f0c2738e-950d-4d6f-8275-fcdb713a880e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_157c49ce-f3bd-4514-ba28-7789886b24b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9d2adff8-982b-4152-841a-175964fd5835_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_989de24e-d2da-4007-ba93-a682f2bfc4dc_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_be523fd1-6be1-4f9d-894e-15a9a25770ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_b59c058e-a5ad-4c23-b5b9-6e14d73fa1c6_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c4146f9d-7d88-4b8f-92fa-c52244c62cac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available -for-Sale Investments by Balance Sheet Classification</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e18d38b6-3cb7-4b46-9462-94d3cbe3bcab_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bb38191d-0636-407c-b251-e68544549824_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_de5b8494-a26b-42c9-917a-691ed0626253_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66ed2174-aae9-45e7-9142-b9480195422c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_da121724-27eb-4a3f-9e88-44c7e4463eaf_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b95b5f2c-0ead-47e1-af9f-07dd72540aee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aaa3c40b-a203-4e1f-a80b-0a940e0c2d6c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of loss per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_bb9c2576-29e8-4f59-a87a-3056f7e7cb8a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a9e7ca7e-4cb1-407c-ac2a-0502c2492ac6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_2c0279de-17ba-4008-bc89-2670c96143d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_cbe7a49a-8c07-453a-8263-aacbe68b396f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0fc23900-7dd9-4259-b3c3-8cb760b38dab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4c479385-a3b1-4b01-a6bc-0e1b2b3c3701_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ConvertibleSeriesA1PreferredStockMember_a67ec795-1442-44b3-b397-1219f5e4a5a6_terseLabel_en-US" xlink:label="lab_rxrx_ConvertibleSeriesA1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesA1PreferredStockMember_label_en-US" xlink:label="lab_rxrx_ConvertibleSeriesA1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series A-1 Preferred Stock [Member]</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesA1PreferredStockMember_documentation_en-US" xlink:label="lab_rxrx_ConvertibleSeriesA1PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series A-1 Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesA1PreferredStockMember" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesA1PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ConvertibleSeriesA1PreferredStockMember" xlink:to="lab_rxrx_ConvertibleSeriesA1PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_efedcdee-96e8-41ca-88b5-6cf21e2e532e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_f3b748b4-7b97-47c5-bd2e-33223b987f26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_513ea434-4453-4b37-ad30-5e47eafd6dc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_68bc119b-eec3-4aad-ba89-92aa714aef18_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_91f95239-6044-4bc0-bd9f-09ae3513650a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_36b043b0-97ef-4d8a-970b-8f384ebb8e16_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e8a4dde6-620a-4151-8ee8-85c1c8386cab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Investments by Type of Security</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c74f825d-516e-4ea2-b797-6b3cd0e62161_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a3ebe8a5-9ad3-45d5-ac45-20ebbde1b83c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_716ea68c-2ddf-4340-b6c8-2f4da4bdfb17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_64765d7c-69ca-4bd1-ba34-ced6063ee452_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ViumIncMember_19ada9bb-b043-451d-bedd-e94bd533bd1a_terseLabel_en-US" xlink:label="lab_rxrx_ViumIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vium</link:label>
    <link:label id="lab_rxrx_ViumIncMember_label_en-US" xlink:label="lab_rxrx_ViumIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vium Inc. [Member]</link:label>
    <link:label id="lab_rxrx_ViumIncMember_documentation_en-US" xlink:label="lab_rxrx_ViumIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vium Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ViumIncMember" xlink:href="rxrx-20210930.xsd#rxrx_ViumIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ViumIncMember" xlink:to="lab_rxrx_ViumIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7b5a94b4-6d6d-4e47-9cbe-73df12a850fc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8636ee78-0fb7-41d4-ab7e-0556054f53a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2494bf59-580c-43e4-bd2e-cacbb24f7d51_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, number at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8336107e-df49-4bcd-99aa-35f4f3c44148_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, number at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c4353239-ef52-4db1-9b44-1dc19b459a38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AccruedDevelopmentCostsCurrent_10c1ea98-bef6-4bd2-9664-c4db55b3991c_terseLabel_en-US" xlink:label="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued development expenses</link:label>
    <link:label id="lab_rxrx_AccruedDevelopmentCostsCurrent_label_en-US" xlink:label="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Costs, Current</link:label>
    <link:label id="lab_rxrx_AccruedDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedDevelopmentCostsCurrent" xlink:href="rxrx-20210930.xsd#rxrx_AccruedDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AccruedDevelopmentCostsCurrent" xlink:to="lab_rxrx_AccruedDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_30b1bc8a-881b-4f67-a598-815cfccab650_terseLabel_en-US" xlink:label="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research project, fees and milestones payments receivable for an option on a development candidate</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_label_en-US" xlink:label="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Development Candidate</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_documentation_en-US" xlink:label="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Development Candidate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" xlink:to="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_59766960-170c-4eea-af4f-5f97666d8869_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_8d8e776c-ca77-44b2-8c6b-f51660195e6e_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1ab88897-b997-447f-9dc3-0d7152d2a19a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_628393c2-9f92-4bac-beb0-b537f85c8b7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f296f1c5-cd88-4f8d-83f6-78fada5b6c42_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock and stock warrant exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1fd03f71-3751-4854-9b3e-1049b3f922cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period, value of conversion of convertible securities</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_KomasMember_a035fbd5-7d14-4b42-bc7c-aa68c60de657_terseLabel_en-US" xlink:label="lab_rxrx_KomasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Komas</link:label>
    <link:label id="lab_rxrx_KomasMember_label_en-US" xlink:label="lab_rxrx_KomasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Komas [Member]</link:label>
    <link:label id="lab_rxrx_KomasMember_documentation_en-US" xlink:label="lab_rxrx_KomasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Komas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_KomasMember" xlink:href="rxrx-20210930.xsd#rxrx_KomasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_KomasMember" xlink:to="lab_rxrx_KomasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_929b8c0b-075e-4e96-b626-a9a01d398d3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2935b0b0-e53f-4b5d-945c-824d1d3cc5c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_add9945a-5e0b-472c-9cf4-0e5580a20cde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0d7bb02f-aca5-47ac-9b86-c02d6fcfc758_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7bf94350-fc65-4f68-834a-19ade685b792_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_7a94c563-33a4-4927-947b-1647d4f7ba65_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of temporary equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_8c3339d9-a66f-4e36-b53b-a6380e5e8055_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_0dd075a0-7426-49ed-86a0-5a7ce2791c4e_terseLabel_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted in period, fair value</link:label>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_label_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</link:label>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_documentation_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_83d5133f-6bbf-426f-9537-8144c9a6c7ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1bfbf95e-0dd3-412e-9b64-e266c6172a26_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fa6f9fd7-d5cf-400e-af87-389872bb61f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2420ac61-208b-4fdc-9ee2-04c219aad285_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveFromLessor_6eede7a6-5ae8-4bc8-b3c1-879fd1a6f4aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive from lessor</link:label>
    <link:label id="lab_us-gaap_IncentiveFromLessor_label_en-US" xlink:label="lab_us-gaap_IncentiveFromLessor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive from Lessor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveFromLessor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveFromLessor" xlink:to="lab_us-gaap_IncentiveFromLessor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_034c59a3-1cde-4107-b34f-62412e9b6c9a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5406fe57-5c01-40bb-8d9c-646595ea2815_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of Class A and B common stock, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3c9eaa3f-fabf-4edb-9afe-fd2fe066860c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_07253cd5-b6d4-486a-892c-d3d3e1012f99_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants at beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0251bed0-8b96-4c09-8d55-72dbad14a36e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants at end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_504c9efd-d665-4f36-9fb8-d728a1e0713a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbf9d1ce-d93f-4a45-8d61-b31f3c00aef2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_651c7735-a8d3-4aa9-a8ae-a988665ed4a0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_57eafbc4-efbe-4958-ad0d-cdc39488bc2b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue_86205870-d5ac-43bc-894d-bd0b7c799e94_terseLabel_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, grand date fair value (in dollars per share)</link:label>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue_label_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Grant Date Fair Value</link:label>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue_documentation_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightGrantDateFairValue" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ClassOfWarrantOrRightGrantDateFairValue" xlink:to="lab_rxrx_ClassOfWarrantOrRightGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b4ea96d3-ec8e-429b-9421-4bad88fa28ee_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TemporaryEquityTextBlock_fd3ae8a8-b2b3-43cc-bda1-8ca338cd4337_terseLabel_en-US" xlink:label="lab_rxrx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_rxrx_TemporaryEquityTextBlock_label_en-US" xlink:label="lab_rxrx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Text Block]</link:label>
    <link:label id="lab_rxrx_TemporaryEquityTextBlock_documentation_en-US" xlink:label="lab_rxrx_TemporaryEquityTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityTextBlock" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TemporaryEquityTextBlock" xlink:to="lab_rxrx_TemporaryEquityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent_28f4ae2b-2ade-4453-be42-851b0c76c447_terseLabel_en-US" xlink:label="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued early discovery expenses</link:label>
    <link:label id="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent_label_en-US" xlink:label="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Early Discovery Expenses, Current</link:label>
    <link:label id="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent_documentation_en-US" xlink:label="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Early Discovery Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:href="rxrx-20210930.xsd#rxrx_AccruedEarlyDiscoveryExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:to="lab_rxrx_AccruedEarlyDiscoveryExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_f1a93e8a-93ab-4a43-bb82-efc29189b873_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0383ba2b-b12e-4709-808f-da3c2370c26a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c18122f4-9cf9-4351-9a04-03786796c46a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_06e10520-afe3-410c-bd76-6f0eb47db0fc_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested RSU Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_2caa1cee-ca7b-4aa0-86d8-d0abe303f09a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_976baecc-a228-4629-b42c-8fbd706e0195_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_4e7872ba-76f4-4f07-8e37-52a9d43c161a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_ea5a7625-e50a-402f-98df-927255159a36_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9f5b294a-c41f-4b24-a34f-cfab05bb7fef_terseLabel_en-US" xlink:label="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series D Convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228 (in shares)</link:label>
    <link:label id="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_37c83379-e69f-4417-be2e-acebe93694b0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5fd742d2-3531-4672-96cb-1079b4242f3b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_36beabb2-a080-4216-95f8-39674f8884dd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d585140b-4e1b-4b22-96f3-a4add6c571a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e4d5f73-6b35-49ef-a47b-1de58b8066a6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0cdf57cf-cc41-4943-b861-fbcd842ecade_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_47abe807-8340-4afd-aee7-d7bd956dbd19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7433a335-300f-4a4c-90db-7b8351ab1e7a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_e39fe63d-a895-4575-b240-b3f5d357b9b2_terseLabel_en-US" xlink:label="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:href="rxrx-20210930.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_PaymentsOfStockIssuanceExpenses_5815799a-5384-4518-a720-20f55b9df9b4_terseLabel_en-US" xlink:label="lab_rxrx_PaymentsOfStockIssuanceExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO, expenses costs</link:label>
    <link:label id="lab_rxrx_PaymentsOfStockIssuanceExpenses_label_en-US" xlink:label="lab_rxrx_PaymentsOfStockIssuanceExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Expenses</link:label>
    <link:label id="lab_rxrx_PaymentsOfStockIssuanceExpenses_documentation_en-US" xlink:label="lab_rxrx_PaymentsOfStockIssuanceExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PaymentsOfStockIssuanceExpenses" xlink:href="rxrx-20210930.xsd#rxrx_PaymentsOfStockIssuanceExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_PaymentsOfStockIssuanceExpenses" xlink:to="lab_rxrx_PaymentsOfStockIssuanceExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_755bb694-f5c6-4c41-bcb6-60f59204c827_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CorporateBondsMember_80bc2066-5d73-4fee-8df3-a9ad2cfbea5c_terseLabel_en-US" xlink:label="lab_rxrx_CorporateBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_rxrx_CorporateBondsMember_label_en-US" xlink:label="lab_rxrx_CorporateBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds [Member]</link:label>
    <link:label id="lab_rxrx_CorporateBondsMember_documentation_en-US" xlink:label="lab_rxrx_CorporateBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CorporateBondsMember" xlink:href="rxrx-20210930.xsd#rxrx_CorporateBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CorporateBondsMember" xlink:to="lab_rxrx_CorporateBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_5e3a5b63-633c-4948-8f20-08a22b84fc05_terseLabel_en-US" xlink:label="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research project, fees and milestones payments receivable for an option on a lead series</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_label_en-US" xlink:label="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Lead Series</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_documentation_en-US" xlink:label="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Lead Series</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" xlink:to="lab_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_PacificWesternBankLoanMember_a41fcf09-4673-49a9-942e-609f997aca13_terseLabel_en-US" xlink:label="lab_rxrx_PacificWesternBankLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Western Bank loan</link:label>
    <link:label id="lab_rxrx_PacificWesternBankLoanMember_label_en-US" xlink:label="lab_rxrx_PacificWesternBankLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Western Bank Loan [Member]</link:label>
    <link:label id="lab_rxrx_PacificWesternBankLoanMember_documentation_en-US" xlink:label="lab_rxrx_PacificWesternBankLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Western Bank Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PacificWesternBankLoanMember" xlink:href="rxrx-20210930.xsd#rxrx_PacificWesternBankLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_PacificWesternBankLoanMember" xlink:to="lab_rxrx_PacificWesternBankLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_54ffe08b-3c88-454f-a880-bb0b9ba19a13_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d57f8d1e-6f3d-44d4-9cfb-3b7219b2f0c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_c8201ec0-4a4d-47b8-9ee4-4c4b53b0a5fe_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f7c2adc8-d558-464b-bccb-ff84b9a04c9c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_a8afef77-77f1-46bb-b47f-e3dcb1075f48_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseIncentivePayableCurrent_097afdc2-e087-490e-bfe6-e66eaa2e1cdb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease incentive obligation</link:label>
    <link:label id="lab_us-gaap_LeaseIncentivePayableCurrent_label_en-US" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incentive, Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncentivePayableCurrent" xlink:to="lab_us-gaap_LeaseIncentivePayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bcf0b207-c082-4f71-a9b5-73057f485655_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised in period, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_9e5ef137-250c-45e8-b7f7-6d0b6e86d568_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0bee5eb9-8eb9-4713-a9b9-6bab85801adf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_49f72b56-3042-428a-ba59-8798c4669283_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c0151ee-9e42-499c-851b-f83c392790d2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d48b9048-3491-4242-8c10-c5c004830f42_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_de1c51e1-7f65-4ba6-ac7b-d680cd09813a_terseLabel_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share-Based Payment Award, Purchase Period</link:label>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share-Based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_b907064b-2073-4c9c-aedf-e868064a0146_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_980bc4c3-e9e4-49e5-b746-2d3a9f172cb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ConvertibleSeriesCPreferredStockMember_e6a28e12-8f1f-46f4-93dc-e96c58255c26_terseLabel_en-US" xlink:label="lab_rxrx_ConvertibleSeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesCPreferredStockMember_label_en-US" xlink:label="lab_rxrx_ConvertibleSeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series C Preferred Stock [Member]</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesCPreferredStockMember_documentation_en-US" xlink:label="lab_rxrx_ConvertibleSeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series C Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesCPreferredStockMember" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ConvertibleSeriesCPreferredStockMember" xlink:to="lab_rxrx_ConvertibleSeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_342542ea-5883-458c-a67d-aef3fdf22d4f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_61bb7ec3-f375-4d56-b014-33b08386b2c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_da20da1d-e8af-4bcf-b8ee-fb2f35ebe873_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book values</link:label>
    <link:label id="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Other than Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f7e16131-58e8-453a-9d57-cf23583d52be_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d1c9243a-50fe-4503-9a24-32aff87ec78b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises and other</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_4bf57a18-4ed7-46fe-b223-93d5a3d2c669_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_1019a43e-2e2c-4d81-a84b-256f8da8af9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_119898cb-c417-4dd5-a1d6-349d697fde88_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_f89d205f-13b0-4dac-aa22-a7eec49a684f_terseLabel_en-US" xlink:label="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:label id="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_label_en-US" xlink:label="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet And Income Statement Information [Text Block]</link:label>
    <link:label id="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_documentation_en-US" xlink:label="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet And Income Statement Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:to="lab_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_84df0ed1-4abb-4e45-8299-80c06f4e3dd0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d0419256-30f0-400c-bae5-93da6387cb22_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6b71d1ee-a55b-4643-ba65-f628e233836c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b43931f7-90e2-4614-bf7b-a90112725a9c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9ee86a29-ba7f-4b0d-a5ed-fe16c89d7603_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_cd2efb14-ceb5-482e-b50c-1180d700fb57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_cb2922a1-4c44-4fb7-8bcb-304b7b752dc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of business acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d0d2d7a3-9c99-44a2-906e-565b955cd472_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansAndLeasesReceivableRelatedParties_428057b1-922d-47cd-8eaf-130aadc603ec_terseLabel_en-US" xlink:label="lab_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan to related party</link:label>
    <link:label id="lab_us-gaap_LoansAndLeasesReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and Leases Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="lab_us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8bb18934-f701-4d46-9dd5-9fbb4b4e9959_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_70cb9765-df6f-40e4-9c9a-9613ef86b420_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance for initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cf53c45e-4956-42d8-ba13-47b72813d43e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e5297715-4737-4d8d-a898-d166d03c1323_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of a business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2ea990a6-007f-40ce-99c4-77621c63bf6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_96a1076e-beb0-4076-a1ad-5dacb30a3216_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_171c013b-4386-43ab-9e4a-c9fd6cff7c51_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_30e2fd99-400b-4c71-a3ae-f2ca371b0b19_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_72922454-baa9-491a-a9fb-3170e78c2a2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47898ff1-2e19-4388-8624-fb56e1b56db1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b7fa881a-a33a-45fe-ad32-4e23f2ed46d7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO, underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0eec2599-33d5-4e50-9850-04ac0ec7eb9a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance for initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_0d8137ce-0242-48fc-a482-959a837bdb47_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LeaseIncentivePayableNoncurrent_6fac5a47-03a8-4cf4-9ad6-5e7373b7b170_terseLabel_en-US" xlink:label="lab_rxrx_LeaseIncentivePayableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive obligation, net of current portion</link:label>
    <link:label id="lab_rxrx_LeaseIncentivePayableNoncurrent_label_en-US" xlink:label="lab_rxrx_LeaseIncentivePayableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incentive, Payable, Noncurrent</link:label>
    <link:label id="lab_rxrx_LeaseIncentivePayableNoncurrent_documentation_en-US" xlink:label="lab_rxrx_LeaseIncentivePayableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incentive, Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseIncentivePayableNoncurrent" xlink:href="rxrx-20210930.xsd#rxrx_LeaseIncentivePayableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LeaseIncentivePayableNoncurrent" xlink:to="lab_rxrx_LeaseIncentivePayableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_80a42d08-cf4f-4bfa-8db5-8bdaf152717f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and expense disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_bf857ce7-eebd-4476-8b08-c79c91187d04_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock (Class A and B), $0.00001 par value; 2,000,000,000 (Class A 1,989,032,117, Class B 10,967,883) and 188,400,000 shares authorized as of September&#160;30, 2021 and December&#160;31, 2020, respectively; 168,634,959 (Class A 159,167,076, Class B 9,467,883) and 22,314,685 shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3639e6ba-a686-4852-aaa7-1cc57173ed27_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8cbc55d0-234f-4538-b62c-f932ef9a0d48_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1691707c-9dc7-4ecd-a7a9-f6dac14cf0e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, outstanding Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_180ef302-68db-4eb9-8bb2-6e5dd8c2c0e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, outstanding Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_65274181-c90d-4289-9b49-cd3bf5648392_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and emerging growth company</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a2b20e45-b1c1-4f42-b4ee-2b713849b722_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f8f25ae8-5cdc-482e-a122-ea2e969f4ba1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_b6f72860-465c-4de8-b257-a74da15783e3_terseLabel_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_label_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee. Operating Lease, Tenant Improvement Allowance</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_documentation_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee. Operating Lease, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseTenantImprovementAllowance" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LesseeOperatingLeaseTenantImprovementAllowance" xlink:to="lab_rxrx_LesseeOperatingLeaseTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a5aed143-a9a8-40a5-9774-8992af81692b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_4505bd20-bb0f-4e33-9c51-ec6615348c39_terseLabel_en-US" xlink:label="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment received</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_label_en-US" xlink:label="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Refundable Upfront Payment Received</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Refundable Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" xlink:to="lab_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_efff5fb2-f98f-4f38-b507-dd2567fd9b2b_terseLabel_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options (in extension periods)</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_05fa44e5-8d29-4805-bc77-9ac2da6447d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_e979953c-d37e-4039-9653-9d64cb9afbc3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b44b0eb5-75f3-4aed-8469-8c3d7d8e02ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_c9aa3570-f4f9-4766-959c-2d09c21fe10c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of fees in connection with the midcap loan agreement</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_efda6e91-c06f-47a7-a64e-04dbc230e4d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_09b5af64-06e8-47c6-9c5a-11da942b68cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:to="lab_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_166198b3-ce29-4fa0-9c66-45ee1c0e951c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b4f32331-5426-4819-af04-5fe62358dcdf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_4da0b231-ec57-4b18-97a2-d6520dbda3e5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPreferredUnitsTable_db0c065e-54fc-4e7d-aafa-325a97c1af44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPreferredUnitsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Units [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPreferredUnitsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPreferredUnitsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Units [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPreferredUnitsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable" xlink:to="lab_us-gaap_ScheduleOfPreferredUnitsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_e206b913-a364-4996-bbc6-1fbbc4491d9d_negatedTerseLabel_en-US" xlink:label="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Value, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:to="lab_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_50a8cec6-2633-44a7-8d4a-4f6c339efdce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightIssued_d9890d04-3af5-4c0d-97cc-9d49c25833f1_terseLabel_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightIssued" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ClassOfWarrantOrRightIssued" xlink:to="lab_rxrx_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5d9e8c55-7efa-4204-9c5f-f9cfd1ff600e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_e657bc08-aa9e-4781-bc1e-4f8b218f67f2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_54d35be1-1f8a-43ff-ade5-29e6347eb99d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d1c6805a-ba9e-4f01-812d-df00dd21fca3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dd1a48d7-0a2e-44f5-8e9e-b31ab58ffdae_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_45f687e7-5f81-4266-a54d-4f43f40bfc45_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO, net proceeds received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_982e580b-a601-42c7-aef2-a018c341d9b3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b6660492-7187-48d7-bb41-d71801791166_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock (series A, A-1, B, C and D), $0.00001 par value; 200,000,000 and 121,434,713 shares authorized as of September&#160;30, 2021 and December&#160;31, 2020, respectively; 0 and 112,088,065 shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively; liquidation preference of $0 and $450,850 as of September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1bca7ee4-c19a-4bc8-bb75-7131f2091c78_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount attributable to parent at beginning of period</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1fb099d8-7fb1-4e8c-8c02-a97b0e658685_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount attributable to parent at end of period</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_78e76436-440d-4a56-89e0-fde1254917a2_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_0e3b6f63-fb59-4701-8c5a-98249feedfd0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_99397cfe-081c-4d17-9e0b-b0f996130938_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_60bac38d-3922-491d-9128-be19bacf5054_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e9a0e704-a2c0-468a-bde3-5572ba68965e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_edf32ce4-9c34-4bd3-9c81-cc5265cd3073_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cc002e77-fd04-43f2-9e37-bb3589f7ba36_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_13eda16d-a39b-4114-b07b-3747b33b7978_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_97fa0609-4513-42ca-bad4-ad5552a3912f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LeaseArrangementNameDomain_3ca94316-bee8-4915-9bd6-bf03c77fb738_terseLabel_en-US" xlink:label="lab_rxrx_LeaseArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement Name [Domain]</link:label>
    <link:label id="lab_rxrx_LeaseArrangementNameDomain_label_en-US" xlink:label="lab_rxrx_LeaseArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement Name [Domain]</link:label>
    <link:label id="lab_rxrx_LeaseArrangementNameDomain_documentation_en-US" xlink:label="lab_rxrx_LeaseArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameDomain" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LeaseArrangementNameDomain" xlink:to="lab_rxrx_LeaseArrangementNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_d391fef9-b203-4f56-82c1-a80a21500902_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f46f3fca-0038-4065-94a7-417399667768_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (Class A and B)</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_395e2677-96a0-40d8-9f3e-92c1bdfd8d2e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ff4d3274-b0e8-4a73-af4f-020a104aefc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_60113e8f-109b-4fa9-ad28-91f6b815f6d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c1d40f46-f00e-4ad6-a616-8d5c815870aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c44b5ccf-ce8c-42c2-b84a-a497cf9fb042_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development Contracts</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_a8bc4438-2e23-4d9a-a9f1-d046785902bf_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series D convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_77b31399-5c9b-4c2f-9cb1-f5df9c2aed93_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_97742ae1-4918-4e60-b8f1-b7a76654ea12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_67efcf14-339b-42b6-ae04-6a57c2c6de2c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in-Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ecff6fc-ef95-4386-9bb2-61dfd0ba8e52_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e6e7f642-05ba-4430-8871-5eb5a3199742_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1ed0848a-b6a3-43b7-ae89-395b901ac5a3_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_ff6eea5b-f5e7-4e47-a13f-2ac02c8850c1_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b21be611-2785-4ed6-b3dd-5208ae273144_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d0a6c7a9-1887-4d64-9698-c1e5fc67a073_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivate</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e48e22b8-ae28-451a-88c6-34cb80bb81e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2b79f22-7904-429f-afb8-7c22763c3087_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_7ed20b3f-ebb2-4d73-91b0-00b63533b59b_terseLabel_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued development expense</link:label>
    <link:label id="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_label_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Development Expense</link:label>
    <link:label id="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_documentation_en-US" xlink:label="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:href="rxrx-20210930.xsd#rxrx_IncreaseDecreaseInAccruedDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:to="lab_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_ea1fa021-2210-4c91-9071-c41c16d4ceea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_e05fafb2-65ff-414e-a7ef-2159e490dfd5_terseLabel_en-US" xlink:label="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated holders, potential ownership percentage when outstanding equity awards vest</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_label_en-US" xlink:label="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest</link:label>
    <link:label id="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_documentation_en-US" xlink:label="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:href="rxrx-20210930.xsd#rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:to="lab_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_ca009d58-6ab4-45c0-b112-d511df59795d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e14aa9d-af31-43f2-8b4e-2d986ccc37ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ConvertibleSeriesAPreferredStockMember_2e93a4ab-f090-4974-a9a5-181541971441_terseLabel_en-US" xlink:label="lab_rxrx_ConvertibleSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesAPreferredStockMember_label_en-US" xlink:label="lab_rxrx_ConvertibleSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series A Preferred Stock [Member]</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesAPreferredStockMember_documentation_en-US" xlink:label="lab_rxrx_ConvertibleSeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series A Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesAPreferredStockMember" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ConvertibleSeriesAPreferredStockMember" xlink:to="lab_rxrx_ConvertibleSeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissued_6d667dc3-aafd-4411-8ff7-b21d33692192_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issuable upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Subscribed but Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:to="lab_us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_af183da0-623c-41da-be5d-46a0ea6c54a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3bc91d25-ca76-48f9-b84f-5134a77bad1d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_acf58946-03c2-42c7-a052-4e82ba15a016_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fbe5dea2-3f21-4b21-ada5-f1535a2a2318_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ff97ae37-ed0b-4e2a-9aa1-026a506f01c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27d5f0dc-8129-4913-94d7-db12410f8d96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5ab03158-7ab8-469d-964a-ec619980b589_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_578a96e1-16dd-47f0-9006-7f5776c69048_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit) at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fbf2ebf8-e31e-481c-9394-9d91bfc0fe91_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit) at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_WarrantsArrangementsTable_1e90c540-3766-4dde-bc4c-81988d8d9046_terseLabel_en-US" xlink:label="lab_rxrx_WarrantsArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Arrangements [Table]</link:label>
    <link:label id="lab_rxrx_WarrantsArrangementsTable_label_en-US" xlink:label="lab_rxrx_WarrantsArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Arrangements [Table]</link:label>
    <link:label id="lab_rxrx_WarrantsArrangementsTable_documentation_en-US" xlink:label="lab_rxrx_WarrantsArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsTable" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_WarrantsArrangementsTable" xlink:to="lab_rxrx_WarrantsArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_34771a4f-f644-41ab-9024-8e428f470f3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_146855c3-967f-4401-be4f-172a7ed88551_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded in equity upon exercise</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0eda7890-7c0a-4fd5-9990-cd2e310d3855_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_517f95b5-43a8-4685-966a-a06763d16c5c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet" xlink:to="lab_us-gaap_InterestRevenueExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_6ff4599d-2edb-4d34-92e9-ce2895791601_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_96039df0-14a1-4d44-8b2e-25069cdaa58a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to equity</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b944a03a-0574-4692-9c3d-fff8d0c8bd58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_67b7f6ea-2a3c-4076-87b2-af5551c9bc11_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_1688fb3b-83d5-4309-9201-0d5af3bf4234_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_d68fd799-7e21-4fa7-b0a6-2392700ff6f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses, deferred rent and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c0c11a6f-2ab1-4171-a510-08eea7eb5317_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_8c0cc973-0d16-4505-9b84-cc58c3120888_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f8313aad-9dd9-4878-9ef5-d788ee937f7d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non&#8212;cash investing and financing information</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d8b4ed51-881a-4620-9a47-e892a0fbb4b2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6bc7ff84-a597-4556-9bea-1dabf7b1cb7c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_026783cc-097a-4a28-93d2-bdb878ffdde9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0f1c39ab-0084-4951-bfe6-37cd9de068fc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5444e6a5-73d6-4150-9c25-d0685da6a0cc_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_65c71be9-2f7d-406e-b6fb-59743da7dba2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cc1912b8-d34e-4ff9-8b9d-cfcd63d58dd7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_f6015fde-26b5-499b-ad56-aeb3bcb1a889_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e14bcb9f-debf-4fb0-b8e0-3920d9523728_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_06d443d4-cc88-47cb-bbe7-fb83fd6e8997_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bf0001e8-86e8-419c-9e2c-38d621756fbc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_f124f1e8-fb80-4655-a4b1-16f6900c8561_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_dac4f223-3f73-4162-a3d2-baf6479a84bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_c36c4605-f620-4f17-b970-cda6096748f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of available for sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_21fd6f14-52ea-448b-b1a2-daedf2f7c7a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_c7a7bfc6-1bfb-4646-b97c-669a4621154d_terseLabel_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, estimated fair value at grand date</link:label>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_label_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Estimated Fair Value At Grand Date</link:label>
    <link:label id="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_documentation_en-US" xlink:label="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Estimated Fair Value At Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" xlink:to="lab_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_Station41LeaseMember_55039b66-fc66-45af-a7cb-70ee2c3425d7_terseLabel_en-US" xlink:label="lab_rxrx_Station41LeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 41 lease</link:label>
    <link:label id="lab_rxrx_Station41LeaseMember_label_en-US" xlink:label="lab_rxrx_Station41LeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 41 Lease [Member]</link:label>
    <link:label id="lab_rxrx_Station41LeaseMember_documentation_en-US" xlink:label="lab_rxrx_Station41LeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 41 Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember" xlink:href="rxrx-20210930.xsd#rxrx_Station41LeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_Station41LeaseMember" xlink:to="lab_rxrx_Station41LeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_da6c7562-70ca-4143-add6-d038f8bd0043_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_Station56Member_7c72852e-74ff-43dc-ba42-4718b1fb7b55_terseLabel_en-US" xlink:label="lab_rxrx_Station56Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 56</link:label>
    <link:label id="lab_rxrx_Station56Member_label_en-US" xlink:label="lab_rxrx_Station56Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 56 [Member]</link:label>
    <link:label id="lab_rxrx_Station56Member_documentation_en-US" xlink:label="lab_rxrx_Station56Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 56</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station56Member" xlink:href="rxrx-20210930.xsd#rxrx_Station56Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_Station56Member" xlink:to="lab_rxrx_Station56Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7bafc672-cef5-4d66-b9dc-2fa0e67710fc_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d1f186af-ed67-4325-882f-4a25e1ba1e51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Changes In Company's Warrant Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ConvertibleSeriesDPreferredStockMember_5e007c5f-3066-444a-8071-364162365a31_terseLabel_en-US" xlink:label="lab_rxrx_ConvertibleSeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesDPreferredStockMember_label_en-US" xlink:label="lab_rxrx_ConvertibleSeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series D Preferred Stock [Member]</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesDPreferredStockMember_documentation_en-US" xlink:label="lab_rxrx_ConvertibleSeriesDPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series D Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesDPreferredStockMember" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesDPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ConvertibleSeriesDPreferredStockMember" xlink:to="lab_rxrx_ConvertibleSeriesDPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4198a10a-3b35-44a1-ad7a-ee73153e8c79_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_f4096027-c5b2-440e-a116-be6758d4c43e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2dc17528-71ab-4d00-9fcc-2ae5b87bb9bf_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_A2017WarrantsMember_19a5f31c-7680-469e-b3cf-21d662a29523_terseLabel_en-US" xlink:label="lab_rxrx_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants</link:label>
    <link:label id="lab_rxrx_A2017WarrantsMember_label_en-US" xlink:label="lab_rxrx_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants [Member]</link:label>
    <link:label id="lab_rxrx_A2017WarrantsMember_documentation_en-US" xlink:label="lab_rxrx_A2017WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2017WarrantsMember" xlink:href="rxrx-20210930.xsd#rxrx_A2017WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_A2017WarrantsMember" xlink:to="lab_rxrx_A2017WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_53a8731a-3724-40e7-aa3c-223243251a32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_227b8337-34f0-43a1-869f-7eee1f8927b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, cancelled in period, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aca7a9e5-69d2-4bb5-9ff7-646a3e75ce71_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_8976d973-e4ba-4b69-ac82-d89851d138b7_terseLabel_en-US" xlink:label="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Midcap loan agreement, tranche 1</link:label>
    <link:label id="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_label_en-US" xlink:label="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Midcap Loan Agreement, Term Loan Facility, Tranche One Member [Member]</link:label>
    <link:label id="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_documentation_en-US" xlink:label="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Midcap Loan Agreement, Term Loan Facility, Tranche One Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" xlink:href="rxrx-20210930.xsd#rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" xlink:to="lab_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e7ac89a0-a63a-42cf-b651-6f1ff21c8058_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c25cfbab-753e-4735-94ec-c39c3d2145b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_PacificWesternLetterOfCreditMember_d85059e0-5321-4cad-a19f-67956662ed13_terseLabel_en-US" xlink:label="lab_rxrx_PacificWesternLetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Western letter of credit</link:label>
    <link:label id="lab_rxrx_PacificWesternLetterOfCreditMember_label_en-US" xlink:label="lab_rxrx_PacificWesternLetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Western Letter Of Credit [Member]</link:label>
    <link:label id="lab_rxrx_PacificWesternLetterOfCreditMember_documentation_en-US" xlink:label="lab_rxrx_PacificWesternLetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Western Letter Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PacificWesternLetterOfCreditMember" xlink:href="rxrx-20210930.xsd#rxrx_PacificWesternLetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_PacificWesternLetterOfCreditMember" xlink:to="lab_rxrx_PacificWesternLetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a2954af1-f6be-4a45-9335-af6f437da571_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a27aa2b-e04c-4329-b79e-6a4238cc1b8e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3c4792a6-0a91-472e-b04b-64e449a68bf0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_fff79c77-b639-43a7-af72-f271702709c8_terseLabel_en-US" xlink:label="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of projects that may be initiated (in projects)</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_label_en-US" xlink:label="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number Of Projects That May Be Initiated</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_documentation_en-US" xlink:label="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number Of Projects That May Be Initiated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" xlink:to="lab_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4b44fd53-6bcd-43c9-9fb0-7bd80f6d4e8d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9d092afc-4574-46ff-a6f7-04246652a8ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dfa88117-77ac-413c-a6b1-4dd4c85ea158_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_9df1578e-524b-46d3-abce-a09e39ce6b4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7bcd65ca-e425-443d-b940-017f531bec17_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredUnitsLineItems_6a7f8c2c-adcb-4203-bae8-5a6f4947abcc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Units [Line Items]</link:label>
    <link:label id="lab_us-gaap_PreferredUnitsLineItems_label_en-US" xlink:label="lab_us-gaap_PreferredUnitsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Units [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredUnitsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredUnitsLineItems" xlink:to="lab_us-gaap_PreferredUnitsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88992b60-de96-4b8e-b6e7-9d4bcfc9a41e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested stock options, unamortized stock-based compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1ddb1adc-86da-4c71-8c2d-fce34e73a1ac_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a5e24fda-d7b5-440e-b83b-1a92c2c68c18_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_234bfec7-13e1-41d2-b116-66297e44b844_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_bc439c22-7a99-45ad-a655-3e10d96c836a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_60c27754-8f60-4744-bebb-57b1138e84fb_negatedTerseLabel_en-US" xlink:label="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:to="lab_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ff450903-4463-4e48-879a-69682431b0c4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SeriesAAndSeriesBWarrantsMember_8a8710a1-b99a-4133-8ed1-72620bd43aab_terseLabel_en-US" xlink:label="lab_rxrx_SeriesAAndSeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A and Series B Warrants</link:label>
    <link:label id="lab_rxrx_SeriesAAndSeriesBWarrantsMember_label_en-US" xlink:label="lab_rxrx_SeriesAAndSeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A And Series B Warrants [Member]</link:label>
    <link:label id="lab_rxrx_SeriesAAndSeriesBWarrantsMember_documentation_en-US" xlink:label="lab_rxrx_SeriesAAndSeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A And Series B Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SeriesAAndSeriesBWarrantsMember" xlink:href="rxrx-20210930.xsd#rxrx_SeriesAAndSeriesBWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SeriesAAndSeriesBWarrantsMember" xlink:to="lab_rxrx_SeriesAAndSeriesBWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_205912b6-6e3f-46f2-8229-b48ebe421921_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_4645d19a-7ee9-40c7-be46-603bc284fbf8_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c04c2bf0-0a21-4a99-8b1c-dc1970d76195_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_42fc55ec-8dbf-4751-9cbe-dba543df5f1c_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db7279ad-1592-44b3-a596-e566124f5283_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_67e920d8-3331-449f-8f74-3fd788caaba5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f2465370-0871-414f-926e-a5fdc90439e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_d7379e21-5425-43ea-842f-f837dcc9e04a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_A2018WarrantsMember_071d9a36-a089-4dff-b751-347f6f7f3ade_terseLabel_en-US" xlink:label="lab_rxrx_A2018WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrants</link:label>
    <link:label id="lab_rxrx_A2018WarrantsMember_label_en-US" xlink:label="lab_rxrx_A2018WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrants [Member]</link:label>
    <link:label id="lab_rxrx_A2018WarrantsMember_documentation_en-US" xlink:label="lab_rxrx_A2018WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2018WarrantsMember" xlink:href="rxrx-20210930.xsd#rxrx_A2018WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_A2018WarrantsMember" xlink:to="lab_rxrx_A2018WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1c205167-e6e3-4cda-97dc-56a15a932903_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_A2021EmployeeStockPurchasePlanMember_e18ececa-f456-4085-924f-c8c035592acc_terseLabel_en-US" xlink:label="lab_rxrx_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_rxrx_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_rxrx_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_rxrx_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_rxrx_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EmployeeStockPurchasePlanMember" xlink:href="rxrx-20210930.xsd#rxrx_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_rxrx_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3c17d96c-f682-42f9-8526-a4a8fe1ec311_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a2e55143-3011-4fdf-aa1c-4928da7e725d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_d106e54b-c67a-4113-b930-edeb9278042b_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bef9af67-8fed-4501-a9c9-81d54ff595ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8c81ea89-d9cd-4185-910d-d91117bcaa56_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_64bde2d8-89c8-4363-a25d-ff236a9cfec3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_2b07ad5a-a97a-43bd-873c-069472698438_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9a9563e7-690c-4157-8795-e613e0d4d1e2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d0d1d641-f8e8-45fa-90a0-59915b0896dc_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_c9578903-c0a6-44f0-9b8c-10694e237306_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Minimum Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_18c9c8c9-5511-4fe2-a911-26d09042a767_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0a6083bd-2ffc-4df2-9fa8-bacf6ac4f8fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e12af0ae-0f38-4229-ae7a-b1e396664222_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_89ff9fe4-d252-48cf-8470-30c6d4b36662_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_19d0df41-071c-4a4a-a43c-9e7f9ab81e4e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d5936e8e-e030-4ff2-b291-101fe852c9c0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_A2016WarrantsMember_0950f307-b22f-4eef-92f5-3e41e63f6dc8_terseLabel_en-US" xlink:label="lab_rxrx_A2016WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Warrants</link:label>
    <link:label id="lab_rxrx_A2016WarrantsMember_label_en-US" xlink:label="lab_rxrx_A2016WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Warrants [Member]</link:label>
    <link:label id="lab_rxrx_A2016WarrantsMember_documentation_en-US" xlink:label="lab_rxrx_A2016WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2016WarrantsMember" xlink:href="rxrx-20210930.xsd#rxrx_A2016WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_A2016WarrantsMember" xlink:to="lab_rxrx_A2016WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_984591e0-9221-4e35-935c-938ca3bd5f2c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_bca52249-545b-4f17-8457-3b3ec901f7e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_82ffd8f2-cb8d-42a0-a1d7-483a7f17df62_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_8c439ac9-f312-428d-9070-00e86143ada8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="lab_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_f7369bc9-66c6-4ce1-b744-2e1b071ff276_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ad9bbb48-997c-4095-9361-0021c0b55187_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ffa4f99d-43b9-4eda-bd77-79073c67366b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_129089d9-d1f4-4b3d-ba4c-4debc6b3bb82_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2a7b2310-11e9-4561-b3ef-392fcc461c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7f6eed30-9c88-4c75-b1fb-39fbfe01127c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_32e6d56c-a713-4704-acbb-6d79c307a83f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_afea6934-e4b6-4171-b316-cf4050216131_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ea1352d2-d91a-490e-a06f-df3a16b5ae5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-based Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d505e326-35ca-4251-84b9-f339ea25fc5b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0d28c302-0a97-4539-9e39-408fe102ea94_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CommonStockVotePerShare_dbbf0047-836e-4acb-9c64-85a35a6c1242_terseLabel_en-US" xlink:label="lab_rxrx_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vote per share of common stock (in votes)</link:label>
    <link:label id="lab_rxrx_CommonStockVotePerShare_label_en-US" xlink:label="lab_rxrx_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:label id="lab_rxrx_CommonStockVotePerShare_documentation_en-US" xlink:label="lab_rxrx_CommonStockVotePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Vote Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockVotePerShare" xlink:href="rxrx-20210930.xsd#rxrx_CommonStockVotePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CommonStockVotePerShare" xlink:to="lab_rxrx_CommonStockVotePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_686c4b56-08ea-49a6-89fb-9e37b8fd5f51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ddf6f12d-2349-4f3f-920d-438d2f96eebe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4bd0ce87-48d3-4234-9a09-0743368a5b43_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9e16470b-ed49-41e0-b3cd-060930946b89_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_098835e9-5859-490a-bd10-15108fcc6ba4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_07ccc4ad-8f15-4bff-9a16-6e76d3990faf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e82517a1-b1cf-42cb-8c0a-8377c2ec5dca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_79df3cab-d02b-471c-970e-3460a65681d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7f7793cd-5b98-47b8-aa35-29dc59223891_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_753069d7-3c4c-4551-abda-bb5e5ff1c683_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_eb9d132a-2ccc-42ed-a449-7c3807896559_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized losses (gains) on investments reclassified into net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_afc99a05-2330-469b-9299-329452aaa254_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_801fe3eb-fdda-4703-9c12-57782911666a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d109b6dd-1702-4c18-9bb9-46cb00560d02_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ChristopherGibsonAndAffiliatesMember_6e53838c-2673-4764-972a-a5e12fec773b_terseLabel_en-US" xlink:label="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christopher Gibson and his affiliates</link:label>
    <link:label id="lab_rxrx_ChristopherGibsonAndAffiliatesMember_label_en-US" xlink:label="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christopher Gibson And Affiliates [Member]</link:label>
    <link:label id="lab_rxrx_ChristopherGibsonAndAffiliatesMember_documentation_en-US" xlink:label="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christopher Gibson And Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:href="rxrx-20210930.xsd#rxrx_ChristopherGibsonAndAffiliatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:to="lab_rxrx_ChristopherGibsonAndAffiliatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ba6459af-63d5-4a5e-a2c9-a3843e416669_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a0f444b9-2f5b-439a-bdf3-efbedb8e460c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightFairValue_9384176b-d45b-4353-a7e2-d8b8216a1bdc_terseLabel_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, fair value</link:label>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightFairValue_label_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value</link:label>
    <link:label id="lab_rxrx_ClassOfWarrantOrRightFairValue_documentation_en-US" xlink:label="lab_rxrx_ClassOfWarrantOrRightFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightFairValue" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ClassOfWarrantOrRightFairValue" xlink:to="lab_rxrx_ClassOfWarrantOrRightFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_844ea5f8-283b-4038-897f-130f2a6b9328_terseLabel_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Size of leased asset (in square feet)</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_label_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Size Of Leased Asset</link:label>
    <link:label id="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_documentation_en-US" xlink:label="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Size Of Leased Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseSizeOfLeasedAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" xlink:to="lab_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_c64ec48f-d43a-48c7-9353-524f2a66d11d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_AssetUnderConstructionMember_label_en-US" xlink:label="lab_us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset under Construction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetUnderConstructionMember" xlink:to="lab_us-gaap_AssetUnderConstructionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf824b76-f3b3-4f74-93fd-c8ebc4facd7d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a9057a4-3fbe-440f-936c-9d5b76276b99_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d6361648-345d-49b8-b4cb-612e968ddbb0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of Class A and B common stock, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_53af4051-8300-4cc9-9a59-9a828a39045b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_5afde42d-1b75-4d7c-9fa7-838383d12ed7_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating revenue</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_27f53b09-8f67-470d-802c-422a2e2fcef0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4012cc33-d4d0-4cce-94b9-2f71e7456ada_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bc14a25f-bb10-41b6-b4aa-6f7643b761ff_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_1f00e411-a17b-4d9a-bd5d-3d0902933d8e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_b1462207-68f0-48d1-8c26-961db12ef687_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_WarrantsArrangementsLineItems_34010374-6199-44ca-9707-cf3c7e84a248_terseLabel_en-US" xlink:label="lab_rxrx_WarrantsArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Arrangements [Line Items]</link:label>
    <link:label id="lab_rxrx_WarrantsArrangementsLineItems_label_en-US" xlink:label="lab_rxrx_WarrantsArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Arrangements [Line Items]</link:label>
    <link:label id="lab_rxrx_WarrantsArrangementsLineItems_documentation_en-US" xlink:label="lab_rxrx_WarrantsArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsLineItems" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_WarrantsArrangementsLineItems" xlink:to="lab_rxrx_WarrantsArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_48055aed-e721-4f3c-9ffc-101fc5a8de72_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0323085e-9cfc-48e8-8cd8-596c7e8b0133_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_a723a3c3-3688-4732-ae39-93623d13a06d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ca128e74-5d66-4e41-9cd3-b6a218631c3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_c3b724cd-d9b1-4055-9de0-82ce0734d61c_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2d6adfd1-4d6c-4e25-876a-91fa87292572_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_dded5f12-7800-41e5-b9a6-81ca9a034f49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in the period, upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d0a6a1f8-a7c4-4e8c-80c3-3c4a527f55da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_1b4ef73c-832d-4786-b71e-1979f977850e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_105cb9f4-1b5f-4981-b658-8b76ab31743f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_059cbfec-200c-4d34-93e2-932652858463_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_MidcapLoanAgreementMember_3f403b46-3252-4555-8b04-65238a39286d_terseLabel_en-US" xlink:label="lab_rxrx_MidcapLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Midcap loan agreement</link:label>
    <link:label id="lab_rxrx_MidcapLoanAgreementMember_label_en-US" xlink:label="lab_rxrx_MidcapLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Midcap Loan Agreement [Member]</link:label>
    <link:label id="lab_rxrx_MidcapLoanAgreementMember_documentation_en-US" xlink:label="lab_rxrx_MidcapLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Midcap Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MidcapLoanAgreementMember" xlink:href="rxrx-20210930.xsd#rxrx_MidcapLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_MidcapLoanAgreementMember" xlink:to="lab_rxrx_MidcapLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_997938e6-495a-4dc2-99f4-e72884255bac_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c60608b0-c5e6-4ab9-b138-2e2566d1af75_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8c5d058a-b66c-44af-9e7a-c506910dd993_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_eb26ee62-6bde-4ba7-afea-f7f5d7a17f7f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dfb4d0f8-14ea-494f-8ad3-6eb563d10672_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_9882cd96-0797-4420-a1e3-7b10be4a5cc6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7449e9e7-396d-45c8-a818-071b565ba8ca_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common sock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a6d1f5a8-3770-4f63-ae47-4f83872f18fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding at beginning period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f7156784-710c-43e6-b184-0844649908c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding at end period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e8efb3e7-b28c-4ecb-97cd-44f808163c16_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_104bbf0d-95af-4f4a-9fdd-6ff0b2a7735e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_68ffa25a-7200-447f-a2a3-66e453fa5407_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5d118190-06e1-4e8f-a7e7-af62d4f3a0d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_db9b9d5b-1cfb-4169-80f8-97df1f67c0c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f48b4134-840a-40c4-9442-7efbd67345f5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_764c0252-f271-47df-901b-1ed90796b705_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_05cc54fe-3bfe-4110-bbe4-989f7f78bf36_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e5487d70-f320-491e-a9b4-cae6e846eaac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_fd98490e-84f2-4456-853c-9ed1a1411d7c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_a004cca4-3d3e-4237-872b-6aa978460336_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_978e2698-1751-4195-beec-dfee983ff113_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_c243bf17-7b9a-4ad3-8f7f-4e03d1d87ce2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incentive, payable</link:label>
    <link:label id="lab_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incentive, Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseIncentivePayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_d8f6b467-7254-4a96-9c35-67cf9c97b573_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_aa7c64a2-bf65-4956-85bd-0c1805d29750_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6f910f50-121d-4c0d-8cdd-0d0e75bd523f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_12da5b01-fa6a-46d3-a853-d3594309a39a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_86b28b7c-0641-4cb5-b83f-d90916cd2956_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_Station41Member_a04dcd62-4a24-47b1-a562-b5b7a802588d_terseLabel_en-US" xlink:label="lab_rxrx_Station41Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 41</link:label>
    <link:label id="lab_rxrx_Station41Member_label_en-US" xlink:label="lab_rxrx_Station41Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 41 [Member]</link:label>
    <link:label id="lab_rxrx_Station41Member_documentation_en-US" xlink:label="lab_rxrx_Station41Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Station 41</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41Member" xlink:href="rxrx-20210930.xsd#rxrx_Station41Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_Station41Member" xlink:to="lab_rxrx_Station41Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_88674928-2845-4c6e-b413-149059288693_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_c1a80c16-b4b8-4eb3-a6e3-39df57b4a69f_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_a9627bdf-aead-4d27-995c-36fca1ed1fdb_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Preferences</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aa2254bf-1cc9-46bc-bc7e-bc77c7f2f76e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e384aa63-6e79-453c-afd2-e1f44e19d873_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_65745588-821a-4d41-9803-f48ff8cb32d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e6bfffeb-6804-422c-9ba5-cdc905d220a6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share data</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_99a291e9-289c-40f0-9b84-62f18f68e71a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a085e2ca-e84f-4148-9924-9be629e53174_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_7ba6a540-199d-4882-acbb-386c47b16710_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_42aa20bc-7291-497a-9271-a26420253f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f09ebf82-d265-4998-87a6-f39d14ef9232_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables and assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dee50cd4-ab22-47ef-911d-751bffbf739d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_cfd580bb-0eb2-46f5-b36e-61f3c9bd27ab_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0dd04665-619c-4ef4-a9af-18d87943f544_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, weighted average exercise price at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9f8fd46-0a2b-4725-9e8d-7062ccdf4f79_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, outstanding, weighted average exercise price at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_CollaborativeAgreementTerm_554f9905-a088-4b3f-83e2-d6849f44be91_terseLabel_en-US" xlink:label="lab_rxrx_CollaborativeAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, term</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementTerm_label_en-US" xlink:label="lab_rxrx_CollaborativeAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Term</link:label>
    <link:label id="lab_rxrx_CollaborativeAgreementTerm_documentation_en-US" xlink:label="lab_rxrx_CollaborativeAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementTerm" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_CollaborativeAgreementTerm" xlink:to="lab_rxrx_CollaborativeAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_90fb2413-06ba-46d1-b1f1-7e33aea94455_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_fb09a5b9-5f80-48e2-a95e-1885ffaf3bb3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, vesting period</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b040d2f2-1793-499f-9210-ccfcedd0646c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a2af3642-206c-425f-b35e-e55c68de433d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of unrealized loss positions (in positions)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6d7ed5e-fd67-420f-a90e-084b490e696a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cee84cfe-b5ac-40eb-be50-def8fe193ea7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SaleOfStockConvertedPricePerShare_309c671e-471e-45a6-b124-c6412e2c2328_terseLabel_en-US" xlink:label="lab_rxrx_SaleOfStockConvertedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per converted share (in dollars per share)</link:label>
    <link:label id="lab_rxrx_SaleOfStockConvertedPricePerShare_label_en-US" xlink:label="lab_rxrx_SaleOfStockConvertedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Converted Price Per Share</link:label>
    <link:label id="lab_rxrx_SaleOfStockConvertedPricePerShare_documentation_en-US" xlink:label="lab_rxrx_SaleOfStockConvertedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Converted Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockConvertedPricePerShare" xlink:href="rxrx-20210930.xsd#rxrx_SaleOfStockConvertedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SaleOfStockConvertedPricePerShare" xlink:to="lab_rxrx_SaleOfStockConvertedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_590a5918-6859-4a52-a976-3c1ce011befa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_f4036d3e-d802-48ad-83ef-9db444b87443_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_326c33e6-4fbb-4046-b150-f1815d8c4806_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7f82088-afb6-43e0-8f54-700a2bf81016_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cb579280-c439-44d1-9dc8-5cb0d1937871_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_6cac1f7f-6090-40c4-8625-6e20c4a99d8a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5c85934d-51f9-4cfa-9589-68a07f05dc45_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_178a2af5-34e6-46fb-816a-1fcb2d696fc0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_2b276ba9-2658-47d2-a983-40ecaa6998c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d963107-2d8b-4620-9dd7-6b8aee6d7a03_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233dfa58-4751-4d4f-b243-9f18bae430c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8bb32b79-4885-44ea-a114-dd7e657ba7fc_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cd2f0f9f-b0c0-4d91-8a5b-767510734018_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO, number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2d33c44b-a1e9-467c-8251-f6f529a29920_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_46ad0420-8889-4640-97a4-4a04e85f6fa4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_55ba7351-43c1-41d7-9a9b-bbdea6ad3e50_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1e3ee708-bcf4-4a83-8fc6-a3dfffa2a1cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5f30bba0-c186-4574-b8a8-5bc95fbb9ffe_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a8eafe15-ae0b-45fc-bc3d-90a75165d477_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_444ace7d-4003-49ec-abb9-c6b574311c8d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment additions</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_52c56c34-babd-489c-a459-dcefa9de80ad_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_98c0bf90-be3f-41a3-829b-f5e4835f44fd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_cd9d9f88-e75d-4cf5-aef4-5145ade988eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_721d4e1d-fdee-476d-a326-9cd02aa2da1a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30525849-bc0b-4a33-9ac6-ae782c3eb3ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised in period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4778ab20-4c0b-4cac-921c-5cc50701d555_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae187133-05c0-4ca6-9cf0-bc58b701ac36_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_699897aa-02c8-4677-88a7-f6a5b13489c6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f670da44-3c52-4acb-aca9-d93c56ac86a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_3b9440c2-6a3c-4952-b694-65f793aa4db6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from note receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4109ed51-115e-4ed4-aaa2-e539d67332c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9e7697b7-0627-4648-95dc-21a75f60651f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ca29e08c-d807-4329-9c6b-46afa47de30c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5d84db1a-bd04-473e-b1de-8f6346e664c0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ba2fb273-0b3b-45ba-a0d3-5b171bdb3d29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7ae3f618-2988-45fd-afd8-e8654ddcdc4f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_3d6a3287-e02e-4d1f-aa53-a8529d49a866_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4c003174-802c-4f68-9749-7184444db2f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1980d402-dd30-4fed-b3b6-79e3467d3529_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_50684924-36bc-4ea8-8225-3b91edbb3f69_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_33218c5b-5af5-4cd1-9a7d-c8983c027908_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9ce5cadb-e1ac-467b-970a-aaa6ff202220_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_69ec950e-24cc-4202-8c12-9580e7700523_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7aa364ad-6359-4497-ac1c-6cc097180641_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18a2bc30-27f7-42c3-913a-1a6fdfc38601_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_30477a1b-9052-4df9-93dc-d1f6a1503f6b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8d991f3b-4fb9-42fc-b488-b5a3aba02454_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a1d40555-24bb-4f86-8c24-331f265760fc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b8f063a-1027-4089-bf86-57fa9ba874c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5cb7d070-0a2a-43de-95fd-baae7ad32a53_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_d914e028-8c78-40ad-8bb1-6f0286b52aa4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_721ad510-fc04-4b39-ad5e-5ea1b3c1f6e6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_StockIssuanceCostsNoncash_6528be1b-437a-473d-b4ae-2101ab233948_terseLabel_en-US" xlink:label="lab_rxrx_StockIssuanceCostsNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred issuance costs recorded in equity</link:label>
    <link:label id="lab_rxrx_StockIssuanceCostsNoncash_label_en-US" xlink:label="lab_rxrx_StockIssuanceCostsNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Noncash</link:label>
    <link:label id="lab_rxrx_StockIssuanceCostsNoncash_documentation_en-US" xlink:label="lab_rxrx_StockIssuanceCostsNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_StockIssuanceCostsNoncash" xlink:href="rxrx-20210930.xsd#rxrx_StockIssuanceCostsNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_StockIssuanceCostsNoncash" xlink:to="lab_rxrx_StockIssuanceCostsNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_7511ba03-1fa2-44d6-91c4-7f12c312b262_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired based on fair values:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3b5e3a44-b99b-4051-b208-a6d2ed080664_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_fb8bd9f4-fa7b-40fa-a59b-1d41583a004c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6e219f2a-1764-4769-aea0-185d253e354d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6f534ef6-d6cf-475d-b9ac-506d23a0af03_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LaboratoryEquipmentMember_c4ddb9f4-d740-46df-9d12-ce17565d3541_terseLabel_en-US" xlink:label="lab_rxrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_rxrx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_rxrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_rxrx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_rxrx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LaboratoryEquipmentMember" xlink:href="rxrx-20210930.xsd#rxrx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LaboratoryEquipmentMember" xlink:to="lab_rxrx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_WarrantsIssuedInJanuary2020Member_a0fb5a97-160a-42db-a945-22ad638b3e35_terseLabel_en-US" xlink:label="lab_rxrx_WarrantsIssuedInJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued In January 2020</link:label>
    <link:label id="lab_rxrx_WarrantsIssuedInJanuary2020Member_label_en-US" xlink:label="lab_rxrx_WarrantsIssuedInJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued In January 2020 [Member]</link:label>
    <link:label id="lab_rxrx_WarrantsIssuedInJanuary2020Member_documentation_en-US" xlink:label="lab_rxrx_WarrantsIssuedInJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued In January 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsIssuedInJanuary2020Member" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsIssuedInJanuary2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_WarrantsIssuedInJanuary2020Member" xlink:to="lab_rxrx_WarrantsIssuedInJanuary2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_1855aa5e-7d0f-4a50-b0fc-57c24e5d2fc0_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_fd1a4606-8732-45d7-9369-a44315ef6f1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bd862df3-6e0c-47f4-8cf3-6cbd170571a0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3cfa3d24-65c4-4a63-81c8-aa54c855d7cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_08f3c891-ba1b-456f-91dc-944467c771d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_93da9b4c-7505-4d61-b706-17e1f8555e33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_376724f4-04ff-4dbb-96f6-2f18b737eec8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e6dd037b-7bfa-4c5f-b99a-bbfc1564b278_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4d5b9c6d-dc51-41d9-99d9-377cfb6ff4d7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_MilpitasMember_3f2c7bde-4c63-4c85-a095-8b1b0462ef6b_terseLabel_en-US" xlink:label="lab_rxrx_MilpitasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milpitas</link:label>
    <link:label id="lab_rxrx_MilpitasMember_label_en-US" xlink:label="lab_rxrx_MilpitasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milpitas [Member]</link:label>
    <link:label id="lab_rxrx_MilpitasMember_documentation_en-US" xlink:label="lab_rxrx_MilpitasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milpitas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MilpitasMember" xlink:href="rxrx-20210930.xsd#rxrx_MilpitasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_MilpitasMember" xlink:to="lab_rxrx_MilpitasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_eafe95f8-ea21-4abf-a0ad-87fa0d300094_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e1639b94-3196-4669-a655-fb7987df3966_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_A2021EquityIncentivePlanMember_5fc232d7-8db3-432b-8b37-370a5cd6402c_terseLabel_en-US" xlink:label="lab_rxrx_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:label id="lab_rxrx_A2021EquityIncentivePlanMember_label_en-US" xlink:label="lab_rxrx_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_rxrx_A2021EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_rxrx_A2021EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EquityIncentivePlanMember" xlink:href="rxrx-20210930.xsd#rxrx_A2021EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_A2021EquityIncentivePlanMember" xlink:to="lab_rxrx_A2021EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LeaseArrangementNameAxis_dd40e525-daa6-45c8-8068-5c2e2d5b94ea_terseLabel_en-US" xlink:label="lab_rxrx_LeaseArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement Name [Axis]</link:label>
    <link:label id="lab_rxrx_LeaseArrangementNameAxis_label_en-US" xlink:label="lab_rxrx_LeaseArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement Name [Axis]</link:label>
    <link:label id="lab_rxrx_LeaseArrangementNameAxis_documentation_en-US" xlink:label="lab_rxrx_LeaseArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameAxis" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LeaseArrangementNameAxis" xlink:to="lab_rxrx_LeaseArrangementNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_BayerAGMember_43dc60b3-370b-456f-83a7-6a45e2fec8f3_terseLabel_en-US" xlink:label="lab_rxrx_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_rxrx_BayerAGMember_label_en-US" xlink:label="lab_rxrx_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_rxrx_BayerAGMember_documentation_en-US" xlink:label="lab_rxrx_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BayerAGMember" xlink:href="rxrx-20210930.xsd#rxrx_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_BayerAGMember" xlink:to="lab_rxrx_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_436c9e59-bc50-484b-bcfb-7fdc5cfd205a_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a15d3fe2-93a9-4c4f-b3a9-3c6843f77b95_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_8f589a77-8e47-402e-85dc-dcc152d6a41d_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_SupplementalFinancialInformationAbstract_label_en-US" xlink:label="lab_rxrx_SupplementalFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information [Abstract]</link:label>
    <link:label id="lab_rxrx_SupplementalFinancialInformationAbstract_documentation_en-US" xlink:label="lab_rxrx_SupplementalFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract" xlink:to="lab_rxrx_SupplementalFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_a07078a9-0bf6-4bf1-871f-658a9ef01e46_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_87ca0307-9c32-483f-97a0-dcf81695ba91_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_d5be5c97-d8b6-44fc-8dcc-731d42910f3c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_AccruedInvestmentPurchasesCurrent_a690c183-2723-4f3d-8f2d-ce7091f5fb64_terseLabel_en-US" xlink:label="lab_rxrx_AccruedInvestmentPurchasesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued investment purchases</link:label>
    <link:label id="lab_rxrx_AccruedInvestmentPurchasesCurrent_label_en-US" xlink:label="lab_rxrx_AccruedInvestmentPurchasesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Investment Purchases, Current</link:label>
    <link:label id="lab_rxrx_AccruedInvestmentPurchasesCurrent_documentation_en-US" xlink:label="lab_rxrx_AccruedInvestmentPurchasesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Investment Purchases, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedInvestmentPurchasesCurrent" xlink:href="rxrx-20210930.xsd#rxrx_AccruedInvestmentPurchasesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_AccruedInvestmentPurchasesCurrent" xlink:to="lab_rxrx_AccruedInvestmentPurchasesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsDiluted_20861d5f-e1a6-4dee-952e-b6be1e0ce453_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed earnings, diluted</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsDiluted" xlink:to="lab_us-gaap_UndistributedEarningsDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_LongTermDebtMaturityAfterYearFour_be04e3c8-2775-45c2-8da1-89535c7a7fbd_terseLabel_en-US" xlink:label="lab_rxrx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_rxrx_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_rxrx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_rxrx_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_rxrx_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LongTermDebtMaturityAfterYearFour" xlink:href="rxrx-20210930.xsd#rxrx_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_LongTermDebtMaturityAfterYearFour" xlink:to="lab_rxrx_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_2df95046-ab3f-4f49-ae32-447d64e197e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e950c9c6-ddb4-4ab5-8efb-ab02d24e32fe_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rxrx_ConvertibleSeriesBPreferredStockMember_78308816-1a45-4456-857b-ed31c7cccc27_terseLabel_en-US" xlink:label="lab_rxrx_ConvertibleSeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesBPreferredStockMember_label_en-US" xlink:label="lab_rxrx_ConvertibleSeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series B Preferred Stock [Member]</link:label>
    <link:label id="lab_rxrx_ConvertibleSeriesBPreferredStockMember_documentation_en-US" xlink:label="lab_rxrx_ConvertibleSeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Series B Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesBPreferredStockMember" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rxrx_ConvertibleSeriesBPreferredStockMember" xlink:to="lab_rxrx_ConvertibleSeriesBPreferredStockMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rxrx-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bb127273-35b3-457d-ab21-bda4843992dc,g:487b784e-5d7c-455e-b63d-c9a591fced83-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.recursion.com/role/CoverPage" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f2520530-9b65-47e7-9399-67070e87e1a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f2520530-9b65-47e7-9399-67070e87e1a8" xlink:to="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c8761540-67fa-44a8-bb91-5b219ad8aa4f" xlink:to="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_44634aae-fa2e-425b-a698-52e0d789d849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:to="loc_us-gaap_CommonClassAMember_44634aae-fa2e-425b-a698-52e0d789d849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_948e7472-cab9-4382-9aa1-b0cf011d0e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_82e13e94-dd9b-4e69-8eaa-766600b98b9f" xlink:to="loc_us-gaap_CommonClassBMember_948e7472-cab9-4382-9aa1-b0cf011d0e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_4af3d576-032b-456f-abed-330b3530d3f6" xlink:to="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7d6627d0-dde3-4332-b957-a18c8ea40f29" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentType_7d6627d0-dde3-4332-b957-a18c8ea40f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_50dd4693-b7ec-4bbe-b583-e59d4cd014b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentQuarterlyReport_50dd4693-b7ec-4bbe-b583-e59d4cd014b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc77f3d5-2b19-46a1-ae13-c094b22227ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentPeriodEndDate_fc77f3d5-2b19-46a1-ae13-c094b22227ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3529df05-0afd-47da-b8ef-06623be5e4ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentTransitionReport_3529df05-0afd-47da-b8ef-06623be5e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7961c051-1346-4d05-89a3-e32eaa5d04b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityFileNumber_7961c051-1346-4d05-89a3-e32eaa5d04b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b4b3f3e7-42ad-4790-808d-dbbac1415ce6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityRegistrantName_b4b3f3e7-42ad-4790-808d-dbbac1415ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5bcfd748-ab02-4bb4-b77f-42683610debf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5bcfd748-ab02-4bb4-b77f-42683610debf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3468128d-4dee-419a-930c-54604bda5f3f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityTaxIdentificationNumber_3468128d-4dee-419a-930c-54604bda5f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_57f514eb-f4fd-4c53-9081-eb9253d38dc5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressAddressLine1_57f514eb-f4fd-4c53-9081-eb9253d38dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_91ea46c1-c8ac-4fa5-9eba-bddb3e7df17f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressCityOrTown_91ea46c1-c8ac-4fa5-9eba-bddb3e7df17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_912b6a36-df7f-4eb7-aa74-ac8260ae732c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressStateOrProvince_912b6a36-df7f-4eb7-aa74-ac8260ae732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6ac9f6ab-7b7e-4a08-86ee-b7020d7f5646" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityAddressPostalZipCode_6ac9f6ab-7b7e-4a08-86ee-b7020d7f5646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8ea6dbed-6699-4ed9-afee-97c7f566f8ec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_CityAreaCode_8ea6dbed-6699-4ed9-afee-97c7f566f8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cdc6e65d-ad60-4289-8d47-edcc56ea0d0a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_LocalPhoneNumber_cdc6e65d-ad60-4289-8d47-edcc56ea0d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_63ef779c-3572-465f-9877-a0461719819c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_Security12bTitle_63ef779c-3572-465f-9877-a0461719819c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ff69e661-4fd6-4d99-97c2-c6e42061c008" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_TradingSymbol_ff69e661-4fd6-4d99-97c2-c6e42061c008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e96c02e7-8afc-44b2-b092-c8d1d0a55156" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_SecurityExchangeName_e96c02e7-8afc-44b2-b092-c8d1d0a55156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7e0170a8-b2b6-498a-a0ad-ed0a19236bb1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityCurrentReportingStatus_7e0170a8-b2b6-498a-a0ad-ed0a19236bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_63ea4aad-fdd1-485f-a974-85fe5780c7f9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityInteractiveDataCurrent_63ea4aad-fdd1-485f-a974-85fe5780c7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_342bf806-7d11-4f24-bf2a-7cc7563f0cc5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityFilerCategory_342bf806-7d11-4f24-bf2a-7cc7563f0cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9fef2fb9-07e7-4822-a034-ce41bcd80d95" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntitySmallBusiness_9fef2fb9-07e7-4822-a034-ce41bcd80d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_13258345-7adf-4b06-b36f-8f577a4ae74b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityEmergingGrowthCompany_13258345-7adf-4b06-b36f-8f577a4ae74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_d044bad9-d81b-4379-8f30-6f4f189957cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityExTransitionPeriod_d044bad9-d81b-4379-8f30-6f4f189957cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cfa036ba-2f60-40d2-bb35-6cb188df9d19" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityShellCompany_cfa036ba-2f60-40d2-bb35-6cb188df9d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5f0169dd-d38b-424f-b1fc-24984d9f3071" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5f0169dd-d38b-424f-b1fc-24984d9f3071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b8604bc5-0f36-4e96-8695-567142eb0d36" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_EntityCentralIndexKey_b8604bc5-0f36-4e96-8695-567142eb0d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1c95b2da-8612-45a9-82ea-68ef834d15b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_AmendmentFlag_1c95b2da-8612-45a9-82ea-68ef834d15b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a2b55972-61c4-48aa-a35a-44c49b6da9b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentFiscalYearFocus_a2b55972-61c4-48aa-a35a-44c49b6da9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fe7cbc09-eae3-4eb2-9103-02b38195f301" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fe7cbc09-eae3-4eb2-9103-02b38195f301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4e45d1d4-a268-43bb-9f96-87f1c5451347" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_248cda97-4f78-4a4b-bd5f-4ed7607d4100" xlink:to="loc_dei_CurrentFiscalYearEndDate_4e45d1d4-a268-43bb-9f96-87f1c5451347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_edd3d79d-a94a-4c1c-9835-3e527ac4ccd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd3d79d-a94a-4c1c-9835-3e527ac4ccd4" xlink:to="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:to="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e41de25-4292-4c3a-a2df-52ad244e5c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e41de25-4292-4c3a-a2df-52ad244e5c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_08c2f2f3-bbb0-4244-940d-c43179b92ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_RestrictedCashCurrent_08c2f2f3-bbb0-4244-940d-c43179b92ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_489d4061-7e51-416c-b006-e8a1f322c91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_489d4061-7e51-416c-b006-e8a1f322c91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_9a71256f-5919-4eb9-957f-07563a67caeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_9a71256f-5919-4eb9-957f-07563a67caeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2c8d9a53-241a-4e0e-b69a-18e527459e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_ShortTermInvestments_2c8d9a53-241a-4e0e-b69a-18e527459e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b5e84802-ce04-4de9-9965-a43d7466a9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_OtherAssetsCurrent_b5e84802-ce04-4de9-9965-a43d7466a9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_263c6753-f6f8-444d-be0c-9f2817200e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_78646501-0bb1-426f-9917-7805969e2159" xlink:to="loc_us-gaap_AssetsCurrent_263c6753-f6f8-444d-be0c-9f2817200e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_240a4e92-38e0-48dc-94ee-d57d99894b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_240a4e92-38e0-48dc-94ee-d57d99894b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ae0f6901-e0cd-426d-a3c7-c8257ad8b79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_ae0f6901-e0cd-426d-a3c7-c8257ad8b79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dda3e12f-e7fc-4dc5-b171-245499fac9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dda3e12f-e7fc-4dc5-b171-245499fac9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_566ce2a7-9c63-4532-bee6-6c3c6c8a4430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_717b1475-3723-4cce-9e5e-5f0b56269d04" xlink:to="loc_us-gaap_Assets_566ce2a7-9c63-4532-bee6-6c3c6c8a4430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_edd3d79d-a94a-4c1c-9835-3e527ac4ccd4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_54407736-63a5-42cd-81d0-f4d99022d6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:to="loc_us-gaap_AccountsPayableCurrent_54407736-63a5-42cd-81d0-f4d99022d6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d7941e2c-8806-4736-9bc4-db6469f4c696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d7941e2c-8806-4736-9bc4-db6469f4c696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f3b15d6-9542-49a5-9d9e-5effbb2014ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f3b15d6-9542-49a5-9d9e-5effbb2014ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_611680e7-6b4f-4788-94aa-28a8f6650922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:to="loc_us-gaap_NotesPayableCurrent_611680e7-6b4f-4788-94aa-28a8f6650922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_025bb94e-22c2-45ca-8850-a4513574826c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_025bb94e-22c2-45ca-8850-a4513574826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63104e50-5c83-4667-b4ed-9b6bcfdbd3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_119d4c78-a39c-4cc3-8483-e979062769fb" xlink:to="loc_us-gaap_LiabilitiesCurrent_63104e50-5c83-4667-b4ed-9b6bcfdbd3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_1588a290-96ba-45be-9781-3bf720c45795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_1588a290-96ba-45be-9781-3bf720c45795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5e549740-314a-4298-9092-ffe76eb2b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5e549740-314a-4298-9092-ffe76eb2b70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_746ab24a-d812-4373-b2e5-14332203b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_LongTermNotesPayable_746ab24a-d812-4373-b2e5-14332203b26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseIncentivePayableNoncurrent_d8842b98-b8d0-4d3c-aa8b-03aac9d678d2" xlink:href="rxrx-20210930.xsd#rxrx_LeaseIncentivePayableNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_rxrx_LeaseIncentivePayableNoncurrent_d8842b98-b8d0-4d3c-aa8b-03aac9d678d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3be87670-26c1-4320-add5-c16469d01bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_Liabilities_3be87670-26c1-4320-add5-c16469d01bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5798e9cc-6457-45ac-8dcc-fe212b3761ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5798e9cc-6457-45ac-8dcc-fe212b3761ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8667f760-74f5-44b2-931a-c302be5025a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_8667f760-74f5-44b2-931a-c302be5025a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9c5dae3f-db69-4699-936f-0e28ea60ec13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:to="loc_us-gaap_CommonStockValue_9c5dae3f-db69-4699-936f-0e28ea60ec13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f4a13097-37bf-4deb-8343-a1391d25eefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f4a13097-37bf-4deb-8343-a1391d25eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c90a4694-230b-433c-924c-5369c620d54a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c90a4694-230b-433c-924c-5369c620d54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9b47a19d-f490-4833-bab3-426c4fb87260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9b47a19d-f490-4833-bab3-426c4fb87260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1315fd0c-9157-4630-9ced-f7a832b11881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e3a7420f-914f-4516-85c3-622ac808cc3c" xlink:to="loc_us-gaap_StockholdersEquity_1315fd0c-9157-4630-9ced-f7a832b11881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f72f9c0d-2aeb-4c94-b523-950dae6cd683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2bc1da7a-d30a-4902-b6c3-db4719acc9ac" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f72f9c0d-2aeb-4c94-b523-950dae6cd683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_143c0460-11e8-4b8d-9f0a-2079fe2d4b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_143c0460-11e8-4b8d-9f0a-2079fe2d4b5b" xlink:to="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_9da01e7c-6194-4a50-b1a3-38bf9a3c44d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_9da01e7c-6194-4a50-b1a3-38bf9a3c44d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_df9dcb5d-2935-477b-b764-28c85faf9c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_df9dcb5d-2935-477b-b764-28c85faf9c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_a59b60e9-0785-4383-98a3-f1b6f1d447e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_a59b60e9-0785-4383-98a3-f1b6f1d447e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d58e13da-0050-4c67-a28a-fc400e046d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_d58e13da-0050-4c67-a28a-fc400e046d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_77a95029-e78d-4006-9fba-5d05c1848848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_a862dc43-07a2-437a-893c-99970d58b080" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_77a95029-e78d-4006-9fba-5d05c1848848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3164dd94-c73c-405b-987b-7137fdabc05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_143c0460-11e8-4b8d-9f0a-2079fe2d4b5b" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3164dd94-c73c-405b-987b-7137fdabc05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3164dd94-c73c-405b-987b-7137fdabc05c" xlink:to="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f3c3244a-67a8-430c-952b-39fdb163179a" xlink:to="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3637cdf6-5035-4031-9d97-e32faeb7db0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:to="loc_us-gaap_CommonClassAMember_3637cdf6-5035-4031-9d97-e32faeb7db0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0cf5dd4c-60cf-42f1-bbf5-4c23b9a6a19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_840b68b0-237d-4226-bc95-e37c84c0ecb7" xlink:to="loc_us-gaap_CommonClassBMember_0cf5dd4c-60cf-42f1-bbf5-4c23b9a6a19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_05a1955e-06e9-4bc0-9639-088b11715069" xlink:to="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e53cbfb-dd4b-42ad-8a94-358329f0aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e53cbfb-dd4b-42ad-8a94-358329f0aeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_52e135a4-256a-47d3-9e0b-522ffc318fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_52e135a4-256a-47d3-9e0b-522ffc318fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_16f8a238-29e0-431a-9cf5-8628ca12e6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockSharesIssued_16f8a238-29e0-431a-9cf5-8628ca12e6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6b0b4d96-3ba8-4009-96b9-5f73ae021f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bc736c67-c170-4f06-a994-6b5dc278bccd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6b0b4d96-3ba8-4009-96b9-5f73ae021f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_597ea680-808d-4416-b699-cbd635dc9102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_597ea680-808d-4416-b699-cbd635dc9102" xlink:to="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:to="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_94d158d7-1d28-4342-a57f-243bfd2e41e0" xlink:to="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_e7d1ad5a-e236-4b81-908f-27befc642656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:to="loc_us-gaap_GrantMember_e7d1ad5a-e236-4b81-908f-27befc642656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_2c6a5f70-6af2-4463-8ae8-e808750c2fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c29cdb0-b6fb-4903-ae1c-1db03635f0da" xlink:to="loc_us-gaap_LicenseAndServiceMember_2c6a5f70-6af2-4463-8ae8-e808750c2fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9a615665-de9a-4944-98bd-c6d1eeeb8018" xlink:to="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d8f7f77d-230b-42ca-9ee0-8475a37a084e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_RevenuesAbstract_d8f7f77d-230b-42ca-9ee0-8475a37a084e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9af5a6-a716-4e78-9517-da0996fbb704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d8f7f77d-230b-42ca-9ee0-8475a37a084e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d9af5a6-a716-4e78-9517-da0996fbb704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_183fc040-cfa9-4605-bd04-a38e562340b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_183fc040-cfa9-4605-bd04-a38e562340b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1ef6dbc6-ff57-4925-ab47-cbee8e7fbef6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1ef6dbc6-ff57-4925-ab47-cbee8e7fbef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d5cbf547-66ef-4e68-bef2-d9cec528c007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c0df09fe-0cdd-443a-b7f9-7466af639ac7" xlink:to="loc_us-gaap_OperatingExpenses_d5cbf547-66ef-4e68-bef2-d9cec528c007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96d2c3d2-7081-4bf0-a4b7-4bceaabfbab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_OperatingIncomeLoss_96d2c3d2-7081-4bf0-a4b7-4bceaabfbab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4e75d5e7-1634-4340-9a78-f7ee8c938445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4e75d5e7-1634-4340-9a78-f7ee8c938445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_707ab1e8-7c2f-4e47-a448-e743371f3328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_NetIncomeLoss_707ab1e8-7c2f-4e47-a448-e743371f3328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3d551869-01a7-4a7a-bd37-99ca5c8f959f" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d7e9d89d-9e30-4a2b-8bcd-5db81be09e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_EarningsPerShareBasic_d7e9d89d-9e30-4a2b-8bcd-5db81be09e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_60552a70-5c46-45ba-9d02-8c77a0458084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_60552a70-5c46-45ba-9d02-8c77a0458084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31313ba0-9149-4f29-9546-c9968cd0edeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31313ba0-9149-4f29-9546-c9968cd0edeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4bb673d-7a3a-448b-82a4-2cc3a4ed0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6bce6aba-60c9-48ed-bf50-a4ec25e6562b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4bb673d-7a3a-448b-82a4-2cc3a4ed0ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6631d8-ab38-4eb2-b595-42b21caaf6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_064b8021-c24d-42a8-8e3d-14581a695792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6631d8-ab38-4eb2-b595-42b21caaf6cd" xlink:to="loc_us-gaap_NetIncomeLoss_064b8021-c24d-42a8-8e3d-14581a695792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6599094d-6ef3-4faa-becf-0980a7b163b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6631d8-ab38-4eb2-b595-42b21caaf6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6599094d-6ef3-4faa-becf-0980a7b163b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_406a7401-43de-49b6-8b24-29320ee06458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6631d8-ab38-4eb2-b595-42b21caaf6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_406a7401-43de-49b6-8b24-29320ee06458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f7f63ade-a319-43f9-a324-a3c7a6e6110f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6631d8-ab38-4eb2-b595-42b21caaf6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f7f63ade-a319-43f9-a324-a3c7a6e6110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0682831c-a53b-4213-82d9-bd01e4d60467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6631d8-ab38-4eb2-b595-42b21caaf6cd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0682831c-a53b-4213-82d9-bd01e4d60467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e0a39c56-e72e-4b38-a1f2-dde00d49a6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e0a39c56-e72e-4b38-a1f2-dde00d49a6f7" xlink:to="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d8ef121-e2f4-42ca-b6de-886312d1fbdf" xlink:to="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c1c7c275-591e-4242-b38d-39f6273bdb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_CommonStockMember_c1c7c275-591e-4242-b38d-39f6273bdb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_98993835-0cf3-4edc-a4b9-4308fe56096c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_98993835-0cf3-4edc-a4b9-4308fe56096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_33bd722a-7484-486b-8ca8-ef68bb73aba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_RetainedEarningsMember_33bd722a-7484-486b-8ca8-ef68bb73aba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b4e1b8a0-83e4-4fbe-9613-f152dc6e1a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05e3eba6-eee3-4b5d-8900-765d81c116be" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b4e1b8a0-83e4-4fbe-9613-f152dc6e1a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_24a99793-e33f-4277-9a96-89604db1d24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dcf45b7f-c2bd-4dd2-890c-a113d672aff4" xlink:to="loc_us-gaap_ClassOfStockDomain_24a99793-e33f-4277-9a96-89604db1d24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b06bc6d1-4d0e-4361-ad98-47b709cb288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_24a99793-e33f-4277-9a96-89604db1d24c" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b06bc6d1-4d0e-4361-ad98-47b709cb288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_92424210-ed07-41ba-a8ad-666ddc368d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_04848990-33e4-4135-bbe6-66884e0e6369" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_92424210-ed07-41ba-a8ad-666ddc368d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SeriesAAndSeriesBWarrantsMember_ec7830ad-59bf-43d0-8d94-032c23a8a30e" xlink:href="rxrx-20210930.xsd#rxrx_SeriesAAndSeriesBWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92424210-ed07-41ba-a8ad-666ddc368d7c" xlink:to="loc_rxrx_SeriesAAndSeriesBWarrantsMember_ec7830ad-59bf-43d0-8d94-032c23a8a30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06397e0e-38fd-4a48-931a-ade1ab2ffe04" xlink:to="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_89cbeebe-901e-46ed-8d75-2144da66c2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_89cbeebe-901e-46ed-8d75-2144da66c2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6b79edc4-35c0-4ee0-9ecc-53811a1bd814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6b79edc4-35c0-4ee0-9ecc-53811a1bd814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_81ce9594-74c0-47c8-86bd-2208fb40d079" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities_81ce9594-74c0-47c8-86bd-2208fb40d079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_9be820ba-e2df-446e-80cd-0654cfcf5a32" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities_9be820ba-e2df-446e-80cd-0654cfcf5a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4a2b96b3-e45e-48f0-a965-81ac6719db9d" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4a2b96b3-e45e-48f0-a965-81ac6719db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d3c8d9c1-cb03-4f2b-9364-d8b34a8aa1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_d3c8d9c1-cb03-4f2b-9364-d8b34a8aa1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b520f0c5-33c6-4557-8b7a-29296d546c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_b520f0c5-33c6-4557-8b7a-29296d546c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_59c2d449-5f91-469f-8150-9c3a0896cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_868326ea-1fce-4bed-839b-622b1208cb61" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_59c2d449-5f91-469f-8150-9c3a0896cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423fc1f9-8fb3-45d7-81ad-20836a29902b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8f81d53c-6061-4cb8-86de-ee5f066fa0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8f81d53c-6061-4cb8-86de-ee5f066fa0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_72ec2936-1695-464c-8457-e2f739882e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockholdersEquity_72ec2936-1695-464c-8457-e2f739882e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b89561be-144f-465e-9f2c-d6451901ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_NetIncomeLoss_b89561be-144f-465e-9f2c-d6451901ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c834d7-a7e3-45ad-93be-5122de46e984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c834d7-a7e3-45ad-93be-5122de46e984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c07092d-d052-458a-b0d7-55fc44ff096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8c07092d-d052-458a-b0d7-55fc44ff096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c6bf818b-d508-49b5-bca9-95ed7e4f4be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c6bf818b-d508-49b5-bca9-95ed7e4f4be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_82b96184-0726-401f-b90c-c50cbf8897d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_82b96184-0726-401f-b90c-c50cbf8897d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_681310b3-1a14-4500-af4a-f8e861b10535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_681310b3-1a14-4500-af4a-f8e861b10535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f372f6f-dcac-429e-8d1b-fef9ecf2d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f372f6f-dcac-429e-8d1b-fef9ecf2d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2443f4a-2147-4fdd-8740-d301c3d4deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a2443f4a-2147-4fdd-8740-d301c3d4deb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b4315abe-4b7c-4bff-802f-d04b3577b6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b4315abe-4b7c-4bff-802f-d04b3577b6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3bbd8fc3-41c7-4e33-8793-3cdbbceffac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3bbd8fc3-41c7-4e33-8793-3cdbbceffac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c4c926a1-f808-4a1b-ac78-80ca2566992b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0798cc22-5c45-4ead-9aee-14e377ea81f2" xlink:to="loc_us-gaap_StockholdersEquity_c4c926a1-f808-4a1b-ac78-80ca2566992b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d01e9d46-ea3f-42fe-b5e5-cb9b806fbbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityIssuanceCosts_4f8dedb7-3b39-4399-9934-272faab68a77" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d01e9d46-ea3f-42fe-b5e5-cb9b806fbbf0" xlink:to="loc_rxrx_TemporaryEquityIssuanceCosts_4f8dedb7-3b39-4399-9934-272faab68a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5dd037b-0f0b-44ca-8ac6-58c57295d481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5dd037b-0f0b-44ca-8ac6-58c57295d481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6797ed12-62e2-4b8b-b848-ca6905a6d567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5dd037b-0f0b-44ca-8ac6-58c57295d481" xlink:to="loc_us-gaap_NetIncomeLoss_6797ed12-62e2-4b8b-b848-ca6905a6d567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5dd037b-0f0b-44ca-8ac6-58c57295d481" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98e0ff5f-6744-4a5c-b961-ef14643a16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98e0ff5f-6744-4a5c-b961-ef14643a16a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_21bbe9db-52ee-4b9e-a5dc-8648b70baa19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:to="loc_us-gaap_ShareBasedCompensation_21bbe9db-52ee-4b9e-a5dc-8648b70baa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e2ec7356-1fbe-48e6-9e9e-29b7acadfa16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:to="loc_us-gaap_AssetImpairmentCharges_e2ec7356-1fbe-48e6-9e9e-29b7acadfa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_54d08de1-0490-4ff6-8f0c-74cb0f01d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_54d08de1-0490-4ff6-8f0c-74cb0f01d51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_81d95a28-1512-4c5e-8398-f20c386fa6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_81d95a28-1512-4c5e-8398-f20c386fa6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c855f866-fa34-4185-b76d-9dd38e72cd32" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_364c9a77-3aa7-49ac-a9d1-928b3eea5fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_364c9a77-3aa7-49ac-a9d1-928b3eea5fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9d6e7c3b-213f-4d6b-9056-1aed2604db88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9d6e7c3b-213f-4d6b-9056-1aed2604db88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6edf96f2-77ae-4db4-b14c-db5c204359be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6edf96f2-77ae-4db4-b14c-db5c204359be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef9a9324-ffbb-40fc-bd73-bf9a2e5d14f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ef9a9324-ffbb-40fc-bd73-bf9a2e5d14f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_5478d317-a977-4b33-b93f-d9c08d012636" xlink:href="rxrx-20210930.xsd#rxrx_IncreaseDecreaseInAccruedDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:to="loc_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense_5478d317-a977-4b33-b93f-d9c08d012636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c0e8e4c4-d0c6-4f74-94cb-71b13b51158b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_47fa86b0-0363-45c4-a598-102272ad5220" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_c0e8e4c4-d0c6-4f74-94cb-71b13b51158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d89d355b-9ee5-4585-9621-541ebb07bf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5dd037b-0f0b-44ca-8ac6-58c57295d481" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d89d355b-9ee5-4585-9621-541ebb07bf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e3b0bca-fea9-43a0-9611-7894b6ae28b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6e3b0bca-fea9-43a0-9611-7894b6ae28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8252aec4-cb49-4f66-90f8-b5032bad4e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8252aec4-cb49-4f66-90f8-b5032bad4e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_74b7910b-9437-4f30-8729-949e9424ebc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_74b7910b-9437-4f30-8729-949e9424ebc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_8966a65c-ac70-4fdf-af31-38da661f6083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_8966a65c-ac70-4fdf-af31-38da661f6083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cbd895e-bb49-43cb-8dc8-04673a9789ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d7d7df3b-232c-4777-9de6-d393d9bfd463" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cbd895e-bb49-43cb-8dc8-04673a9789ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ca9af4ff-7af1-47ca-916c-feca85a3c943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_ca9af4ff-7af1-47ca-916c-feca85a3c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_013027f6-e5b6-4e10-8b52-2338bc677154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_013027f6-e5b6-4e10-8b52-2338bc677154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_69e1495d-acca-45dd-91e9-50672e6c343c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_69e1495d-acca-45dd-91e9-50672e6c343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cfbd98cf-7081-45ef-8405-a8fda4f34270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cfbd98cf-7081-45ef-8405-a8fda4f34270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1bf9dcbb-1584-4abe-8ed7-e71e56c9f5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1bf9dcbb-1584-4abe-8ed7-e71e56c9f5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a72d4ac-73ef-491c-a552-32ca58d9965a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9c8907d7-1bbb-40ca-99f5-e4dd182449df" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a72d4ac-73ef-491c-a552-32ca58d9965a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71183d68-931b-42cc-a49d-30231466e0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71183d68-931b-42cc-a49d-30231466e0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f52f8e4-6f84-44ac-bced-fa9df77478d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f52f8e4-6f84-44ac-bced-fa9df77478d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9150b65-bff5-4148-bf2a-3eb793f68b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9150b65-bff5-4148-bf2a-3eb793f68b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0f25541-d8f9-4b29-bc1c-06a761445f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0f25541-d8f9-4b29-bc1c-06a761445f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_529a6a09-a759-4e6e-974e-53491af09372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0f25541-d8f9-4b29-bc1c-06a761445f40" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_529a6a09-a759-4e6e-974e-53491af09372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_10ba02e6-d6a4-48f3-afce-7c225ed49be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0f25541-d8f9-4b29-bc1c-06a761445f40" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_10ba02e6-d6a4-48f3-afce-7c225ed49be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_StockIssuanceCostsNoncash_fc138648-506d-4b40-b299-a694e91677e0" xlink:href="rxrx-20210930.xsd#rxrx_StockIssuanceCostsNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0f25541-d8f9-4b29-bc1c-06a761445f40" xlink:to="loc_rxrx_StockIssuanceCostsNoncash_fc138648-506d-4b40-b299-a694e91677e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c7711700-3b66-493a-b039-e29351a71d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e0f25541-d8f9-4b29-bc1c-06a761445f40" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c7711700-3b66-493a-b039-e29351a71d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f55ab19-5765-446c-afdc-e3bdb34405e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c1064cc8-6c69-4cae-a319-3b738090bfa5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f55ab19-5765-446c-afdc-e3bdb34405e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ed106914-d6de-4fe3-b30b-12cea2b55ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f55ab19-5765-446c-afdc-e3bdb34405e5" xlink:to="loc_us-gaap_InterestPaidNet_ed106914-d6de-4fe3-b30b-12cea2b55ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="rxrx-20210930.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cebba798-6da8-49d2-bacf-e219a7a6c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_8fa83d4f-59d0-4de9-9c94-0cd552e5f509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cebba798-6da8-49d2-bacf-e219a7a6c5bf" xlink:to="loc_us-gaap_NatureOfOperations_8fa83d4f-59d0-4de9-9c94-0cd552e5f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#DescriptionoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ffe1f5f-cc5b-4d50-bbb2-b9e518fc9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f557e6b0-1641-4bbd-b6dd-55c1f0acab35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ffe1f5f-cc5b-4d50-bbb2-b9e518fc9b79" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f557e6b0-1641-4bbd-b6dd-55c1f0acab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/BasisofPresentation" xlink:type="simple" xlink:href="rxrx-20210930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e7535c37-7921-4a01-9e5e-a5ab55676b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_06d58c5d-4094-492b-b28b-2728039ffcae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e7535c37-7921-4a01-9e5e-a5ab55676b56" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_06d58c5d-4094-492b-b28b-2728039ffcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="rxrx-20210930.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b311f271-6f3c-4838-bd20-4305fca2cfff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d9d16d1c-664f-4442-9efb-7c98745db10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b311f271-6f3c-4838-bd20-4305fca2cfff" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d9d16d1c-664f-4442-9efb-7c98745db10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f39a2cd-8f00-4891-ac0a-fd1ed28a64cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b311f271-6f3c-4838-bd20-4305fca2cfff" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7f39a2cd-8f00-4891-ac0a-fd1ed28a64cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/BasisofPresentationDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#BasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/BasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe4d06ef-696a-435a-8eb8-3ef16fad0fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe4d06ef-696a-435a-8eb8-3ef16fad0fa4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46834675-e3c2-4619-a1b3-b0a754bf4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c8dbf1f-7854-4a01-b157-9168e3d46ceb" xlink:to="loc_us-gaap_EquityComponentDomain_46834675-e3c2-4619-a1b3-b0a754bf4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_705f1e63-ebc9-48c8-bea2-e967d47876cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_46834675-e3c2-4619-a1b3-b0a754bf4cf0" xlink:to="loc_us-gaap_CommonStockMember_705f1e63-ebc9-48c8-bea2-e967d47876cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f0ee95bd-f47a-4143-bb16-eb04928a8c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_043eed19-30e5-4eba-bad9-d3ee5d80435a" xlink:to="loc_us-gaap_ClassOfStockLineItems_f0ee95bd-f47a-4143-bb16-eb04928a8c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2204c9c3-ea3b-4f57-b61b-adc30fa076a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f0ee95bd-f47a-4143-bb16-eb04928a8c9f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2204c9c3-ea3b-4f57-b61b-adc30fa076a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/Acquisitions" xlink:type="simple" xlink:href="rxrx-20210930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9e3bd4d5-e5ea-4d95-8e9e-f5b805bf5c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e0026ca1-ae4c-4aea-ac0b-febe5ec1e19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9e3bd4d5-e5ea-4d95-8e9e-f5b805bf5c8b" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e0026ca1-ae4c-4aea-ac0b-febe5ec1e19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a9361eaa-57ad-4915-bab2-308c687679db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_aa6b0220-829f-4f8e-a91c-3e115f44a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a9361eaa-57ad-4915-bab2-308c687679db" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_aa6b0220-829f-4f8e-a91c-3e115f44a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/AcquisitionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#AcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/AcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6d387c19-3255-4af3-9922-113ae9174723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6d387c19-3255-4af3-9922-113ae9174723" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a167d3f-c851-4943-877c-c0281657aee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38adf8aa-cc95-444e-9b80-fc3efa3bd6cc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a167d3f-c851-4943-877c-c0281657aee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ViumIncMember_3c51f2b8-abd3-4b7a-9136-9ba1757c23fb" xlink:href="rxrx-20210930.xsd#rxrx_ViumIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4a167d3f-c851-4943-877c-c0281657aee3" xlink:to="loc_rxrx_ViumIncMember_3c51f2b8-abd3-4b7a-9136-9ba1757c23fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf9f9481-3029-47d2-8495-b97fd1b627fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b0cbfbad-2b11-48d3-a284-481f777ca452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf9f9481-3029-47d2-8495-b97fd1b627fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fde43839-2407-43fd-8a39-c4ab0fbd7522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf9f9481-3029-47d2-8495-b97fd1b627fc" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_fde43839-2407-43fd-8a39-c4ab0fbd7522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b19be3f-e5b3-4f86-8f26-bac0b122e65b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bd1d13b3-c67f-46b2-b4b7-d59cd2cadbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bd1d13b3-c67f-46b2-b4b7-d59cd2cadbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_798583e7-c7b2-40f7-b0f7-399feaffacb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_798583e7-c7b2-40f7-b0f7-399feaffacb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_53e716b1-28e4-4c4c-addf-acaf78e89224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_53e716b1-28e4-4c4c-addf-acaf78e89224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a29fcd54-dfa8-4fff-b8b6-d15451903199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a29fcd54-dfa8-4fff-b8b6-d15451903199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3f24be0c-a3b3-4943-84e5-bedf0e2e8cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3f24be0c-a3b3-4943-84e5-bedf0e2e8cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ae64d515-d112-4b99-87f6-0ac5d027d053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ae64d515-d112-4b99-87f6-0ac5d027d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_86d5b569-47dc-4cbe-a63f-2a8710862f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_86d5b569-47dc-4cbe-a63f-2a8710862f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_576c55d3-1cbd-41cb-b901-8476b183516c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_Goodwill_576c55d3-1cbd-41cb-b901-8476b183516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2276cb55-b237-4278-9d41-f5ce6ba8d772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_c9de02cf-1ae3-4c0a-9cfd-53530cbbed15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2276cb55-b237-4278-9d41-f5ce6ba8d772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_956ff3c8-2986-4707-a0a0-884fba9f93cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0ab7fbe4-99bd-4d6f-a12b-9d624571eab1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_956ff3c8-2986-4707-a0a0-884fba9f93cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformation" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_700e2a35-7735-4d40-9544-338c48200b6b" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_0005d709-0dda-4455-b164-540b18427254" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_700e2a35-7735-4d40-9544-338c48200b6b" xlink:to="loc_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock_0005d709-0dda-4455-b164-540b18427254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_d4564278-85b6-4d77-b5da-c21d889f0955" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e1415ee-b655-4a1b-a6e1-c78f4be55e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_d4564278-85b6-4d77-b5da-c21d889f0955" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e1415ee-b655-4a1b-a6e1-c78f4be55e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8118b9f1-e594-4e40-98fd-93e7874bc565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_d4564278-85b6-4d77-b5da-c21d889f0955" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8118b9f1-e594-4e40-98fd-93e7874bc565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_179b8a9a-0891-4dc9-808f-36fde6d4627f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_d4564278-85b6-4d77-b5da-c21d889f0955" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_179b8a9a-0891-4dc9-808f-36fde6d4627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationPPEDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_35cffce3-bb79-46e6-bde7-cbe6f98d6041" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_35cffce3-bb79-46e6-bde7-cbe6f98d6041" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2849e318-1db9-41a9-ac57-7aa2278b7084" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LaboratoryEquipmentMember_690f02ae-c6a4-42ef-9356-7b33962fdd09" xlink:href="rxrx-20210930.xsd#rxrx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_rxrx_LaboratoryEquipmentMember_690f02ae-c6a4-42ef-9356-7b33962fdd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e67b5156-e824-4d05-900c-f86cabb127d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e67b5156-e824-4d05-900c-f86cabb127d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_d3c425a2-273a-4a27-95a3-46989749ca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_us-gaap_OfficeEquipmentMember_d3c425a2-273a-4a27-95a3-46989749ca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetUnderConstructionMember_8c289dd2-db30-480d-92e7-e15030ccc20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetUnderConstructionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_24ca5224-5cee-4210-a699-df7cd128d3eb" xlink:to="loc_us-gaap_AssetUnderConstructionMember_8c289dd2-db30-480d-92e7-e15030ccc20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a347882-a7f5-4186-ad41-aa97e548cb11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8443b35f-e38b-4338-b42b-1e094cdf3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8443b35f-e38b-4338-b42b-1e094cdf3c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d0b6adb-2e8a-4c89-b012-7ad468717589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d0b6adb-2e8a-4c89-b012-7ad468717589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f335b805-c04b-4c6c-9281-914584df3309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f335b805-c04b-4c6c-9281-914584df3309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e62bc4b0-19c6-4de4-9ee5-5320d0ae7a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_Depreciation_e62bc4b0-19c6-4de4-9ee5-5320d0ae7a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_bc32fdca-364e-499e-8f2f-6b791485cdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0503373-e74f-475d-969f-9daeaca62eb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_bc32fdca-364e-499e-8f2f-6b791485cdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5960f6fb-e920-46a8-83ac-53a0b386ec6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5960f6fb-e920-46a8-83ac-53a0b386ec6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedDevelopmentCostsCurrent_7aaef863-e4eb-473f-8c60-b915d8924187" xlink:href="rxrx-20210930.xsd#rxrx_AccruedDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_rxrx_AccruedDevelopmentCostsCurrent_7aaef863-e4eb-473f-8c60-b915d8924187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_d87a0c38-9698-4d53-b1ed-c004ee7ec8a0" xlink:href="rxrx-20210930.xsd#rxrx_AccruedEarlyDiscoveryExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_rxrx_AccruedEarlyDiscoveryExpensesCurrent_d87a0c38-9698-4d53-b1ed-c004ee7ec8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AccruedInvestmentPurchasesCurrent_91a4d40d-a943-49ec-96a1-326c76e1083d" xlink:href="rxrx-20210930.xsd#rxrx_AccruedInvestmentPurchasesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_rxrx_AccruedInvestmentPurchasesCurrent_91a4d40d-a943-49ec-96a1-326c76e1083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrent_fa0afbfd-c48a-4b0d-b4ad-fd953173a513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_us-gaap_ConstructionPayableCurrent_fa0afbfd-c48a-4b0d-b4ad-fd953173a513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7312428e-e97b-4936-9732-cf0b303c1411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7312428e-e97b-4936-9732-cf0b303c1411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c1531aeb-d18a-43a2-889f-1c6f6b956074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_9dcd7d55-94df-4935-8ad7-e9bdad3cc06f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c1531aeb-d18a-43a2-889f-1c6f6b956074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#SupplementalFinancialInformationInterestDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SupplementalFinancialInformationAbstract_fd741784-1a3a-4fb2-82c9-fee7a20f9417" xlink:href="rxrx-20210930.xsd#rxrx_SupplementalFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_06ef366a-1934-4aa6-a78e-6dd6d1262502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_fd741784-1a3a-4fb2-82c9-fee7a20f9417" xlink:to="loc_us-gaap_InterestExpense_06ef366a-1934-4aa6-a78e-6dd6d1262502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_d4f12aa0-04d7-40ff-9cf1-e6bc3add1834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_fd741784-1a3a-4fb2-82c9-fee7a20f9417" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_d4f12aa0-04d7-40ff-9cf1-e6bc3add1834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_6fe962c3-d88f-415b-a0dc-2dbf5e180981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_SupplementalFinancialInformationAbstract_fd741784-1a3a-4fb2-82c9-fee7a20f9417" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_6fe962c3-d88f-415b-a0dc-2dbf5e180981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/Investments" xlink:type="simple" xlink:href="rxrx-20210930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3bb87868-5bc8-470a-8466-50d379749744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b3d9079a-cc0b-4bad-b8b3-f010fb608180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3bb87868-5bc8-470a-8466-50d379749744" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b3d9079a-cc0b-4bad-b8b3-f010fb608180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4a4069f-7a0e-4776-abca-5c7adf5ebe72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_aa2334bc-08c2-404c-9eb0-ceb48a59f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4a4069f-7a0e-4776-abca-5c7adf5ebe72" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_aa2334bc-08c2-404c-9eb0-ceb48a59f6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3e91e9d6-83c8-49dd-9445-32bdd17443cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4a4069f-7a0e-4776-abca-5c7adf5ebe72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3e91e9d6-83c8-49dd-9445-32bdd17443cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsTypeofSecurityDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/InvestmentsTypeofSecurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4e2b7ba-770b-4cff-8180-012ffe0b2367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f4e2b7ba-770b-4cff-8180-012ffe0b2367" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1ef6ae13-70dc-4353-b2f1-ef39df3e6139" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_434e474c-9b36-4575-95ab-9793a099401c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_us-gaap_MoneyMarketFundsMember_434e474c-9b36-4575-95ab-9793a099401c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CorporateBondsMember_22371a4d-e088-4493-8371-d41211dcee4b" xlink:href="rxrx-20210930.xsd#rxrx_CorporateBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_rxrx_CorporateBondsMember_22371a4d-e088-4493-8371-d41211dcee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_33d8e2b2-3659-4b47-9854-26178e031cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_us-gaap_CertificatesOfDepositMember_33d8e2b2-3659-4b47-9854-26178e031cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_432a3b72-347f-4047-92f4-9b86b5e2360d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fd2ec76-281b-47a8-b04e-b7e75813ac68" xlink:to="loc_us-gaap_CommercialPaperMember_432a3b72-347f-4047-92f4-9b86b5e2360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b2f13e08-e2a2-493a-8802-2a6550f081fb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7502a600-3e04-4995-9df7-6ee8379a8ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7502a600-3e04-4995-9df7-6ee8379a8ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2245ce0c-cc98-4e81-91bf-a5c94e9ed0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2245ce0c-cc98-4e81-91bf-a5c94e9ed0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fb2c746f-b8dc-4ba6-9736-606af4bb9204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fb2c746f-b8dc-4ba6-9736-606af4bb9204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16cec1e-c481-43ed-aba5-1e2e2efd6559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67c810e0-1b6d-4dcd-9ecd-001a12bf8a1e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e16cec1e-c481-43ed-aba5-1e2e2efd6559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsBalanceSheetClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5c8bc402-33c1-4089-9dc0-d5095cffb75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5c8bc402-33c1-4089-9dc0-d5095cffb75b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_409c967f-dd5a-4266-97f8-09549509c587" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_41ec88c3-f066-4c4f-a669-ce34e262b5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_41ec88c3-f066-4c4f-a669-ce34e262b5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_9892cb96-18a4-4b57-bdc9-12e5440abf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4b4205a5-a0e2-4cb6-a490-827c0946e0ff" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_9892cb96-18a4-4b57-bdc9-12e5440abf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1256b73d-3952-41bf-903d-eeb379bf7ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c8f46182-3006-4906-82a1-52cc30d90fef" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1256b73d-3952-41bf-903d-eeb379bf7ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d35ff08a-132d-4b9d-8c9d-fea473e3e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1256b73d-3952-41bf-903d-eeb379bf7ffb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d35ff08a-132d-4b9d-8c9d-fea473e3e9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45beb4ed-f0ff-4cef-909a-c6033245ef76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_af4e292b-447f-421f-9992-1f8277312ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45beb4ed-f0ff-4cef-909a-c6033245ef76" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_af4e292b-447f-421f-9992-1f8277312ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_55124ff1-9249-444c-b3d2-cb0c232f0a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45beb4ed-f0ff-4cef-909a-c6033245ef76" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_55124ff1-9249-444c-b3d2-cb0c232f0a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="rxrx-20210930.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d0fec762-faba-4167-ad13-7bf6382bf6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b4d31711-7d23-4c17-b46e-530691049db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d0fec762-faba-4167-ad13-7bf6382bf6b0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b4d31711-7d23-4c17-b46e-530691049db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43d47f80-3c45-4fb7-862f-d3d35b6ff1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a64a70cf-b529-42b3-a6f7-c02bc1d1f4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43d47f80-3c45-4fb7-862f-d3d35b6ff1db" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a64a70cf-b529-42b3-a6f7-c02bc1d1f4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8c02585b-4b5e-453e-b7b4-41fafada1bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43d47f80-3c45-4fb7-862f-d3d35b6ff1db" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8c02585b-4b5e-453e-b7b4-41fafada1bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#GoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_84ee9e63-d4d3-4601-ad6d-c9ffb2d93387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_Goodwill_84ee9e63-d4d3-4601-ad6d-c9ffb2d93387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_8ff1ec74-1fc7-45dd-810d-33668bc0b718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_8ff1ec74-1fc7-45dd-810d-33668bc0b718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_55b9052c-4380-47f8-8d33-29fa11ba25b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_55b9052c-4380-47f8-8d33-29fa11ba25b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fd49b5af-e0ee-47bd-bb34-283c1f660890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fd49b5af-e0ee-47bd-bb34-283c1f660890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_838c581f-aadc-4dad-aa4f-aaaeaa8cb247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_838c581f-aadc-4dad-aa4f-aaaeaa8cb247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47ca7bcb-ab03-4415-af71-b433867b0f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_47ca7bcb-ab03-4415-af71-b433867b0f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_57ba4f6e-4ad8-4ad1-baa2-02d2d719095b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_57ba4f6e-4ad8-4ad1-baa2-02d2d719095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e0ebe383-5560-4ebf-8a43-d9ffd345ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e0ebe383-5560-4ebf-8a43-d9ffd345ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_da1d2b3d-68cb-4f13-b7fb-a73842492122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_da1d2b3d-68cb-4f13-b7fb-a73842492122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f22a2f5d-0738-4f58-bfa9-5c2e58c6f837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f22a2f5d-0738-4f58-bfa9-5c2e58c6f837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ec515037-1290-4d83-9239-e188995a2b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33a9cf0f-9bc5-4bc8-8709-387a23b52271" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ec515037-1290-4d83-9239-e188995a2b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="rxrx-20210930.xsd#GoodwillandIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayable" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayable"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce10ca6b-2ebd-4151-93db-1b011abb6474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ca455d1a-0c16-4183-b2a6-d1020f278cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce10ca6b-2ebd-4151-93db-1b011abb6474" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ca455d1a-0c16-4183-b2a6-d1020f278cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_76b4890a-c47f-4a94-8b08-868e9272b353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_4b527f39-d1ff-4210-acb4-67023d0161c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76b4890a-c47f-4a94-8b08-868e9272b353" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_4b527f39-d1ff-4210-acb4-67023d0161c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4ea6427d-da7c-49a2-896f-b4d7c0623783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_76b4890a-c47f-4a94-8b08-868e9272b353" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4ea6427d-da7c-49a2-896f-b4d7c0623783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableMidcapFinancialDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableMidcapFinancialDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayableMidcapFinancialDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_11bfaee1-ed14-4250-830d-96f6c1217c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11bfaee1-ed14-4250-830d-96f6c1217c4c" xlink:to="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:to="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8a69e408-04e8-4474-b907-fc469880159c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_96396b26-1c9c-4fb0-8622-41af507c605f" xlink:href="rxrx-20210930.xsd#rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:to="loc_rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember_96396b26-1c9c-4fb0-8622-41af507c605f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PacificWesternBankLoanMember_8e0b8ef7-1357-4fce-8d5e-1e44f5af507a" xlink:href="rxrx-20210930.xsd#rxrx_PacificWesternBankLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:to="loc_rxrx_PacificWesternBankLoanMember_8e0b8ef7-1357-4fce-8d5e-1e44f5af507a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MidcapLoanAgreementMember_e85e615b-b115-441a-b49e-92eb825696a8" xlink:href="rxrx-20210930.xsd#rxrx_MidcapLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953799e4-99f6-4349-9fce-83e35d2c5b5d" xlink:to="loc_rxrx_MidcapLoanAgreementMember_e85e615b-b115-441a-b49e-92eb825696a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5822cd3a-9419-4d1f-a37f-f517a5f0e394" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_7b962cdb-474b-461f-88f8-8f1ba64ed620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:to="loc_us-gaap_LineOfCreditMember_7b962cdb-474b-461f-88f8-8f1ba64ed620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8764eef7-cb96-4dda-9792-ab0d34f43dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2a8df8f3-acb6-4834-bdda-be094f61cc21" xlink:to="loc_us-gaap_LoansPayableMember_8764eef7-cb96-4dda-9792-ab0d34f43dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72906c0d-5509-4090-8b10-69d1696bae78" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3f4efa2c-577d-4658-b2a3-917925bc77a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3f4efa2c-577d-4658-b2a3-917925bc77a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_0182928e-fd7c-4971-a2f8-7f51f4ec1546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_RepaymentsOfDebt_0182928e-fd7c-4971-a2f8-7f51f4ec1546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09b82149-99f9-4102-aaca-db8d29edae76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09b82149-99f9-4102-aaca-db8d29edae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d6de0e79-e1c7-4f3c-9d6a-fc46c213264c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_LineOfCredit_d6de0e79-e1c7-4f3c-9d6a-fc46c213264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ac81ac0-175e-4a63-a3e7-3ed6ced7f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a9511de6-cb9f-4644-80b9-794084abf689" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2ac81ac0-175e-4a63-a3e7-3ed6ced7f60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayablePacificWesternDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayablePacificWesternDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayablePacificWesternDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0f4e422f-2fda-446f-a066-10a3359c79ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0f4e422f-2fda-446f-a066-10a3359c79ac" xlink:to="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:to="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1d3a9e50-32d3-4272-9d8c-f915ca8247b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2aed8616-20ab-46eb-a59f-deedd77b14e4" xlink:to="loc_us-gaap_CreditFacilityDomain_1d3a9e50-32d3-4272-9d8c-f915ca8247b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_103593f7-31af-4267-b738-c5ce2289d025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1d3a9e50-32d3-4272-9d8c-f915ca8247b8" xlink:to="loc_us-gaap_LetterOfCreditMember_103593f7-31af-4267-b738-c5ce2289d025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:to="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_781bbae5-4504-4138-b26f-bb3ccd9a03a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9c58162-e0c5-4324-aa67-b9bc6c9b6e3a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_781bbae5-4504-4138-b26f-bb3ccd9a03a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PacificWesternLetterOfCreditMember_5b6cdcdc-6901-4754-8d11-9e9a180ff9ce" xlink:href="rxrx-20210930.xsd#rxrx_PacificWesternLetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_781bbae5-4504-4138-b26f-bb3ccd9a03a6" xlink:to="loc_rxrx_PacificWesternLetterOfCreditMember_5b6cdcdc-6901-4754-8d11-9e9a180ff9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bf765c68-48ea-4e53-990f-843fbd6f0c7c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2aee5909-34cb-4650-9c19-0cfa8ee583ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2aee5909-34cb-4650-9c19-0cfa8ee583ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_226d602e-ca4c-48e4-9649-250b6135fb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_LineOfCredit_226d602e-ca4c-48e4-9649-250b6135fb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3f6f1b18-950c-4519-834f-3790335c3df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_358c91f5-865a-4ab4-88c5-f71236c4c18e" xlink:to="loc_us-gaap_RestrictedCash_3f6f1b18-950c-4519-834f-3790335c3df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableConvertibleNotesDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayableConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_40f2a460-ebbf-42e2-909b-824bd5d0b6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_40f2a460-ebbf-42e2-909b-824bd5d0b6fb" xlink:to="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2042b0bb-f85a-461e-b9ea-7237a5e80513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c1ee13fc-8430-41e0-a82b-314af8e3dbba" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2042b0bb-f85a-461e-b9ea-7237a5e80513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_de2c082a-f0e6-4f5e-92fb-e0506e46027f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2042b0bb-f85a-461e-b9ea-7237a5e80513" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_de2c082a-f0e6-4f5e-92fb-e0506e46027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_736fcae3-a0e6-46cf-bbbc-ae981442bffd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6dbd795d-4c6c-4989-81bf-95ecb80efe30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6dbd795d-4c6c-4989-81bf-95ecb80efe30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78465ce8-c951-4ce1-9b5c-f9e67f867b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_78465ce8-c951-4ce1-9b5c-f9e67f867b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3327d9b1-588d-4a01-8c21-35095dd17feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3327d9b1-588d-4a01-8c21-35095dd17feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c7f460ed-cb40-4078-81ce-cc282c142706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e6fc9f2-3b87-45f8-a412-b39fa20151fe" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c7f460ed-cb40-4078-81ce-cc282c142706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableNotesPayableforTenantImprovementAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9c441c52-5910-4781-853c-96be19613cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9c441c52-5910-4781-853c-96be19613cbf" xlink:to="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_480498b8-b86b-4b32-9db7-d0241b1d2ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0e0f57e7-5686-476b-829d-d62a7560fbe1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_480498b8-b86b-4b32-9db7-d0241b1d2ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_7586b079-8078-4451-af5b-0170fa8552ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_480498b8-b86b-4b32-9db7-d0241b1d2ab6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_7586b079-8078-4451-af5b-0170fa8552ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5c1212c0-0a36-42fe-b0ee-9781eb4d0989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0fad8bc-1f2d-4eaa-8998-63c034dc3821" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5c1212c0-0a36-42fe-b0ee-9781eb4d0989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember_63a5dc69-d258-4fa8-b9a7-5ce18070fe5b" xlink:href="rxrx-20210930.xsd#rxrx_Station41LeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5c1212c0-0a36-42fe-b0ee-9781eb4d0989" xlink:to="loc_rxrx_Station41LeaseMember_63a5dc69-d258-4fa8-b9a7-5ce18070fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a54b30b8-c0a6-43ee-9037-e743e4b07f5a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0a1d9ce9-b38a-417e-bd3c-42ba5bff0828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0a1d9ce9-b38a-417e-bd3c-42ba5bff0828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3bd29f0d-e353-4240-a44f-ea364366b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_DebtInstrumentTerm_3bd29f0d-e353-4240-a44f-ea364366b4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91e5f75-5d67-4015-ba3c-a4ee817fc712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_91749aea-2858-4d1c-b102-89a805221e44" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b91e5f75-5d67-4015-ba3c-a4ee817fc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayableCurrentNoncurrentDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0f15d51b-54d6-468d-a162-151961983155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0f15d51b-54d6-468d-a162-151961983155" xlink:to="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af39c1bc-a156-4d98-a57f-bf94b7359404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3cb9194a-63ea-4e69-b032-b78c8f6df5e5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af39c1bc-a156-4d98-a57f-bf94b7359404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f5622b23-fcb1-49f4-b527-a8ec2eea7ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_af39c1bc-a156-4d98-a57f-bf94b7359404" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f5622b23-fcb1-49f4-b527-a8ec2eea7ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1415c05-4f67-478a-8380-051f35540b11" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9fadaef2-2b6a-44ef-b889-933077912a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_LongTermDebtCurrent_9fadaef2-2b6a-44ef-b889-933077912a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ccc9fe01-562d-4463-84f9-63d344b9d8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ccc9fe01-562d-4463-84f9-63d344b9d8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1ec97c42-a915-42c5-8dbc-433b8ecaa0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1ec97c42-a915-42c5-8dbc-433b8ecaa0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eae93a71-0404-49eb-b1ff-4de94b7ac60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5afc72c4-461f-4ab8-b6ba-46ddcc80e36b" xlink:to="loc_us-gaap_LongTermDebt_eae93a71-0404-49eb-b1ff-4de94b7ac60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NotesPayablePrincipalRepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_5922a0ba-8ab7-43aa-bd7d-6cb583b7689d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_5922a0ba-8ab7-43aa-bd7d-6cb583b7689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b3b11312-0205-47ce-b03f-1a0c902b9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b3b11312-0205-47ce-b03f-1a0c902b9b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_cd6231dc-3a6b-4a64-aeac-145878a6c08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_cd6231dc-3a6b-4a64-aeac-145878a6c08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6a7e00e5-5389-425f-ac63-5e65f5f3d086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6a7e00e5-5389-425f-ac63-5e65f5f3d086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c93e1485-c6ad-413a-8a2b-31af751d4f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c93e1485-c6ad-413a-8a2b-31af751d4f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LongTermDebtMaturityAfterYearFour_af765693-4a2e-4aa9-a959-ab608e4d6097" xlink:href="rxrx-20210930.xsd#rxrx_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_rxrx_LongTermDebtMaturityAfterYearFour_af765693-4a2e-4aa9-a959-ab608e4d6097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_52a01f27-39a4-46ff-a272-346373c47f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bc1caf0-7940-4bf0-90c5-4765516c03c7" xlink:to="loc_us-gaap_LongTermDebt_52a01f27-39a4-46ff-a272-346373c47f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cc8b8c8-d89c-432e-b8f1-d809b57db413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e319d398-2a2a-4147-b03d-2d1404f33d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cc8b8c8-d89c-432e-b8f1-d809b57db413" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e319d398-2a2a-4147-b03d-2d1404f33d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fd03122-b13b-4590-9006-07541dc96ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_77f5908a-4f91-4868-9b50-09a0c0dcdefb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fd03122-b13b-4590-9006-07541dc96ec4" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_77f5908a-4f91-4868-9b50-09a0c0dcdefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46ca22f9-1e04-4de5-9d9a-ea47a113ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46ca22f9-1e04-4de5-9d9a-ea47a113ae86" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:href="rxrx-20210930.xsd#rxrx_LeaseArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseArrangementNameAxis_499e7c77-25de-427a-af83-2861904c6c93" xlink:to="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_KomasMember_89775382-c5c9-4ad2-8ca4-9584f98751e6" xlink:href="rxrx-20210930.xsd#rxrx_KomasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:to="loc_rxrx_KomasMember_89775382-c5c9-4ad2-8ca4-9584f98751e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41Member_5c735a48-cdee-46a2-b593-b381cfe2a725" xlink:href="rxrx-20210930.xsd#rxrx_Station41Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:to="loc_rxrx_Station41Member_5c735a48-cdee-46a2-b593-b381cfe2a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station56Member_77b6716d-ba38-4215-9627-079e36cda571" xlink:href="rxrx-20210930.xsd#rxrx_Station56Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_LeaseArrangementNameDomain_54a52d96-c0a5-4139-87b1-aa17b01a6238" xlink:to="loc_rxrx_Station56Member_77b6716d-ba38-4215-9627-079e36cda571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88e93317-5e6f-4360-9910-a2276fab254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f0de6e57-e1ca-441b-b948-b1fc7033d52b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88e93317-5e6f-4360-9910-a2276fab254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41LeaseMember_d138845d-4dfc-4fef-8e5d-1856388a604d" xlink:href="rxrx-20210930.xsd#rxrx_Station41LeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88e93317-5e6f-4360-9910-a2276fab254d" xlink:to="loc_rxrx_Station41LeaseMember_d138845d-4dfc-4fef-8e5d-1856388a604d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3276d307-c0b8-4db9-8caa-2be63d37eb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fde2b6f-deb0-4e14-86d6-1664f1cb1676" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3276d307-c0b8-4db9-8caa-2be63d37eb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_52f88777-73c2-49f6-9218-f2255eb283e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3276d307-c0b8-4db9-8caa-2be63d37eb05" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_52f88777-73c2-49f6-9218-f2255eb283e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_211dd375-7b79-4927-a48a-d8bf42fa2b17" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station41Member_f1a4ca6e-d228-4bcb-b716-122e7d56a0b2" xlink:href="rxrx-20210930.xsd#rxrx_Station41Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:to="loc_rxrx_Station41Member_f1a4ca6e-d228-4bcb-b716-122e7d56a0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_MilpitasMember_24762930-bc72-4b0e-9634-926de696329e" xlink:href="rxrx-20210930.xsd#rxrx_MilpitasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:to="loc_rxrx_MilpitasMember_24762930-bc72-4b0e-9634-926de696329e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_Station56Member_71bb64fb-95c2-4904-95f1-30761fac9dd7" xlink:href="rxrx-20210930.xsd#rxrx_Station56Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a43e4a32-9dcf-4dbd-93f8-626711305f07" xlink:to="loc_rxrx_Station56Member_71bb64fb-95c2-4904-95f1-30761fac9dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_491ee787-0038-4cbf-b919-8519ad22b2f0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_41744428-4c83-4ba6-8eca-741590cc3b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LeaseAndRentalExpense_41744428-4c83-4ba6-8eca-741590cc3b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f4009c1b-2890-4992-aa4a-d069ffdd8d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f4009c1b-2890-4992-aa4a-d069ffdd8d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveFromLessor_f6e25ed7-b3ba-423c-99bf-d4dbc56c1b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveFromLessor"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_IncentiveFromLessor_f6e25ed7-b3ba-423c-99bf-d4dbc56c1b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_7e8b7ae2-4657-4442-8cdc-daa1d77e4c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseIncentivePayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent_7e8b7ae2-4657-4442-8cdc-daa1d77e4c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_1ef5b0f9-9cda-4b82-a79d-5d433a926804" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions_1ef5b0f9-9cda-4b82-a79d-5d433a926804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_40a4eead-0573-466e-929f-d4a13c9b1a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_40a4eead-0573-466e-929f-d4a13c9b1a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7e6a924-6ca2-47f5-b2a2-497f71e3f965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7e6a924-6ca2-47f5-b2a2-497f71e3f965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9eb9275e-d669-43bd-a63c-5ba91ef0a1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9eb9275e-d669-43bd-a63c-5ba91ef0a1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_d9990883-77a5-4d42-bfdc-b4a8cd3d19da" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseSizeOfLeasedAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset_d9990883-77a5-4d42-bfdc-b4a8cd3d19da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650d1356-7687-435a-863c-93baf8013a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_650d1356-7687-435a-863c-93baf8013a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_ae635d1b-d520-4e46-b688-34d037893834" xlink:href="rxrx-20210930.xsd#rxrx_LesseeOperatingLeaseTenantImprovementAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fff93bcf-05cd-4420-8de7-abb0f8ebef85" xlink:to="loc_rxrx_LesseeOperatingLeaseTenantImprovementAllowance_ae635d1b-d520-4e46-b688-34d037893834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommitmentsandContingenciesMinimumpaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2e495aa2-3018-40fb-8160-e9f1a4bb19f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2e495aa2-3018-40fb-8160-e9f1a4bb19f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_c89e304b-20d0-43a2-9519-f84630e7db35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_c89e304b-20d0-43a2-9519-f84630e7db35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_90aae739-9280-4f5f-9c8f-9e6566551cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_90aae739-9280-4f5f-9c8f-9e6566551cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_104f2355-ff10-432c-8dfc-0f2d0c74ca70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_104f2355-ff10-432c-8dfc-0f2d0c74ca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_cc1a471c-821f-4a5a-a7f7-d180fceb8572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_cc1a471c-821f-4a5a-a7f7-d180fceb8572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f63ba066-5839-41c2-94d2-44df3d10525f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_f63ba066-5839-41c2-94d2-44df3d10525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bd0ad2b2-19f1-426b-ac20-9aaf2b09d0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f730ca8-7721-4880-ba2c-c29395d44c56" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_bd0ad2b2-19f1-426b-ac20-9aaf2b09d0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/ConvertiblePreferredStock" xlink:type="simple" xlink:href="rxrx-20210930.xsd#ConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/ConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_622f7681-22a3-44d6-bfb7-c02c7a67d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_TemporaryEquityTextBlock_702b1aed-21fc-4b3b-8850-998b39b695f1" xlink:href="rxrx-20210930.xsd#rxrx_TemporaryEquityTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_622f7681-22a3-44d6-bfb7-c02c7a67d59e" xlink:to="loc_rxrx_TemporaryEquityTextBlock_702b1aed-21fc-4b3b-8850-998b39b695f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/ConvertiblePreferredStockTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#ConvertiblePreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/ConvertiblePreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_d9873756-149f-46a2-bf56-e4e449c65679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_00cc661c-0a46-4a3e-ac86-6113819b5422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_d9873756-149f-46a2-bf56-e4e449c65679" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_00cc661c-0a46-4a3e-ac86-6113819b5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#ConvertiblePreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_87b5fd1e-af5c-4dd7-a8d1-1991b471b89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_87b5fd1e-af5c-4dd7-a8d1-1991b471b89c" xlink:to="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecb39128-2ee1-408c-ab55-b27cc30e17b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d13ab710-90d9-417e-b1a0-e3f2f0aa9ec8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecb39128-2ee1-408c-ab55-b27cc30e17b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_0cf604e5-8eab-46a3-a618-2b42cfc38eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ecb39128-2ee1-408c-ab55-b27cc30e17b2" xlink:to="loc_us-gaap_IPOMember_0cf604e5-8eab-46a3-a618-2b42cfc38eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ffac770-e323-41bb-a082-b42dacd0cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_846f5a25-559c-4af3-8278-2f8cd3c4a68d" xlink:to="loc_us-gaap_ClassOfStockDomain_1ffac770-e323-41bb-a082-b42dacd0cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesDPreferredStockMember_3d1a55e9-5641-4e6a-89cb-73c853731914" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesDPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ffac770-e323-41bb-a082-b42dacd0cd4d" xlink:to="loc_rxrx_ConvertibleSeriesDPreferredStockMember_3d1a55e9-5641-4e6a-89cb-73c853731914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_84db1a97-928b-40f9-95bb-7d5a62942b6d" xlink:to="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5742068f-d9fd-4bb2-b8d5-85cd71caa4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5742068f-d9fd-4bb2-b8d5-85cd71caa4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_b4d6fbbb-622c-4e23-bf67-1c820e55edf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_b4d6fbbb-622c-4e23-bf67-1c820e55edf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51821ba1-48ef-41c2-9fba-0dc410b95e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_51821ba1-48ef-41c2-9fba-0dc410b95e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06a2c418-5cb3-4e71-b9c6-b950c7085005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06a2c418-5cb3-4e71-b9c6-b950c7085005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52f41f92-4dc9-4696-abc0-27382528bf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_52f41f92-4dc9-4696-abc0-27382528bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_SaleOfStockConvertedPricePerShare_5ecb963b-e1c8-4278-b2b0-e71daa5e7c2c" xlink:href="rxrx-20210930.xsd#rxrx_SaleOfStockConvertedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_d3fc8776-75af-4272-922b-c20af0d507ef" xlink:to="loc_rxrx_SaleOfStockConvertedPricePerShare_5ecb963b-e1c8-4278-b2b0-e71daa5e7c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#ConvertiblePreferredStockSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_bc6fc70a-96f1-4fe8-8d42-ea2c46fc860b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPreferredUnitsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_bc6fc70a-96f1-4fe8-8d42-ea2c46fc860b" xlink:to="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dcff7899-d325-4d74-a73d-0772238ba7ed" xlink:to="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesAPreferredStockMember_5162dc67-c05f-4889-bd79-42753ef3e2bf" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesAPreferredStockMember_5162dc67-c05f-4889-bd79-42753ef3e2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesA1PreferredStockMember_da845993-fa84-4dbd-b8de-91fae47f1f2b" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesA1PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesA1PreferredStockMember_da845993-fa84-4dbd-b8de-91fae47f1f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesBPreferredStockMember_e52c7ded-f252-4042-ae97-dca30ea84f3b" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesBPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesBPreferredStockMember_e52c7ded-f252-4042-ae97-dca30ea84f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesCPreferredStockMember_069969c5-c2ac-4106-9b7e-e1038d6add26" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesCPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesCPreferredStockMember_069969c5-c2ac-4106-9b7e-e1038d6add26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesDPreferredStockMember_59a87a46-ba49-4d86-bdeb-96969a5864fc" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesDPreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_18a5a9fe-fe14-4c10-b118-ba6d1837e387" xlink:to="loc_rxrx_ConvertibleSeriesDPreferredStockMember_59a87a46-ba49-4d86-bdeb-96969a5864fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredUnitsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPreferredUnitsTable_b8d73793-ab85-49e8-9a6a-ebcc4b44c3d6" xlink:to="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bc91b517-2fd2-43d0-9fe0-e5be9702fec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bc91b517-2fd2-43d0-9fe0-e5be9702fec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_85b88073-3705-4193-8536-742dcff6d446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_85b88073-3705-4193-8536-742dcff6d446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_d9a24c33-951b-4148-ad62-4d8a0839e10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_d9a24c33-951b-4148-ad62-4d8a0839e10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5a7b47e5-a565-4b5d-80b3-923cf9c8b760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5a7b47e5-a565-4b5d-80b3-923cf9c8b760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_97e0793f-fabb-4ec4-8365-184914c2e679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_97e0793f-fabb-4ec4-8365-184914c2e679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissued_3d40dbf8-7798-4efc-9a5b-575bbde64537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredUnitsLineItems_288203cb-243e-4e84-a4b2-2368a97f6972" xlink:to="loc_us-gaap_TemporaryEquitySharesSubscribedButUnissued_3d40dbf8-7798-4efc-9a5b-575bbde64537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommonStock" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0682c27e-52de-4d74-a4bf-0dc4c434fa31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bede1cf8-9198-463a-be52-026dfa1f9470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0682c27e-52de-4d74-a4bf-0dc4c434fa31" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bede1cf8-9198-463a-be52-026dfa1f9470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CommonStockNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_76185cd5-ddbe-4605-b6e2-a82340d1f5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76185cd5-ddbe-4605-b6e2-a82340d1f5ec" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f1a460-f39a-404f-bc25-56afd3dbef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_feb98036-4187-43e6-9417-09485cdf8f85" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f1a460-f39a-404f-bc25-56afd3dbef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_815c4fb2-82e3-4720-b4c5-e339b39a2cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b5f1a460-f39a-404f-bc25-56afd3dbef3f" xlink:to="loc_us-gaap_IPOMember_815c4fb2-82e3-4720-b4c5-e339b39a2cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f205c21b-e509-4572-9372-5f032042c1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_410cd4af-5b95-499a-a8d6-ad5b64426097" xlink:to="loc_us-gaap_RelatedPartyDomain_f205c21b-e509-4572-9372-5f032042c1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ChristopherGibsonAndAffiliatesMember_e60ec38c-9fb0-4ab0-a28f-bc9df0ada2d6" xlink:href="rxrx-20210930.xsd#rxrx_ChristopherGibsonAndAffiliatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f205c21b-e509-4572-9372-5f032042c1a2" xlink:to="loc_rxrx_ChristopherGibsonAndAffiliatesMember_e60ec38c-9fb0-4ab0-a28f-bc9df0ada2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3f1d777e-0c94-447a-88ce-9b8b5d260738" xlink:to="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_93977176-1bb4-45a1-8e1a-b2fa92779f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:to="loc_us-gaap_CommonClassAMember_93977176-1bb4-45a1-8e1a-b2fa92779f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_0abdf9de-d4ad-48c0-babf-ee8399661e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e6f54736-4770-4f38-a02a-1195a4dc07ff" xlink:to="loc_us-gaap_CommonClassBMember_0abdf9de-d4ad-48c0-babf-ee8399661e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e5e6b114-17d2-4525-b479-e3dbca7b2f78" xlink:to="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CommonStockVotePerShare_aa5e039c-fb08-4904-b57b-145cbea8b43c" xlink:href="rxrx-20210930.xsd#rxrx_CommonStockVotePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_CommonStockVotePerShare_aa5e039c-fb08-4904-b57b-145cbea8b43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84e4d3e2-ecfc-4741-b5ae-30d70a649f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84e4d3e2-ecfc-4741-b5ae-30d70a649f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_dc32ce57-b2d7-45d1-ab5c-d395da57b31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_dc32ce57-b2d7-45d1-ab5c-d395da57b31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_43eaa61e-868b-4383-a77f-8665c9ce90ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_43eaa61e-868b-4383-a77f-8665c9ce90ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_829a2756-e185-49b9-a75e-9290231e48a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_829a2756-e185-49b9-a75e-9290231e48a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_PaymentsOfStockIssuanceExpenses_c05f549a-e17a-4045-8bc1-104a3722452b" xlink:href="rxrx-20210930.xsd#rxrx_PaymentsOfStockIssuanceExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_PaymentsOfStockIssuanceExpenses_c05f549a-e17a-4045-8bc1-104a3722452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b1f9c003-6b84-44d4-b872-c23dcdafa86a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b1f9c003-6b84-44d4-b872-c23dcdafa86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e5c4e6fd-27ee-4e66-8545-c52ba2e9f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_e5c4e6fd-27ee-4e66-8545-c52ba2e9f196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersOwnershipPercentage_c5bcd3f3-7acf-4108-9e4a-0d6561181f13" xlink:href="rxrx-20210930.xsd#rxrx_AffiliatedHoldersOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_AffiliatedHoldersOwnershipPercentage_c5bcd3f3-7acf-4108-9e4a-0d6561181f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_196985a3-9261-47a9-ace9-7bb623a41a68" xlink:href="rxrx-20210930.xsd#rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_98eb8856-f02b-4dd8-ae12-2977def27538" xlink:to="loc_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest_196985a3-9261-47a9-ace9-7bb623a41a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContracts" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CollaborativeDevelopmentContracts"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CollaborativeDevelopmentContracts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89e7ec8a-f53c-41c8-ada6-b3e7a749940a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3e1cb5bd-07c5-4637-bb6f-0eb62b80e0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89e7ec8a-f53c-41c8-ada6-b3e7a749940a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3e1cb5bd-07c5-4637-bb6f-0eb62b80e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#CollaborativeDevelopmentContractsBayerAGDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c706ecbc-04c5-4d5c-8be9-4915c3b78749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c706ecbc-04c5-4d5c-8be9-4915c3b78749" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:to="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f64c8d1b-a12b-4c24-a359-f7b78d97701c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_857a6f2e-2024-4657-9c3e-7117238d20e2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f64c8d1b-a12b-4c24-a359-f7b78d97701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_BayerAGMember_b0f8165e-9bdf-4fbd-b356-6c1152b00cf1" xlink:href="rxrx-20210930.xsd#rxrx_BayerAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f64c8d1b-a12b-4c24-a359-f7b78d97701c" xlink:to="loc_rxrx_BayerAGMember_b0f8165e-9bdf-4fbd-b356-6c1152b00cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b39009a-4fb1-4c77-821e-af26c80ef836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7dede07d-abc8-4a99-b012-340e8e488c29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b39009a-4fb1-4c77-821e-af26c80ef836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e70b8db9-7d31-4e25-8d7b-adc3854c502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b39009a-4fb1-4c77-821e-af26c80ef836" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e70b8db9-7d31-4e25-8d7b-adc3854c502a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1cb1f225-6f8b-4adf-b365-aba5f2cd5e43" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementTerm_553561aa-54db-4694-a242-56a6020db037" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementTerm_553561aa-54db-4694-a242-56a6020db037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_a477e99d-eca0-497c-b30e-abd55d9d2000" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated_a477e99d-eca0-497c-b30e-abd55d9d2000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_5d9017bc-25c3-4299-854e-e93fe972ab25" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived_5d9017bc-25c3-4299-854e-e93fe972ab25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1b185377-cd7c-43e2-aa4b-9e94c89a8915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1b185377-cd7c-43e2-aa4b-9e94c89a8915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc111f32-8d79-4744-9b34-2679d6809ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc111f32-8d79-4744-9b34-2679d6809ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_024586ec-be8e-451e-81dd-ff40db86f7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_024586ec-be8e-451e-81dd-ff40db86f7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_79b11d4c-3908-4992-8afd-21e812873771" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries_79b11d4c-3908-4992-8afd-21e812873771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_b1ef5e3d-eb12-42ec-9175-6253451c27f1" xlink:href="rxrx-20210930.xsd#rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d21b712c-1784-4383-b2ab-90f4bb72a040" xlink:to="loc_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate_b1ef5e3d-eb12-42ec-9175-6253451c27f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92e44bf0-8600-4078-8340-231e22b2358f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ce2d11b0-4398-4ff7-ba0e-2b7900636c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92e44bf0-8600-4078-8340-231e22b2358f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ce2d11b0-4398-4ff7-ba0e-2b7900636c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_69bbe737-cd10-4a00-bd51-d1edf3a292a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_69bbe737-cd10-4a00-bd51-d1edf3a292a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4e05e265-d85a-484f-bef4-7e5e2938d8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4e05e265-d85a-484f-bef4-7e5e2938d8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c845a77f-b99a-41c4-a4f8-7a5548ad2535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c845a77f-b99a-41c4-a4f8-7a5548ad2535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_49821fd1-e581-468c-b26a-a7ec18c402c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_49821fd1-e581-468c-b26a-a7ec18c402c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_647b718e-8803-4d48-9eb6-d67f17b657a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_647b718e-8803-4d48-9eb6-d67f17b657a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b0fb7806-c76a-41b0-8fbf-f12f9af04508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cb3e1cfd-d641-49c8-a350-624e6bdda15c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b0fb7806-c76a-41b0-8fbf-f12f9af04508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5faa4e4-44ea-4f97-acc1-28fde3498c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5faa4e4-44ea-4f97-acc1-28fde3498c00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5c5f3085-51ab-4c22-ac2c-4c8d6cee7662" xlink:to="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EquityIncentivePlanMember_653c573d-7c01-42eb-90fa-364bc7a1faca" xlink:href="rxrx-20210930.xsd#rxrx_A2021EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:to="loc_rxrx_A2021EquityIncentivePlanMember_653c573d-7c01-42eb-90fa-364bc7a1faca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2021EmployeeStockPurchasePlanMember_2b1c8bd7-9f3c-4e17-8358-f978fc61a7a9" xlink:href="rxrx-20210930.xsd#rxrx_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fcb8b5b9-919c-4fdd-a966-d9439e566945" xlink:to="loc_rxrx_A2021EmployeeStockPurchasePlanMember_2b1c8bd7-9f3c-4e17-8358-f978fc61a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b1d74ce9-70fa-4af3-a921-e2ce06d90a1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_90bc9bcc-2eaf-409e-a78f-c515dbc0d115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_PerformanceSharesMember_90bc9bcc-2eaf-409e-a78f-c515dbc0d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3bd42af6-13a0-4899-a57c-81a334bcaa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_RestrictedStockMember_3bd42af6-13a0-4899-a57c-81a334bcaa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8bea6cab-0df6-476a-b246-605f321d4e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8bea6cab-0df6-476a-b246-605f321d4e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_592c0c56-94f7-475e-8763-ca0ade4e192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c56ae4c-6c92-406e-acc1-ac8712f4408c" xlink:to="loc_us-gaap_EmployeeStockMember_592c0c56-94f7-475e-8763-ca0ade4e192c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_e4c40699-01b3-45b7-a8bf-c8db3668a111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_236da44b-98d5-41c3-8112-11cc3335a22b" xlink:to="loc_us-gaap_GranteeStatusDomain_e4c40699-01b3-45b7-a8bf-c8db3668a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4b67dbd2-a2e3-430a-9baf-4692fc164aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_e4c40699-01b3-45b7-a8bf-c8db3668a111" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_4b67dbd2-a2e3-430a-9baf-4692fc164aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9cff9e32-487a-457f-9666-3786b3f0205e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_531471c8-5912-47c5-9695-e33239998dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_531471c8-5912-47c5-9695-e33239998dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b280d94-5921-4678-a263-e20513887ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1b280d94-5921-4678-a263-e20513887ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1ccf8a8a-c5c1-4394-9164-56c53ad35b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1ccf8a8a-c5c1-4394-9164-56c53ad35b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49c6747c-7161-4a01-8e32-50136147874f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_49c6747c-7161-4a01-8e32-50136147874f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c57b73b-8fcd-4c31-84ce-9f24b8f280ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c57b73b-8fcd-4c31-84ce-9f24b8f280ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6fff6aa6-5df6-46ea-8788-a9d4d6525503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6fff6aa6-5df6-46ea-8788-a9d4d6525503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_0b957e47-12c9-43cb-b908-9618e2c6b07e" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_0b957e47-12c9-43cb-b908-9618e2c6b07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ebcebf8-3101-4d49-9fbb-4ce855ae1aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ebcebf8-3101-4d49-9fbb-4ce855ae1aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_80b627f2-7333-42bf-b87f-450929ec361b" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate_80b627f2-7333-42bf-b87f-450929ec361b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a308b081-88b9-42b4-82d8-e86d400284d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a308b081-88b9-42b4-82d8-e86d400284d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d5106665-b85f-4030-ad97-56d4a41f95a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d5106665-b85f-4030-ad97-56d4a41f95a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dda96482-a620-4daf-bc31-9afc608a11d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dda96482-a620-4daf-bc31-9afc608a11d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c1cea792-c7df-44fa-b4f2-01c81fb3c45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c1cea792-c7df-44fa-b4f2-01c81fb3c45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_ed5048bd-78b4-45b2-ace1-5d3e4073a7d5" xlink:href="rxrx-20210930.xsd#rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_ed5048bd-78b4-45b2-ace1-5d3e4073a7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7e4548f0-692e-48ec-ba18-102c43979461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7e4548f0-692e-48ec-ba18-102c43979461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_652ecc95-9e80-4a7c-bce8-7236911f1442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_652ecc95-9e80-4a7c-bce8-7236911f1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99c7e6ff-2eff-474f-b4d0-f3b3c91a986c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c75efbcc-8b3a-4e04-aba0-db570083f0ce" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_99c7e6ff-2eff-474f-b4d0-f3b3c91a986c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f1cdd95-a777-433a-8b6f-f9d3348281e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f1cdd95-a777-433a-8b6f-f9d3348281e6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c6e7bec-deea-4230-a1ad-878ed28c3742" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_962df8e1-50ec-4799-8858-8bbcc3c8918e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_962df8e1-50ec-4799-8858-8bbcc3c8918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbcd23ee-d008-4b3f-993d-7a556bad7693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcc74dbb-5394-4330-a9ef-50a3dc3c0d06" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_cbcd23ee-d008-4b3f-993d-7a556bad7693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e58173c-d6ac-47ab-a9b2-e813c169b5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7d8d9339-d9c4-40dc-9a24-324ac161fa7e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e58173c-d6ac-47ab-a9b2-e813c169b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_559c33fb-fbc7-400e-b446-b0c0a4dc4276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e58173c-d6ac-47ab-a9b2-e813c169b5cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_559c33fb-fbc7-400e-b446-b0c0a4dc4276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5afb27d-9d86-49d2-82ce-8829579f040c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5afb27d-9d86-49d2-82ce-8829579f040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b84c7c99-ee58-41be-968a-8a8522f460ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b84c7c99-ee58-41be-968a-8a8522f460ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f36f49aa-af12-4476-b6ed-06459f7b575e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f36f49aa-af12-4476-b6ed-06459f7b575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_267bfac6-5472-44f4-8582-b63b673d7724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_267bfac6-5472-44f4-8582-b63b673d7724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7cf84391-30ae-47e3-b4c6-455f8585c525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee0a6f49-4d09-4b9b-9b62-a1ed522bd613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7cf84391-30ae-47e3-b4c6-455f8585c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_163eac89-d50c-402a-86d6-e39fffc8d73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_163eac89-d50c-402a-86d6-e39fffc8d73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a73f4a82-bf06-4844-93df-7456524c1400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a73f4a82-bf06-4844-93df-7456524c1400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f7185867-e1cc-437f-a776-f5fb7964a410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f7185867-e1cc-437f-a776-f5fb7964a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d2daa767-97ea-4e50-93ba-58d82afa7b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d2daa767-97ea-4e50-93ba-58d82afa7b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8389bf10-8dc9-4a16-be35-5e7be95e288a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8389bf10-8dc9-4a16-be35-5e7be95e288a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9efd4ba3-3bf7-413a-9eb7-15e834734178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_276f0a69-889e-4456-a119-c31c25378333" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9efd4ba3-3bf7-413a-9eb7-15e834734178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fdada043-e68c-46b8-a4ea-d2dc7c14aba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fdada043-e68c-46b8-a4ea-d2dc7c14aba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d13167e5-6e60-43d4-b55c-0315e5004c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d13167e5-6e60-43d4-b55c-0315e5004c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7f57e9bf-d563-47ff-9803-fb246da9986f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7f57e9bf-d563-47ff-9803-fb246da9986f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49cd58b0-a087-4469-af95-a1e2d052cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_49cd58b0-a087-4469-af95-a1e2d052cf95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2d80fe9-066c-44a3-a020-6bc4e55bb21f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2d80fe9-066c-44a3-a020-6bc4e55bb21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4f80fa49-defa-43d0-b259-c3c74e4e2843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5afdb14-ecbc-46fe-b067-7b15998c6f58" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4f80fa49-defa-43d0-b259-c3c74e4e2843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47cf5394-410c-42d2-9a47-440158c4c9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47cf5394-410c-42d2-9a47-440158c4c9bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:to="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d812ba6-106d-4e27-8c10-584bcd97238f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b8fb6571-8245-45ad-b03e-ab0eedd6ee72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d812ba6-106d-4e27-8c10-584bcd97238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_84c365d1-b132-4e84-9c64-ebd5c33e9acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d812ba6-106d-4e27-8c10-584bcd97238f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_84c365d1-b132-4e84-9c64-ebd5c33e9acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_807255d3-f71a-4cba-bc83-a95dda2edc14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c4a51939-48ab-496c-a310-366d8212ea31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c4a51939-48ab-496c-a310-366d8212ea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a765275-5ba6-4edc-bca0-24fef9c05a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8a765275-5ba6-4edc-bca0-24fef9c05a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c969a17-a7b9-44b5-99f9-c0b9a9c8ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c969a17-a7b9-44b5-99f9-c0b9a9c8ea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9ff36136-8395-4ef6-9bee-c93277e18049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7393d4da-3e80-42ad-9eed-3147bd0db548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9ff36136-8395-4ef6-9bee-c93277e18049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6d61947-c139-44f5-97f0-a05a1bba9b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6d61947-c139-44f5-97f0-a05a1bba9b33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:to="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abf44462-ba64-45dc-bd8d-6962bbba8c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a2f29a39-1884-4e75-b2af-34f7db8f32c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abf44462-ba64-45dc-bd8d-6962bbba8c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3dfbdc7e-46e1-4387-9ac0-0345b66071b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abf44462-ba64-45dc-bd8d-6962bbba8c09" xlink:to="loc_us-gaap_RestrictedStockMember_3dfbdc7e-46e1-4387-9ac0-0345b66071b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4126547a-2eb3-4064-b7f7-9c18dffc7168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b5e6084-c607-495f-92e1-5064ec4d076c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9b5e6084-c607-495f-92e1-5064ec4d076c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11c47f0a-0927-4afc-a550-587809e8f1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11c47f0a-0927-4afc-a550-587809e8f1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc4cf276-553e-4488-abaf-c0d17570932a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cc4cf276-553e-4488-abaf-c0d17570932a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b2d82e15-9b59-45a9-aad5-6860d32836e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b2d82e15-9b59-45a9-aad5-6860d32836e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d56c264-304c-4e6d-b34f-bb9176637637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a2d45814-0c09-4fcc-be7a-c2b660b8848f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4d56c264-304c-4e6d-b34f-bb9176637637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefb7ab8-0586-4e6c-916e-c42f13eac748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_338585bc-06f5-406a-800f-cb48d2464613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_338585bc-06f5-406a-800f-cb48d2464613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536c9ade-19ce-452e-90a6-b559fc2eb2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536c9ade-19ce-452e-90a6-b559fc2eb2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90b52001-3bcf-4797-a01d-81648bfa5eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_90b52001-3bcf-4797-a01d-81648bfa5eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_541dd342-ea6d-4ddf-8304-7a9980f462e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_541dd342-ea6d-4ddf-8304-7a9980f462e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71d77ead-594b-4c6a-b0ff-b333544afabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e8d65537-9b3d-4623-b66d-8b03d4dda11f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71d77ead-594b-4c6a-b0ff-b333544afabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3cadace-88c0-4e8f-bf54-498c3393e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3cadace-88c0-4e8f-bf54-498c3393e0f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:to="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fee6dc6-48b7-466f-8daa-3b8b5757dbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e58c9b4c-f085-4d70-8195-93fadd283a07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fee6dc6-48b7-466f-8daa-3b8b5757dbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b2be7fe4-780d-4524-949c-0259ca4ba056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fee6dc6-48b7-466f-8daa-3b8b5757dbee" xlink:to="loc_us-gaap_EmployeeStockMember_b2be7fe4-780d-4524-949c-0259ca4ba056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6492c6fa-8aa3-4982-9878-db1ec0ba48c8" xlink:to="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80f5e827-4c2b-4866-a3d4-0a3aa68b0976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80f5e827-4c2b-4866-a3d4-0a3aa68b0976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a21be2c8-e539-422e-be8d-1772e4ce1f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a21be2c8-e539-422e-be8d-1772e4ce1f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80204d-57bb-44d1-b251-6a4eda050ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80204d-57bb-44d1-b251-6a4eda050ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f1c031d-f65d-40e1-b5b2-13e7f2d35bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_56f99fba-3f33-4cd0-a54e-23ff86a2d574" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f1c031d-f65d-40e1-b5b2-13e7f2d35bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb1b3b56-9c3e-478b-a294-cd8527bdc673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb1b3b56-9c3e-478b-a294-cd8527bdc673" xlink:to="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9883fb8e-8817-4aa6-9649-8c5fea27b955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2016WarrantsMember_2a587f94-cefb-4106-a0e4-a0364319fffd" xlink:href="rxrx-20210930.xsd#rxrx_A2016WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_A2016WarrantsMember_2a587f94-cefb-4106-a0e4-a0364319fffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2017WarrantsMember_5f9e5616-dd91-4efe-a531-e6b911c4bc1a" xlink:href="rxrx-20210930.xsd#rxrx_A2017WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_A2017WarrantsMember_5f9e5616-dd91-4efe-a531-e6b911c4bc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_A2018WarrantsMember_93ff2181-bc0f-4101-ab5f-26062ee35fc5" xlink:href="rxrx-20210930.xsd#rxrx_A2018WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_A2018WarrantsMember_93ff2181-bc0f-4101-ab5f-26062ee35fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsIssuedInJanuary2020Member_ecd0e63b-dcf1-49f1-9db1-88b9ddbd8528" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsIssuedInJanuary2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_e64499a0-4010-4139-a286-760eb2dfa8b1" xlink:to="loc_rxrx_WarrantsIssuedInJanuary2020Member_ecd0e63b-dcf1-49f1-9db1-88b9ddbd8528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58fe850b-ae0d-44da-9ffd-f01262b0d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c5b905df-2d05-44ac-930a-418787459cac" xlink:to="loc_us-gaap_ClassOfStockDomain_58fe850b-ae0d-44da-9ffd-f01262b0d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ConvertibleSeriesCPreferredStockMember_00285683-a279-4daf-b813-5b04efcc5392" xlink:href="rxrx-20210930.xsd#rxrx_ConvertibleSeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_58fe850b-ae0d-44da-9ffd-f01262b0d1fd" xlink:to="loc_rxrx_ConvertibleSeriesCPreferredStockMember_00285683-a279-4daf-b813-5b04efcc5392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:href="rxrx-20210930.xsd#rxrx_WarrantsArrangementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsTable_3da7ce02-a32a-4bf5-963a-0474627a1fd2" xlink:to="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_90511a0c-b2bc-4593-96ae-22d57de8358d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_90511a0c-b2bc-4593-96ae-22d57de8358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65461cfb-a9ab-4eb8-a966-dd062c23500e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65461cfb-a9ab-4eb8-a966-dd062c23500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightFairValue_ed263360-b587-46cd-beb8-93d2f14d7bcc" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_ClassOfWarrantOrRightFairValue_ed263360-b587-46cd-beb8-93d2f14d7bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightIssued_79ee88ff-7b65-45ba-9770-11b3ce8392b9" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_ClassOfWarrantOrRightIssued_79ee88ff-7b65-45ba-9770-11b3ce8392b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_22b2a078-081a-40fe-81b9-5b09f9ca247a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_22b2a078-081a-40fe-81b9-5b09f9ca247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_ClassOfWarrantOrRightGrantDateFairValue_cfaa74e6-49e0-4f72-9f31-cb0cee42cb31" xlink:href="rxrx-20210930.xsd#rxrx_ClassOfWarrantOrRightGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rxrx_WarrantsArrangementsLineItems_10576185-ee39-4332-a1f7-4994da655e38" xlink:to="loc_rxrx_ClassOfWarrantOrRightGrantDateFairValue_cfaa74e6-49e0-4f72-9f31-cb0cee42cb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f8d6785-81a4-45b5-9a26-5c7a57f8bd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f8d6785-81a4-45b5-9a26-5c7a57f8bd78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dde7b5b8-6f34-423a-a60f-345367030332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_abe05418-a2c9-4aa0-a5bf-53a207f2e97a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dde7b5b8-6f34-423a-a60f-345367030332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_32344ebc-84e2-4e4b-9149-2aeb8ffcdbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dde7b5b8-6f34-423a-a60f-345367030332" xlink:to="loc_us-gaap_WarrantMember_32344ebc-84e2-4e4b-9149-2aeb8ffcdbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_82d0fa92-70bc-4e83-823c-351df969bf54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_a1a81ecd-efa1-4aa8-a213-55decc08c2de" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_82d0fa92-70bc-4e83-823c-351df969bf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_82d0fa92-70bc-4e83-823c-351df969bf54" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ad1f4469-dfa2-4995-9569-1e6fe202ea28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ad1f4469-dfa2-4995-9569-1e6fe202ea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39210876-0db9-4127-a88b-2928d9ab1959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39210876-0db9-4127-a88b-2928d9ab1959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e48560dc-7b60-4bc3-8ee8-0c1379827c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e48560dc-7b60-4bc3-8ee8-0c1379827c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a592fbb8-fa06-43c4-952f-2f8ebce908bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8b7f4b88-855e-4c3f-98f5-44a5b5bd22fc" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a592fbb8-fa06-43c4-952f-2f8ebce908bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rxrx-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6bd6bb5-5997-48b5-802a-64a53585cb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_41d314f9-b966-4d85-9ed0-328334eb8ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6bd6bb5-5997-48b5-802a-64a53585cb74" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_41d314f9-b966-4d85-9ed0-328334eb8ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1e9fd5a2-e254-4ab3-9338-a27c74bffbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d818fcc0-5b81-4d76-a616-ab34ecfe19dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1e9fd5a2-e254-4ab3-9338-a27c74bffbeb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d818fcc0-5b81-4d76-a616-ab34ecfe19dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShare" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dfbe8165-2614-406d-81d6-e4b1ba41d573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0655c994-3e9e-4e63-bd54-0d306e614dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dfbe8165-2614-406d-81d6-e4b1ba41d573" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0655c994-3e9e-4e63-bd54-0d306e614dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_85a941f7-33f3-4119-98bb-7fb4c5528349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56f47fd1-7582-42e9-84b7-8586d4e1d0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85a941f7-33f3-4119-98bb-7fb4c5528349" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56f47fd1-7582-42e9-84b7-8586d4e1d0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1011dd0a-38f3-4ecc-9063-4984fbac60c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_85a941f7-33f3-4119-98bb-7fb4c5528349" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1011dd0a-38f3-4ecc-9063-4984fbac60c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8f5f7ad4-5482-4bfd-bc37-c4c427d291ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8f5f7ad4-5482-4bfd-bc37-c4c427d291ec" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5afdc5e6-1b78-4a47-90c7-73bae28e5480" xlink:to="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e29c8478-1da3-4ce1-9e9a-4e3b576c41e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:to="loc_us-gaap_CommonClassAMember_e29c8478-1da3-4ce1-9e9a-4e3b576c41e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_be3165a8-357e-4f6d-8f5a-34a35b2afe89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fd4c4939-9cb0-466f-b3dd-2f748105eeed" xlink:to="loc_us-gaap_CommonClassBMember_be3165a8-357e-4f6d-8f5a-34a35b2afe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_97f91058-1a2d-42f4-9fc4-b6a94e572764" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings_08d74e50-2c46-4419-b62e-da76da1f4935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:to="loc_us-gaap_UndistributedEarnings_08d74e50-2c46-4419-b62e-da76da1f4935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsDiluted_6346fb8d-b68c-43c4-b144-929e2c94f998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ce6506f0-229d-4508-b3bf-e935598deca4" xlink:to="loc_us-gaap_UndistributedEarningsDiluted_6346fb8d-b68c-43c4-b144-929e2c94f998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0fad93b2-4a90-40d7-ae07-f4a38fd83f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0fad93b2-4a90-40d7-ae07-f4a38fd83f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3156e862-1e5c-4ac7-817a-bb0852f24613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3276ccf0-daf6-45b5-9c18-dc4ea38041fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3156e862-1e5c-4ac7-817a-bb0852f24613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_34733818-6bc9-47f3-a930-417856620e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_EarningsPerShareBasic_34733818-6bc9-47f3-a930-417856620e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_873e652f-bc52-4cd6-80ac-47a6f1f20e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0bfa9758-a1b5-4c40-9aa5-f9c0237428f7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_873e652f-bc52-4cd6-80ac-47a6f1f20e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b8303a6-5fe5-470f-8ad3-5ba08697b218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b8303a6-5fe5-470f-8ad3-5ba08697b218" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_405b64be-fe19-49f7-9cc6-86c67b41fd3f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_954c22d5-83fc-4479-b8b8-a46c081cb2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_954c22d5-83fc-4479-b8b8-a46c081cb2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_409001ac-7270-461f-9d5b-7134cda20deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_StockCompensationPlanMember_409001ac-7270-461f-9d5b-7134cda20deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d3da4cd2-1560-42c1-963a-7a8b08f0db5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_WarrantMember_d3da4cd2-1560-42c1-963a-7a8b08f0db5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_51ec2e61-a0aa-4fdf-9c37-2819d0028904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_EmployeeStockMember_51ec2e61-a0aa-4fdf-9c37-2819d0028904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_868281cc-22a9-4424-abd2-f211f487c345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2fda1404-a712-48a9-b56b-c95a9fbf4a18" xlink:to="loc_us-gaap_EmployeeStockOptionMember_868281cc-22a9-4424-abd2-f211f487c345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b248ece2-c0c9-4b0d-998f-807964acfe4c" xlink:to="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_15f9a535-7b24-4493-95fe-6ff0b3686353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:to="loc_us-gaap_CommonClassAMember_15f9a535-7b24-4493-95fe-6ff0b3686353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ebbf57b3-5ad9-44e1-9b9e-b6ee07043914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_850e9dda-d117-4a9d-b5bc-d79f358dd254" xlink:to="loc_us-gaap_CommonClassBMember_ebbf57b3-5ad9-44e1-9b9e-b6ee07043914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6393be5c-6fff-4ad4-91d2-c4f706b70622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13cf09e6-735a-45d8-a0cf-2b992d3d55d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6393be5c-6fff-4ad4-91d2-c4f706b70622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74a19ae9-9b81-4c15-8bae-58c28b6f12c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6393be5c-6fff-4ad4-91d2-c4f706b70622" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_74a19ae9-9b81-4c15-8bae-58c28b6f12c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_464a0c50-cf0e-446b-ae6e-0d69aa17c593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_615ffb59-d7f1-4a9b-8e88-dade83d24c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_464a0c50-cf0e-446b-ae6e-0d69aa17c593" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_615ffb59-d7f1-4a9b-8e88-dade83d24c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_60400ee9-8568-4f5a-8771-ad0cab7da43d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_da047d00-4ace-4e2e-a7f1-7fcbd1f3f66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60400ee9-8568-4f5a-8771-ad0cab7da43d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_da047d00-4ace-4e2e-a7f1-7fcbd1f3f66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_80ba84a0-061b-489e-bfe6-31e3d462ca54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_60400ee9-8568-4f5a-8771-ad0cab7da43d" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_80ba84a0-061b-489e-bfe6-31e3d462ca54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_747b3f22-785f-45ab-b1d2-4b7ba63160a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_747b3f22-785f-45ab-b1d2-4b7ba63160a4" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bda99059-0cb5-458a-8c4b-403c7d35d31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b0b4c54-ee60-43e3-aeb3-2bf4c8fbb081" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bda99059-0cb5-458a-8c4b-403c7d35d31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_326fbc21-5155-4227-837d-527b80942c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bda99059-0cb5-458a-8c4b-403c7d35d31b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_326fbc21-5155-4227-837d-527b80942c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8440c30b-2437-484c-a95e-4fd115546acd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1001cb8a-18d9-4fe1-9a1b-fbdea0110eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1001cb8a-18d9-4fe1-9a1b-fbdea0110eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b88cff28-9fc4-4a28-8413-4f28a7b909e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b88cff28-9fc4-4a28-8413-4f28a7b909e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_502f23fa-cb3e-4879-ad8e-a2ded13e03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3888a6f6-2072-409e-8153-34a6d1827065" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_502f23fa-cb3e-4879-ad8e-a2ded13e03a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_413d1235-a419-410b-a1df-60ca10881f33" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_910ec788-44db-42f7-9378-5ef774765f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_910ec788-44db-42f7-9378-5ef774765f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fe7f4743-a142-4743-816c-2ca85351a7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51420da6-15ba-4183-9231-3bb2b97dedfd" xlink:to="loc_us-gaap_CommercialPaperMember_fe7f4743-a142-4743-816c-2ca85351a7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ec254759-fdd4-42cd-b0df-e68a2c9891ae" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6ee77a39-ec5b-46d6-8da5-8c6351dbf9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6ee77a39-ec5b-46d6-8da5-8c6351dbf9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e88961cc-4efd-4bb3-9b87-aebfe5cb42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e88961cc-4efd-4bb3-9b87-aebfe5cb42f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_cc065bd8-0f90-49f4-a8eb-db825bb58d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ca3fa6c-e69a-4185-a750-a9980d86f962" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_cc065bd8-0f90-49f4-a8eb-db825bb58d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_5b57b625-886a-47f8-8968-3c0a0f1cbb46" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8b439a4-fb91-4f21-b368-5ca43bb20cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8b439a4-fb91-4f21-b368-5ca43bb20cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_675b26b6-fa85-4b60-8078-1b36e178158d" xlink:href="rxrx-20210930.xsd#rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure_675b26b6-fa85-4b60-8078-1b36e178158d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8f629a5b-eb27-4a36-8f7b-d5e8626d87e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8f629a5b-eb27-4a36-8f7b-d5e8626d87e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5323b4a1-3c38-4e7f-b4d0-e5557905ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5323b4a1-3c38-4e7f-b4d0-e5557905ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_330a6bc2-f820-4e14-97e1-846da821306a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_330a6bc2-f820-4e14-97e1-846da821306a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0d843ced-503c-40d3-bb57-05d472ed2e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b688d6a0-c064-4d1f-b198-fe495e309dac" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0d843ced-503c-40d3-bb57-05d472ed2e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_90958d51-a335-400b-b916-48eb06999403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_90958d51-a335-400b-b916-48eb06999403" xlink:to="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_292d565c-fdfc-4df2-abfd-017caac32d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_ee58bcab-cd7f-4951-8ab3-05311ce6f71a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_292d565c-fdfc-4df2-abfd-017caac32d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_292d565c-fdfc-4df2-abfd-017caac32d55" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_beae14d2-afc4-41a4-8140-a25f390bf078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:to="loc_us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember_beae14d2-afc4-41a4-8140-a25f390bf078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_055c33f2-b960-4028-b5ed-aa0a50d3a5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_edd8916c-7ff1-4a5e-9579-9299cdf02fde" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_055c33f2-b960-4028-b5ed-aa0a50d3a5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6ec4debe-8ee8-4144-9cc8-60fd130ab2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c2688b83-dcaa-4715-b197-178c43ba0bb8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6ec4debe-8ee8-4144-9cc8-60fd130ab2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f2490b56-f733-4121-a9c3-b5f6eeeb397f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6ec4debe-8ee8-4144-9cc8-60fd130ab2a1" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f2490b56-f733-4121-a9c3-b5f6eeeb397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable_9f5d397c-f49e-49c1-9dba-dc3a17525bdc" xlink:to="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a288add8-3b05-423b-9744-634c7307d124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_LongTermDebtCurrent_a288add8-3b05-423b-9744-634c7307d124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5335c3d9-ff75-4e35-b002-be014b533189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5335c3d9-ff75-4e35-b002-be014b533189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_3fefea97-d362-4128-8283-111ff304358f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_5ac11941-540d-4d15-b386-f696cfd0632a" xlink:to="loc_us-gaap_LongTermDebtFairValue_3fefea97-d362-4128-8283-111ff304358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="rxrx-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a7a991b9-8238-4cfd-87ac-cc268e9e1413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d0741f14-b644-4663-8966-8eaadf720be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a7a991b9-8238-4cfd-87ac-cc268e9e1413" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d0741f14-b644-4663-8966-8eaadf720be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.recursion.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="rxrx-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.recursion.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_78d586b0-7f9e-49bf-b089-393778de8d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_78d586b0-7f9e-49bf-b089-393778de8d01" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4b336a38-f153-49a6-927e-5d1aa356ade1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0595fe6c-a947-4511-9322-95ede8911544" xlink:to="loc_us-gaap_RelatedPartyDomain_4b336a38-f153-49a6-927e-5d1aa356ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_2b93d276-001a-4d40-8e75-7e9d4d61b27e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4b336a38-f153-49a6-927e-5d1aa356ade1" xlink:to="loc_srt_ChiefExecutiveOfficerMember_2b93d276-001a-4d40-8e75-7e9d4d61b27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7c70b596-cb3d-4393-9e53-a91e6382bfd4" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansAndLeasesReceivableRelatedParties_a90f9e34-4b31-4984-bf16-129f08125731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:to="loc_us-gaap_LoansAndLeasesReceivableRelatedParties_a90f9e34-4b31-4984-bf16-129f08125731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a5d15cb2-58a8-4256-93b0-51cfe952a1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e071dbaa-aac4-4893-b3d9-9522b52d3b5d" xlink:to="loc_us-gaap_DebtInstrumentTerm_a5d15cb2-58a8-4256-93b0-51cfe952a1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>rxrx-20210930_g1.jpg
<TEXT>
begin 644 rxrx-20210930_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_X3ED17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C W.C,P(#$Q.C,U.C(V   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P-P  DI(  @    ,P-P  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,3HP-SHS," Q,3HS-#HQ,0 R,#(Q.C W.C,P(#$Q.C,T.C$Q      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  )[<         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ RP$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MX^W773/^L-)_;.I_\_\ <_\ ?PT<D>P?6:W\S%_M?5 <&^NLCMYAI/[9U/\
MY_[G_OZ:.2/8/K-;^9A_;.I_\_\ <_\ ?TT?VSJ?_/\ W/\ W]-')'L'UJM_
M,P_MG4_^?^Y_[^FC^V=3_P"?^Y_[^FCDCV#ZU6_F8?VSJ?\ S_W/_?TT?VSJ
M?_/_ '/_ ']-')'L'UJM_,P_MG4_^?\ N?\ OZ:/[9U/_G_N?^_IHY(]@^M5
MOYF']LZG_P _]S_W]-']LZG_ ,_]S_W]-')'L'UJM_,P_MG4_P#G_N?^_IKU
M&>]O(/!]O<6YW7#6J'>W."5&3]:Y<3%)*Q[F259U)SYG?8V+)Y9+&!YP/-*
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M0)VZ!5G6/^0#-_US_I4R-J'4OVW_ !ZP_P"XO\JEJ#H"B@ K-^VZ/GF]L_\
MO\O^-7&,I?"KB<5+</MNC?\ /[9_]_E_QH^VZ-_S^V?_ '^7_&J]E5_E?W"]
MFNP?;=&_Y_;/_O\ +_C1]MT;_G]L_P#O\O\ C1[*K_*_N#V:[!]MT;_G]L_^
M_P O^-'VW1O^?VS_ ._R_P"-'LJO\K^X/9KL'VW1O^?VS_[_ "_XTHU#2%!
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MLF-DGW2I7'W^V<^N>N: (U^(^M+"L;1VCXWAG97W,&=GP2&[,Y(QCT.12?\
M"Q=9^QM (K17:W-L9PK^9L*;.N[&<<YQU_*@#(U_Q'?>)+BWGOO+WP0B)?+!
M QDG/)/))/3 ]JR* "B@ HH ** "B@ K[BN/^1/B_P"O5/\ T$4 ;%M_QZP_
M[B_RJ6@ K.US_D#W'^X: +"PK<::D+9VO$ <?2O #X0^'^?^0'>_^!;?XT )
M_P (AX _Z =[_P"!;?XT?\(AX _Z =[_ .!;?XT '_"(> /^@'>_^!;?XT?\
M(AX _P"@'>_^!;?XT '_  B'@#_H!WO_ (%M_C1_PB'@#_H!WO\ X%M_C0 ?
M\(AX _Z =[_X%M_C1_PB'@#_ * =[_X%M_C0 ?\ "(> /^@'>_\ @6W^-'_"
M(> /^@'>_P#@6W^- !_PB'@#_H!WO_@6W^-7]&^'O@+6-4AL4TB[C:3=AFNF
M(& 3Z^U &O??!_P-97)@;3KEB #D7+_XU6_X55X%_P"@9=?^!3?XT '_  JK
MP+_T#+K_ ,"F_P :/^%5>!?^@9=?^!3?XT '_"JO O\ T#+K_P "F_QH_P"%
M5>!?^@9=?^!3?XT '_"JO O_ $#+K_P*;_&C_A57@7_H&77_ (%-_C0 ?\*J
M\"_] RZ_\"F_QH_X55X%_P"@9=?^!3?XT '_  JKP+_T#+K_ ,"F_P :/^%5
M>!?^@9=?^!3?XT *OPK\"!@3I5T1W'VI^?UKU;542+P])'&NV-8MJCT '% &
MA;?\>L/^XO\ *I: "L[7/^01<?[IH N6W_'K#_N+_*O!MC_W3^5 !L;^Z?RH
MV-_=/Y4 .C#)(K&,L%()&.M;"ZM:"Y$SZ0KD'(RV.<@]E]J #^U;-Q$CZ0NQ
M6Y^;G''M[?K3(M1M(I)%.EK+"TC,H/! )&!G'M0 JZI:"/8='C8 D\M^7:HI
M[ZUDAE2/2EC+* K;B2IP,GI0!F;&_NG\J-C?W3^5 !L;^Z?RKH/!"L/%MF2I
M'#]O]AJ .RUX'^U7X/W5_E69M/H?RH -I]#^5&T^A_*@#%OM%O;G49+J#4I+
M<,@4(JDX(##UQU(/3^&J)\+ZLZ'?X@F,F\N'$)&#AP/XNP8?]\_D 3G0]6D-
M[%)JK^5(4,#$-N3#$G.".Q Z\XYIK>&]2:02G7;@2 XW*A'R[2,8W8SDY^OX
M8 %_L#62K;O$,^XHH!6'&&XR>O?!X[9KH0K  8)]\4 +M/H?RHVGT/Y4 &T^
MA_*NKUC_ ) 4O_7/^E %^V_X]8?]Q?Y5+0 4C*KKM8 CT- "U'Y$/_/&/_OD
M4 4I+:Y_M*,QI!]DQ\P*C/\ *I[KR+6VDF-NK!!G 4<T )9F"[M4G%NJ!NQ4
M5#]FN/[3SLA^Q[>FT9_EGK0!+>M!9VK3FV5]O8**?;""YMHYA;JH<9P5&10!
M7CMKC^TI#)'#]DQ\HVC/\J??RP6-MYQME?D# 44 30I!- DH@50ZAL%1D56M
M[:X%[,9XX3;_ /+,!1_A0 [4)K>P@64VJOEMN HJU"L3(DJ1*A901\H!&: )
M"BDY*@_4512*[_M-RPB^R8^48&?\: )+Z>.RM6F,._!Q@ 5);M'<6\<PBVAQ
MG!'(H KP178U"8S",VV/D  I]_<QV%N)C!ORP7  H GB\N6%)!& &4'!'(JK
M:178NIS<B(PY_=X H 74+N*PC1S!OW-C@#BK:JC(K>6!D9P10!3L8KL--]M$
M1&X>7M _'^E%_>16)B!M]_F''R@<4 7 B$9V+^5.9%==K $>AH 6B@ HH *P
MY-0NED8"7@$@?*/\* &_VC=_\]?_ !T?X4?VC=_\]?\ QT?X4 ']HW7_ #U_
M\='^%']HW?\ SU_\='^% !_:-U_SU_\ '1_A1_:-U_SU_P#'1_A0 ?VC=_\
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M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L
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M^O_:  P# 0 "$0,1 #\ _5.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#47PZ_Z#[_^ 5Q_\;H^K5OY6']LY=_S_C]Y[#NHW5X]_P -1?#K_H/O_P"
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M@^__ (!7'_QNCZM6_E8?VSEW_/\ C]Y[#NHW5X]_PU%\.O\ H/O_ . 5Q_\
M&Z/^&HOAU_T'W_\  *X_^-T?5JW\K#^V<N_Y_P ?O/8=U&ZO'O\ AJ+X=?\
M0??_ , KC_XW1_PU%\.O^@^__@%<?_&Z/JU;^5A_;.7?\_X_>>P[J-U>/?\
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M^&HOAU_T'W_\ KC_ .-T?5JW\K#^V<N_Y_Q^\]AW4;J\>_X:B^'7_0??_P
MKC_XW1_PU%\.O^@^_P#X!7'_ ,;H^K5OY6']LY=_S_C]Y[#NHW5X]_PU%\.O
M^@^__@%<?_&Z/^&HOAU_T'W_ / *X_\ C='U:M_*P_MG+O\ G_'[SV'=1NKQ
M[_AJ+X=?]!]__ *X_P#C='_#47PZ_P"@^_\ X!7'_P ;H^K5OY6']LY=_P _
MX_>>P[J-U>/?\-1?#K_H/O\ ^ 5Q_P#&Z/\ AJ+X=?\ 0??_ , KC_XW1]6K
M?RL/[9R[_G_'[SV'=1NKQ[_AJ+X=?]!]_P#P"N/_ (W1_P -1?#K_H/O_P"
M5Q_\;H^K5OY6']LY=_S_ (_>>P[J-U>/?\-1?#K_ *#[_P#@%<?_ !NC_AJ+
MX=?]!]__  "N/_C='U:M_*P_MG+O^?\ '[SV'=1NKQ[_ (:B^'7_ $'W_P#
M*X_^-T?\-1?#K_H/O_X!7'_QNCZM6_E8?VSEW_/^/WGL.ZC=7CW_  U%\.O^
M@^__ (!7'_QNC_AJ+X=?]!]__ *X_P#C='U:M_*P_MG+O^?\?O/8=U&ZO'O^
M&HOAU_T'W_\  *X_^-T?\-1?#K_H/O\ ^ 5Q_P#&Z/JU;^5A_;.7?\_X_>>P
M[J-U>/?\-1?#K_H/O_X!7'_QNC_AJ+X=?]!]_P#P"N/_ (W1]6K?RL/[9R[_
M )_Q^\]AW4;J\>_X:B^'7_0??_P"N/\ XW1_PU%\.O\ H/O_ . 5Q_\ &Z/J
MU;^5A_;.7?\ /^/WGL.ZC=7CW_#47PZ_Z#[_ /@%<?\ QNC_ (:B^'7_ $'W
M_P# *X_^-T?5JW\K#^V<N_Y_Q^\]AW4;J\>_X:B^'7_0??\ \ KC_P"-T?\
M#47PZ_Z#[_\ @%<?_&Z/JU;^5A_;.7?\_P"/WGL.ZC=7CW_#47PZ_P"@^_\
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M_#47PZ_Z#[_^ 5Q_\;H^K5OY6']LY=_S_C]Y[#NHW5X]_P -1?#K_H/O_P"
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M@^__ (!7'_QNCZM6_E8?VSEW_/\ C]Y[#NHW5X]_PU%\.O\ H/O_ . 5Q_\
M&Z/^&HOAU_T'W_\  *X_^-T?5JW\K#^V<N_Y_P ?O/8=U&ZO'O\ AJ+X=?\
M0??_ , KC_XW1_PU%\.O^@^__@%<?_&Z/JU;^5A_;.7?\_X_>>P[J-U>/?\
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M^&HOAU_T'W_\ KC_ .-T?5JW\K#^V<N_Y_Q^\]AW4;J\>_X:B^'7_0??_P
MKC_XW1_PU%\.O^@^_P#X!7'_ ,;H^K5OY6']LY=_S_C]Y[#NHW5X]_PU%\.O
M^@^__@%<?_&Z/^&HOAU_T'W_ / *X_\ C='U:M_*P_MG+O\ G_'[SV'=1NKQ
M[_AJ+X=?]!]__ *X_P#C='_#47PZ_P"@^_\ X!7'_P ;H^K5OY6']LY=_P _
MX_>>P[J-U>/?\-1?#K_H/O\ ^ 5Q_P#&Z/\ AJ+X=?\ 0??_ , KC_XW1]6K
M?RL/[9R[_G_'[SV'=1NKQ[_AJ+X=?]!]_P#P"N/_ (W1_P -1?#K_H/O_P"
M5Q_\;H^K5OY6']LY=_S_ (_>>P[J-U>/?\-1?#K_ *#[_P#@%<?_ !NC_AJ+
MX=?]!]__  "N/_C='U:M_*P_MG+O^?\ '[SV'=1NKQ[_ (:B^'7_ $'W_P#
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M_P# *X_^-T?5JW\K#^V<N_Y_Q^\]AW4;J\>_X:B^'7_0??\ \ KC_P"-T?\
M#47PZ_Z#[_\ @%<?_&Z/JU;^5A_;.7?\_P"/WGL.ZC=7CW_#47PZ_P"@^_\
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M/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444
M'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'
MY444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#
M\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y44
M4 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/
MP'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 '
MX#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y
M444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\
MJ/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444
M 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P
M'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X
M#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y4
M44 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J
M/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444 'X#\J/P'Y444
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MH*?NVRM]W_@;C\D8'KF@#U+X'_&"#XN:)J-SY7V6\L[R1'MC]Y868M"Q_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<^*_N/0!XUXF^^WTKY^UG_D,7W_7>3_T(U] ^)OOM]*^?M9_Y#%]_P!=Y/\
MT(U[V4?'/T/R7Q#_ -UP_P#B?Y%.BBBOIS\,"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** #L3_ )'U]**56:-U=6*NK!@5ZCT(/K7Z-?"G
MQ)!XW\ Z+K 2/S9[=1,%7@2+\K@?\"!KAQF)>%BI)7/K.'LDAG=:=%U>1I7V
MO<_.3MGM_GC_ #ZT5]%_MG>$_P"S_%>C:]#'M2]MFMI"HQ^\C.1SZE7_ /'*
M^=*UP]?ZQ24UU/+S?+I93C)X23O;9]T'YXZ?_6I!TSVQFO:_V3?"G]O?%!;^
M1"T&EVSS[L<;V^10?P+G_@-?9?B34[/POH&I:O=(HM[*W>X<]R%4G'U[5Q8O
M'?5ZBIQ5SZG(^%?[6P<L94J<D4WTZ(_,KIUHJWK&IS:YJUYJ%R<SW4SSR>FY
MF+']352O4B[I,^"J14)M1U2_$****JQGKN2VEK+?745M GF3S.(XTSC+$X S
M_CCZUZ0O[-7Q(90P\-,5/.?MEO\ _'*X?PF<>*-&]KV$C_OXM?II:X^SQ_[H
MKR,?BYX:W)U/T/A3A_"YVJSQ$FN6VWF?E]J.GW&DZA=6-W'Y-U;2M#+'N#;7
M4D,,@D'!!Z'%5ZZ'XB?\E \3_P#84NO_ $:U<]7J4VYP3/A,135*O.G'9-K[
MF%%%%6<X4444 %%%%/4 HHHHV *3/&>V?PI:Z+X;_P#)0O#/_83MA^'FKQ2>
MBN:TH>UJ1I]VD<[BBOU&CLX=BG8O ]*H2:UHJSF%[VS$P.TQF5=V>XQGK7SO
M]JMZ*%S]?GP!3BKRQ7*GW7_!/S(]/3K_ /7_ #HK]'_%'PT\)^.H"NJZ-9WK
M,NT7'EA90.O$@^8#\:^0_CI^SW=?"YO[6TV274/#<CA?,D'[RV8]%D('(/0-
MCKP<9&>S#YA3JRY)*S/FLXX/Q66TGB:,E."WMOZGCE%%%>L? >:"D[X_#GBE
MI4V[EW9*YY &?6C8:5VD;.F^!_$>M6*WVG:!JE]9-G%Q;V<LD9P<'Y@I'%8S
M*8V96!5E.&4\$5^DO@77M#U+PCI]UI%U;MIGD*$,;C;&H&-I]"N,$=L5\-_'
MW5M'UKXL:Y>:&\<UD[HIFA(*22!5WL".""P//>O*PV,G6K.FXV/N\ZX=PV5X
M&GBZ5?FE+IIU['GM%)].E+7J^9\%H@HHHH'UL%%%% !1110 4444 %%%%, H
MHHHLQ77<****0!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:S_R&+[_ *[R?^A&OH'Q-]]OI7S]K/\ R&+[_KO)_P"A&O>RCXY^A^2^(?\
MNN'_ ,3_ "*=%%%?3GX8%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8[A81YMV%/+*I8A!UY);D=*YC]H+X,Z=\(;K1%TV^NKV/4%E++=;<J8S&."
M.N_ICMUKZ)^+7[3.C?#'5FT>"RDUG5T"F:)9!%'%D9 9R"=V"#@*>O.*^9OC
M9\:9/C))I$C:0=*.GB8!1<^;NW[#UV+C[GZT\+4QE6I&;?ND9Y@^'\OPE7#8
M?6NO6Z\NQZ3I7[%\NIZ79W@\8+'Y\22[?[-SC< >OF\]:\EU;X81:-\7/^$)
MN=7PGVB*U_M+[,?O2*K+F/?TW,!G=WS7WUX/P?"ND=#_ *)%_P"@BOA7]HJ5
M[?XX>(Y8V*RI-"RLO!!$,9!!J<)B*M6O*$GW-N(LHP& RZAB:=.S;C?5[6U/
M4U_8CE90R^+U/<?\2WK_ .1:^9]0L9M,U"YLK@;9[>5H9!Z,I((_,&OT=^&?
MBF/QMX%T764(+7%NID"]%D PZ_@P(_"OBW]I?PQ_PC'Q>UD(FR'4 M_'C_;!
M#'_OL-58+$U)8B5*KJ<_$^2X+#Y=1Q^!A9.U_1K0?\%_@+<_&"SU*Z75/[)@
MM)%B5S;><)&(R1]]<8&W_OJM/XO?LZP_"7PO'JT_B87\LTZV\-JMEY>]B"2=
MWF' "@GI7T;^S+X7_P"$;^$>E%DV3W^Z^?WW_<_\<"?E7AG[9'C#^U/&MAH$
M,FZ#3+?S) #QYLG8CU"A?^^C26(JU,9[*+]U,O$9+E^ X>6*Q%.]62T=^KV^
MX\0\-^&=3\7:O!IFD6<E[?3?=BC_ %)/0 =R>!7T?X7_ &*V>&.7Q#X@*.R_
M-;Z=%]T_[[]>/]D5W/[*OPYM_#7@2+6YX -4U?$ID8<K#G,:CV(^;_@0]!3/
MVA/VA+CX7WUKHNB6\%QJ\T8GEDN%+)#&20 %!&6.#WXQ[T\1BZU2M[##FN5\
M/Y=@,N6:9O[U[.W:^VG5G+>(?V)[-H2VA^(KB*4 G9?Q+(&/8;EV[?K@U\X>
M./ >M?#S7)-*UNU^SW YCD5BT<RYX9&QR#] 1@\=J^F?@5^TYJOC?Q9%X?\
M$=K:B6Y0_9KFT4K\Z@L5<%CU /(QC&._'=?M+> [?QE\,=2N?+!U#24:]MY
M.0%&77Z%0>/4*>U1'$XC"U53Q&J.C%9'E.=8">,RE<LHWT].EOR/ECX*_!9O
MC%-JL::P-*^PK$V3;>;OW[O]M<8VG\Z[3Q=^R#K.APZ<-)U==:N;R\6V,;6O
MD)"A1V,K-O;Y1MQT[\9. =W]B/G4/%?_ %SMOYRU](>-O&6F> /#MWK6K.Z6
M< QM1=SR,3A44=R3@#\S@9-+&8NM1Q')!Z:#R'A[+<;DZQ&*C:6MY>A\_?\
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M;'7:2!@CN#@CKCD5R%?8GQH^+GPX\?\ PXU?2X];AN+Y8_/LP(9,^<G*8)7
M)(V_\"-?'7';I7L8.M4JP_>1LT?G'$6783+L4E@JBG"2OO>WD+1117>?*A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z-?"'_DF?A'_L
M$6G_ *)2OSEK]&OA#_R3/PC_ -@BT_\ 1*5X.;_!#U/UKP\_WK$?X5^9VM+2
M4M?,'[F%%%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_UAKR']HW_D0;'_L)
MQ_\ HJ6O7M2_UAKR']HW_D0;'_L)Q_\ HJ6@#S[]F7_DM_AKZW/_ *335]_P
M_=6O@#]F7_DM_AKZW/\ Z335]_P_=6@">BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *:_W:=37^[0!DZA]TUYSXK^X]
M>C:A]TUYSXK^X] 'C7B;[[?2OG[6?^0Q??\ 7>3_ -"-?0/B;[[?2OG[6?\
MD,7W_7>3_P!"->]E'QS]#\E\0_\ =</_ (G^13HHHKZ<_# HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?D89X]:XO_AF/X9').B$_P#;_<>G_72K?[0?PPN?BEX'^S6!5=5LI?M-LA;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M) .:\3_2CT]J*].C0AAX\L#X3,,RQ.:5G7Q,KO\ +T"BBBMSS HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]&OA#_P DS\(_]@BT_P#1
M*5^<M?HU\(?^29^$?^P1:?\ HE*\'-_@AZGZUX>?[UB/\*_,[6EI*6OF#]S"
MBBB@"O<?=-<SK'0_2NFN/NFN9UCH?I0!PVI?ZPUY#^T;_P B#8_]A./_ -%2
MUZ]J7^L->0_M&_\ (@V/_83C_P#14M 'GW[,O_);_#7UN?\ TFFK[_A^ZM?
M'[,O_);_  U];G_TFFK[_A^ZM $]%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4U_NTZFO\ =H R=0^Z:\Y\5_<>O1M0
M^Z:\Y\5_<>@#QKQ-]]OI7S]K/_(8OO\ KO)_Z$:^@?$WWV^E?/VL_P#(8OO^
MN\G_ *$:][*/CGZ'Y+XA_P"ZX?\ Q/\ (IT445].?A@4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *:_W:=37^[0!DZA]TUYSXK^X]>C:A]TUY
MSXK^X] 'C7B;[[?2OG[6?^0Q??\ 7>3_ -"-?0/B;[[?2OG[6?\ D,7W_7>3
M_P!"->]E'QS]#\E\0_\ =</_ (G^13HHHKZ<_# HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OT:^$/_),_"/\ V"+3_P!$I7YR
MU^C7PA_Y)GX1_P"P1:?^B4KP<W^"'J?K7AY_O6(_PK\SM:6DI:^8/W,****
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M:][*/CGZ'Y+XA_[KA_\ $_R*=%%%?3GX8%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\U[V4_'+T/R;Q#3^JT'_ 'G^11HHHKZ<_"PHHHHU ****-0"BBBC4 HHHHU
M****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ***
M*-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0
M"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BB
MBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4
M HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HH
MHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU
M ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU **
M**-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-
M0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"B
MBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC
M4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 H
MHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHH
MU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU ****-0"BBBC4 HHHHU *
M***-0"BBBC4 HHHHU ****-0"BBBC4 HHH_&C4 HH_SUHH *_1KX0_\ ),_"
M/_8(M/\ T2E?G+_GT_S]?6OT>^%-O):_#GPK%*ACECTJU1T88((A4$&O!S?X
M(>I^M>'B?UFN^G*OS.QI:2EKY@_<PHHHH KW'W37,ZQT/TKIKC[IKF=8Z'Z4
M <-J7^L->0_M&_\ (@V/_83C_P#14M>O:E_K#7D/[1O_ "(-C_V$X_\ T5+0
M!Y]^S+_R6_PU];G_ -)IJ^_X?NK7P!^S+_R6_P -?6Y_])IJ^_X?NK0!/111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY]#_ -_7_P :]R_X1'_8H_X1'_8H^L5OYF']BY=_SXC]QX;_ ,*YT[_GT/\
MW]?_ !H_X5SIW_/H?^_K_P"->Y?\(C_L4?\ "(_[%'UBM_,P_L7+O^?$?N/#
M?^%<Z=_SZ'_OZ_\ C1_PKG3O^?0_]_7_ ,:]R_X1'_8H_P"$1_V*/K%;^9A_
M8N7?\^(_<>&_\*YT[_GT/_?U_P#&C_A7.G?\^A_[^O\ XU[E_P (C_L4?\(C
M_L4?6*W\S#^Q<N_Y\1^X\-_X5SIW_/H?^_K_ .-'_"N=._Y]#_W]?_&O<O\
MA$?]BC_A$?\ 8H^L5OYF']BY=_SXC]QX;_PKG3O^?0_]_7_QH_X5SIW_ #Z'
M_OZ_^->Y?\(C_L4?\(C_ +%'UBM_,P_L7+O^?$?N/#?^%<Z=_P ^A_[^O_C1
M_P *YT[_ )]#_P!_7_QKW+_A$?\ 8H_X1'_8H^L5OYF']BY=_P ^(_<>&_\
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MV+EW_/B/W'AO_"N=._Y]#_W]?_&C_A7.G?\ /H?^_K_XU[E_PB/^Q1_PB/\
ML4?6*W\S#^Q<N_Y\1^X\-_X5SIW_ #Z'_OZ_^-'_  KG3O\ GT/_ ']?_&O<
MO^$1_P!BC_A$?]BCZQ6_F8?V+EW_ #XC]QX;_P *YT[_ )]#_P!_7_QH_P"%
M<Z=_SZ'_ +^O_C7N7_"(_P"Q1_PB/^Q1]8K?S,/[%R[_ )\1^X\-_P"%<Z=_
MSZ'_ +^O_C1_PKG3O^?0_P#?U_\ &O<O^$1_V*/^$1_V*/K%;^9A_8N7?\^(
M_<>&_P#"N=._Y]#_ -_7_P :/^%<Z=_SZ'_OZ_\ C7N7_"(_[%'_  B/^Q1]
M8K?S,/[%R[_GQ'[CPW_A7.G?\^A_[^O_ (T?\*YT[_GT/_?U_P#&O<O^$1_V
M*/\ A$?]BCZQ6_F8?V+EW_/B/W'AO_"N=._Y]#_W]?\ QH_X5SIW_/H?^_K_
M .->Y?\ "(_[%'_"(_[%'UBM_,P_L7+O^?$?N/#?^%<Z=_SZ'_OZ_P#C1_PK
MG3O^?0_]_7_QKW+_ (1'_8H_X1'_ &*/K%;^9A_8N7?\^(_<>&_\*YT[_GT/
M_?U_\:/^%<Z=_P ^A_[^O_C7N7_"(_[%'_"(_P"Q1]8K?S,/[%R[_GQ'[CPW
M_A7.G?\ /H?^_K_XT?\ "N=._P"?0_\ ?U_\:]R_X1'_ &*/^$1_V*/K%;^9
MA_8N7?\ /B/W'AO_  KG3O\ GT/_ ']?_&C_ (5SIW_/H?\ OZ_^->Y?\(C_
M +%'_"(_[%'UBM_,P_L7+O\ GQ'[CPW_ (5SIW_/H?\ OZ_^-'_"N=._Y]#_
M -_7_P :]R_X1'_8H_X1'_8H^L5OYF']BY=_SXC]QX;_ ,*YT[_GT/\ W]?_
M !H_X5SIW_/H?^_K_P"->Y?\(C_L4?\ "(_[%'UBM_,P_L7+O^?$?N/#?^%<
MZ=_SZ'_OZ_\ C1_PKG3O^?0_]_7_ ,:]R_X1'_8H_P"$1_V*/K%;^9A_8N7?
M\^(_<>&_\*YT[_GT/_?U_P#&C_A7.G?\^A_[^O\ XU[E_P (C_L4?\(C_L4?
M6*W\S#^Q<N_Y\1^X\-_X5SIW_/H?^_K_ .-'_"N=._Y]#_W]?_&O<O\ A$?]
MBC_A$?\ 8H^L5OYF']BY=_SXC]QX;_PKG3O^?0_]_7_QH_X5SIW_ #Z'_OZ_
M^->Y?\(C_L4?\(C_ +%'UBM_,P_L7+O^?$?N/#?^%<Z=_P ^A_[^O_C1_P *
MYT[_ )]#_P!_7_QKW+_A$?\ 8H_X1'_8H^L5OYF']BY=_P ^(_<>&_\ "N=.
M_P"?0_\ ?U_\:/\ A7.G?\^A_P"_K_XU[E_PB/\ L4?\(C_L4?6*W\S#^Q<N
M_P"?$?N/#?\ A7.G?\^A_P"_K_XT?\*YT[_GT/\ W]?_ !KW+_A$?]BC_A$?
M]BCZQ6_F8?V+EW_/B/W'AO\ PKG3O^?0_P#?U_\ &C_A7.G?\^A_[^O_ (U[
ME_PB/^Q1_P (C_L4?6*W\S#^Q<N_Y\1^X\-_X5SIW_/H?^_K_P"-'_"N=._Y
M]#_W]?\ QKW+_A$?]BC_ (1'_8H^L5OYF']BY=_SXC]QX;_PKG3O^?0_]_7_
M ,:/^%<Z=_SZ'_OZ_P#C7N7_  B/^Q1_PB/^Q1]8K?S,/[%R[_GQ'[CPW_A7
M.G?\^A_[^O\ XT?\*YT[_GT/_?U_\:]R_P"$1_V*/^$1_P!BCZQ6_F8?V+EW
M_/B/W'AO_"N=._Y]#_W]?_&C_A7.G?\ /H?^_K_XU[E_PB/^Q1_PB/\ L4?6
M*W\S#^Q<N_Y\1^X\-_X5SIW_ #Z'_OZ_^-'_  KG3O\ GT/_ ']?_&O<O^$1
M_P!BC_A$?]BCZQ6_F8?V+EW_ #XC]QX;_P *YT[_ )]#_P!_7_QH_P"%<Z=_
MSZ'_ +^O_C7N7_"(_P"Q1_PB/^Q1]8K?S,/[%R[_ )\1^X\-_P"%<Z=_SZ'_
M +^O_C1_PKG3O^?0_P#?U_\ &O<O^$1_V*/^$1_V*/K%;^9A_8N7?\^(_<>&
M_P#"N=._Y]#_ -_7_P :/^%<Z=_SZ'_OZ_\ C7N7_"(_[%'_  B/^Q1]8K?S
M,/[%R[_GQ'[CPW_A7.G?\^A_[^O_ (T?\*YT[_GT/_?U_P#&O<O^$1_V*/\
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MBCZQ6_F8?V+EW_/B/W'AO_"N=._Y]#_W]?\ QH_X5SIW_/H?^_K_ .->Y?\
M"(_[%'_"(_[%'UBM_,P_L7+O^?$?N/#?^%<Z=_SZ'_OZ_P#C1_PKG3O^?0_]
M_7_QKW+_ (1'_8H_X1'_ &*/K%;^9A_8N7?\^(_<>&_\*YT[_GT/_?U_\:/^
M%<Z=_P ^A_[^O_C7N7_"(_[%'_"(_P"Q1]8K?S,/[%R[_GQ'[CPW_A7.G?\
M/H?^_K_XT?\ "N=._P"?0_\ ?U_\:]R_X1'_ &*/^$1_V*/K%;^9A_8N7?\
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M<N_Y\1^X\-_X5SIW_/H?^_K_ .-'_"N=._Y]#_W]?_&O<O\ A$?]BC_A$?\
M8H^L5OYF']BY=_SXC]QX;_PKG3O^?0_]_7_QH_X5SIW_ #Z'_OZ_^->Y?\(C
M_L4?\(C_ +%'UBM_,P_L7+O^?$?N/#?^%<Z=_P ^A_[^O_C1_P *YT[_ )]#
M_P!_7_QKW+_A$?\ 8H_X1'_8H^L5OYF']BY=_P ^(_<>&_\ "N=._P"?0_\
M?U_\:/\ A7.G?\^A_P"_K_XU[E_PB/\ L4?\(C_L4?6*W\S#^Q<N_P"?$?N/
M#?\ A7.G?\^A_P"_K_XT?\*YT[_GT/\ W]?_ !KW+_A$?]BC_A$?]BCZQ6_F
M8?V+EW_/B/W'AO\ PKG3O^?0_P#?U_\ &C_A7.G?\^A_[^O_ (U[E_PB/^Q1
M_P (C_L4?6*W\S#^Q<N_Y\1^X\-_X5SIW_/H?^_K_P"-'_"N=._Y]#_W]?\
MQKW+_A$?]BC_ (1'_8H^L5OYF']BY=_SXC]QX;_PKG3O^?0_]_7_ ,:/^%<Z
M=_SZ'_OZ_P#C7N7_  B/^Q1_PB/^Q1]8K?S,/[%R[_GQ'[CPW_A7.G?\^A_[
M^O\ XT?\*YT[_GT/_?U_\:]R_P"$1_V*/^$1_P!BCZQ6_F8?V+EW_/B/W'AO
M_"N=._Y]#_W]?_&C_A7.G?\ /H?^_K_XU[E_PB/^Q1_PB/\ L4?6*W\S#^Q<
MN_Y\1^X\-_X5SIW_ #Z'_OZ_^-'_  KG3O\ GT/_ ']?_&O<O^$1_P!BC_A$
M?]BCZQ6_F8?V+EW_ #XC]QX;_P *YT[_ )]#_P!_7_QH_P"%<Z=_SZ'_ +^O
M_C7N7_"(_P"Q1_PB/^Q1]8K?S,/[%R[_ )\1^X\-_P"%<Z=_SZ'_ +^O_C1_
MPKG3O^?0_P#?U_\ &O<O^$1_V*/^$1_V*/K%;^9A_8N7?\^(_<>&_P#"N=._
MY]#_ -_7_P :/^%<Z=_SZ'_OZ_\ C7N7_"(_[%'_  B/^Q1]8K?S,/[%R[_G
MQ'[CPW_A7.G?\^A_[^O_ (T?\*YT[_GT/_?U_P#&O<O^$1_V*/\ A$?]BCZQ
M6_F8?V+EW_/B/W'AO_"N=._Y]#_W]?\ QH_X5SIW_/H?^_K_ .->Y?\ "(_[
M%'_"(_[%'UBM_,P_L7+O^?$?N/#?^%<Z=_SZ'_OZ_P#C1_PKG3O^?0_]_7_Q
MKW+_ (1'_8H_X1'_ &*/K%;^9A_8N7?\^(_<>&_\*YT[_GT/_?U_\:/^%<Z=
M_P ^A_[^O_C7N7_"(_[%'_"(_P"Q1]8K?S,/[%R[_GQ'[CPW_A7.G?\ /H?^
M_K_XT?\ "N=._P"?0_\ ?U_\:]R_X1'_ &*/^$1_V*/K%;^9A_8N7?\ /B/W
M'AO_  KG3O\ GT/_ ']?_&C_ (5SIW_/H?\ OZ_^->Y?\(C_ +%'_"(_[%'U
MBM_,P_L7+O\ GQ'[CPW_ (5SIW_/H?\ OZ_^-'_"N=._Y]#_ -_7_P :]R_X
M1'_8H_X1'_8H^L5OYF']BY=_SXC]QX;_ ,*YT[_GT/\ W]?_ !H_X5SIW_/H
M?^_K_P"->Y?\(C_L4?\ "(_[%'UBM_,P_L7+O^?$?N/#?^%<Z=_SZ'_OZ_\
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M:/\ A7.G?\^A_P"_K_XU[E_PB/\ L4?\(C_L4?6*W\S#^Q<N_P"?$?N/#?\
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MZ'Z4 <-J7^L->0_M&_\ (@V/_83C_P#14M>O:E_K#7D/[1O_ "(-C_V$X_\
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MT_\ SSB_(_XT>SD'UB W^Q4_NT?V*G]VG?V]/_SSB_(_XT?V]/\ \\XOR/\
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M_C1_;T__ #SB_(_XT>SD'UB W^Q4_NT?V*G]VG?V]/\ \\XOR/\ C1_;T_\
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MQ4_NT[^WI_\ GG%^1_QH_MZ?_GG%^1_QH]G(/K$!O]BI_=H_L5/[M._MZ?\
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MI_\ GG%^1_QH_MZ?_GG%^1_QH]G(/K$!O]BI_=H_L5/[M._MZ?\ YYQ?D?\
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M1_QH_MZ?_GG%^1_QH]G(/K$!O]BI_=H_L5/[M._MZ?\ YYQ?D?\ &C^WI_\
MGG%^1_QH]G(/K$!O]BI_=H_L5/[M._MZ?_GG%^1_QH_MZ?\ YYQ?D?\ &CV<
M@^L0&_V*G]VC^Q4_NT[^WI_^><7Y'_&C^WI_^><7Y'_&CV<@^L0&_P!BI_=I
MPT1/[E']O3_\\XOR/^-']O3_ //.+\C_ (T>SD'UB ^/1U4_=JY#IRKCBJ/]
MOW'_ #SB_(_XTO\ PD%P/^6<7Y'_ !H]G(/K$#<AA"\8JRJXKG8_$<^X;XXR
MG?:#G^==##()HD<=& (J91<=S2%2,]A]%%%0:!1110!7N/NFN9UCH?I737'W
M37,ZQT/TH X;4O\ 6&O(?VC?^1!L?^PG'_Z*EKU[4O\ 6&O(?VC?^1!L?^PG
M'_Z*EH \^_9E_P"2W^&OK<_^DTU??\/W5KX _9E_Y+?X:^MS_P"DTU??\/W5
MH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4![27<M?;/]C]:/MG^Q^M5:*
M]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/MG^Q^M5:* ]I+N6OMG^Q^
MM'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_L?K1]L_V/UJK10'M
M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4![27<M?;/]C]:/MG
M^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/MG^Q^M5:* ]I+
MN6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_L?K1]L_V
M/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4![27<M?;
M/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/MG^Q^
MM5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_
ML?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4
M![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C
M]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/
M:2[EK[9_L?K5A6W*#TR,UFUHQ?ZM/H*.IM3DY/4ZW0_^07#_ ,"_]"-7SVJA
MH?\ R"X?^!?S-7FKAEN?00^%&%XF^];G_>_I7/RR>2H.,\XZUT'B;_EW_P"!
M?TKG+O\ U8_WJZ:?PGF8AV;L-^V?['ZT?;/]C]:JT5J>9[27<M?;/]C]:/MG
M^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/MG^Q^M5:* ]I+
MN6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_L?K1]L_V
M/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4![27<M?;
M/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/MG^Q^
MM5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_
ML?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4
M![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C
M]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/
M:2[EK[9_L?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;
M/]C]:JT4![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=
MRU]L_P!C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_
ML?K56B@/:2[EK[9_L?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^
MV?['ZT?;/]C]:JT4![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/U
MJK10'M)=RU]L_P!C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS
M_8_6C[9_L?K56B@/:2[EK[9_L?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5H
MH#VDNY:^V?['ZT?;/]C]:JT4![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M
M'VS_ &/UJK10/VDB_#-YN?EQ6SX;'^G/_P!<S_,5@6?\=;_AO_C^?_KF?YBH
MG\+/0P\KR5SIJ::44A[UQ'L'#57:[VL1LS@XZU8K/E_UC_4UWGS]:3CL3_;/
M]C]:/MG^Q^M5:*9S>TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_L?K1]L_V/UJK
M10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4![27<M?;/]C]
M:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/MG^Q^M5:*
M ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[EK[9_L?K1
M]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]:JT4![27
M<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L_P!C]:/M
MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K56B@/:2[E
MK[9_L?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['ZT?;/]C]
M:JT4![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10'M)=RU]L
M_P!C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6C[9_L?K5
M6B@/:2[EK[9_L?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VDNY:^V?['
MZT?;/]C]:JT4![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_ &/UJK10
M'M)=RU]L_P!C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW+7VS_8_6
MC[9_L?K56B@/:2[EK[9_L?K1]L_V/UJK10'M)=RU]L_V/UH^V?['ZU5HH#VD
MNY:^V?['ZT?;/]C]:JT4![27<M?;/]C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_
M &/UJK10'M)=RU]L_P!C]:/MG^Q^M5:* ]I+N6OMG^Q^M'VS_8_6JM% >TEW
M+7VS_8_6C[9_L?K56B@/:2[EK[9_L?K1]L_V.?K56E].*!JI*^II5V>G_P#'
MC;_]<U_E7&5V>G_\>-M_US7^585=D>SA=V6****YCO"BBB@"O<?=-<SK'0_2
MNFN/NFN9UCH?I0!PVI?ZPUY#^T;_ ,B#8_\ 83C_ /14M>O:E_K#7D/[1O\
MR(-C_P!A./\ ]%2T >??LR_\EO\ #7UN?_2::OO^'[JU\ ?LR_\ );_#7UN?
M_2::OO\ A^ZM $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7%WW_']<?]=&_F:[2N+OO^/ZX_ZZ-_,U
MO2W9R8C9&7<?ZYOPJ&IKC_7-^%0UTGS\MV%%%%!(4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% @HHHH&
M%%%% !1111W **** "BBB@ HHHH ****/, HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "M&+_5I]!6=6C%_JT^@HZF]'=G6Z'_R"X?^!?S-
M7FJCH?\ R"X?^!?S-7FKAEN?1P^%&%XF_P"7?_@7]*YR[_U8_P!ZNC\3?\N_
M_ OZ5SEW_JQ_O5U4_A/*Q6[*=%%%:'E!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110(****!A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!9L_XJW_#?_'\_P#US/\ ,5@6?\5;_AO_ (_G_P"N9_F*
MB?PL]/#;Q.E6D/>E6D/>N(]HX:L^7_6/]36A6?+_ *Q_J:[SYVN,HHHIG(%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110(****!A1110 4444
M %%%% !1110 4444 %%%% !1110(****!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2K24JT :5=GI__ !XVW_7-
M?Y5QE=GI_P#QXVW_ %S7^585=D>]AMV6****YCO"BBB@"O<?=-<SK'0_2NFN
M/NFN9UCH?I0!PVI?ZPUY#^T;_P B#8_]A./_ -%2UZ]J7^L->0_M&_\ (@V/
M_83C_P#14M 'GW[,O_);_#7UN?\ TFFK[_A^ZM? '[,O_);_  U];G_TFFK[
M_A^ZM $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7%WW_']<?\ 71OYFNTKB[[_ (_KC_KHW\S6]+=G
M)B-D9=Q_KF_"H:FN/]<WX5#72?/RW84444$A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '^%>>ZA^T9
M\)])O[FQO?B?X-L[RVE:&>WN-?M(Y(I%)#(RM("K @@@C((KT+WK^>[XP:6V
ML?M#>-[&-UC>Z\4WT*LW0%KMU!_6L)5&JG(CNP^'C4@Y2=K'[C_\--?![M\5
M_ Y/_8QV?_QRNX\/^)]&\6::NH:'J]AK-@X^6[T^Y2XB/_ D)'ZU^7I_X(\>
M-!D#Q_H+'L/LTW/''0?Y]Z^=_%GA?XL?L%_&*& :HVCZRD:7,%]IDS/9ZA 2
M1R& WID,"CKD$=.AJN?EERST+CAZ=1/V4[L_=>[NH;&UFN;F5+>WA0R222,
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MNO#'B/2/$5M&</-I-]%=(AZX)C8XXI)I[%.,DKM&]12_ABDIDA1110 4444
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MX)$%CI^MVT\\A )(6-'+$X!/ Z FM%?BEX,D\6+X67Q=H3>)V) T5=2@-Z2
M20(-^\D $].@I)IZ(IPDMT=/145U=P6-O)<7,L=O;QKO>:5PJJOJ2> .O?M7
M#6/[07PMU+4ETZS^)7A"\U!FV+:V^NVKRLW3:$$F2?;&:7,MK@H2:O8[ZOF'
MXY?\%"OAS^S_ /$B]\%>(M&\3WFJVD<4LDNF6ML\)61 ZX+W"-G!&<J/QKZ>
M5@ZAE.X'H1T.>G-?BM_P4T/_ !E]XB_Z\[$_^2Z5E.<HU81[G=A*,*RFY=#]
MDO!_BBT\;>$=&\0V*316>K64-_!'< "14E0.H8 D!L,,X)&>YK8KR3X5^._#
M7@/]GKX;WWB?Q%I7AVR?P_8*MSJU[%:QLWV:/@-(P!/7I_\ J]"\+>-/#WCJ
MP-]X;U[3/$%B&VFZTJ\CNH@?3=&Q'ZUU22YW&/0\^TK<S5C&^+GQ<\,? _P/
M>>+/%U__ &?I%L53<J&2261CA8T5>2QY_ $G@$CD/V>_VK? '[3%KJ3^#[N\
M6\TT*]WI^I6_DSQHQ(5^"RLIP>C''&<9JM^UU\+/!7Q?^#-[HGCOQ+:^#M+2
MYBN+?7+RXBA2UN1N"$M(50@AF7:2,ACC!P1Y7^PC^SM\,O@K=>)+KPC\4M)^
M)WB"ZBCBN[C2KBW9+6WW$J/*BED*EF'+,_.T  <YQIMRFTSIE"'L.9;GU[17
M#^(/CI\-O".LSZ1KOQ"\*Z+JUO@36.HZU;03QD@,-R,X89!!Y X(/>M+Q7\4
M?!G@-;=O$WBW0O#BW"[H#J^IPVOFCU7>PSZ\57-'=,QY)WM8Z:BL_0?$6E>*
MM,AU+1-3L]8TZ;F.\L)TGB<>SJ2#T[$UH>G<?S^E-Z;D=;!17'>)_C-\/_!-
M^+#Q'XZ\->'[[&?LVIZM;V\F/7:[@_I6]X>\4:-XNTU-1T'5K'6M/<X6ZTZY
M2XB/T9"03]#233V'RM;HTZ*/\\'-%,04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!9L_XJW_#?_'\__7,_S%8%G_%6
M_P"&_P#C^?\ ZYG^8J)_"ST\-O$Z5:0]Z5:0]ZXCVCAJSY?]8_U-:%9\O^L?
MZFN\^=KC****9R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1111OH"W#_"N C_:$^%DVJ+ID?Q+\'OJ33?9ELUUZU,QE+;1&$\S);/&,
M9S7?]_?/_P!:OY__  T^/VJ]+Q_T.<7_ *7"N?VC]LJ?2QVT</&I3<WNC^@&
MDK*\3>*]$\%:/+JWB'6;#0=*A*K)?:I=1VT"%B%4&21@H)) &3WK/\'_ !.\
M'?$);UO"OBS0_$HLPIN6T?48;L0;MVW?Y;';G:V,XSM/I73*T9./8XHIRBI6
MW.EHKB;/XX?#C4->_L2U^('A>XUDR^4-.BUFW>XW]U\L/NR/3%=M]1CV_"DM
M=AM..C"F7$RV\$LK!BL:EB%&3P,G _S^%5]6UBP\/Z?<7^J7MOIUA NZ6ZNY
M5BBC &<LS$ "N7T?XJ>"OB!8ZE!X7\8:#XDEA@<RQZ/J<-VR#!ZB-CC\:B4K
M)M=C6G3<I*ZTN> _"W_@I5\,?BY\0]%\&Z1H?BRVU35;D6L$U]:6J0*V"<LR
MW+$#CLIKZQK\)/V(V_XRZ^'A!_YBXZ'_ &6K]L_&'Q4\%?#N>VA\5>,-!\,S
M7*EX(]8U."U:50<,5$C@L 2!QGK3B_W492W9OBJ*IUG"!U%%9GAGQ5HGC31X
M=6\/ZQ8:[I<Q817NFW4=Q!(5)#!70D'!!!QT(K"\6?&3P!X"U1=-\3^.?#?A
MS46C646FK:M;VLQC.0'V2.#M)!Y]JIZ;G&HR;LD=A15/1]8L/$6EVNI:5?6V
MIZ==QB:WN[.5989D/1T=20R^XX-5_$GBO0_!NFMJ&OZSI^A:>I :[U*Z2WA7
M/J[D"DVHZ,$FW9&I17*>$?BSX'^(%S);>%_&7A_Q'<1C=)#I.J073H/5EC=B
M!]?_ ->MXH\7:%X)T=]5\1ZUI^@:6C!'O=4NH[:!6)PJF1V"@GL">2<4[V5Q
M\KO;KV-;KG%(S*JEF8*@!8L>@'K7XE_'C]IKQ[_PTEXL_P"$<^*_B(^%O[=E
M^Q?V7XCN#8_9_,X\K9)L\O'IQBOV(\(?$KP7\3K>[M_#7BS0_%/D(HNX](U*
M&[,0<$#>(W8C.&QGDX.*SIRYZ3J+?L=-;#_5YJ,M4>,^&?\ @H1\&O%GQ2C\
M"6&M7AOY[D65MJ,EH18W,Y8(J))G=RW 9E53V.",_27';D5^;OP[_8K^ 'A_
MX\Z7K5E\>= U:VM]4CFT_P )QZE9FY:X64&* RB<M(-^%VB,,>F>]?I'U[[C
M^.:N/\*,GN9XB,83M#82BN9\7?%#P9\/VB7Q1XMT+PXTH)C75M3@M2_^[YCC
M-7/"OCCPYXZLFO/#7B#2_$5FIP;C2;V.YC_[Z1B*:M+8RE&4=T;5%1W5U#8V
MLUS<S);VT*-)+-*P5$4#)8D\ #U)KC_"_P ;?AWXVU:+2O#OCWPQK^J2!F2Q
MTO6;>YG90,DA$<DX'-&E["Y7:]M#M**XWQ!\:/A[X3UC^R=<\=^&=&U08'V'
M4-8MH)^>@V,X;]*ZZVN(KVWBN+:5+B"5 \<D3!D=3T8,."#ZT+57023CNB2J
MFKZQ8>']+NM2U2]M]-TZTB::XO+N58H88U^\[NV JCN2<"K?TY%>2?M=?\FO
M?%/_ +%R]_\ 1+5G4DZ<')&E*'M*B@^IT_A?XV?#OQOK$>D^'?'WAC7]4D5F
M2QTO6;:YG95&6(2-RQ '/ KM*_%G_@F!\W[7&@Y_Z!]]_P"B&K]IZUW@I]PK
M0]G5=-;*PE%%5-6UBPT#3Y;_ %.]M]-L85W27-Y*L42+W)=B !_GO4MI;F:3
MEL6Z*XCP_P#'/X;^+-333=$^(/A76=1D.U+33]:MIY6/H$1R3^7:NX_,_A5>
M:!WCH]SY;^-7_!1+X;_ GXF:KX'U_1?%%YJVFB(S3:;:VSP'S(EE7:SW"'HX
MSD"OI'PSKUOXJ\-Z5K5HDD=KJ5I%>0I, '5)$#J& ) .&&<$CW-?BU_P4>8?
M\-F>-?\ =L#_ .24%?K'X*^)7A#X>?![P ?%/BK1?#*S:%8^4=7U"&T$F+=/
MN^8RY_"L:,^>CSR>MSOQ6'5*48TU>Z_R/5**SO#WB32/%VFQ:CH6JV6M:?*<
M1W>GW"7$+XZX="0>W^>*T1@XP>O3W]*U>FYY_6S"BN0\5?&/P#X%OA9>)/''
MAOP]>$9%OJFK6]M(1ZA9'4_I6WX<\5:)XQTU=0T#6-/URP;[MUIMU'<1-UX#
M(2#233V'RR6Z-2BEI*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *5:2E6@#2KL]/\ ^/&V_P"N:_RKC*[/3_\ CQMO^N:_RK"K
MLCWL-NRQ1117,=X4444 5[C[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_ %AKR']H
MW_D0;'_L)Q_^BI:]>U+_ %AKR']HW_D0;'_L)Q_^BI: //OV9?\ DM_AKZW/
M_I--7W_#]U:^ /V9?^2W^&OK<_\ I--7W_#]U: )Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+OO\
MC^N/^NC?S-=I7%WW_']<?]=&_F:WI;LY,1LC+N/]<WX5#4UQ_KF_"H:Z3Y^6
M["BBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#J_4$$#C/Z%?L,_M&:A^T5\ KRZ\03+/XIT1GT_4;D*%-R/+W13D#H67(/\
MM(QP,XKXK\>_LY_MM?%+0&T/Q59ZKKVD-(LS6=UX@TTH67.UB!/VR:^C?^"<
M_P"SG\1_V?M)^):^/] _L)=4BM#9+]NM[@2&-;CS#^YD?;]]/O8SFB%W"JI=
MG8*W*U3;:<DU\]3\P/AWJWBG1_B%I\_@M[I/%$L[VM@;)=TWF3*T6$Q_%AS@
MCH>>U?>/[(/[ ?Q;^%WQT\'^/_%<.E6EA9R337EN=0$UTN^&5.0H*L=SKG#G
MK7RU^Q)G_AKGX= ]M7&/^^6K]W./_K^O^<XK6BE&$*G4G'5I1J2I);GXS?\
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MVK2^#_%>F6ND^,8H&N+:;3]PMKU%/S *Q8I(H.[&XAL$\8Q7Q!_P4T;_ (S
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M#2]Y=3\!OBE\,T^''QC\0>!UU$W\>EZH^FB_,(0R!7V[]@8X^F?QK]@OV/\
M]C&#]D^3Q-<1>+9/$W]N0P(5DL!:^3Y?F'_GJV[/F'TZ5^6G[3^?^&O_ !X,
M_P#,SS 9ZC]\:_=^/_CV4YP=@_E6=/\ W1U'N_\ (Z\9-JO"FMG9_BC\#O@O
M\W[6W@K/0>-;/'_@<E?JM^W]^T]>_LX_">!?#[K'XO\ $,KVFGRLH;[*B@&6
M<*>"RY7&?XG4\XQ7Y4_!7_D[;P4.W_":V?\ Z7)7U?\ \%BOM/\ PG'PXWY^
MR'3KKR_3?YB;_P!-E*3:PM-=V:U(1GC5?HG^9XE^S/\ L:^.OVRKK6O%-_XD
M;3=*CN/+N=>U027EQ=W) 9E52P+D!E+,S#&Y<9YQD_&;X*_$S]@CXH:/>6GB
M$PRW"M/I>O:4S(DZHPWQNC#J,INC;<I#+RP-?I%_P3-^S#]D7PSY(3S/M=]Y
M^T\[_M#<GWV[?Z5Y5_P6"%K_ ,*E\#%]GVX:VXCZ!O+^SMOP.N,^7^E5B(^P
M<>3R_$RH5G6K2IS6FOX'NOPE^/$?[17[(NJ>+G2*#5/['OK34K>'[L=U' V_
M:,DA6!5P,\!P.U?C]^SOIOCO7?BYI&C?#:^?3/%FK+/8P74<OE&&-XF$S[\$
MH!'O.Y?F&,K\V*^[_P#@FKYO_#(7Q@W;O(^T7NW(X+?8$S_[+^8KY9_X)SL?
M^&R/ @([WW_I#/6JBJF+CTNE^I--^RP]5+HW^1VW[0G_  33\8?!/X9:CXZ;
MQ;8>)ET]5FU.VC@DBEC5F"ET9B?, +#.=IQDXXKTW_@D;\9-7D\4>(OAK>W<
MMUHYLCJMA%*VY;61)%614S]T/YH8CIE">I.?M;]LS_DU7XH8 '_$DG. ,<XK
M\X_^"2^#^TQJ?_8N77_HZWJ<-_'E#H34FZV$<Y;H_8*O)/VNO^37OBG_ -BY
M>_\ HEJ]<_6O(_VNO^37_BG_ -B[>_\ HEJC$?PF<.&O[:/J?EI_P2__ .3M
M]!_[!][_ .B&K]IJ_%G_ ()?_P#)V^A?]>%[_P"B&K]IJZH_PH?,>*_WF?HA
MEQ,+>WEE*L_EJ7*1KEB ,\#]*_&WXF^ OVB/VPOCA;?\))X.\6:!I-[?&&Q7
M5]'N[?3=(MR3@L3'M!"#YF/+$=>@'[%ZMJEKHNEW>H7LJP6=I"]Q-(QX1$!9
MF/T /;I7Y*^.?VZ/C?\ M/?%:/P=\*;J;POI^I7#6VFV.G;(KN5!EO-FN#\T
M9"J6.PJJ@$<XR>25I55U?8Z<+S*FW%)+N9G[5'_!.74OV<_AB_C>P\:KXIL[
M::*&^MY-.-H\2R-M61#YLFX;R 0<8SG)YQ](?\$K?VA/$/Q&\.>(? WB749M
M6ET".*YTV[NFWS+;L2C1%CRRH=N,DD!\=  / _VD?V7/VBOA[\%=;\2?$'XO
MR>)_#EL8/MNBGQ!J%VLA>9%3Y)4"-M8JW/3''2MO_@C_ /\ )6/&X_Z@@_\
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M;^9K>ENSDQ&R,NX_US?A4-37'^N;\*AKI/GY;L****"0HHHH **** "BBB@
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M_@7]*YR[_P!6/]ZNJG\)Y6*W93HHHK0\H**** "BBB@ HHHH **** "BBB@
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M6VCN%D))+B14#!CDY.><UVS*&4J1D'J,54J;E34;[$/%6K^VBNEC\7_V8O\
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M'2?]G'XK6/C:VTF+7);6":#['+.8E;S$*9W '&,^E?8G_#X[6\9_X5AI^/\
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M^'[JU\ ?LR_\EO\ #7UN?_2::OO^'[JT 3T444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'RM\9?^"<?PU^.'Q*U?QQKNM^*K35M4:-IH=.N[
M9(%V1K&-H>W9AP@SECSFOIS0])AT'1;#3+=G>"RMX[:-I""Q5%"@D@ 9P/2K
MM%**4%RK8TG4E4LY,****9F%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!9L_P"*M_PW_P ?S_\ 7,_S
M%8%G_%6_X;_X_G_ZYG^8J)_"ST\-O$Z5:0]Z5:0]ZXCVCAJSY?\ 6/\ 4UH5
MGR_ZQ_J:[SYVN,HHHIG(%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MJTE*M &E79Z?_P >-M_US7^5<979Z?\ \>-M_P!<U_E6%79'O8;=EBBBBN8[
MPHHHH KW'W37,ZQT/TKIKC[IKF=8Z'Z4 <-J7^L->0_M&_\ (@V/_83C_P#1
M4M>O:E_K#7D/[1O_ "(-C_V$X_\ T5+0!Y]^S+_R6_PU];G_ -)IJ^_X?NK7
MP!^S+_R6_P -?6Y_])IJ^_X?NK0!/1110 4444 %%%% !1110 4444 %%%%
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M?Z4?8O\ ;_2@/9S[%6BK7V+_ &_TH^Q?[?Z4![.?8JT5:^Q?[?Z4?8O]O]*
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M?Z4?8O\ ;_2@/9S[%6BK7V+_ &_TH^Q?[?Z4![.?8JT5:^Q?[?Z4?8O]O]*
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MY+?X:^MS_P"DTU??\/W5H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"%=+11[20?5X'-?\(W=?WX?^^C_A1_PC=U_?A_[Z/^%=+11[20?5X'-?\
M"-W7]^'_ +Z/^%'_  C=U_?A_P"^C_A72T4>TD'U>!S7_"-W7]^'_OH_X4?\
M(W=?WX?^^C_A72T4>TD'U>!S7_"-W7]^'_OH_P"%'_"-W7]^'_OH_P"%=+11
M[20?5X'-?\(W=?WX?^^C_A1_PC=U_?A_[Z/^%=+11[20?5X'-?\ "-W7]^'_
M +Z/^%'_  C=U_?A_P"^C_A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^
M^C_A72T4>TD'U>!S7_"-W7]^'_OH_P"%'_"-W7]^'_OH_P"%=+11[20?5X'-
M?\(W=?WX?^^C_A1_PC=U_?A_[Z/^%=+11[20?5X'-?\ "-W7]^'_ +Z/^%'_
M  C=U_?A_P"^C_A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4
M>TD'U>!S7_"-W7]^'_OH_P"%'_"-W7]^'_OH_P"%=+11[20?5X'-?\(W=?WX
M?^^C_A1_PC=U_?A_[Z/^%=+11[20?5X'-?\ "-W7]^'_ +Z/^%'_  C=U_?A
M_P"^C_A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S
M7_"-W7]^'_OH_P"%'_"-W7]^'_OH_P"%=+11[20?5X'-?\(W=?WX?^^C_A1_
MPC=U_?A_[Z/^%=+11[20?5X'-?\ "-W7]^'_ +Z/^%'_  C=U_?A_P"^C_A7
M2T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_"-W7]^
M'_OH_P"%'_"-W7]^'_OH_P"%=+11[20?5X'-?\(W=?WX?^^C_A1_PC=U_?A_
M[Z/^%=+11[20?5X'-?\ "-W7]^'_ +Z/^%'_  C=U_?A_P"^C_A72T4>TD'U
M>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_"-W7]^'_OH_P"%
M'_"-W7]^'_OH_P"%=+11[20?5X'-?\(W=?WX?^^C_A1_PC=U_?A_[Z/^%=+1
M1[20?5X'-?\ "-W7]^'_ +Z/^%'_  C=U_?A_P"^C_A72T4>TD'U>!S7_"-W
M7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_"-W7]^'_OH_P"%'_"-W7]^
M'_OH_P"%=+11[20?5X'-?\(W=?WX?^^C_A1_PC=U_?A_[Z/^%=+11[20?5X'
M-?\ "-W7]^'_ +Z/^%'_  C=U_?A_P"^C_A72T4>TD'U>!S7_"-W7]^'_OH_
MX4?\(W=?WX?^^C_A72T4>TD'U>!S7_"-W7]^'_OH_P"%'_"-W7]^'_OH_P"%
M=+11[20?5X'-?\(W=?WX?^^C_A1_PC=U_?A_[Z/^%=+11[20?5X'-?\ "-W7
M]^'_ +Z/^%'_  C=U_?A_P"^C_A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?
MWX?^^C_A72T4>TD'U>!S7_"-W7]^'_OH_P"%'_"-W7]^'_OH_P"%=+11[20?
M5X'-?\(W=?WX?^^C_A2KX<N-PW21@>Q)_I7248I>TD'L($%I;"UMTB!R%'6I
MS1MHK,WVT10U73?[0C4!@KKG&>G/_P"JLG_A&[G^_#_WT?\ "NEQ15J;CL92
MI1F[LYK_ (1NZ_OP_P#?1_PH_P"$;NO[\/\ WT?\*Z6BJ]I(CZO YK_A&[K^
M_#_WT?\ "C_A&[K^_#_WT?\ "NEHH]I(?U>!S7_"-W7]^'_OH_X4?\(W=?WX
M?^^C_A72T4>TD'U>!S7_  C=U_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%'M)!
M]7@<U_PC=U_?A_[Z/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/\
MA1_PC=U_?A_[Z/\ A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72
MT4>TD'U>!S7_  C=U_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%'M)!]7@<U_PC
M=U_?A_[Z/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/\ A1_PC=U_
M?A_[Z/\ A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>
M!S7_  C=U_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%'M)!]7@<U_PC=U_?A_[Z
M/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/\ A1_PC=U_?A_[Z/\
MA72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_  C=
MU_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/^%'_"-W
M7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/\ A1_PC=U_?A_[Z/\ A72T4>TD
M'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_  C=U_?A_P"^
MC_A1_P (W=?WX?\ OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/^%'_"-W7]^'_OH_
MX5TM%'M)!]7@<U_PC=U_?A_[Z/\ A1_PC=U_?A_[Z/\ A72T4>TD'U>!S7_"
M-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_  C=U_?A_P"^C_A1_P (
MW=?WX?\ OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/^%'_"-W7]^'_OH_X5TM%'M)
M!]7@<U_PC=U_?A_[Z/\ A1_PC=U_?A_[Z/\ A72T4>TD'U>!S7_"-W7]^'_O
MH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_  C=U_?A_P"^C_A1_P (W=?WX?\
MOH_X5TM%'M)!]7@<U_PC=U_?A_[Z/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_P
MC=U_?A_[Z/\ A1_PC=U_?A_[Z/\ A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W
M=?WX?^^C_A72T4>TD'U>!S7_  C=U_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%
M'M)!]7@<U_PC=U_?A_[Z/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[
MZ/\ A1_PC=U_?A_[Z/\ A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C
M_A72T4>TD'U>!S7_  C=U_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%'M)!]7@<
MU_PC=U_?A_[Z/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/\ A1_P
MC=U_?A_[Z/\ A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>T
MD'U>!S7_  C=U_?A_P"^C_A1_P (W=?WX?\ OH_X5TM%'M)!]7@<U_PC=U_?
MA_[Z/^%'_"-W7]^'_OH_X5TM%'M)!]7@<U_PC=U_?A_[Z/\ A1_PC=U_?A_[
MZ/\ A72T4>TD'U>!S7_"-W7]^'_OH_X4?\(W=?WX?^^C_A72T4>TD'U>!S7_
M  C=U_?A_P"^C_A6EI.DG3V:21@SL,?+TK3HJ7-O1E1HQB[H*0TN*,5!L<]<
M>')?-8Q2+L)R V0:C_X1NZ_OP_\ ?1_PKI< 45I[21SNA!G-?\(W=?WX?^^C
M_A1_PC=U_?A_[Z/^%=+13]I(/J\#FO\ A&[K^_#_ -]'_"C_ (1NZ_OP_P#?
M1_PKI:*/:2#ZO YK_A&[K^_#_P!]'_"C_A&[K^_#_P!]'_"NEHH]I(/J\#FO
M^$;NO[\/_?1_PH_X1NZ_OP_]]'_"NEHH]I(/J\#FO^$;NO[\/_?1_P */^$;
MNO[\/_?1_P *Z6BCVD@^KP.:_P"$;NO[\/\ WT?\*/\ A&[K^_#_ -]'_"NE
MHH]I(/J\#FO^$;NO[\/_ 'T?\*/^$;NO[\/_ 'T?\*Z6BCVD@^KP.:_X1NZ_
MOP_]]'_"C_A&[K^_#_WT?\*Z6BCVD@^KP.:_X1NZ_OP_]]'_  H_X1NZ_OP_
M]]'_  KI:*/:2#ZO YK_ (1NZ_OP_P#?1_PH_P"$;NO[\/\ WT?\*Z6BCVD@
M^KP.:_X1NZ_OP_\ ?1_PH_X1NZ_OP_\ ?1_PKI:*/:2#ZO YK_A&[K^_#_WT
M?\*/^$;NO[\/_?1_PKI:*/:2#ZO YK_A&[K^_#_WT?\ "C_A&[K^_#_WT?\
M"NEHH]I(/J\#FO\ A&[K^_#_ -]'_"C_ (1NZ_OP_P#?1_PKI:*/:2#ZO YK
M_A&[K^_#_P!]'_"C_A&[K^_#_P!]'_"NEHH]I(/J\#FO^$;NO[\/_?1_PH_X
M1NZ_OP_]]'_"NEHH]I(/J\#FO^$;NO[\/_?1_P */^$;NO[\/_?1_P *Z6BC
MVD@^KP.:_P"$;NO[\/\ WT?\*/\ A&[K^_#_ -]'_"NEHH]I(/J\#FO^$;NO
M[\/_ 'T?\*/^$;NO[\/_ 'T?\*Z6BCVD@^KP.:_X1NZ_OP_]]'_"C_A&[K^_
M#_WT?\*Z6BCVD@^KP.:_X1NZ_OP_]]'_  H_X1NZ_OP_]]'_  KI:*/:2#ZO
M YK_ (1NZ_OP_P#?1_PH_P"$;NO[\/\ WT?\*Z6BCVD@^KP.:_X1NZ_OP_\
M?1_PH_X1NZ_OP_\ ?1_PKI:*/:2#ZO YK_A&[K^_#_WT?\*/^$;NO[\/_?1_
MPKI:*/:2#ZO YK_A&[K^_#_WT?\ "C_A&[K^_#_WT?\ "NEHH]I(/J\#FO\
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M1_PH_P"$;NO[\/\ WT?\*Z6BCVD@^KP.:_X1NZ_OP_\ ?1_PH_X1NZ_OP_\
M?1_PKI:*/:2#ZO YK_A&[K^_#_WT?\*/^$;NO[\/_?1_PKI:*/:2#ZO YK_A
M&[K^_#_WT?\ "C_A&[K^_#_WT?\ "NEHH]I(/J\#FO\ A&[K^_#_ -]'_"C_
M (1NZ_OP_P#?1_PKI:*/:2#ZO YK_A&[K^_#_P!]'_"C_A&[K^_#_P!]'_"N
MEHH]I(/J\#FO^$;NO[\/_?1_PH_X1NZ_OP_]]'_"NEHH]I(/J\#FO^$;NO[\
M/_?1_P */^$;NO[\/_?1_P *Z6BCVD@^KP.:_P"$;NO[\/\ WT?\*/\ A&[K
M^_#_ -]'_"NEHH]I(/J\#FO^$;NO[\/_ 'T?\*/^$=NO[\7_ 'T?\*Z6EH]I
M(/J\#FX_#<^X;Y(]N><9)_E70PQB&)$'10 *=BEJ)2<MS2-.,-@HHHJ30***
M* *]Q]TUS.L=#]*Z:X^Z:YG6.A^E '#:E_K#7D/[1O\ R(-C_P!A./\ ]%2U
MZ]J7^L->0_M&_P#(@V/_ &$X_P#T5+0!Y]^S+_R6_P -?6Y_])IJ^_X?NK7P
M!^S+_P EO\-?6Y_])IJ^_P"'[JT 3T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_UAKR']HW_ )$&Q_["<?\ Z*EK
MU[4O]8:\A_:-_P"1!L?^PG'_ .BI: //OV9?^2W^&OK<_P#I--7W_#]U:^ /
MV9?^2W^&OK<_^DTU??\ #]U: )Z*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"O<?=-<SK'0_2NFN/NFN9UCH?I0!PVI?ZPUY#^T;_P B#8_]A./_ -%2UZ]J
M7^L->0_M&_\ (@V/_83C_P#14M 'GW[,O_);_#7UN?\ TFFK[_A^ZM? '[,O
M_);_  U];G_TFFK[_A^ZM $]%%% !1110 4444 %%%% !1110 4444 %%%%
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M?@/RI**/8T_Y%]P"_@/RH_ ?E244>QI_R+[@%_ ?E1^ _*DHH]C3_D7W +^
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M%_ ?E1^ _*DHH]C3_D7W +^ _*C\!^5)11[&G_(ON 7\!^5'X#\J2BCV-/\
MD7W +^ _*C\!^5)11[&G_(ON 7\!^5'X#\J2BCV-/^1?< OX#\J/P'Y4E%'L
M:?\ (ON 7\!^5'X#\J2BCV-/^1?< OX#\J/P'Y4E%'L:?\B^X!?P'Y4?@/RI
M**/8T_Y%]P"_@/RH_ ?E244>QI_R+[@%_ ?E1^ _*DHH]C3_ )%]P"_@/RH_
M ?E244>QI_R+[@%_ ?E1^ _*DHH]C3_D7W +^ _*C\!^5)11[&G_ "+[@%_
M?E1^ _*DHH]C3_D7W +^ _*C\!^5)11[&G_(ON 7\!^5'X#\J2BCV-/^1?<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^]?^"5_^N^)?TTW_P!NZ_0:
M/I7Y\?\ !*__ %_Q+^FF_P [NOT'CZ5_/?$__(VK>J_)'/+<?1117RQ 4444
M 5[C[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_6&O(?VC?^1!L?\ L)Q_^BI:]>U+
M_6&O(?VC?^1!L?\ L)Q_^BI: //OV9?^2W^&OK<_^DTU??\ #]U:^ /V9?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /O3_@E?_P ?'Q+^FF?S
MNZ_0:+[M?GS_ ,$K_P#CX^)?TTS^=W7Z#1?=K^>^)_\ D;5O5?DCGEN24445
M\L0%%%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_UAKR']HW_D0;'_L)Q_\
MHJ6O7M2_UAKR']HW_D0;'_L)Q_\ HJ6@#S[]F7_DM_AKZW/_ *335]_P_=6O
M@#]F7_DM_AKZW/\ Z335]_P_=6@">BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBBF 4444@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^]/\ @E?_ ,?'Q+^F
MF?SNZ_0:+[M?GS_P2O\ ^/CXE_33/YW=?H-%]VOY[XG_ .1M6]5^2.>6Y)11
M17RQ 4444 5[C[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_6&O(?VC?\ D0;'_L)Q
M_P#HJ6O7M2_UAKR']HW_ )$&Q_["<?\ Z*EH \^_9E_Y+?X:^MS_ .DTU??\
M/W5KX _9E_Y+?X:^MS_Z335]_P /W5H GHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $IK+3Z* *D\8(-<[JT0VMQ73S=#7/:O\ <- ' ZLO[PUYS\: /^%5ZY_V
MP_\ 1\=>DZM]\UYQ\:O^25ZY_P!L/_1\= 'SU\+AGXF^$?\ L+V8_P#(Z5^D
M%M&-HK\W_A9_R4[PA_V&+/\ ]'I7Z26_W!0!,JXIXH%+0 4444 %-?[M.IK_
M ': ,G4/NFO.?%?W'KT;4/NFO.?%?W'H \:\3??;Z5^<WQ&_Y*%XH_["EU_Z
M.:OT9\3??;Z5^<WQ&_Y*%XH_["EU_P"CFK],X'_WFM_A7YFM/<YVBBBOV$V"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHIK< _P GFBOU$^"'[%OP
M<\8_!_P5KFK^$3=ZIJ&D6MU<S_VG>)YDCQ*S-M68 9))P !Z5VO_  P7\#/^
MA(/_ (-[[_X_7Y[5XSP=&<J<J<KIVZ?YF:J1>I^0WKQVS2]S7ZZS?L#_  -E
MC*IX->(_WX]5O20?QF(_.O /C9_P33CL=+N-4^&NK7-W<PJSMHFK.K-+WVQ3
M +@XX"N.<C+BM\+QAEV(FH2O%OOM^!2DF['P114UY9SZ?=3VMU!);7,#M%+#
M,A1D=3AE8'D$'@@]"*AK[F,E)71044450!1112 ****/4 HHHI@%%%%( HHH
MH **** "BBB@ HHHI^H!1Z=^W7O17Z.?L#_L]_#[Q)\'$\5:[H.F^)]8U"ZF
MAD75($NDM5C<A8UC<%5)QOSC)WCM7BYMF=/*</\ 6*D;ZVL1*7*TC\X^WIQG
M\**^U_\ @HQ\$O!7PY7PQK_AC3++P]=ZA++;W.GV,:Q12*B@B58Q@*5S@E0,
M[AGGK\4?ABM,LS"&9X:.)@FD^Y?1/N%%%%>J 4444=+@%%%%'6P!1110 444
M4 +2<_3U)-?6O[ GP(\#_&^^\:Q>--%_ME-.CM&MA]JFA\LN9=Q_=NN<[%ZY
MZ5]B_P##!/P,[>"3D\9_M:^_^/5\7F'%.&RW$2PM2$FU;:WKW,^>)^0M%>H?
MM+?"Q/@W\:O$OAJVA>'2XY_M&GABS?Z-( Z*&8DG;DIN).2AKR_]:^LPV(AB
MJ4*]/:2N:N-MP]?;WQ2UW?P)^';?%?XN^%O"VPO!?WJ"YVD@BW4%YB".AV*W
MXD<U^GW_  P3\#-H_P"*(.?^PM??_'Z^?S;B'#934C3JQ<FU?2VGJ9<Z3Y3\
MA2<45]@_M]? +P+\$+?P6W@O1#HS:A)=BY;[9/-Y@01%1^\D;&"[=,=:^/J]
M7+<PAF>&6)III/N:VLD^X4445Z@@HHHI+57 ****8!1110 4444@"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%'_84NO_ $<U?IG _P#O-;_"OS-:>YSM%%%?L)L%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'WI_P2O_X^/B7]-,_G=U^@T7W:
M_/G_ ()7_P#'Q\2_IIG\[NOT&B^[7\]\3_\ (VK>J_)'/+<DHHHKY8@****
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M\E"\4?\ 84NO_1S5^F<#_P"\UO\ "OS-:>YSM%%%?L)L%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR[D 4S*IY,;<'(SC=@G(K\C/#FAS>)O$.F:/;210W&H745I').2(T:1PBER
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MR@_8=_Y.D\"@?\];G_TFEK]7_B?_ ,DU\5\\?V5=#_R$U?E!^PZ?^,I/ O\
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M)1117RQ 4444 5[C[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_6&O(?VC?^1!L?\
ML)Q_^BI:]>U+_6&O(?VC?^1!L?\ L)Q_^BI: //OV9?^2W^&OK<_^DTU??\
M#]U:^ /V9?\ DM_AKZW/_I--7W_#]U: )Z*** "BBB@ HHHH **** "BBB@
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MI7YS?$;_ )*%XH_["EU_Z.:OTS@?_>:W^%?F:T]SG:***_838**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5Z3^SG\2M,^$/QF\-^+M8@NKK3M->9I8
M;%4>9M\$B#:&90?F<9R1T->;4O\ +&,5C7HQQ%*5&IM)68FKZ,_2/QE_P4G^
M&OB+PCK6E6^A>*XY[ZRFM8WEM;4(&=&4$D7!XR>V:_-NCZ''OWHKR<LR?"Y3
MS?5K^]O=W''2/*%%%%>X 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!]Z?\$K_ /CX^)?TTS^=W7Z#1?=K\^?^"5__ !\?$OZ:9_.[K]!H
MONU_/?$__(VK>J_)'/+<DHHHKY8@**** *]Q]TUS.L=#]*Z:X^Z:YG6.A^E
M'#:E_K#7D/[1O_(@V/\ V$X__14M>O:E_K#7D/[1O_(@V/\ V$X__14M 'GW
M[,O_ "6_PU];G_TFFK[_ (?NK7P!^S+_ ,EO\-?6Y_\ 2::OO^'[JT 3T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!#-T-<]K'^K/TKH9NAKGM8_U9^E '
M":M]\UYQ\:O^25ZY_P!L/_1\=>CZM]\UYQ\:O^25ZY_VP_\ 1\= 'SU\+/\
MDIWA#_L,6?\ Z/2OTDM_N"OS;^%G_)3O"'_88L__ $>E?I);_<% %FEI*6@
MHHHH *:_W:=37^[0!DZA]TUYSXK^X]>C:A]TUYSXK^X] 'C7B;[[?2OSF^(W
M_)0O%'_84NO_ $<U?HSXF^^WTK\YOB-_R4+Q1_V%+K_T<U?IG _^\UO\*_,U
MI[G.T445^PFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "4+Q1_V%+K_ -'-7Z,^)OOM]*_.;XC?\E"\4?\ 84NO_1S5^F<#_P"\UO\
M"OS-:>YSM%%%?L)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!]Z?\ !*__ (^/B7]-,_G=U^@T7W:_/G_@E?\ \?'Q+^FF?SNZ
M_0:+[M?SWQ/_ ,C:MZK\D<\MR2BBBOEB HHHH KW'W37,ZQT/TKIKC[IKF=8
MZ'Z4 <-J7^L->0_M&_\ (@V/_83C_P#14M>O:E_K#7D/[1O_ "(-C_V$X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_C5?=7_")'^Y^E'_  B1_N?I1_KAFO\ ,ON#G9\*_P##)_C#_G_T;_O]-_\
M&J/^&3_&'_/_ *-_W^F_^-5]U?\ ")'^Y^E'_")'^Y^E'^N&:_S+[@YV?"O_
M  R?XP_Y_P#1O^_TW_QJC_AD_P 8?\_^C?\ ?Z;_ .-5]U?\(D?[GZ4?\(D?
M[GZ4?ZX9K_,ON#G9\*_\,G^,/^?_ $;_ +_3?_&J/^&3_&'_ #_Z-_W^F_\
MC5?=7_")'^Y^E'_")'^Y^E'^N&:_S+[@YV?"O_#)_C#_ )_]&_[_ $W_ ,:H
M_P"&3_&'_/\ Z-_W^F_^-5]U?\(D?[GZ4?\ ")'^Y^E'^N&:_P R^X.=GPK_
M ,,G^,/^?_1O^_TW_P :H_X9/\8?\_\ HW_?Z;_XU7W5_P (D?[GZ4?\(D?[
MGZ4?ZX9K_,ON#G9\*_\ #)_C#_G_ -&_[_3?_&J/^&3_ !A_S_Z-_P!_IO\
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M8?\ /_HW_?Z;_P"-5]U?\(D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\,G^,/\
MG_T;_O\ 3?\ QJC_ (9/\8?\_P#HW_?Z;_XU7W5_PB1_N?I1_P (D?[GZ4?Z
MX9K_ #+[@YV?"O\ PR?XP_Y_]&_[_3?_ !JC_AD_QA_S_P"C?]_IO_C5?=7_
M  B1_N?I1_PB1_N?I1_KAFO\R^X.=GPK_P ,G^,/^?\ T;_O]-_\:H_X9/\
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M1_N?I1_PB1_N?I1_KAFO\R^X.=GPK_PR?XP_Y_\ 1O\ O]-_\:H_X9/\8?\
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ME'_")'^Y^E'^N&:_S+[@YV?"O_#)_C#_ )_]&_[_ $W_ ,:H_P"&3_&'_/\
MZ-_W^F_^-5]U?\(D?[GZ4?\ ")'^Y^E'^N&:_P R^X.=GPK_ ,,G^,/^?_1O
M^_TW_P :H_X9/\8?\_\ HW_?Z;_XU7W5_P (D?[GZ4?\(D?[GZ4?ZX9K_,ON
M#G9\*_\ #)_C#_G_ -&_[_3?_&J/^&3_ !A_S_Z-_P!_IO\ XU7W5_PB1_N?
MI1_PB1_N?I1_KAFO\R^X.=GPK_PR?XP_Y_\ 1O\ O]-_\:H_X9/\8?\ /_HW
M_?Z;_P"-5]U?\(D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\,G^,/\ G_T;_O\
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M_P"-5]U?\(D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\,G^,/\ G_T;_O\ 3?\
MQJC_ (9/\8?\_P#HW_?Z;_XU7W5_PB1_N?I1_P (D?[GZ4?ZX9K_ #+[@YV?
M"O\ PR?XP_Y_]&_[_3?_ !JC_AD_QA_S_P"C?]_IO_C5?=7_  B1_N?I1_PB
M1_N?I1_KAFO\R^X.=GPK_P ,G^,/^?\ T;_O]-_\:H_X9/\ &'_/_HW_ '^F
M_P#C5?=7_")'^Y^E'_")'^Y^E'^N&:_S+[@YV?"O_#)_C#_G_P!&_P"_TW_Q
MJC_AD_QA_P _^C?]_IO_ (U7W5_PB1_N?I1_PB1_N?I1_KAFO\R^X.=GPK_P
MR?XP_P"?_1O^_P!-_P#&J/\ AD_QA_S_ .C?]_IO_C5?=7_")'^Y^E'_  B1
M_N?I1_KAFO\ ,ON#G9\*_P##)_C#_G_T;_O]-_\ &J/^&3_&'_/_ *-_W^F_
M^-5]U?\ ")'^Y^E'_")'^Y^E'^N&:_S+[@YV?"O_  R?XP_Y_P#1O^_TW_QJ
MC_AD_P 8?\_^C?\ ?Z;_ .-5]U?\(D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\
M,G^,/^?_ $;_ +_3?_&J/^&3_&'_ #_Z-_W^F_\ C5?=7_")'^Y^E'_")'^Y
M^E'^N&:_S+[@YV?"O_#)_C#_ )_]&_[_ $W_ ,:H_P"&3_&'_/\ Z-_W^F_^
M-5]U?\(D?[GZ4?\ ")'^Y^E'^N&:_P R^X.=GPK_ ,,G^,/^?_1O^_TW_P :
MH_X9/\8?\_\ HW_?Z;_XU7W5_P (D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\
M#)_C#_G_ -&_[_3?_&J/^&3_ !A_S_Z-_P!_IO\ XU7W5_PB1_N?I1_PB1_N
M?I1_KAFO\R^X.=GPK_PR?XP_Y_\ 1O\ O]-_\:H_X9/\8?\ /_HW_?Z;_P"-
M5]U?\(D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\,G^,/\ G_T;_O\ 3?\ QJC_
M (9/\8?\_P#HW_?Z;_XU7W5_PB1_N?I1_P (D?[GZ4?ZX9K_ #+[@YV?"O\
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MFO\ ,ON#G9\*_P##)_C#_G_T;_O]-_\ &J/^&3_&'_/_ *-_W^F_^-5]U?\
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M_P!-_P#&J/\ AD_QA_S_ .C?]_IO_C5?=7_")'^Y^E'_  B1_N?I1_KAFO\
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M4?\ ")'^Y^E'^N&:_P R^X.=GPK_ ,,G^,/^?_1O^_TW_P :H_X9/\8?\_\
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M_")'^Y^E'^N&:_S+[@YV?"O_  R?XP_Y_P#1O^_TW_QJC_AD_P 8?\_^C?\
M?Z;_ .-5]U?\(D?[GZ4?\(D?[GZ4?ZX9K_,ON#G9\*_\,G^,/^?_ $;_ +_3
M?_&J/^&3_&'_ #_Z-_W^F_\ C5?=7_")'^Y^E'_")'^Y^E'^N&:_S+[@YV?"
MO_#)_C#_ )_]&_[_ $W_ ,:H_P"&3_&'_/\ Z-_W^F_^-5]U?\(D?[GZ4?\
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MO7/^V'_H^.@#YZ^%G_)3O"'_ &&+/_T>E?I);_<%?FW\+/\ DIWA#_L,6?\
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M/^$DM?\ GE+^0_QH_P"$DM?^>4OY#_&CV%7^4+&?_P (ZG]RC_A'4_N5H?\
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M?^>4OY#_ !H_X22U_P">4OY#_&CV%7^4+&?_ ,(ZG]RC_A'4_N5H?\)):_\
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M_A)+7_GE+^0_QH]A5_E"QG_\(ZG]RC_A'4_N5H?\)):_\\I?R'^-'_"26O\
MSRE_(?XT>PJ_RA8S_P#A'4_N4?\ ".I_<K0_X22U_P">4OY#_&C_ (22U_YY
M2_D/\:/85?Y0L9__  CJ?W*/^$=3^Y6A_P )):_\\I?R'^-'_"26O_/*7\A_
MC1["K_*%C/\ ^$=3^Y1_PCJ?W*T/^$DM?^>4OY#_ !H_X22U_P">4OY#_&CV
M%7^4+&?_ ,(ZG]RC_A'4_N5H?\)):_\ /*7\A_C1_P )):_\\I?R'^-'L*O\
MH6,__A'4_N4?\(ZG]RM#_A)+7_GE+^0_QH_X22U_YY2_D/\ &CV%7^4+&?\
M\(ZG]RC_ (1U/[E:'_"26O\ SRE_(?XT?\)):_\ /*7\A_C1["K_ "A8S_\
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MRC_A'4_N5H?\)):_\\I?R'^-'_"26O\ SRE_(?XT>PJ_RA8S_P#A'4_N4?\
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M6+3B[,0M%%%( HHHH KW'W37,ZQT/TKIKC[IKF=8Z'Z4 <-J7^L->0_M&_\
M(@V/_83C_P#14M>O:E_K#7D/[1O_ "(-C_V$X_\ T5+0!Y]^S+_R6_PU];G_
M -)IJ^_X?NK7P!^S+_R6_P -?6Y_])IJ^_X?NK0!/1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5_R2O7/^V'_H^.O1]6^^:\X^-7_)*]<_[8?^CXZ /GKX6?\ )3O"'_88L_\
MT>E?I);_ '!7YM_"S_DIWA#_ +#%G_Z/2OTDM_N"@"S2TE+0 4444 %%%% %
M>XX4UR^O-^[;Z5U%Q]TURFO?ZIOI0!Y/XLFQOYK$^'$QD\57()X^RL?_ !]*
MU/%WWI*Q?AG_ ,C==#_IT?\ ]#2MZ'\1 >ITM%%>\6%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1111U Z/P;Q)=?\  ?ZUV4?W:XWP
M=_K+G_@/]:[*/[HKQ,1\9+'4M)2URB"BBB@"O<?=-<SK'0_2NFN/NFN9UCH?
MI0!PVI?ZPUY#^T;_ ,B#8_\ 83C_ /14M>O:E_K#7D/[1O\ R(-C_P!A./\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBBGY""BBBD,**** "BBB@ HHHH ****-.X!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% @HHHH&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:O\ DE>N?]L/_1\= 'SU\+/^2G>$/^PQ9_\ H]*_22W^X*_-OX6?\E.\(?\
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MKZ(I:OEZG<T5\;Z3_P %6/@IJ6N1V$]OXHTNV9]IU*[TZ,P*/[Q$<SR8_P"
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M 7Q&^!OC#XFP:5KD'ACP\TEM>V]_:PB><A$8K&@F*-D2*OS.O7%</^P]X@^
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MV9VM%?-?QJ_;X^'?P)^*#>!->T[Q!=ZNB0.\^G6]N]O'YH!4,TDZ,, @GY>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9P1XQ^V)\.]#^$?[6UWH'P\MCI<$,EC/;V<<C.+:Z=4?:A8DXW$, 2<;N,#
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MC'L,"N:L[7P]\'?AS' NS2/#'AO3<%E4E8+:%/F; Y)"J3P"2?K6#\'OVA/
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MW.B<]!'QUJ?_ ()1^$SKG[1&NZ]*N^+2M'F;>>TDLB(/S7S*Y']H>Z;X'_\
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M@#X*^(_!,W@C2(]!FU>WN3>6-N[&'$9C"2*&)VD[V!QP=HXSDG[R_8+\*_\
M"(_LG_#^V9=LEW:/J#G'_/>5Y5_\=9?R%?FQ^WU\?]#_ &C/C=IT_A":;4-
MTNQCTZVG>%HQ<2F1W=T5@& )=5&0"=O3&#7[$> /#<7@[P+X<T&%0L.EZ=;V
M: # Q'$J#^5/!VY9SMN[?(NM9U8I=$;V?E)Z>IK\7/A<?^%V_P#!1"TO2?/A
MO/%\^HIW_=02O,H^FR(5^O'Q;\4KX'^%OB_Q#(<+I>D75Y]2D3,/U K\@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHHZ@=%X/_P!9<?\  ?ZUV<?W17&>#_\ 67'_
M  '^M=G']T5XF(^,ECJ6DI:Y1!1110!7N/NFN9UCH?I737'W37,ZQT/TH X;
M4O\ 6&O(?VC?^1!L?^PG'_Z*EKU[4O\ 6&O(?VC?^1!L?^PG'_Z*EH \^_9E
M_P"2W^&OK<_^DTU??\/W5KX _9E_Y+?X:^MS_P"DTU??\/W5H GHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"&;H:Y[6/]6?I70S=#7/:Q_JS]* .$U;[Y
MKSCXU?\ )*]<_P"V'_H^.O1]6^^:\X^-7_)*]<_[8?\ H^.@#YZ^%G_)3O"'
M_88L_P#T>E?I);_<%?FW\+/^2G>$/^PQ9_\ H]*_22W^X* +-+24M !1110
M4444 5[C[IKE->_U3_2NKN/NFN4U[_5/]* /(/%WWI*Q?AG_ ,C==?\ 7H__
M *,CK:\7?>DK%^&?_(W77_7H_P#Z,CK>A_$0'JE%%%>\6%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M Q+^8K['KQK]I#]EGPO^U#IFBZ?XIU77-.M=)FDGBCT:>&+S'=54E_,BDS@
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M5+N]L=-UBW-M<3:<Z).$)!(4NK 9QCE3P37R;_PZ/^#_ #_Q4?C?_P #K/\
M^1:^W**RE1A)\\EJ5>ZLSYL^$W_!/7X,?"34[?5+?0KCQ)JUNV^&\\13BZ,9
M&,$1!5BR",ABF0>A%?2=%%:Q2BK):$<JO<\L^.7[,WP]_:(T^"#QGH@NKNU4
MK:ZE:R&&[M\]ED'49YVL&7/.,UXMX._X)<?!/PKK"7UW'K_B98V#K9ZQ?IY
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MJ22#DG)))).3FNZKFOB3X#LOBAX!UWPEJ5S=V>GZQ:/9W$U@ZI.L;C#;"RL
M2..5/6LIT[4I1IK<J/+SJ4C\E_\ @F]\*-)^,GQM\2Q^*-,AUK1(="N3<0W2
M[E,DLB(#GJ&P7((P01D'(K[/T3_@EK\$M'\3C5I4\0:I:K(9%T>^U!#:#T7Y
M(UD('H9#G'.:]*_9M_8]\%_LMW6O7'A74-;U&76$A2=M9GAE*+&7(">7%'C.
M\YSGH.E>Z55.C"$(JVJ,]9.3EU.+^('PFT3X@?"W4OA_(9]#\/WUHM@5T7RX
M'A@!'R1Y1E487&-IX)QBN&_9L_9(\&_LMQZ\OA6^UG46UDP_:)-9GBE91%OV
MA/+BCP/WC9SGM7MM%:<JYG/JRFKI+M^!\W?'[]@[P'^T=X^7Q=XGUOQ-:ZBE
MK'9K#IEU;QPK&A8C >!SDEFSSWKV[Q?X%L/&7P_U;P?/-<V.F:EITFER2V3*
MLT<+QF,["RLH(4G&5(]JZ.BIC3C&+A;1]"KOFYNIX)^S?^QAX'_9?UK6=5\+
M:AKFHW>J6Z6TK:Q<0RB-%;=\GEPQXR<9SGH*],^*/PE\(_&CPO+X>\9:);ZW
MI;L)%CFW*\3@8#QNI#(V#C<I!QQTXKKZ*;@G'DZ$KW6VNI\;67_!*7X*VNM?
M;I;GQ3>6V_=_9L^I1B#']W*0K)C_ ('GWKZ0M?@OX4T7X5:A\/?#^GCPQX<O
M+*:Q,>DX21%E0H\@9@VZ0@YWN&)/)S7<T4*G"*Y4M ^US'S_ /LY?L3^!/V8
MO$FJ:YX8U#7=1OM0M19R'6+B"14CWASL\N&/!)49R3TJS^TE^QSX._:BU#1+
MOQ7J_B"P;2(I(K>/1[B"-")&4L6$D,F3\HZ$=*]WHI2IQE%1:T0X^[>W4YSX
M=^!=.^&7@30O">DM-)IFCV4=C ]TRM*Z(H4,Y  +'&3@ <G@=*^;/&W_  3#
M^#/C+Q=<Z\@U[0/M,IGETW2+V-+1G));"R1.R@DGY58 9P !7UM13E",Y<\E
MJA+2/)T([>!+6WBAC&(XU"*"<\ 8%2445;U!*RL>3_M&?LV^&_VG/"NF^'_%
M&I:QIUA8W@OD.CS11.\@1D 8R1N" ';H!6G\!?@5X>_9V^'T7@_PS/?W6G1W
M$MR9]2DC>=WD()W%$13C  ^7H*]%HJ8Q49.25F]QRU=^P5\[?'+]@OX3_'K7
M9M=U?3[[0]>N"#<ZEH-PL$EQCO(CH\9/JVS<>,G@5]$T5,J<:GQJX)M+0^=_
M@E^P7\(_@5K,&M:3I-WK>O6Y)M]3UZX%Q)"3CE$54C5ACA@FX<X/)KZ&DC29
M&21%=&!5E8<$'J,4ZBKY4URM:"24=CY)\??\$P?@IXXUZ75+:#6O"AF8O)::
M!>1QV[,3DD)+%)L'^RFU1V KUOX&_LK_  W_ &>+>8^#]"$.HW$?E7&K7DAG
MNY5XRI<_=4D E4"J2 <<5ZW140IQI_ K US;GS]^T9^Q3X+_ &G?%&F:YXJU
MKQ'8SZ=:?8X+?2;FWCA"[V<L1) YW$M@G.,*./7V+1O ^CZ+X%L/" M$O-"L
M]/CTQ;:\195D@2,1[7!&ULJ,$8P>>*WZ*?)%)I+<J]VI/=(^0/%O_!+3X)^)
MM:DO[,>(?#44AW-8Z1J">1G.3@312,,^@8 =@*]G^"'[+?PV_9[CF;P;X?6V
MU"XC$5QJ=U*T]U*N02N]C\JD@$J@520#BO6**4(1IZP6I+2>^H4445H,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBCJ!
MT7@__67'_ ?ZUV<?W17&>#_]9<?\!_K79Q_=%>)B/C)8ZEI*6N404444 5[C
M[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_6&O(?VC?^1!L?\ L)Q_^BI:]>U+_6&O
M(?VC?^1!L?\ L)Q_^BI: //OV9?^2W^&OK<_^DTU??\ #]U:^ /V9?\ DM_A
MKZW/_I--7W_#]U: )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AFZ&N>U
MC_5GZ5T,W0USVL?ZL_2@#A-6^^:\X^-7_)*]<_[8?^CXZ]'U;[YKSCXU?\DK
MUS_MA_Z/CH ^>OA9_P E.\(?]ABS_P#1Z5^DEO\ <%?FW\+/^2G>$/\ L,6?
M_H]*_22W^X* +-+24M !1110 4444 5[C[IKE->_U3_2NKN/NFN4U[_5/]*
M/(/%WWI*Q?AG_P C==?]>C_^C(ZVO%WWI*Q?AG_R-UU_UZ/_ .C(ZWH?Q$!Z
MI1117O%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4=0.B\'_ .LN/^ _UKLX_NBN,\'_ .LN/^ _UKLX_NBO$Q'QDL=2TE+7*(**
M** *]Q]TUS.L=#]*Z:X^Z:YG6.A^E '#:E_K#7D/[1O_ "(-C_V$X_\ T5+7
MKVI?ZPUY#^T;_P B#8_]A./_ -%2T >??LR_\EO\-?6Y_P#2::OO^'[JU\ ?
MLR_\EO\ #7UN?_2::OO^'[JT 3T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!#-T-<]K'^K/TKH9NAKGM8_U9^E '":M]\UYQ\:O^25ZY_VP_\ 1\=>CZM]
M\UYQ\:O^25ZY_P!L/_1\= 'SU\+/^2G>$/\ L,6?_H]*_22W^X*_-OX6?\E.
M\(?]ABS_ /1Z5^DEO]P4 6:6DI: "BBB@ HHHH KW'W37*:]_JG^E=7<?=-<
MIKW^J?Z4 >0>+OO25B_#/_D;KK_KT?\ ]&1UM>+OO25B_#/_ )&ZZ_Z]'_\
M1D=;T/XB ]4HHHKWBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH AFZ&N>UC_5GZ5T,W0USVL?ZL_2@#A-6^^:\X^-7_ "2O7/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH **** *]Q]TURFO?ZI_I75W'W37*:]_JG^E 'D'B[[TE8OPS_ .1NNO\
MKT?_ -&1UM>+OO25B_#/_D;KK_KT?_T9'6]#^(@/5****]XL**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI@%%%%( HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHHZ@=%X/_P!9<?\  ?ZU
MV<?W17&>#_\ 67'_  '^M=G']T5XF(^,ECJ6DI:Y1!1110!7N/NFN9UCH?I7
M37'W37,ZQT/TH X;4O\ 6&O(?VC?^1!L?^PG'_Z*EKU[4O\ 6&O(?VC?^1!L
M?^PG'_Z*EH \^_9E_P"2W^&OK<_^DTU??\/W5KX _9E_Y+?X:^MS_P"DTU??
M\/W5H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &LVVO,/BM^TEX$^#LOV77M6+ZIMWKIEC&9K@C&1D#"IGMO(SVKM?&6N
M#POX3UK62 PT^SFNBK=#Y:%OZ5^.NI7VK>.O$T]W<?:-5UK5+G>VU#))-*['
M   Y.>@_*H3<I\B+LE'F9]\R_P#!1CP KL(_#_B1U'\30VZG\O.IO_#QGP%_
MT+WB+_OW;_\ QVOF&R_8N^,-[:I.OA/RE<!@LVH6RM@^H,@(^A&:G_X8C^,?
M_0KQ?^#.U_\ CE:$'TO_ ,/&? 7_ $+WB+_OW;__ !VOH;X;>/[/XG>"=+\3
MZ=;W%M9:A&TD<-T )5 <KR 2.JGH:_.+_AB/XQ_]"O%_X,[7_P".5]]?L[>#
M]5\ _!OPUH&N6PL]4L872>%9%D"DR.P^920>&'>G969#;YD>E9Z4ZFJ.!GK3
MJDL**** "BBB@ HHHH AFZ&N>UC_ %9^E=#-T-<]K'^K/TH X35OOFO./C5_
MR2O7/^V'_H^.O1]6^^:\X^-7_)*]<_[8?^CXZ /GKX6?\E.\(?\ 88L__1Z5
M^DEO]P5^;?PL_P"2G>$/^PQ9_P#H]*_22W^X* +-+24M !1110 4444 5[C[
MIKE->_U3_2NKN/NFN4U[_5/]* /(/%WWI*Q?AG_R-UU_UZ/_ .C(ZVO%WWI*
MQ?AG_P C==?]>C_^C(ZWH?Q$!ZI1117O%A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC7^]C(_/I7Y5^ OVK_BM\.6B72_&>H7%K'C%GJ;_ &R' _A EW;1_ND5]/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !111SV%&@!0,L< 9/M5V2PATW3Y=3UB]M]'TJ!?,FN
M[R18T1?4EB H]S7S9\6/^"@W@OP#Y^G_  ]T\>+M70;?[3NMT=E&P'4?Q.,Y
M^Z%!XPQK;#8>OC9^SPT')_A\V-)O8^F8]!DCM7N[Z6/3K.-=[S7#!0JCJ3D\
M#ZFO#?B=^W!\*?A5YUKH;MX\UR/@+I[#[*K?[4^"N/= _O7Y^?%7]H'Q[\9[
MIG\4^(;J\M-^Y-.B8Q6L?IB)<#CU.3ZDUYYUZ\_6ON<'PES6ECJE_P"ZMOOW
M+4.Y]&?%+]O3XJ?$;SK6RU*/PAID@(%MHH*2X_VIB2^<?W2H/I7SQ=7D^H74
MEU<SRW-Q(=SS2N6=SZEB<D_4U#UXHK[O"X'#8*/)AX**+L+Z \CWI/UHHKO&
M%%%%( HHHH ***7GTH] $HHS10 44JJ6. "Q]%&:LQZ7>R\I:3N/:-O\*ASB
MMV!5HJ^N@ZFW33KL_2!O\*<WAW55Y.F7@'O;O_A2]I#^9 9U%6VT>_3[UE<+
M]8F']*@D@DA.)$9#Z,I%/VD'LP(Z*.]%6 44?C10 4444P"BBBD 4M)10 5[
M1\+OVP/BE\)?)BT[Q')J>FQ?\PS6LW,&.R@D[T'^XRUXO2Y/8X^E<N)PF'Q<
M.2O!27F*Q^EGPK_X*1^"_&"Q:?X]TF3PO=L0OVR(&ZLW/3/ WQ]1V(']ZOI;
M3;;0?&NDQZMX8U:TU"QF!:.>TF6:%_8,IZ\_A7X>?CVQ73>!?B9XJ^&6JC4?
M"VO7VAW606-K*0DF.SH?E<>S U\'C>#Z3;J8"?(^SU1#@C]C+[2+K3FQ-$57
M. XY7\ZI_@:^5O@O_P %+5D6#2_B?I'RM\G]M:7'D'MF6 _J4)]DQ7UYX;U3
MPG\4-&36?"&LV>I6<A_UEG('0'^ZR]4;V/(]*^$Q>%Q>72Y<73:\UL0TT9E%
M6]0TNYTML3QX7LX^Z:J?7C\*YXR4E=,D****8PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444=0.B\'_P"LN/\
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M1110 4444 0S=#7/:Q_JS]*Z&;H:Y[6/]6?I0!PFK??-><?&K_DE>N?]L/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444=0.B\'_P"LN/\ @/\ 6NSC^Z*X
MSP?_ *RX_P" _P!:[./[HKQ,1\9+'4M)2URB"BBB@"O<?=-<SK'0_2NFN/NF
MN9UCH?I0!PVI?ZPUY#^T;_R(-C_V$X__ $5+7KVI?ZPUY#^T;_R(-C_V$X__
M $5+0!Y]^S+_ ,EO\-?6Y_\ 2::OO^'[JU\ ?LR_\EO\-?6Y_P#2::OO^'[J
MT 3T444 %%%% !1110 4444 %%%% !7+_$ZPFU3X<>*K*W#&XN-*NH8PO4LT
M+  >_-=13)%W*0>AJ)+F5AK1W/R8_9@U*TT?X^^";B_=(K?[=Y6Z3A0[JRJ3
MG_:*\GI7W1^W-_R;KK6.!]IM?_1RU\T?'#]CWQ;I?Q@2/P=ILEYHNMW+36MS
M&"L=@Q.YDE8?<5>2&/4 8R0:]\_:PTO5=$_9)FL=;U,:WJ]NUE'<ZAY8C\]Q
M,N3CM_DT3?-02?0J'NUW+N>7?L ^.O#?@S0?&KZ_K^EZ())[9XQJ%Y' 9 %D
MR5#$%L9 XSSQ7DO[8'Q>TCXP?%*.ZT%C<:5IMHME'=E2//.]V9P#SMRV![ F
MO%+&QNM3NEM[*WFN[F0@+'!&7=CVP "<_2OH[X"_L6^)_'FKVNH^,-/N/#OA
MB-M[PW:F.ZNU!SY:QGYD4]V8#@\ U?+SM-]#-2Y.:W4^L_V,M"GT#]GGPRMR
MACEN_.O-I!SMDE8H?Q7:?QKW%?NBJUCI]OIMG!:6L2P6\$:QQ1H,*BJ,  >@
M JS5SESR<B81Y8I"T445!84E+3"WI0 I4'/I7PW^U;^QWJU]X@U#QGX$LC?I
M=,T]_H\( E63JTD(_C#')*CG=T!SQ]N7MXMC97%TX+)#&TC*N"< $\<^U> ?
M"_\ ;4\)?%;QSIGA?3=%UJUO[XR!);N.$1+LC:0Y*R$]%/:HMS25MRK\L6^A
M^:E]87.EWDUI>6\UI<PMB2&X0I(A!Z%3SG/KWJ#&XA0,DD  ']!]?U]Z_:/6
MO"NB^)HU35]'L-4C X2]MDF _!@:J:-\._"GANY^TZ3X:T?2[CM+96$,+_FJ
M@U:TW%Z'Y_?LV_L?ZY\0M9L];\6:?/I'A2%ED\JY0QS7V#D(J'D(>,L1TX7/
M)'Z/P6\=O#'%$BQQHH5448  Z #L*\#^/G[6EA\!O%MIH=YX=N=6>YLUO5FA
MNEC 4NZ;2"I[H?SKTWX0_$JT^+WP_P!,\4V5K)90WOF#[/*P9HV1V0@D=>5S
M^(JN;GCILC/EY97>[.SI:;FG5)84444 %%%% !1110!#-T-<]K'^K/TKH9NA
MKGM8_P!6?I0!PFK??-><?&K_ ))7KG_;#_T?'7H^K??-><?&K_DE>N?]L/\
MT?'0!\]?"S_DIWA#_L,6?_H]*_22W^X*_-OX6?\ )3O"'_88L_\ T>E?I);_
M '!0!9I:2EH **** "BBB@"O<?=-<IKW^J?Z5U=Q]TURFO?ZI_I0!Y!XN^])
M6+\,_P#D;KK_ *]'_P#1D=;7B[[TE8OPS_Y&ZZ_Z]'_]&1UO0_B(#U2BBBO>
M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT8].?6JUY8P7L+PW$*30N,-'(H8'\ZT66HV2M8R<7=: >3^*O@S#.KW&B/\
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MC(ZWH?Q$!ZI1117O%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"9K+OM6CMT9Y'"(.K,< 5$I**NV*Z6YJ2707_P#752XU2*WC:21UCC499F/
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M4DSU(SC/6+"BBBNDL****0!1110 4444 %%%% !1110 4444 %%%% !1110
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M-3>72^74\P$'ET>6/2I_+I/+HY@(?+I/+J?RZ/+]J.8"OY9I/+JSY=-VFGS
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M_)DQV#,UO=/@9.V&4([?4+QWKU']?<<_C_GUK2^ER4TPHHHH&%%%%, HHHI
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MK*@N8%N(9(G >-U*LI&00>HJ)J\65'1IGY+?LUWFF6/QV\%SZNT*V:WZY>?
M02$$1L3VPY7GVK];%/&3T]Z_)O\ :(^">H_!/X@7=A) YT2ZD:?2[I?NR1$G
M"9[.N0I''0'N*UO!G[8?Q3\$:?#80>(%U.TA3;''JENL[*.@ <@.0.P+8'I6
MD9*5.,>Q,HVFVNI^IXQ7YQ?\% KS2I_C/9QV+1_;8-+BCOC%QMDWN4#$=PA4
M_0BN?\0?MO\ Q8UVS>W36;72T<;6DT^R17(([,VX@^XP:\M\&>#_ !%\7O'%
MOI6G)/JFLZA*6EGF9G*Y(+RRN><#J2>O3VK/V;J27D5S**;/T4_8>2:/]G/0
M/-&%:>Z,60?N^>_]=U>^CH*YOX=^";/X=^"-%\-V)WV^FVR0!SP9"!\SGW9L
MD_6NDK>I+FFVC&FFHI,6BBBLS0*;M'.>].IM(!C*&!! 8=*^=_CA^TMX$^ .
MJ)I]GH%KK'BE%\PVMDB0BV4@?ZR0*2I*G(55)(ZX!!/O/B36$\/^']3U249C
MLK:2Y<>R*6/\J_(W0]"\3?'KXG-:V9^V:_K=U)</)<.512<L[NW.%51V!XX
M[5*O*HHHK10<F?J'\"OB9/\ %[X8:3XJNK&+39KTS!K:&0R*FR5TX;OD*#7A
MWQF_;VTSP+XDO-"\*Z-'XAGLV:.>_GG,<"R X*H ,N 1@MD#TSUK<UBUU+]E
MS]CV^TVYO8;G6;.":VAN+3.SS;B9MI7< <J),\C^&OACX,_!_5_C=XWB\/:5
M+';'RVN+F\F!\N"($ N0.222 !QDGKUJG[U5QALB8>[34I[L^SO@S^WIH_CC
M7[30_%6D+X;NKIQ%!?1SF2V>0]%;(!CSP-V6&3R17U>&X%?DM\?/@+K'P"\3
M6VGZA>0ZC9WD9FM-0@0QK(%(W!DYVLI(R,G@@\U^B_[,OC6Y\?? _P *:M>.
MTEY]F-M,[_>9XF,18^YV9_&KTE'F1&JE9]3U.EI :6I+"BBB@ HHHH ****
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M L /3=&9/J44489>RJNA+LF<DM8JKYGZQ_7K1Z?7%,FF2WB>65A'&@+.S<
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MQOXB\>?L^ZCJ/B;Q!JGB+45UVXB6\U:]DNI1&(8<*'D8D $G ]2:_-S]I_\
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M")2^O3A?3E/2P+?.SMJ*2EK]O/="BBB@84444P"BBBD 4444 %%%% !1110
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MBOU7\"^$;'P!X+T+PUIJ[;#2+*&R@]2L:!03[G&3[FORJ_X*T+G]HO1<\?\
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MG6.A^E '#:E_K#7D/[1O_(@V/_83C_\ 14M>O:E_K#7D/[1O_(@V/_83C_\
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M "BBB@ HHHH AFZ&N>UC_5GZ5T,W0USVL?ZL_2@#A-6^^:\X^-7_ "2O7/\
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M-N"7EY=74)^L4LK(1[%:]ZL;"VTNR@L[.WBM+2W010P01A(XT P%50,  <
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M4M^Q^59OF\LTG%\MDMB:EHHKZT^>"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#P'Q1^P;\"_&GB75/$&L^!_MNKZG<R7EW<_VO?1^;+(Q9VVI.%&22<
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MY&2"?<5Z=\/?V)_B;XZ$<UUIL?A>Q;_EOK+F.3'M" 7!]F"_6OISX>_\$_\
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MGX5O=-T^RU!+B>ZD9-J(O)!PV><8_&OTE7[HK234DI&:3C)H6BBBH- HHHH
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M^'[JU\ ?LR_\EO\ #7UN?_2::OO^'[JT 3T444 %%%% !1110 4444 %%%%
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M?P[@TG2+AK;6=>D:%9HVVO% H!E93V)RJY_VCZ5$Y<J+C'F=C5^*G[8OPT\
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MM3'/X8UY;VP ) >WWB6$$^C1LH/U-?N1X2\36'C3PKI'B#2Y1-INJ6D5Y;R
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M1&8%!/MO'UKX3\)W-E\9/CC:7?Q'\3?V5I^LZDUSK.M3DY1#EWP<'!(&Q>"
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MJF^DKZ5T9C!IAC]J5@,&/25X^6KT.GJN.*T1"/2G".BP$$< 7C%3B.G4M,!
M,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% CYS_X*
M&?\ )GOQ!_ZYV?\ Z6P5\!?\$J?^3H)?^P#=_P#H<5??O_!0S_DSWX@_]<[/
M_P!+8*^ O^"5'_)T,G_8!N__ $.*O+A_OWW?D7B/X$?G^9]]?MC?MA?\,FP^
M%9/^$2_X2G^W6N1C^TOL?D^5Y?\ TRDW9\SVQM]Z\ZTO_@J3\/U^$MOXIUS2
M9[+Q%<W4UO#X6TV\2\GVH%(EDD*QB-#NQEER<':&VFO-/^"Q?RV?PLX'^LU+
MM[6M<_\ \$V/V4?AU\8/ .O>,O&NC_\ "17=MJC:9;V=S*ZV\*+#'(7VJ1N8
MF4CYB0-O !YJZ<JM6=2,7LPKV@X>:1V_A'_@K]X=U/78[?Q%\.[_ $32V;!O
M;'4UO709QN,1BBX'4X8GT!K[T\+^)M+\9^'=.U[1;R/4-)U"!+FVN8#N62-A
MD$>_MV.17Y(_\%*OV>/!OP)\<>$[GP5IHT6RURTG:XT^.1WB26)U!=0Y)7<)
M!P#@;> *^O/^":.N:EKG[(DMI!*3>:;J%]9V1D)PF565>?0/*?Y5K2JRE"?,
MM8&;O&K&^S-O]H;_ (**_#KX$:]>>'+:WO/&'B:TREQ:Z:RI;VT@Q^[EG;.&
M]=BOC!!P17B_A_\ X+#:/<:DD>N?#"^TZP)^::PUA+J4#VC>&('_ +[%?!_P
M[O-%\(_'C39OBKI-YJ6E6.JM_;NGR@F9V5CO#C.6(?EAGD CO7Z,?$+P7^RY
M^U9\._["^'^O>!?!_BAY8SIUY!91:;=*P8;HV@(B>52FX!>0"01R,UA3J591
M]I%W\BI-.;@]$?6/P<^-?A#X\>$8O$?@W55U*P9_*EC92D]M(!DQRH>5;&/8
MY!!((-?)?[97[9?A'X4?%]/"7B3X+:+\1)]-M8;JVU/4[F(-%Y@W%45[60I@
M@<AN:[?]C?\ 8GU_]EGQAK6HS>-[?Q!I.K60MIM-@L6AS,KAHY"2[=%,B_\
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M5OOFO./C5_R2O7/^V'_H^.@#YZ^%G_)3O"'_ &&+/_T>E?I);_<%?FW\+/\
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M\0)'+'*0"0OG1A/+''WBC?UKJ?VP/^";;?%SQ9>^-OAUJ-EI6NW[F74-(O\
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M-7W_  _=6O@#]F7_ )+?X:^MS_Z335]_P_=6@">BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %&3D'N.GX'(HHH$'H>XZ'.3_GBCZ#
MHHH&'^>M'_ZZ**+:6N+R#]>U'KZGN>3113U .^:3Z\^M+12U&&2<$G)I*6BF
M ?Y%'XG/UHHI:] "DQUI:*/40=P>XZ4=L=O2BBGKW&'^.:2EHI"#CTH],\_7
M_/%%%'6XQ, \'GZTM%%'D)ZAZ?I2;1TP,4M%&NXV'^?Z_P _YT>F>:** #Z\
MG.>:/KSZYYHHIZ]P <'/XTE+12U>X!UZ\T?Y_P _Y[T44:[ '3IQWX'ZTF!Z
M#VXZ4M% =;A^-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;G28O[%_M;[<DC;OM7D[-FT=-C9Y;]*Z/X;_ !.TKXF>&I-4TT/#+!E;BTF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444"#_/6D_6EHH\KC#MCMC%&X]>]%%&H!Z>W3
MVI,#T'Y?A_GZ4M%&H!1GG(X/8CBBBGKW$(./IZ4O^>.***-@\A&SM(!4'MN'
MRCTR/2OR7^*7B;]JO]F7XT>*/&-S)J%U:ZO<>?/?6=J;W1;F%3B-=N&$050%
M )5P!U())_6GIC'8Y_&DQU__ %_YXXKFJ47.2G&5FB^:\>5K0_$_XC?M=?';
M]JS2_P#A#D@DN["X \_1_"VF2$W6W!'F8WR$#@XR%[D5]A?\$[_V)M<^#M]<
M?$+QY:K8^([FV:VT[2"RN]G$YP\LI!P)& P%!RJD[N6POW?_ "Z8QD>]!^;K
MSVYYIT:*I2<WK(QE%S5GL'7K\P/KSD4F/7GZTM%;E^@E+113\@#KUY^O\Z/K
MSZ\444@"BBB@ HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%%'4#HO!_P#K+C_@/]:[./[HKC/!_P#K+C_@/]:[./[HKQ,1\9+'
M4M)2URB"BBB@"O<?=-<SK'0_2NFN/NFN9UCH?I0!PVI?ZPUY#^T;_P B#8_]
MA./_ -%2UZ]J7^L->0_M&_\ (@V/_83C_P#14M 'GW[,O_);_#7UN?\ TFFK
M[_A^ZM? '[,O_);_  U];G_TFFK[_A^ZM $]%%% !1110 4444 %%%% !111
M0 444GK0 M)M%-WGTJJ=:L1>"S^VV_VL]+?S5\S_ +YSF@"WM'%.IGF<XIV:
M %HI.:* %HI :6@ HHI,T +15:]O%L;2>YD!\N&-I&VC)P 2<?E7SM_PW]\+
M>_\ ;6?^O$?_ !=*ZO8=GN?25%?-O_#?WPL_ZC?_ ( C_P"+I/\ AO[X6_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4_TKJ[C[IKE->_U3_2@#R#Q=]Z2L7X9_\C==?]>C_P#HR.MKQ=]Z2L7X9_\
M(W77_7H__HR.MZ'\1 >J4445[Q84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5T/[,OP%O_@KI.L-K-Q8WFK7\R_O;!F>-847Y1N95.26?MZ5[RT?M4+Q]?\
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M(8>])6EXDM_LVL7 QPQW_GS_ #S6;7X[!\T4S ****L84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444=0.B\'_ZRX_X
M#_6NSC^Z*XSP?_K+C_@/]:[./[HKQ,1\9+'4M)2URB"BBB@"O<?=-<SK'0_2
MNFN/NFN9UCH?I0!PVI?ZPUY#^T;_ ,B#8_\ 83C_ /14M>O:E_K#7D/[1O\
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M HHHK4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4_TKJ[C[IKE->_U3_2@#R#Q=]Z2L7X9_\C==?]>C_P#HR.MKQ=]Z2L7X9_\
M(W77_7H__HR.MZ'\1 >J4445[Q84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWZF#W"BBBN 04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P D%?J\W"Y/^>*_&OQ%JC:UXAU346.YKR[EN"?=W+'^=?>\)T_WU2?9?F7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<]K'^K/TH X35OOFO./C5_R2O7/^V'_H^.O1]6^^:\X^-7_)*]<_[8?^CXZ
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M'[PK_,U^-OP8B$WQ@\"Q]=^O6 Q_V\)7[)>,_P#D*1_]<1_,U^5\76^NT/\
M"_S,I&#1117Q2("BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1111U Z+P?_K+C_@/]:[./[HKC/!_^LN/^ _UKLX_NBO$
MQ'QDL=2TE+7*(**** *]Q]TUS.L=#]*Z:X^Z:YG6.A^E '#:E_K#7D/[1O\
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M?]<[?_X[2?\ #Q;P%W\/>(O^_=O_ /':^:O^&(_C'_T*\?\ X,[7_P".4?\
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MKE$%%%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_UAKR']HW_D0;'_L)Q_\
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MK??-><?&K_DE>N?]L/\ T?'0!\]?"S_DIWA#_L,6?_H]*_22W^X*_-OX6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#D/C!:?;OA+XUM@,F;1;U!]3 ^/Z5^1%?L
MMXBT_P#M;0-3L>]U;20_]](5_K7XU$%201@CBOTCA*7N58>:-(B4445^@&@5
M[M\)I-W@VU7^Y)(O_CQ/]:\)KV;X+W'F>';F+J8[D_D57_ UX^:QOA_F-'H\
M=6(S5:.K$=?#2[#+,9JQ&:K1U8CKGD!:C-6$JO'5A*PD!8CJRM5HZL*>E8R
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&U^'9U4]MFE>2V5E]R,9;A1117D$A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1111U Z+P?_ *RX_P" _P!:[./[HKC/
M!_\ K+C_ (#_ %KLX_NBO$Q'QDL=2TE+7*(**** *]Q]TUS.L=#]*Z:X^Z:Y
MG6.A^E '#:E_K#7D/[1O_(@V/_83C_\ 14M>O:E_K#7D/[1O_(@V/_83C_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3?W%NS7$<S+/N/[SJ>1[]:^$S3CW!X"?+1C[2*=FU^G<Z\OIK,,1["F];/\
M ]N\S\#574+.VU2TEMKJ%)[>0;6C=<C&,?A7*Z/XZ29A%?JL3'@2IG:?J.U=
M-'<I-'YD;+(I'#*<C\Z^PRO.LNSZCSX6:=]T]_FC>MAJ^!G>5TULT>/^-?@)
M#Y<EUX;D97 XL)F&TG/\#D\<=FS]:\;U+3;O1[Q[:^MI;2X4\QS+L./7GM[]
MZ^Q&D^;.3GUK&\0>'].\367V74;=9XQG83]Y"01E3V/->/F7"M#$)U<+[DNW
M1GVF5<78C#6I8OWX]^J/B?Q9_P ?EKZ^0/\ T-ZP9I%MX_,D8(O;/4_0=_\
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M4DE0/6Z0$4AZU6D:IY&JM(:W2 B<]ZKR&II*K2&MXH")N]5Y&J:1N*KR&NA
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^CXZ]'U;[YKSCXU?\DKUS_MA_Z/CH ^>OA9_P E.\(?]ABS_P#1Z5^DEO\
M<%?FW\+/^2G>$/\ L,6?_H]*_22W^X* +-+24M !1110 4444 5[C[IKE->_
MU3_2NKN/NFN4U[_5/]* /(/%WWI*Q?AG_P C==?]>C_^C(ZVO%WWI*Q?AG_R
M-UU_UZ/_ .C(ZWH?Q$!ZI1117O%A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%'Z?6@-0HJEJVM:?H-M]HU*]M["'G]Y<2*@^
MG)Y/M7F6K?'5M2OWTOP9HT^OWW*BX*E8D/\ >QU(]R5JXP<MCR<7FF$P.E6?
MO=$M7]R/66945F8[0HR2<8QZGG@5\P?ME>-O#7BCX3:KH5E='4=2MY8[N-K5
M0\4;(^&)?./N%^F??%=V/A/XJ\?72W'C?6_)LP=RZ78-\J]_3:/K\Q]378M\
M)?#,'AG5]&LM,BMX]3M);2:9B7D99$*'YR21QZ''I7=A:D</7A4;U3/.HXK,
M\;-2I4_94^KE\37DNA^1U)5G4M/GTC4KNPNDV7-K,\$J8QAE)5A^8JM7[M&2
MG%274^NWU"BBBF,]Z^%VI_;_  C:@ME[<M"Q^AR/_'2*[*,UY!\%=2VW&HV#
M'AE6=!]#M;^:UZ[&:^"S"G[.O)(HM1FK$9JK'4\;5Y# MQFK$9JI&U6(VK!@
M6T-3QM5:,U-&:PD!<0U/&U58VJ9:PD!<0U/&>:JQMTJ=37.P+D;5.IJG&U68
MVK%@68VJS&U4U.*L1M6# MQM5J-NE45-6(WZ5BP+\;59C:J,;58C:LF!H1M4
MZ-5*-ZL1M2%8OQO5F-JSHWJS&]9M"+RM7C?QZ;=JVE'_ *8-_P"A"O7XWKQW
MX[<ZKI9_Z8M_Z%7'B5:FV?)\3_\ (MGZH\QJ6(F1?*)VX^9<COZ?I5JPT.ZO
ML,$\N'N[>GL*ZC3]&MM.PT:[Y1_RT;K^'I7%'+YXN/*U9'XBI*.YE:/X1GO-
MLEV#;0'G;_&?;':NOL=/@TZ'RX(PB]3ZD^I-30R>=&')RW\1]*?7)3P$,&W#
M=]STHJ-KH]/^%3;='NQ_TW_/Y17<+)7!?"]]NDW7_7?_ -E%=FLE>O'X3]JR
M77 4O0Y[Q5\1(M#U'^RH0@U!HQ(#*V!M)/W1W/!]/QKA[V^N-0F,MS*TTA_B
M8UR?Q[;_ (KF,CK]CC_]"<US>A^.+K2PL5R/M<&>KMAQ]#W_ ,\UX?%' F8Y
MQA8XS 5N;3^&]%\O^"?!XCBR%',*F#QBLHNR:/2:T=/_ -0W^]_2L'2]8M-7
M@$EO*"1]Z-N'7V([5O:>/W#9X.[G(QC@5_*>>X+$Y?&5#$TW&::5FC]9X3KT
M\1C8U*4DTT[6+63ZG\ZMV.MSZ+NECF$<:_.PD/R8'4UYWXX^,&@^"?-MWE^W
M:D@_X]+<Y(..-[=%_4^U?/OC/XI:_P"-))$N;DVUBQXLK<[4QVW'JWX\>PI9
M'DN92JQQ-.3I)=>OR/Z$P?#M?-$O:*T.[1]R^!_B/I7CZWOGTR=9_L4@BF>,
M,4W$9&TD#=^%=(TE?.?[&S;?#7B'L?MD>/;Y*^@FDXK^N,LE4G@Z<JDN9VW[
M^9^.<18"GEN9U<+2^&+/E;]IYL_$B/'_ #X1#_QZ2O)7V7!7SE,@7@$-M8=.
MA[].A]37J_[3!S\1HS_TX1?^A/7D_?'7UK\WS)M8RK;N?TQPS_R)L,_[I0FL
M'B&Y"KQYP&)"]20,YZ=.O09Q65=S)<3;HQMC4!5X&<#OQW)Y]L]>*V=4NY+.
M-%C=DFE&<JV&VYZ?B1^GO6.[1RQA60(ZK@.@ZCGJ/RYK:C@:DJ7M$M3Z^G%V
MN5QT'&/H,5]>?LTMM^%L _Z>IOYBODB:W>'!.UD8_*ZG*G\?7VZC/0U]9_LV
M-_Q:^#L/M4W\Q7LY%&4<79KHS\U\1?\ D3K_ !(]39J@DDI9)/PJO(]?HUC^
M8D,D>H':G.U02-5H=ADC54D;K4DCU6D:JL,9(U59&J21JK2-6J0$;G-02&I'
M-5Y&K5(".0U#(U/9J@D:MD!%(:KLU2R-5=VK= 1R-5>0YJ61JKN:Z(H".2JT
MC5-(U5W-;H"*1JKR&I9&JO(U;) 12&J\AJ61J@D-=$0(7KPCXQ:E]N\5"V4Y
M6TB5/^!-DG]"OY5[E=3);P22R-LC12S-[ 9-?+^L:@^K:M>7C\-/,TF/3)X'
MX#BOI\GI<U5S?03*=%%%?7B"O5/V6_!__"=?M">!=**>9#_:4=U,O4&.#,[@
MY[$1D?C7E=?8G_!-/P:^H?$SQ-XJ>,-;Z)I?DH[\!9IF&T@_]<XY!_P(5XN=
M8GZKE]:I>SM9>KT%Y'WOXGN!<:Q-M.53$8],@=/SS657AUQ\:/&OP]F8^/\
MPT]Q9NW.JZ;@K\Q!PV3MR,MU*$D  'K7IG@_XD>&_'5NDNCZK#<R-UMF;9.I
MQD@H>>@/(!!P<&OP>C5ARJ&S\SU,3DV,PU-57'F@^L=5^!TM%'KR/KFBNH\3
M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ****.H'1>#_ /67'_ ?ZUV<?W17&>#_ /67'_ ?ZUV<?W17B8CXR6.I:2EK
ME$%%%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_UAKR']HW_ )$&Q_["<?\
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MUZ/_ .C(ZVO%WWI*Q?AG_P C==?]>C_^C(ZWH?Q$!ZI1117O%A1110 4444
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MR,'^X?ZU[TTE>UE<6L+"+T:/YUXQ:EGE=Q=U?]#YD_:38-\0XSG_ )<8P?\
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MQ=]Z2L7X9_\ (W77_7H__HR.MZ'\1 >J4445[Q84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110'J'^>*^-_%G_!4[X4>
M#?%6L^'[WP_XREO=*O9K&9[>RM6C:2*0HQ4M<@E<J<9 ..PK[(_QK^>[XXJ)
M/CQ\04;[K>)-0S_X%25PUJLXU5"'4;2C3YO,_3JT_P""M7P<N+B..30_&=I&
M[ &::PM2B>YVW)./H":^D?A#^T/\//CM92W'@GQ/::Q)"-TUG\T-S".FYXG
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MWI*Q?AG_ ,C==?\ 7H__ *,CK>A_$0'JE%%%>\6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444"%]*_GN^-W_)>O'_\
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ME0Q*,""" S @CDYQ7ZX_LD_&.\^/'P"\,>+M3C6/5YXWMKWRU"J\\3F-G '
MW[=V!P,XK\EOVO\ X0_%3X0^)- L_BGXU_X334+NT:6SN?[4N[_R(@Y4KNN$
M4KEN<#BOTB_X)F\?LD>'CW-[??\ H]JTP4G[\6]C.I%*I&RW/JBBBBN\KH%%
M%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0MB@!::S 4QY-M5I
MKI5SS0!9,F*8TXYYK'OM9BM8GDEE2.-1EF9N!]:\L\6_'[3M,+P:0HU.ZY'F
M9VPK[YQEOT^M7&,I_">3CLTP>6P]IB:BC^?W'LT]_#:PO--,D,*#+22$*JCU
M.:Q='^(WAS7[Z2SL-7M[BY0E?+!*Y/ ^7<!N!) !&<U\F>*/'6M^,92VI7TD
MD6<K;K\L:_1<_J<GWK"C=H9 Z$HZG(9>"._&*[8X73WGJ?EN*\0/WZ6%HWAY
MO5GWJ&!. 1FESFOE/P7\=M=\,+%;7K'5M/7 \N5L2(ORCAN^%!Z]S7O'@WXK
MZ#XS1%MKL07A W6MQ\KY^7@>O+ >]<TZ,X>A]SE7$^7YHE&,N6?9Z':T4U6#
M'&?\:=6!]<%%%% PHHHH$%%'^<]NM10W4-UYGDRQR&-S')Y;;MCCDJ<=#@YQ
M3L)R2:3>Y+111ZT%;!14<]S#:PO--*D4* EI'8!0/<UYKKOQXT>WN#8Z#:77
MB34CD)'9H?+)'^UC)'^Z#GU%4H2EL>;C,QPN!7[^:3[=?DCTUB%4D\#WKC/%
MWQ>\,>#XY!<:@EW=KD?9+-EDDR#C!YPO/]X@UQ<7AGXB?$B*1];U8>&-,E^8
M6-K&/-8>C8((&.S.?I7;>#OA+X;\%+&]I8K<7J<B\NE#R!O5>,+_ ,! _&M.
M6$?BU9XWU[,<PTP=/DA_-/\ 1'%_\)%\1/B;"_\ 8UC#X4TJ086ZNV)E<>JG
M'/MA1_O5L>&_@#H.FM]JUMIO$&I,V^2>Z9@N[K]W.6Y_O9KT[)YY]J/P _"D
MZCVCH;4<CH\RJXR3JR_O/3Y+8CM[>*SA2&")((HQA(XE"J@[;0.GX5)1163U
M/HXQ4%:.B[!11104%%%%( HHHH **** "BBB@ KY+_X*!?#@ZQX/TCQC:P[I
M])E^R794<F"4C83[!QCZRFOK2L?QCX7LO&WA35M U!-]EJ5N]M*/3<, CW!P
M1Z$ UZ&7XEX/$PK+H_P&MS\<?UHK6\5>&KSP=XFU30M079?:?<R6TW&!N5B,
MCV.,CVQZUDU^ZPE&I%2CLS8*7I245?DQGM?PE\0#4= ^PR-_I%D=HSU,9Y4_
MATKOX_RKYR\%^(#X;\06]T2?LY/ES*.Z'K^7!_"OHF%Q(JE6#*>C#I['Z5\5
MF>']E6NMF47(S4Z-5.-JL(U>&T!;1JGC:JB-4Z-7/) 7$:IU:J<;581JP: M
MQM4ZM5-&Q4Z-63 MHU3HU5%:ID:L&@+B-4T;541JF1JQ: N(]3*U4T>IT:L6
M@+:-4ZM5-6J5&K%H"XK5/')5-&J16K-H#022I5>J*/4R25FT!>5Z\[^*ASJ%
MA_UR/_H5=ZLE>>?%*9([JS=V"*L1RQ(P/FKV<GM];C<^&XT3>3S26MU^9QM3
M6FJKH\RSR/MB/# _Q?0=36!?>(%7*VHRW3S&!Q^%8TTSW$A>1C(Q[L:^ZJ5U
MLC\&PN62NIU7;R.RUCQE/=[HK3-M#T+9^9O3\*YTL68MDDGN345K-YD84DET
M]^HZ?IQ^=25I3:DKH].=/V+LCFO&+;7M"%!QN." ?[OK]*H6UY/8W45[932V
MDJDM'+$Y5T8'LP.1U_(CUJ]XR^]:#KP_]*Q+&0,Q@8<.<KQT;T_'@?EZ5C4B
MI+57/M,MJ>SIPMV/<O /[26H::T=IXF4ZA:X"K=1H%G7G'S#(#@#T&?K7OWA
M_P 6:5XHL1=Z3?PW\'<QMROLPZJ3Z$5\)]CGUY'3/UK1T+Q!J/AG48[[3+N2
MSNH^CIT[\$'@CGN*^<Q64TZWO4O=?X'VV&S2I1]V:NC[P\S:>O(]J/,''/TK
MP;P'^TA!?,EGXEACLY, +?0 ^6YR!\R\[?<@XX/ KU35/&VB:/I"ZG<ZI;BR
M=2T4J2*_G8[( 3N_"OE*V$JT)<LD?6X6M'%M*B[OL=*9<D\_Y^E<MXU^)FA^
M [?.I76;IE)CM(@6ED_#^$>[8%>(^//VB+W6(I++P[$^G0-P;R3'G./]D=%'
MOR:\>N+B6[F>::5YI7.YI)&)9CZDGG-;4L&Y>]/0^ZR_AV=2T\4[+MU/1_'G
MQXU[QC')9VA_L;3GR##;R'S''H[\?D,>]>6WETMO;D#F1\@#(Z=R0?R_KQ5A
M1NSSA5&6.> !U)_7\JQ;RZ:\F+D84#:J]0%';^I]Z]"T::M%'ZUD>5THS_=Q
MM&(K1K'#!M ^9,G'0G<?\!2(S1MN0E#C'RG''/'ZG\Z?)S#;Y.?D/_H35'CV
M)^@KRI64C]*A9Q3:-.SN4N3B8%"N2T@X7&1UXXZX!]2!CN+$^YI"S+MW_, .
MF/\ ]7'7MC@U7CA-I&J$Y?AWVYSTX'7MS^9IT<ACX&"O=3R#P1_4\UJXN4=6
M=<+K5L?7TM\!FV_#V$?]/$O\Q7S7N29F*XC/4AFX'T/Y]?3K7TA\#,Q^ 8E8
M$,+F4$'UST_2N9Q<=&?FOB$^;*$NO,CT5FJ)FIC25"\E)'\T=ATDE5W?-([Y
MJ)FJT@!FJ)WH9Z@D:M4A@[5"S4K-4+O6L4 CM4#M2NU0LU;)"&LU0R-3G:H'
M:MHH!CM4+M3G:H7:MT@&.U0.U.9JAD:MD@&2-5=VI\C5 [5LD QVKYM^*5Q<
MS>.=36Z8DHRK&">!'M! 'X'/UKZ.=J\#^-%D+7QCYJ_\O5LDA^H)7^2C\Z^D
MR9I5[/L)F;X/^(6H^%I(XB[76G;L-;N?NCOL/8_H:S_&>O#Q+XCO+Z,21P2-
MMA2;&]8QPH('3CGZDUB^OOZTGZ?05]='#TXU/;15F(****Z?4 KIOAKX$OOB
M=X^T'PKIX(NM6NTM1)M+")"?WDA&.B*"Q]E-<S7V_P#\$XOA:L<GB+XG7T*L
MMFK:3I.X YG8 S..X*J47/<._I7BYQCE@,%.JG[VR]7L2WH?:%U9V>C6UCHV
MG1>1IFDVT=E;0 G")&H55_  #\*JTN[)SU.<T5^'Q7*K&(44450!1110 444
M4 %%%% @H_QS111ON&VQP7C;X(^$?'DS7%]I_P!FOWSNO+$B*5LC[S<;6(..
M2">*X2/PE\4?A7<%] U2/Q=H>218WC$2C+<XSR#SU5N<'Y>Q]WZ\=J7_ #ZU
MRRP\)/FCH^Z/H\+GN*H1]C5M5I_RSU^Y[H\D\*?M':#JE\=,\06UQX3U1"(W
MBU!-D0?;DJ6(&SG^^%&,<UZM;74-["LUO*EQ"WW7B8,&['!'OD?45C^*/ N@
M>-(/*UK2K>_ !57D7#J"".'&&'4]#U.:\I;X#^(O FH3WWP^\326L3_.VEZA
MDQN>."0-IXR!E01Q\W.1/-7I;KF7XG9[#*<R_A3]A-]):Q;]=U\SW.BO#M*_
M:"U+PO=#3OB'X=NM&N!A1J%M&7AD;D9V]P=IY0MSD8&*]<\/^*M(\56C7.CZ
ME;:A I(=H9 2AYX(ZC\?Y5K"M"IHF>5C<GQF!7/5A>/\RU7WHU:***W/&"BF
M32+;QM)(RQHJ[BS'  ').?I20W$5U"DT,J30R*'22-@592,@@C@@CO1IL/E=
MN9+0DHHHIDA1136;%(8M)NJ)Y@M59KQ4SD\4 6VF"TS[0/6N6\1>---\-V;7
M6I7L-E;C^*5L;CZ#U/L*\,\;?M0RGS+;PS:E>,?;KM>?^ )_4_E7+6Q-.C\3
M/HLJX?S#.)I8:GIW>B^\^BM>\6:5X7L&O=5U"WL+9?XYG S[#')/L!FHO"OC
MO0O&MJ9M%U."^5?O*I*R+_O(1N'XBO@K7/$&I>);YKS5+Z>^N3QYDSDD#T'H
M/8<>U0:;JEYH]Y'=V-U-9W,9RDL+E6'XBO'_ +5?-I'0_5(^&T?JOOU_WOII
M_F?HT&!]O?M3J^5O /[5.HZ88K7Q1;?VE;C ^VVX"SC_ 'E^ZW_CI^M?0_A'
MQWH?C:S^T:-J,-X ,M&"1*G^\A^8?EBO7HXJE76CU/S#-N',QRB7^T0]WNM4
M=%12*V[_ #Q2UUGRX4444#"BBB@ HHHH **** "BBB@ HHHH **** "D:EI&
MJ)_"P6Y^!/[47_)R?Q-SQ_Q4FH8[_P#+S)7ZN>&OV_O@%8^'=*MI_B';QS0V
MD4;I_9UX=K! "/\ 4^HK\HOVI%#?M)?$X=/^*EU ?^3+U]C:/_P1]_M;2;*^
M_P"%M>3]J@2;R_\ A&B=NY0<9^U#.,^@KRL+*HJ3Y%I<NO\ QV<=_P %%OVQ
M/!WQXT?P_P"#_ EQ+JVEZ?>G4;O59+=X8Y)1&8TCC$@#' =]Q*@'Y,$]O9?^
M"1_PSU+0? OB_P 97L$D%IKMQ!:V/F*5\U(!)OD7/5=TFW/K&U;'PQ_X)-_#
MWPKJ$-YXN\1:IXS:%MPLXXUL+63_ 'U5GD/T#BOMG1]%L/#NE6NEZ596^G:;
M:1"&WM+6(1Q11J,*JJ   !TQ7;0I.GS5'N[F,^:HU?9'X1_M?-L_:@^)1!'&
MN7./^_AKT.P_8_\ VB?VC//^(FH:)+=R:N!>K>ZQ>Q6TMRI^[LC9@43  7(5
M=N-O&*\\_:]./VH?B3CC_B?7/_HPU^Z/@]0OA'0P !BQ@QQT_=KT]*Y<%24J
M:DWLS6NW[:274^.O^"A/[4VL? ?P'H7@CPK='3?%VM6@>XOXF'FV-JH"$QG^
M%W8,H8?="N1@X(^+OV=_V&/B'^U-HM[XQ75K32-)DG=1J6KO)++>S;OG*@ E
ML,2"S$9;(&2#CJ_^"K!G_P"&GH#+N\O^P;0Q;NFW?-G'MNW?K7Z%_L+?8_\
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M#^T;_P B#8_]A./_ -%2T >??LR_\EO\-?6Y_P#2::OO^'[JU\ ?LR_\EO\
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MDM_N"@"S2TE+0 4444 %%%% %>X^Z:Y37O\ 5/\ 2NKN/NFN4U[_ %3_ $H
M\@\7?>DK%^&?_(W77_7H_P#Z,CK:\7?>DK%^&?\ R-UU_P!>C_\ HR.MZ'\1
M >J4445[Q84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 ?XU_/=\=&\OXZ_$%QSCQ'J!'O_ *3)7]"->>W_ .SK\*=5
MOKF]O?AEX.O+RYD::>XN- M9))9&)+.S-&2S$DDDG))KCK4'.HIQ=K%-\T.5
M]S\TKK_@K9\6)-/:WMO#?A&UD*;%N!:W+LG&-P#3D9^N1[5Y9\+?@1\6?VVO
MB5+X@O6O+BVOI]^J>*]2CVVT2CA@F,!V50 (X^G .U>1^OUI^SE\)]/NH[FU
M^&'@VVN(VW)+#X?M%=2.X(CR#]*]!AB2WC2.)%BC0 *B *%QP, =,"A8=RGS
MU7=F>MN5;'+_  Y^&>C?"WX=Z3X,T.%[?2-.M1:Q[L&1\_?D8X&79BS$XZD_
M2OQ"^(_P_P#&G[(?QXA-U:-;:AHNI+?Z5>W$1-O>QI(&CD4\!E(P& .1D@X(
MK]Y\5E^)/"FB>,M-?3M?T>PUS3WY:TU&V2XB)]2C@@_E55J,IS56#M)%QLJ?
MLGL?E]XR_P""CGQ/_:"\,7'@+P3\/[>QUC6;62TNY[*22]FDB9")/*0JHC&W
M(+-O 4GD'YAX)^PGJD.B_M;?#F>YD6*.2_>#?(<#=)#)&H^I9@/J:_:[PG\-
M_"7@&&XB\,>%M%\.17&/.32=.AM5DQ_>$:C=WZ^M8-E^SS\*]-U"'4+3X9^#
M[6_@E6>*Z@T&T26.0'*NK"/(8$ @CG(I1HRC656^IG).4.1L\S_X*!?#C6?B
M9^S#XBL-!M);_4[&6'45LX%WR3)$V9 H'4A&8X')*X'45^5W[+W[4_B+]ECQ
M#J]_HFFV&K0ZI MO=6FH!P#M8E65E((()/KP3[$?N]ZUQ&M? WX<>)=6?5=7
M^'_A?5=3D;<][?:+;33L?4R,A8G\:4J$E6]I%[FDK3@HOH?%W[;G@+Q7^T_^
MRS\,/B=I&EFYU6QLQJ=]I6GH6*PW443.T:\LVQHUR.N"3SBOEK]DW]NC7?V6
M= U;P_'X;M/$^BWUR;Q89+EK:6*8HJDAPK J0B?*5[=1DU^U%K:PV-M%;VT,
M=O;Q*$CBA4*B*!@* . ,=JY#6?@G\._$>M-J^K> O#.J:LS!S?WNCV\TY8=#
MYC(6S[YH=&4:DITY64MQ2]Z*YMT?BU^U#\9/B%^T%JVB>._&.C+HNC74<UGH
MB6\#);F.-@TFQF.9#F1<OT)X&,$#](O^"7FK0:C^RG8VT<BM)I^J7EO*J]48
ML) &]\2 X[YKZ2\6?#/P?X\M[*W\3>%-#\106.[[+%JVFPW26^0 ?+$BD+G
MZ8Z"IO"/P_\ "_P^M)[7PMX;TCPU;3OYDL.CV,5JCMC&YEC4 G  R>U7AZ/L
M7)]R9ISE&78W_P!****Z1A1110,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** &LVVH)9@N<T^5NOI65J%UL4TF(2[U 1YYKS'XC?%Q?"4R6=O;FYO98_,
M&XXC122,D]^5/%;NM:QY>[FO!/BI=_;O$43GD?9E7_QYZVH)3J),^/XKS#$9
M;EDJ^&=I72^\RO$GC+5_%4I;4+MI(\_+ ORQK]%_QR:Q,T45[2BH[(_FBOB*
MV)FZE:;DWU"BBBF<_F%+'(T+JZ,R.IRK*<$<YX-)13''W7='I?@GX[Z[X8$5
MM>L=6T]< QS-B1%^4?*W?Y0>O<U]*^$_$T'B_P /V6KVJLD-TA8*W56!VD'Z
M,#7P_7UM\"&Q\+=$_P"V^/\ O_)7G8BG&*ND?LW V<8S$8B6$KS<HI75^AZ%
M124M>>?M"5D%'J2?_K45R7Q)^(5K\.]!^VRIY]W,Q2UMP<>8X7DGV'4_E5*+
MD^5'-BL32P=&5>L[1CU,/XR?%2+P+I;V-E)OUZZCQ"!C]PIR/,/O_=SWP3Q7
MG?[-WC4VFN7VB7<S,NH?Z3 S-G]\H.[KU++@\_\ /,"O(M<UN\\2:O=:E?R^
M?=W+EW8]/0 #T P,>@J'3]0N=*OH+VUE:&YMY%ECE7J&4@@^^,=#7J1HI4^5
M[G\]8GBVO6S>&.C_  X.RCY?YL^W=<\2Z5X9MS-JFH6]B@' FD"EO91U8^P!
MKS2X^-NH^*;N:Q\#^'I]6=1@7UQ\D:^Y![>FY@?:F> ?A#HFMVEGXDUC4IO$
M\]Y&LJM<,5C'J"N<L5.1@G''2O6;'3[73+=;>SM8;2W3[L,$815^@' _"N#W
M*;MNS]AI_P!IYI!3YE1IOMK)I^>R/)+'X.Z[XQD%WXZ\07%QN(==-M)0(U[X
M_NC_ ("/QKTOPWX1T?PC;F#2=/ALD;[Q0$N_^\QRS?B36Q25$IN1ZF#RC"8-
M\\8\TOYGJ_Q%^IS]311169[(4444#"BBB@ HHHH **** "BBB@ HHHH ****
M "D_PQ2T4:/1@?!_[??PK;2/%&G^.;*'%KJBBTO2H^[<(/D8_P"]&,>WEGUK
MY)_6OUV^+?P]M?BG\.]:\-76U/MD)\B5AGRIEPT<GX, 3ZC([U^2NK:3=:#J
MEYIM]"UM>6<S030OU1U8JP]\$$5^L\-X[ZSA?92^*'Y=#6+N4Z***^O]2PKV
M[X5^)/[8T(64K[KJR 3!/+)GY3^'(_"O$:UO"_B"3PUK5O>QY95)$B _>0XW
M#^6/I7!C</\ 6*375; ?2B-[YJ=&K.L[R*\MXKB%Q)#(H=9!T(/0_P"?2KJ-
M7P,H\KLRBVC5/&U5$:ID:N=H"Y&U3QM5-&J>-JP: N*U3(U5$:IE:LF@+B-4
MRM5-'J=&K%H"W&U3JU4U:IE>L91 N*U3(]4U:I5:L6@+R/4BM517J9&K%H"V
MK5,KU35JD5ZSL!<5JE63%5%DJ56K-Q N+)5'7O#NG^*+/[/?0[P.5E3[Z'KP
M:E5ZE63D'."*492@[Q=F95*4*T7"HKIGC/BKX6:CH2M<6;?VE9Y_@4^8GU S
MGZ_H*XD]Z^H5EYSFN:\4?#[2_$X:4I]CO>OVB) <G_:'\7Z5[N'S)K2LOF?!
MYCPPI7J81V\O\CP:&7R9%?&0#_\ KK0X(!'((R/\*N^)O!&I^%9";A/.MNUS
M$,I^/H?K658RA@8B>1\RX_4?Y]*^FPU=2]Z+NC\WQF%J46X5HM-'/^,OOVGT
M;^E<Y].*Z/QE_K+7Z-_2N<[D5W[GJX7^#%KL7O,^T1B3^+&U^._K^(_D:5(V
M=MH&3[50748+"4B5V(/RO&@RWOGTQBI+BZ>3*$JL?]U/NMZ'W'UKEGIL?386
M#JK5D\EQ%"I(83.".5^[],]^A_.L'5O$5]8Z@NUUEC,?^JE7Y,Y/;^$\#IW
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M)LN_'\3#.W\,].U>R:7IMGH=C'9V%O':6T?W8XQC'_U_QJ=I*B:2N=R<MS\
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M1.1\I&0<'G(R1R!C Q7L5)WST/J.*QG1A4^)'J8/,\7@'^XG9=MT_5'@UO\
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M$?&2QU+24M<H@HHHH KW'W37,ZQT/TKIKC[IKF=8Z'Z4 <-J7^L->0_M&_\
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MBBB@ HHHH **** "BCZ_7VI/8\?7C_/^>: %HH_SS10 4444 %%%% !1110
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MH **** "BBC_ /5[_E^= !11^';/^?\ /:C]* "BBB@ HHHH **** "BBB@
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M@2#]*[R*WCMX4BB011H-JJ@ "@= !6M];F6NQG^&O#MCX5T'3]'TR'[/I]C
MEO!$/X44  >_3K6I24M3N[C2MH%%%% PKX,_X*/>&YX?%'A/Q $+6LUI)9,P
M'W71]X&?<.<?0U]YUY]\;OA+I_QH\ 7_ (=OF%O,_P"]L[O;N-O.N=KX].2"
M/1CWYK*HKI-=#2#L]3Y@_8%^-6CZ3I=YX UB\CL+V:[-UIK3-M6<N%#Q GC=
ME<@=]QQR*^W5;Y0>U?C=\1/AKX@^%GB*XT/Q'I\EC=QGY#C,<Z9X>-NC*>N1
MW.#@Y%;OAG]HCXE>#H$@TOQIJL-O&,)#//YZ*.P590P ^@K=R]IJ8J/)H?KK
MN]>*I:QK5CH&FW&HZG>0:?8VZ[Y;FYD$<:*.Y8\"ORW;]L+XP2(RGQK<888.
MVTMP?P(CS7 >+OB9XK\?.#XB\1:EK*J=RPW=T[QKD8.U,[5)_P!D5F[O1%Z=
M3M/VH/BM:_&'XN:EK.F[CI-NB65FSY!>-,_.0>1N9F(]B,U]]?L@^&9O"O[/
MOA:"Y0QSW4;WK*1@@2R,Z_\ CI6OB?\ 9A_9EU3XRZ];ZIJEM)9^#+23=<74
MBE?M>#_J8O7/.YAPH/K@'].;>UBM;>*&%%BBC4(D:#"JH&  .P%:Q7LX./<S
MD^>:?1$BT^DQ2U!84444 %%%% !1110!#-T-<]K'^K/TKH9NAKGM8_U9^E '
M":M]\UYQ\:O^25ZY_P!L/_1\=>CZM]\UYQ\:O^25ZY_VP_\ 1\= 'SU\+/\
MDIWA#_L,6?\ Z/2OTDM_N"OS;^%G_)3O"'_88L__ $>E?I);_<% %FEI*6@
MHHHH **** *]Q]TURFO?ZI_I75W'W37*:]_JG^E 'D'B[[TE8OPS_P"1NNO^
MO1__ $9'6UXN^])6+\,_^1NNO^O1_P#T9'6]#^(@/5****]XL**** "BBB@
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MWOA\312VJD\R>7)))YN/[H*GW/2OTOT[5+75M,M=0LYTN+&ZA6XAN(S\DD;
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M4C)<J/V7@;*<9A\1+%UH<L&K*^_W'0KTIU-7I3J\\_:@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D
M;]NSX'C6M'C^(.DV^;[3T6+5$0<RVX/RRX'4H3@_[)S_  XKX2Z<5^T%Y9P:
MA:36MS"D]M,C1RQ.N5=6!!4CT(-?EG^T=\&)_@K\1+G3D1SH=X3<Z9.W.Z$G
M_5D_WD/!]MI[U^E\-9DJD/JE5ZQV_P C2+/-;73;N^C>2WM9YXX_OO%&6"_4
M@<55^[P>OI7W7\-]$M_#_@70[2WA2'%I'))M4?-(R@LQXY.2:LZYX%\/>)-W
M]IZ-9W;-UD>(;_\ OL?-^M>?+C6%.O*$Z3LG;1BYSX+QTKHO _BA_"NM)*Q/
MV.7Y)T]5]?J.OZ5]'Z[^S!X3U+>VGR7FDRGH(I!+'^*MEOUKS_5OV4]<M9A_
M9VK65Y#N _>JT,@&<\###]:]VGQ+E>,@XSERW[HI31V5O.LT22(P9'4,K#H0
M>AJRK4RW\(ZCX?L+:TDM)3';Q+$)%&X$* ,Y'TIJM[5X'M*=1MTY)HU3N6T:
MIU:J:-T-3J]2T!;5JF1JJ*U2JU8R0%U'J96JDC5.KUBT!;5JF5JJ*U2*U9-
M75:I%:JBO4RM63B!;5JE5JIJU2J]9.(%M6J57JHLE2JU9M 6U>I%>J:M4BO6
M30%T/FG!O2JJO[T]9/>HL!:62GB2JRR4[<*SL!:62GB2J@8TX24F@+?F4[?Z
M$CO53S/>E\RIL!E^+/!.C>-+41:K9I*RX*3JH6:, Y^5@,XR.1T-?/OCCX#Z
MSX762[T]O[7L%RQ,:%98E ).Y>A&!U!_ 5],>9QCM2^9SG\:[\-C*N&TCJNQ
MY^)P%+%?$K/N?%&EW(W&W9L;CN3IQ_\ K_P]:S=>A:;4H8U4EF0#]23_ )]
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MG\[<?9O@\QJTJ6%GS.%[VV+%+24M>T?DP4444 %%%% !1110 4444 %?(?\
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M"6!QC=D@'.G6A5?+'<3=F>D?\%#/^3/OB#_USL__ $M@KX:_X))G_C(S7O\
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M]$4=J]0_9=_:._9@^"_PGTG3-:T2;4_%=Q")=7OKK0TN6>8\F-7;_EFG"@#
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MZW/_ *335]_P_=6O@#]F7_DM_AKZW/\ Z335]_P_=6@">BBB@ HHHH ****
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M1:V^6,G1I9#]YS]>WH*DH_G17N1BJ:Y44%%%%6,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $QFHWC'I4M%
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MW_V:?^"=/Q7^!GQP\*^.+O6O!]Y8Z9<,;F"VO;KS6A=&CDV!K8 L%<D D D
M9[U]M_'WX):+^T)\,=4\&:Y));PW6V2"\AP7MIE/[N0 ]<$G([J6'>O1?YT5
MK[.+I*E+84;QDY)[GY1WG_!(GXDPZRZ6/C#PK<Z4),+=7#744Q7/5HA"R@^V
M\_6OL7]I[]F/Q)\8OV9_#GPW\/:EI<.K:6UCONM2:6*!U@A:-B/+CD8$D@@$
M5]+8[]Z7\*CV$?9^RZ,4=)\Y\?\ [!7['_C']EJ_\93>*]3T+4%UB*U2 :/<
M32%#&92V_P R&/ (D7&,]#7JG[37[)_A#]J#P_;VNN>;IFN62LNGZU:A?.@R
M,[&!X>,GJO7T(YKVS\3_ )__ %T?I]!6DJ<9Q49*]AP]QW1^4.M?\$A_B1#J
M3QZ/XQ\*WVG9^2>^-S;3%?4QK%( ?;<?K7T+^S+_ ,$R_#OP?\16/BKQGJZ>
M,=>LV$UI916_EV5M*""&(8EI6!&5)"@==N0"/MFBIA1A3=UJ3**>AYS^T5\.
M=3^+?P1\7^#]'GM;;4]7LOLT$U\SI"K%U.7*JQ PIZ U\H_L5_L$^/\ ]F_X
MROXM\2ZQX;O=.;39[(1:7=7#S;W9"#B2!!CY#_%7WF,#H*7Z<41HQ57VW4<U
MSQ47LCRC]J?X3ZO\<?@1XI\$Z%<V=KJNJ+ L,VH.Z0J4N(Y3N**[#A#C /X5
M\T_L1_L(^/?V:OB]=^*_$VL>&[_3I=)FL5CTFZN))!(TD3 D20(-N$;OGIQ7
MW9Z4HXQCUS35-1J.JMQS_>0Y'T"BBBM0"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBBCJ!T7@__ %EQ_P !_K79Q_=%<9X/_P!9<?\  ?ZUV<?W17B8CXR6
M.I:2EKE$%%%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_P!8:\A_:-_Y$&Q_
M["<?_HJ6O7M2_P!8:\A_:-_Y$&Q_["<?_HJ6@#S[]F7_ )+?X:^MS_Z335]_
MP_=6O@#]F7_DM_AKZW/_ *335]_P_=6@">BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ****!!Z \CTQQ1_/J#Z444>8P_EV'4"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!,9I-HIU% #=@I=HI:* "BBB@ HHHH **** "BBB@
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M_P"PQ9_^CTK])+?[@K\V_A9_R4[PA_V&+/\ ]'I7Z26_W!0!9I:2EH ****
M"BBB@"O<?=-<IKW^J?Z5U=Q]TURFO?ZI_I0!Y!XN^])6+\,_^1NNO^O1_P#T
M9'6UXN^])6+\,_\ D;KK_KT?_P!&1UO0_B(#U2BBBO>+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "2O7/\ MA_Z/CKT?5OOFO./C5_R2O7/^V'_ */CH ^>OA9_R4[PA_V&+/\
M]'I7Z26_W!7YM_"S_DIWA#_L,6?_ */2OTDM_N"@"S2TE+0 4444 %%%% %>
MX^Z:Y37O]4_TKJ[C[IKE->_U3_2@#R#Q=]Z2L7X9_P#(W77_ %Z/_P"C(ZVO
M%WWI*Q?AG_R-UU_UZ/\ ^C(ZWH?Q$!ZI1117O%A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M****]XL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1111U Z+P?_K+C
M_@/]:[./[HKC/!_^LN/^ _UKLX_NBO$Q'QDL=2TE+7*(**** *]Q]TUS.L=#
M]*Z:X^Z:YG6.A^E '#:E_K#7D/[1O_(@V/\ V$X__14M>O:E_K#7D/[1O_(@
MV/\ V$X__14M 'GW[,O_ "6_PU];G_TFFK[_ (?NK7P!^S+_ ,EO\-?6Y_\
M2::OO^'[JT 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**M)=!A1115 %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****.H'1>#_\ 67'_
M  '^M=G']T5QG@__ %EQ_P !_K79Q_=%>)B/C)8ZEI*6N404444 5[C[IKF=
M8Z'Z5TUQ]TUS.L=#]* .&U+_ %AKR']HW_D0;'_L)Q_^BI:]>U+_ %AKR']H
MW_D0;'_L)Q_^BI: //OV9?\ DM_AKZW/_I--7W_#]U:^ /V9?^2W^&OK<_\
MI--7W_#]U: )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***8!1112 **** "BBB@ HHHH ****8@HHHI#"BBB@ HHHH$%%%% PHHHH *
M*** "BBB@ HHHH **** "BBB@.M@HHHI@%%%%( HHHI@%%%% !1112 ****
M"BBB@ HHHH ****8@HHHI#"BBB@ HHHH ****!!1113&%%%%( HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****.H'1>#_\ 67'_  '^M=G']T5QG@__
M %EQ_P !_K79Q_=%>)B/C)8ZEI*6N404444 5[C[IKF=8Z'Z5TUQ]TUS.L=#
M]* .&U+_ %AKR']HW_D0;'_L)Q_^BI:]>U+_ %AKR']HW_D0;'_L)Q_^BI:
M//OV9?\ DM_AKZW/_I--7W_#]U:^ /V9?^2W^&OK<_\ I--7W_#]U: )Z***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FTZFXH I:M
M:O?:7>6T9 DFA>-2QZ$@@'Z5\ #_ ()T>/V&?^$@\-CZS7'_ ,9K]"N/6GKT
M%39<URN9VL?GE_P[G^('_0P>&O\ O]<?_&:0_P#!.GQ__P!#!X;_ ._UQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8A0 !D\GZ?E7D7P-_:P^&G[0RR0^$=>#ZK#%YLVD7T9M[N->,ML/#J,C+(6
MR,D5YE^V7^VEX7^!=KKO@&>QUFX\6:IH$LME<6<,36T+S++''YK-*K##*2<*
M<#&,]*FK5C3CS7]/,=-*;\CW3P_\=?AMXLUBWTG1/B'X4UG5;@E8+'3];MIY
MI2 6(5$<DX4$\>E7?BQ\0K?X4_#3Q+XPN;26^@T6QDO#:PD!Y2HX7/;)_BY
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M?P):W!>:>0L)M7G#9:)&/.W.=\F<]5'S$E9]K.M5Y:.RW!OD@N;=GZ??L_\
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M@S2["/AKF[TJU1<]ADIR3V'4UG:TN9EW]WE/R4I.1T./3M_*OU ^'=W^S_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\1"+6WZ(^%_@U\/_ !/^W9^TQ<?\)%K$X-Z9-2U?4(QN:WM48#RX0<@<LD:
MY R#@@'/UI^UI_P3M^&W@?X#:WXE\#VU]I>M^';;[9*\U[)<+>1)CS0ZMD [
M?F!3:,KC!SQPO_!'^:S_ .%@>/XI'3^T&TRW,*L?G:,2GS"!W /EY_"OK?\
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M+W[)]FW;PJ[0F]\ !!R6YYKHPL7#G;6_W$S]Z46NA[%11176:A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7KG_ &P_]'QT ?/7PL_Y*=X0_P"PQ9_^CTK])+?[@K\V_A9_R4[PA_V&+/\
M]'I7Z26_W!0!9I:2EH **** "BBB@"O<?=-<IKW^J?Z5U=Q]TURFO?ZI_I0!
MY!XN^])6+\,_^1NNO^O1_P#T9'6UXN^])6+\,_\ D;KK_KT?_P!&1UO0_B(#
MU2BBBO>+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^O1__1D=;T/XB ]4HHHKWBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBBGY 'XD?2LKQ'X5T3QAIKZ=KVCV&MZ>YRUIJ-LEQ"Q]2
MC@J>W;L*U:*EI/=!KM<Y/PG\)? W@.ZDN?#/@OP]X=N)!AY=)TN"U9AZ$QJ"
M1P*ZSTYX'2BBFO=TCL+2X4444#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M '[3_P"+H_X6UI7_ #YW_P#W[3_XNCV]+^8+G;T5Q'_"VM*_Y\[_ /[]I_\
M%T?\+:TK_GSO_P#OVG_Q='MZ7\P7.WHKB/\ A;6E?\^=_P#]^T_^+H_X6UI7
M_/G?_P#?M/\ XNCV]+^8+G;T5Q'_  MK2O\ GSO_ /OVG_Q='_"VM*_Y\[__
M +]I_P#%T>WI?S!<[>BN(_X6UI7_ #YW_P#W[3_XNC_A;6E?\^=__P!^T_\
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M^?.__P"_:?\ Q='MZ7\P7.WHKB/^%M:5_P ^=_\ ]^T_^+H_X6UI7_/G?_\
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M )\[_P#[]I_\71[>E_,%SMZ*XC_A;6E?\^=__P!^T_\ BZ/^%M:5_P ^=_\
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M .+H_P"%M:5_SYW_ /W[3_XNCV]+^8+G;T5Q'_"VM*_Y\[__ +]I_P#%T?\
M"VM*_P"?._\ ^_:?_%T>WI?S!<[>BN(_X6UI7_/G?_\ ?M/_ (NC_A;6E?\
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M -^T_P#BZ/\ A;6E?\^=_P#]^T_^+H]O2_F"YV]%<1_PMK2O^?.__P"_:?\
MQ='_  MK2O\ GSO_ /OVG_Q='MZ7\P7.WHKB/^%M:5_SYW__ '[3_P"+H_X6
MUI7_ #YW_P#W[3_XNCV]+^8+G;T5Q'_"VM*_Y\[_ /[]I_\ %T?\+:TK_GSO
M_P#OVG_Q='MZ7\P7.WHKB/\ A;6E?\^=_P#]^T_^+H_X6UI7_/G?_P#?M/\
MXNCV]+^8+G;T5Q'_  MK2O\ GSO_ /OVG_Q='_"VM*_Y\[__ +]I_P#%T>WI
M?S!<[>BN(_X6UI7_ #YW_P#W[3_XNC_A;6E?\^=__P!^T_\ BZ/;TOY@N=O1
M7$?\+:TK_GSO_P#OVG_Q='_"VM*_Y\[_ /[]I_\ %T>WI?S!<[>BN(_X6UI7
M_/G?_P#?M/\ XNC_ (6UI7_/G?\ _?M/_BZ/;TOY@N=O17$?\+:TK_GSO_\
MOVG_ ,71_P +:TK_ )\[_P#[]I_\71[>E_,%SMZ*XC_A;6E?\^=__P!^T_\
MBZ/^%M:5_P ^=_\ ]^T_^+H]O2_F"YV]%<1_PMK2O^?._P#^_:?_ !='_"VM
M*_Y\[_\ []I_\71[>E_,%SMZ*XC_ (6UI7_/G?\ _?M/_BZ/^%M:5_SYW_\
MW[3_ .+H]O2_F"YV]%<1_P +:TK_ )\[_P#[]I_\71_PMK2O^?.__P"_:?\
MQ='MZ7\P7.WHKB/^%M:5_P ^=_\ ]^T_^+H_X6UI7_/G?_\ ?M/_ (NCV]+^
M8+G;T5Q'_"VM*_Y\[_\ []I_\71_PMK2O^?._P#^_:?_ !='MZ7\P7.WHKB/
M^%M:5_SYW_\ W[3_ .+H_P"%M:5_SYW_ /W[3_XNCV]+^8+G;T5Q'_"VM*_Y
M\[__ +]I_P#%T?\ "VM*_P"?._\ ^_:?_%T>WI?S!<[>BN(_X6UI7_/G?_\
M?M/_ (NC_A;6E?\ /G?_ /?M/_BZ/;TOY@N=O17$?\+:TK_GSO\ _OVG_P 7
M1_PMK2O^?.__ ._:?_%T>WI?S!<[>BN(_P"%M:5_SYW_ /W[3_XNC_A;6E?\
M^=__ -^T_P#BZ/;TOY@N=O17$?\ "VM*_P"?._\ ^_:?_%T?\+:TK_GSO_\
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MEKU[4O\ 6&O(?VC?^1!L?^PG'_Z*EH \^_9E_P"2W^&OK<_^DTU??\/W5KX
M_9E_Y+?X:^MS_P"DTU??\/W5H GHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *KWEY%8V\MQ/(D,$2EY)9&"JB@$EF)Z  58KY:_;
M\^(ESX4^%]EH%E,89_$%P8IF4\_9XP&=?;+-&#ZC(Z&LYRY5H5%<S.;^*?\
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M(>\<7!/L7QT^Z:^A/V:_%&I^-/@GX8UK6KQ[_5+R&22>Y=54NWG2#HH ' '
MXXK\ZOA'^S'X[^,$D5QIFF'3]()!;5M1S%!@==G&Z0]?NC'J17Z8?"'X??\
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MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\
MA$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?
M[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\
MA$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#/
M/]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$C_SS_2O9/^$:7^Z*/^$:
M7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC_A&E_NB@#QO_ (1(_P#/
M/]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\\_TH_P"$2/\ SS_2O9/^
M$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TKV3_A&E_NBC_A&E_NB@#Q
MO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[HH \;_P"$2/\ SS_2C_A$
MC_SS_2O9/^$:7^Z*/^$:7^Z* /&_^$2/_//]*/\ A$C_ ,\_TKV3_A&E_NBC
M_A&E_NB@#QO_ (1(_P#//]*/^$2/_//]*]D_X1I?[HH_X1I?[HH \;_X1(_\
M\_TH_P"$2/\ SS_2O9/^$:7^Z*/^$:7^Z* /&_\ A$C_ ,\_TH_X1(_\\_TK
MV3_A&E_NBC_A&E_NB@#QO_A$C_SS_2C_ (1(_P#//]*]D_X1I?[HH_X1I?[H
MH \;_P"$3/\ <_2IH?"IW ;/TKU[_A&E_NBGIX;7^Y0!Y]I/AWRV'R?I7>Z%
MIIA"\8K1M=!52/EK9L]/$8'%("U8Q[5%:2=*AABVC%3@8H 6BBB@ HHHH KW
M'W37,ZQT/TKIKC[IKF=8Z'Z4 <-J7^L->0_M&_\ (@V/_83C_P#14M>O:E_K
M#7D/[1O_ "(-C_V$X_\ T5+0!Y]^S+_R6_PU];G_ -)IJ^_X?NK7P!^S+_R6
M_P -?6Y_])IJ^_X?NK0!/1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5\(_\ !261O[=\#)GY/L]V<>^Z+_ ?E7W=7P?_ ,%)?^1A
M\#_]>UU_Z%'653[/JC:GU]#O/^"=-G#'\+?$%TJ 7$NL-&[]RJPQ%1^!=OSK
MZP*].3UK\P?@)^UEJ/P&\*WFAVGA^UU5+F]:\,UQ<-&5W(B8  Z?NZ]-_P"'
MD6N_]"5IX_[?'_\ B:Z*C4GH<L$U>_<^?_VC+6&Q^.WCF&!%BC&JSG:HQC+9
M) ^IK[5_9Y_8^\"^'?#FA^)=6M?^$FU>]M(;Q?[00?9X"Z!PJP]&QG[S[CQD
M8KX&^(OC.7XA>.-;\236R6<NIW#W+6Z,66,M@D XKZ2\-?\ !0;6O#7AW2])
MC\'V,T=A:Q6JR/=N"X1 H)&WJ<5G3]VG;J7/WIWZ'Z!QPI%&J( B*,*JC  ]
M!3M@]*^#?^'D>N_]"7IW_@9)_P#$U]=_!GXA3_%#X9Z'XIN;2.PEU&)I&MXW
M+*F)&7@GK]VJUM<+I-([FBDSTI:0PHHHH **** "BBB@"&;H:Y[6/]6?I70S
M=#7/:Q_JS]* .$U;[YKSCXU?\DKUS_MA_P"CXZ]'U;[YKSCXU?\ )*]<_P"V
M'_H^.@#YZ^%G_)3O"'_88L__ $>E?I);_<%?FW\+/^2G>$/^PQ9_^CTK])+?
M[@H LTM)2T %%%% !1110 4QES3Z* *[0ANU,-F#VJW10!2-F/[M)]C']VKN
MVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;
M0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2
M^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC
M^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1
M]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C'
M]VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VK
MNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC
M;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!
M2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^Q
MC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[
M1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C
M']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']V
MKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNV
MC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0
M!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^
MQC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^
M[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]
MC']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']
MVKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKN
MVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;
M0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2
M^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC
M^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1
M]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C'
M]VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VK
MNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC
M;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!
M2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^Q
MC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[
M1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C
M']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']V
MKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNV
MC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0
M!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^
MQC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^
M[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]
MC']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']
MVKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKN
MVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;
M0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2
M^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC
M^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[1]C']VKNVC;0!2^QC^[2
MBS7^[5S;10!56U"]JE6$+VJ:B@! M+110 4444 %%%% %>X^Z:YG6.A^E=-<
M?=-<SK'0_2@#AM2_UAKR']HW_D0;'_L)Q_\ HJ6O7M2_UAKR']HW_D0;'_L)
MQ_\ HJ6@#S[]F7_DM_AKZW/_ *335]_P_=6O@#]F7_DM_AKZW/\ Z335]_P_
M=6@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY
MG_:X_9L\3?'K5O#EQX?OM)LTTV&=)1J4LJ%BY0C;LC?/W3UQVKZ8IGEC.:F4
M5*URHR<=C\[!_P $Z_B1_P!!OPMS_P!/ES_\CTO_  [K^)'_ $&_"O\ X%W/
M_P CU^BF**HD_.O_ (=U_$C_ *#GA;_P+N?_ )'H_P"'=7Q(_P"@WX5_\"[G
M_P"1Z_12B@#\Z_\ AW5\2/\ H-^%?_ NY_\ D>OM3X%^ ]0^&/PJ\/\ AC5)
M;:?4-/B>.62S9FA8M([#:652>&'4"O0*3:,D^O6G<35]11VI:**0PHHHH **
M** "BBB@"&;H:Y[6/]6?I70S=#7/:Q_JS]* .$U;[YKSCXU?\DKUS_MA_P"C
MXZ]'U;[YKSCXU?\ )*]<_P"V'_H^.@#YZ^%G_)3O"'_88L__ $>E?I);_<%?
MFW\+/^2G>$/^PQ9_^CTK])+?[@H LTM)2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHJG]K7UH^UKZT 7**I_:U]:/M:^M %RBJ?VM?6C[6OK0!<HJG]K7UH^UKZT
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MHJG]K7UH^UKZT 7**I_:U]:/M:^M %RBJ?VM?6C[6OK0!<HJG]K7UH^UKZT
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M1!L?^PG'_P"BI:]>U+_6&O(?VC?^1!L?^PG'_P"BI: //OV9?^2W^&OK<_\
MI--7W_#]U:^ /V9?^2W^&OK<_P#I--7W_#]U: )Z*** "BBB@ HHHH ****
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M$^3KO\4:HWYW<M 'GE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4N]A@@X(Z>U)10!^P7_!%WXM>)O&G@7XA^%-;U:XU/3/#<]A
M+IJW4AD:W6Y%P'B4GD)F $+G +,1U-?I*.@K\I_^"'!Y^-0_[ O_ +?U^JZG
MB@!U%%% !1110!7N/NFN9UCH?I737'W37,ZQT/TH X;4O]8:\A_:-_Y$&Q_[
M"<?_ **EKU[4O]8:\A_:-_Y$&Q_["<?_ **EH \^_9E_Y+?X:^MS_P"DTU??
M\/W5KX _9E_Y+?X:^MS_ .DTU??\/W5H GHHHH **** "BBB@ HHHH ****
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MX^Z:YG6.A^E '#:E_K#7D/[1O_(@V/\ V$X__14M>O:E_K#7D/[1O_(@V/\
MV$X__14M 'GW[,O_ "6_PU];G_TFFK[_ (?NK7P!^S+_ ,EO\-?6Y_\ 2::O
MO^'[JT 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#-T-<]K'^K/TKH9N
MAKGM8_U9^E '":M]\UYQ\:O^25ZY_P!L/_1\=>CZM]\UYQ\:O^25ZY_VP_\
M1\= 'SU\+/\ DIWA#_L,6?\ Z/2OTDM_N"OS;^%G_)3O"'_88L__ $>E?I);
M_<% %FEI*6@ HHHH *:_W:=37^[0!DZA]TUYSXJ^X_TKT;4/NFO.?%?W'H \
M:\3_ 'FK\4?CE_R6SX@_]C#J'_I3)7[7>)OOM]*_%'XY?\EL^(/_ &,.H?\
MI3)0!Q%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?J5_P0\_UGQG_[@O\ [?U^K<=?E)_P0\_UGQG_ .X+_P"W]?JW'0 ^
MBBB@ HHHH KW'W37,ZQT/TKIKC[IKF=8Z'Z4 <-J7^L->0_M&_\ (@V/_83C
M_P#14M>O:E_K#7D/[1O_ "(-C_V$X_\ T5+0!Y]^S+_R6_PU];G_ -)IJ^_X
M?NK7P!^S+_R6_P -?6Y_])IJ^_X?NK0!/1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $,W0USVL?ZL_2NAFZ&N>UC_5GZ4 <)JWWS7G'QJ_Y)7KG_;#_P!'
MQUZ/JWWS7G'QJ_Y)7KG_ &P_]'QT ?/7PL_Y*=X0_P"PQ9_^CTK])+?[@K\V
M_A9_R4[PA_V&+/\ ]'I7Z26_W!0!9I:2EH **** "FO]VG4U_NT 9.H?=-><
M^*_N/7HVH?=-><^*_N/0!XUXF^^WTK\4?CE_R6SX@_\ 8PZA_P"E,E?M=XF^
M^WTK\4?CE_R6SX@_]C#J'_I3)0!Q%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444NV@!**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH _4K_@AY_K/C/\ ]P7_ -OZ_5N.ORD_
MX(>?ZSXS_P#<%_\ ;^OU;CH ?1110 4444 5[C[IKF=8Z'Z5TUQ]TUS.L=#]
M* .&U+_6&O(?VC?^1!L?^PG'_P"BI:]>U+_6&O(?VC?^1!L?^PG'_P"BI: /
M/OV9?^2W^&OK<_\ I--7W_#]U:^ /V9?^2W^&OK<_P#I--7W_#]U: )Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH AFZ&N>UC_ %9^E=#-T-<]K'^K/TH
MX35OOFO./C5_R2O7/^V'_H^.O1]6^^:\X^-7_)*]<_[8?^CXZ /GKX6?\E.\
M(?\ 88L__1Z5^DEO]P5^;?PL_P"2G>$/^PQ9_P#H]*_22W^X* +-+24M !11
M10 4U_NTZFO]V@#)U#[IKSGQ7]QZ]&U#[IKSGQ7]QZ /&O$WWV^E?BC\<O\
MDMGQ!_[&'4/_ $IDK]KO$WWV^E?BC\<O^2V?$'_L8=0_]*9* .(HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^I7_!#S_6?&?_ +@O_M_7ZMQU^4G_  0\_P!9\9_^X+_[
M?U^K<= #Z*** "BBB@"O<?=-<SK'0_2NFN/NFN9UCH?I0!PVI?ZPUY#^T;_R
M(-C_ -A./_T5+7KVI?ZPUY#^T;_R(-C_ -A./_T5+0!Y]^S+_P EO\-?6Y_]
M)IJ^_P"'[JU\ ?LR_P#);_#7UN?_ $FFK[_A^ZM $]%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 0S=#7/:Q_JS]*Z&;H:Y[6/]6?I0!PFK??-><?&K_DE>
MN?\ ;#_T?'7H^K??-><?&K_DE>N?]L/_ $?'0!\]?"S_ )*=X0_[#%G_ .CT
MK])+?[@K\V_A9_R4[PA_V&+/_P!'I7Z26_W!0!9I:2EH **** "FO]VG4U_N
MT 9.H?=-><^*_N/7HVH?=-><^*_N/0!XUXF^^WTK\4?CE_R6SX@_]C#J'_I3
M)7[7>)OOM]*_%'XY?\EL^(/_ &,.H?\ I3)0!Q%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %._A_&FT[^'\:!G[3?\$7?^38_$O\ V-=Q
M_P"D=G7,?\%MO^24?#O_ +#4O_H@UT__  1=_P"38_$O_8UW'_I'9UR__!;8
M?\6G^'9_ZC4O_H@T9E_&CZQ_(,/U^9^5/@CX6^,OB9-<P^$/"6N^*Y[50]Q%
MH>FS7C0J>%9Q&K%02.":O^,O@;\1?ASI*:IXM\ ^*/"VFR2K M[K6BW-I"9"
M"0@>1 -Q"L<=< ^E??G_  1$&?'GQ-_[!EI_Z->OTQ^,?@WP'XL\+PW7Q&MM
M/N?#?A^Z76W.K,OV2)X4<"27=\I50['!XXYR.*JHE"S)IRYFT?S_ 'PU_8Z^
M-'Q=TN/4O"OPXUS4--D0217TT M;>93T,<DQ17'^Z37._%+]GWXC?!.=(_'/
M@O6?#22/Y<=S>VK"WE?&=L<PS&YQV5C7[<^'?^"FG[.OB+Q5;:!9^.6@EN)D
MMX+FZTNZ@M7=CM \QXP$&<?,^U1G.<=/H?QYX%T'XF>#]2\,^)-.@U;1-2A,
M-Q:SKN5U/<>C \@CD$ CI43;C'F14&KVD?S)^&?">M>--;M='\/:1?Z[K-T6
M$&GZ9:O<W$VU2QVQH"S8 )X!X!]*_9S_ ()$_"GQ)\,/@OXO'BSPMJ_A76+W
M7R1!K6GRV<TD*V\(1@LBJ2NYI!G&,Y%?GU\))]%_8I_;[C7Q=<7(T/P?J]_;
M2W,,)EEDA:":.&3:,9++)&?^!5^TO[/_ .T=X+_:8\*W_B+P/<W5UIEE>-8S
M/=VS0,)0B.0%;J,.M;1DG3YH]3.<?>Y7T/FO_@K-H_Q(\6?!7P]X;^'^A^(-
M?BU'5?\ B;6GA^QGNI'@2-F191$I/E[]IP>"57TK\:_%7PQ\9> ]:M-'\3>%
M-<\.ZM>*LEM8ZMITUK<3*S%%9(W4,P+*5! ()!'6OZ'OVAOVGO O[,.CZ5JO
MCNZO+6SU.X:VMFL[5K@F15W$$+T&*_);]MW]H_P5^TQ^U!\.?$/@>YNKO2[.
MWL;"9[RV:!O-%Y*Y&UNVV1>:Y*2]]):W9T-^XV^B;/G;_AD_XV]3\'O'WL?^
M$8O<?^BJSOAC^SS\2?C-JMSIW@SP5K&O7-JYBN6@MBL5LXS\DLK82-N.C,#7
M]+,*B2VC!Z$<UYQ!J'PN_9I\,VFE7>N^'/ >ERRR2Q_VKJ%O9"XF=R\DA,C+
MO=F))/O6S=I-&"DY0374_G>^+'P7\:? [Q(N@>.M N?#NKM MREO<,C[XR2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/B#_ -C#J'_I3)0!Q%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %._A_&FT[M0,_:;_@B[_P FQ^)?^QKN/_2.SKF/^"VW_))_AY_V&IO_
M $0:ZC_@B]_R;'XF_P"QLN/_ $CLZY?_ (+;?\DG^'G_ &&I?_1!HS+^-'U7
MY"P_7YGF?_!$/_D?/B;_ -@RT_\ 1KU]9?\ !5IF3]BOQ;AB UYIX;GJ/M49
MKY-_X(B<>.OB:?\ J&VG_HUZ^L?^"KW_ "97XK_Z_M/_ /2J.GBOAC\OS%A_
MC;\_T/P@M6S<1_[PK^G'X0W<VH_"GP9=7,C37$^BV<LDC=68P(23[Y)K^8ZU
M_P"/B/ZU_3;\%?\ DC?@3_L!6/\ Z3I6S_@V\_T,7_&7H_S1^%/_  4K C_;
M<^)H50!]HM#Q[V5N3^M??_\ P19_Y-S\6_\ 8TR_^DEM7P#_ ,%+_P#D]SXF
M_P#7>S_](;>OO_\ X(L_\FY^+?\ L:9?_22VJ</_  )>B_,VQ'QKU,'_ (+:
M'_BU'P\_[#<O_H@U^4OPU;_BXGA;_L*6O_HU:_5K_@MI_P DH^'G_8;F_P#1
M!K\I/AK_ ,E%\+_]A2U_]&K7+@_C?^(>(_AOT/Z>8?EM4Q_=K^</]KSQAK/C
M3]IGXFWFMZA-J-Q!XBOK.%YVW>7!#.\<4:^BJBJ !Z5_1[%C[*O^[7\U7[2G
M_)QGQ4_[&K5?_2N6A_QG?L%+2BK>7Y'&>'?$6K>$=8M-7T+5+S1M6M6\RWOM
M/N&@N(6QC*.A#*<$C(]37WQ^S_\ LV_MD?M":!:ZU=?%GQ?X0\*7R*T=UXA\
M3ZAYMW V<O%;JY9E(Y'F; P(()%?/O\ P3^^%6E_&+]J[P1H.N6Z7FBQRR:A
M=VLHRDRP1M(J,#PRLZH"IX()%?O9\4O&B?#'X8^*_%7V7[7'H.E7.H_95(7S
M?)B:39GMG;C-=,^6G34I=28WG4]G'^KGYKV__!#N7RU:3XTHDAZA?"^\#Z$W
M@_E7Z._!7X<GX1?";PEX*.HG5_[!TV#3OMY@\GS_ "D"[]FYMN<=-QQZU^#/
MQ'_;T^/?Q(UZYO[GXF:_HJ22L8K+P[>2:;!"I)(11"5) ' +EF..23S7[@?L
MCZUJ?B']F/X8ZGK-]=:GJEYX?LYKF]OI6EGGD:)2SN[$LS'.<DY.<U*YG'FZ
M!.T9I==3\G/^"PFV/]KBW(49/ARS8X'4^;/_ (5^E?[ /Q^\/_'#]G'PI'IM
M[&=<\/Z?;:1J]@Q E@EBC$8<K_<D";E8<<D=58#\W?\ @KS92ZE^V%86D"!K
MBXT"QBC5F"@LTTP&2< #)ZDXKG/A_P#L'_M@?"OQ);^(/!_A'4_#NKP\)>:?
MX@T^)F7()5L7&&0X&58%3CD&L\-*V'49;%58WJ)IZGW9^UQ_P2ST']HCQYJ7
MCKP[XNF\)>(]0VR7UO<V@NK.XD5 @889&B8A1N.6!QG;G.?D;7/V*?VO?V5?
M#^H?\(%X@U#4-!=VN[J/P'J\P8L %#M;,(Y'?:!_JU<\8R<5>\%_\%?/C1\-
M=5DT/Q[X=T'Q?+ITTEK>,R&RO6D1MK R1$P\$$?+%CTK](/V1_VNO#/[77@:
M[US1+"[T;4=.E6WU+2;QU=H)&0,"CKP\9^8!L*3M;*CNU3:C[CT"535>T6I^
M"WQ)^-?Q*^)EO%I7COQEX@\116,[,EIK5[+,()0"I.US\K8R#QFOO/\ X(C_
M /(^_$X'_H&6G_HV2K?_  6:^!>@:#<>%/B=I-C#8:IJMT^EZJ84V_:G$>^&
M5@.-X5)%+=2-G]VJ?_!$<[?'OQ-]?[,M./\ MJ]7AY*2G;?4FNN51[:?F?77
M_!5+C]B7QR?^F^G?^ET%?@M;G]\GUK]Z?^"J'S?L3>.1T'VC3N?^WZ&OP7A4
M>8O/>LZ/\1V[K\D:S^!']/OPX_Y)[X8_[!=K_P"BEK\)?^"FWBS5O$7[9'CJ
MUU&_FN[;2I8+2Q@D8E+>'[/$VQ%Z %F9CZEB37[M?#G_ ))[X8_[!=K_ .BE
MK\#_ /@HW_R>I\4/^OV'_P!)8:53^,OG^@J/\+[CQ+X:L?\ A8GA<=O[4M?_
M $:M?T]6_P#QZQ_[M?R__#^Y2S\=>'KB3[D.H6\C?02*37]/\.1;H/\ 9K>?
M\'YO\D<O_,1\OU/YN/VL/^3F_BM_V-&I_P#I7)7WU_P0Y^]\8OII/_MY7P3^
MUG"\/[3GQ66161AXHU+Y6&#_ ,?4AK[Z_P""'UO+''\8)C&WE,VE()"/E+ 7
M9(SZ@$?F*6%_A2?]W]4=>*_B?,]@_P""R7_)K.C?]C1:_P#I-=5F_P#!&7PA
M#I'[./B'7-BB[U;Q!*C28Y,44,(1<^S-(?\ @5:7_!9+_DUG1O\ L:+7_P!)
MKJLW_@C/XPAUC]G/Q#H/F*;O2=?D=HP>1%+#$4;'H660?\!-3A[<M7OH&(^"
MCZLX7_@MQXQO+/PK\,?#$4Q6QOKR\U&>,?Q/"D:1G/H!/)^8]*_++P7XHO/!
M/B[1/$6GR-'?:3>PW\#(=I$D3JZG/U6OU,_X+;>#[V]\*_#'Q1% 6L+"[O-/
MGE .4>9(GC!]B()/R%?E7X>T&\\4>(--T?3H_/O]0N8[2WB )W2.X11P">20
M.G>LJ&[Y=[E5K<D4]K'Z=G_@N&&C,9^"V1MQG_A*O_N*OA?]G/4H-:_:^^'%
M_:VBZ?;7?C;3YXK16W"!&OHR(P<#(4'&<#IT%?2O_#E_XV+'O/BCP"%QG_D(
M7O'_ ))U\S_LVZ4V@_M<_#7399X;A[/QIIUNT]N28G*7T:ED) )4XR,@<=J[
M,-R_64^IA*_L7;X3^CF9?]'?_=K^83XBMM^('B;_ +"EU_Z-:OZ?)C_H[@?W
M?Z5_,)\1 &\?^)2>G]IW/_HUJ\__ )B/E^IO'^#\U^1^S7_!'7_DU&\_[&.[
M_P#1,%>-_P#!<+_D'_"3_KKJ?\K6O6_^"-^H1W7[+&K0H"'M_$UU&V[U-O;-
MQ^#"O*/^"WUO+)I/PGF"-Y"SZDADV_*"5MB!GU.UN/8UV8[^+\T9X312])'Y
MW?LQ_P#)QWPL_P"QJTO_ -*XJ_I3F_X\V_W?Z5_-A^R_ \W[2'PL2-&D?_A*
M=+PJJ2?^/J(GC\Z_I.F_X\VS_=IXC_=E_P!O&<?XI_.=\*?^3T/"?_8^VG_I
MP2OZ,93MMV8<';FOYSOA3_R>AX3_ .Q]M/\ TX)7]&,V&MFS_=K*3M@X>C_)
M&DO]XE_74_F9^.'BS5_&WQ<\8:QKFH7&IZE<ZI<&2XN9"[$"1@JC/15 "A1P
M  !@"OH;_@E5X.@\7?MB>&YKB,2QZ+9W6I[6'&Y8_+0_@TJD>ZBOF+XC?\E
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]2O^"'G^L^,_P#W!?\
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M;Z5^*/QR_P"2V?$'_L8=0_\ 2F2OVN\3??;Z5^*/QR_Y+9\0?^QAU#_TIDH
MXBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G4VEW4 ?M/
M_P $7V _9C\2GK_Q5EP/_).SKE_^"VF6^$_P\/3_ (G<P_\ (!K\MO!?QQ^(
MOPWTN33/"7CWQ-X7TZ24SR6>BZQ<6D+R$!2[)&ZJ6(51DC.%'I47C;XT>/\
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MA'V,K^=PJ>_'E\C^IF)<6JCVK^:C]I3/_#1GQ3_[&O5?_2N6KO\ PUC\;O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@"&;H:Y[6/]6?I70S=#7/:Q_JS]*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]2O^"'
MG^L^,_\ W!?_ &_K]6XZ_*3_ ((>?ZSXS_\ <%_]OZ_5N.@!]%%% !1110!7
MN/NFN9UCH?I737'W37,ZQT/TH X;4O\ 6&O(?VC?^1!L?^PG'_Z*EKU[4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#]2O^"'G^L^,__<%_]OZ_5N.ORD_X(>?ZSXS_ /<%_P#;
M^OU;CH ?1110 4444 5[C[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_6&O(?VC?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\
M#N7XE?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!
MGPO_ .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^
ME 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?J
MK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\
M09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=
MS_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\
M#N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?JK_PB9_N?
MI1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\ 09\+_P#@
M7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_
M  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\ #N7XE?\
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MGZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_  [E^)7_ $&?"_\
MX%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1
M_P .Y?B5_P!!GPO_ .!=S_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_
M $&?"_\ X%W/_P CT?\ #N7XE?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?
M[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P C
MU^JO_")G^Y^E'_")G^Y^E 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5
M_P!!GPO_ .!=S_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\
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MG^Y^E 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\
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M_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\
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MS_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\
M#N7XE?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!
MGPO_ .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^
ME 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?J
MK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\
M09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=
MS_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\
M#N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?JK_PB9_N?
MI1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\ 09\+_P#@
M7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_
M  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\ #N7XE?\
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MGZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_  [E^)7_ $&?"_\
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M_P!!GPO_ .!=S_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\
MX%W/_P CT?\ #N7XE?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5
M_P .Y?B5_P!!GPO_ .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G
M^Y^E'_")G^Y^E 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_
M .!=S_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P C
MT?\ #N7XE?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5
M_P!!GPO_ .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")
MG^Y^E 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\
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M_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\
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MS_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\
M#N7XE?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!
MGPO_ .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^
ME 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?J
MK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\
M09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=
MS_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\
M#N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?JK_PB9_N?
MI1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\ 09\+_P#@
M7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_
M  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y5?\ #N7XE?\
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MGZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\ (]'_  [E^)7_ $&?"_\
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M_P!!GPO_ .!=S_\ (]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\
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MG^Y^E 'Y5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\
M(]?JK_PB9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7X
ME?\ 09\+_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_
M .!=S_\ (]'_  [E^)7_ $&?"_\ X%W/_P CU^JO_")G^Y^E'_")G^Y^E 'Y
M5?\ #N7XE?\ 09\+_P#@7<__ "/1_P .Y?B5_P!!GPO_ .!=S_\ (]?JK_PB
M9_N?I1_PB9_N?I0!^57_  [E^)7_ $&?"_\ X%W/_P CT?\ #N7XE?\ 09\+
M_P#@7<__ "/7ZJ_\(F?[GZ4?\(F?[GZ4 ?E5_P .Y?B5_P!!GPO_ .!=S_\
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M_H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\
M#3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[
ME8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/
M^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*
M_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W
M_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\
MXU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\
M +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\
M]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AI
MCX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\
M:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\
M@!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^
MAE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -
M,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5
MB?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X
M1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_
M '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_
M  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C
M5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P
MNO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T
M,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/
MA?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJ
MC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P"
M%U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&
M4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ
M\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)
M_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&
M5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\
M<H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\
M",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4
M ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z
M_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0R
MC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%
M_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/
M^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 7
M7_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91
M_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'P
MO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_
M  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97
M^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!R
MC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (
MRO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!
MM_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_
M .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/
M_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_
M /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X
M:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?
M_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_
M ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"_
M_H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\
M#3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[
ME8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/
M^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*
M_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W
M_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\
MXU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\
M +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\
M]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AI
MCX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -,?"__H91_P" %U_\
M:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\
M@!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^
MAE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_ '*/^$97^Y6)_P -
M,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_  C*_P!RC_A&5_N5
MB?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C5 &W_P (RO\ <H_X
M1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P NO\ XU0!M_\ ",K_
M '*/^$97^Y6)_P -,?"__H91_P" %U_\:H_X:8^%_P#T,H_\ +K_ .-4 ;?_
M  C*_P!RC_A&5_N5B?\ #3'PO_Z&4?\ @!=?_&J/^&F/A?\ ]#*/_ "Z_P#C
M5 &W_P (RO\ <H_X1E?[E8G_  TQ\+_^AE'_ ( 77_QJC_AICX7_ /0RC_P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >K? UF:/64)^13"0O;)\S/\ (?E7JM>4_ O_ )C7_;#_
M -J5ZM0 4444 %%%% %>X^Z:YG6.A^E=-<?=-<SK'0_2@#AM2_UAKR']HW_D
M0;'_ +"<?_HJ6O7M2_UAKR']HW_D0;'_ +"<?_HJ6@#S[]F7_DM_AKZW/_I-
M-7W_  _=6O@#]F7_ )+?X:^MS_Z335]_P_=6@">BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** (9NAKGM8_U9^E=#-T-<]K'^K/TH X35OOFO./C5_R2O7/^
MV'_H^.O1]6^^:\X^-7_)*]<_[8?^CXZ /GKX6?\ )3O"'_88L_\ T>E?I);_
M '!7YM_"S_DIWA#_ +#%G_Z/2OTDM_N"@"S2TE+0 4444 %%%% !1110 5^:
MGQ9_Y*IXR_[#5[_Z/>OTKK\U/BS_ ,E4\9?]AJ]_]'O0!RE%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4>OTHH]?I0!^JU%%% !1110 5Y]
M\;/^15M/^OU/_1<E>@UY]\;/^15M/^OU/_1<E 'BM%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2O7/^V'_ */CKT?5OOFO./C5_P DKUS_ +8?^CXZ /GKX6?\E.\(?]ABS_\
M1Z5^DEO]P5^;?PL_Y*=X0_[#%G_Z/2OTDM_N"@"S2TE+0 4444 %%%% !111
M0 5^:GQ9_P"2J>,O^PU>_P#H]Z_2NOS4^+/_ "53QE_V&KW_ -'O0!RE%%%
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M1Z^HZCBE^N?KB@!**._4>^#1SW'^?Z4 %%'ZT4 %%%% !1110 4444 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH ]5^!?_,:_[8?^U*]6KRGX%_\
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M2-EQNC8CKU!![C/<$U=_9+OI[;XRV4<<C!+FVGCE&?O*$W8_-0:]@_;84?\
M"$:"<<C4<9_V3&^1^@K2:?NM/<(R5VGT/,/V?OV<E^)5FVO:]--;:&KE(;>W
M.)+EAU.XCY4!XXY)STQ7N>J?LR_"MT.G?8/[.OIDQ&T6I2^</]I4=V!_[Y-=
MSX#M(/"OPIT58ES%::5')P/O'RPS'ZDDG\:_.W7O$%]XEUR\U;4+AI[ZZE,L
MDA/.2>@] .@ Z 53=ZGLR8)\G,?;6D?LI^ --T.*'4-);5;^.,B2\:ZGC,IY
MP=JR!1QC@#M7PQ.H6>0#H&('YU^DOP[NIK[X9>&[FYE>>XETJVDDED.6=C"I
M+$]R2:_-JX_X^)?]X_SJ):5&C2.M-,CK]%O@5_R1WPK_ ->$?\J_.FOT6^!9
MQ\'?"G_7A'T^E7]EF+^.)\.^.O".NS>-_$,D>BZA)&VHW#*RVKD$&5L$''(K
MJ?V>?#&LV/QD\-7%SI-];P)-(6DDMG55!B<<DCUQ^=?06K?MA>#-#U:]TZ?3
M-<>:SF>W=HH(2I9&*DC,P.,CN!5_P7^U-X4\>>*M.T&PT_6(KR]<K&]U#$J#
M"EN2)2>BGH*4-+6*J:WN)^UU_P D9N_^ONW_ /0Z^<?@+\ 9_BY//?7MT^GZ
M#:OY;RQ >;/)P2B9&  ""6(/4  ]1]&_M<?\D9N_^ONW_P#0Z\%^ =Y\6-<L
MGT;P3J46G:-;R%Y;FZMH3#&[<G+-&S,WL,XXZ"LZ7QS^1<_AB>W3? ?X*Z#>
M6NDZA'9)J<BJ$BO-7DCGD)X!""1>IZ8 &>E>>_'#]E>P\.^'[OQ#X1DG2&S4
MS7&FW#F0",#YFC;&>!R0<Y&<'C!U]<_9!U/Q7JL^L:YX]6;5+IMTTHTH ,V!
MC&)5Z8X&!^%?0MUIWE>$9K.XE^V%+$Q22LN/-Q'@DCMGDX]ZJ:]SFZA%^_;H
M?%G[+OP[\/\ Q%\7:K8^(M/_ +0MH+'S8X_.DBVOYBC.48'H3W[U[W>?LE>!
M[KQ1;W<=G)9Z1#"1)I\=S*WVB0DX+.S%E4+V4C.>HQ@^3_L3?\C]KG_8-_\
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M^8QL4_=A<X88'/O7R;^V!X/L_AK^TKXGLM%B6PLS-#?V\=O\HB,D:2-M ^Z
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MEK]./VE_!/\ PL+X#^-M$6/SIY-.DGMT'/[Z(>;&![ED%*K>-%,J.M:QY?\
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MLR?#CQA>WGC#PO=>)?&NHR?:[BRTW4;HR MR'E'VA8XQZ+UP00N#FN(\6?\
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M ,.7@6XCL9I+=X2<Y@F!;GZDR#\*E_;)\2?V5\-K32T(674[U%*]S'&-Y_\
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M&01C#(V<^XKY.U#P'\>['5CIZ:AXENN2([BWUF1H7'][>91@?[V#[5P_PO\
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M.TU+60_\#>24?I7UO\+?A+X6^#7AE-"\*:6FG66[S)6W%I9Y.[R.>68X^@'
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MA#I>E6:>7!:VZX5!_,DGDDY))YK4HDU?384=M0HHHJ2@HHHH **** "BBB@
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M^73J:2B@ [YSS2_YZTE% "],4@XSBBB@ ]N@]N*,?C^%%% !^'O2_7GZTE%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH */7Z44>OTH _5:BBB@ HHHH *\^^
M-G_(JVG_ %^I_P"BY*]!KS[XV?\ (JVG_7ZG_HN2@#Q6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** #\:*** #CH1D=Z*** #_]5 XZ
M<#T'%%% P[8//;_(H_ ?E110(/Q/YXH_S_D444 ')[\T?@/:BB@ H_#]/Z44
M4 'Y_G2YQ_\ KI** #]**** #MBN'^-7POC^,WPUUCPA)JUWHJZ@JJ+RT))0
M@@@,O&]"1\R9&X$\@UW%!YZ\_49%2US*PTW%W1^8=S^Q?^T7\*[J>U\$:I-=
M6$[[FF\/:]]A#CL9$D>+YL>F['J:T_AS_P $Y_B%XR\0)JGQ'U6'1;.23S;Q
M?M8O+^<[AD;AN0%AGYR[$'JIK]*>M'OW_*K4FM>J$]K(RO"OA?3/!/AO3=!T
M:U6STK3X%MK>!22%11QDGDG.22>222:U:**&[N_<6UDN@4444AA^%%%% !Z'
MH11110 4?KVHHH **** #_\ 7THHHH **** #Z<4444 %'48/-%% !UZ_7V_
M*C]!Z#I113 .P':BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >J_ O\ YC7_ &P_]J5ZM7E/P+_YC7_;#_VI7JU !111
M0 4444 5[C[IKF=8Z'Z5TUQ]TUS.L=#]* .&U+_6&O(?VC?^1!L?^PG'_P"B
MI:]>U+_6&O(?VC?^1!L?^PG'_P"BI: //OV9?^2W^&OK<_\ I--7W_#]U:^
M/V9?^2W^&OK<_P#I--7W_#]U: )Z*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH AFZ&N>UC_ %9^E=#-T-<]K'^K- '":M]\UYQ\:O\ DE>N?]L/_1\=>CZM
M_K#7G'QJS_PJO7/^V'_H^.@#YZ^%G_)3O"'_ &&+/_T>E?I);_<%?FW\+/\
MDIWA#_L,6?\ Z/2OTDM_N"@"S2TE+0 4444 %%%% !1110 5^:GQ9_Y*IXR_
M[#5[_P"CWK]*Z_-3XL_\E4\9?]AJ]_\ 1[T <I1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJHH ^5:*^JJ* /E6BOJJB@#Y5HKZJHH ^5:*^JJ* /E6BOJJB@#Y5HKZJHH
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M1\HK'T^$JH'M6S#0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC Q0!](4M<!X7^,NC:XZ6]^&T2^/_+&Z8;&XS\LG0\8ZXY..:[SS.,_G[>]
M#Z*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBF[AS[=: '4QGV]<#\:X/Q5\9-&\/R2VMB&US4HR5:"S8>7$
MWI)+]U<=P,M_LUY;K7CWQ-XBNEEGU673(U?<EII9,:J/]IOO/Z=0.X H ^C]
MWT]J=7B7AOXV:CII6'Q!:_VC#CF]M%VR_P# H^AR3VQ@#/->L:#XGTSQ1:?:
M=+O8;R+OY9^9>3]Y3RO3N* -6BF[O\*=0 4444 %%%% !1110 4444 %%%%
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M''0@\$'D'@B@#1HI!R :6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%-W4 .HHHH **** "BBB@ HHHH ****
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M'TH =1110 4444 %%%% !1110 4444 %%%% 'G7QL\1:GX?T'2ETN\>PDO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;2%I3IUZ2T9"@G"MU0_>/!Y.,^E?3XZ4 +1110 4444 %%%% !1110 4444
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MMK.#C%G,1@]#Y9YK[ KX_P#%G_(JZSZ_8YO_ $6U?8% !1110 4444 %%%%
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M44 )#_R&-!_[#.G>W_+Y#7U97RI"/^)QH'_89T[_ -+(:^JZ "BBB@ HHHH
M**** "BBB@ II4-G(R/>G44 -V#KW]:X36/@GX6U:^6Y2WGTP,V9[?39C!%<
M=R&4?=)/5DVL>[5WM% &=HOA[3?#=BEEI=E#86BG<(;= J[CU8XZL>I8\GN3
M5_:/2G44 %%%% !1110 4444 %%%% !1110!XG\?!_Q57A0_].6H=O\ II:5
MP'Z_6N_^/C?\55X4_P"O+4/_ $99UP% !1110 ?SKO\ X!_\C5XL_P"O+3__
M $.\K@*] ^ ?_(U>+/\ KRT__P!#NZ /:Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 %9/B?0U\3>'-7T>65H(]0M)K1I4 +(LB%21GC(R:UJ3;UH
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ' ?$[X=7'C:;3KVRODM+W3TFC2.=,Q2B4QDAB.1CR@>*\8UC3=0\-7'
MV?6+&73G/W9'^:)QUR''!P,9]SBOJ3:-V>]0WEC;:A;/;74$=S;N,-%,H=6^
MH- 'RYTYSQ_G-+@]!R<X]>?2O4_$GP/MV+S^'+HZ=+U^QW!,ENS?7[R]68]<
MDCI2>&_@9;1E)_$MU_:<@'_'C;YCM5]F_BD_'"G^[0!YEHVGZAXGNC;Z)8R:
MDZG:\J_)!'Z[Y#P,>@R?:O9_AC\.;CP/)J-[?7J75_J$<,<J0(1%$L1D*A2>
M6.96R>,X' KMK2QM[&UBMK:".VMXU"I#"@1%&,8 '&*G"XH *6DI: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $VTM%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -*ALY&1[T;1Z
M9IU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)M&<]Z6B@!-M+110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)MI:* &[1UIU
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -V^Y%!4'K3
MJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *3:*6B@!-O2EHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DV]:6B@!NT>E+2T4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 FWK0%QTI:* $I:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F[J=44OWA]5_G0
M!)FBA?NBEH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2
MBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2DW8ZTZH_\ EH/H?YB@"2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>rxrx-20210930_g2.jpg
<TEXT>
begin 644 rxrx-20210930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (< \ # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (:?^#?_ $5KP-_X4EG_ /': /3:*\R_X:?^#?\ T5KP-_X4EG_\=H_X:?\
M@W_T5KP-_P"%)9__ !V@#TVBO,O^&G_@W_T5KP-_X4EG_P#':/\ AI_X-_\
M16O W_A26?\ \=H ]-HKS+_AI_X-_P#16O W_A26?_QVC_AI_P"#?_16O W_
M (4EG_\ ': /3:*\R_X:?^#?_16O W_A26?_ ,=H_P"&G_@W_P!%:\#?^%)9
M_P#QV@#TVBO,O^&G_@W_ -%:\#?^%)9__':[3PGXT\/>/-)_M3PSKNF>(M,\
MQHOMNDWD=U#O&,KOC8C(R,C/>@#9HHHH **** "BBB@ HHHH *PM0\;:-I?B
M"WT6YNF34)PI"K!(T<>XD())0I2,N58*'92Y!"Y-;M<+KWP[O]9\91ZU%K,-
ME L9C:.&S87$B>5(@BDE64))$&D,@22-BK%BK*2" #LK34+74+>">UN8;F">
M/S8I89 ZR(<?,I'!'(Y'K4JS1R;-KJV]=RX(.1QR/;D?G7@OB/\ 9QNG2PNX
M=1MKM=)L+>TM--L],\DR"*'RC&V;I(WB;?,2CX;$K*)0"<ZGPQ^ 4GACQ+;>
M*=6FLVU1I)KMK6U2XC2UEE,V4B"W'E",">3Y6B<[G8[SD$ 'JFM^*-,\._8_
MMUP4:\NDLH(XHGE>29@6"!4!/W59B<8 !)( S4,/C/1YO$4VAK=,-1A;RV1H
M)%C+^6)/+60KL9PC!R@8L%.<8YK@_#'P*&B>*=(UF\U6VO\ ^RSF&*/3_+:0
MA;@++*YD8O-FZE+.  Q/"K4?BKX&7GC*/5+;4O$$#6-Q?3:C;0PV$D;I*Z>5
MB:03[I$$):(A/*)#GD'& #UE9%D0.K!D89# Y!'K5*+7+&;4IK!+E6NH88;A
MTP<".5G6,[NAW&-Q@'/'N*\I?]F^R;1[O3TU/[/#-9>2((DG,(N&F>2:=M]P
MTK>8K"(CS00AD ;Y_EKR?LX"#3)+>UU:V3S(IX'BDLIKB,),C!S&);EF67=)
M.RN[N%$SKM(H ]I:XB7=F11M(5LL."<8!^N1^=*)HSMPZG<2HY')&<@>_!_*
MOGW0_P!EV>^T*-?$.JV#7LVC26$L-OI8V)-*'WS.6E;S909[@;QM!#C &#NV
M=?\ V9K+5]0:YM]2ALDS,T,*6\Z):NTOF1O"D5Q&@*D1;MZN'\I>%Y% 'LG]
MH6OVJ.U^TP_:9%=DA\P;V"$!R%SDA2R@^FX>M6*\V\"_!/3_  'XNEUBQDM1
M;F%X(;5+%8V@4QVL8"N&_NVBY^7DGMCGTF@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KY ^'/PO\&_$C]M3]IK_ (2WPEH?BG[%_P (S]E_
MMK38;SR-^FMOV>8K;=VQ<XZ[1GH*^OZ^9O@+_P GJ?M3?]RK_P"FV2@#TS_A
MF'X-_P#1)? W_A-V?_QJC_AF'X-_]$E\#?\ A-V?_P :KTVN!T[XZ^"]5\4+
MH-MJ5VUS)<-9Q7KZ5=IIT]PI(:&*^:(6TDH*LOEI(6RK#&5( !0_X9A^#?\
MT27P-_X3=G_\:H_X9A^#?_1)? W_ (3=G_\ &J]!U+5K31XX'O)U@6>>.VC+
M9^:1V"HH]R2!4.L^(]-\/VD=S?W:00R7$5JC8+;I9)5B10%!/+NH]LY. ":
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MAZ;\=-.TZT@T_3[/XK:[;VUI:Q+'%!$BVZHB(H 55    P  *^HZ^9OV'_\
MFO\ _P!E<\0?^T* /IFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB>GN/2K4^YPULM25Z3^1Z)14=O.EU"DL3;HW&Y2/2I*U/#VT84444""BBB@
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M]/L9/.LX)/[T:G]*\PKT;0'\S1;,_P#3,#\N*UJ;(Z<5LF:%%%%<YYX4444
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M9_\ ,A:;_P#$4?\ "^OVC?\ HUG_ ,R%IO\ \17TS10!\S?\+Z_:-_Z-9_\
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M$:1EPY9_+ VH744 ?3=%<M\,?'EO\3O NE^)[2..*TU 2/#Y4PF1D61D5E<
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MUKU_>VT4:D%5CAN)W2/&.JJ#CCI7>T44 %%%% !1110 4444 %%%% !1110
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M+.X2W2(VDLUQ%'$H1!-(&#RD <N0\G/_ $T;N<UITSF.;U+X:>$-8UIM8O\
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M3_C1B7^\G_?)_P : )**CQ+_ 'D_[Y/^-&)?[R?]\G_&@"2BH\2_WD_[Y/\
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M3_C0!)14>)?[R?\ ?)_QHQ+_ 'D_[Y/^- $E%1XE_O)_WR?\:,2_WD_[Y/\
MC0!)14>)?[R?]\G_ !HQ+_>3_OD_XT 245'B7^\G_?)_QHQ+_>3_ +Y/^- $
ME%1XE_O)_P!\G_&C$O\ >3_OD_XT 245'B7^\G_?)_QHQ+_>3_OD_P"- $E%
M1XE_O)_WR?\ &C$O]Y/^^3_C0!)14>)?[R?]\G_&C$O]Y/\ OD_XT 245'B7
M^\G_ 'R?\:,2_P!Y/^^3_C0!)14>)?[R?]\G_&C$O]Y/^^3_ (T 245'B7^\
MG_?)_P :,2_WD_[Y/^- $E%1XE_O)_WR?\:,2_WD_P"^3_C0!)14>)?[R?\
M?)_QHQ+_ 'D_[Y/^- $E%1XE_O)_WR?\:,2_WD_[Y/\ C0!)1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$^-
M?^0K%_UQ'\S7;5P_C0_\39!_TR7^9K2G\1TX?XS!KM/!)_XELP_Z:G^0KBZ[
M+P.?]!N1_P!-?Z"M:GPG9B/X9TE%%%<QY04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4C*&4@C(/!I:* /++RW-K=S0G_ )9N5_(U%6SX
MNM_L^M2,!@2JK_T/\JQJY7HS[6C/VE.,NZ"BBBD;$EK ;JYBA'61POYFO4E4
M(H4#  P*X'PG;_:-:B)&1&"Y_+ _4UZ!6\-CYS,IWJ1AV04445H>.%%%% !6
M7J6JF%S%#C>/O-Z>U7[J;[/;R2?W1D5R^2<D\D\FO%S+%2HI4Z;LV=F'I*;Y
MI;$C7,TARTKD_P"\:6.\GA.5E8?4Y%0T5\Q[2:=^9W/2Y8VM8Z#3=2%X"CC;
M*/R/O5ZN5MYC;S)(.JG-=2K!@".AKZS+\5+$4VI[H\O$4U3E=;,6BBBO5.4*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KA?&)SK./2)?YFNZK@O%QSKDGLBC]*UI[G5A_C
M,:NO\#-_HUV/^F@_E7(5UG@5ODO1[J?T-:S^$[*_\-G54445RGDA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R?CJW^6TG [LA_F
M/Y&N3KO?&$/G:+(W>-E?]<?UK@JPGN?4Y?+FH)=@HHHK,](ZOP+;_-=SD?W4
M'\S_ $KK:P_!L/E:*K]Y'9OZ?TK<KICL?(8R7/7D_P"M HHHJCC"BBB@"AK3
M;;$C^\P%8%;NN?\ 'FO^^/ZUA5\CFC_VCY(]7#?PPHKD_B)XVNO!]OHMMIFF
M1ZQKNN7_ /9NFV=Q<FU@>8037#&68(YC18K>5B0CDE0 I)I_@'Q=?^*+?5H-
M8TF+1M9TB^^P7MM;79NK<N88IU:*4I&SH8YX^6C0AMPQQD^5RNW,=5U>QU-=
M-8MOLX3_ +(KS'X@>,I_!NGZ:UG81ZEJ.IZA#IMI!<7/V>'S),G,D@1RJA5;
MHC$G QSD4K/X[26/@[Q#J%YH"Q76B6=C*;:+48Y4EFN<JJ>:J[0BO@&09^4D
M[<C;7N92FJDGTL<6*^%'L=%>$S?M(:M'KMCI'_"*Z>ER;^72[^XEUB4VMM=B
M=8HHUDCM'.V0N,/,L*EB(UW/\M<O?_M?>(]$72FU+X?Z>/MK7 \NPUZXN'_=
M7IM"%_T!5R75G^=HP$4G)/RU].>:?3U%?/5E^U?<R0W5Q=>$H8+9K>:>R,.K
M>8\QA%GYJR*85\L?Z:NTJ9,[#G;D4E]^UPFG^'K'5Y?"Q^SS16=S.%O\F&&:
M\N+>1A^Z^8QI;-)CC=G;E<;J /H:BO$='_:-N_%'A&[UG1/#$$TO_"4KX=L8
MKW5##%=1.(VCNS(D+E%>.17"A6X(YYXY;6OVR)X=,TR[T;P4^I&^L8KY8Y+N
MX8JKV<ER01:VEPW'E[=VW;SDD=" ?2]%?/FC?M1:MJMKX9B?P7#;:OXBBA>Q
MMY]0NK>$-(ZJ!*\]E%(%"ESN2)P2JA<[B5V_ O[1$_BZ;7+>Z\-)IMSI-A=7
M<J1:HETC/ 4#(KHFT@ESA@3P.G.  >T45X[H?QTU;5OAGX=\1OX6AM=6\07]
MO86&F3WEU;PAID#AI99[.*15 #\I"X8A=I.<CG+?]JZY&GRWU[X1@M8/-NK.
M%(M;CN)'N[;RA.AV1E1%F1MD@9BP4;D0M@ 'T+17B7B;X^>(-*U[[)IOA'3;
M^Q74[[3'N+K7)+>4-:VK7+.(UM) 0R(0!O'S8[<UI_"SXZ7/Q%\63Z1=:##H
MD1LA>V<K7TDTET@$.\K^X6(A6EVL$E=T^3S$C+@4 >M4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R'B;XP> _!>N0
MZ+XA\;>'-!UB95>+3]3U:WM[AU8E5*QNX8@D$ @<D&ED^+_@2+Q</"C^-O#J
M>*#(L(T1M5@%[O*A@OD;]^2""!C.#FOGWXH_!/Q9\6/VA/B)IMI>0^'O"VM^
M#-/TR[U34- >_2X!FNQ)';2&6.-)E5P<D2$;E.T=_--:^"/B^Q\7>+;!=*U&
MZ^'47CK0?M$<6C2RZM/;06EHBWMM<$D-&DL48EV1%MHE(<8(H ^Q]-^-?P\U
MKQ,WAS3_ ![X9OO$*R21'2;;6+>2[#QAC(OE*Y?*A6)&,C:<]*FTWXO^!-9T
MVYU'3_&OAV^T^VNH[*>[MM5@DBBN)&"QPLZN0KLQ "DY)( %?&GAK0?'VH?#
M?XM_#V&SU.RO];N/$JZ7I]QX'U&W+M-//)&QU=V%L$E3(4%0#YBC=GK<^*VF
MQ^,O#D.J>%O@OXGT:328O#MK>:FVDW5K<R)!J4$KVD>G)'F=841W,Z*P'W4+
M F@#[3U_QIX>\*-MUO7M,T=OL\MYC4+R. ^1%M\V7YV'R)N7<W1=PR1FHKKX
M@>%[&%);GQ)I%O$^GMJRO+?1*K62[=UR"6YA&]<R?=&X<\BOE#]J:/5?C):C
M5/"WA;Q1=V__  A'B?3O+NO#U[:S?:)$M/*C\J6)7W/AMG'S;6QG!QP%Y\'?
MB'X4NO%GA,^']6UCPQ8?"K6+3PWJ$=O-/(1=-;.NFOP29HG25$7.YHPG'RF@
M#[JO/B1X2T_7]-T*Z\4Z+;:WJ:"2QTV;4(4N;M#G#11EMS@X/*@]*T&\4:,F
MMS:,VK6*ZQ#:_;I=/-R@N([?<5\YH\[A'N!&XC&1C-?'</A&YT*[\?:!XF^$
MVM>/-4\5:EH][I,D-M+;VS01VMK&HEU&,'[(;:2&5L.5;^X&WFLJ+PQ\3(?C
M!<?&E_!%Q]AUW6;O0YK9&NFU=-'DC%I;^;8_9_DC66WBN2WF$XD8E0#D 'V_
MHNMZ=XDTFUU32;^UU33+N,2V]Y93+-#,AZ,CJ2&!]0:NUX#^QCXB,/P0\%^#
MK_0O$FB:[H>BP17L6M>'[VPB5U #*DLT2(Y!/16)[].:]^H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O/_%3;M=N/8*/_ !T5Z!7C/QGU/6=+\,^,K_PY:_;O$-KI
MUS-IMKMW>=<I QB3&1G+A1C(ZUK3W.O#?$WY&A74>!F_?7B_[*G^=?+W@K5O
M#5MXS\'#P;X_U/Q;>:M)+_;5O=:W-J0:V%K,_P!H>W=V6R(N%A3]VD2@R&/;
MRH7W'6_%EWX'\(^(-:L8X9;NTMT>-+A2T9S*JG(!!Z,>]:RUBSJJOFIL]>HK
MXVU;]L7QZMM':Z=H6B#5(9-0CNIKJWG\@_+*^GF-1*,AEAD$GS?>C.-N[BV_
M[:&OR:[J\K:9H^D>&_L$DNF2ZFLJ3R7:VLY6"0F15WM<VTR*@&YE3CGD<IY1
M]?45\D^./VMO&?A&X\16<NBZ7;2VCWTEA>36\K0216]O$S+(6FC594ED^8%U
M!1TP5PY'=^)OCMJNC^!?!VJ+KGA;33K*WCSZ_JL0;38VA1F2 "WNY%#R$8!6
MXD_U;X5B=H />Z*^6_B)^U-XP\)6NOF#PW:6Z:?<ZA#'JEXJ-9OY%O%(J@&Z
MCDW!I&W&18E(7[R]:IZ]^U9XFTO3KFYM+_PC>7=M!!)!I#Q?Z5K =96>2U:&
M\EB C*!"/,D3*/NECX4 'UA17S)X$_:"^)7C#6KZ6#PWI>I:;IMH9M3T^Q@=
M9[*?R[EFM&F:?<TR2Q10%5MCN8NP*C ',6?[7WC2\\1-I6E6?ASQ<L4>FSF[
MTB":.*X,[IY]I$3,X^T1H67!/WGCW!<D4 ?85%>#?"?XO>,/B5XH\)S?;-#A
M\,ZUHMWJ_P!G71[A+P"&Y2!5$C7.%W"0,=T61M(QSD>6Q_M>>.X?%VFZ3J7_
M  C.DVU_=L([F[LXX&$&ZZ5=@FU2-9!_HPS+N0DEE$1(. #[+HKY*_X:M\6M
M=:W8)/X5EO[1KDK)]FD%K;JJRF(O(MTQ)'E_,LJVS@J=R1(RR5K6G[2'BN/3
M8/$4]_H-]H'_  CVH:L;*VT25;RXN;:Y2V2VBD2^FC8R2R*JF/S58XV,X8-0
M!]/T5\H:A^UMXKTW1]'NI= M&D&GR0:R&L+N)[/4UO([96\AR)$MG)) <!U\
MZ$DXW56U#]K+Q-#KWA^V76/!=O'JEY+!>63P_P"EZ,5,^V"X\^^MXS(1$.=R
M/\KXA88( /KBBD7E0<Y]Q2T %%%% !1110 4444 4M:A\_2;M/6)OT&:\SKU
M:9?,B=3_ !*17E6-O'IQ6-0^@RN7NR045\R^(_$UI]A\::SJGC34M)^)NF:A
M?P:-X?AUF:)<)+(NG1)IJR".Z%Q$L+Y:-V<S. R[0$^BO$4MU!X?U.2Q#&]2
MUE: 1IO;S AVX7!R<XXQ69Z\9\USUG0H?(T>S3_IF#^?/]:OU\N-X@^-?@OP
M)H=UJMQJ.J75]9WBHEAI2WUU!<'3T-JLZPVD8C_TE93GRPB@JLCFM?Q)\1_B
M3#X=UFSTFQUR;Q7I_B*%DC.@2""XTY1&SQ).8/)</\Z%E8L-Q.1MR.H^+G+F
MDY=SZ,HKY,T;XC?&NXU"ZN-4L]?M(Y]0\_1M/@\/*4F262U9;.[D\IC#'%#*
MZF8M'EUES(=FT-;XC?'F/3]4TDZ+K5QJUU;LFE:G:Z- $5IM0*K(XD"QI);V
MRR_+*RHX6%CDR4$'UK17RS=^,/C;XE\4:==V$.L>%M/N;"!9+&ZTR*:WMKW[
M'<2R1N/LK2,#/%''YHF" -@#<Z$^^_"^YU[4/ &B7_B8LNNWT O;JV>(1FT:
M4F06V-JG$08198;CY>6Y)H VM:7-B3Z,#6!72:HNZQF]AG\C7-U\GFL;5T^Z
M_P SU,*_<L8OBKP=I/C2SMK;5H)95M;A;NWFM[F6VF@F4$!XY8F5T.UF4[6&
M5=E.0Q!/"W@_2O!MM=PZ7#,GVRY:[N9KJZENIYYBJIO>65F=B$1$&6.%15&
MH VJ*\?F=K7T.OS.2^*%]HEGX69/$&FV>JZ7/,B36]_;B> *,NSLA!W;%1F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ:LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #/.C_OK^8H\Z/^^OYBEVK_='Y4;5_NC\J $\Z/\ OK^8
MH\Z/^^OYBEVK_='Y4;5_NC\J $\Z/^^OYBCSH_[Z_F*7:O\ ='Y4;5_NC\J
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M1YT?]]?S%+M7^Z/RHVK_ '1^5 ">='_?7\Q1YT?]]?S%+M7^Z/RHVK_='Y4
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MCSH_[Z_F*7:O]T?E1M7^Z/RH 3SH_P"^OYBCSH_[Z_F*7:O]T?E1M7^Z/RH
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M?4 %%,AF2XB26)UDC=0RNAR&!Y!![BGT %%%% !1110 4444 %%%% !1110
M4444 %%%% #9#A&/M7E->J7!VV\I]%/\J\J'05E4Z'O97M/Y?J+24M(WW36)
M[IZM"<PH?]D?RI]0V9W6D!]47^535UGPKW"BBB@04444 %)2T4 <I,GERNG]
MUB*FT^/S+V$?[6?RYIVJ1^7?2^YS^E2Z(FZ\+?W5-?$4Z7^U*GVE^3/9E+]U
MS>1O4445]N>,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA&7CMT[5T=>(?$C]J;1OAG9^ 9M2M(%E\56K7GE2WZQ&V3RX]N,KF4F:>"/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&J,%SDR5V=YX\O[CX0?\)5I[Z8-373X[R6-&:[ME?8KO&&5D)ZD G!'!([4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLVG&V:VAM)I;<I;[Q;B61&$(8LYM8R=[,H);:J@@#VRBD2>*^"OV3_"?P_\
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M_P!*FT,_Z&P_VS_(5X4'_P *,O3]$=K_ -W1HT445[IQ!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/
MBQ_](MU]%)_7_P"M6%6MXGDW:D%_NQ@?S-9->U15J:/G\0[U9&AH+[-6@]\C
M]#79UPNF/Y>HVS?]-!_A7=5Q8KXDST,$_<:\PHHHKB/0"BBB@ HHHH ****
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MQX_RV2>[']!7)5SSW/JL K8=?,****@]$['P*V;.Z7TD!_,#_"NGKDO ;_\
M'ZG^X?YUUM=,=CY+&JV(E_70****HX0HHHH **** ,;7C^]A'L34N@G]Q*/]
MK^E5]<;_ $I!Z)_6I=!;B<>X/\Z^;A+_ (4G_70]"2_V<UZ***^D//"BBB@
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MU,US4VBZ;Y*D9'I-%%%>.>\%%%% !1110 4444 %%%% !1110 4444 %%%%
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MC*C'_P"%G^.+7P#!\3[IM _X0J2SCU9] CL9O[1AL'4/YGVS[08WE6,[S&(
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M7AZ3Q#IL&NZ?<VUYI^K#3]::*#1HK/[983B=$BF656#).=KJ6'H3T'A_P?\
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M>,HQIJ$J*?GU_+UZ=?)'F-W\1=86/9:-97=]-*@6SM[0O);KND#(X-PNYQL
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 C#*D X/J.U5_LLO_/Y-^2?_$U9HH K?99?^?R;\D_^)H^RR_\
M/Y-^2?\ Q-6:* *WV67_ )_)OR3_ .)H^RR_\_DWY)_\35FB@"M]EE_Y_)OR
M3_XFC[++_P _DWY)_P#$U9HH K?99?\ G\F_)/\ XFC[++_S^3?DG_Q-6:*
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M-GI[SRW,D<$(6,3.]LI1"IVS%9"V=S+U&!6CI'Q.CU;4K,+8^1I-TKJEY-.
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M3[N%-F94B21LLTXVO#(VP?-M.T'MW5U\6/#^EI=-J%T8DMY)$>2WMYYT7:9
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MD\YI1(K!EPYW9!  ..G%<GJ'PSU*XTN&T>\T^_N+F]M9+R6:P/V98+:/,2"
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M&Q!UY"@'CBIK?X>Z%:3^?;VLUM/]JFO3+!>3QNTLK!I-Q5P64E5^0_*-H &
M*Z2B@#%M?!VD6-G<6L%H8X+BU%E(OFN2T0+D+G=D',KG<#GYNO K,TSX9Z-I
M.NV6I6\<I-E'(MNDT\DQ5W5$9R\C,QPD2(HZ*-WKQUM% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>rxrx-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rxrx="http://www.recursion.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rxrx-20210930.xsd" xlink:type="simple"/>
    <context id="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec0cf3fd3c7f46d58081b8db6dd0a213_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i014b7cc1c107456880d54adcaf72ca6c_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i227689ec41e7442c8fc5bdd888e16504_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id81600d989114130b43235d442b1e71d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ecc7deafb5e4f9c982501dc4510e260_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if22f0a3e4f5d4143bce97be2c742375b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if98a6d661e4e47aab1f3971da19db8fa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if3cb24ed3206446e9ec9135d7c55c2b5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifbae21d8d86e4d03b1dc645c4d773d58_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9367de1805594f3ea5232c87da29a431_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a193d7c195b410a9442788aa6400f38_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia091bf9e820244ad994cca02e9749f08_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iafc80a548fed40e799b5efc628f47c0f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc0cf13b1f9d4529bf1fb83789fc572c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1f2f2c074b1e43afaf522e34126788a5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if0ff446e32064366bc8ac2fb705f08c7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i28cbfc7f295d41798a3535412b1097ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b650a6bb07749f0a6edf5919d0a3161_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i285746a4957648a9b7d4042cbb79af11_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40cfd8df988f4d82810e987c2d28b259_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e44c4c74c4244ad9325ce8ee3d87c39_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43267d208dab4736ae222644e2d2c456_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51f4b84aaf944dbe9a02fd4931d34296_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if4b3bdbb908941fe9dd8a36f77aa3125_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0b9cf913bc7c43ca9b2e069af2d8729b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i40174ea8bb02463794d3b4d1c442fb95_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i30420430e079491d8ed1cccc567ce1a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c9e3fea7fdb4088a7ed864903989ab8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75c52a0d323d498e8014b63cf8a7850d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0eb56eae1b564d73804d37ddfe5ab0ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91d161d487e84f1f904d7fda0b4884fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i776c6fde78c34963b7743761ab97c975_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9c4548723a94137977675db77d39056_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4482ced31be5421b8f43d4f1dbe206c4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5705097d3db6486b875714c0fdd8511f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if5e93eef6c0643958f8d3941866bed9b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1352bc1f243c4c93b8a1a85f705f61bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i881224a385cd4b5bb6c214cf65fbdc6f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4b4fd7858ca4d1b8cbd0d11d1d96c2e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29a9bdffe7f94be498dcc2410790c11f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i872955c4fcdd4c5eaf64056f28e5f425_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2a95d59cc58842588ef57ba5c32d5d71_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4cfdf3f6f12e4ce0ae4dfac0a5ed90d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i28896c19aa0048d895dddd0ae8427e87_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0e2b80f5d48496fa52384c883bedd9d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3209489bac6541a49f8dc6490492263d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5058a871b06b4ce2a3fa07e2e0a0bfb2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f381af37b384806826160a459ac1a6a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if7ff4d3f153a469d96516e024f93f1cc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8338d53d46ff438abc85d037a8e6da2f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i869c72f28c2245f8b0f7ccc8daabd4fd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5e11557b1837454f993cb507031865c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b7ae49e496a4f9888670cd3e0d4b725_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77586c203c024828a9a78bdb39902891_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb73e0e9cb754e1bbe802d6ae2551e64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icee0f1fd845e456095af44bb0a898324_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i182ec792f9954c3580432f8d5bb60d4c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i16660690238a4cba84cc971aaa39f2bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i778df7726a034719acdc84318d53c893_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ia31781556c024ff299dfa585947bf905_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie4e5e9f454354e0898d008f9b70e031f_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="idd4cc970bf084e72a23bc5618284498a_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ic76fe27fdee64641b854285105025b00_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i1fc1f03ee515432fa42136f5abffdeca_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rxrx:ViumIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i664743a93bb344148d7136746fd74f72_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4bc65b757b0943af90388d031f257341_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rxrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d68dbe3edaa4b9280d1ffb236378a0b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i817c708d2c01406eb506b6bb2d083fd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7bf122307ee643a0845c0597e111bdfc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9ae7b4560de940f1ba648b0647540789_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac3d0f8815254b29b2f5393fc3e65f2c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc7703b2a8b748759f610e861ada8589_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e32a03cb9fc49e4b252453d837334e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90fa6b131e76491793a97c75f8dfec99_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6feede82f4cb4ac49b0be949785d9497_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rxrx:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7296ea094e2d4b13917424c13cfba62e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5217d88f4c3e49a69c131211ccc0f740_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8495e49fee3844bab82f503ea301cd51_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icd2a77b480e946b1a98b623504da657e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id524b0a380484a13b1423d25efdc9ce6_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i17e592cb3484481d8f3bdf27f4b46fb5_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:PacificWesternBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i61c469b1d47e4489abb014373df5e6a8_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i712dde3d59e94dbba069d3ea10c0fb15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice8000a9bf874bc2a077c5140c2c981d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:MidcapLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc2eb416e12e4f8a8c617e89412832c8_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:PacificWesternLetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i38cdee8154a14b54b5c1a723df0dbb8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:PacificWesternLetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2921e91a9279497f81a20c55ba343d96_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1d0e548c03ea4dd7b12d2c5350a4d3a3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i691d5ffc27f14a19a75ef556811825c4_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c1a2671a54b4d92ac1029a3f54a040c_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50773bc073fb4acea17c712bc1126a6b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3ccad45b4c84988b490de168ac87d85_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie16333b91755459cbc141c348c781d1e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6b6e8d11e94a4bc8a66fa0b30b88119e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rxrx:Station41LeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i52b9725b29684ee8a41390d35b177c5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91f13a3891e14799978936761e6b66eb_I20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:KomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="i97ab0048367c48bcbdd713b807fbd5e6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:KomasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if53c3048ea9f49fdada4b25a94aa8898_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ie9dfd0688b804a938bbb48c0edbe5056_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i532e90ec1ce24d4395f470300c0303ad_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i570b1109d5a14f2cbffa015a78fae6ae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station41Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib7019fd2b10448cf9b45ac7687f8df45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station41Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifff20fde529149e6b553db40f2b4c2c5_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:MilpitasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ia41f6975e5dd422096f973c5f9c36e59_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station56Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i21570e1162e44757bb2fe76c1778ed38_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station56Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i54a01ea1f999425489bb8e0b81240782_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rxrx:LeaseArrangementNameAxis">rxrx:Station56Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i44bce2b5c9264b77a056d1235fca4c45_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">rxrx:Station56Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6b8e1278f8d04c5bb2a24c4705c97839_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i254f679cd4904fd2ae4f87879e686402_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea9aa8f9e434498bb2d91529de11b85c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie140edce6ab14151a2b4993eaf954127_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54664e6f89084434b268927edece521c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6830fb8120554381b4ac31b7bc4f1b20_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="ice0bed1c8a884eb9b91557f3c6c8fbc6_I20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="ida225ec4cb3e47f0b2b397b7d9fc8ea1_D20210409-20210409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="ifb46e3752d19457fb9b591d8ac77a4af_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rxrx:ChristopherGibsonAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i579b43fe01ce4c56a9134274deed89c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87ec7c8bf2994d2e9b1fab9c0703332a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i236ba6571e724a009ebcfe23594fc46f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rxrx:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i911deb0a783d45d48883d1a7b215ba7f_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ic110f6aa94f44a0ea151f7f1d1355795_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7ac5bbd776f34c14905561c10878b1d4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6eea4fe55d0492db79350755e48b8b9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i005b6369f9a04da2b37d8abb0937ccd6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c86ed481ac0466f814feccb1b0dfc44_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac787d8519de4fb7b4312d4d537327cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8946372da4bb412ebce1e7fbd111ba10_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe55087b940747989ca8778b35a30ba2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a0aa783282d499eabe30b6edf7958f4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ce5ea44684646478e321a6f5da5f498_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4381c37b0f434d1292766458d6f33a83_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ia5509909b8164d1392214698e190db36_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i12720851e14f4054b18ea160b3ae9c16_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84ca49f352744d10969d369737887491_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaec16661eb85408985324c4bec4ce6bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd1b4082185f4ff8b95aa9ccc5e14905_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a0b13ec20ca48d586c285f56d52aaf7_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ie6d027f3b69840d8bbb90d7865d8a14f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23ab811b0acb4f168c59b520becd7a72_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc8d774d0f354dffa104fb6ec49d31f5_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ia59ee14c284b45dfb5c8bbaae6df4885_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rxrx:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i624cda05c6f442e482227cdcb651b01e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c8780804ec9494aa5a5c9fa23f6bcc6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibfd006ea4f4945efaeb183fc075f012d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:A2016WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i209f333c943b42e79aab9462added11c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:A2017WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33aa98d15eec4725a67ba5499bcbbc29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:A2018WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0015342eeae14a93b10cef24c0a7eb00_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:WarrantsIssuedInJanuary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ic1ead2550bf14c0893a228633bcb285d_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:WarrantsIssuedInJanuary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i2848f38457cf43dfb9f1a86a2619c3ec_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">rxrx:WarrantsIssuedInJanuary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rxrx:ConvertibleSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2bd3ed16cc3a40d9b40309215a26d2d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3660f34156d445c9c45640b5093824c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb672f271cdc43bab7ca1eac36b7098e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6c7aac41dc2042ada5f77fd1aa3b0fbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if14c65e722904f9f939058b7366b4e72_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie51a0fc21e8f4d418cb515efcc6a3eaf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i31c907d87561487794a79022d9299487_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf3bd2b3f1de4ca2ab977e7dc5e21061_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i25149b9a570440e894a302d56c3419d4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3102e5c386934e08baf3f55a99f19f8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53e651de692a4311baff885fe1d206fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i70f6c3f9030e468f943ac8072eca5c43_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b9f157f6cc14838be0480cbdd9ff968_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66ff3b8c31df4b4b8a24cb74978eff8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3a1c33e0c004ee7bcc3a113bfdbe90e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26eb528b81cf4adf8be643e9113fd19c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5628df5a4848456eb3ec9ada5263c011_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ba0f31dd7d94a7aa2ea877325c0bb72_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia222d34dfedb42a989e65c18da7342b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied40c52ff827437a831df98fbdf2c99c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ice8b605c718747d2acbf2c3db10e6ec0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7afc904b0874b9c80f044ef16fb6c10_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29d4ed7ff0ab424a9e1664b17448dcd5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43c8d5736faa4c1983958144094f549c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1407ac7645fc47fa897329aea3c530a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i610ce8d6e6fb4af2aed56ad3de0f1a9f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iebe1a1be865947f4aa113d844800ea59_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibec53fdf9f59440fb5fcf12d42df3d39_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaab494b26364446fba34ae32a935dfc1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i190cd4db6d464d718e8e7930d9ca1083_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic3214dd56bf64eedbbf429ee3a167178_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51038493a87f4438a225fa0f3eb3d1a8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a01352bcbd0418da5a4d83c3911cb35_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaac2c0d34aa14f4b86eb9fb680095a93_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if2b0eacaa900484a97d3551758e92093_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if6fec666dd574bdd860d28ccf54b11c1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d40bedd685247d78f2216e50d9a8eff_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie30ba9ac44034c578ac0d736845582c9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic3de39547ef349e992ca21d173027833_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic04ee2989244405a8478ecdc58c1d93c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i620b4c771b704d6bbc4945cbd1c5dc27_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ida224670f66a4cd1b60d191c2e281cce_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ief95da0bc6cf471e9f41eac09bb2d67b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idf2d0d327cf84c748140d0325b4ebd61_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i564180300205478f9ed895f99b4dfe03_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i441ebff9e64d4bac86210ac2f3fe7cbe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie20600623f4948c3a5c474d9eecc9162_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0872f901a90f4c1abc3c5b8804f79732_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icee4c5b8987c42068342ac8fe0f80772_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i013dda72d65e48359f86e04e7a20b9e3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1296a5886a6f470cb0230592349be9eb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ice6b0ed534a640c5931de64b79a5225c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i40d9ff00f3094561b99abddcbbc1196c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d4a620cd1204890aa34ec28087d8251_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b15c90e4b864e4fac918da8be88c86f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a713b2042cb45f4baae40157f292534_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc102fb1bc82413aa69f0cd8e15bbcb7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i242c9fb9e9d34e39bc8bb5ea202c9f5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6914913f4c29445486a40ba822c76f9c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7d8622a762a34db69acf56d2140a8afe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f4c24f5df41449c8a6537fb7c6f3dc2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7749db1c1872417f962d0cc10eb2a200_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9cf7bd8980049bea59d3c2a32ae4c09_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i18aaa35da92e4cfcab63c485c3c4aaac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i774ee2b9287545a0a57464dbab971920_I20171205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-05</instant>
        </period>
    </context>
    <context id="ia19aa404aca14cc6acdaf9338dfc7ff5_D20171205-20171205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-05</startDate>
            <endDate>2017-12-05</endDate>
        </period>
    </context>
    <context id="i6893f1ac3dd94238a44159176b56e2aa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5fc41eefa45d46c3ad7b8fa3931ff65b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601830</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>rxrx:position</measure>
    </unit>
    <unit id="extensionperiod">
        <measure>rxrx:extensionPeriod</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>rxrx:vote</measure>
    </unit>
    <unit id="project">
        <measure>rxrx:project</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV8xLTEtMS0xLTA_3d8a0563-ac3b-4567-ba87-d3f12bbb20bb">0001601830</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV8yLTEtMS0xLTA_9efc6705-aadc-4d41-b5ce-44a359e9fa7c">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV8zLTEtMS0xLTA_4f894f93-8577-4328-bc07-8ec65481a028">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV80LTEtMS0xLTA_8524b89e-c0b4-47bd-9e02-649f19c0cede">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80L2ZyYWc6YjMzNWZkNTk4NGVmNGE2YWI3YjA1ZmZhNjE2Y2UzNTEvdGFibGU6ZDE0Njk3MzA5YjExNDgwMjk3ZmJlY2JiYmE2YWM0YTEvdGFibGVyYW5nZTpkMTQ2OTczMDliMTE0ODAyOTdmYmVjYmJiYTZhYzRhMV81LTEtMS0xLTA_d0f1a6b6-e801-4063-b1f6-a1a62987ba0a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQ2_b2f45390-64b1-44d5-943f-cb4d523ed4c7">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzMx_b9020e71-f133-4b05-9381-fc4ae9c74db6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMjg_7d750711-f0a6-460b-9797-cb42e25ce52e">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzMy_2fff5b0a-f8f7-4b2e-8627-21e620840c03">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzM0_21ac43f0-2d54-4f9b-a5d0-43a170de09bc">001-40323</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQ4_049c08be-a22f-4f62-941f-4a16d101167a">Recursion Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6MjA1M2NmODZlNGViNDQ1MmFiY2QwZTlmMTkxYmI3YjMvdGFibGVyYW5nZToyMDUzY2Y4NmU0ZWI0NDUyYWJjZDBlOWYxOTFiYjdiM18wLTEtMS0xLTA_b07dd7c7-71ed-4464-98e6-d81b5ad21429">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6MjA1M2NmODZlNGViNDQ1MmFiY2QwZTlmMTkxYmI3YjMvdGFibGVyYW5nZToyMDUzY2Y4NmU0ZWI0NDUyYWJjZDBlOWYxOTFiYjdiM18wLTQtMS0xLTA_0da10f05-f56c-41c0-9d1d-d93a9fc7ddc4">46-4099738</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQw_6db98f99-dd8a-4932-aab3-5b03c398941d">41 S Rio Grande Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzI3_310635fd-80ab-47b1-9327-a77511678b78">Salt Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQx_09fccbec-cf7c-4adb-9a83-ab94e0d348bf">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV81ODA_cad5c304-5898-4174-bf32-a6f8ce08789d">84101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzQz_702db905-b08a-4f57-87dd-1f4525468a62">385</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzM2_af9bf635-b972-4c15-92f3-04d2dfa5d419">269 - 0203</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6Yzc3NDNlMzJlZjQyNGNjZTkxNTFhMmU3YmY2Nzk1MGEvdGFibGVyYW5nZTpjNzc0M2UzMmVmNDI0Y2NlOTE1MWEyZTdiZjY3OTUwYV8xLTAtMS0xLTA_1261f737-4ab3-4a24-b91d-697af51deda6">Class A Common Stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6Yzc3NDNlMzJlZjQyNGNjZTkxNTFhMmU3YmY2Nzk1MGEvdGFibGVyYW5nZTpjNzc0M2UzMmVmNDI0Y2NlOTE1MWEyZTdiZjY3OTUwYV8xLTEtMS0xLTA_e042e971-a03a-4185-96da-879c7abff31e">RXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6Yzc3NDNlMzJlZjQyNGNjZTkxNTFhMmU3YmY2Nzk1MGEvdGFibGVyYW5nZTpjNzc0M2UzMmVmNDI0Y2NlOTE1MWEyZTdiZjY3OTUwYV8xLTItMS0xLTA_30bd5f98-9cee-4ebe-bd61-60d0b7522be9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzM3_1b77c91d-7570-4a1a-990c-9703a312127d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzI4_f1d83745-4fd1-4dba-8a97-36492b54424c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6OTI2YzNlYmJlMzBjNDI2N2JjNzI3NzZjOTNlNGEyYzUvdGFibGVyYW5nZTo5MjZjM2ViYmUzMGM0MjY3YmM3Mjc3NmM5M2U0YTJjNV8wLTMtMS0xLTA_d9e64020-25fc-4b80-9391-10f97cc9ee0e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6OTI2YzNlYmJlMzBjNDI2N2JjNzI3NzZjOTNlNGEyYzUvdGFibGVyYW5nZTo5MjZjM2ViYmUzMGM0MjY3YmM3Mjc3NmM5M2U0YTJjNV8xLTQtMS0xLTA_5cd03927-2ff3-47a9-9888-e2801c4f3067">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGFibGU6OTI2YzNlYmJlMzBjNDI2N2JjNzI3NzZjOTNlNGEyYzUvdGFibGVyYW5nZTo5MjZjM2ViYmUzMGM0MjY3YmM3Mjc3NmM5M2U0YTJjNV8yLTQtMS0xLTA_276f4d6e-ba36-4736-8a7a-3ab52513f086">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMzI5_9e0ee8ab-39db-46ad-95ab-1e9e6fd8a683">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV82MDQ3MzEzOTU1MTE3_835f5fb2-be22-40d8-b00f-5843775bb89f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iec0cf3fd3c7f46d58081b8db6dd0a213_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMjE0_b2f97709-3bfa-45a4-b0c8-cdbe276f669e"
      unitRef="shares">159525190</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i014b7cc1c107456880d54adcaf72ca6c_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xL2ZyYWc6ZmZiMDE2NDk2YjkwNGRmY2E2OWE1M2Q2MmNhNjI2N2EvdGV4dHJlZ2lvbjpmZmIwMTY0OTZiOTA0ZGZjYTY5YTUzZDYyY2E2MjY3YV8yMjIx_c1ba1aa1-6656-4125-8ef6-7f445156128f"
      unitRef="shares">9467883</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNC0xLTEtMS0w_36ab3738-69c7-4b41-b5dc-14b118dc7491"
      unitRef="usd">394721000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNC0yLTEtMS0w_b42532f1-8b86-49da-88c6-98dcb98ef10c"
      unitRef="usd">262126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNS0xLTEtMS0w_789a902a-12ff-4c5c-9f85-2dd4c1c5b365"
      unitRef="usd">10233000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNS0yLTEtMS0w_4873becc-66b7-4005-a8d4-028a18e49a6b"
      unitRef="usd">5041000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNi0xLTEtMS0w_b1d6e9b6-5d52-4abe-9109-bdbfcfb29648"
      unitRef="usd">34000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNi0yLTEtMS0w_f301d7a8-f7d1-4e4b-8577-eed42fa29f99"
      unitRef="usd">156000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0xLTEtMS0xNDcwOQ_cdd46b20-8ded-4f16-9dc3-2cc652b4a99e"
      unitRef="usd">2248000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0yLTEtMS0xNDcxNg_3c32ac8e-a7d2-44b4-8014-cc7939cae97e"
      unitRef="usd">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0xLTEtMS0xNDY4NQ_d1b4bdb2-1156-4ebe-bd05-ec952a293ae8"
      unitRef="usd">184189000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0yLTEtMS0xNDY5Mg_bc3dacaf-0178-4bf9-b7bb-9a2bc85487f2"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:OtherAssetsCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0xLTEtMS0w_847342c4-9ed4-4e38-a426-12d1988c588a"
      unitRef="usd">9445000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfNy0yLTEtMS0w_e6ddce38-8e99-43d7-868d-b11e45276639"
      unitRef="usd">2155000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfOC0xLTEtMS0w_08220ab5-07fa-4c66-a47b-5c39fdf30bdf"
      unitRef="usd">600870000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfOC0yLTEtMS0w_1f26be42-f2b9-4cea-971f-0e971053bdf0"
      unitRef="usd">269478000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTAtMS0xLTEtMA_5db78f9a-9b60-4cde-9357-3bef3333545d"
      unitRef="usd">55439000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTAtMi0xLTEtMA_4cb6b733-079f-4a94-a424-504759207faf"
      unitRef="usd">25967000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTEtMS0xLTEtMA_781ccabb-3c1f-4b18-906a-20ca686bafd7"
      unitRef="usd">2262000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTEtMi0xLTEtMA_69185d35-9b1e-4774-869a-1ac5e28c05b3"
      unitRef="usd">2490000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTItMS0xLTEtMA_f3328892-f8e3-438d-a1e6-7f01eb83b975"
      unitRef="usd">35000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTItMi0xLTEtMA_e4b729e0-e96a-45f7-901e-7c9199a6e650"
      unitRef="usd">650000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTMtMS0xLTEtMA_f7c810f1-b913-4a80-949b-764ea07980ed"
      unitRef="usd">658606000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTMtMi0xLTEtMA_f2b7276a-7c50-48de-bb13-57930ec6d57c"
      unitRef="usd">298585000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTctMS0xLTEtMA_1c932d55-b734-4924-9ad4-5576a92fdcdc"
      unitRef="usd">6326000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTctMi0xLTEtMA_27e8338e-6d31-4cde-8c78-173c919f9beb"
      unitRef="usd">1074000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTgtMS0xLTEtMA_a9d69a16-dbe9-4563-81be-e91e304c438d"
      unitRef="usd">25113000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTgtMi0xLTEtMA_b2b44f06-0fc6-4dff-99ac-57f46d076b11"
      unitRef="usd">10485000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTktMS0xLTEtMA_3f33ba1a-99c0-4626-a350-c97fd154ca11"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMTktMi0xLTEtMA_46ce3bf6-b0de-492d-90e2-c45e92a15d15"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjAtMS0xLTEtMA_b23097c4-4e64-4ca6-b466-74cf7b40ebd9"
      unitRef="usd">88000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjAtMi0xLTEtMA_a5164060-16c8-4356-a8ba-3bd8be2fba94"
      unitRef="usd">1073000</us-gaap:NotesPayableCurrent>
    <us-gaap:LeaseIncentivePayableCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjEtMS0xLTEtMA_764e75e5-2a99-48a5-82dd-6550c33a616b"
      unitRef="usd">1416000</us-gaap:LeaseIncentivePayableCurrent>
    <us-gaap:LeaseIncentivePayableCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjEtMi0xLTEtMA_cc706071-8342-4a6a-a35d-bf83e6ab7f6a"
      unitRef="usd">467000</us-gaap:LeaseIncentivePayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjItMS0xLTEtMA_db6a1131-aa14-4025-a3dd-cf37e857fe9a"
      unitRef="usd">42943000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjItMi0xLTEtMA_871a883f-7a69-4325-b396-034b2e196ece"
      unitRef="usd">23099000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjQtMS0xLTEtMA_eb1d6ac2-fbd3-42a5-b8a5-a789fcbc4975"
      unitRef="usd">3348000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjQtMi0xLTEtMA_b7112c7c-e0ca-4346-b86f-ea34a1b2f0e0"
      unitRef="usd">2674000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjUtMS0xLTEtMA_e79ec675-d85e-4620-82a9-dc15429dd1ef"
      unitRef="usd">9167000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjUtMi0xLTEtMA_902ee95e-c6c7-432a-be39-16a760b3c4f1"
      unitRef="usd">16667000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjYtMS0xLTEtMA_2800a2b9-deaf-48ab-84c8-9865e09b1523"
      unitRef="usd">656000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjYtMi0xLTEtMA_8ef99d6a-a834-4586-a56c-b0707f8e2c94"
      unitRef="usd">11414000</us-gaap:LongTermNotesPayable>
    <rxrx:LeaseIncentivePayableNoncurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjctMS0xLTEtMA_54241f33-ac09-45dd-8454-81c44203c205"
      unitRef="usd">3460000</rxrx:LeaseIncentivePayableNoncurrent>
    <rxrx:LeaseIncentivePayableNoncurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjctMi0xLTEtMA_5263745f-bc80-4585-b1bb-52930968e52c"
      unitRef="usd">2708000</rxrx:LeaseIncentivePayableNoncurrent>
    <us-gaap:Liabilities
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjgtMS0xLTEtMA_e6670d44-a704-4e59-a3c4-8218d5752248"
      unitRef="usd">59574000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMjgtMi0xLTEtMA_1d1033b2-11a8-4e97-83b3-ee3404acea9f"
      unitRef="usd">56562000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzAtMS0xLTEtMA_686902be-6a6e-4bda-8f5f-1321864994c7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzAtMi0xLTEtMA_f6838349-8d3c-4edd-9918-23405255b124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzYz_aaf6305e-3ede-49ad-95d0-8d66765f6663"
      unitRef="usdPerShare">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzYz_e93eac96-7f3c-4539-bff7-0730bb94a1bc"
      unitRef="usdPerShare">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0Xzc3_78c21a14-a802-4323-844a-370f2488344d"
      unitRef="shares">200000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0Xzg0_ef241c25-d2c7-4cbb-8196-558220194588"
      unitRef="shares">121434713</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzEzNg_2cfdb4b9-d308-4fdf-aca0-61d32fe40143"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzEzNg_dab78415-91da-4065-8ca6-2de7e114e715"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzE0Mw_8172cf5e-b1af-436d-9293-b490c3ba0790"
      unitRef="shares">112088065</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzE0Mw_b5b1686e-1bc8-4ca6-999a-a8ef722b5033"
      unitRef="shares">112088065</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzIzMw_68a04d48-c634-4498-af51-3ad22f852412"
      unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjk1Mjc2NjJkYTg0NzQzMTZiOTcxYTdiMTIwMGE1MmM0XzI0MA_bddd6bcc-5737-4dfe-9d6a-f612713f5a6d"
      unitRef="usd">450850000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMS0xLTEtMA_52dc87d2-c1b0-45c7-9488-729cda548aa4"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzItMi0xLTEtMA_abd5e789-1040-4a86-8e62-ec4de595e721"
      unitRef="usd">448312000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzM1_68f43972-646a-4cd5-ab11-f2c2cb5fc095"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzM1_ee63c101-2fd4-431f-9612-a3a8a06addcc"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzQ5_ac0b9e63-8f69-4275-b7c0-d106d8c8bc55"
      unitRef="shares">2000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzYx_45ccd4d0-b275-4e4b-8e2a-887703b5dc55"
      unitRef="shares">1989032117</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzcz_877f404c-53f9-4a6a-aaae-463c0ae6dfd9"
      unitRef="shares">10967883</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzgx_a0dcf639-a9a0-479d-94ab-51095b49b586"
      unitRef="shares">188400000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzEzMw_727f0a8b-55a0-4fba-8770-f4e2edf9ddc4"
      unitRef="shares">168634959</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzEzMw_ccee2ca5-9d44-4296-b5e0-e18872b37ff1"
      unitRef="shares">168634959</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE0NQ_7fa5c835-2809-4e6c-b87e-cf3c0adebee8"
      unitRef="shares">159167076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE0NQ_a195cc7d-6af1-45b6-ae3b-57b5c8082613"
      unitRef="shares">159167076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE1Nw_494e9d92-7fe5-40eb-a134-7cbb6d5ae913"
      unitRef="shares">9467883</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE1Nw_953f8813-8c9c-4c68-ac13-770168053030"
      unitRef="shares">9467883</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE2NQ_5b25efdb-3dd4-4a38-aecc-bb40317b5534"
      unitRef="shares">22314685</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmQ1MmEyMzFmZTY2MjQ4MDI5M2MzNWU2OTgzYjc5NWZiXzE2NQ_80bad785-4d76-473b-b90a-4a0804de8996"
      unitRef="shares">22314685</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMS0xLTEtMA_fc30d4fd-1dbb-4cd7-aa0f-1d402a0a5d75"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzQtMi0xLTEtMA_c1fe3a13-98d5-47d4-8441-422d06296ddc"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzUtMS0xLTEtMA_ab637cb4-3988-4038-a068-ba68c0aaff70"
      unitRef="usd">934175000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzUtMi0xLTEtMA_93c2b79c-5edc-4eba-9f70-d1d8c837d901"
      unitRef="usd">7312000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzYtMS0xLTEtMA_45252170-58e5-484b-b024-54a9093ed484"
      unitRef="usd">-335147000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzYtMi0xLTEtMA_6aa06103-9c89-4c33-b7ab-dced98e9420b"
      unitRef="usd">-213601000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMS0xLTEtNjA4Mg_f18afe37-47f4-4211-b72b-5d56420b3934"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMi0xLTEtNjEwMw_3cdb4cbc-9804-4768-ace9-c4031a3fc957"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMS0xLTEtMA_e5f775c9-2758-40d4-ac62-e6395ee80f37"
      unitRef="usd">599032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzctMi0xLTEtMA_01fb8f07-7a26-4ad1-bfaa-5055c4418086"
      unitRef="usd">-206289000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzktMS0xLTEtMA_6c055924-8377-46c7-9317-837a4bae5eac"
      unitRef="usd">658606000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8xOS9mcmFnOjY2MzA4ZjA2Njc4YTQyMzhhMTRjN2I4OTI1YmRjZThhL3RhYmxlOjZiMzg0MjE2ZDgxNjQwOGRiZmI5ZjM1MWM4NWJiYmM1L3RhYmxlcmFuZ2U6NmIzODQyMTZkODE2NDA4ZGJmYjlmMzUxYzg1YmJiYzVfMzktMi0xLTEtMA_a34ca35e-0aad-4e3b-a633-e373480f9f25"
      unitRef="usd">298585000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if98a6d661e4e47aab1f3971da19db8fa_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC0xLTEtMS0w_09a741f0-2d0f-4810-80c3-7b637bd9a4ce"
      unitRef="usd">34000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3cb24ed3206446e9ec9135d7c55c2b5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC0yLTEtMS0w_f12a26c2-0a48-42f4-9e49-c5c8bc015c4d"
      unitRef="usd">163000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbae21d8d86e4d03b1dc645c4d773d58_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC00LTEtMS0w_b417461e-c8ee-409b-8a7d-08cc94f16742"
      unitRef="usd">145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9367de1805594f3ea5232c87da29a431_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNC01LTEtMS0w_44bcdaf8-2129-44ba-bbbd-10952379a59b"
      unitRef="usd">409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a193d7c195b410a9442788aa6400f38_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS0xLTEtMS0w_e6739fe6-14b8-4693-8130-abe229807d3b"
      unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia091bf9e820244ad994cca02e9749f08_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS0yLTEtMS0w_f9f5199a-a5d0-4355-9563-84e822fd86a2"
      unitRef="usd">862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafc80a548fed40e799b5efc628f47c0f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS00LTEtMS0w_fd3fbcbb-8c9b-4aaf-be5f-149db933f2ff"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc0cf13b1f9d4529bf1fb83789fc572c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNS01LTEtMS0w_d7fd438e-2e1e-4364-9607-ee7b869e98f6"
      unitRef="usd">862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi0xLTEtMS0w_8c61cef8-adbc-485d-b896-f790b31805ee"
      unitRef="usd">2534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi0yLTEtMS0w_a177f220-25c7-4527-90fb-4e394657683c"
      unitRef="usd">1025000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi00LTEtMS0w_351d2069-abf1-4565-8989-5072e0d90daa"
      unitRef="usd">7645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfNi01LTEtMS0w_335891c7-6e20-440e-9d48-e805a6cfd443"
      unitRef="usd">1271000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS0xLTEtMS0w_387c5d8c-c9db-45fa-acc6-9488d7acedbf"
      unitRef="usd">33246000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS0yLTEtMS0w_8d641bf1-34db-470a-82fc-d4a8e8251e21"
      unitRef="usd">16535000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS00LTEtMS0w_e3558297-708b-411a-b43c-1b749d5b23ed"
      unitRef="usd">86979000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfOS01LTEtMS0w_e50d99b6-ecbc-4e98-910b-62ad617795d0"
      unitRef="usd">42621000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtMS0xLTEtMA_eb313dcb-ef7c-420a-9560-957190800590"
      unitRef="usd">15690000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtMi0xLTEtMA_f13b0be2-2afa-4adb-ae99-1d12dcac6e03"
      unitRef="usd">6964000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtNC0xLTEtMA_48ea6d26-49ad-4e64-b7f3-715db985255f"
      unitRef="usd">38481000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTAtNS0xLTEtMA_febfa8f1-294e-4191-8272-ea716852633c"
      unitRef="usd">17684000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtMS0xLTEtMA_4b31b682-59db-4812-97af-8ff35661e397"
      unitRef="usd">48936000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtMi0xLTEtMA_6a1725c6-aa70-4410-a87e-9a7d1c28173d"
      unitRef="usd">23499000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtNC0xLTEtMA_a71b199e-f988-4d74-8d53-b0a7781cc336"
      unitRef="usd">125460000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTEtNS0xLTEtMA_606a0dbc-94cd-4c94-85aa-a61ab77396ea"
      unitRef="usd">60305000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtMS0xLTEtMA_cd681856-d300-4b2b-92d1-99d2cb0150e5"
      unitRef="usd">-46402000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtMi0xLTEtMA_4f7e86c9-5fd5-49f5-a0ea-92a04c314e66"
      unitRef="usd">-22474000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtNC0xLTEtMA_3dde48db-8c3e-46a1-a262-b7fd0f07c648"
      unitRef="usd">-117815000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTMtNS0xLTEtMA_7e0ed0c6-e950-467a-ba4b-4be25132eb36"
      unitRef="usd">-59034000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtMS0xLTEtMA_984bfad8-9864-4723-b3b6-a298fbccff28"
      unitRef="usd">-1026000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtMi0xLTEtMA_968ef75f-6657-498b-87d0-d4d149b9e9b3"
      unitRef="usd">-1399000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtNC0xLTEtMA_f1fca121-9d21-4056-bde0-100a441cfd1b"
      unitRef="usd">-3731000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTQtNS0xLTEtMA_5633c84b-3f07-40b8-8e7d-a663c5ef24ef"
      unitRef="usd">-2206000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtMS0xLTEtMA_0ea56690-0b00-43c6-95d6-0207a10f0810"
      unitRef="usd">-47428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtMi0xLTEtMA_c0043f6c-fa5b-45a2-a5e0-d8cb47b4d95f"
      unitRef="usd">-23873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtNC0xLTEtMA_b30269c2-08e2-4b09-a896-362ffb221c4b"
      unitRef="usd">-121546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTUtNS0xLTEtMA_0330aedf-267b-429b-bda3-c70a040a7dbe"
      unitRef="usd">-61240000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMS0xLTEtMA_e8eb82f7-dbe2-4deb-971c-6ff84cd642fe"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMS0xLTEtMA_fb3bdc4d-e275-4800-8b23-303da26eb478"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMi0xLTEtMA_043b9a93-db50-432c-aa07-3681ac555d6c"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtMi0xLTEtMA_8ffed737-28a9-4087-ad02-13d5be56dd39"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNC0xLTEtMA_7f37ce18-0582-4a11-8093-b92338f8f43b"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNC0xLTEtMA_9bc3dcf5-5066-453b-9b33-ec300f9821d8"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNS0xLTEtMA_991947eb-70f8-41a3-9391-ea474b0f6dc9"
      unitRef="usdPerShare">-2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTgtNS0xLTEtMA_df0ed233-36fc-49af-9474-f836573023bb"
      unitRef="usdPerShare">-2.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMS0xLTEtMA_354eafaa-b1fe-43ec-9510-817cb4f4b071"
      unitRef="shares">168533550</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMS0xLTEtMA_d54c7abe-c92f-44e4-a2e6-3c08591a9108"
      unitRef="shares">168533550</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMi0xLTEtMA_5ba4742a-ea85-4bdc-8943-ff2c1a2babc0"
      unitRef="shares">21817900</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktMi0xLTEtMA_73ff164d-4be7-4f32-a124-d07dc0be8f55"
      unitRef="shares">21817900</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNC0xLTEtMA_0646a43e-90eb-40db-b2e2-49fe35bdf21e"
      unitRef="shares">110513231</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNC0xLTEtMA_5b753e4c-1225-4c75-912f-2b491fb60bce"
      unitRef="shares">110513231</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNS0xLTEtMA_930e80ff-f128-4de7-ae0a-cff978d3bc09"
      unitRef="shares">21704008</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yMi9mcmFnOjA5NTk2ZTZjOGQ4ZjRjN2JhOTM3NWQ0NmZhYWEyOWI5L3RhYmxlOmQ3MjFhMmRiNTk2NzQ0Mzc5NjNjODAyZDBlMWQ2MTIyL3RhYmxlcmFuZ2U6ZDcyMWEyZGI1OTY3NDQzNzk2M2M4MDJkMGUxZDYxMjJfMTktNS0xLTEtMA_c8f203d5-2cfb-4a89-b0a9-a7ca953c3003"
      unitRef="shares">21704008</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtMS0xLTEtNTMyNg_619e9600-eda9-4384-85a3-caf87fbcd010"
      unitRef="usd">-47428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtMi0xLTEtNTMyNg_966ee677-ce13-4954-b8eb-aa1e34b5b699"
      unitRef="usd">-23873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtNC0xLTEtNTMxMA_00f2a78e-5f8d-460b-a458-f3bac263f710"
      unitRef="usd">-121546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzMtNS0xLTEtNTMxMA_a077b2d0-fd22-4751-88e8-aa28a3c2fa62"
      unitRef="usd">-61240000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtMS0xLTEtNTU3Mw_764a97a7-74f6-4983-b2ef-00698c4ab85b"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtMi0xLTEtNTU3Mw_f3a39a16-a7c4-4429-ba65-d82dd8424557"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtNC0xLTEtNTYwNw_25576a2a-05f1-43cd-8ff7-584fedee3cfa"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzUtNS0xLTEtNTYwNw_aac36e8f-ec6f-48b2-8d7a-27944cc1ea32"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtMS0xLTEtNTU3Mw_c61930d4-cfb3-4f93-a0df-880dab74e704"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtMi0xLTEtNTU3Mw_39512ecd-052f-45b9-a072-d7141f1e5700"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtNC0xLTEtNTYwNw_2bd091aa-a1dc-442c-9da7-e9574c5ee5ba"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzYtNS0xLTEtNTYwNw_3cb5268b-d0fd-4fd0-9b45-1b19762288dd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctMS0xLTEtMTMxMDk_e336e560-e9e9-4707-92f8-45d0a75dd75f"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctMi0xLTEtMTMxMDk_ed83cdfe-a2b2-493e-8b36-3424070e832f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctNC0xLTEtMTMxMTI_a8d78383-5f72-4fd7-874b-5a80b6c4a5a9"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzctNS0xLTEtMTMxMTI_9242d8f1-20c2-413e-a958-3f86c8776d06"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtMS0xLTEtMTMxMDk_b6cad1b4-2ff6-4579-85fb-ead77b03651f"
      unitRef="usd">-47426000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtMi0xLTEtMTMxMDk_26978c4d-df0d-4f21-b726-998c950fd877"
      unitRef="usd">-23873000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtNC0xLTEtMTMxMTI_900e4586-3b0a-486c-bb4b-cb0bfadaca2e"
      unitRef="usd">-121544000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NzQvZnJhZzozYTZiOGQzYWM4NzQ0YTM2YTAyZjJhMWUxYjNlZmE4MC90YWJsZTo2MTcxMDg3OGRjNzI0M2FlYmI1MDhlZmRkM2NjMjJjYS90YWJsZXJhbmdlOjYxNzEwODc4ZGM3MjQzYWViYjUwOGVmZGQzY2MyMmNhXzgtNS0xLTEtMTMxMTI_d829f2af-ca62-4e20-a005-a4cce9fa5c8a"
      unitRef="usd">-61240000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi0xLTEtMS0xODE4Ng_747d6a3b-4322-493b-9898-ad0a7bf0e4ea"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi0yLTEtMS0xODE4Ng_3b1633c6-5d37-4469-9e44-bd5ec87ca3fb"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1f2f2c074b1e43afaf522e34126788a5_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi0zLTEtMS0w_3ff64be2-92e9-4478-9a73-c9590d3cc6fe"
      unitRef="shares">168425907</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1f2f2c074b1e43afaf522e34126788a5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi00LTEtMS0w_2888b386-9003-462b-982a-3242bd8fa545"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0ff446e32064366bc8ac2fb705f08c7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi01LTEtMS0w_7d7117fd-ec6b-471b-9931-5a99f6c50d1b"
      unitRef="usd">930431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28cbfc7f295d41798a3535412b1097ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi02LTEtMS0w_128d00dc-c651-4e16-b91b-6790f1d3a752"
      unitRef="usd">-287719000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b650a6bb07749f0a6edf5919d0a3161_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi03LTEtMS01OTI0_ac97d280-fd00-47ec-a226-84a3010033c7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c9aedd7890a474881e0f2ee83a5bb75_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMi03LTEtMS0w_b998513f-5253-4a51-a4ac-9e7e69bfe510"
      unitRef="usd">642714000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i285746a4957648a9b7d4042cbb79af11_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMy02LTEtMS0w_bf3a2678-d3aa-4f25-9521-e94d77b1ee89"
      unitRef="usd">-47428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfMy03LTEtMS0w_bd98a177-37a4-4768-892f-89f686341809"
      unitRef="usd">-47428000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i40cfd8df988f4d82810e987c2d28b259_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNC03LTEtMS01ODA2_c844fa7b-c37c-4184-819d-5d7e991f1832"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNC04LTEtMS0xODE3OQ_912dbaf7-984b-46ac-9d83-54922b00abd2"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6e44c4c74c4244ad9325ce8ee3d87c39_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy0zLTEtMS0w_2bc9e656-17be-4fad-84e8-8b76c69b9f51"
      unitRef="shares">209052</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i43267d208dab4736ae222644e2d2c456_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy01LTEtMS0w_eb69fb25-d8eb-4298-aa6c-bb53046b8588"
      unitRef="usd">382000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy03LTEtMS0w_562ccb5d-5441-4f3f-bd0d-b4c56559e0c1"
      unitRef="usd">382000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i43267d208dab4736ae222644e2d2c456_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOC01LTEtMS0w_6a90f70b-c2c9-4993-be0f-476ac2028af7"
      unitRef="usd">3362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOC03LTEtMS0w_92553d70-13f9-48da-8253-dbce003276ef"
      unitRef="usd">3362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy0xLTEtMS0xODE4Ng_a9687855-ff60-4746-b78a-672cc293336a"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy0yLTEtMS0xODE4Ng_707edfd5-5c17-4044-8bc3-ec55f4fc406b"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS0zLTEtMS0w_2856e969-60d0-4c56-abe2-69fd4c313ae9"
      unitRef="shares">168634959</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS00LTEtMS0w_41410097-48bf-4b27-bd70-27e702cb7bd5"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4b3bdbb908941fe9dd8a36f77aa3125_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS01LTEtMS0w_75407563-8453-4d11-9d8f-82a42ad67e61"
      unitRef="usd">934175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b9cf913bc7c43ca9b2e069af2d8729b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS02LTEtMS0w_a3574b93-5530-4aab-b2c4-85f7c303f39b"
      unitRef="usd">-335147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40174ea8bb02463794d3b4d1c442fb95_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfNy03LTEtMS0xODE4NA_8dfe8210-ad0a-4120-a928-7972a3e8414c"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjYyMWE1YWZlNGVlYzRjNmE4NjU4Mzg4OGE3ZmY4MWU3L3RhYmxlcmFuZ2U6NjIxYTVhZmU0ZWVjNGM2YTg2NTgzODg4YTdmZjgxZTdfOS03LTEtMS0w_8e1c305e-ff21-41b5-acd2-57788dc0220b"
      unitRef="usd">599032000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi0xLTEtMS0w_b77e5520-0f43-4ee0-872e-d714e8ae82e0"
      unitRef="shares">112088065</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi0yLTEtMS0w_1d04b2b3-2b88-417a-b282-4c9996258921"
      unitRef="usd">448312000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i30420430e079491d8ed1cccc567ce1a4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi0zLTEtMS0w_59a3e899-17d5-408d-bb76-75c2c0fabf34"
      unitRef="shares">22314685</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i30420430e079491d8ed1cccc567ce1a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi00LTEtMS0w_949709fc-e9f7-4211-b9c6-b37f34249840"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c9e3fea7fdb4088a7ed864903989ab8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi01LTEtMS0w_b2b0e74b-d4f7-473c-80af-cc1264a8e10d"
      unitRef="usd">7312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i75c52a0d323d498e8014b63cf8a7850d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi02LTEtMS0w_af9d70af-cede-469c-b13c-e57e18d88063"
      unitRef="usd">-213601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0eb56eae1b564d73804d37ddfe5ab0ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi03LTEtMS01OTM4_a553f2eb-d0f4-415f-9bbe-c5ff17678b4e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMi03LTEtMS0w_0e620aee-7caf-49c5-af7c-507c3b498377"
      unitRef="usd">-206289000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i91d161d487e84f1f904d7fda0b4884fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMy02LTEtMS0w_dea507b3-93fc-4489-b2bc-f3aab3a7fcec"
      unitRef="usd">-121546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMy03LTEtMS0w_93e4ef58-8bc0-431f-8dfa-c41ec31df4e1"
      unitRef="usd">-121546000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i776c6fde78c34963b7743761ab97c975_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC03LTEtMS01ODQw_e5742b2f-3e33-448f-87a3-e2150c876659"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC04LTEtMS0xODE3NA_d84a63f6-5556-49b0-a100-d5d6244bff12"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC0zLTEtMS0w_d9135068-a7af-4775-b765-3e5c8ef84da4"
      unitRef="shares">27878787</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC00LTEtMS0w_c044e022-c49b-4d07-9c8d-40bde881994d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic9c4548723a94137977675db77d39056_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC01LTEtMS0w_8dd2ade8-5b6d-4019-9cc5-3a809e0f942b"
      unitRef="usd">462353000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNC03LTEtMS0w_f1ddd6a7-fc97-491d-bf2b-f1d62894f31e"
      unitRef="usd">462354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rxrx:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS0xLTEtMS0w_7639a316-1705-47c5-896d-7597316482d2"
      unitRef="shares">112088065</rxrx:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <rxrx:TemporaryEquityValueConversionOfConvertibleSecurities
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS0yLTEtMS0w_399c8488-6209-4eb5-9b4c-850473d0ec60"
      unitRef="usd">448312000</rxrx:TemporaryEquityValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i4482ced31be5421b8f43d4f1dbe206c4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS0zLTEtMS0w_9e59e09b-1682-4fbd-b691-ba432673e4ef"
      unitRef="shares">115598018</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4482ced31be5421b8f43d4f1dbe206c4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS00LTEtMS0w_063d08f9-4074-409c-9747-9e88ed0cd0bd"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5705097d3db6486b875714c0fdd8511f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS01LTEtMS0w_0042e0e9-2dd5-41e5-a82c-70dabf6d97a1"
      unitRef="usd">448311000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if5e93eef6c0643958f8d3941866bed9b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNS03LTEtMS0w_facf7812-f208-464f-87c0-bf91be82e3e8"
      unitRef="usd">448312000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i1352bc1f243c4c93b8a1a85f705f61bd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNi0zLTEtMS0w_697596ec-a338-46b6-8a00-3dfa935c4037"
      unitRef="shares">129963</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i881224a385cd4b5bb6c214cf65fbdc6f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNi01LTEtMS0w_26cc102f-61af-4409-863c-1ddd8e71efba"
      unitRef="usd">2340000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie4b4fd7858ca4d1b8cbd0d11d1d96c2e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNi03LTEtMS0w_6e77d905-3d05-4aeb-a4d1-003c5e206ab9"
      unitRef="usd">2340000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if73d88c6905d43d9845387c7410b96a9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNy0zLTEtMS0w_e21ded27-af72-40f3-a6f0-e14038d16409"
      unitRef="shares">2713506</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic9c4548723a94137977675db77d39056_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNy01LTEtMS0w_b2303509-fb23-47d0-886d-8cd4fc027d05"
      unitRef="usd">3359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfNy03LTEtMS0w_b7eddf62-9917-4ef6-b8ef-4fc32fc65e43"
      unitRef="usd">3359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic9c4548723a94137977675db77d39056_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOC01LTEtMS0w_b8058f3f-dabe-4868-9b0c-f7cffa7d5a78"
      unitRef="usd">10500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOC03LTEtMS0w_249f5c3c-3784-4da3-87bd-b18a89c1166e"
      unitRef="usd">10500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS0xLTEtMS0w_4f34f5fa-873d-4e82-9136-e0600033e87d"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS0yLTEtMS0w_8a2777ca-c758-4e4c-84f9-fff6bc052138"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS0zLTEtMS0w_b0442f96-c0bd-48e6-acd1-77c2f10cc3c6"
      unitRef="shares">168634959</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i51f4b84aaf944dbe9a02fd4931d34296_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS00LTEtMS0w_f27a0a98-e896-4c79-8d52-95a7b4a274c5"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4b3bdbb908941fe9dd8a36f77aa3125_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS01LTEtMS0w_695c81df-3fd6-4947-9822-5352699d1681"
      unitRef="usd">934175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0b9cf913bc7c43ca9b2e069af2d8729b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS02LTEtMS0w_bb4147b9-5e00-4a7d-bac0-74107ba942e2"
      unitRef="usd">-335147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40174ea8bb02463794d3b4d1c442fb95_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfMTAtNy0xLTEtMTgxNzc_f6938c87-6940-46ea-8a4a-f5c7a39ecd48"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOjM1MDllZjYzY2FhYzQ5YTFiMjA5Mzg0Y2Q5ZTQ5N2M2L3RhYmxlcmFuZ2U6MzUwOWVmNjNjYWFjNDlhMWIyMDkzODRjZDllNDk3YzZfOS03LTEtMS0w_88a90553-8cbe-4ffb-a07b-c166a0abae13"
      unitRef="usd">599032000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i29a9bdffe7f94be498dcc2410790c11f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi0xLTEtMS0w_390d9d1e-5876-432d-8389-a90323ab5a23"
      unitRef="shares">75189517</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i29a9bdffe7f94be498dcc2410790c11f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi0yLTEtMS0w_fd388c6b-fffa-4890-b5a2-b6a954e70a15"
      unitRef="usd">201109000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i872955c4fcdd4c5eaf64056f28e5f425_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi0zLTEtMS0w_d695778a-c669-4f1c-9101-02a863157a0a"
      unitRef="shares">21652277</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i872955c4fcdd4c5eaf64056f28e5f425_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi00LTEtMS0w_4f442a2c-96ee-43c2-aecd-f7d3bd7cd211"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a95d59cc58842588ef57ba5c32d5d71_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi01LTEtMS0w_9d9a2711-ac8f-4d76-9268-7d81fecd769c"
      unitRef="usd">4524000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cfdf3f6f12e4ce0ae4dfac0a5ed90d2_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi02LTEtMS0w_93405808-0ecd-448e-89e0-931b6bb33e13"
      unitRef="usd">-163962000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i29a9bdffe7f94be498dcc2410790c11f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMi03LTEtMS0w_fd1087b9-9b63-4f51-9637-a1739be162ff"
      unitRef="usd">-159438000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i28896c19aa0048d895dddd0ae8427e87_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMy02LTEtMS0w_39313815-2157-4e52-8be6-03f34e71e405"
      unitRef="usd">-23873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfMy03LTEtMS0w_029316d7-238c-4b35-8a3c-dbceef0c6398"
      unitRef="usd">-23873000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia0e2b80f5d48496fa52384c883bedd9d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC0zLTEtMS00OTI5_0862dba9-ab81-40d2-a048-aa0ebbe7bd29"
      unitRef="shares">282215</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3209489bac6541a49f8dc6490492263d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC01LTEtMS00OTI5_b79e528a-0498-4afb-849e-8d7a452f2309"
      unitRef="usd">211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC03LTEtMS00OTI5_4642f23f-1879-4a2e-8c8a-399c70779105"
      unitRef="usd">211000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rxrx:TemporaryEquityIssuanceCosts
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0wLTEtMS0xMzQxMy90ZXh0cmVnaW9uOmUzYjQxYWYwYjhmOTQzMzY5OTE1YWE1NTU1N2ZmZDRmXzY1OTcwNjk3NjY3Nzg_315960ef-2ce3-4ffe-8bcf-80d7d3d48f19"
      unitRef="usd">228000</rxrx:TemporaryEquityIssuanceCosts>
    <rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i5058a871b06b4ce2a3fa07e2e0a0bfb2_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0xLTEtMS03MDg2_33f5fd97-a626-42f6-966c-ecbd025c7af1"
      unitRef="shares">35349630</rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0yLTEtMS03MTEw_f911142f-1c2a-4e50-997f-2da505e12b11"
      unitRef="usd">236813000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3209489bac6541a49f8dc6490492263d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC01LTEtMS0w_0cacfe01-5c6c-40a9-8b04-f843b4f32320"
      unitRef="usd">1025000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNC03LTEtMS0w_3a555d39-b6a3-4077-a088-ee2148d6f48d"
      unitRef="usd">1025000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0xLTEtMS0w_1bae6939-532b-485f-8803-6a10971bc212"
      unitRef="shares">110539147</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0yLTEtMS0w_53b709f7-fe71-4303-9b02-caed3ac2117d"
      unitRef="usd">437922000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS0zLTEtMS0w_738aba03-11ad-42fb-8483-ef75657830ef"
      unitRef="shares">21934492</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS00LTEtMS0w_61a3c7bb-01bb-4bb4-a294-2c53b513997e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8338d53d46ff438abc85d037a8e6da2f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS01LTEtMS0w_4ceb39bb-ac30-4f63-8e2f-edfd5eaa6e43"
      unitRef="usd">5760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i869c72f28c2245f8b0f7ccc8daabd4fd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS02LTEtMS0w_857f1c72-6474-4b3d-a86b-3b9e4afe4764"
      unitRef="usd">-187835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmEyZTAwYWY2ZDBlNzQ4OGNhYTQzNjk1M2I3ZWFlZjMwL3RhYmxlcmFuZ2U6YTJlMDBhZjZkMGU3NDg4Y2FhNDM2OTUzYjdlYWVmMzBfNS03LTEtMS0w_0781aa51-5b67-42ae-ae0e-8df701d6ced1"
      unitRef="usd">-182075000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5e11557b1837454f993cb507031865c5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi0xLTEtMS0w_57a7b905-518f-40ec-b191-53af011461b4"
      unitRef="shares">75189517</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5e11557b1837454f993cb507031865c5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi0yLTEtMS0w_6086aefa-f14a-4036-bff5-41225411c2a9"
      unitRef="usd">201109000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0b7ae49e496a4f9888670cd3e0d4b725_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi0zLTEtMS0w_cbc5cfef-5e6f-4cce-9e96-a2fa49307dbe"
      unitRef="shares">21637609</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0b7ae49e496a4f9888670cd3e0d4b725_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi00LTEtMS0w_d2841943-d0dd-4f95-9968-453f3272764b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77586c203c024828a9a78bdb39902891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi01LTEtMS0w_58d003e6-bcee-4914-8b89-23e19449b6a4"
      unitRef="usd">2330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb73e0e9cb754e1bbe802d6ae2551e64_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi02LTEtMS0w_258dfb85-fb69-4d16-ac44-eef0a962260f"
      unitRef="usd">-126595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e11557b1837454f993cb507031865c5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMi03LTEtMS0w_7116fe7b-1a3d-4bb4-9a0e-e50abe254cc1"
      unitRef="usd">-124265000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icee0f1fd845e456095af44bb0a898324_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMy02LTEtMS0w_95f87f38-5a27-4098-8d29-7166fbbe9c54"
      unitRef="usd">-61240000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfMy03LTEtMS0w_475af47b-4f9f-447f-85ed-0ddb00262725"
      unitRef="usd">-61240000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i182ec792f9954c3580432f8d5bb60d4c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNC0zLTEtMS0w_099788b4-736b-44a0-b603-84b21b1b0ca7"
      unitRef="shares">296883</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i16660690238a4cba84cc971aaa39f2bc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNC01LTEtMS0w_160ba0a9-e03d-45b0-a54d-5d856caad7f6"
      unitRef="usd">227000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNC03LTEtMS0w_18d504ea-06e6-4352-8271-70defc65d097"
      unitRef="usd">227000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <rxrx:TemporaryEquityIssuanceCosts
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS0wLTEtMS0xODQ5NS90ZXh0cmVnaW9uOmNkMzVjODliNWE3MDQ0YzBiZTgyODE5NjQyOTE1MzNmXzY1OTcwNjk3NjY3Nzg_de6e8a81-1b56-40d5-be3d-9ccf8f74661e"
      unitRef="usd">228000</rxrx:TemporaryEquityIssuanceCosts>
    <rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS0xLTEtMS03MTc3_42f91446-74cf-4044-bc13-264d61f5c8d9"
      unitRef="shares">35349630</rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS0yLTEtMS03MTc3_f9892f46-3410-447a-8d6a-dd8a9c8e439e"
      unitRef="usd">236813000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i16660690238a4cba84cc971aaa39f2bc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS01LTEtMS0w_3262a41a-adb6-4a97-947b-4443709c1e19"
      unitRef="usd">3203000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNS03LTEtMS0w_b24aa5f5-421c-449d-80ac-c2793d3ba892"
      unitRef="usd">3203000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi0xLTEtMS0w_4cb2ee84-96d3-41fc-a59a-66793f399002"
      unitRef="shares">110539147</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi0yLTEtMS0w_1df3b8fb-723c-4185-85f2-5df77dad332d"
      unitRef="usd">437922000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi0zLTEtMS0w_11867643-9baf-47d7-bff4-c4e8a2c112cb"
      unitRef="shares">21934492</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if7ff4d3f153a469d96516e024f93f1cc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi00LTEtMS0w_9309de6e-0aae-4169-8dd9-fb58f93686e2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8338d53d46ff438abc85d037a8e6da2f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi01LTEtMS0w_a5e80c51-7f10-4ca6-b1d8-ddc12fccc891"
      unitRef="usd">5760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i869c72f28c2245f8b0f7ccc8daabd4fd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi02LTEtMS0w_327824b5-f7f5-479d-ae05-0ed75138b48e"
      unitRef="usd">-187835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yNS9mcmFnOmRhMTAxNzA0ZWI5YzQ5ZDY5OTZkOWU3MTc3MTIyN2E5L3RhYmxlOmFjYzgyYmMyNzllYjRhZDA5YWM2MWY5OWI5ZmMyZTZiL3RhYmxlcmFuZ2U6YWNjODJiYzI3OWViNGFkMDlhYzYxZjk5YjlmYzJlNmJfNi03LTEtMS0w_87a4e129-6db0-4250-9491-c78d53fc7519"
      unitRef="usd">-182075000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNC0xLTEtMS0w_db61c954-474d-4d16-8be0-e61c45a5bd10"
      unitRef="usd">-121546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNC0yLTEtMS0w_a96b1b66-710d-4b1a-bd90-e9c5f724d238"
      unitRef="usd">-61240000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNi0xLTEtMS0w_7ef911b4-47f5-4bb0-b41c-a578d6f0b18b"
      unitRef="usd">6169000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNi0yLTEtMS0w_3c09dc5e-6f9d-4845-9d87-004b8ec06ad4"
      unitRef="usd">2818000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNy0xLTEtMS0w_f08d9e1b-86e8-47ff-b0a1-19fe5e96fdf3"
      unitRef="usd">10501000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNy0yLTEtMS0w_1525c3ce-711a-4f4a-b39a-f4d5e7a51238"
      unitRef="usd">3104000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0xLTEtMS0xMjY5MA_9b1ed40e-abd3-418c-a1d7-0d2e0629c8c0"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0yLTEtMS0xMjY3Ng_5c4029c9-300e-4d94-9877-6a148e0ffb06"
      unitRef="usd">874000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOS0xLTEtMS0xMjY5MA_8144d013-b53f-4a0c-bd60-2caf61e83345"
      unitRef="usd">-827000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOS0yLTEtMS0xMjY4Mw_ed56d041-b02c-4fea-96dc-796895037d7c"
      unitRef="usd">-883000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0xLTEtMS0w_efa54568-fff0-4aa5-b6ec-af319e82b5ea"
      unitRef="usd">-2940000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfOC0yLTEtMS0w_19f082f9-491a-407d-ba35-703ac80db205"
      unitRef="usd">-309000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTAtMS0xLTEtMA_5c752a1e-28a6-4039-a926-966fdefe0897"
      unitRef="usd">-114000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTAtMi0xLTEtMA_0f0d7840-aa73-4461-8b5f-be1a35d1e2de"
      unitRef="usd">30048000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTEtMS0xLTEtMA_8f10b722-4b2f-4f39-a8b0-b60d3316c21b"
      unitRef="usd">6860000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTEtMi0xLTEtMA_1a85a19d-a845-427c-97d1-1fbe2e8d2217"
      unitRef="usd">677000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTItMS0xLTEtMA_12ee21bd-be21-4177-9d8a-7da903f6d3ec"
      unitRef="usd">-7500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTItMi0xLTEtMA_979581c6-46bb-4dc0-8cbe-32ff715174ea"
      unitRef="usd">29167000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTMtMS0xLTEtMA_4f455f2e-77ea-4e0a-8e3d-fc8583d086a2"
      unitRef="usd">5252000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTMtMi0xLTEtMA_bc6f841e-b5b6-44f8-b6d9-f41a519cb1dc"
      unitRef="usd">37000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <rxrx:IncreaseDecreaseInAccruedDevelopmentExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTQtMS0xLTEtMA_24164a27-1da5-4414-a7cd-2ba4d1724c1c"
      unitRef="usd">1524000</rxrx:IncreaseDecreaseInAccruedDevelopmentExpense>
    <rxrx:IncreaseDecreaseInAccruedDevelopmentExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTQtMi0xLTEtMA_e6997e9a-c13b-40a9-9d53-38963ffad274"
      unitRef="usd">-195000</rxrx:IncreaseDecreaseInAccruedDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTUtMS0xLTEtMA_b643a27d-694f-4907-af8d-bf0ad967e86f"
      unitRef="usd">11123000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTUtMi0xLTEtMA_11ef7605-3515-4221-bad0-f417eebb2595"
      unitRef="usd">996000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTYtMS0xLTEtMA_c3140d87-6936-4907-bc5e-9174d977d2cb"
      unitRef="usd">-97456000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTYtMi0xLTEtMA_dfb349cc-0ae4-45a4-8a1b-62a27f6105f5"
      unitRef="usd">-53972000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTktMS0xLTEtMA_788333fd-2422-47c6-93a7-c423c8ff0388"
      unitRef="usd">35334000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMTktMi0xLTEtMA_76566b77-8a2c-40b5-bfc7-a0c2a5a9656f"
      unitRef="usd">2144000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMS0xLTEtMTk3OA_de0b5e9e-b844-4259-8f2a-ca35733c8b25"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMi0xLTEtMjAwMg_8bac9ab7-b952-49f5-86de-12749dc37158"
      unitRef="usd">2600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMS0xLTEtMTkwOQ_608a5473-13d7-45ce-8ea0-90df84d99047"
      unitRef="usd">184167000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMi0xLTEtMTkzNA_b729ba1d-924a-4462-a1c6-13a067ccecfe"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMS0xLTEtMA_67dfe49a-16e5-4f3f-b29a-103f17b650ae"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjAtMi0xLTEtMA_02c53528-cbcc-49d7-9902-4f180528fac9"
      unitRef="usd">595000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjEtMS0xLTEtMA_a07ef781-5983-4458-881f-379f179677d4"
      unitRef="usd">-219501000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjEtMi0xLTEtMA_74a3e210-65fb-488b-ad64-f0b5ae7bac2f"
      unitRef="usd">-4149000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjQtMS0xLTEtMA_8ad264a8-d538-4b4d-badc-94368ae94641"
      unitRef="usd">462901000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjQtMi0xLTEtMA_85e6dd87-e2d2-41d7-8814-21751dd8d7e7"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjktMS0xLTEtMTI1OTY_21a54a75-2478-4752-90cf-7e536882219c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjktMi0xLTEtMTI1ODk_4f7e0b7d-00be-4f01-8dce-c74b838ad5de"
      unitRef="usd">229530000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjUtMS0xLTEtMA_326db931-ac6b-4642-8fde-92a50c89c17b"
      unitRef="usd">4620000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjUtMi0xLTEtMA_829fa462-676d-478a-a4ea-e92132eb9657"
      unitRef="usd">227000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjYtMS0xLTEtMA_5ce8cbca-ccaa-4a31-940a-5f62e6e6f383"
      unitRef="usd">12777000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjYtMi0xLTEtMA_c0312a90-9f21-42f0-b41c-729c4aba41e5"
      unitRef="usd">57000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjctMS0xLTEtMA_e8c7de8d-eb6c-4941-9819-306512a6788f"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjctMi0xLTEtMA_bf7dc222-aee8-4095-b160-74fa87764ab6"
      unitRef="usd">6400000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjgtMS0xLTEtMA_8280201c-7a09-4829-968e-95823a256c98"
      unitRef="usd">454744000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMjgtMi0xLTEtMA_d0d0676d-2f09-451c-96e1-d52c1a9289c2"
      unitRef="usd">236100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzAtMS0xLTEtMA_e39cacfa-1c51-4834-aea9-fabee4a270b0"
      unitRef="usd">137787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzAtMi0xLTEtMA_b742899a-1389-487d-922b-c217bd679187"
      unitRef="usd">177979000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzEtMS0xLTEtMA_c19a8dbf-badc-444a-93e8-b9603d6e452a"
      unitRef="usd">267167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e11557b1837454f993cb507031865c5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzEtMi0xLTEtMA_153aca46-f934-4a8a-b091-c802299f5e57"
      unitRef="usd">75171000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzItMS0xLTEtMA_19c9cfef-ae4c-4b7e-9617-e0e37d827c8f"
      unitRef="usd">404954000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzItMi0xLTEtMA_388b7ab0-b624-4038-b7ee-9316053eb571"
      unitRef="usd">253150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzUtMS0xLTEtMA_65c077e9-c06c-48fd-bb94-969a6cce26ad"
      unitRef="usd">448312000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzUtMi0xLTEtMA_1365c7a3-266b-4543-b9e8-6d9ec7165120"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDItMS0xLTEtMTY5MzQ_209cb22c-99b0-4b73-9cf7-da5d536eb917"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDItMi0xLTEtMTY5MzQ_f82d6123-eba3-4fd7-965f-c7026c06a2b1"
      unitRef="usd">8071000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <rxrx:StockIssuanceCostsNoncash
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzYtMS0xLTEtMA_6b224dfe-6b5b-46e7-a772-b01b042bd32d"
      unitRef="usd">547000</rxrx:StockIssuanceCostsNoncash>
    <rxrx:StockIssuanceCostsNoncash
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzYtMi0xLTEtMA_5abe33cb-004b-4c4e-b4a6-570b181b2694"
      unitRef="usd">0</rxrx:StockIssuanceCostsNoncash>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzctMS0xLTEtMA_f81f898d-8777-420c-818d-5a99368bf571"
      unitRef="usd">413000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfMzctMi0xLTEtMA_04f007cb-c6ec-4a55-b938-63d23d877d50"
      unitRef="usd">42000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDAtMS0xLTEtMA_9ae892cd-b544-4200-8065-43e2bb96215a"
      unitRef="usd">665000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8yOC9mcmFnOjhmZjNjNmFmY2FlYTQ5NzFhZDI4MTZlNjg5YjhiNmRmL3RhYmxlOmY4ZmUwNzdmYmVjODQxMzY5OTE1N2E5NDJjYWIwMzNlL3RhYmxlcmFuZ2U6ZjhmZTA3N2ZiZWM4NDEzNjk5MTU3YTk0MmNhYjAzM2VfNDAtMi0xLTEtMA_036f5c95-0f60-43c0-9d55-281d7edd5861"
      unitRef="usd">823000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNC9mcmFnOjQ0YzI0MGI1MDhkZDRlNzNiNmMzMjMyMTU2NThiYzYyL3RleHRyZWdpb246NDRjMjQwYjUwOGRkNGU3M2I2YzMyMzIxNTY1OGJjNjJfMzA2NQ_6a35878a-cbc9-4a2c-b706-6ac3b36b7a0b">Description of the Business &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us or our) was originally formed as a limited liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and changed our name to Recursion Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion is a biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. Recursion&#x2019;s rich, relatable database of biological images generated in-house on the Company&#x2019;s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people&#x2019;s lives. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had an accumulated deficit of $335.1 million. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration&#160;with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has funded its operations to date through the issuance of convertible preferred stock (see Note 9, &#x201c;Convertible Preferred Stock&#x201d; for additional details) and the issuance of Class A common stock in an Initial Public Offering (IPO), which was completed in April 2021 (see Note 10, &#x201c;Common Stock&#x201d; for additional details). Recursion will likely be required to raise additional capital. As of September&#160;30, 2021, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company&#x2019;s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company believes that the net proceeds from the IPO, together with the Company&#x2019;s existing cash and cash equivalents and borrowings available to it, will be sufficient to fund the Company&#x2019;s operating expenses and capital expenditures for at least the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNC9mcmFnOjQ0YzI0MGI1MDhkZDRlNzNiNmMzMjMyMTU2NThiYzYyL3RleHRyZWdpb246NDRjMjQwYjUwOGRkNGU3M2I2YzMyMzIxNTY1OGJjNjJfMTAxMg_91ff49c0-c573-479a-bcd5-b3e8159cb570"
      unitRef="usd">-335100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfNDE4NA_b0a06aac-ff60-4aac-9b77-8773983c5033">Basis of Presentation &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes for the year ended December&#160;31, 2020 included in the Company&#x2019;s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company completed a 1.5-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 10, &#x201c;Common Stock&#x201d; for additional details. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company&#x2019;s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a one-for-one basis. The creation and issuance of the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 10, &#x201c;Common Stock&#x201d; for additional details. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is management&#x2019;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial statements. Revenues and net loss for any interim period are not necessarily indicative of future or annual results.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emerging Growth Company &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards, although the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company&#x2019;s financial statements with other public companies difficult because of the potential differences in accounting standards used. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion may remain an EGC until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#x201c;large accelerated filer;&#x201d; or (b) have annual gross revenues of $1.07&#160;billion or more; or (3) the date on which we have issued more than $1.0&#160;billion of non-convertible debt over a three-year period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02). Under ASC (Accounting Standards Codification) 842 - Leases, the Company will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) on its Condensed Consolidated Balance Sheet at the commencement date of each lease. ASC 842 is effective for annual and interim periods beginning on or after December 15, 2021 and early adoption is permitted. The Company must adopt the standard using the modified retrospective approach either: (1) as of the earliest period presented and through the comparative periods in the entity&#x2019;s financial statements or (2) as of the effective date of ASC 842, with a cumulative-effect adjustment to equity. The Company expects the adoption to materially increase assets and liabilities on the Condensed Consolidated Balance Sheets related to those leases classified as operating and not recognized on the Condensed Consolidated Balance Sheets under current GAAP. The Company is continuing to evaluate the effect that ASC 842 will have on its consolidated financial statements and related disclosures. The Company will adopt the new standard on January 1, 2022.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfNDE4NQ_519dcaa6-bd71-47d8-9d18-ac7ba8121772">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes for the year ended December&#160;31, 2020 included in the Company&#x2019;s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company completed a 1.5-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 10, &#x201c;Common Stock&#x201d; for additional details. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company&#x2019;s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a one-for-one basis. The creation and issuance of the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 10, &#x201c;Common Stock&#x201d; for additional details. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is management&#x2019;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial statements. Revenues and net loss for any interim period are not necessarily indicative of future or annual results.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emerging Growth Company &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards, although the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company&#x2019;s financial statements with other public companies difficult because of the potential differences in accounting standards used. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion may remain an EGC until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#x201c;large accelerated filer;&#x201d; or (b) have annual gross revenues of $1.07&#160;billion or more; or (3) the date on which we have issued more than $1.0&#160;billion of non-convertible debt over a three-year period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i778df7726a034719acdc84318d53c893_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfODU1_ef6d1ef5-bdde-414d-8fd9-28987c47c050"
      unitRef="number">1.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ia31781556c024ff299dfa585947bf905_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfMTI5Mw_e8698712-a2e7-47da-86d7-193cebccf3ba"
      unitRef="number">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV8zNy9mcmFnOmI1MjRlM2VjNGM3OTQ0NGViMDUyYWUwMTA3YTQyNjZjL3RleHRyZWdpb246YjUyNGUzZWM0Yzc5NDQ0ZWIwNTJhZTAxMDdhNDI2NmNfNDE4Ng_a25a7f6e-9159-43f5-a7fc-80e059cb2568">Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02). Under ASC (Accounting Standards Codification) 842 - Leases, the Company will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) on its Condensed Consolidated Balance Sheet at the commencement date of each lease. ASC 842 is effective for annual and interim periods beginning on or after December 15, 2021 and early adoption is permitted. The Company must adopt the standard using the modified retrospective approach either: (1) as of the earliest period presented and through the comparative periods in the entity&#x2019;s financial statements or (2) as of the effective date of ASC 842, with a cumulative-effect adjustment to equity. The Company expects the adoption to materially increase assets and liabilities on the Condensed Consolidated Balance Sheets related to those leases classified as operating and not recognized on the Condensed Consolidated Balance Sheets under current GAAP. The Company is continuing to evaluate the effect that ASC 842 will have on its consolidated financial statements and related disclosures. The Company will adopt the new standard on January 1, 2022.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTcwMjE_16d68b65-8c20-4319-8b10-593286da8212">Acquisitions&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into an asset purchase agreement to purchase 100% of the assets of Vium, Inc. (Vium) for a total cash consideration of $2.6 million. The primary purpose of the acquisition was to obtain Vium&#x2019;s technology. This was a related party transaction, see Note 16, &#x201c;Related Party Transactions&#x201d; for additional details. The acquisition of Vium has been accounted for as a business combination using the acquisition method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair values of assets acquired as of the July 2020 acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations of Vium have been included in our Condensed Consolidated Statements of Operations  since the date the business was acquired and were not significant. The technology intangible asset is being amortized on a straight-line basis over its three-year useful life. The inventory and other intangible assets were fully impaired at the time they were acquired as the Company did not intend to use them. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill includes the value of potential future technologies as well as the overall strategic benefits provided to the business.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTcwMjQ_00c604fa-1c37-4d9b-8102-a7ff61cf1248"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="idd4cc970bf084e72a23bc5618284498a_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzcxNDY4MjU1ODQ4MzA_4958b9a0-3b39-475b-9e44-73ec3edb66f9"
      unitRef="usd">2600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTcwMjI_15588352-a5c5-4963-ada0-3d239b52e594">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair values of assets acquired as of the July 2020 acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangibles assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzEtMS0xLTEtMjU5OA_94be0819-039f-4d76-a44d-7f1a80f633c9"
      unitRef="usd">232000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzItMS0xLTEtMjU5OA_bfb1c2f6-5955-4d21-b98d-48889447a5a6"
      unitRef="usd">14000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ic76fe27fdee64641b854285105025b00_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzMtMS0xLTEtMjU5OA_f5b59c09-ed40-4847-8db4-c3d0ab6bb393"
      unitRef="usd">911000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzQtMS0xLTEtMjU5OA_625fc871-1257-4766-a4c9-96ef1fa8d42a"
      unitRef="usd">642000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzUtMS0xLTEtMTMxNzY_2020d916-c239-4bea-878c-4e129302e73a"
      unitRef="usd">1799000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzYtMS0xLTEtMjY0Ng_db8fe8d2-325c-4c21-8e88-62b428757b80"
      unitRef="usd">801000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ie4e5e9f454354e0898d008f9b70e031f_I20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90YWJsZToyNWE1OTU3ZGVlNWQ0NTI0ODc2ZGRjN2JhODExYWYyOS90YWJsZXJhbmdlOjI1YTU5NTdkZWU1ZDQ1MjQ4NzZkZGM3YmE4MTFhZjI5XzctMS0xLTEtMTMxNzY_056a28b4-ff2e-4068-89c3-b604980200c5"
      unitRef="usd">2600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1fc1f03ee515432fa42136f5abffdeca_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80NDcvZnJhZzo5MTE1Y2FkN2ZiNjQ0Y2VjYmJjMDU0MmMwMmJiOTk0OS90ZXh0cmVnaW9uOjkxMTVjYWQ3ZmI2NDRjZWNiYmMwNTQyYzAyYmI5OTQ5XzYwNDczMTM5NTc2ODQ_49667a98-63f0-43c7-b730-cde69fcc0885">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA1_0d8a5da5-c2b4-4330-832b-dce24677d3ab">Supplemental Financial Information &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense on property and equipment was $2.5 million and $6.3 million during the three and nine months ended September 30, 2021, respectively, and $1.1 million and $3.1 million during the three and nine months ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the nine months ended September 30, 2021, the Company purchased a Dell EMC supercomputer for $17.9 million. The purchase was classified as office equipment in the above table. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued early discovery expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued investment purchases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expense and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the nine months ended September 30, 2021, interest expense primarily related to changes in fair value of the Series A and B warrants (see Note 12, &#x201c;Stock-based Compensation&#x201d; for additional details on the warrants). The Company also had expenses for the Midcap loan and tenant improvement allowance notes (see Note 7, &#x201c;Notes Payable&#x201d; for additional details.) For the nine months ended September 30, 2020, interest expense included expenses on the Midcap loan, convertible notes and tenant improvement allowance notes (see Note 7, &#x201c;Notes Payable&#x201d; for additional details). Interest expense was included in &#x201c;Other loss, net&#x201d; on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA2_c57fc696-5751-40b8-98e0-d116caecbc35">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i664743a93bb344148d7136746fd74f72_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMi0xLTEtMS0w_0637e80f-4494-46d6-a8b4-a736a964148b"
      unitRef="usd">29664000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4bc65b757b0943af90388d031f257341_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMi0yLTEtMS0w_4f63bd82-641f-4e6b-a469-06bf688873b1"
      unitRef="usd">19701000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d68dbe3edaa4b9280d1ffb236378a0b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMy0xLTEtMS0w_4ee3fbd2-7563-4ce0-912b-29edd762b30f"
      unitRef="usd">13795000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i817c708d2c01406eb506b6bb2d083fd0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfMy0yLTEtMS0w_1a9d3ccb-ebe6-4014-9339-ee4a9f346bc9"
      unitRef="usd">13792000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7bf122307ee643a0845c0597e111bdfc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNC0xLTEtMS0w_788c57b9-cf4f-40a0-b51e-0f4d617380c3"
      unitRef="usd">20005000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9ae7b4560de940f1ba648b0647540789_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNC0yLTEtMS0w_6bfdaf16-22f6-46f9-acea-3841afc93d0d"
      unitRef="usd">1075000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iac3d0f8815254b29b2f5393fc3e65f2c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNS0xLTEtMS0w_5a14d55f-d440-4926-9ddc-b99230c6c50d"
      unitRef="usd">8198000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc7703b2a8b748759f610e861ada8589_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNS0yLTEtMS0w_b987ded4-4897-41b0-a6db-b85558482b11"
      unitRef="usd">1361000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNi0xLTEtMS0w_25543477-bc86-47df-8f46-4ce98d55311c"
      unitRef="usd">71662000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNi0yLTEtMS0w_768836ea-7af7-4e43-a172-1b2e774b7062"
      unitRef="usd">35929000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNy0xLTEtMS0w_3ff4c7eb-d0ff-40ec-a8db-1fd20aecc704"
      unitRef="usd">16223000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfNy0yLTEtMS0w_03cc7801-c04d-48c6-8fb4-192ac692e0db"
      unitRef="usd">9962000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfOC0xLTEtMS0w_99e307ff-24f5-45eb-b98f-c7155b94891b"
      unitRef="usd">55439000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOmFiOThiYjRiMTM2MDQ5YjlhNzEyOGNlMTZiMDIzOGIxL3RhYmxlcmFuZ2U6YWI5OGJiNGIxMzYwNDliOWE3MTI4Y2UxNmIwMjM4YjFfOC0yLTEtMS0w_b6a80f6c-d277-4320-bf04-e151ec80c580"
      unitRef="usd">25967000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTI4_763c6ed3-05b3-4b38-a34f-d5226846e749"
      unitRef="usd">2500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTM1_66458910-2c43-4a80-9c40-90f222cac8a1"
      unitRef="usd">6300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTgx_cae97fc7-054f-45f6-9915-af7dd11c892e"
      unitRef="usd">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMTg4_b6377caa-4d7c-4d82-8d5e-db07aec0112e"
      unitRef="usd">3100000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i4e32a03cb9fc49e4b252453d837334e6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfMjk1_a07ebfd0-38e3-480b-ade4-bcf536adf492"
      unitRef="usd">17900000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA3_f848ac29-0320-4e7e-aa1a-b708ff2ab36c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued early discovery expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued investment purchases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expense and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMi0xLTEtMS0w_ff0ac1d3-21c2-45de-ad3a-f4c669c465f9"
      unitRef="usd">7261000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMi0yLTEtMS0w_1a1653ef-a0cf-406d-9627-094d2b4852ea"
      unitRef="usd">3085000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <rxrx:AccruedDevelopmentCostsCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMy0xLTEtMS0w_c36c3f1b-904e-45b3-95bb-c9b95e6c4312"
      unitRef="usd">3813000</rxrx:AccruedDevelopmentCostsCurrent>
    <rxrx:AccruedDevelopmentCostsCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfMy0yLTEtMS0w_3c7d4d27-c8cf-4d0e-86bf-cbf69ae1039a"
      unitRef="usd">2289000</rxrx:AccruedDevelopmentCostsCurrent>
    <rxrx:AccruedEarlyDiscoveryExpensesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNC0xLTEtMS0w_561555a5-c766-435c-83a2-99ef6ce5e3f2"
      unitRef="usd">1520000</rxrx:AccruedEarlyDiscoveryExpensesCurrent>
    <rxrx:AccruedEarlyDiscoveryExpensesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNC0yLTEtMS0w_a616c58f-fc7e-4c60-93ef-7eb168a06b1a"
      unitRef="usd">338000</rxrx:AccruedEarlyDiscoveryExpensesCurrent>
    <rxrx:AccruedInvestmentPurchasesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0xLTEtMS0xNTIxNQ_7c932a58-2df9-464e-9bc8-3f5a363d616d"
      unitRef="usd">5898000</rxrx:AccruedInvestmentPurchasesCurrent>
    <rxrx:AccruedInvestmentPurchasesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0yLTEtMS0xNTIzMQ_8b70e1bc-56fe-420f-8d1a-09978f85bedb"
      unitRef="usd">0</rxrx:AccruedInvestmentPurchasesCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0xLTEtMS0xNTUwNg_7e60e7d3-ccc3-40ce-9468-ace4e0d65216"
      unitRef="usd">996000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0yLTEtMS0xNTUxMQ_c89436ed-bf1a-4743-9f81-c54c59561877"
      unitRef="usd">0</us-gaap:ConstructionPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0xLTEtMS0w_70f0ff18-e3cf-4ffc-bd97-49d6983b1bd8"
      unitRef="usd">5625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNS0yLTEtMS0w_fe74cd73-399f-464b-824b-70f33874e835"
      unitRef="usd">4773000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0xLTEtMS0w_6ca158a1-3027-4c47-81ae-97105879bcc1"
      unitRef="usd">25113000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjY4YTM4MmU1MDUxYTRhY2M4N2FhNGY2YTQ5ZTU4NzRjL3RhYmxlcmFuZ2U6NjhhMzgyZTUwNTFhNGFjYzg3YWE0ZjZhNDllNTg3NGNfNi0yLTEtMS0w_ba69c50b-eb43-4200-8a72-8371a784dfb5"
      unitRef="usd">10485000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RleHRyZWdpb246OGU5MTBjZDc2ZjFjNDFkNTg2NGY5YWYyM2Q3YWEwNjdfOTA4_5c3a5762-315f-4b23-91dd-4eea54a2e9da">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense, net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi0xLTEtMS0w_ffbc150a-1dd2-4c3a-898b-dbd3f42b789e"
      unitRef="usd">220000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi0yLTEtMS0w_e05a512f-f605-43f4-a4f8-29fd0f4fe3ac"
      unitRef="usd">401000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi00LTEtMS0w_5334139b-059d-4436-aec5-4aa873c34208"
      unitRef="usd">2971000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMi01LTEtMS0w_59da03a9-8b4c-4f61-baec-0039aa9eee88"
      unitRef="usd">1129000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy0xLTEtMS0w_b828b366-3ca4-4b04-a5ed-25bc44522700"
      unitRef="usd">50000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy0yLTEtMS0w_cf393d30-a029-48f4-823f-183287ee130f"
      unitRef="usd">46000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy00LTEtMS0w_a6a21ca6-d429-4381-a05a-a25bbb5d29aa"
      unitRef="usd">94000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfMy01LTEtMS0w_9017b295-e0a4-4daf-8bb2-c05a5b642375"
      unitRef="usd">290000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC0xLTEtMS0w_bb06600b-7112-4101-a4ce-c18803d7fad3"
      unitRef="usd">-170000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC0yLTEtMS0w_03a99082-3290-4f63-8579-b38f37842d88"
      unitRef="usd">-355000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC00LTEtMS0w_f57f22cb-9613-40dc-ae63-fbcdb0eda25c"
      unitRef="usd">-2877000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MC9mcmFnOjhlOTEwY2Q3NmYxYzQxZDU4NjRmOWFmMjNkN2FhMDY3L3RhYmxlOjFlYWVhMmZkYjgzYjQ1OTJhZTVhNmYyMjA3ZjI5NDY2L3RhYmxlcmFuZ2U6MWVhZWEyZmRiODNiNDU5MmFlNWE2ZjIyMDdmMjk0NjZfNC01LTEtMS0w_399bd634-b92a-4ee5-96e2-e24271c1d4b8"
      unitRef="usd">-839000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzYwNDczMTM5NTc5NDU_17d15e2f-41f9-48d8-a99e-d99745dda96e">Investments&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company invested cash in an investment portfolio. The primary objectives of the investment portfolio are to preserve principal, maintain prudent levels of liquidity and obtain investment returns. Recursion&#x2019;s investment policy limits investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings and it places restrictions on maturities and concentration by asset class and issuer.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the investments for declines in fair value below their cost basis each quarter or whenever circumstances indicate that the cost basis of an asset may not be recoverable and assesses whether the decline was due to credit-related factors or other factors. The evaluation is based on a number of factors, including the extent to which the fair value is below the cost basis; adverse conditions related specifically to the security, such as any changes to the credit rating of the security; and the intent to sell, or whether Recursion will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is impaired could change in the future based on new developments or changes in assumptions related to that particular security.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s available-for-sale investments by type of security: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of the Company&#x2019;s available-for-sale investments on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of September&#160;30, 2021, all of the Company&#x2019;s available-for-sale investments mature in one year or less. &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company held a total of 16 positions, which were in an unrealized loss position as of September&#160;30, 2021. The unrealized losses were primarily due to changes in interest rates. T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;here were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; significant unrealized losses as of September&#160;30, 2021. &lt;/span&gt;Realized gains and losses on the Company&#x2019;s investments were insignificant during the three and nine months ended September 30, 2021. No impairments were recorded during the three and nine months ended September 30, 2021. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Condensed Consolidated Statements of Income.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzYwNDczMTM5NTc5NDY_0749158f-b7bc-44f5-bdd2-74baf2a4fe62">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s available-for-sale investments by type of security: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItMS0xLTEtMjA3Nw_1bf9af3c-de56-4b41-96ab-f9245b67f434"
      unitRef="usd">187225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItMi0xLTEtMjA3Nw_3073cc30-aaaf-423a-a8da-e38760bc2c86"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItMy0xLTEtMjA3Nw_c31dbe35-b72e-427c-a3c6-196cd86a7d54"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i90fa6b131e76491793a97c75f8dfec99_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzItNC0xLTEtMjA3Nw_c2f350d9-74dd-47db-b689-bfb1ed2e3fcf"
      unitRef="usd">187225000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtMS0xLTEtMjA5Mg_8871a2fd-e2dd-4569-b306-c50bf686c75e"
      unitRef="usd">5886000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtMi0xLTEtMjA5Mg_4ed7443f-6e00-4683-ada3-90186a4c1127"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtMy0xLTEtMjA5Mg_525cab9b-3701-40e1-90a8-5917af8a829f"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6feede82f4cb4ac49b0be949785d9497_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzQtNC0xLTEtMjA5Mg_20f1485c-ac29-4fd3-bb69-98d9e5400519"
      unitRef="usd">5885000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtMS0xLTEtMjA5Mg_560b5c70-4818-4de6-8538-6765ca1acfbc"
      unitRef="usd">21450000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtMi0xLTEtMjA5Mg_1f031cb7-b102-4c3b-bc8f-961618af090c"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtMy0xLTEtMjA5Mg_81477564-7e5e-41c6-87f6-4e358b0acb6e"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7296ea094e2d4b13917424c13cfba62e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzYtNC0xLTEtMjA5Mg_263a482b-a2ff-40d8-a3c9-19459ac37a63"
      unitRef="usd">21450000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctMS0xLTEtMjA5Mg_257b04eb-cac3-411c-98b1-48df25ebfa36"
      unitRef="usd">191348000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctMi0xLTEtMjA5Mg_4c5091ec-5961-45cd-b384-194037b66ebd"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctMy0xLTEtMjA5Mg_868e4a49-1f03-4fb7-b3bc-0008b5407794"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5217d88f4c3e49a69c131211ccc0f740_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzctNC0xLTEtMjA5Mg_0e31be97-7c27-41f8-8830-567e0f13f51d"
      unitRef="usd">191351000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtMS0xLTEtMTM0MTk_70e09cc7-2a41-4ad1-af5b-a890b1bbdf9a"
      unitRef="usd">405909000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtMi0xLTEtMTM0MTk_8bce10f2-c29b-418e-939d-25dafa12073f"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtMy0xLTEtMTM0MTk_6ada445d-8c4c-4214-a280-695ad85a4cde"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTphZDBiY2YxNGFiNzE0NWY5YjEwMTBlMzFmOTE0YzYzMC90YWJsZXJhbmdlOmFkMGJjZjE0YWI3MTQ1ZjliMTAxMGUzMWY5MTRjNjMwXzgtNC0xLTEtMTM0MTk_e5180391-592e-4f3a-a33f-f11ff5c6ff9b"
      unitRef="usd">405911000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzYwNDczMTM5NTc5NDc_fcfbeee7-bc59-421c-a412-dad1419d6d84">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of the Company&#x2019;s available-for-sale investments on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8495e49fee3844bab82f503ea301cd51_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTo5NzQwODk0Zjk2Zjg0ZDFjOGJjNmI3MzFkNmMyMTRkNy90YWJsZXJhbmdlOjk3NDA4OTRmOTZmODRkMWM4YmM2YjczMWQ2YzIxNGQ3XzEtMS0xLTEtMjIwMw_1d78a610-281e-476a-ace9-e2675ba17841"
      unitRef="usd">221722000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd2a77b480e946b1a98b623504da657e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTo5NzQwODk0Zjk2Zjg0ZDFjOGJjNmI3MzFkNmMyMTRkNy90YWJsZXJhbmdlOjk3NDA4OTRmOTZmODRkMWM4YmM2YjczMWQ2YzIxNGQ3XzItMS0xLTEtMjIwMw_06612074-7deb-44b8-8cd0-721f4f85b96f"
      unitRef="usd">184189000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90YWJsZTo5NzQwODk0Zjk2Zjg0ZDFjOGJjNmI3MzFkNmMyMTRkNy90YWJsZXJhbmdlOjk3NDA4OTRmOTZmODRkMWM4YmM2YjczMWQ2YzIxNGQ3XzQtMS0xLTEtMTM0MjU_f7d2d5ff-dfa6-4f6a-ba3a-1a7349efc134"
      unitRef="usd">405911000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzY1OTcwNjk3Njg4MjU_96cdb105-20ee-4577-b2a1-fb8daefdc69f"
      unitRef="position">16</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzY1OTcwNjk3Njg4NTE_7f26e297-38f3-46e4-969d-3a9b06135d46"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80MjgvZnJhZzpjNGY2MGY1OGZjNzc0ZWFkODMwMGU2ZDFkMTUwMzQ2Yy90ZXh0cmVnaW9uOmM0ZjYwZjU4ZmM3NzRlYWQ4MzAwZTZkMWQxNTAzNDZjXzY1OTcwNjk3Njg4NTE_b67543ca-0d6b-4dbf-88f2-9868db4af48d"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMTA1Ng_371135cf-74f1-422a-b323-ac0351c3af94">Goodwill and Intangible Assets &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of goodwill was $801 thousand as of September&#160;30, 2021. There were no changes to the carrying amount of goodwill during the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2020, the goodwill addition related to the purchase of Vium (see Note 3, &#x201c;Acquisitions&#x201d; for additional details on the acquisition). No goodwill impairment was recorded during the three and nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense was $76 thousand and $228 thousand during the three and nine months ended September 30, 2021, respectively. Amortization expense was $51 thousand during the three and nine months ended September 30, 2020. Amortization expense was included in research and development in the Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The indefinite-lived intangible asset represents the Recursion domain name that the Company purchased. No indefinite-lived intangible asset impairment charges were recorded during the three and nine months ended September 30, 2021. There were no indefinite-lived intangible assets on the Condensed Consolidated Balance Sheet as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfOTI_8bdace92-881e-4651-be13-41becf30f22a"
      unitRef="usd">801000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjA0NzMxMzk1NjE1Mw_24b3d6ed-d9b7-4bdf-bf2c-caa303e27292"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjA0NzMxMzk1NjE1Mw_b99e673f-ca3d-4b8f-864d-58fd3298643f"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_5e5378a7-7eb2-412b-a3bb-10e48ad13dc8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_af02938e-1f78-4977-9cd5-150370653c30"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_de5df63c-bd7c-44b5-9b10-70f5f72ad4a0"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMjc1_f9103484-92fc-4bd9-b099-0913cab48198"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMTA1OQ_3e6f96f5-758d-4812-a278-9284d676ffb8">The following table summarizes intangible assets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfMTA1OQ_5d1c2801-c4d6-4abe-8808-209b26cba0f6">The following table summarizes intangible assets:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi0xLTEtMS0w_57934f42-bede-421e-852f-cc716c88b742"
      unitRef="usd">911000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi0yLTEtMS0w_843edcff-e11c-46ba-ad4c-62199272fdbe"
      unitRef="usd">354000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi0zLTEtMS0w_2cd1ba8d-aa8b-43da-819a-03c523e94e3a"
      unitRef="usd">557000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi01LTEtMS0w_db08ba1f-cd78-4cd0-a18d-10dabf027f9a"
      unitRef="usd">911000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi02LTEtMS0w_bab28fa2-ba36-413e-94f6-aefbc3a9bc19"
      unitRef="usd">127000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMi03LTEtMS0w_a645dbe1-8d8b-4a9a-801a-f83bdfbcac40"
      unitRef="usd">784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy0xLTEtMS0w_543797b0-176e-4fb5-aea4-503b726d2df9"
      unitRef="usd">904000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy0zLTEtMS0w_485df7d4-b1e3-428c-a4f2-24042ae2cdaf"
      unitRef="usd">904000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy01LTEtMS0w_644a38ae-1a4e-4c4d-9bba-cf8760eb132d"
      unitRef="usd">904000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfMy03LTEtMS0w_20c5667a-243e-41b1-bafe-f1bdccf28683"
      unitRef="usd">904000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC0xLTEtMS0w_5ed7894e-d847-42bc-a162-6051b825e494"
      unitRef="usd">1815000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC0yLTEtMS0w_da622b89-f88c-46ea-a905-67f71a36b281"
      unitRef="usd">354000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC0zLTEtMS0w_f45dcab4-6d01-4b21-be15-e0e039fa677b"
      unitRef="usd">1461000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC01LTEtMS0w_be8b4165-fda6-4b5f-972d-a2b876817a0a"
      unitRef="usd">1815000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC02LTEtMS0w_f97f0b4c-5ecf-4892-944a-c981ac17c4e3"
      unitRef="usd">127000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RhYmxlOmY2MWQ2ZGVjOTkzNzQwNmJhZWI2NjA3NTkzN2RhYmQyL3RhYmxlcmFuZ2U6ZjYxZDZkZWM5OTM3NDA2YmFlYjY2MDc1OTM3ZGFiZDJfNC03LTEtMS0w_f17b5c81-c40c-4db8-8722-e647890a925d"
      unitRef="usd">1688000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNDM2_e32a1e9a-ee96-4a4e-8ba5-3c5f291678b8"
      unitRef="usd">76000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNDQz_e2937e53-772f-4c9b-b946-d624d5d647cf"
      unitRef="usd">228000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjU5NzA2OTc2NzkzMA_46a27453-aca9-47fe-82bc-81f449a95219"
      unitRef="usd">51000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjU5NzA2OTc2NzkzMA_dab6ebf8-9b43-4880-90db-126d67fcf836"
      unitRef="usd">51000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfOTYw_9b187234-97fe-4be3-b960-0d5d07b0b345"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfOTYw_d29c8d13-5a4a-4ed2-bf9b-02d9abba42a7"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3f381af37b384806826160a459ac1a6a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80My9mcmFnOjc2OTBlOTQyMzdkMjRjZmRhMzAxZmM2NWQ3OTAzMjNlL3RleHRyZWdpb246NzY5MGU5NDIzN2QyNGNmZGEzMDFmYzY1ZDc5MDMyM2VfNjA0NzMxMzk1NTM4OA_95b3c04e-e793-4cef-801e-8781280a10b8"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDcyMA_6c439e33-8450-45ef-8949-07ffe2d40c1f">Notes Payable &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Midcap Financial &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a new Credit and Security Agreement with Midcap Financial Trust (Midcap) and the other lenders party thereto (the Midcap loan agreement). The Midcap loan agreement provided for a term loan facility that included&#160;an initial tranche of $11.9 million. The Company used $11.2 million of the proceeds from the initial tranche to fully repay a previously outstanding term loan with Pacific Western Bank (Pacific). In July 2021, the Company paid the balance due under the Midcap loan agreement. The total amount paid was $12.7 million. The Company recorded an early extinguishment loss of $996 thousand, which was included in &#x201c;Other expense, net&#x201d; on the Condensed Consolidated Statements of Operations. As of December&#160;31, 2020, the outstanding principal balance under the Midcap loan agreement was $11.9 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company paid fees of approximately $298 thousand in connection with the origination of the Midcap Loan Agreement. These fees were deferred and recorded as a direct deduction from the carrying value of the loan payable and were amortized to interest expense over the expected remaining term of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pacific Western &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, Pacific issued a standby letter of credit of $3.8 million for the benefit of the Company&#x2019;s landlord, securing certain Company obligations relating to tenant improvements. This letter of credit was transferred to J.P. Morgan during the nine months ended September 30, 2021. See Note 15, &#x201c;Fair Value Measurements&#x201d; for additional details. As of December&#160;31, 2020, the outstanding letter of credit was $3.8 million, for which the Company held $4.0 million of restricted cash as collateral.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April of 2020, the Company issued convertible promissory notes for an aggregate principal amount of $6.4 million. Under certain conditions, the principal was convertible into an amount of equity with a fair value that exceeded the amount of the notes&#x2019; principal on the conversion date. This feature of the notes was accounted for separately at fair value as a derivative liability. These notes converted to 1,203,231 shares of Series D Preferred Stock in September 2020. Upon conversion of the notes, the Company recorded the $1.6 million fair value of the derivative liability as equity on the Condensed Consolidated Balance Sheet. Changes in the fair value of the derivative were recorded in &#x201c;Other loss, net&#x201d; in the Condensed Consolidated Statements of Operations and were $161 thousand and $484 thousand during the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Notes Payable for Tenant Improvement Allowance &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company borrowed $992 thousand, which was available as part of the Station 41 lease from its landlord for use on tenant improvements (see Note 8, &#x201c;Commitments and Contingencies&#x201d; for additional details). Under the terms of the lease, the note will be repaid over a 10-year period at an 8% interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes payable consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information regarding the Company&#x2019;s debt principal repayment obligations as of September&#160;30, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt principal payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id524b0a380484a13b1423d25efdc9ce6_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzE4_6296bcb0-d6b1-443d-b95c-7b9afe30add6"
      unitRef="usd">11900000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfDebt
      contextRef="i17e592cb3484481d8f3bdf27f4b46fb5_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDQ0_f2cd659b-7442-458b-9bf4-18a9f82ea5c7"
      unitRef="usd">11200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i61c469b1d47e4489abb014373df5e6a8_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MjM5Ng_d0509485-fc8a-46fe-8b3a-374f332e7977"
      unitRef="usd">12700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i61c469b1d47e4489abb014373df5e6a8_D20210701-20210731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3NDc3NQ_dbe8df62-2ecc-4331-91bc-ec7261c07a1f"
      unitRef="usd">-996000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCredit
      contextRef="i712dde3d59e94dbba069d3ea10c0fb15_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNzM1_c2e56adc-9e36-4b0d-b036-06ed71185362"
      unitRef="usd">11900000</us-gaap:LineOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ice8000a9bf874bc2a077c5140c2c981d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMjU5Mg_c33fc4ec-a8f6-4633-b6ff-78d927dbba22"
      unitRef="usd">298000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibc2eb416e12e4f8a8c617e89412832c8_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMjkyMg_6c4200da-f587-47a2-b5d5-4ea7f02cb30a"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i38cdee8154a14b54b5c1a723df0dbb8b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzIyNg_730edf27-e558-4548-b8be-19543e028acf"
      unitRef="usd">3800000</us-gaap:LineOfCredit>
    <us-gaap:RestrictedCash
      contextRef="i38cdee8154a14b54b5c1a723df0dbb8b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzI1Nw_dc246607-d647-43f2-af1e-51549f745b84"
      unitRef="usd">4000000</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2921e91a9279497f81a20c55ba343d96_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTUzNA_d79ac09b-7f30-43fc-ae68-2a1360b1331b"
      unitRef="usd">6400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1d0e548c03ea4dd7b12d2c5350a4d3a3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTUzNA_ed7557dd-43a6-4019-98ca-3d9d00d8a291"
      unitRef="usd">6400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i691d5ffc27f14a19a75ef556811825c4_D20200901-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTY2MQ_40422235-3213-4566-bff9-45fc83a52be8"
      unitRef="shares">1203231</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4c1a2671a54b4d92ac1029a3f54a040c_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNzE0NjgyNTU4ODkxMQ_481de8ac-ffbc-4bb2-b214-4279dbb8383b"
      unitRef="usd">1600000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i50773bc073fb4acea17c712bc1126a6b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfMzg1MA_9e0621af-128c-49b6-8046-629a1d9a2110"
      unitRef="usd">-161000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="id3ccad45b4c84988b490de168ac87d85_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNjU5NzA2OTc3MTg0NA_bbaae9c3-9cdb-4017-af40-eff870281bfb"
      unitRef="usd">-484000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie16333b91755459cbc141c348c781d1e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDE4MQ_bae1e94a-3a2c-4e2a-b60a-2e8f18163a3f"
      unitRef="usd">992000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie16333b91755459cbc141c348c781d1e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDQxOA_8daf122a-8659-4899-b15e-8ffa3cf468c0">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b6e8d11e94a4bc8a66fa0b30b88119e_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDQzOQ_6b00266e-713b-4492-91a2-6b7c29ea0b99"
      unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDcyMQ_7ec897ad-1496-4d23-933b-fcdf2851fbff">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notes payable consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebtCurrent
      contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMi0xLTEtMS0w_3c0aecbb-a47a-4c4f-8c1f-d5fd5869e0ee"
      unitRef="usd">88000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMi0yLTEtMS0w_cc6805a5-3c13-4542-8877-61f2bf35d428"
      unitRef="usd">1073000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMy0xLTEtMS0w_e5ee7e31-e9d5-4e19-b618-c9728fa35356"
      unitRef="usd">656000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfMy0yLTEtMS0w_d07e3c33-c53d-4287-a5ff-a6f08da3d0db"
      unitRef="usd">11615000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNC0xLTEtMS0w_9e0ef981-2c93-4ffb-a28c-fe6fdacdafd4"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNC0yLTEtMS0w_8755044a-5f1b-4066-858d-7b45141eb3a7"
      unitRef="usd">201000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNS0xLTEtMS0w_376790e6-96d2-4248-9267-8b7e523773b1"
      unitRef="usd">744000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i52b9725b29684ee8a41390d35b177c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOjA5YWEyYmRkYjQ0MDQ1YWI4N2VjNzk1OTc3YzllNTIwL3RhYmxlcmFuZ2U6MDlhYTJiZGRiNDQwNDVhYjg3ZWM3OTU5NzdjOWU1MjBfNS0yLTEtMS0w_901216fe-3582-4301-bf23-d87e419be1b3"
      unitRef="usd">12487000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RleHRyZWdpb246NWZlYTI0ZGM4YzRiNGM2NzliYzEwMmIwMTU3ODZjMjhfNDcyMg_d9a4447c-44f9-4079-8aef-930f06cc32fe">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information regarding the Company&#x2019;s debt principal repayment obligations as of September&#160;30, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt principal payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfMS0xLTEtMS0w_14bdf124-4ef1-4cbf-adc7-9c9d8a54afa9"
      unitRef="usd">21000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfMi0xLTEtMS0w_e148cecc-adc5-416c-9c66-a0b227119685"
      unitRef="usd">90000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfMy0xLTEtMS0w_99b6ccfc-21a9-465a-a3f1-76db78bb416a"
      unitRef="usd">97000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNC0xLTEtMS0w_bb4619e2-7917-48c6-9ff2-24720d5b2222"
      unitRef="usd">105000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNS0xLTEtMS0w_5ff295fc-5433-4ec0-962d-a1d615c367ff"
      unitRef="usd">114000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <rxrx:LongTermDebtMaturityAfterYearFour
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNi0xLTEtMS0w_918ae752-8987-46e4-bf6a-9952a2c0e86a"
      unitRef="usd">317000</rxrx:LongTermDebtMaturityAfterYearFour>
    <us-gaap:LongTermDebt
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80Ni9mcmFnOjVmZWEyNGRjOGM0YjRjNjc5YmMxMDJiMDE1Nzg2YzI4L3RhYmxlOmZlYzg4OWE4NmJiOTQyN2M5NzBmYjllOWYzZjcyMGFhL3RhYmxlcmFuZ2U6ZmVjODg5YTg2YmI5NDI3Yzk3MGZiOWU5ZjNmNzIwYWFfNy0xLTEtMS0w_239f85da-62ac-428d-9523-6d48676b794a"
      unitRef="usd">744000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTM5MQ_7ff638fc-e031-4005-b075-8bc3381e62bc">Commitments and Contingencies &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various long-term real estate leases primarily related to office, research and development (R&amp;amp;D) and operating activities. For the three and nine months ended September 30, 2021, total rent &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expense was $1.7 million and $4.4 million, respectively. For the three and nine months ended September 30, 2020, total rent expense was $1.1 million and $3.2 million, respectively. The leases described below are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Komas Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2016, the Company entered into a new facilities lease, with the right of use and payments beginning in January 2017. The term of the lease is 7 years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. This lease included an allowance for tenant improvements. Tenant improvements were recorded as property and equipment and are being depreciated over the term of the lease. In conjunction with the allowance for tenant improvements, the Company recorded a lease incentive obligation of $847 thousand which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $282 thousand. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Station 41 Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company entered into a new facilities lease, with the right of use beginning in December 2017 and payments beginning in June 2018. The term of the lease is 10 years, with one five-year renewal option. This lease includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. This lease included an allowance for tenant improvements of $4.0&#160;million, the full amount of which was drawn in 2017. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. The Company recorded a leasehold obligation for tenant improvements, which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $2.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company elected to draw an additional tenant improvement loan of $992&#160;thousand available under the Station 41 lease. This loan is incorporated into and acts to increase the base rent over the remaining life of the lease. The increase in rent includes a charge for interest, which accrues on the principal amount outstanding at a rate equal to 8%. The Company accounts for this additional tenant improvement loan as a note payable on the Condensed Consolidated Balance Sheets with the current portion included in the Current Portion of Notes Payable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company amended the Station 41 lease to include additional space in the conjoining unit with the right to use the new space beginning in June 2020 for an additional seven years. This amendment for the extra space includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Milpitas Lease&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company entered into a new facilities lease, with the right of use and payments beginning in August 2019. The term of the lease is 9 years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Station 56 Lease&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a new facilities lease with 91,478 square feet adjacent to the Station 41 lease. The right of use began in August 2021 and the term of the lease is approximately 11 years with a five-year renewal option. The lease includes provisions for escalating rent payments, with total minimum payments of $32.0 million. Rent expense is recognized straight-line over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease includes a tenant improvement allowance of up to approximately $10.1 million. As of September&#160;30, 2021, $2.2 million of the tenant improvement allowance has been utilized. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. The Company recorded a leasehold obligation for the tenant improvements, which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $2.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Future Minimum Lease Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum commitments as of September&#160;30, 2021 under the Company&#x2019;s lease agreements are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors&#160;for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#x2019;s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company&#x2019;s exposure and enable it to recover a portion of any amounts it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of September&#160;30, 2021 and December&#160;31, 2020, as no amounts in excess of insurance coverage are probable or estimable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Agreements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters &lt;/span&gt;&lt;/div&gt;The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#x2019;s future financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjYy_aaa76984-4e8d-4b09-8519-9514785e3e31"
      unitRef="usd">1700000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjY5_243121be-4b47-4543-b6c8-90d979238f2d"
      unitRef="usd">4400000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMzMy_1164baee-7c20-43d8-8153-a521a1b1a654"
      unitRef="usd">1100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMzM5_95c874fb-6b01-4639-a910-f5a347f866a5"
      unitRef="usd">3200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i91f13a3891e14799978936761e6b66eb_I20160831"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTk4_f2f31a94-4430-41b9-a647-c9d835b0f88d">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:IncentiveFromLessor
      contextRef="i91f13a3891e14799978936761e6b66eb_I20160831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTAyNw_6ef845fa-98c5-42bc-965a-c9b50f95fa15"
      unitRef="usd">847000</us-gaap:IncentiveFromLessor>
    <us-gaap:LeaseIncentivePayableCurrentAndNoncurrent
      contextRef="i97ab0048367c48bcbdd713b807fbd5e6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTE3OQ_71a29ce8-9842-4b63-ab82-fc8bf619d320"
      unitRef="usd">282000</us-gaap:LeaseIncentivePayableCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if53c3048ea9f49fdada4b25a94aa8898_I20170831"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTM1Mg_245957d1-f073-4975-9cc7-f652b1d7d3da">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <rxrx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="ie9dfd0688b804a938bbb48c0edbe5056_D20170801-20170831"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTM2MQ_ebcdc7c6-4d9b-4507-b77b-183f568f5e13"
      unitRef="extensionperiod">1</rxrx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if53c3048ea9f49fdada4b25a94aa8898_I20170831"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTM5Mw_301c643b-8df1-4919-b077-5bba9f752516">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:IncentiveFromLessor
      contextRef="i532e90ec1ce24d4395f470300c0303ad_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTYwNQ_8a0b9b87-1902-4bc1-97c7-b2e9521f47e5"
      unitRef="usd">4000000</us-gaap:IncentiveFromLessor>
    <us-gaap:LeaseIncentivePayableCurrentAndNoncurrent
      contextRef="i570b1109d5a14f2cbffa015a78fae6ae_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjAyOA_c0c919e5-211f-4774-a1c5-6a5590cf3065"
      unitRef="usd">2500000</us-gaap:LeaseIncentivePayableCurrentAndNoncurrent>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie16333b91755459cbc141c348c781d1e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjExMA_bae1e94a-3a2c-4e2a-b60a-2e8f18163a3f"
      unitRef="usd">992000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b6e8d11e94a4bc8a66fa0b30b88119e_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjM3Nw_6b00266e-713b-4492-91a2-6b7c29ea0b99"
      unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib7019fd2b10448cf9b45ac7687f8df45_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMjc1NQ_960fbf5a-4a33-4069-b680-ec0388c812cf">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ifff20fde529149e6b553db40f2b4c2c5_I20190831"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMzM4Mw_45f4f86a-4773-4945-8cb6-106895827f66">P9Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <rxrx:LesseeOperatingLeaseSizeOfLeasedAsset
      contextRef="ia41f6975e5dd422096f973c5f9c36e59_D20210101-20210131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjA0NzMxMzk1OTg3NQ_24601ba7-d1c4-4df7-a121-8b1987c461f0"
      unitRef="sqft">91478</rxrx:LesseeOperatingLeaseSizeOfLeasedAsset>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i21570e1162e44757bb2fe76c1778ed38_I20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjA0NzMxMzk1OTg0OQ_2aae3017-edf5-4e70-bdb3-c5ad9c1711a9">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i54a01ea1f999425489bb8e0b81240782_I20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjA0NzMxMzk1OTg2Ng_eed6e627-8277-4baf-a2d7-1d850bf2404e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i21570e1162e44757bb2fe76c1778ed38_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfMTA5OTUxMTYzMzYzOA_5e80dfbb-ad6d-4f68-9353-1dd68737866f"
      unitRef="usd">32000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <rxrx:LesseeOperatingLeaseTenantImprovementAllowance
      contextRef="i21570e1162e44757bb2fe76c1778ed38_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjU5NzA2OTc3NDQ4Mg_33748d29-1304-42df-a38c-bf19a9cc8daa"
      unitRef="usd">10100000</rxrx:LesseeOperatingLeaseTenantImprovementAllowance>
    <us-gaap:IncentiveFromLessor
      contextRef="i44bce2b5c9264b77a056d1235fca4c45_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjU5NzA2OTc3Mzc4OA_b707bbf3-e727-4007-86c3-be35a28b47af"
      unitRef="usd">2200000</us-gaap:IncentiveFromLessor>
    <us-gaap:LeaseIncentivePayableCurrentAndNoncurrent
      contextRef="i44bce2b5c9264b77a056d1235fca4c45_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNjU5NzA2OTc3NDQ5MA_c8cc79c1-a569-4fc5-a2bf-3de941654958"
      unitRef="usd">2100000</us-gaap:LeaseIncentivePayableCurrentAndNoncurrent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RleHRyZWdpb246ZThlZTY0OTNjMjc5NGE0ZDk1NjI5NzI4ODcyOWE1YTlfNTM5NQ_9178bbc6-6c58-456f-b17b-b5b2f4a7ab73">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum commitments as of September&#160;30, 2021 under the Company&#x2019;s lease agreements are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Minimum Payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfMS0xLTEtMS0w_af33609c-9de6-434d-9c14-47d730d10b31"
      unitRef="usd">977000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfMi0xLTEtMS0w_3d8c8812-883d-4292-af83-8acb53e86de8"
      unitRef="usd">3977000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfMy0xLTEtMS0w_4187d10d-7c80-4405-bf45-2aedb9e5ed86"
      unitRef="usd">7053000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNC0xLTEtMS0w_c175efd6-e824-4cce-9833-049d73365c7d"
      unitRef="usd">7325000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNS0xLTEtMS0w_fbe23264-7946-480d-9fdf-eaf1a61c0910"
      unitRef="usd">7513000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNi0xLTEtMS0w_bc553583-563e-433d-aefb-f42a723207d9"
      unitRef="usd">34187000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV80OS9mcmFnOmU4ZWU2NDkzYzI3OTRhNGQ5NTYyOTcyODg3MjlhNWE5L3RhYmxlOmUyNWIyOTdhMmRjYjQwOGJhMzk1MDFhYzllYzQ1NjRmL3RhYmxlcmFuZ2U6ZTI1YjI5N2EyZGNiNDA4YmEzOTUwMWFjOWVjNDU2NGZfNy0xLTEtMS0w_f5b78c46-f1b9-4eb3-8604-445401f5db38"
      unitRef="usd">61032000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <rxrx:TemporaryEquityTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMTE1Mg_1924cf5b-1fe4-4845-b6ad-2b8a2d520af1">Convertible Preferred Stock &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has issued preferred stock as part of various financing events. In April 2021, all outstanding shares of convertible preferred stock converted into 115,598,018 shares of Class A common stock as part of the IPO (see Note 10, &#x201c;Common Stock&#x201d; for additional details on the IPO). There was no convertible preferred stock outstanding as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No convertible preferred stock was issued during the three and nine months ended September 30, 2021. The Company issued 35,349,630 shares of Series D convertible preferred stock for an aggregate purchase price of $235.2&#160;million ($6.70 per purchased share and $5.37 per converted share) during the three and nine months ended September 30, 2020. As part of the Series D issuance, outstanding convertible notes were converted into Series D shares. As of September&#160;30, 2020, there were no cumulative dividends owed or in arrears on the preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible preferred stock consisted of the following as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands except share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Issued&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferences &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&#160;Issuable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Upon&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Conversion &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,078,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,965,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,965,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,497,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,471,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,471,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,956,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,776,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,286,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,926,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,898,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,898,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,434,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,088,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,598,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Balance Sheet Classification &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s convertible preferred stock was classified outside of stockholders&#x2019; equity (deficit) on the Condensed Consolidated Balance Sheets because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event.</rxrx:TemporaryEquityTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i6b8e1278f8d04c5bb2a24c4705c97839_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMTk1_df104106-8ac6-4463-88e7-8480d868b00d"
      unitRef="shares">115598018</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMzIy_3f774fc4-2b4b-41af-a4a4-2c8393f7e37d"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i254f679cd4904fd2ae4f87879e686402_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMxMw_33e8247f-bcd1-44d5-8c67-a9a94d676621"
      unitRef="shares">35349630</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMxMw_eee16585-7cdd-444b-ae07-febea8fe928a"
      unitRef="shares">35349630</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i254f679cd4904fd2ae4f87879e686402_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMwMA_1df1e336-9a03-4568-9c1d-37eca6432357"
      unitRef="usd">235200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODMwMA_876673aa-ed47-4354-ab99-b88bffc2b20e"
      unitRef="usd">235200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iea9aa8f9e434498bb2d91529de11b85c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODM5Ng_031c87c6-65cd-4760-898c-6c435f1ed01c"
      unitRef="usdPerShare">6.70</us-gaap:SaleOfStockPricePerShare>
    <rxrx:SaleOfStockConvertedPricePerShare
      contextRef="iea9aa8f9e434498bb2d91529de11b85c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfNjU5NzA2OTc2ODQwOA_50a372cc-7995-4111-be79-6dfc708d7740"
      unitRef="usdPerShare">5.37</rxrx:SaleOfStockConvertedPricePerShare>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RleHRyZWdpb246YzIxZDFiMDAxNmM4NDUxZDk4ZjVjN2Y3OTAxOGZiODdfMTE1Mw_755fbaef-9fc5-4c7e-9935-ca0c85a04a09">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible preferred stock consisted of the following as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands except share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Issued&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Preferences &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&#160;Issuable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Upon&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Conversion &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,078,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,965,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,965,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,497,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,471,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,471,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,956,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,776,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,286,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,926,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,898,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,898,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,434,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,088,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,598,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0xLTEtMS0w_8ada96db-b9c2-4533-8b39-1a56ea64227b"
      unitRef="shares">30078402</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0yLTEtMS0w_38c37cd7-0fcb-4ba3-b251-2b4ff2c931d1"
      unitRef="shares">29965754</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0yLTEtMS0w_48430d39-6791-4c87-802b-e0880f0bd749"
      unitRef="shares">29965754</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi0zLTEtMS0w_f996029e-6bfd-4d2d-ae36-664f3dd3d74a"
      unitRef="usd">21281000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi00LTEtMS0w_839705ca-88e5-41c8-879d-894447da1426"
      unitRef="usd">21281000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="ie140edce6ab14151a2b4993eaf954127_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMi01LTEtMS0w_b4b5cb5b-d1b2-40de-bd98-9b06fac1e3f7"
      unitRef="shares">29965754</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0xLTEtMS0w_ba5e9f2e-0da3-4df8-9561-5b247735d991"
      unitRef="shares">4975521</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0yLTEtMS0w_17a03e20-b1d7-4594-902f-acb2362a028b"
      unitRef="shares">4975520</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0yLTEtMS0w_d7c1d9bf-aa80-4d0b-aa8b-cef98417ad96"
      unitRef="shares">4975520</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy0zLTEtMS0w_eb68d182-5da8-40cc-a11d-d3d2333e871e"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy00LTEtMS0w_80a8cf3f-8e00-4d93-88d8-6cf4b2b3dabc"
      unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="id0cdbb7ca602427aa9d10c9705dd6f27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfMy01LTEtMS0w_ede275a5-2fc0-455f-b709-06560314dccb"
      unitRef="shares">4975520</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i54664e6f89084434b268927edece521c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0xLTEtMS0w_cbf7c929-0744-4a5c-b4a3-feb2fbbd507b"
      unitRef="shares">21497667</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i54664e6f89084434b268927edece521c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0yLTEtMS0w_53f43264-b1bb-41dd-95c0-55215646131b"
      unitRef="shares">21471898</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i54664e6f89084434b268927edece521c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0yLTEtMS0w_7e7131fa-e22a-47f0-8e92-08ff0cead99c"
      unitRef="shares">21471898</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i54664e6f89084434b268927edece521c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC0zLTEtMS0w_5ec1f2a2-9313-45b3-8eba-76157572eb5d"
      unitRef="usd">59913000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i54664e6f89084434b268927edece521c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC00LTEtMS0w_d8818324-9d7b-45aa-bf28-6c5a000948d7"
      unitRef="usd">60000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="i54664e6f89084434b268927edece521c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNC01LTEtMS0w_b1664213-942a-44e5-a8a9-ff6c0be3f742"
      unitRef="shares">21471898</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0xLTEtMS0w_7e501915-df5a-4b5e-b2a4-4f0bb74315af"
      unitRef="shares">18956354</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0yLTEtMS0w_57ed85a0-bad5-4c1f-9880-f7b4784f56c4"
      unitRef="shares">18776345</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0yLTEtMS0w_f122307e-0d49-414c-8a39-6a150abf0c1f"
      unitRef="shares">18776345</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS0zLTEtMS0w_ea0f1f61-9c5a-4920-a74f-8cbb8df2ad0e"
      unitRef="usd">119915000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS00LTEtMS0w_43806c8c-d704-469a-8c03-c348d2d5b81e"
      unitRef="usd">122058000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="ic205e7e2b2b840e2bc87f376d3065cf6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNS01LTEtMS0w_4ea806f3-9b95-48aa-b899-9dc067bb9e44"
      unitRef="shares">22286298</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0xLTEtMS0w_fc3e0ef7-03ab-49dc-8ef3-9e4370be21d8"
      unitRef="shares">45926769</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0yLTEtMS0w_064ed59a-ac45-4c49-8529-6fc1539fa10c"
      unitRef="shares">36898548</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0yLTEtMS0w_fbe45b32-dbaa-4124-80f6-69afe1c3c3ef"
      unitRef="shares">36898548</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi0zLTEtMS0w_885a0097-2649-4d08-9093-10f8071b1e63"
      unitRef="usd">247203000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi00LTEtMS0w_0b43589a-4018-4b55-9f43-02e05914f21e"
      unitRef="usd">247511000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="i6830fb8120554381b4ac31b7bc4f1b20_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNi01LTEtMS0w_aa44ba01-85ee-487f-9145-2ffdfe3984fa"
      unitRef="shares">36898548</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0xLTEtMS0w_18fdbb6d-0c00-4961-b535-fd25cd30b5c1"
      unitRef="shares">121434713</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0yLTEtMS0w_4ed48cb6-df98-4e6e-bf5a-73cd174f5d81"
      unitRef="shares">112088065</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0yLTEtMS0w_cfad05b6-d456-4ccb-ba45-cd413ef9f3b1"
      unitRef="shares">112088065</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy0zLTEtMS0w_179ab814-4919-4fea-bc33-fd446c1f7a60"
      unitRef="usd">448312000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy00LTEtMS0w_34efdc31-d8af-4647-b969-93617504efdb"
      unitRef="usd">450850000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81Mi9mcmFnOmMyMWQxYjAwMTZjODQ1MWQ5OGY1YzdmNzkwMThmYjg3L3RhYmxlOmEzN2U4NGIwMWI1YjRlZjM5ZmJjZjQwMjI1Mzk3NDJmL3RhYmxlcmFuZ2U6YTM3ZTg0YjAxYjViNGVmMzlmYmNmNDAyMjUzOTc0MmZfNy01LTEtMS0w_a1384664-bca1-4670-a6d7-8ac3825ea767"
      unitRef="shares">115598018</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfMjk4Mw_6be7c4a7-b931-4f24-afc7-e799da8d5cda">Common Stock &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Class A common stock entitles the holder to one vote per share and each share of Class B common stock entitles the holder to 10 votes per share on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#x2019;s board of directors. As of September&#160;30, 2021 and December&#160;31, 2020, no dividends had been declared. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;20, 2021, the Company closed its IPO and issued 27,878,787 shares of its Class A common stock at a price of $18.00 per share for net proceeds of $462.4 million, after deducting underwriting discounts and commissions of $35.1 million and other offering costs of $4.3 million. In connection with the IPO, all shares of convertible preferred stock converted into 115,598,018 shares of Class A common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Board of Directors approved a 1.5-for-1 forward stock split of the Company&#x2019;s common and convertible preferred stock. Each shareholder of record on April&#160;9, 2021 received 1.5 shares for each then-held share. The split proportionally increased the authorized shares and did not change the par values of the Company&#x2019;s stock. The split affected all stockholders uniformly and did not affect any stockholder's ownership percentage of the Company's shares of common stock. All shares and per share amounts presented within these Condensed Consolidated Financial Statements were adjusted to reflect the forward stock split for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Class A and B Common Shares Authorization&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company&#x2019;s Board of Directors authorized two classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to 10 votes per share and is convertible at any time into one share of Class A common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Class B common stock is held by Christopher Gibson, Ph.D., our Chief Executive Officer (CEO), or his affiliate. As of September&#160;30, 2021, Dr. Gibson and his affiliate held outstanding shares of Class B common stock representing approximately 37% of the voting power of the Company&#x2019;s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the equity awards held by &lt;/span&gt;&lt;/div&gt;Dr. Gibson had been fully vested and exercised and exchanged for shares of Class B common stock as of September&#160;30, 2021, Dr. Gibson and his affiliate would hold approximately 41% of the voting power of the Company&#x2019;s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the board of directors; the adoption of amendments to the Company&#x2019;s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company&#x2019;s assets, or other major corporate transaction.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <rxrx:CommonStockVotePerShare
      contextRef="i7ecc7deafb5e4f9c982501dc4510e260_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfODY_5ba13917-0567-4e91-b921-e9354fce811c"
      unitRef="vote">1</rxrx:CommonStockVotePerShare>
    <rxrx:CommonStockVotePerShare
      contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfMTY2_4a1f6eea-061e-4532-8d70-418abaa37ec4"
      unitRef="vote">10</rxrx:CommonStockVotePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNDg0_2ff370cb-51a4-4005-b94b-8a359c1613ea"
      unitRef="shares">27878787</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ice0bed1c8a884eb9b91557f3c6c8fbc6_I20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNTI4_af750a17-0d66-4976-9fa4-f0f41901244b"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNTYx_f2f7a961-c2aa-4488-9a5f-77eb313f64c2"
      unitRef="usd">462400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjIz_cd24e8c3-c5ce-4e4e-a47d-287239d7d704"
      unitRef="usd">35100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <rxrx:PaymentsOfStockIssuanceExpenses
      contextRef="i6f346aeecf9b49c8bbe537c86235e1cf_D20210420-20210420"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjU0_90d120d4-6353-4406-9083-0a509dadf74f"
      unitRef="usd">4300000</rxrx:PaymentsOfStockIssuanceExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i6b8e1278f8d04c5bb2a24c4705c97839_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNzY5_df104106-8ac6-4463-88e7-8480d868b00d"
      unitRef="shares">115598018</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i778df7726a034719acdc84318d53c893_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfODU5_ce1353bd-ffd7-493b-9898-7f95a9ac4197"
      unitRef="number">1.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ida225ec4cb3e47f0b2b397b7d9fc8ea1_D20210409-20210409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfOTg3_e882bb92-f005-485b-bfe9-9622a4660f22"
      unitRef="number">1.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <rxrx:CommonStockVotePerShare
      contextRef="if22f0a3e4f5d4143bce97be2c742375b_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfMTg0Mg_4a1f6eea-061e-4532-8d70-418abaa37ec4"
      unitRef="vote">10</rxrx:CommonStockVotePerShare>
    <rxrx:AffiliatedHoldersOwnershipPercentage
      contextRef="ifb46e3752d19457fb9b591d8ac77a4af_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjU5NzA2OTc2OTY4MA_e91895eb-e7da-42e0-87d7-61b6be22455d"
      unitRef="number">0.37</rxrx:AffiliatedHoldersOwnershipPercentage>
    <rxrx:AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest
      contextRef="ifb46e3752d19457fb9b591d8ac77a4af_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81NS9mcmFnOjA1ZjViNGU4ZjNhMDQ1YTBhOGNjNmQ4ZjVmMjgzN2NmL3RleHRyZWdpb246MDVmNWI0ZThmM2EwNDVhMGE4Y2M2ZDhmNWYyODM3Y2ZfNjU5NzA2OTc2OTY4Nw_f96d4266-9920-4abe-83e1-413d1737bdcc"
      unitRef="number">0.41</rxrx:AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMzExNQ_66e63931-f6b2-49d8-aa55-2e716ae006f4">Collaborative Development Contracts &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the Company entered into a Research Collaboration and Option Agreement (the Bayer Agreement) with Bayer AG (Bayer) for a five-year term pursuant to which the Company and Bayer may initiate approximately 10 research projects related to fibrosis across multiple organ systems, including the lung, liver and heart. Under the agreement, the Company contributed compounds from our proprietary library and Bayer contributed compounds from its proprietary library and will contribute scientific expertise throughout the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under the terms of the agreement, the Company received a non-refundable upfront payment of $30.0 million, which was recorded as unearned revenue on the Condensed Consolidated Balance Sheet. The Company determined that it has one performance obligation under the agreement, which is to perform research and development services for Bayer. Recursion determined the transaction price to be the $30.0 million upfront payment received and allocated the amount to the single performance obligation. The Company is recognizing the revenue over time using a cost-based input method, based on labor costs incurred to perform the research and development services. This method of recognizing revenue requires the Company to make estimates of the total costs to provide the services required under the performance obligation. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the three and nine months ended September 30, 2021, the Company recognized $2.5 million and $7.5 million, respectively, of revenue resulting from the collaboration. There was $10.0 million and $9.2 million of current and non-current unearned revenue, respectively, remaining as of September&#160;30, 2021. The allocation of unearned revenue between current and non-current is based on Recursion&#x2019;s estimates of when the Company expects to incur the related costs. &lt;/span&gt;&lt;/div&gt;Under each research project, the Company will work with Bayer to identify potential candidates for development. Under the agreement, Bayer has the first option for licenses to potential candidates. Each such license could potentially result in option exercise fees and development and commercial milestone payments payable to the Company, with an aggregate value of up to approximately $100.0 million (for an option on a lead series) or up to approximately $120.0 million (for an option on a development candidate), as well as tiered royalties for each such license, ranging from low- to mid-single digit percentages of sales, depending on commercial success.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rxrx:CollaborativeAgreementTerm
      contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMzExNg_dab4ee17-edcd-4c9d-8bbd-6962e754f094">P5Y</rxrx:CollaborativeAgreementTerm>
    <rxrx:CollaborativeAgreementNumberOfProjectsThatMayBeInitiated
      contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMzExNw_e5cd2db2-63d2-448f-ae36-8c4d2480120d"
      unitRef="project">10</rxrx:CollaborativeAgreementNumberOfProjectsThatMayBeInitiated>
    <rxrx:CollaborativeAgreementNonRefundableUpfrontPaymentReceived
      contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfNzEw_ce01c25f-f8d9-426d-8c59-33eabbbb6bf6"
      unitRef="usd">30000000</rxrx:CollaborativeAgreementNonRefundableUpfrontPaymentReceived>
    <rxrx:CollaborativeAgreementNonRefundableUpfrontPaymentReceived
      contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfOTk5_ce01c25f-f8d9-426d-8c59-33eabbbb6bf6"
      unitRef="usd">30000000</rxrx:CollaborativeAgreementNonRefundableUpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i579b43fe01ce4c56a9134274deed89c9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTU5NA_c9f564b5-09f3-4dd6-986f-18bcb69d221d"
      unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i87ec7c8bf2994d2e9b1fab9c0703332a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTYwMQ_1cdb9a61-b208-481b-ae02-93daed40eb53"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i236ba6571e724a009ebcfe23594fc46f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTY3NA_38a68075-be77-4c4c-8991-89ce61345abc"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i236ba6571e724a009ebcfe23594fc46f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMTY4MQ_30f23f33-0733-45b0-8489-f19b0ab5c846"
      unitRef="usd">9200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <rxrx:CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries
      contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMjMwOA_915d42a7-b6ab-4de4-9c14-df07c8a3610e"
      unitRef="usd">100000000</rxrx:CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries>
    <rxrx:CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate
      contextRef="i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV81OC9mcmFnOjc0MTQ2YzY5YjI4NzQ2N2RhMTJhMjVhMzA5ZmM4ZjM3L3RleHRyZWdpb246NzQxNDZjNjliMjg3NDY3ZGExMmEyNWEzMDlmYzhmMzdfMjM2Nw_44aa38cc-26f7-40b0-b86c-827db41c279d"
      unitRef="usd">120000000</rxrx:CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4NQ_421b01df-d05b-491e-8712-3779edcb0bda">Stock-Based Compensation &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). Under the 2021 Plan, 16,186,000 shares of Class A common stock were reserved. Additionally, shares were reserved for all outstanding awards under the previous 2016 Plan. The Company may grant stock options, restricted stock units (RSUs), stock appreciation rights, restricted stock awards and other forms of stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, 15,580,505 shares of Class A common stock were available for grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of stock-based compensation expense for stock options and RSUs for employees and non-employees within the Condensed Consolidated Statements of Operations: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options generally vest over four years and expire no later than 10 years from the date of grant. Stock option activity during the nine months ended September 30, 2021 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands except share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&#160;Contractual Life (In Years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,937,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,840,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,203,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,711,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,963,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the nine months ended September 30, 2021 and 2020 were $6.41 and $1.49, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2021, the Company granted 150,000 shares of stock options with a performance and service condition that had a fair value of $358 thousand. The grant was fully expensed during the three months ended June 30, 2021 as the performance and service conditions were met.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March 2020, the Company granted 1,500,000 shares of stock options with performance, market and service conditions. At grant date, the Company estimated that the fair value of the options was approximately $2.0 million. For the three and nine months ended September 30, 2021, $41 thousand and $1.6 million of expense was recorded, respectively, as several of the conditions were met during the three months ended June 30, 2021. For the three and nine months ended September 30, 2020, no expense was recorded as the performance conditions were not considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of September&#160;30, 2021, $27.9 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next three years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, Recursion redesigned certain aspects of its long-term incentive program. As a result, equity awards granted to employees since the redesign generally consist of a combination of stock options and RSUs. RSUs awarded to employees pursuant to the 2021 Plan generally vest over four years. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion&#x2019;s common stock on the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes Recursion&#x2019;s RSU activity during the nine months ended September 30, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,723&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,528)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(673)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,522&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of September&#160;30, 2021, $3.6 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next three years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Share Purchase Plan (ESPP)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Board of Directors and stockholders of the Company adopted the 2021 Employee Stock Purchase Plan (the 2021 ESPP). Under the 2021 ESPP, 3,238,000 shares of Class A common stock were reserved. The 2021 ESPP has consecutive six-month offering periods. The offering periods are scheduled to start on the first trading day on or after May 20 and November 20 of each year, except the first offering period, which commenced on the Plan Effectiveness Date and will end on the first trading day on or after November 20, 2021. The second offering period will commence on the first trading day on or after November 20, 2021. The per share purchase price will be 85% of the lower of the fair market value on (1) the first trading day of the offering period or (2) the exercise date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the ESPP grants is measured at grant date. The fair value is determined considering the purchase discount and the fair value of the look-back feature. Black-Scholes pricing models are used to calculate the fair value of the look-back feature. The weighted-average assumptions used in the Black-Scholes models were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, no shares were issued under the 2021 ESPP. For the three and nine months ended September 30, 2021, Recursion recognized expense of $233 thousand and $450 thousand, respectively. As of September&#160;30, 2021, $136 thousand of unrecognized compensation cost related to the 2021 ESPP is expected to be recognized as expense over approximately the next two months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Pacific loan agreement (see Note&#160;7, &#x201c;Notes Payable&#x201d; for additional details), the Company issued to Pacific fully vested warrants to purchase 84,486 shares of Series A Preferred Stock (Series A warrants) at a purchase price of $0.71 per share. In May 2017, the Company drew on additional borrowing capacity under the Pacific loan agreement, which required the Company to issue additional fully vested warrants for 28,161 shares of Series A Preferred Stock at a purchase price of $0.71 per share. These Series A warrants were exercised in April 2021. As of December&#160;31, 2020, their fair value was $77 thousand.    &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company drew on additional borrowing capacity under an amended agreement. This required the Company to issue fully vested warrants to purchase 25,762 shares of Series B Preferred Stock (Series B warrants) at a purchase price of $2.79 per share. These Series B warrants were exercised in April 2021. As of December&#160;31, 2020, their fair value was $48 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the Company issued warrants to purchase 180,000 shares of Series&#160;C Preferred Stock (Series C warrants) at a purchase price of $6.51 per share as part of a services agreement. The warrants vest ratably over 18 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;months. The Series C warrants remained outstanding and were fully vested and exercisable as of September&#160;30, 2021. The grant date fair value was $4.10 per share. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The FASB has issued accounting guidance on the classification of freestanding warrants and other similar instruments for shares that are redeemable (either puttable or mandatorily redeemable). The guidance requires liability classification for certain warrants that are exercisable into convertible preferred stock. The initial fair values of the Series A and B warrants were recorded as debt issuance costs, which resulted in a reduction in the carrying value of the debt and subsequent accretion. The Company remeasured the Series A and B warrants on each Condensed Consolidated Balance Sheet date. The change in valuation was recorded in the Condensed Consolidated Statements of Operations in &#x201c;Other loss, net.&#x201d; The liability was recorded to equity upon the exercise of the Series A and B warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Series C warrants&#x2019; compensation expense was recorded in general and administrative expense ratably over the requisite service period based on the award&#x2019;s fair value at the date of grant. These warrants were classified as equity as they were issued to non-employees for services and the convertible preferred stock was not redeemable, except in the event of a deemed liquidation event, which was not considered probable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following is a summary of the changes in the Company&#x2019;s Series A and B warrant liability balance during the nine months ended September 30, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net increase in fair value of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in fair value of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recorded in equity upon exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i911deb0a783d45d48883d1a7b215ba7f_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3NzcxOA_a7c329eb-f531-417c-8fc7-cb05634300ad"
      unitRef="shares">16186000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic110f6aa94f44a0ea151f7f1d1355795_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3ODAxMQ_0c7096e7-67ec-42b7-b7a5-5c939c40e11d"
      unitRef="shares">15580505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4MQ_03788d12-b6f8-472b-ab25-460a86cc9dcc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the classification of stock-based compensation expense for stock options and RSUs for employees and non-employees within the Condensed Consolidated Statements of Operations: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ac5bbd776f34c14905561c10878b1d4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi0xLTEtMS0w_bfd68ee1-d2f1-436f-9833-9c5190e709d1"
      unitRef="usd">1305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6eea4fe55d0492db79350755e48b8b9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi0yLTEtMS0w_f2d0dfd1-4636-4604-827c-e9c0eda81113"
      unitRef="usd">312000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i005b6369f9a04da2b37d8abb0937ccd6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi00LTEtMS0w_1b277f53-32a9-4df4-b3f9-0d43348ea892"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c86ed481ac0466f814feccb1b0dfc44_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMi01LTEtMS0w_4a27218e-d924-4ff2-bc08-c419e3b61d6c"
      unitRef="usd">1288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac787d8519de4fb7b4312d4d537327cd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy0xLTEtMS0w_d47e15e5-41e1-4ed4-8c7e-c02f8b2c2799"
      unitRef="usd">1791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8946372da4bb412ebce1e7fbd111ba10_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy0yLTEtMS0w_4b71e37e-b993-4e5d-b82b-41be8307e450"
      unitRef="usd">512000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe55087b940747989ca8778b35a30ba2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy00LTEtMS0w_dc8da729-78ac-4c24-93e9-33d18f878a6a"
      unitRef="usd">6771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a0aa783282d499eabe30b6edf7958f4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfMy01LTEtMS0w_06e8a5fc-8a87-465b-9ce9-d57c6eea9ba8"
      unitRef="usd">1570000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC0xLTEtMS0w_cc9eec55-57e9-4d67-8740-7389c7c37ac8"
      unitRef="usd">3096000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC0yLTEtMS0w_24b75245-d5d5-4aa4-8e1b-63889ecaf53c"
      unitRef="usd">824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC00LTEtMS0w_da1c630f-398d-477c-8ba1-3381080e3902"
      unitRef="usd">9771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmJkMTk3NmEwZTMxOTRkM2Y5ODgxNTc1MDY3NTEyYTM0L3RhYmxlcmFuZ2U6YmQxOTc2YTBlMzE5NGQzZjk4ODE1NzUwNjc1MTJhMzRfNC01LTEtMS0w_109fd1a3-2d53-40b5-955a-0e67b0999702"
      unitRef="usd">2858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTUxNQ_ac406a21-3205-4bfd-9c02-1e0c120b76c6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTU0Mw_daa25a2e-7dca-4043-b9a1-4b7cec81ebfc">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4OA_2c14f085-f0dc-4a7b-af42-d94943b78a99">Stock option activity during the nine months ended September 30, 2021 was as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands except share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&#160;Contractual Life (In Years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,937,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,840,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,203,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,711,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,963,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS0xLTEtMS0w_f39d5c35-3ae6-414d-bf54-c743386dfa4c"
      unitRef="shares">20937443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS0yLTEtMS0w_02ee372d-7f7a-4a18-aef6-0e75118c433c"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4ce5ea44684646478e321a6f5da5f498_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS0zLTEtMS0w_1b5e7782-3ae1-4e82-8f42-cb4a17a73995">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id81600d989114130b43235d442b1e71d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMS00LTEtMS0w_541e3805-4768-4892-8da6-7ce00bd08f3c"
      unitRef="usd">12956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMi0xLTEtMS0w_880979d9-60fa-44e9-91b3-b6414dcb94ec"
      unitRef="shares">2840467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMi0yLTEtMS0w_57bf05e9-e5db-4854-80ee-e3117dba7432"
      unitRef="usdPerShare">10.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMy0xLTEtMS0w_e0f1559e-0c41-49c2-9e46-c98a64ea1a4d"
      unitRef="shares">1203239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfMy0yLTEtMS0w_35fa1f72-edbc-4cf6-8e41-acf2215c2164"
      unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNC0xLTEtMS0w_5f167a05-eabc-498b-873e-9ae6193e01e5"
      unitRef="shares">2711021</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNC0yLTEtMS0w_c359e781-1da4-4486-a864-a8adbb424570"
      unitRef="usdPerShare">1.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNC00LTEtMS0w_de677fbb-9da4-4fc5-93e4-c17c14b2d1a7"
      unitRef="usd">14376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS0xLTEtMS0w_f0aabc5b-ab2b-4e88-820b-af52c3d39e15"
      unitRef="shares">19863650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS0yLTEtMS0w_f6a3f3a8-d554-4a1c-9443-6a3a994dc248"
      unitRef="usdPerShare">3.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS0zLTEtMS0w_fb00896f-52e4-4be8-99cb-1c8cfa69440b">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNS00LTEtMS0w_fdbfd464-ae5a-4b32-8e2e-3ec89968ce2b"
      unitRef="usd">396084000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi0xLTEtMS0w_e73a18a0-40db-4b54-80f5-4872f79abfc3"
      unitRef="shares">7963568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi0yLTEtMS0w_17addf5c-b7f5-4cb9-96c2-e42e91b9e37d"
      unitRef="usdPerShare">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi0zLTEtMS0w_57f6f83d-4217-48c1-a314-5934034fcd2f">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOmNlMTdhMGQxOTA1NDQ0N2NhMzBkNzEyY2U2YTI0ZmEzL3RhYmxlcmFuZ2U6Y2UxN2EwZDE5MDU0NDQ3Y2EzMGQ3MTJjZTZhMjRmYTNfNi00LTEtMS0w_b2f0a6c0-5c11-452c-a1e2-495996143215"
      unitRef="usd">169803000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTg0OQ_0c4f2e4d-46fe-46cc-8d42-ee9db2198937"
      unitRef="usdPerShare">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTg1Ng_6f2a5303-837c-4774-ade4-e9e0c1427c93"
      unitRef="usdPerShare">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ3Ng_8ad609b1-cd7e-44dc-aed4-9a2235e6fbee">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMi0xLTEtMS0w_9bcf4c65-151a-4adb-bc46-632f41c505e4">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMi0yLTEtMS0w_b2879bbf-9735-4d6e-b5f0-ce1a721b12dc">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMy0xLTEtMS0w_30e02373-4e58-45f6-b87a-f8e06315b70e"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfMy0yLTEtMS0w_8eb1a725-fec4-4be5-b3ca-9797793cbb9e"
      unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNC0xLTEtMS0w_ed81b8fb-9c0f-428a-936d-54b0503a8d28"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNC0yLTEtMS0w_e233948d-6fb9-4005-8723-6f4c3fe65d52"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i791d376bba2b4de991216d3882aab0e0_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNS0xLTEtMS0w_497530c9-e527-4013-8206-6d332fd114f2"
      unitRef="number">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3593a21b1db24ddb9a190720383788c5_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjlhNWFiNzI0MDk1ZjQ0YWY4MDMyNjAxYmJlODliN2IzL3RhYmxlcmFuZ2U6OWE1YWI3MjQwOTVmNDRhZjgwMzI2MDFiYmU4OWI3YjNfNS0yLTEtMS0w_94a7c2b1-8edf-44fa-b734-21dfb62aac76"
      unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4381c37b0f434d1292766458d6f33a83_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjAzOA_f3cf609a-66f4-4035-b85e-96d9dcfd1c7d"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="i4381c37b0f434d1292766458d6f33a83_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjEzMQ_4f783fd1-080a-4e81-910c-884d7ccf9d13"
      unitRef="usd">358000</rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia5509909b8164d1392214698e190db36_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjI2Ng_7df3e76a-ff55-4664-bbb7-61be05806d45"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate
      contextRef="ia5509909b8164d1392214698e190db36_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjQzMg_735f92c0-a679-42a7-8d47-0b11b647c605"
      unitRef="usd">2000000</rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12720851e14f4054b18ea160b3ae9c16_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3ODgxNg_dfd4aa96-922b-4323-827f-affccf194ccb"
      unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84ca49f352744d10969d369737887491_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTA5OTUxMTYzNjY5Ng_2a291fca-015f-495d-8431-f313312bf881"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaec16661eb85408985324c4bec4ce6bc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjU0Ng_2209eadc-1de4-4f39-95f1-1c7d9ae2f443"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd1b4082185f4ff8b95aa9ccc5e14905_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMjU0Ng_d8820a77-6294-4233-b078-e065ec2f7de8"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i227689ec41e7442c8fc5bdd888e16504_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMzQxOQ_18b778e8-9db9-43c1-b2fb-fff373ca88c4"
      unitRef="usd">27900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMzU0OQ_432d0b8d-aaf4-413d-8765-46c201a9a129">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6a0b13ec20ca48d586c285f56d52aaf7_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4NA_90dadcd9-04fa-4088-b050-bec60d4de8b1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4OQ_c296cdc5-9169-4ed9-abdc-ab38f1a4ebc5">The following table summarizes Recursion&#x2019;s RSU activity during the nine months ended September 30, 2021: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,723&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,528)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(673)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,522&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie6d027f3b69840d8bbb90d7865d8a14f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMS0xLTEtMS0w_6be04d8d-4f32-479f-8da4-ee7c688b7759"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie6d027f3b69840d8bbb90d7865d8a14f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMS0yLTEtMS0w_53742752-a83c-4d6b-baa9-d0456967e3e6"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMi0xLTEtMS0w_17ef6dd9-6a51-4801-b09b-1958ba941510"
      unitRef="shares">143723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMi0yLTEtMS0w_2977d549-bd17-4f8f-a663-d725707f9d13"
      unitRef="usdPerShare">29.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMy0xLTEtMS0w_528605e6-d03f-4eee-9700-379b714536fe"
      unitRef="shares">2528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfMy0yLTEtMS0w_6adc78e6-faa8-43e9-8814-ac829c289a42"
      unitRef="usdPerShare">34.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNC0xLTEtMS0w_cf54cab5-4ff9-4b8e-b0fc-1dd73644f9f6"
      unitRef="shares">673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNC0yLTEtMS0w_4cda9564-ab6d-4606-ad45-5d44684eb5c2"
      unitRef="usdPerShare">29.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i23ab811b0acb4f168c59b520becd7a72_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNS0xLTEtMS0w_0e5adb8a-96c4-4d6d-950f-1019104ea64a"
      unitRef="shares">140522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i23ab811b0acb4f168c59b520becd7a72_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjhkMmEzZDhlODFhOTQ3YTNiNGY0MTliZWUxMTcyOGNhL3RhYmxlcmFuZ2U6OGQyYTNkOGU4MWE5NDdhM2I0ZjQxOWJlZTExNzI4Y2FfNS0yLTEtMS0w_564de6cf-038d-4806-a61d-16fac15c0e04"
      unitRef="usdPerShare">29.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i23ab811b0acb4f168c59b520becd7a72_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDEzMg_3d91e585-9cc4-4109-995c-e6ae90c67171"
      unitRef="usd">3600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5178af52d1e344b2b4bb0e63f30c7ce1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDI1Mw_507cc34b-4e48-4ca9-a068-ecec1d426719">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibc8d774d0f354dffa104fb6ec49d31f5_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDQ0OQ_2bb9d726-8591-4421-b0f5-ea56231900e3"
      unitRef="shares">3238000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="ia59ee14c284b45dfb5c8bbaae6df4885_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ3OQ_6f1f5436-d621-4762-92d6-ee0234321fde">P6M</rxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ia59ee14c284b45dfb5c8bbaae6df4885_D20210401-20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNDk2MA_322d28f9-672a-4f4d-85a8-6fde20858ae0"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ5MA_73891a70-9800-4ca7-a202-92f21d171307">The weighted-average assumptions used in the Black-Scholes models were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfMi0yLTEtMS0w_849455b4-005f-4503-a29d-fc45529ad0c3">P0Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfMy0yLTEtMS0w_45cb2126-649c-43a8-885e-3905e723b40e"
      unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfNC0yLTEtMS0w_1547b7ab-1c52-47c2-9830-59cfd7095fb1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjU1MmFiZTIyMmJjMDRkODQ4MWVjM2I0MmRiZjk5NDczL3RhYmxlcmFuZ2U6NTUyYWJlMjIyYmMwNGQ4NDgxZWMzYjQyZGJmOTk0NzNfNS0yLTEtMS0w_ef7ecbe2-5a9f-403f-a565-21665f0b695f"
      unitRef="number">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTQzNA_85cb3b33-d3ea-4e68-8e54-2020f43d6e0f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i624cda05c6f442e482227cdcb651b01e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfMTA5OTUxMTYzNjU3Nw_2ce82efd-65bb-4e8e-ae94-799ded061bf6"
      unitRef="usd">233000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjU5NzA2OTc3OTAwMQ_e0827309-34db-41db-b00d-60ae683e5646"
      unitRef="usd">450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0c8780804ec9494aa5a5c9fa23f6bcc6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTU2OA_1d38948b-d784-4420-ad97-915c1bd51038"
      unitRef="usd">136000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icfd5c060ab594cae9f6247af22410df8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTY5OA_41ae53f3-31fb-4692-91fc-963b2d4a5257">P2M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibfd006ea4f4945efaeb183fc075f012d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTg5NQ_77831024-6153-4d19-9427-545286fdd365"
      unitRef="shares">84486</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibfd006ea4f4945efaeb183fc075f012d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNTk2Ng_fb34bc87-4e9a-4011-948d-c9d2ceead4d6"
      unitRef="usdPerShare">0.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i209f333c943b42e79aab9462added11c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjE1MA_879a4920-b7af-4aa3-a527-1a425e609cb1"
      unitRef="shares">28161</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i209f333c943b42e79aab9462added11c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjIwMQ_f8bcfe21-ba84-4351-8ee2-f6a055b37b8f"
      unitRef="usdPerShare">0.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rxrx:ClassOfWarrantOrRightFairValue
      contextRef="i209f333c943b42e79aab9462added11c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjMwMA_d9827342-c431-4f17-b2ff-b9c153581b92"
      unitRef="usd">77000</rxrx:ClassOfWarrantOrRightFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i33aa98d15eec4725a67ba5499bcbbc29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjQ2Mw_036e9350-df5f-4406-9f2a-6e0349eed156"
      unitRef="shares">25762</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i33aa98d15eec4725a67ba5499bcbbc29_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjUzNA_0f95da71-8f8e-4cba-ae92-1dd6aeb7a3db"
      unitRef="usdPerShare">2.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <rxrx:ClassOfWarrantOrRightFairValue
      contextRef="i33aa98d15eec4725a67ba5499bcbbc29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjYzMw_3c60c8c6-d300-4aec-bb4b-d432d563feef"
      unitRef="usd">48000</rxrx:ClassOfWarrantOrRightFairValue>
    <rxrx:ClassOfWarrantOrRightIssued
      contextRef="i0015342eeae14a93b10cef24c0a7eb00_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjY4NQ_48f7bb6e-067e-4377-93b5-f0643f4df160"
      unitRef="shares">180000</rxrx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic1ead2550bf14c0893a228633bcb285d_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjc2Ng_6f321bcc-a78b-4a01-a98b-5b7756631f73"
      unitRef="usdPerShare">6.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic1ead2550bf14c0893a228633bcb285d_I20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjg0Mw_0183fa3a-3803-4163-9eef-36e94d9c7212">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <rxrx:ClassOfWarrantOrRightGrantDateFairValue
      contextRef="i2848f38457cf43dfb9f1a86a2619c3ec_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfNjk2NQ_1bf185c3-4c24-4df6-9c39-d19314e74351"
      unitRef="usdPerShare">4.10</rxrx:ClassOfWarrantOrRightGrantDateFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RleHRyZWdpb246ZDlmZGY0MDJjZmM1NGUzMDg1NDY2YjI2NDZhOGQwMDhfODQ4Nw_c59a6caf-3a58-4f8f-a400-cbf82e975bab">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following is a summary of the changes in the Company&#x2019;s Series A and B warrant liability balance during the nine months ended September 30, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net increase in fair value of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in fair value of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recorded in equity upon exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2bd3ed16cc3a40d9b40309215a26d2d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfMS0xLTEtMS0w_d574dbb7-c4e5-4e5c-9ca5-ae2ee1474e5f"
      unitRef="usd">128000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib3660f34156d445c9c45640b5093824c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfMi0xLTEtMS0w_5cded4db-5619-4d78-8da0-a337c69c68bf"
      unitRef="usd">-2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ieb672f271cdc43bab7ca1eac36b7098e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfMy0xLTEtMS0w_0e479348-5541-433a-8480-bb22032d5fa5"
      unitRef="usd">130000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6c7aac41dc2042ada5f77fd1aa3b0fbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfNS0xLTEtMS0w_fda0e392-78fb-4f94-9db5-23cecae3e9ec"
      unitRef="usd">125000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if14c65e722904f9f939058b7366b4e72_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfNi0xLTEtMS0w_b6c5335e-f7ba-44ac-b998-8093aa04fc59"
      unitRef="usd">-2215000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="if14c65e722904f9f939058b7366b4e72_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfNy0xLTEtMS0w_4f577a1a-d682-4194-b9b1-e305b4e13291"
      unitRef="usd">2340000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie51a0fc21e8f4d418cb515efcc6a3eaf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82MS9mcmFnOmQ5ZmRmNDAyY2ZjNTRlMzA4NTQ2NmIyNjQ2YThkMDA4L3RhYmxlOjA2ZmRlZDM5MmEyYTRiNTdiNTI2NmMwYmI0NWI0NzZmL3RhYmxlcmFuZ2U6MDZmZGVkMzkyYTJhNGI1N2I1MjY2YzBiYjQ1YjQ3NmZfOC0xLTEtMS0w_80b83a35-ad35-442e-994d-f05c990db841"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfMTYwNw_c0e022d0-f2a8-45e3-b686-de36b7ac7691">Income Taxes &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not record any income tax expense during the three and nine months ended September 30, 2021 and 2020. The Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. Valuation allowances are recorded when the expected realization of the deferred tax assets does not meet a &#x201c;more likely than not&#x201d; criterion. Realization of the Company&#x2019;s deferred tax assets are dependent upon the generation of future taxable income, the amount and timing of which are uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards (NOLs) and tax credit carry-forwards are subject to review by the Internal Revenue Service (IRS) and may become subject to annual limitations due to ownership changes that have occurred previously or that could occur in the future under Section&#160;382 of the Internal Revenue Code. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. Any limitation may result in expiration of a portion of the NOLs or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the United States, Utah and California. The Company is not currently under examination in any of these jurisdictions. The Company is subject to income tax examinations on all federal returns since the 2018 tax return.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_8ce99c65-9c5b-4891-9930-f3ddc1b77792"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_ae46c046-501e-4f53-8635-dcc4f132d760"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_dbbd4429-6174-4d59-a83d-9d0e54c1f8c9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV82Ny9mcmFnOjAxZTc1YWU4ZjE5MzRjNGI5OTg3YjE0MmFkMzc1NGVmL3RleHRyZWdpb246MDFlNzVhZThmMTkzNGM0Yjk5ODdiMTQyYWQzNzU0ZWZfNDU_e7a14926-70f2-4ade-b07a-35e9c027018a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RleHRyZWdpb246OGQxOGE0NDA2OWJmNDQwNTljY2RlNmYyZThkZWIzYjlfMzI0Mg_96816a54-a07d-44a7-a904-e3043851c39d">Net Loss Per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021, Recursion calculated net loss per share of Class A and Class B common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. For the three and nine months ended September 30, 2021, the Company reported a net loss and therefore basic and diluted loss per share are the same.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rights, including the liquidation and dividend rights, of the holders of the Company&#x2019;s Class A and Class B common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A and Class B common shares as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A and Class B common stock was the same during the three and nine months ended September 30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recursion issued certain shares of convertible preferred stock that were outstanding until April 2021 and were concluded to be participating securities. For the three and nine months ended September 30, 2020, there was only one class of common stock outstanding. Due to the presence of participating securities, Recursion calculated net loss per share for the three and nine months ended September 30, 2020 using the more dilutive of the treasury stock or the two-class method. For periods presented in which the Company reports a net loss, the losses are not allocated to the participating securities. As the Company reported a net loss during the three and nine months ended September 30, 2020, diluted net loss per share was the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The preferred stock converted to common stock in April 2021 as part of the Company&#x2019;s IPO. See Note 10, &#x201c;Common stock&#x201d; for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share amount)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allocation of undistributed earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,065,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,467,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,045,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,467,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,324,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,506,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,965,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,016,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share during 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,817,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,704,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,839,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,453,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,576,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,589,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,531,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,158,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RleHRyZWdpb246OGQxOGE0NDA2OWJmNDQwNTljY2RlNmYyZThkZWIzYjlfMzI0Mw_17897279-391a-4513-ad7b-96a061d820af">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share amount)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allocation of undistributed earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,065,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,467,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,045,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,467,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share during 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,817,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,704,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:UndistributedEarningsDiluted
      contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0xLTEtMS0w_0573fcc8-f2ab-4db2-86e9-34d57f2064b5"
      unitRef="usd">-44763000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:UndistributedEarnings
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0xLTEtMS0w_635417c9-c8e3-451c-81bd-ed7225929dd0"
      unitRef="usd">-44763000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarningsDiluted
      contextRef="i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0yLTEtMS0w_94f8ec77-1168-44e6-bfe7-2f3985773d56"
      unitRef="usd">-2664000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:UndistributedEarnings
      contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC0yLTEtMS0w_bc046644-7825-44fd-a171-7a3812698d77"
      unitRef="usd">-2664000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarnings
      contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC00LTEtMS0w_a6162b1e-d377-454d-af91-de4cc2cf2010"
      unitRef="usd">-111133000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarningsDiluted
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC00LTEtMS0w_c2ec7687-2a66-46a2-a35c-997f720df570"
      unitRef="usd">-111133000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:UndistributedEarnings
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC01LTEtMS0w_e4fd0674-56d5-400c-9102-2cb87c4811d4"
      unitRef="usd">-10413000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarningsDiluted
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNC01LTEtMS0w_f44b1184-9847-4017-890f-f0bd832d2f47"
      unitRef="usd">-10413000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0xLTEtMS0w_1704a993-e3cb-456f-93b4-b328c42ed268"
      unitRef="shares">159065667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0xLTEtMS0w_5f3c7583-fc25-4141-8c52-12e2d97b6cca"
      unitRef="shares">159065667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0yLTEtMS0w_ca4ee1de-4109-494e-8d33-2c1e932be89e"
      unitRef="shares">9467883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi0yLTEtMS0w_d017da3f-6dcf-430f-90ad-4241e2ab4cd7"
      unitRef="shares">9467883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi00LTEtMS0w_c0ecd5ee-388f-44f3-90c7-ddc2f82dedc5"
      unitRef="shares">101045348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi00LTEtMS0w_efe108e4-617a-4dca-b982-d8e72ff177ee"
      unitRef="shares">101045348</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi01LTEtMS0w_224e3cf4-ce9d-49a7-a093-6c7c5b8b90c5"
      unitRef="shares">9467883</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNi01LTEtMS0w_bd78ce90-b434-4629-a065-856cae274e33"
      unitRef="shares">9467883</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0xLTEtMS0w_51864beb-e354-4965-9d2c-211f11116058"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0xLTEtMS0w_5878acf9-a784-4ed9-bcef-9924e4b1e0f7"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0yLTEtMS0w_6e2be9b3-eadc-4a41-95be-0a2c63af5f0f"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy0yLTEtMS0w_b1c84710-8145-4f13-ae4f-6f480ed68b63"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy00LTEtMS0w_2c5866a3-6a5a-40c8-a04f-007e945617ce"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy00LTEtMS0w_335d7c77-089f-432e-bd18-e1f43c4e88a5"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy01LTEtMS0w_87e4bb6e-b944-43dc-af45-7237dbde13ef"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmFlMjM1ZDExNDA1NTQzZDZhYTViMzA1MmVkMzhjMTU2L3RhYmxlcmFuZ2U6YWUyMzVkMTE0MDU1NDNkNmFhNWIzMDUyZWQzOGMxNTZfNy01LTEtMS0w_f5b9cd70-feb5-47c7-a511-960eb27ccf56"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RleHRyZWdpb246OGQxOGE0NDA2OWJmNDQwNTljY2RlNmYyZThkZWIzYjlfMzI0NA_95cf1f3d-79d2-4ddf-bdb4-b894e3eeeda9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Class B&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,324,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,764,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,506,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,965,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,016,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,839,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,453,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,576,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,589,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,531,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,158,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf3bd2b3f1de4ca2ab977e7dc5e21061_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy0xLTEtMS0w_43769199-43c0-4042-8025-688c4c5dc31a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i25149b9a570440e894a302d56c3419d4_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy0yLTEtMS0w_3e5916f8-6e62-4104-928e-0c2505adfc22"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3102e5c386934e08baf3f55a99f19f8f_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy00LTEtMS0w_e3cc65d5-0096-4b6f-8ffa-05fb6cdf67af"
      unitRef="shares">46324206</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i53e651de692a4311baff885fe1d206fd_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfMy01LTEtMS0w_1def27f6-00a1-4552-9f8d-b622f737233a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70f6c3f9030e468f943ac8072eca5c43_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC0xLTEtMS0w_d941c6af-ccfd-4dac-ae2d-0499b0b1f6f5"
      unitRef="shares">16764023</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b9f157f6cc14838be0480cbdd9ff968_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC0yLTEtMS0w_1d52e8e6-0af5-4945-bfb2-cd2cd69d93e1"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i66ff3b8c31df4b4b8a24cb74978eff8f_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC00LTEtMS0w_6e5a756d-8021-4ec8-9748-508e3c78f518"
      unitRef="shares">15506429</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib3a1c33e0c004ee7bcc3a113bfdbe90e_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNC01LTEtMS0w_9c7fec35-0386-4b27-bbcf-519fc10321f4"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i26eb528b81cf4adf8be643e9113fd19c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS0xLTEtMS0w_b061083c-03aa-400e-8f57-cede72cc3e27"
      unitRef="shares">163958</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5628df5a4848456eb3ec9ada5263c011_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS0yLTEtMS0w_eaca3bcf-cf23-480d-a667-447d5a7313cc"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5ba0f31dd7d94a7aa2ea877325c0bb72_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS00LTEtMS0w_9cdc9e98-1458-40c0-8285-f10087449aec"
      unitRef="shares">180479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia222d34dfedb42a989e65c18da7342b2_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNS01LTEtMS0w_39dc77dd-b10d-4376-bf3e-4a7fb38a20d5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ied40c52ff827437a831df98fbdf2c99c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi0xLTEtMS0w_add0ab22-bdfc-47c1-aa0e-ebbac45d22fd"
      unitRef="shares">37917</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice8b605c718747d2acbf2c3db10e6ec0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi0yLTEtMS0w_3867a538-f6b5-46b7-931b-33a7df8e8aac"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7afc904b0874b9c80f044ef16fb6c10_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi00LTEtMS0w_bcc27b48-6cde-455e-be21-c2e4e19152f1"
      unitRef="shares">5109</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i29d4ed7ff0ab424a9e1664b17448dcd5_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNi01LTEtMS0w_03fac065-994c-4544-afc3-cbc89cfd8208"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i31c907d87561487794a79022d9299487_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy0xLTEtMS0w_227b8e8f-af7c-49fb-890d-0a256d90a4dd"
      unitRef="shares">16965898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i756c7d0b565b426a875ce5edaf4246da_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy0yLTEtMS0w_a8a1f1cf-eaec-45d3-89d3-3d7cec66c0bb"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i43d68d556edc469f8dbbfc00b0bcd81a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy00LTEtMS0w_cf8b6d52-d464-4ec9-acca-f78eef36be83"
      unitRef="shares">62016223</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9dbb8973cbf243ddb6a0cff4c11e1625_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmYwNjg4ZGU2OWE1YzQyZWQ4ZWYwMWRjZmViZjVkODc1L3RhYmxlcmFuZ2U6ZjA2ODhkZTY5YTVjNDJlZDhlZjAxZGNmZWJmNWQ4NzVfNy01LTEtMS0w_3796b188-45c0-4ebc-9cc4-791a7e6af676"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NetIncomeLoss
      contextRef="i28896c19aa0048d895dddd0ae8427e87_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfMy0xLTEtMS0w_39313815-2157-4e52-8be6-03f34e71e405"
      unitRef="usd">-23873000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icee0f1fd845e456095af44bb0a898324_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfMy0yLTEtMS0w_18e4222e-6488-44ae-8eeb-00ddc7127969"
      unitRef="usd">-61240000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0xLTEtMS0w_3cadf291-fc9f-434e-a552-7d4425d408af"
      unitRef="shares">21817900</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0xLTEtMS0w_d1b94fd2-1e52-4c11-8066-50596dd7fc51"
      unitRef="shares">21817900</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0yLTEtMS0w_6bfa7fc2-546e-4356-9991-7a2672b652aa"
      unitRef="shares">21704008</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNS0yLTEtMS0w_ecd91a91-4323-41fb-af65-5486e1c00860"
      unitRef="shares">21704008</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0xLTEtMS0w_17f844da-22de-4ef2-816b-63c0eed64922"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0xLTEtMS0w_ac48f523-b7c0-4271-ab59-798f5067558d"
      unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0yLTEtMS0w_3dcb9ec4-1c13-4d4f-9461-258cdd70b276"
      unitRef="usdPerShare">-2.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOmNlZjQ2NjFkZTQwMjRlZTc5MmMwOTcwMmFhOTY4ZDk0L3RhYmxlcmFuZ2U6Y2VmNDY2MWRlNDAyNGVlNzkyYzA5NzAyYWE5NjhkOTRfNi0yLTEtMS0w_84661191-605b-499b-9780-7d07b50497de"
      unitRef="usdPerShare">-2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i43c8d5736faa4c1983958144094f549c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMi0xLTEtMS0w_7433f0ab-3c7e-49e2-8954-b813bd29e9f1"
      unitRef="shares">89839055</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1407ac7645fc47fa897329aea3c530a8_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMi0yLTEtMS0w_42f0bb90-e9a8-4959-801a-8c32bb6b3304"
      unitRef="shares">82453474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i610ce8d6e6fb4af2aed56ad3de0f1a9f_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMy0xLTEtMS0w_efa4280e-5b7e-4f8d-893f-006603e15157"
      unitRef="shares">3576910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iebe1a1be865947f4aa113d844800ea59_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfMy0yLTEtMS0w_2b5be312-777b-40ef-a962-c340d55c6e9c"
      unitRef="shares">3589986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibec53fdf9f59440fb5fcf12d42df3d39_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNC0xLTEtMS0w_67e42ba7-6e9a-408a-adbb-4d98fbf9f8a5"
      unitRef="shares">115107</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaab494b26364446fba34ae32a935dfc1_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNC0yLTEtMS0w_498ac237-d6c7-41b2-a450-7b487d7c8d26"
      unitRef="shares">115107</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1109a8a918954e10aa56a87593b248c0_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNS0xLTEtMS0w_92a2bdc6-20e9-4475-b7c3-f855e25931f2"
      unitRef="shares">93531072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0fa1bd3b7c2942c89b9f4bffe0469586_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83MC9mcmFnOjhkMThhNDQwNjliZjQ0MDU5Y2NkZTZmMmU4ZGViM2I5L3RhYmxlOjY1ZDg0NjQ1Yzk5ZDQ3Njg5OGE1OGEwYzExOGU5MzIxL3RhYmxlcmFuZ2U6NjVkODQ2NDVjOTlkNDc2ODk4YTU4YTBjMTE4ZTkzMjFfNS0yLTEtMS0w_22ae6c62-41ee-4ad3-bc2d-6ae0daeedc7c"
      unitRef="shares">86158567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RleHRyZWdpb246MjI0ZjA0MDMxMjNmNDhmOThjNmJkMjQ4ZTA2NmFiYTRfMjA0Nw_72ccea86-bfca-4bf6-99d8-59744013f02c">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 1 &#x2014; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 2 &#x2014; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Level 3 &#x2014; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to maintain a cash balance in a collateralized account to secure the Company&#x2019;s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company measured the Series A and B preferred stock warrant liabilities at fair value using a Black-Scholes option-pricing model. See Note 12, &#x201c;Stock-based Compensation&#x201d; for details on the valuation of the warrant liabilities and a reconciliation of the balance. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheets, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments that are not measured at fair value: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Book values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RleHRyZWdpb246MjI0ZjA0MDMxMjNmNDhmOThjNmJkMjQ4ZTA2NmFiYTRfMjA0OA_a40f30fb-653b-48f7-9d26-834911ae2236">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basis of fair value measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i190cd4db6d464d718e8e7930d9ca1083_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0xLTEtMS0xODIyOQ_fe1feb49-5519-481a-8131-2a96f31dca23"
      unitRef="usd">187225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3214dd56bf64eedbbf429ee3a167178_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0yLTEtMS0xNjMxNQ_ee0f8ce7-c301-43dd-9930-af5adffc03e1"
      unitRef="usd">187225000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i51038493a87f4438a225fa0f3eb3d1a8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0zLTEtMS0xNjMxNQ_a90350e4-209c-4c63-ae87-ae695739b6d4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a01352bcbd0418da5a4d83c3911cb35_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS00LTEtMS0xNjMxNQ_79bd0844-6c7c-43b5-892e-59b92d7509e8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaac2c0d34aa14f4b86eb9fb680095a93_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNi0xLTEtMS0xODIyOQ_50820a15-4e7f-4f80-a075-78f328e8fcf1"
      unitRef="usd">34497000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if2b0eacaa900484a97d3551758e92093_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNi0yLTEtMS0xNjIyNA_54a59010-c639-4f68-8652-ca38f37a22d3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if6fec666dd574bdd860d28ccf54b11c1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0zLTEtMS0xNjE2NA_67d851fe-4040-466e-8b71-2c4502bcb921"
      unitRef="usd">34497000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d40bedd685247d78f2216e50d9a8eff_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNi00LTEtMS0xNjIyNA_2dc07249-e91b-4c41-95fc-784b99d08be0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ie30ba9ac44034c578ac0d736845582c9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy0xLTEtMS0xODIyOQ_7a614377-9778-4574-aee7-3412cb941051"
      unitRef="usd">10233000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ic3de39547ef349e992ca21d173027833_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy0yLTEtMS0xNjI2NQ_af82bc09-a681-41e2-9ebb-e0c5c4be0608"
      unitRef="usd">10233000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ic04ee2989244405a8478ecdc58c1d93c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy0zLTEtMS0xNjI2NQ_f5ec6804-bf58-4165-a57e-2fbb8453afcf"
      unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i620b4c771b704d6bbc4945cbd1c5dc27_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNy00LTEtMS0xNjI2NQ_315f1cb0-b317-404a-a7c6-45a5b7ccf30c"
      unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ida224670f66a4cd1b60d191c2e281cce_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS0xLTEtMS0xMzAxMA_ece04ba8-972a-453a-a323-149a671120c9"
      unitRef="usd">5884000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ief95da0bc6cf471e9f41eac09bb2d67b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS0yLTEtMS0xMzAxMA_5b064bad-4ecb-47f8-96ef-a8d00c097c32"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idf2d0d327cf84c748140d0325b4ebd61_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS0zLTEtMS0xMzAxMA_97e3378e-e805-46cc-bd61-e7efc713293f"
      unitRef="usd">5884000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i564180300205478f9ed895f99b4dfe03_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfOS00LTEtMS0xMzAxMA_1d2b248c-ea2c-450d-8b67-cfcc778e945a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i441ebff9e64d4bac86210ac2f3fe7cbe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtMS0xLTEtMTMwMTA_b8f8bc78-b0de-433c-bc98-8d0fcacf8938"
      unitRef="usd">21450000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie20600623f4948c3a5c474d9eecc9162_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtMi0xLTEtMTMwMTA_280d3af1-76fd-4995-b3ce-4c26de1d849c"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0872f901a90f4c1abc3c5b8804f79732_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtMy0xLTEtMTMwMTA_6c88644d-a166-4e41-a7eb-f381e3630fc4"
      unitRef="usd">21450000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="icee4c5b8987c42068342ac8fe0f80772_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTEtNC0xLTEtMTMwMTA_6bc1e231-2a12-4a5a-9cdb-4db8dfee6944"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i013dda72d65e48359f86e04e7a20b9e3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItMS0xLTEtMTMwMTA_dcbb3e8f-e024-42ab-a25b-14faf66ab722"
      unitRef="usd">156854000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1296a5886a6f470cb0230592349be9eb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItMi0xLTEtMTMwMTA_7ead7da0-edc1-4bc3-8a81-5de21629b134"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ice6b0ed534a640c5931de64b79a5225c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItMy0xLTEtMTMwMTA_ff133076-9804-4851-9744-2ddf5753792d"
      unitRef="usd">156854000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i40d9ff00f3094561b99abddcbbc1196c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfMTItNC0xLTEtMTMwMTA_146745ae-ab15-4aec-99a8-69472f060dff"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie30ba9ac44034c578ac0d736845582c9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0xLTEtMS0w_e4dca323-b0fc-4715-bddc-4cf05a500c25"
      unitRef="usd">416143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic3de39547ef349e992ca21d173027833_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0yLTEtMS0w_32dc0bc2-305c-4945-b7a1-e85e44e72871"
      unitRef="usd">197458000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic04ee2989244405a8478ecdc58c1d93c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS0zLTEtMS0w_beba590d-51b2-4f82-9fdf-d5e9f1a94f71"
      unitRef="usd">218685000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i620b4c771b704d6bbc4945cbd1c5dc27_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjZiMDI1OGQ3MzUwZDQyMTg4OTBkYWZhNTVlZTdkMDZjL3RhYmxlcmFuZ2U6NmIwMjU4ZDczNTBkNDIxODg5MGRhZmE1NWVlN2QwNmNfNS00LTEtMS0w_409b7cb1-a573-433c-9dae-8cf79259fa99"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC0xLTEtMS0w_0b64858e-e5cf-4d8c-bc88-0be68e4e1eb3"
      unitRef="usd">5041000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC0yLTEtMS0w_8ce287b8-275c-48cd-9de1-c30cc1a2cbbe"
      unitRef="usd">5041000</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC0zLTEtMS0w_3020ff06-d27a-4d57-9868-bb2b4f4fb7f0"
      unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i1a713b2042cb45f4baae40157f292534_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNC00LTEtMS0w_7c40f88e-ca6a-4744-b753-afe80ac790c7"
      unitRef="usd">0</rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS0xLTEtMS0w_27c54d89-4002-4e8e-ac8d-e68f9de5efd0"
      unitRef="usd">5041000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS0yLTEtMS0w_5377a716-f3e7-4aa4-b13f-1eec1bef1b75"
      unitRef="usd">5041000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS0zLTEtMS0w_4f37ec4b-36fa-440e-be33-d10e98d8c5f7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1a713b2042cb45f4baae40157f292534_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNS00LTEtMS0w_68d8c4ff-f5e5-43e2-a8e0-78c882723f72"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy0xLTEtMS0w_0cd9ddb6-270c-46aa-abe0-3f42c8c60862"
      unitRef="usd">125000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy0yLTEtMS0w_6f9b9cd5-ec3b-4eb1-bf4a-590e78015031"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy0zLTEtMS0w_8381bd94-539a-43e9-9283-34b9b0274822"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i1a713b2042cb45f4baae40157f292534_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfNy00LTEtMS0w_11b20eb0-b6ad-4414-bdd4-f8ace458a087"
      unitRef="usd">125000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8d4a620cd1204890aa34ec28087d8251_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC0xLTEtMS0w_80e17168-e7d1-4870-a0ec-238adcd4f457"
      unitRef="usd">125000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5c0eaa2c18ad4155a24b7bf783e3177e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC0yLTEtMS0w_e5540255-e354-40c6-be11-876160a6435d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8b15c90e4b864e4fac918da8be88c86f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC0zLTEtMS0w_831fbd15-c6d2-4a86-a427-15e56ecd5cca"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1a713b2042cb45f4baae40157f292534_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjBjMWU0N2U4NjBjNjQzMzliMjFiYmJiZGE5NDFjYjVhL3RhYmxlcmFuZ2U6MGMxZTQ3ZTg2MGM2NDMzOWIyMWJiYmJkYTk0MWNiNWFfOC00LTEtMS0w_4be2965f-e855-46db-b9d7-a308cdb8d705"
      unitRef="usd">125000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RleHRyZWdpb246MjI0ZjA0MDMxMjNmNDhmOThjNmJkMjQ4ZTA2NmFiYTRfMjA0Ng_8472d96f-dd9e-4401-90cc-d07d51c7ffac">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments that are not measured at fair value: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Book values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Notes payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock>
    <us-gaap:LongTermDebtCurrent
      contextRef="ifc102fb1bc82413aa69f0cd8e15bbcb7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy0xLTEtMS0w_9eb7c568-ae89-4417-b8e2-b86f1b365258"
      unitRef="usd">88000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i242c9fb9e9d34e39bc8bb5ea202c9f5c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy0yLTEtMS0w_7232c794-08c3-4e23-b892-abb4bc4491c5"
      unitRef="usd">1073000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6914913f4c29445486a40ba822c76f9c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy00LTEtMS0w_fcbc5a5c-b5da-466b-a0ab-7ea3446bfad2"
      unitRef="usd">88000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7d8622a762a34db69acf56d2140a8afe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfMy01LTEtMS0w_1468fada-805c-4986-b027-301cebee394e"
      unitRef="usd">1073000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifc102fb1bc82413aa69f0cd8e15bbcb7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC0xLTEtMS0w_ba561d4e-dd74-43f4-b89d-9756f985665e"
      unitRef="usd">656000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i242c9fb9e9d34e39bc8bb5ea202c9f5c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC0yLTEtMS0w_ef9dc1e6-c4cc-4165-a62b-e4a3cbf12d4f"
      unitRef="usd">11414000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6914913f4c29445486a40ba822c76f9c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC00LTEtMS0w_ffa02ee3-0c9a-4f99-8e5e-25437c56b9eb"
      unitRef="usd">656000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7d8622a762a34db69acf56d2140a8afe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNC01LTEtMS0w_5a8fab6d-6b63-43b5-900f-8e274b7f8cab"
      unitRef="usd">11414000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9f4c24f5df41449c8a6537fb7c6f3dc2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS0xLTEtMS0w_5f05b91f-494a-4c1b-bed3-af0a3f7e0f09"
      unitRef="usd">744000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7749db1c1872417f962d0cc10eb2a200_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS0yLTEtMS0w_dc46f016-7c75-4407-b908-6961fbece49f"
      unitRef="usd">12487000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id9cf7bd8980049bea59d3c2a32ae4c09_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS00LTEtMS0w_25adef53-d016-4f6c-a1aa-81b7949ab5be"
      unitRef="usd">744000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i18aaa35da92e4cfcab63c485c3c4aaac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83My9mcmFnOjIyNGYwNDAzMTIzZjQ4Zjk4YzZiZDI0OGUwNjZhYmE0L3RhYmxlOjg4NWYyY2RiNzkyYjQ2ODFhODkxNTc5MmM1MWIyZTBiL3RhYmxlcmFuZ2U6ODg1ZjJjZGI3OTJiNDY4MWE4OTE1NzkyYzUxYjJlMGJfNS01LTEtMS0w_1c5177ca-8944-47f7-8dd2-b0b4393d311c"
      unitRef="usd">12487000</us-gaap:LongTermDebtFairValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMjc5_ca2715bc-c361-4fdd-a267-da7d960483b7">Related Party Transactions On December&#160;5, 2017, the Company entered into a loan agreement with its CEO to provide a loan of $595 thousand. The loan had a seven-year term. As of September&#160;30, 2021 and 2020, no amount remained outstanding on the loan as the balance was fully paid during the nine months ended September 30, 2020. The acquisition of Vium was a related party transaction due to the fact that Vium was affiliated with certain investors of the Company. See Note 3, &#x201c;Acquisitions&#x201d; for additional details on the acquisition.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="i774ee2b9287545a0a57464dbab971920_I20171205"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMTQw_ab4faeb2-85b4-4ad8-8866-80a3a397e743"
      unitRef="usd">595000</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:DebtInstrumentTerm
      contextRef="ia19aa404aca14cc6acdaf9338dfc7ff5_D20171205-20171205"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMjgx_ccd6b959-8274-4d7b-a8e4-5d2d4caaf02c">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="i6893f1ac3dd94238a44159176b56e2aa_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMTkw_585e4f4a-b7bc-4c71-bd34-817e6f02ec2e"
      unitRef="usd">0</us-gaap:LoansAndLeasesReceivableRelatedParties>
    <us-gaap:LoansAndLeasesReceivableRelatedParties
      contextRef="i5fc41eefa45d46c3ad7b8fa3931ff65b_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjBiYjA2MGRkYjdlZjQwODRiMGU5ZTkyODZmYzUzMWIxL3NlYzowYmIwNjBkZGI3ZWY0MDg0YjBlOWU5Mjg2ZmM1MzFiMV83Ni9mcmFnOjNlYjU5NDNiNGFkMzRkOWJhNjQ5ZmMzMjNjYjQzZTI2L3RleHRyZWdpb246M2ViNTk0M2I0YWQzNGQ5YmE2NDlmYzMyM2NiNDNlMjZfMTkw_84726900-ff2a-4b66-89cb-9f869f7e8fbb"
      unitRef="usd">0</us-gaap:LoansAndLeasesReceivableRelatedParties>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426490676728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Recursion Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4099738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">41 S Rio Grande Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">269 - 0203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, par value $0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001601830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,525,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,467,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489773208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 394,721<span></span>
</td>
<td class="nump">$ 262,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">10,233<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">2,248<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">184,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">9,445<span></span>
</td>
<td class="nump">2,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">600,870<span></span>
</td>
<td class="nump">269,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">55,439<span></span>
</td>
<td class="nump">25,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">2,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">658,606<span></span>
</td>
<td class="nump">298,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">25,113<span></span>
</td>
<td class="nump">10,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of unearned revenue</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrent', window );">Current portion of lease incentive obligation</a></td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,943<span></span>
</td>
<td class="nump">23,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">2,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Unearned revenue, net of current portion</a></td>
<td class="nump">9,167<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of current portion</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">11,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LeaseIncentivePayableNoncurrent', window );">Lease incentive obligation, net of current portion</a></td>
<td class="nump">3,460<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">59,574<span></span>
</td>
<td class="nump">56,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note&#160;8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock (series A, A-1, B, C and D), $0.00001 par value; 200,000,000 and 121,434,713 shares authorized as of September&#160;30, 2021 and December&#160;31, 2020, respectively; 0 and 112,088,065 shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively; liquidation preference of $0 and $450,850 as of September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">448,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock (Class A and B), $0.00001 par value; 2,000,000,000 (Class A 1,989,032,117, Class B 10,967,883) and 188,400,000 shares authorized as of September&#160;30, 2021 and December&#160;31, 2020, respectively; 168,634,959 (Class A 159,167,076, Class B 9,467,883) and 22,314,685 shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">934,175<span></span>
</td>
<td class="nump">7,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(335,147)<span></span>
</td>
<td class="num">(213,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">599,032<span></span>
</td>
<td class="num">(206,289)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 658,606<span></span>
</td>
<td class="nump">$ 298,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LeaseIncentivePayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Incentive, Payable, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LeaseIncentivePayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386226&amp;loc=d3e41614-112719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5.02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426599019256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">121,434,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,088,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,088,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 450,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">188,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">168,634,959<span></span>
</td>
<td class="nump">22,314,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">168,634,959<span></span>
</td>
<td class="nump">22,314,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,989,032,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">159,167,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">159,167,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">10,967,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">9,467,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common sock, shares outstanding (in shares)</a></td>
<td class="nump">9,467,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489927512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,534<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 7,645<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">33,246<span></span>
</td>
<td class="nump">16,535<span></span>
</td>
<td class="nump">86,979<span></span>
</td>
<td class="nump">42,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,690<span></span>
</td>
<td class="nump">6,964<span></span>
</td>
<td class="nump">38,481<span></span>
</td>
<td class="nump">17,684<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">48,936<span></span>
</td>
<td class="nump">23,499<span></span>
</td>
<td class="nump">125,460<span></span>
</td>
<td class="nump">60,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(46,402)<span></span>
</td>
<td class="num">(22,474)<span></span>
</td>
<td class="num">(117,815)<span></span>
</td>
<td class="num">(59,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other loss, net</a></td>
<td class="num">(1,026)<span></span>
</td>
<td class="num">(1,399)<span></span>
</td>
<td class="num">(3,731)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,428)<span></span>
</td>
<td class="num">$ (23,873)<span></span>
</td>
<td class="num">$ (121,546)<span></span>
</td>
<td class="num">$ (61,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of Class A and B common stock, basic (in dollars per share)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of Class A and B common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">168,533,550<span></span>
</td>
<td class="nump">21,817,900<span></span>
</td>
<td class="nump">110,513,231<span></span>
</td>
<td class="nump">21,704,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">168,533,550<span></span>
</td>
<td class="nump">21,817,900<span></span>
</td>
<td class="nump">110,513,231<span></span>
</td>
<td class="nump">21,704,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">Operating revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426594959608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,428)<span></span>
</td>
<td class="num">$ (23,873)<span></span>
</td>
<td class="num">$ (121,546)<span></span>
</td>
<td class="num">$ (61,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains on investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Net realized losses (gains) on investments reclassified into net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (47,426)<span></span>
</td>
<td class="num">$ (23,873)<span></span>
</td>
<td class="num">$ (121,544)<span></span>
</td>
<td class="num">$ (61,240)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426481160904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A and Series B Warrants</div></th>
<th class="th"><div>Convertible preferred stock</div></th>
<th class="th"><div>Common Stock (Class A and B)</div></th>
<th class="th">
<div>Common Stock (Class A and B) </div>
<div>Series A and Series B Warrants</div>
</th>
<th class="th">
<div>Common Stock (Class A and B) </div>
<div>Convertible preferred stock</div>
</th>
<th class="th"><div>Additional Paid-in-Capital</div></th>
<th class="th">
<div>Additional Paid-in-Capital </div>
<div>Series A and Series B Warrants</div>
</th>
<th class="th">
<div>Additional Paid-in-Capital </div>
<div>Convertible preferred stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">75,189,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 201,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series D Convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,349,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series D convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at end of period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">110,539,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at end of period at Sep. 30, 2020</a></td>
<td class="nump">$ 437,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at beginning period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,637,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at beginning of period at Dec. 31, 2019</a></td>
<td class="num">(124,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises and other</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at end period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,934,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at end of period at Sep. 30, 2020</a></td>
<td class="num">$ (182,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">75,189,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at beginning of period at Jun. 30, 2020</a></td>
<td class="nump">$ 201,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series D Convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,349,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series D convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228</a></td>
<td class="nump">$ 236,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at end of period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">110,539,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at end of period at Sep. 30, 2020</a></td>
<td class="nump">$ 437,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at beginning period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,652,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at beginning of period at Jun. 30, 2020</a></td>
<td class="num">(159,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises and other</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at end period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,934,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at end of period at Sep. 30, 2020</a></td>
<td class="num">$ (182,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">112,088,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 448,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(112,088,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (448,312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at end of period at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at beginning period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">22,314,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,314,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at beginning of period at Dec. 31, 2020</a></td>
<td class="num">$ (206,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,601)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(121,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance for initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,878,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance for initial public offering, net of issuance costs</a></td>
<td class="nump">$ 462,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,963<span></span>
</td>
<td class="nump">115,598,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock and stock warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,340<span></span>
</td>
<td class="nump">$ 448,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,340<span></span>
</td>
<td class="nump">$ 448,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises and other (in shares)</a></td>
<td class="nump">2,711,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,713,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises and other</a></td>
<td class="nump">$ 3,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at end period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">168,634,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,634,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at end of period at Sep. 30, 2021</a></td>
<td class="nump">$ 599,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(335,147)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, carrying amount attributable to parent at end of period at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at beginning period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,425,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at beginning of period at Jun. 30, 2021</a></td>
<td class="nump">642,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287,719)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercises and other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises and other</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding at end period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">168,634,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,634,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit) at end of period at Sep. 30, 2021</a></td>
<td class="nump">$ 599,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (335,147)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_TemporaryEquityValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Value, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_TemporaryEquityValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489915112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_TemporaryEquityIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426488586728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (121,546)<span></span>
</td>
<td class="num">$ (61,240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,169<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,501<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(30,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other receivables and assets</a></td>
<td class="num">(6,860)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Unearned revenue</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="nump">29,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">5,252<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses, deferred rent and other current liabilities</a></td>
<td class="nump">11,123<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(97,456)<span></span>
</td>
<td class="num">(53,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(35,334)<span></span>
</td>
<td class="num">(2,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of a business</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(184,167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(219,501)<span></span>
</td>
<td class="num">(4,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of common stock, net of issuance costs</a></td>
<td class="nump">462,901<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from sale of preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">229,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from equity incentive plans</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(12,777)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">454,744<span></span>
</td>
<td class="nump">236,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">137,787<span></span>
</td>
<td class="nump">177,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">267,167<span></span>
</td>
<td class="nump">75,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">404,954<span></span>
</td>
<td class="nump">253,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non&#8212;cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">448,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_StockIssuanceCostsNoncash', window );">Deferred issuance costs recorded in equity</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 665<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_IncreaseDecreaseInAccruedDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_IncreaseDecreaseInAccruedDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_StockIssuanceCostsNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Noncash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_StockIssuanceCostsNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482833576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">Description of the Business <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we, us or our) was originally formed as a limited liability</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and changed our name to Recursion Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is a biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. Recursion&#8217;s rich, relatable database of biological images generated in-house on the Company&#8217;s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people&#8217;s lives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had an accumulated deficit of $335.1 million. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration&#160;with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has funded its operations to date through the issuance of convertible preferred stock (see Note 9, &#8220;Convertible Preferred Stock&#8221; for additional details) and the issuance of Class A common stock in an Initial Public Offering (IPO), which was completed in April 2021 (see Note 10, &#8220;Common Stock&#8221; for additional details). Recursion will likely be required to raise additional capital. As of September&#160;30, 2021, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company&#8217;s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the net proceeds from the IPO, together with the Company&#8217;s existing cash and cash equivalents and borrowings available to it, will be sufficient to fund the Company&#8217;s operating expenses and capital expenditures for at least the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484696056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes for the year ended December&#160;31, 2020 included in the Company&#8217;s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company completed a 1.5-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 10, &#8220;Common Stock&#8221; for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company&#8217;s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a one-for-one basis. The creation and issuance of the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 10, &#8220;Common Stock&#8221; for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#8217;s financial statements. Revenues and net loss for any interim period are not necessarily indicative of future or annual results.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards, although the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company&#8217;s financial statements with other public companies difficult because of the potential differences in accounting standards used. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion may remain an EGC until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#8220;large accelerated filer;&#8221; or (b) have annual gross revenues of $1.07&#160;billion or more; or (3) the date on which we have issued more than $1.0&#160;billion of non-convertible debt over a three-year period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div>In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02). Under ASC (Accounting Standards Codification) 842 - Leases, the Company will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) on its Condensed Consolidated Balance Sheet at the commencement date of each lease. ASC 842 is effective for annual and interim periods beginning on or after December 15, 2021 and early adoption is permitted. The Company must adopt the standard using the modified retrospective approach either: (1) as of the earliest period presented and through the comparative periods in the entity&#8217;s financial statements or (2) as of the effective date of ASC 842, with a cumulative-effect adjustment to equity. The Company expects the adoption to materially increase assets and liabilities on the Condensed Consolidated Balance Sheets related to those leases classified as operating and not recognized on the Condensed Consolidated Balance Sheets under current GAAP. The Company is continuing to evaluate the effect that ASC 842 will have on its consolidated financial statements and related disclosures. The Company will adopt the new standard on January 1, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484233144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into an asset purchase agreement to purchase 100% of the assets of Vium, Inc. (Vium) for a total cash consideration of $2.6 million. The primary purpose of the acquisition was to obtain Vium&#8217;s technology. This was a related party transaction, see Note 16, &#8220;Related Party Transactions&#8221; for additional details. The acquisition of Vium has been accounted for as a business combination using the acquisition method of accounting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired as of the July 2020 acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Vium have been included in our Condensed Consolidated Statements of Operations  since the date the business was acquired and were not significant. The technology intangible asset is being amortized on a straight-line basis over its three-year useful life. The inventory and other intangible assets were fully impaired at the time they were acquired as the Company did not intend to use them. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill includes the value of potential future technologies as well as the overall strategic benefits provided to the business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482472568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock', window );">Supplemental Financial Information</a></td>
<td class="text">Supplemental Financial Information <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense on property and equipment was $2.5 million and $6.3 million during the three and nine months ended September 30, 2021, respectively, and $1.1 million and $3.1 million during the three and nine months ended September 30, 2020, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the nine months ended September 30, 2021, the Company purchased a Dell EMC supercomputer for $17.9 million. The purchase was classified as office equipment in the above table. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued early discovery expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued investment purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the nine months ended September 30, 2021, interest expense primarily related to changes in fair value of the Series A and B warrants (see Note 12, &#8220;Stock-based Compensation&#8221; for additional details on the warrants). The Company also had expenses for the Midcap loan and tenant improvement allowance notes (see Note 7, &#8220;Notes Payable&#8221; for additional details.) For the nine months ended September 30, 2020, interest expense included expenses on the Midcap loan, convertible notes and tenant improvement allowance notes (see Note 7, &#8220;Notes Payable&#8221; for additional details). Interest expense was included in &#8220;Other loss, net&#8221; on the Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet And Income Statement Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482829528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company invested cash in an investment portfolio. The primary objectives of the investment portfolio are to preserve principal, maintain prudent levels of liquidity and obtain investment returns. Recursion&#8217;s investment policy limits investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings and it places restrictions on maturities and concentration by asset class and issuer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the investments for declines in fair value below their cost basis each quarter or whenever circumstances indicate that the cost basis of an asset may not be recoverable and assesses whether the decline was due to credit-related factors or other factors. The evaluation is based on a number of factors, including the extent to which the fair value is below the cost basis; adverse conditions related specifically to the security, such as any changes to the credit rating of the security; and the intent to sell, or whether Recursion will more likely than not be required to sell the security before recovery of its amortized cost basis. The assessment of whether a security is impaired could change in the future based on new developments or changes in assumptions related to that particular security.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s available-for-sale investments by type of security: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of the Company&#8217;s available-for-sale investments on the Condensed Consolidated Balance Sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of September&#160;30, 2021, all of the Company&#8217;s available-for-sale investments mature in one year or less. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company held a total of 16 positions, which were in an unrealized loss position as of September&#160;30, 2021. The unrealized losses were primarily due to changes in interest rates. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">here were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> significant unrealized losses as of September&#160;30, 2021. </span>Realized gains and losses on the Company&#8217;s investments were insignificant during the three and nine months ended September 30, 2021. No impairments were recorded during the three and nine months ended September 30, 2021. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Condensed Consolidated Statements of Income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426595237736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of goodwill was $801 thousand as of September&#160;30, 2021. There were no changes to the carrying amount of goodwill during the three and nine months ended September 30, 2021. For the three and nine months ended September 30, 2020, the goodwill addition related to the purchase of Vium (see Note 3, &#8220;Acquisitions&#8221; for additional details on the acquisition). No goodwill impairment was recorded during the three and nine months ended September 30, 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible assets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible asset </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $76 thousand and $228 thousand during the three and nine months ended September 30, 2021, respectively. Amortization expense was $51 thousand during the three and nine months ended September 30, 2020. Amortization expense was included in research and development in the Condensed Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The indefinite-lived intangible asset represents the Recursion domain name that the Company purchased. No indefinite-lived intangible asset impairment charges were recorded during the three and nine months ended September 30, 2021. There were no indefinite-lived intangible assets on the Condensed Consolidated Balance Sheet as of September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482848968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">Notes Payable <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Midcap Financial </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a new Credit and Security Agreement with Midcap Financial Trust (Midcap) and the other lenders party thereto (the Midcap loan agreement). The Midcap loan agreement provided for a term loan facility that included&#160;an initial tranche of $11.9 million. The Company used $11.2 million of the proceeds from the initial tranche to fully repay a previously outstanding term loan with Pacific Western Bank (Pacific). In July 2021, the Company paid the balance due under the Midcap loan agreement. The total amount paid was $12.7 million. The Company recorded an early extinguishment loss of $996 thousand, which was included in &#8220;Other expense, net&#8221; on the Condensed Consolidated Statements of Operations. As of December&#160;31, 2020, the outstanding principal balance under the Midcap loan agreement was $11.9 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company paid fees of approximately $298 thousand in connection with the origination of the Midcap Loan Agreement. These fees were deferred and recorded as a direct deduction from the carrying value of the loan payable and were amortized to interest expense over the expected remaining term of the agreement. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pacific Western </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, Pacific issued a standby letter of credit of $3.8 million for the benefit of the Company&#8217;s landlord, securing certain Company obligations relating to tenant improvements. This letter of credit was transferred to J.P. Morgan during the nine months ended September 30, 2021. See Note 15, &#8220;Fair Value Measurements&#8221; for additional details. As of December&#160;31, 2020, the outstanding letter of credit was $3.8 million, for which the Company held $4.0 million of restricted cash as collateral.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April of 2020, the Company issued convertible promissory notes for an aggregate principal amount of $6.4 million. Under certain conditions, the principal was convertible into an amount of equity with a fair value that exceeded the amount of the notes&#8217; principal on the conversion date. This feature of the notes was accounted for separately at fair value as a derivative liability. These notes converted to 1,203,231 shares of Series D Preferred Stock in September 2020. Upon conversion of the notes, the Company recorded the $1.6 million fair value of the derivative liability as equity on the Condensed Consolidated Balance Sheet. Changes in the fair value of the derivative were recorded in &#8220;Other loss, net&#8221; in the Condensed Consolidated Statements of Operations and were $161 thousand and $484 thousand during the three and nine months ended September 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Notes Payable for Tenant Improvement Allowance </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company borrowed $992 thousand, which was available as part of the Station 41 lease from its landlord for use on tenant improvements (see Note 8, &#8220;Commitments and Contingencies&#8221; for additional details). Under the terms of the lease, the note will be repaid over a 10-year period at an 8% interest rate.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable consisted of the following: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding the Company&#8217;s debt principal repayment obligations as of September&#160;30, 2021: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426565801928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various long-term real estate leases primarily related to office, research and development (R&amp;D) and operating activities. For the three and nine months ended September 30, 2021, total rent </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense was $1.7 million and $4.4 million, respectively. For the three and nine months ended September 30, 2020, total rent expense was $1.1 million and $3.2 million, respectively. The leases described below are classified as operating leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Komas Lease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company entered into a new facilities lease, with the right of use and payments beginning in January 2017. The term of the lease is 7 years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. This lease included an allowance for tenant improvements. Tenant improvements were recorded as property and equipment and are being depreciated over the term of the lease. In conjunction with the allowance for tenant improvements, the Company recorded a lease incentive obligation of $847 thousand which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $282 thousand. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Station 41 Lease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a new facilities lease, with the right of use beginning in December 2017 and payments beginning in June 2018. The term of the lease is 10 years, with one five-year renewal option. This lease includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. This lease included an allowance for tenant improvements of $4.0&#160;million, the full amount of which was drawn in 2017. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. The Company recorded a leasehold obligation for tenant improvements, which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $2.5 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company elected to draw an additional tenant improvement loan of $992&#160;thousand available under the Station 41 lease. This loan is incorporated into and acts to increase the base rent over the remaining life of the lease. The increase in rent includes a charge for interest, which accrues on the principal amount outstanding at a rate equal to 8%. The Company accounts for this additional tenant improvement loan as a note payable on the Condensed Consolidated Balance Sheets with the current portion included in the Current Portion of Notes Payable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company amended the Station 41 lease to include additional space in the conjoining unit with the right to use the new space beginning in June 2020 for an additional seven years. This amendment for the extra space includes provisions for escalating rent payments. Rent expense is recognized straight-line over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Milpitas Lease</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a new facilities lease, with the right of use and payments beginning in August 2019. The term of the lease is 9 years. This lease includes provisions for escalating rent payments. Rent expense is recognized on a straight-line basis over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Station 56 Lease</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a new facilities lease with 91,478 square feet adjacent to the Station 41 lease. The right of use began in August 2021 and the term of the lease is approximately 11 years with a five-year renewal option. The lease includes provisions for escalating rent payments, with total minimum payments of $32.0 million. Rent expense is recognized straight-line over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease includes a tenant improvement allowance of up to approximately $10.1 million. As of September&#160;30, 2021, $2.2 million of the tenant improvement allowance has been utilized. Tenant improvements were recorded as property and equipment and are being depreciated over the remaining term of the lease. The Company recorded a leasehold obligation for the tenant improvements, which is being amortized over the term of the lease as a reduction to rent expense. As of September&#160;30, 2021, the unamortized lease incentive obligation was $2.1 million.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Future Minimum Lease Payments</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum commitments as of September&#160;30, 2021 under the Company&#8217;s lease agreements are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Minimum Payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Obligations</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts with clinical research organizations, drug manufacturers and other vendors&#160;for preclinical and clinical research studies, research and development supplies and other services and products for operating purposes. These contracts generally provide for termination on notice and are cancellable contracts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#8217;s request in such capacity. The Company purchases directors and officers liability insurance coverage that provides for reimbursement to the Company for covered obligations and this is intended to limit the Company&#8217;s exposure and enable it to recover a portion of any amounts it pays under its indemnification obligations. The Company had no liabilities recorded for these agreements as of September&#160;30, 2021 and December&#160;31, 2020, as no amounts in excess of insurance coverage are probable or estimable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Agreements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including accelerated vesting of equity incentives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters </span></div>The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business. An unfavorable resolution of any such matter could materially affect the Company&#8217;s future financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482692504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_TemporaryEquityTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">Convertible Preferred Stock <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has issued preferred stock as part of various financing events. In April 2021, all outstanding shares of convertible preferred stock converted into 115,598,018 shares of Class A common stock as part of the IPO (see Note 10, &#8220;Common Stock&#8221; for additional details on the IPO). There was no convertible preferred stock outstanding as of September&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No convertible preferred stock was issued during the three and nine months ended September 30, 2021. The Company issued 35,349,630 shares of Series D convertible preferred stock for an aggregate purchase price of $235.2&#160;million ($6.70 per purchased share and $5.37 per converted share) during the three and nine months ended September 30, 2020. As part of the Series D issuance, outstanding convertible notes were converted into Series D shares. As of September&#160;30, 2020, there were no cumulative dividends owed or in arrears on the preferred stock.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible preferred stock consisted of the following as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands except share data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferences </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Issuable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Upon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,078,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,965,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,965,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,497,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,471,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,471,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,956,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,776,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,286,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,926,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,898,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,898,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,434,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,088,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,312&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,850&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,598,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Classification </span></div>The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; equity (deficit) on the Condensed Consolidated Balance Sheets because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not redeemable, except in the event of a deemed liquidation event.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484153768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Class A common stock entitles the holder to one vote per share and each share of Class B common stock entitles the holder to 10 votes per share on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#8217;s board of directors. As of September&#160;30, 2021 and December&#160;31, 2020, no dividends had been declared. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;20, 2021, the Company closed its IPO and issued 27,878,787 shares of its Class A common stock at a price of $18.00 per share for net proceeds of $462.4 million, after deducting underwriting discounts and commissions of $35.1 million and other offering costs of $4.3 million. In connection with the IPO, all shares of convertible preferred stock converted into 115,598,018 shares of Class A common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Split</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors approved a 1.5-for-1 forward stock split of the Company&#8217;s common and convertible preferred stock. Each shareholder of record on April&#160;9, 2021 received 1.5 shares for each then-held share. The split proportionally increased the authorized shares and did not change the par values of the Company&#8217;s stock. The split affected all stockholders uniformly and did not affect any stockholder's ownership percentage of the Company's shares of common stock. All shares and per share amounts presented within these Condensed Consolidated Financial Statements were adjusted to reflect the forward stock split for all periods presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A and B Common Shares Authorization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company&#8217;s Board of Directors authorized two classes of common stock, Class A and Class B. The rights of the holders of Class A and B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to 10 votes per share and is convertible at any time into one share of Class A common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Class B common stock is held by Christopher Gibson, Ph.D., our Chief Executive Officer (CEO), or his affiliate. As of September&#160;30, 2021, Dr. Gibson and his affiliate held outstanding shares of Class B common stock representing approximately 37% of the voting power of the Company&#8217;s outstanding shares. This voting power may increase over time as Dr. Gibson vests in and exercises equity awards outstanding. If all the equity awards held by </span></div>Dr. Gibson had been fully vested and exercised and exchanged for shares of Class B common stock as of September&#160;30, 2021, Dr. Gibson and his affiliate would hold approximately 41% of the voting power of the Company&#8217;s outstanding shares. As a result, Dr. Gibson will be able to significantly influence any action requiring the approval of Recursion stockholders, including the election of the board of directors; the adoption of amendments to the Company&#8217;s certificate of incorporation and bylaws; and the approval of any merger, consolidation, sale of all or substantially all of the Company&#8217;s assets, or other major corporate transaction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426565684744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Development Contracts<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Development Contracts</a></td>
<td class="text">Collaborative Development Contracts <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer AG</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the Company entered into a Research Collaboration and Option Agreement (the Bayer Agreement) with Bayer AG (Bayer) for a five-year term pursuant to which the Company and Bayer may initiate approximately 10 research projects related to fibrosis across multiple organ systems, including the lung, liver and heart. Under the agreement, the Company contributed compounds from our proprietary library and Bayer contributed compounds from its proprietary library and will contribute scientific expertise throughout the collaboration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, the Company received a non-refundable upfront payment of $30.0 million, which was recorded as unearned revenue on the Condensed Consolidated Balance Sheet. The Company determined that it has one performance obligation under the agreement, which is to perform research and development services for Bayer. Recursion determined the transaction price to be the $30.0 million upfront payment received and allocated the amount to the single performance obligation. The Company is recognizing the revenue over time using a cost-based input method, based on labor costs incurred to perform the research and development services. This method of recognizing revenue requires the Company to make estimates of the total costs to provide the services required under the performance obligation. A significant change in these estimates could have a material effect on the timing and amount of revenue recognized in future periods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September 30, 2021, the Company recognized $2.5 million and $7.5 million, respectively, of revenue resulting from the collaboration. There was $10.0 million and $9.2 million of current and non-current unearned revenue, respectively, remaining as of September&#160;30, 2021. The allocation of unearned revenue between current and non-current is based on Recursion&#8217;s estimates of when the Company expects to incur the related costs. </span></div>Under each research project, the Company will work with Bayer to identify potential candidates for development. Under the agreement, Bayer has the first option for licenses to potential candidates. Each such license could potentially result in option exercise fees and development and commercial milestone payments payable to the Company, with an aggregate value of up to approximately $100.0 million (for an option on a lead series) or up to approximately $120.0 million (for an option on a development candidate), as well as tiered royalties for each such license, ranging from low- to mid-single digit percentages of sales, depending on commercial success.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482854696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors and the stockholders of the Company adopted the 2021 Equity Incentive Plan (the 2021 Plan). Under the 2021 Plan, 16,186,000 shares of Class A common stock were reserved. Additionally, shares were reserved for all outstanding awards under the previous 2016 Plan. The Company may grant stock options, restricted stock units (RSUs), stock appreciation rights, restricted stock awards and other forms of stock-based compensation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, 15,580,505 shares of Class A common stock were available for grant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for stock options and RSUs for employees and non-employees within the Condensed Consolidated Statements of Operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options generally vest over four years and expire no later than 10 years from the date of grant. Stock option activity during the nine months ended September 30, 2021 was as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands except share data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining&#160;Contractual Life (In Years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,937,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,840,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,711,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,963,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted to employees is calculated on the grant date using the Black-Scholes option valuation model. The weighted-average grant-date fair values of stock options granted during the nine months ended September 30, 2021 and 2020 were $6.41 and $1.49, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021, the Company granted 150,000 shares of stock options with a performance and service condition that had a fair value of $358 thousand. The grant was fully expensed during the three months ended June 30, 2021 as the performance and service conditions were met.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the Company granted 1,500,000 shares of stock options with performance, market and service conditions. At grant date, the Company estimated that the fair value of the options was approximately $2.0 million. For the three and nine months ended September 30, 2021, $41 thousand and $1.6 million of expense was recorded, respectively, as several of the conditions were met during the three months ended June 30, 2021. For the three and nine months ended September 30, 2020, no expense was recorded as the performance conditions were not considered probable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, $27.9 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next three years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">RSUs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, Recursion redesigned certain aspects of its long-term incentive program. As a result, equity awards granted to employees since the redesign generally consist of a combination of stock options and RSUs. RSUs awarded to employees pursuant to the 2021 Plan generally vest over four years. The weighted-average grant-date fair value of RSUs generally is determined based on the number of units granted and the quoted price of Recursion&#8217;s common stock on the date of grant.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes Recursion&#8217;s RSU activity during the nine months ended September 30, 2021: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,723</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.46</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,528)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.42</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,522</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, $3.6 million of unrecognized compensation cost related to RSUs is expected to be recognized as expense over approximately the next three years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Share Purchase Plan (ESPP)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Board of Directors and stockholders of the Company adopted the 2021 Employee Stock Purchase Plan (the 2021 ESPP). Under the 2021 ESPP, 3,238,000 shares of Class A common stock were reserved. The 2021 ESPP has consecutive six-month offering periods. The offering periods are scheduled to start on the first trading day on or after May 20 and November 20 of each year, except the first offering period, which commenced on the Plan Effectiveness Date and will end on the first trading day on or after November 20, 2021. The second offering period will commence on the first trading day on or after November 20, 2021. The per share purchase price will be 85% of the lower of the fair market value on (1) the first trading day of the offering period or (2) the exercise date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESPP grants is measured at grant date. The fair value is determined considering the purchase discount and the fair value of the look-back feature. Black-Scholes pricing models are used to calculate the fair value of the look-back feature. The weighted-average assumptions used in the Black-Scholes models were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, no shares were issued under the 2021 ESPP. For the three and nine months ended September 30, 2021, Recursion recognized expense of $233 thousand and $450 thousand, respectively. As of September&#160;30, 2021, $136 thousand of unrecognized compensation cost related to the 2021 ESPP is expected to be recognized as expense over approximately the next two months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Pacific loan agreement (see Note&#160;7, &#8220;Notes Payable&#8221; for additional details), the Company issued to Pacific fully vested warrants to purchase 84,486 shares of Series A Preferred Stock (Series A warrants) at a purchase price of $0.71 per share. In May 2017, the Company drew on additional borrowing capacity under the Pacific loan agreement, which required the Company to issue additional fully vested warrants for 28,161 shares of Series A Preferred Stock at a purchase price of $0.71 per share. These Series A warrants were exercised in April 2021. As of December&#160;31, 2020, their fair value was $77 thousand.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company drew on additional borrowing capacity under an amended agreement. This required the Company to issue fully vested warrants to purchase 25,762 shares of Series B Preferred Stock (Series B warrants) at a purchase price of $2.79 per share. These Series B warrants were exercised in April 2021. As of December&#160;31, 2020, their fair value was $48 thousand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Company issued warrants to purchase 180,000 shares of Series&#160;C Preferred Stock (Series C warrants) at a purchase price of $6.51 per share as part of a services agreement. The warrants vest ratably over 18 </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">months. The Series C warrants remained outstanding and were fully vested and exercisable as of September&#160;30, 2021. The grant date fair value was $4.10 per share. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FASB has issued accounting guidance on the classification of freestanding warrants and other similar instruments for shares that are redeemable (either puttable or mandatorily redeemable). The guidance requires liability classification for certain warrants that are exercisable into convertible preferred stock. The initial fair values of the Series A and B warrants were recorded as debt issuance costs, which resulted in a reduction in the carrying value of the debt and subsequent accretion. The Company remeasured the Series A and B warrants on each Condensed Consolidated Balance Sheet date. The change in valuation was recorded in the Condensed Consolidated Statements of Operations in &#8220;Other loss, net.&#8221; The liability was recorded to equity upon the exercise of the Series A and B warrants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Series C warrants&#8217; compensation expense was recorded in general and administrative expense ratably over the requisite service period based on the award&#8217;s fair value at the date of grant. These warrants were classified as equity as they were issued to non-employees for services and the convertible preferred stock was not redeemable, except in the event of a deemed liquidation event, which was not considered probable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a summary of the changes in the Company&#8217;s Series A and B warrant liability balance during the nine months ended September 30, 2021 and 2020: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in fair value of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recorded in equity upon exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484351320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record any income tax expense during the three and nine months ended September 30, 2021 and 2020. The Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. Valuation allowances are recorded when the expected realization of the deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. Realization of the Company&#8217;s deferred tax assets are dependent upon the generation of future taxable income, the amount and timing of which are uncertain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards (NOLs) and tax credit carry-forwards are subject to review by the Internal Revenue Service (IRS) and may become subject to annual limitations due to ownership changes that have occurred previously or that could occur in the future under Section&#160;382 of the Internal Revenue Code. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. Any limitation may result in expiration of a portion of the NOLs or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, Utah and California. The Company is not currently under examination in any of these jurisdictions. The Company is subject to income tax examinations on all federal returns since the 2018 tax return.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484125576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, Recursion calculated net loss per share of Class A and Class B common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period. Potentially dilutive securities consist of stock options and other contingently issuable shares. For periods presented in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and as such are excluded from the calculation. For the three and nine months ended September 30, 2021, the Company reported a net loss and therefore basic and diluted loss per share are the same.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights, including the liquidation and dividend rights, of the holders of the Company&#8217;s Class A and Class B common stock are identical, except with respect to voting. As a result, the undistributed earnings for each period are allocated based on the contractual participation rights of the Class A and Class B common shares as if the earnings for the period had been distributed. As the liquidation and dividend rights are identical, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A and Class B common stock was the same during the three and nine months ended September 30, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion issued certain shares of convertible preferred stock that were outstanding until April 2021 and were concluded to be participating securities. For the three and nine months ended September 30, 2020, there was only one class of common stock outstanding. Due to the presence of participating securities, Recursion calculated net loss per share for the three and nine months ended September 30, 2020 using the more dilutive of the treasury stock or the two-class method. For periods presented in which the Company reports a net loss, the losses are not allocated to the participating securities. As the Company reported a net loss during the three and nine months ended September 30, 2020, diluted net loss per share was the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The preferred stock converted to common stock in April 2021 as part of the Company&#8217;s IPO. See Note 10, &#8220;Common stock&#8221; for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amount)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,065,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,045,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,324,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,506,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,965,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,016,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share during 2020:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amounts)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,817,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,704,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,839,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,453,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,589,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,531,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,158,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484109944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value hierarchy consists of the following three levels:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 2 &#8212; Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Level 3 &#8212; Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain a cash balance in a collateralized account to secure the Company&#8217;s credit cards. Additionally, the Company holds restricted cash related to an outstanding letter of credit issued by J.P. Morgan, which was obtained to secure certain Company obligations relating to tenant improvements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company measured the Series A and B preferred stock warrant liabilities at fair value using a Black-Scholes option-pricing model. See Note 12, &#8220;Stock-based Compensation&#8221; for details on the valuation of the warrant liabilities and a reconciliation of the balance. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the financial instruments that are recognized at fair value on the Condensed Consolidated Balance Sheets, the Company has certain financial instruments that are recognized at amortized cost or some basis other than fair value. The carrying amount of these instruments are considered to be representative of their approximate fair values. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments that are not measured at fair value: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484125576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions On December&#160;5, 2017, the Company entered into a loan agreement with its CEO to provide a loan of $595 thousand. The loan had a seven-year term. As of September&#160;30, 2021 and 2020, no amount remained outstanding on the loan as the balance was fully paid during the nine months ended September 30, 2020. The acquisition of Vium was a related party transaction due to the fact that Vium was affiliated with certain investors of the Company. See Note 3, &#8220;Acquisitions&#8221; for additional details on the acquisition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484216760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation and emerging growth company</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of Recursion have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes for the year ended December&#160;31, 2020 included in the Company&#8217;s final prospectus dated as of April 15, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on April 16, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company completed a 1.5-for-1 forward stock split of common and convertible preferred stock. All shares presented within these condensed consolidated financial statements were adjusted to reflect the forward stock split for all periods presented. See Note 10, &#8220;Common Stock&#8221; for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company&#8217;s Board of Directors authorized two classes of common stock, Class A and Class B. Certain shares of Class A were exchanged for Class B on a one-for-one basis. The creation and issuance of the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B common stock did not affect the loss per share for the Class A or Class B shares for any period. The Company presented the 2021 net loss per share amounts as if the authorization and exchange occurred as of the start of the 2021 reporting period. See Note 10, &#8220;Common Stock&#8221; for additional details. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is management&#8217;s opinion that these condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company&#8217;s financial statements. Revenues and net loss for any interim period are not necessarily indicative of future or annual results.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company (EGC), as defined by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). The JOBS Act exempts EGCs from being required to comply with new or revised financial accounting standards until private companies are required to comply. Recursion has elected to use the extended transition period for new or revised financial accounting standards, although the Company may adopt certain new or revised accounting standards early. This may make comparisons of the Company&#8217;s financial statements with other public companies difficult because of the potential differences in accounting standards used. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion may remain an EGC until the earlier of (1) December 31, 2026; (2) December 31 of the year in which we (a) become a &#8220;large accelerated filer;&#8221; or (b) have annual gross revenues of $1.07&#160;billion or more; or (3) the date on which we have issued more than $1.0&#160;billion of non-convertible debt over a three-year period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02). Under ASC (Accounting Standards Codification) 842 - Leases, the Company will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) on its Condensed Consolidated Balance Sheet at the commencement date of each lease. ASC 842 is effective for annual and interim periods beginning on or after December 15, 2021 and early adoption is permitted. The Company must adopt the standard using the modified retrospective approach either: (1) as of the earliest period presented and through the comparative periods in the entity&#8217;s financial statements or (2) as of the effective date of ASC 842, with a cumulative-effect adjustment to equity. The Company expects the adoption to materially increase assets and liabilities on the Condensed Consolidated Balance Sheets related to those leases classified as operating and not recognized on the Condensed Consolidated Balance Sheets under current GAAP. The Company is continuing to evaluate the effect that ASC 842 will have on its consolidated financial statements and related disclosures. The Company will adopt the new standard on January 1, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484125576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of the Fair Value of Assets Acquired</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired as of the July 2020 acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.743%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482786760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:69.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued early discovery expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued investment purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expense and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest income and expense disclosure</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484142232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-Sale Investments by Type of Security</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s available-for-sale investments by type of security: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross unrealized losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available -for-Sale Investments by Balance Sheet Classification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of the Company&#8217;s available-for-sale investments on the Condensed Consolidated Balance Sheets:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484074456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text">The following table summarizes intangible assets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible asset </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text">The following table summarizes intangible assets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross carrying amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net carrying amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite-lived intangible asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived intangible asset </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484142232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable consisted of the following: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.613%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities of long-term debt</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding the Company&#8217;s debt principal repayment obligations as of September&#160;30, 2021: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt principal payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484218040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum commitments as of September&#160;30, 2021 under the Company&#8217;s lease agreements are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Minimum Payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482837192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of temporary equity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible preferred stock consisted of the following as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands except share data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferences </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Issuable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Upon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Conversion </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,078,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,965,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,965,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,497,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,471,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,471,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,956,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,776,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,286,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,926,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,898,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,898,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,434,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,088,065&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,312&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,850&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,598,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489679960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for stock options and RSUs for employees and non-employees within the Condensed Consolidated Statements of Operations: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Option, Activity</a></td>
<td class="text">Stock option activity during the nine months ended September 30, 2021 was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in thousands except share data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining&#160;Contractual Life (In Years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,937,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,840,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,711,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,963,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,803&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to calculate the grant-date fair value of stock options: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Nonvested RSU Activity</a></td>
<td class="text">The following table summarizes Recursion&#8217;s RSU activity during the nine months ended September 30, 2021: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock units</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,723</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.46</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,528)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.42</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,522</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions</a></td>
<td class="text">The weighted-average assumptions used in the Black-Scholes models were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary Of Changes In Company's Warrant Liability</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following is a summary of the changes in the Company&#8217;s Series A and B warrant liability balance during the nine months ended September 30, 2021 and 2020: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in fair value of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in fair value of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recorded in equity upon exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482771704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of basic and diluted net loss per share of Class A and Class B common stock during 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amount)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation of undistributed earnings</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,065,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,045,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share during 2020:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share amounts)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,817,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,704,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.09)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class B</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,324,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,764,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,506,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,965,898&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,016,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potential common shares from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three months ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine months ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,839,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,453,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,589,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,531,072&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,158,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426483981624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock', window );">Fair Value Disclosure of Asset and Liability Not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments that are not measured at fair value: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book values</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair values</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about fair value of asset and liability not measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2E<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498357-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426488597080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (335,147)<span></span>
</td>
<td class="num">$ (213,601)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482589944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock (Class A and B)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426485422552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired based on fair values:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ViumIncMember', window );">Vium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired based on fair values:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Other intangibles assets</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">1,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rxrx_ViumIncMember', window );">Vium | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired based on fair values:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Technology intangible asset</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rxrx_ViumIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rxrx_ViumIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489002632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - PPE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 71,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(16,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,962)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">55,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">29,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">20,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property and equipment additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 8,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rxrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489542616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Financial Information - Accruals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 7,261<span></span>
</td>
<td class="nump">$ 3,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_AccruedDevelopmentCostsCurrent', window );">Accrued development expenses</a></td>
<td class="nump">3,813<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_AccruedEarlyDiscoveryExpensesCurrent', window );">Accrued early discovery expenses</a></td>
<td class="nump">1,520<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_AccruedInvestmentPurchasesCurrent', window );">Accrued investment purchases</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Accrued construction</a></td>
<td class="nump">996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">5,625<span></span>
</td>
<td class="nump">4,773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">$ 25,113<span></span>
</td>
<td class="nump">$ 10,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AccruedDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AccruedDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AccruedEarlyDiscoveryExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Early Discovery Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AccruedEarlyDiscoveryExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AccruedInvestmentPurchasesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Investment Purchases, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AccruedInvestmentPurchasesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489294248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Financial Information - Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_SupplementalFinancialInformationAbstract', window );"><strong>Supplemental Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 2,971<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Interest expense, net</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 2,877<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SupplementalFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SupplementalFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426488638600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Type of Security (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 405,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">405,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">187,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">187,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rxrx_CorporateBondsMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">5,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">5,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">21,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">21,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">191,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair values</a></td>
<td class="nump">$ 191,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rxrx_CorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rxrx_CorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489679960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Balance Sheet Classification (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale investments</a></td>
<td class="nump">$ 405,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale investments</a></td>
<td class="nump">221,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale investments</a></td>
<td class="nump">$ 184,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426594986744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of unrealized loss positions (in positions) | position</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment of available for sale securities | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489068440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Change in carrying amount of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 911,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(354,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(354,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible asset</a></td>
<td class="nump">904,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">904,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">904,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross</a></td>
<td class="nump">1,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,688,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426565956872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Midcap Financial (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (827)<span></span>
</td>
<td class="num">$ (883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember', window );">Midcap loan agreement, tranche 1 | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rxrx_PacificWesternBankLoanMember', window );">Pacific Western Bank loan | Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rxrx_MidcapLoanAgreementMember', window );">Midcap loan agreement | Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">$ (996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of fees in connection with the midcap loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_PacificWesternBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_PacificWesternBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_MidcapLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_MidcapLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426566163176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Pacific Western (Details) - Letter of credit - Pacific Western letter of credit - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_PacificWesternLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_PacificWesternLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426576670808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Convertible Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock issued during the period, value of conversion of convertible securities</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued in the period, upon conversion (in shares)</a></td>
<td class="nump">1,203,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of derivate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (161)<span></span>
</td>
<td class="num">$ (484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489646120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Notes Payable for Tenant Improvement Allowance (Details) - Notes payable - Station 41 lease<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426483982744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Current/Noncurrent (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total liabilities</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">11,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: unamortized issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total liabilities</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 12,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489181848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Principal Repayments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LongTermDebtMaturityAfterYearFour', window );">Thereafter</a></td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total liabilities</a></td>
<td class="nump">$ 744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426487164552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>extensionPeriod</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_Station41Member', window );">Station 41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_MilpitasMember', window );">Milpitas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_Station56Member', window );">Station 56</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Incentive from lessor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent', window );">Lease incentive, payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset', window );">Size of leased asset (in square feet) | ft&#178;</a></td>
<td class="nump">91,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseTenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember', window );">Station 41 lease | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LeaseArrangementNameAxis=rxrx_KomasMember', window );">Komas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Incentive from lessor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent', window );">Lease incentive, payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LeaseArrangementNameAxis=rxrx_Station41Member', window );">Station 41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Incentive from lessor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent', window );">Lease incentive, payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options (in extension periods) | extensionPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_LeaseArrangementNameAxis=rxrx_Station56Member', window );">Station 56</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LesseeOperatingLeaseSizeOfLeasedAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Size Of Leased Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LesseeOperatingLeaseSizeOfLeasedAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LesseeOperatingLeaseTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee. Operating Lease, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LesseeOperatingLeaseTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive received by lessee from lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123386226&amp;loc=d3e41620-112719<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_Station41Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_Station41Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_MilpitasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_MilpitasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_Station56Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=rxrx_Station56Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rxrx_Station41LeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LeaseArrangementNameAxis=rxrx_KomasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LeaseArrangementNameAxis=rxrx_KomasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LeaseArrangementNameAxis=rxrx_Station41Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LeaseArrangementNameAxis=rxrx_Station41Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_LeaseArrangementNameAxis=rxrx_Station56Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_LeaseArrangementNameAxis=rxrx_Station56Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489094184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Minimum payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">3,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">7,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">7,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">7,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">34,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total Minimum Payments</a></td>
<td class="nump">$ 61,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426484851976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,539,147<span></span>
</td>
<td class="nump">110,539,147<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,088,065<span></span>
</td>
<td class="nump">75,189,517<span></span>
</td>
<td class="nump">75,189,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesDPreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,898,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,349,630<span></span>
</td>
<td class="nump">35,349,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235.2<span></span>
</td>
<td class="nump">$ 235.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.70<span></span>
</td>
<td class="nump">$ 6.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_SaleOfStockConvertedPricePerShare', window );">Price per converted share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.37<span></span>
</td>
<td class="nump">$ 5.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued in the period, upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,598,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">27,878,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from transaction</a></td>
<td class="nump">$ 462.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_SaleOfStockConvertedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Converted Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_SaleOfStockConvertedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426481390200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,434,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,088,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,088,065<span></span>
</td>
<td class="nump">110,539,147<span></span>
</td>
<td class="nump">75,189,517<span></span>
</td>
<td class="nump">75,189,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 448,312<span></span>
</td>
<td class="nump">$ 437,922<span></span>
</td>
<td class="nump">$ 201,109<span></span>
</td>
<td class="nump">$ 201,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preferences</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Shares of common stock issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,598,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,078,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,965,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,965,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Shares of common stock issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,965,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesA1PreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Shares of common stock issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesBPreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,497,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,471,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,471,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Shares of common stock issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,471,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesCPreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,956,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,776,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,776,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Shares of common stock issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,286,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesDPreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredUnitsLineItems', window );"><strong>Preferred Units [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,926,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,898,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,898,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preferences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Shares of common stock issuable upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,898,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a new issue of securities classified as temporary equity that are allocated to investors for them to buy.  When securities are sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the securities to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426485366056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>vote</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CommonStockVotePerShare', window );">Vote per share of common stock (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CommonStockVotePerShare', window );">Vote per share of common stock (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rxrx_ChristopherGibsonAndAffiliatesMember', window );">Christopher Gibson and his affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_AffiliatedHoldersOwnershipPercentage', window );">Affiliated holders, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest', window );">Affiliated holders, potential ownership percentage when outstanding equity awards vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">IPO, number of shares issued (in shares) | shares</a></td>
<td class="nump">27,878,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">IPO, net proceeds received</a></td>
<td class="nump">$ 462.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">IPO, underwriting discounts and commissions</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_PaymentsOfStockIssuanceExpenses', window );">IPO, expenses costs</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued in the period, upon conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,598,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AffiliatedHoldersOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affiliated Holders, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AffiliatedHoldersOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CommonStockVotePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Vote Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CommonStockVotePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_PaymentsOfStockIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of Stock Issuance Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_PaymentsOfStockIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rxrx_ChristopherGibsonAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rxrx_ChristopherGibsonAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426565678616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Development Contracts - Bayer AG (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>project</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of unearned revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Unearned revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,167<span></span>
</td>
<td class="nump">9,167<span></span>
</td>
<td class="nump">$ 16,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rxrx_BayerAGMember', window );">Bayer AG | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CollaborativeAgreementTerm', window );">Collaborative agreement, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated', window );">Number of projects that may be initiated (in projects) | project</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived', window );">Non-refundable upfront payment received</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of unearned revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Unearned revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries', window );">Research project, fees and milestones payments receivable for an option on a lead series</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate', window );">Research project, fees and milestones payments receivable for an option on a development candidate</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Refundable Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number Of Projects That May Be Initiated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Development Candidate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Lead Series</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_CollaborativeAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_CollaborativeAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rxrx_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rxrx_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426566411848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,840,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,863,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,863,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,937,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,096,000<span></span>
</td>
<td class="nump">$ 824,000<span></span>
</td>
<td class="nump">$ 9,771,000<span></span>
</td>
<td class="nump">$ 2,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unvested stock options, unamortized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Options, granted in period, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate', window );">Options, outstanding, estimated fair value at grand date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxrx_A2021EquityIncentivePlanMember', window );">2021 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">16,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,580,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,580,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rxrx_A2021EmployeeStockPurchasePlanMember', window );">ESPP | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Estimated Fair Value At Grant Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share-Based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxrx_A2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxrx_A2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rxrx_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rxrx_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426488918888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 3,096<span></span>
</td>
<td class="nump">$ 824<span></span>
</td>
<td class="nump">$ 9,771<span></span>
</td>
<td class="nump">$ 2,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 1,791<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 6,771<span></span>
</td>
<td class="nump">$ 1,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489896216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, number at beginning of period (in shares) | shares</a></td>
<td class="nump">20,937,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted in period (in shares) | shares</a></td>
<td class="nump">2,840,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, cancelled in period (in shares) | shares</a></td>
<td class="num">(1,203,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised in period (in shares) | shares</a></td>
<td class="num">(2,711,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, outstanding, number at end of period (in shares) | shares</a></td>
<td class="nump">19,863,650<span></span>
</td>
<td class="nump">20,937,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable, number (in shares) | shares</a></td>
<td class="nump">7,963,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, outstanding, weighted average exercise price at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, grants in period, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, cancelled in period, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, exercised in period, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, outstanding, weighted average exercise price at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">3.03<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options, exercisable, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, outstanding, weighted average remaining contractual life</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options, exercisable, weighted average remaining contractual life</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, outstanding, intrinsic value | $</a></td>
<td class="nump">$ 396,084<span></span>
</td>
<td class="nump">$ 12,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercised in period, intrinsic value | $</a></td>
<td class="nump">14,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options, exercisable, intrinsic value | $</a></td>
<td class="nump">$ 169,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426482641112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426490551832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSU Activity (Details) - Restricted stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">143,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(2,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, outstanding (in shares) | shares</a></td>
<td class="nump">140,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, outstanding Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">29.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">34.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in shares) | $ / shares</a></td>
<td class="nump">29.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, outstanding Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 29.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489405928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details) - ESPP<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_WarrantsArrangementsLineItems', window );"><strong>Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.04%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_WarrantsArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_WarrantsArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426485307272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2016WarrantsMember', window );">2016 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_WarrantsArrangementsLineItems', window );"><strong>Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2017WarrantsMember', window );">2017 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_WarrantsArrangementsLineItems', window );"><strong>Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ClassOfWarrantOrRightFairValue', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2018WarrantsMember', window );">2018 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_WarrantsArrangementsLineItems', window );"><strong>Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ClassOfWarrantOrRightFairValue', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_WarrantsIssuedInJanuary2020Member', window );">Warrants Issued In January 2020 | Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_WarrantsArrangementsLineItems', window );"><strong>Warrants Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ClassOfWarrantOrRightIssued', window );">Warrants issued (in shares)</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, vesting period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_ClassOfWarrantOrRightGrantDateFairValue', window );">Warrants, grand date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ClassOfWarrantOrRightFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ClassOfWarrantOrRightFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ClassOfWarrantOrRightGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ClassOfWarrantOrRightGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_WarrantsArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_WarrantsArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2018WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rxrx_A2018WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=rxrx_WarrantsIssuedInJanuary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=rxrx_WarrantsIssuedInJanuary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rxrx_ConvertibleSeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489517864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details) - Warrants - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants at beginning of period</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net increase in fair value of warrants</a></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Recorded in equity upon exercise</a></td>
<td class="num">(2,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of warrants at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426483995400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489347192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarnings', window );">Undistributed earnings, basic</a></td>
<td class="num">$ (44,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsDiluted', window );">Undistributed earnings, diluted</a></td>
<td class="num">$ (2,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (111,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">168,533,550<span></span>
</td>
<td class="nump">21,817,900<span></span>
</td>
<td class="nump">110,513,231<span></span>
</td>
<td class="nump">21,704,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">168,533,550<span></span>
</td>
<td class="nump">21,817,900<span></span>
</td>
<td class="nump">110,513,231<span></span>
</td>
<td class="nump">21,704,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per shares)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per shares)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarnings', window );">Undistributed earnings, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (111,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsDiluted', window );">Undistributed earnings, diluted</a></td>
<td class="num">$ (44,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">159,065,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,045,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">159,065,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,045,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per shares)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per shares)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarnings', window );">Undistributed earnings, basic</a></td>
<td class="num">$ (2,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsDiluted', window );">Undistributed earnings, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">9,467,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,467,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">9,467,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,467,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per shares)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per shares)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2814-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426481435176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,531,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,158,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">16,965,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,016,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,839,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,453,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,324,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options and RSUs | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">16,764,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,506,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options and RSUs | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">163,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP | Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">37,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP | Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of loss per share, amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,576,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,589,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426566190104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">$ 10,233<span></span>
</td>
<td class="nump">$ 5,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">416,143<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">5,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">21,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">156,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">187,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">34,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">10,233<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">197,458<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">187,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">218,685<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">5,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">21,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">156,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">34,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash and Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426565794584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">11,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Book values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total liabilities</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember', window );">Book values | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">11,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Total liabilities</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair values | Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems', window );"><strong>Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 11,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140426489738216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Chief Executive Officer - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 05, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Loan to related party</a></td>
<td class="nump">$ 595,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.S5#SN;+[1"C81)M/&@/:(:\$(Q:5 \Y9,CH43]0XLB6B,YQ.J1XX@E-,E$
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M]T($S55"%5N1]!Y]0M\7S^CNPSWZ@%B.OB6\E"2/Y<14@$_O8JX:+$\U%GL
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M""'J.U<]4;RHKBU+KN 25 T3N*=2H0U@?<VY>IOHFU![\YW]#U!+ P04
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MU-5MZ$SA5M!<@N+L=@%U51$*/[GU0%VU@8;+C8'-1Q/97PZ,O8<%@WQC ;*
MC+V'!>3V9H7C#6M75^ S=45;.YY/ .Y6;XP^F0#<K8T8_VH"FLCC[9\^RF<6
M5.AK9>#< @H,JL49JEJATSM7R5BQK@ZTA%H^=KFLM\_MT_;0[*XZ*M*>WZ.;
M&;(\GZ.;17TDUM'7)W1?:;%.<@%2ME)-P7&@OM>B/O2J;R3?5J<ZSUQ*GE67
M&T9C5I0 ]7[%N7R[*1MHCQZG_P-02P,$%     @ -3]J4^?O*(DN P  C0H
M !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RE5FUOVC 0_BM6M ^MM#:O
MO*P"I!:85FG=JK)N'Z9],(DA5A.;V0YT^_4[.R$CJ0G5]H7$SO/<W7.^,S?:
M<?$D4T(4>LXS)L=.JM3FRG5EG)(<RTN^(0R^K+C(L8*E6+MR(PA.#"G/W,#S
M^FZ.*7,F([-W+R8C7JB,,G(OD"SR'(M?-R3CN['C._N-![I.E=YP)Z,-7I,%
M48^;>P$KM[:2T)PP23E#@JS&SK5_-1]JO %\I60G#]Z15K+D_$DO;I.QX^F
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M/V</[UGK$*G:B[*DJ/]W'EI9=^)$ZZ+,EJTRMV 9I\W?\&L;B(X"0 8%V"I
M20$!@P)J%9"D 'V# FX5L*P0&!1(JT D!6)2H*T"E16H0<%K%3S9),^@X+<*
MOMR#22%H%0)9 9L&SGT<.5<VRCC6F\&61QN9(@4>AQO4XSUK)E8]*\_#,CPY
MRK,')Z_D>7O50SVU:WT^&>.T6H779<Z_C;E>>7*6I7.^IMC<X4]%EL3SL.0O
MUR7_PQ=;63C9;?75/<O+^"9ASA5?)2S/:YDL^N*$:?NTR)(YRXOOO_,A\'YR
M+OY=Q^4WY^"<W<917!XZ!^LT7,]CWOJA,W7^N#YW#EX=.J^<.'5^7V3K@C=4
M',U*[E-EV2QJ[3]M[(<&^W_/RC#1J)W9U:Y9'K/">=N8W[R<.G^%>1YRGS7M
MG=O;ZT9HM8E04<5%T]C%4&/+)4]037P/SI*P>+3T]%#3VKO=6QL=AI]W[VM<
MB-[;.WH[YS.)9_$P<:[">#Z-T^E9N(KU<^%RU[9&A^?#KCV-"\['@6ZB:+U<
M)_5";I>?II%/VS>2E0N6.U&VY*8M*@2^9WS9\G?6;W?&D\\F \%-!H)U1]BT
M@MERE>6< 3BL3AFOG6(1YCS2G#,4)8]\G-XY8>G<L+LX3:L7GI%6?#"RN7/
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M7,H@%?/TI8Q&4$ZZ2*V7-:6,1LI:RB !L\@.L\]S &.(FXJV $#7]UUJ\D/
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MW?9,[*7S-+80VF*X0)D/XD0/*+ULUP_E9^^6I];:*4[Q'*$M17SP)KY 8<(
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M6*/7QIIT4$5K1,'K/_V.ZC4%=<G97%ZH#(T$<>5T39_"]_//]S. 5%!#:FW
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M"%7J,8$:#QNZ$:^Q-WEI$]MKT1YHG)Q^?WU]-SG@[S$$SI.K=<2.J80K?&W
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MN>DI#L-[MFUW=@UQZ>/9-^S,($F@)%5Z##J=2*4NE$R?8GC;1AQ8E+:GTPG
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M,J%%;$8BS#)*$8NFKV.S;^G0A-X[25A8;C&N$ 0:776Q\Q.2=)(/DANSSRG
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MED[ M"?M]L'I.IQNU]KA63G<[O#CA!LO@.\W&H/8/7@#P^?.^5]02P,$%
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MRB+BITE@ADD,6S\'E84]JD(0VMC]0=R: !T !YGYMJ9"-%=$P1)9 3;/"NV
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M;D@"_;P!SU<&V6MN6$'WB>CZ?U!+ P04    "  U/VI3>O=2@.X(   /'
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6S565US&[<5_2L85LTD,S2_
M94J.I!G)3B9NXU9CN>U#IP_@+D@BW@4V %84\^M[[@5VEY0HIO78;?(B+;'
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M0; L=W;.1AD[3VO5+GWYM$/2J8#1FAI,"]VH\(/.@8GB92^3KN&DZ1")BC6
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MUTH"J30![Y<69[3T@Q2TWP"O_@U02P,$%     @ -3]J4TX.PZV?!   QPH
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ML"MQJ:7W8B[R).*C")F@@B8O0DFBM+H@)X(5UI!8VT"BQGM"D*80M =P\9\
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MXAN-' M@?V51NNT+&]A^]5W\"U!+ P04    "  U/VI3U2F%X3D%  ""#
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M0C;@^\:YV+](@.'?CHM_ 5!+ P04    "  U/VI3<W=ZH2(-   :*   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RU6FUSV[@1_BL8U]>Q9VA9I-Z=
MEQD[R5W3:7(>^^XRG4X_0"0D8<(7A2 MJ[^^SRY BJ0DVTFO'RQ+)+#8?;#[
M8'?)UYLL_VI62A7B,8E3\^9D513KJ\M+$ZY4(DTO6ZL4=Q99GL@"/_/EI5GG
M2D8\*8DO@WY_?)E(G9Z\?<W7;O.WK[.RB'6J;G-ARB21^?9&Q=GFS8E_4EVX
MT\M501<NW[Y>RZ6Z5\7OZ]L<ORYK*9%.5&ITEHI<+=Z<7/M7-T,:SP/^T&IC
M&M\%63+/LJ_TXV/TYJ1/"JE8A05)D/CWH-ZI."9!4..;DWE2+TD3F]\KZ3^S
M[;!E+HUZE\5?=%2LWIQ,3T2D%K*,B[ML\S?E[!F1O#"+#7^*C1T[')R(L#1%
MEKC)T"#1J?TO'QT.C0G3_I$)@9L0L-YV(=;RO2SDV]=YMA$YC88T^L*F\FPH
MIU/:E/LBQUV-><7;^R(+OU[<P*Y(O,L2[+61!-?KRP+2:<QEZ"3=6$G!$4DS
M\2E+BY41'])(1>WYE]"J5BVH5+L)GA1XK]8],>A[(N@'_A/R!K6I Y8W."9O
M)7-U,6=3;^46GE6(ZSR7Z5+Q]W]=STV1PTW^_<1BPWJQ(2\V_!-P?5(21>65
M6<M0O3E!V!F5/ZB3H^+%QU1<KW,=,VB>*%9*W&0RCT2V$.]UCEC(<B-D&O$M
M0V)661PI7,0(ND;B9+H5,LK6A;+C2)CX\*W4Q18KA$ +H21N8YF*L_H^_3SO
MB=^Q_;EH7?6$/_;\Z=CK]_O"T#;P:N]B:8RX%F&6)%"=E1$;E2OA[(QZXCJ*
M-!DFXWCK57-;8P282>"V .68 I;I="GD!C8;4=:Z +H'G94&2OEC5JHG?FM8
MF\BM6,(7"J<&;,>JQJ-EBER'A(2]4Z:Z,.+L[OYW<^ZY:W(-^:&V6Y 3$1R:
MZ90B\#/HE)/F"2/!]YUKAHWMA/U\'Z%0J&2.*54\ -*1-YKVO5%_]")(Y8/4
ML9S'BO%B4RT"BRP&,Q-H!=]F)TMA(L$6DCR]T*$U[0E5A7JD[U9\"T,VF.#B
M6RI9Q]E6*7LYS=*+W96-+E8Z=5Z(K4NM>Z<FBW4D"<C[ O\25@^Z_+I6.2]N
MKF!*KI1(+ 4IHJ .:I\15T_=/^.5X2+0RYQ;Y\5'O_'M#LC(/%RQZI%ZP)&V
M9NHX%;XWP$:<BH$?T"=[.ET-IE/QBTJA9\RS9 02U\0S'$*^-YGY8H1)8V\R
M\?%[-.F+W[("PUG,;(S_TV"(SQF/.!6!-QU-!3, $+ 0W[< 7]H%XZUX@ ^*
M[(%]K<S%%NI;X+%;8 /@+V(@2C&"6/;[;L0BSQ+>!D*=D';^TES&'JC$"%&9
ML_M@?/H,R(SE1D('XQP/6]="'IJ%F&)]FM:7Y^+>^O<7/F)5='$-@Y QB ^/
M*@\U?.X6<:;V[]\I2DM(-S@14WL)7/^A%TJ<@2C_2;:>B^OE,E=+,O0C!FGD
M&Z'X0\:E$K\V&84][KT*G3&^5WF'-QM,O.%P0/O=FX[$M$>.X ?>;#06OQ!P
M@ &;-NQ[P_$$(/<F$_%.@D;C&'?.X"3]@1<,9G"Z'G:ZL@JW F_B^QXP.X?H
M(!#^T!M,Q@?T.H"R/_.FXX$W'I$C#GK] 11CWYR!AZ?U,ASS1X5,O!EDC,93
M-@[N-V$9_AC"(9'Y0^I</#!>D%&[H+.[R!H1KXT(91R6,<=R9B/=LBX[6FDJ
M/[J))5CF/L391,1F'8X6L5R39)&*+7UMJDV7;M-9W@7+VZFV8]D]#;_7>REZ
M>.>95D_'O:&]=NKWAC-F_;7B5#/>=@EV3U>0:YDX?5A<:2QF-4P[B+HF[5ET
M]2S%[9CLPR,I26NI/.$ W-I@&&-_Z:\>\)!!#1U3G(_'XB<Q'N&COAN! <#3
MD=AJ%4?BKW^9!G[PJOY_I\W7BP41LP;6=""*G*SH]V83B/%[8,F?*&?Y6<WS
M$D5!(VVI3N9JG_Q1OY,_M/>3#@\A!8X$+E407KPME"00.80X4#B3(*HKQ$J"
MBSMHG@[ JQ41V;VSSDF$M2B)3]TAU_*:8O_D^7N)C=AYC#U+G]7,^4"BP+3
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M5*8GDE33''F0>"-C5OV>WWS9Y<D(L'1)&#6>-K1:<S_V?)*FN=/_5W:4.#-
M+%5%KTH :/6=#[36I)Z1[5N5:^?5=7WP],X=B6/76#G\ +=K[O+XX\MJ2HM$
M;.<,^AI=J+K-[$J<5K.)>V)UDZ<1]Z[!O-\V,JKCE%6LN"S/=?>X?;IMY<?
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M,CQ:8MDBR!(PY73*LCA(IPEPGSZHJB28S@'L**01%BRRV:!T(BJ$>7_UA;"
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M7^Z41+!I =[35Y/FAA2TWWQO_P=02P,$%     @ -3]J4\C&]#RX @  M@4
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MW.57OJQ!7TU]@X36S2^VX+<.G)T S\DGV9I*D_NVA/+?_CX&.D;+=M'>LK.
MS]!=DRB@A 4L/(,7C=E' U[TX]G_M5AJHU \?Y_AFXQ\DX%O<HH/>ZKL:R!R
M13J%G:7,&^%M2>![+SH;Q[$BG\6T77NC.U[ S,.VU*!>P)L_'8+?[\ )UL]
MLP0U%/$#%-M)2,FE:(FI9*_10U\-!;:/@#SRY3X\<D%83I-D@H,PIVD0DD?
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MFIQ.B1W33=].<+H)$Z_0CN9GV&[HAX7&*]#]6E._]8)W,/P"5W\ 4$L#!!0
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M<&NUPQS^)G!I'.#[6D 5[%Y,@/Z/Q_1O4$L#!!0    ( #4_:E-=)&K[ 00
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MH7%UL=<-[HH@#0.^YP*#T1)&0;]]+OX#4$L#!!0    ( #4_:E/% .BE,@(
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MLON(@Y][QY=+KOT7NB$W#"!OM9'U +8*:B;ZD;X-=3@!1-,+@'@ Q/\+2 :
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MYIP9#H]G<5#Z@\D +/F4"VF67F;M[MKW39Q!SLR5VH'$7U*E<V;Q56]]L]/
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MP*-V#FR.!&B_0FD:L8:_I];72Z,06<,P>J499>8KS*#AVE<JTT@V'-9L=50
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MWM$(K9+5):!J:%'80VLI-!Z!]C7%>Q-($X#]*X&KH&Z8 9J;V.P?4$L#!!0
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M%?HH&\* *R(XDK"=!;?QS=W4^CN'[P3VZF",;"5K(9ZM\6TS"R*;$%"HM(V
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MQ.^;-.7/!\4KQ_HU^?P_4$L#!!0    ( #4_:E/*EKB8&@0  $4.   9
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M*7S;4LW)LVDJVTB6FG%ASJ0:/LPR5!,H< U0SY>,R=U&&RAFVOY?4$L#!!0
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M=&NF;&SEPNDB-).E=M2:PC2C?P$:;T#G:ZW=<>$#U'^7R1]02P,$%     @
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M,^JAJ%T [:^5LON)>T#3E:>_ 5!+ P04    "  U/VI3'"K#A$4"  !I!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6RE55UOFS 4_2L6VD,K;8$
M[;:(("4AT_I0*6K6[6':@P,WP:H_F&U"]N]G&\*RBB;5]@+V]3WG^%SC2]((
M^:1* (T.C'(U]4JMJXGOJ[P$AM5(5,#-RE9(AK69RIVO*@FX<"!&_3 (;GV&
M"??2Q,56,DU$K2GAL))(U8QA^6L.5#13;^P= P]D5VH;\-.DPCM8@WZL5M+,
M_)ZE( RX(H(C"=NI-QM/EK'-=PE?"33J9(RLDXT03W9R5TR]P&X(*.3:,F#S
MVL,"*+5$9AL_.TZOE[3 T_&1_9/S;KQLL(*%H-](H<NI]\%#!6QQ3?6#:#Y#
MY^?&\N6"*O=$39L;11[*:Z4%Z\!F!XSP]HT/71U. (9G&!!V@/ Y('X!$'6
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M$T>V^$.$;A>5GFU# =P2(84E]<T#8"2&446*QGFCWX$%>$/A,U?UB62P_Q+
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M4<8E0=($:P*M$W*="+Q."'8B$#LAV8G [(1H)P*U$[*="-Q."'<BD#LAW8G
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MGXW_FCQ_ 5!+ 0(4 Q0    ( #4_:E,'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ -3]J4Q$V) ;N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ -3]J4YE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  U/VI35L=?9IX%   :&
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ -3]J4TA]5P7R!@  &1P  !@              ("!X0T  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #4_:E/6+*(9KP,
M  4/   8              " @0D5  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  U/VI3SH85#_\$  "&%   &               @('N
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ -3]J4^?O
M*(DN P  C0H  !@              ("!(QX  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( #4_:E/X[\7N_0D  #D^   8
M  " @8<A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  U
M/VI310(CUFH"  "?!0  &               @(&Z*P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ -3]J4]>UNN8Y!P  NQT  !@
M         ("!6BX  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( #4_:E,GL-6U2 <  -L0   8              " @<DU  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  U/VI3UR?T5;X&  !9$
M&0              @(%'/0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( #4_:E.B#:.N7P0  (H)   9              " @3Q$  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ -3]J4Y.36L\I
M!0  ^@P  !D              ("!TD@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  U/VI3#L<X);P%   @#0  &0
M@($R3@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #4_
M:E.:_4EF\ ,   T+   9              " @254  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ -3]J4S.6<,"*!P  +A(  !D
M         ("!3%@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  U/VI3>O=2@.X(   /'   &0              @($-8   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #4_:E-.#L.MGP0  ,<*
M   9              " @3)I  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ -3]J4[$ _L^K!0   0X  !D              ("!"&X
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  U/VI3U2F%
MX3D%  ""#   &0              @('J<P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( #4_:E-S=WJA(@T  !HH   9
M  " @5IY  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M-3]J4[?)B7C&!   I0H  !D              ("!LX8  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  U/VI3C%&AB.4&  "!%0  &0
M            @(&PBP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( #4_:E,:PH2O2P8  #,0   9              " @<R2  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ -3]J4XO>:8CQ @
MA08  !D              ("!3ID  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  U/VI3.Z56R*,(  #_%0  &0              @(%V
MG   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #4_:E/(
MQO0\N (  +8%   9              " @5"E  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ -3]J4P+K(5;V P  T D  !D
M     ("!/Z@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #4_:E-2&EH65@,  /@&   9              "
M@3BY  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ -3]J
M4U,@H:HX!@  *!$  !D              ("!Q;P  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  U/VI3N2UYN(H$  "$#   &0
M        @($TPP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( #4_:E-=)&K[ 00  (D*   9              " @?7'  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ -3]J4\4 Z*4R @  HP0
M !D              ("!+<P  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  U/VI3%8NP"AT"  "1!0  &0              @(&6S@
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #4_:E//]V6"
MC ,  -8+   9              " @>K0  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ -3]J4P$;T,KV P  AQ   !D
M ("!K=0  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  U
M/VI3QZ?)X=$"  !^"   &0              @(':V   >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #4_:E/2$;R'N0(  'H(   9
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M970T-2YX;6Q02P$"% ,4    "  U/VI3PK6SW*H#   1#0  &0
M    @($#[   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M #4_:E/\:&"J4 (  'H%   9              " @>3O  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ -3]J4X7'5&$6 P  E0D  !D
M             ("!:_(  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  U/VI3?[3$('\"  #C!0  &0              @(&X]0  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( #4_:E-D[(U'K (
M )T'   9              " @6[X  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ -3]J4_RO*#=> @  6P8  !D              ("!
M4?L  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  U/VI3
M/-P4PY8%  "Z&@  &0              @('F_0  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( #4_:E.M+QFW90(  ) &   9
M      " @;,# 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ -3]J4Y3GBQ3F P  Y@\  !D              ("!3P8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  U/VI3<J68>8@%   R'P
M&0              @(%L"@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( #4_:E/*EKB8&@0  $4.   9              " @2L0 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ -3]J4XO*8+[Y
M P  2PX  !D              ("!?!0! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  U/VI3C,DJ*DH&  "^'P  &0
M@(&L& $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( #4_
M:E,\R7]*)P,  -\*   9              " @2T? 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ -3]J4Z;W%J"1!   \!(  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( #4_:E-\K*FI 0,  *$'   9
M  " @5<T 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M-3]J4QPJPX1% @  :08  !D              ("!CS<! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    "  U/VI3T66WN8T$  !>%@  &0
M            @($+.@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( #4_:E-T(N[?U@0  !P?   9              " @<\^ 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ -3]J4UM0M%]*!@
MD2L  !D              ("!W$,! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    "  U/VI3!T[,H3\#  "@#0  &0              @(%=
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( #4_:E/T
M8ENU/@(  *(%   9              " @=-- 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ -3]J4V1W]A4K P  $!,   T
M     ( !2% ! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  U/VI3EXJ[',
M   3 @  "P              @ &>4P$ 7W)E;',O+G)E;'-02P$"% ,4
M"  U/VI38#K=QV8%  #X+@  #P              @ &'5 $ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ -3]J4[ % +TV @  '"H  !H
M ( !&EH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M-3]J4^'+1LC] 0  /2D  !,              ( !B%P! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $\ 3P"@%0  MEX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>386</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Supplemental Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformation</Role>
      <ShortName>Supplemental Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/ConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Collaborative Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CollaborativeDevelopmentContracts</Role>
      <ShortName>Collaborative Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2154114 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2158115 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2162116 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/Acquisitions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Supplemental Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationTables</Role>
      <ShortName>Supplemental Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/SupplementalFinancialInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/Investments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/NotesPayable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/ConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/ConvertiblePreferredStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2355309 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2359310 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.recursion.com/role/FairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/DescriptionoftheBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/DescriptionoftheBusiness</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/BasisofPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/BasisofPresentationPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/AcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/AcquisitionsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Supplemental Financial Information - PPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails</Role>
      <ShortName>Supplemental Financial Information - PPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/SupplementalFinancialInformationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Supplemental Financial Information - Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails</Role>
      <ShortName>Supplemental Financial Information - Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Supplemental Financial Information - Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails</Role>
      <ShortName>Supplemental Financial Information - Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Investments - Type of Security (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/InvestmentsTypeofSecurityDetails</Role>
      <ShortName>Investments - Type of Security (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Investments - Balance Sheet Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails</Role>
      <ShortName>Investments - Balance Sheet Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/GoodwillandIntangibleAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Notes Payable - Midcap Financial (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayableMidcapFinancialDetails</Role>
      <ShortName>Notes Payable - Midcap Financial (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Notes Payable - Pacific Western (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayablePacificWesternDetails</Role>
      <ShortName>Notes Payable - Pacific Western (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Notes Payable - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayableConvertibleNotesDetails</Role>
      <ShortName>Notes Payable - Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Notes Payable - Notes Payable for Tenant Improvement Allowance (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails</Role>
      <ShortName>Notes Payable - Notes Payable for Tenant Improvement Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Notes Payable - Current/Noncurrent (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails</Role>
      <ShortName>Notes Payable - Current/Noncurrent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Notes Payable - Principal Repayments (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails</Role>
      <ShortName>Notes Payable - Principal Repayments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Commitments and Contingencies - Minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Convertible Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails</Role>
      <ShortName>Convertible Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Convertible Preferred Stock - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails</Role>
      <ShortName>Convertible Preferred Stock - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CommonStockNarrativeDetails</Role>
      <ShortName>Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Collaborative Development Contracts - Bayer AG (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails</Role>
      <ShortName>Collaborative Development Contracts - Bayer AG (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Stock-Based Compensation - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/IncomeTaxes</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="rxrx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.recursion.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.recursion.com/role/RelatedPartyTransactions</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="rxrx-20210930.htm">rxrx-20210930.htm</File>
    <File>exhibit311-q0321.htm</File>
    <File>exhibit312-q0321.htm</File>
    <File>exhibit321-q0321.htm</File>
    <File>rxrx-20210930.xsd</File>
    <File>rxrx-20210930_cal.xml</File>
    <File>rxrx-20210930_def.xml</File>
    <File>rxrx-20210930_lab.xml</File>
    <File>rxrx-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rxrx-20210930_g1.jpg</File>
    <File>rxrx-20210930_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rxrx-20210930.htm": {
   "axisCustom": 1,
   "axisStandard": 27,
   "contextCount": 238,
   "dts": {
    "calculationLink": {
     "local": [
      "rxrx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rxrx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rxrx-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rxrx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rxrx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rxrx-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 531,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 33,
   "keyStandard": 353,
   "memberCustom": 26,
   "memberStandard": 44,
   "nsprefix": "rxrx",
   "nsuri": "http://www.recursion.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.recursion.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation",
     "role": "http://www.recursion.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Acquisitions",
     "role": "http://www.recursion.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Supplemental Financial Information",
     "role": "http://www.recursion.com/role/SupplementalFinancialInformation",
     "shortName": "Supplemental Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rxrx:SupplementalBalanceSheetAndIncomeStatementInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Investments",
     "role": "http://www.recursion.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.recursion.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Notes Payable",
     "role": "http://www.recursion.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.recursion.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rxrx:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Convertible Preferred Stock",
     "role": "http://www.recursion.com/role/ConvertiblePreferredStock",
     "shortName": "Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rxrx:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Common Stock",
     "role": "http://www.recursion.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Collaborative Development Contracts",
     "role": "http://www.recursion.com/role/CollaborativeDevelopmentContracts",
     "shortName": "Collaborative Development Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.recursion.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Income Taxes",
     "role": "http://www.recursion.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154114 - Disclosure - Net Loss Per Share",
     "role": "http://www.recursion.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158115 - Disclosure - Fair Value Measurements",
     "role": "http://www.recursion.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162116 - Disclosure - Related Party Transactions",
     "role": "http://www.recursion.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.recursion.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.recursion.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Supplemental Financial Information (Tables)",
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationTables",
     "shortName": "Supplemental Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Investments (Tables)",
     "role": "http://www.recursion.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.recursion.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Notes Payable (Tables)",
     "role": "http://www.recursion.com/role/NotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.recursion.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Convertible Preferred Stock (Tables)",
     "role": "http://www.recursion.com/role/ConvertiblePreferredStockTables",
     "shortName": "Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.recursion.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2355309 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.recursion.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359310 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.recursion.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of the Business (Details)",
     "role": "http://www.recursion.com/role/DescriptionoftheBusinessDetails",
     "shortName": "Description of the Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ida225ec4cb3e47f0b2b397b7d9fc8ea1_D20210409-20210409",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.recursion.com/role/BasisofPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ia31781556c024ff299dfa585947bf905_D20210401-20210430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Acquisitions (Details)",
     "role": "http://www.recursion.com/role/AcquisitionsDetails",
     "shortName": "Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie4e5e9f454354e0898d008f9b70e031f_I20200731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Supplemental Financial Information - PPE (Details)",
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails",
     "shortName": "Supplemental Financial Information - PPE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "id81600d989114130b43235d442b1e71d_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (unaudited)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
     "shortName": "Condensed Consolidated Statements of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Supplemental Financial Information - Accruals (Details)",
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails",
     "shortName": "Supplemental Financial Information - Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Supplemental Financial Information - Interest (Details)",
     "role": "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails",
     "shortName": "Supplemental Financial Information - Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Investments - Type of Security (Details)",
     "role": "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails",
     "shortName": "Investments - Type of Security (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Investments - Balance Sheet Classification (Details)",
     "role": "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails",
     "shortName": "Investments - Balance Sheet Classification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i8495e49fee3844bab82f503ea301cd51_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.recursion.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Goodwill and Intangible Assets (Details)",
     "role": "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Notes Payable - Midcap Financial (Details)",
     "role": "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
     "shortName": "Notes Payable - Midcap Financial (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "id524b0a380484a13b1423d25efdc9ce6_I20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ibc2eb416e12e4f8a8c617e89412832c8_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Notes Payable - Pacific Western (Details)",
     "role": "http://www.recursion.com/role/NotesPayablePacificWesternDetails",
     "shortName": "Notes Payable - Pacific Western (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ibc2eb416e12e4f8a8c617e89412832c8_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i4c1a2671a54b4d92ac1029a3f54a040c_D20200901-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Notes Payable - Convertible Notes (Details)",
     "role": "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails",
     "shortName": "Notes Payable - Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i4c1a2671a54b4d92ac1029a3f54a040c_D20200901-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie16333b91755459cbc141c348c781d1e_D20180101-20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Notes Payable - Notes Payable for Tenant Improvement Allowance (Details)",
     "role": "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails",
     "shortName": "Notes Payable - Notes Payable for Tenant Improvement Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie16333b91755459cbc141c348c781d1e_D20180101-20181231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Notes Payable - Current/Noncurrent (Details)",
     "role": "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
     "shortName": "Notes Payable - Current/Noncurrent (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Notes Payable - Principal Repayments (Details)",
     "role": "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails",
     "shortName": "Notes Payable - Principal Repayments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Commitments and Contingencies - Minimum payments (Details)",
     "role": "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails",
     "shortName": "Commitments and Contingencies - Minimum payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i3f381af37b384806826160a459ac1a6a_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Convertible Preferred Stock - Narrative (Details)",
     "role": "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
     "shortName": "Convertible Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "iff923fa8b5684f93a68cdd99414295e8_D20200701-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Convertible Preferred Stock - Summary (Details)",
     "role": "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails",
     "shortName": "Convertible Preferred Stock - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "id81600d989114130b43235d442b1e71d_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesSubscribedButUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ida225ec4cb3e47f0b2b397b7d9fc8ea1_D20210409-20210409",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Common Stock - Narrative (Details)",
     "role": "http://www.recursion.com/role/CommonStockNarrativeDetails",
     "shortName": "Common Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i7ecc7deafb5e4f9c982501dc4510e260_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "rxrx:CommonStockVotePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i227689ec41e7442c8fc5bdd888e16504_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Collaborative Development Contracts - Bayer AG (Details)",
     "role": "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails",
     "shortName": "Collaborative Development Contracts - Bayer AG (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i2beb2e86bb554101bc5776a4c46ea692_D20200801-20200831",
      "decimals": null,
      "lang": "en-US",
      "name": "rxrx:CollaborativeAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i7ac5bbd776f34c14905561c10878b1d4_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i5e11557b1837454f993cb507031865c5_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "id1e19c489d0541559211c4f3b9fc97a3_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "rxrx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "id81600d989114130b43235d442b1e71d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Arrangement, Option, Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i791d376bba2b4de991216d3882aab0e0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumption (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i791d376bba2b4de991216d3882aab0e0_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie6d027f3b69840d8bbb90d7865d8a14f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Stock-Based Compensation - Schedule of RSU Activity (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie6d027f3b69840d8bbb90d7865d8a14f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "icfd5c060ab594cae9f6247af22410df8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "icfd5c060ab594cae9f6247af22410df8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ibfd006ea4f4945efaeb183fc075f012d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Stock-Based Compensation - Warrants (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails",
     "shortName": "Stock-Based Compensation - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ibfd006ea4f4945efaeb183fc075f012d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i6c7aac41dc2042ada5f77fd1aa3b0fbe_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details)",
     "role": "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails",
     "shortName": "Stock-Based Compensation - Summary Of Changes In Company's Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i6c7aac41dc2042ada5f77fd1aa3b0fbe_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Income Taxes (Details)",
     "role": "http://www.recursion.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UndistributedEarningsDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)",
     "role": "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UndistributedEarningsDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i329b0213bcb84aafb9d81a689c66a1d9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i1109a8a918954e10aa56a87593b248c0_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)",
     "role": "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i1109a8a918954e10aa56a87593b248c0_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie30ba9ac44034c578ac0d736845582c9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "ie30ba9ac44034c578ac0d736845582c9_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rxrx:RestrictedCashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i1109a8a918954e10aa56a87593b248c0_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rxrx:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited) (Parenthetical)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i1109a8a918954e10aa56a87593b248c0_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rxrx:TemporaryEquityIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "iaa0d1040f8284cf4b91e4bd58e26b3a1_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)",
     "role": "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Asset and Liability Not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i9f4c24f5df41449c8a6537fb7c6f3dc2_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i774ee2b9287545a0a57464dbab971920_I20171205",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansAndLeasesReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.recursion.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i774ee2b9287545a0a57464dbab971920_I20171205",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansAndLeasesReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business",
     "role": "http://www.recursion.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rxrx-20210930.htm",
      "contextRef": "i08a629d9c1214f8f8aebdac2a99a41d8_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.recursion.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rxrx_A2016WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Warrants",
        "label": "2016 Warrants [Member]",
        "terseLabel": "2016 Warrants"
       }
      }
     },
     "localname": "A2016WarrantsMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_A2017WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Warrants",
        "label": "2017 Warrants [Member]",
        "terseLabel": "2017 Warrants"
       }
      }
     },
     "localname": "A2017WarrantsMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_A2018WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Warrants",
        "label": "2018 Warrants [Member]",
        "terseLabel": "2018 Warrants"
       }
      }
     },
     "localname": "A2018WarrantsMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_A2021EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Equity Incentive Plan",
        "label": "2021 Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2021EquityIncentivePlanMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_AccruedDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Development Costs, Current",
        "label": "Accrued Development Costs, Current",
        "terseLabel": "Accrued development expenses"
       }
      }
     },
     "localname": "AccruedDevelopmentCostsCurrent",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_AccruedEarlyDiscoveryExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Early Discovery Expenses, Current",
        "label": "Accrued Early Discovery Expenses, Current",
        "terseLabel": "Accrued early discovery expenses"
       }
      }
     },
     "localname": "AccruedEarlyDiscoveryExpensesCurrent",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_AccruedInvestmentPurchasesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Investment Purchases, Current",
        "label": "Accrued Investment Purchases, Current",
        "terseLabel": "Accrued investment purchases"
       }
      }
     },
     "localname": "AccruedInvestmentPurchasesCurrent",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_AffiliatedHoldersOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliated Holders, Ownership Percentage",
        "label": "Affiliated Holders, Ownership Percentage",
        "terseLabel": "Affiliated holders, ownership percentage"
       }
      }
     },
     "localname": "AffiliatedHoldersOwnershipPercentage",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rxrx_AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest",
        "label": "Affiliated Holders, Potential Ownership Percentage When Outstanding Equity Awards Vest",
        "terseLabel": "Affiliated holders, potential ownership percentage when outstanding equity awards vest"
       }
      }
     },
     "localname": "AffiliatedHoldersPotentialOwnershipPercentageWhenOutstandingEquityAwardsVest",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rxrx_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ChristopherGibsonAndAffiliatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Christopher Gibson And Affiliates",
        "label": "Christopher Gibson And Affiliates [Member]",
        "terseLabel": "Christopher Gibson and his affiliates"
       }
      }
     },
     "localname": "ChristopherGibsonAndAffiliatesMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ClassOfWarrantOrRightFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Fair Value",
        "label": "Class Of Warrant Or Right, Fair Value",
        "terseLabel": "Warrants, fair value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightFairValue",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_ClassOfWarrantOrRightGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Grant Date Fair Value",
        "label": "Class Of Warrant Or Right, Grant Date Fair Value",
        "terseLabel": "Warrants, grand date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGrantDateFairValue",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rxrx_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued",
        "label": "Class Of Warrant Or Right, Issued",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rxrx_CollaborativeAgreementNonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Refundable Upfront Payment Received",
        "label": "Collaborative Agreement, Non-Refundable Upfront Payment Received",
        "terseLabel": "Non-refundable upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementNonRefundableUpfrontPaymentReceived",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_CollaborativeAgreementNumberOfProjectsThatMayBeInitiated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number Of Projects That May Be Initiated",
        "label": "Collaborative Agreement, Number Of Projects That May Be Initiated",
        "terseLabel": "Number of projects that may be initiated (in projects)"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberOfProjectsThatMayBeInitiated",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Development Candidate",
        "label": "Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Development Candidate",
        "terseLabel": "Research project, fees and milestones payments receivable for an option on a development candidate"
       }
      }
     },
     "localname": "CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnADevelopmentCandidate",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Lead Series",
        "label": "Collaborative Agreement, Research Project, Maximum Fees And Milestones Payments Receivable For An Option On A Lead Series",
        "terseLabel": "Research project, fees and milestones payments receivable for an option on a lead series"
       }
      }
     },
     "localname": "CollaborativeAgreementResearchProjectMaximumFeesAndMilestonesPaymentsReceivableForAnOptionOnALeadSeries",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_CollaborativeAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Term",
        "label": "Collaborative Agreement, Term",
        "terseLabel": "Collaborative agreement, term"
       }
      }
     },
     "localname": "CollaborativeAgreementTerm",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rxrx_CommonStockVotePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Vote Per Share",
        "label": "Common Stock, Vote Per Share",
        "terseLabel": "Vote per share of common stock (in votes)"
       }
      }
     },
     "localname": "CommonStockVotePerShare",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rxrx_ConvertibleSeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Series A-1 Preferred Stock",
        "label": "Convertible Series A-1 Preferred Stock [Member]",
        "terseLabel": "Series A-1"
       }
      }
     },
     "localname": "ConvertibleSeriesA1PreferredStockMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ConvertibleSeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Series A Preferred Stock",
        "label": "Convertible Series A Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "ConvertibleSeriesAPreferredStockMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ConvertibleSeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Series B Preferred Stock",
        "label": "Convertible Series B Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "ConvertibleSeriesBPreferredStockMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ConvertibleSeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Series C Preferred Stock",
        "label": "Convertible Series C Preferred Stock [Member]",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "ConvertibleSeriesCPreferredStockMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails",
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ConvertibleSeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Series D Preferred Stock",
        "label": "Convertible Series D Preferred Stock [Member]",
        "terseLabel": "Series D"
       }
      }
     },
     "localname": "ConvertibleSeriesDPreferredStockMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_CorporateBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds",
        "label": "Corporate Bonds [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondsMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_IncreaseDecreaseInAccruedDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Development Expense",
        "label": "Increase (Decrease) In Accrued Development Expense",
        "terseLabel": "Accrued development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedDevelopmentExpense",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_KomasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Komas",
        "label": "Komas [Member]",
        "terseLabel": "Komas"
       }
      }
     },
     "localname": "KomasMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_LeaseArrangementNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement Name",
        "label": "Lease Arrangement Name [Axis]",
        "terseLabel": "Lease Arrangement Name [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementNameAxis",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rxrx_LeaseArrangementNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement Name [Domain]",
        "label": "Lease Arrangement Name [Domain]",
        "terseLabel": "Lease Arrangement Name [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementNameDomain",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_LeaseIncentivePayableNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Incentive, Payable, Noncurrent",
        "label": "Lease Incentive, Payable, Noncurrent",
        "terseLabel": "Lease incentive obligation, net of current portion"
       }
      }
     },
     "localname": "LeaseIncentivePayableNoncurrent",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of renewal options (in extension periods)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rxrx_LesseeOperatingLeaseSizeOfLeasedAsset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Size Of Leased Asset",
        "label": "Lessee, Operating Lease, Size Of Leased Asset",
        "terseLabel": "Size of leased asset (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSizeOfLeasedAsset",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rxrx_LesseeOperatingLeaseTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee. Operating Lease, Tenant Improvement Allowance",
        "label": "Lessee. Operating Lease, Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTenantImprovementAllowance",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_MidcapLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Midcap Loan Agreement",
        "label": "Midcap Loan Agreement [Member]",
        "terseLabel": "Midcap loan agreement"
       }
      }
     },
     "localname": "MidcapLoanAgreementMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Midcap Loan Agreement, Term Loan Facility, Tranche One Member",
        "label": "Midcap Loan Agreement, Term Loan Facility, Tranche One Member [Member]",
        "terseLabel": "Midcap loan agreement, tranche 1"
       }
      }
     },
     "localname": "MidcapLoanAgreementTermLoanFacilityTrancheOneMemberMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_MilpitasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milpitas",
        "label": "Milpitas [Member]",
        "terseLabel": "Milpitas"
       }
      }
     },
     "localname": "MilpitasMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_PacificWesternBankLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific Western Bank Loan",
        "label": "Pacific Western Bank Loan [Member]",
        "terseLabel": "Pacific Western Bank loan"
       }
      }
     },
     "localname": "PacificWesternBankLoanMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_PacificWesternLetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific Western Letter Of Credit",
        "label": "Pacific Western Letter Of Credit [Member]",
        "terseLabel": "Pacific Western letter of credit"
       }
      }
     },
     "localname": "PacificWesternLetterOfCreditMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_PaymentsOfStockIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of Stock Issuance Expenses",
        "label": "Payments of Stock Issuance Expenses",
        "terseLabel": "IPO, expenses costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceExpenses",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_RestrictedCashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash and Cash Equivalents, Fair Value Disclosure",
        "label": "Restricted Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_SaleOfStockConvertedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Converted Price Per Share",
        "label": "Sale Of Stock, Converted Price Per Share",
        "terseLabel": "Price per converted share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockConvertedPricePerShare",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rxrx_SeriesAAndSeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A And Series B Warrants",
        "label": "Series A And Series B Warrants [Member]",
        "terseLabel": "Series A and Series B Warrants"
       }
      }
     },
     "localname": "SeriesAAndSeriesBWarrantsMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value",
        "terseLabel": "Options, granted in period, fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Estimated Fair Value At Grant Date",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Estimated Fair Value At Grand Date",
        "terseLabel": "Options, outstanding, estimated fair value at grand date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingEstimatedFairValueAtGrandDate",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share-Based Payment Award, Purchase Period",
        "label": "Share Based Compensation Arrangement By Share-Based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rxrx_Station41LeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Station 41 Lease",
        "label": "Station 41 Lease [Member]",
        "terseLabel": "Station 41 lease"
       }
      }
     },
     "localname": "Station41LeaseMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_Station41Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Station 41",
        "label": "Station 41 [Member]",
        "terseLabel": "Station 41"
       }
      }
     },
     "localname": "Station41Member",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_Station56Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Station 56",
        "label": "Station 56 [Member]",
        "terseLabel": "Station 56"
       }
      }
     },
     "localname": "Station56Member",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_StockIssuanceCostsNoncash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Noncash",
        "label": "Stock Issuance Costs, Noncash",
        "terseLabel": "Deferred issuance costs recorded in equity"
       }
      }
     },
     "localname": "StockIssuanceCostsNoncash",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_SupplementalBalanceSheetAndIncomeStatementInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet And Income Statement Information",
        "label": "Supplemental Balance Sheet And Income Statement Information [Text Block]",
        "terseLabel": "Supplemental Financial Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetAndIncomeStatementInformationTextBlock",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rxrx_SupplementalFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Financial Information",
        "label": "Supplemental Financial Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalFinancialInformationAbstract",
     "nsuri": "http://www.recursion.com/20210930",
     "xbrltype": "stringItemType"
    },
    "rxrx_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Issuance Costs",
        "label": "Temporary Equity, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_TemporaryEquitySharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "rxrx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series D Convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228 (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "rxrx_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rxrx_TemporaryEquityValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Value, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "TemporaryEquityValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rxrx_ViumIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vium Inc.",
        "label": "Vium Inc. [Member]",
        "terseLabel": "Vium"
       }
      }
     },
     "localname": "ViumIncMember",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rxrx_WarrantsArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Arrangements",
        "label": "Warrants Arrangements [Line Items]",
        "terseLabel": "Warrants Arrangements [Line Items]"
       }
      }
     },
     "localname": "WarrantsArrangementsLineItems",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rxrx_WarrantsArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Arrangements [Table]",
        "label": "Warrants Arrangements [Table]",
        "terseLabel": "Warrants Arrangements [Table]"
       }
      }
     },
     "localname": "WarrantsArrangementsTable",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rxrx_WarrantsIssuedInJanuary2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued In January 2020",
        "label": "Warrants Issued In January 2020 [Member]",
        "terseLabel": "Warrants Issued In January 2020"
       }
      }
     },
     "localname": "WarrantsIssuedInJanuary2020Member",
     "nsuri": "http://www.recursion.com/20210930",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r105",
      "r106",
      "r245",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r161",
      "r312",
      "r314",
      "r502",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r161",
      "r312",
      "r314",
      "r502",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r105",
      "r106",
      "r245",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r218"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r54",
      "r55",
      "r56",
      "r544",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r65",
      "r66",
      "r67",
      "r109",
      "r110",
      "r111",
      "r404",
      "r555",
      "r556",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r365",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r362",
      "r363",
      "r364",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in-Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r327",
      "r330",
      "r368",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r330",
      "r358",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based payment arrangement, expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r90",
      "r203",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of loss per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r90",
      "r215"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Asset under Construction [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r150",
      "r153",
      "r159",
      "r183",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r401",
      "r405",
      "r430",
      "r467",
      "r469",
      "r520",
      "r541"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r47",
      "r102",
      "r183",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r401",
      "r405",
      "r430",
      "r467",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r171",
      "r190"
     ],
     "calculation": {
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r168",
      "r172",
      "r190",
      "r527"
     ],
     "calculation": {
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair values",
        "verboseLabel": "Available for sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r331",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and emerging growth company"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of business acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r391",
      "r392",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Other intangibles assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Technology intangible asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Net assets acquired based on fair values:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r29",
      "r92"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r92",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r431"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r99",
      "r102",
      "r124",
      "r125",
      "r126",
      "r129",
      "r132",
      "r140",
      "r141",
      "r142",
      "r183",
      "r230",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r281",
      "r282",
      "r286",
      "r290",
      "r430",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails",
      "http://www.recursion.com/role/CoverPage",
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails",
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationDetails",
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r307",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r395",
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Development Contracts"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r315",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r225",
      "r528",
      "r548"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note\u00a08)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r226",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CoverPage",
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CoverPage",
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock (Class A and B)"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationDetails",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, shares outstanding at end period (in shares)",
        "periodStartLabel": "Common stock, shares outstanding at beginning period (in shares)",
        "verboseLabel": "Common sock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock (Class A and B), $0.00001 par value; 2,000,000,000 (Class A 1,989,032,117, Class B 10,967,883) and 188,400,000 shares authorized as of September\u00a030, 2021 and December\u00a031, 2020, respectively; 168,634,959 (Class A 159,167,076, Class B 9,467,883) and 22,314,685 shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r70",
      "r531",
      "r550"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Construction Payable, Current",
        "terseLabel": "Accrued construction"
       }
      }
     },
     "localname": "ConstructionPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r309",
      "r310",
      "r313"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of unearned revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r309",
      "r310",
      "r313"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Unearned revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r521",
      "r539",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r281",
      "r282",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r315",
      "r323",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to equity"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r258",
      "r265",
      "r266",
      "r268",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r101",
      "r107",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r442",
      "r521",
      "r523",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails",
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r241",
      "r270",
      "r271",
      "r440",
      "r442",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r39",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails",
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r101",
      "r107",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r273",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails",
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r40",
      "r101",
      "r107",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r267",
      "r270",
      "r271",
      "r272",
      "r273",
      "r298",
      "r301",
      "r302",
      "r303",
      "r439",
      "r440",
      "r442",
      "r443",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails",
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails",
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Available -for-Sale Investments by Balance Sheet Classification"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r177",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of unrealized loss positions (in positions)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r32",
      "r254",
      "r441"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r17",
      "r446",
      "r458"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r148"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Per share data"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r122",
      "r124",
      "r129",
      "r131",
      "r132",
      "r136",
      "r137",
      "r412",
      "r413",
      "r532",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per shares)",
        "verboseLabel": "Net loss per share of Class A and B common stock, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r124",
      "r129",
      "r131",
      "r132",
      "r136",
      "r137",
      "r412",
      "r413",
      "r532",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per shares)",
        "verboseLabel": "Net loss per share of Class A and B common stock, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unvested stock options, unamortized stock-based compensation cost, weighted average period recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unvested stock options, unamortized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r139",
      "r184",
      "r297",
      "r304",
      "r362",
      "r363",
      "r364",
      "r376",
      "r377",
      "r411",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r555",
      "r556",
      "r557",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationDetails",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r256",
      "r270",
      "r271",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair values"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r414",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r256",
      "r270",
      "r271",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r415",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r256",
      "r270",
      "r271",
      "r414",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r417",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]",
        "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]"
       }
      }
     },
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r256",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about fair value of asset and liability not measured at fair value.",
        "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block]",
        "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r256",
      "r315",
      "r316",
      "r321",
      "r323",
      "r415",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r256",
      "r270",
      "r271",
      "r315",
      "r316",
      "r321",
      "r323",
      "r415",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r256",
      "r270",
      "r271",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r415",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r418",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r418",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary Of Changes In Company's Warrant Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Net increase in fair value of warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Recorded in equity upon exercise"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of warrants at end of period",
        "periodStartLabel": "Fair value of warrants at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r256",
      "r270",
      "r271",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r421",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r267",
      "r295",
      "r410",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r208",
      "r211",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r208",
      "r504"
     ],
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r204",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r208",
      "r503"
     ],
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Change in fair value of derivate"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r90",
      "r274",
      "r275"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r196",
      "r198",
      "r469",
      "r519"
     ],
     "calculation": {
      "http://www.recursion.com/role/AcquisitionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails",
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r90",
      "r197",
      "r199",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Change in carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r326",
      "r328",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r90",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncentiveFromLessor": {
     "auth_ref": [
      "r445",
      "r447",
      "r453",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive received by lessee from lessor.",
        "label": "Incentive from Lessor",
        "terseLabel": "Incentive from lessor"
       }
      }
     },
     "localname": "IncentiveFromLessor",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r373",
      "r374",
      "r375",
      "r378",
      "r380",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r120",
      "r121",
      "r149",
      "r372",
      "r379",
      "r381",
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89",
      "r500"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Unearned revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued expenses, deferred rent and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other receivables and assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible asset"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r202",
      "r206"
     ],
     "calculation": {
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r147",
      "r438",
      "r441",
      "r533"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest income and expense disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r87",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r517",
      "r534",
      "r568",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseIncentivePayableCurrent": {
     "auth_ref": [
      "r48",
      "r447",
      "r448",
      "r452"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Lease Incentive, Payable, Current",
        "terseLabel": "Current portion of lease incentive obligation"
       }
      }
     },
     "localname": "LeaseIncentivePayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseIncentivePayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r522",
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.",
        "label": "Lease Incentive, Payable",
        "terseLabel": "Lease incentive, payable"
       }
      }
     },
     "localname": "LeaseIncentivePayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r102",
      "r154",
      "r183",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r402",
      "r405",
      "r406",
      "r430",
      "r467",
      "r468"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r102",
      "r183",
      "r430",
      "r469",
      "r524",
      "r546"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r102",
      "r183",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r402",
      "r405",
      "r406",
      "r430",
      "r467",
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Operating revenue"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r16",
      "r523",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Line of credit outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansAndLeasesReceivableRelatedParties": {
     "auth_ref": [
      "r462",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.",
        "label": "Loans and Leases Receivable, Related Parties",
        "terseLabel": "Loan to related party"
       }
      }
     },
     "localname": "LoansAndLeasesReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r16",
      "r255",
      "r269",
      "r270",
      "r271",
      "r523",
      "r542"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "verboseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r107",
      "r228",
      "r260"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r107",
      "r228",
      "r260"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r107",
      "r228",
      "r260"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r107",
      "r228",
      "r260"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePrincipalRepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Notes payable, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable, net of current portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r40",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r59",
      "r62",
      "r67",
      "r69",
      "r91",
      "r102",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r127",
      "r150",
      "r152",
      "r155",
      "r158",
      "r160",
      "r183",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r413",
      "r430",
      "r530",
      "r549"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non\u2014cash investing and financing information"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other loss, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested RSU Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails",
      "http://www.recursion.com/role/NotesPayableCurrentNoncurrentDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r150",
      "r152",
      "r155",
      "r158",
      "r160"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total Minimum Payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r444",
      "r449"
     ],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesMinimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r37"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r63",
      "r399",
      "r400",
      "r403"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r178"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Net realized losses (gains) on investments reclassified into net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gains on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment of available for sale securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of fees in connection with the midcap loan agreement"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "IPO, underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r75",
      "r77",
      "r169"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of a business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r331",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtOtherThanFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not measured at fair value.",
        "label": "Portion at Other than Fair Value Measurement [Member]",
        "terseLabel": "Book values"
       }
      }
     },
     "localname": "PortionAtOtherThanFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetandLiabilityNotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredUnitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Preferred Units [Line Items]",
        "terseLabel": "Preferred Units [Line Items]"
       }
      }
     },
     "localname": "PreferredUnitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds from note receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.recursion.com/role/NotesPayableNotesPayableforTenantImprovementAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from sale of preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r80",
      "r361"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Property and equipment additions"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r217"
     ],
     "calculation": {
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r219",
      "r469",
      "r535",
      "r547"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Axis]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease [Domain]"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r322",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r322",
      "r461",
      "r464",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r459",
      "r460",
      "r462",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableMidcapFinancialDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r371",
      "r501",
      "r570"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r97",
      "r518",
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayablePacificWesternDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r10",
      "r97"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r304",
      "r365",
      "r469",
      "r545",
      "r558",
      "r560"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/DescriptionoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r184",
      "r362",
      "r363",
      "r364",
      "r376",
      "r377",
      "r411",
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r151",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r311",
      "r312",
      "r502"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r151",
      "r156",
      "r157",
      "r161",
      "r162",
      "r163",
      "r311",
      "r312",
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "IPO, net proceeds received",
        "verboseLabel": "Consideration received from transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "IPO, number of shares issued (in shares)",
        "verboseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Investments by Type of Security"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of the Fair Value of Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r129",
      "r132",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r330",
      "r357",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationSummaryofStockbasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r330",
      "r357",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r204",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPreferredUnitsTable": {
     "auth_ref": [
      "r306",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule providing details of the units of a Master Limited Partnership that have priority over limited partner units in areas including liquidation, redemption, conversion, tax status of distribution or sharing in distributions. Details include the preferred units authorized, issued and outstanding, the cumulative cash distributions made to preferred partners, the cumulative net income shared by preferred partners, and the aggregate account balances of preferred partners.",
        "label": "Schedule of Preferred Units [Table]",
        "terseLabel": "Schedule of Preferred Units [Table]"
       }
      }
     },
     "localname": "ScheduleOfPreferredUnitsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/SupplementalFinancialInformationPPEDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r331",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r336",
      "r346",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment, Award, ESPP, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r99",
      "r140",
      "r141",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r290",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationDetails",
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance, outstanding (in shares)",
        "periodStartLabel": "Beginning balance, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance, outstanding Weighted average grant date fair value (in dollars per share)",
        "periodStartLabel": "Beginning balance, outstanding Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Stock units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, exercisable, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options, exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options, exercised in period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options, cancelled in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted in period, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options, outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r338",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, outstanding, number at end of period (in shares)",
        "periodStartLabel": "Options, outstanding, number at beginning of period (in shares)",
        "terseLabel": "Options, outstanding, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options, outstanding, weighted average exercise price at end of period (in dollars per share)",
        "periodStartLabel": "Options, outstanding, weighted average exercise price at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued during the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r329",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofRSUActivityDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, exercised in period, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, cancelled in period, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, grants in period, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r328",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r352",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardESPPValuationAssumptionsDetails",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options, exercisable, intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, exercisable, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, outstanding, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r525",
      "r526",
      "r540"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/InvestmentsBalanceSheetClassificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r99",
      "r102",
      "r124",
      "r125",
      "r126",
      "r129",
      "r132",
      "r140",
      "r141",
      "r142",
      "r183",
      "r230",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r281",
      "r282",
      "r286",
      "r290",
      "r297",
      "r430",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails",
      "http://www.recursion.com/role/CoverPage",
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails",
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r45",
      "r65",
      "r66",
      "r67",
      "r109",
      "r110",
      "r111",
      "r113",
      "r119",
      "r121",
      "r139",
      "r184",
      "r297",
      "r304",
      "r362",
      "r363",
      "r364",
      "r376",
      "r377",
      "r411",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r555",
      "r556",
      "r557",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationDetails",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r139",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r259",
      "r297",
      "r298",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued in the period, upon conversion (in shares)",
        "verboseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r297",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock issuance for initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r297",
      "r304",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, exercised in period (in shares)",
        "verboseLabel": "Stock option exercises and other (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/StockBasedCompensationScheduleofSharebasedPaymentArrangementOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r45",
      "r297",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Stock issued during the period, value of conversion of convertible securities",
        "verboseLabel": "Conversion of preferred stock to common stock and stock warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/NotesPayableConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r297",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issuance for initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r297",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock option exercises and other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r102",
      "r167",
      "r183",
      "r430",
      "r469"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Total stockholders\u2019 equity (deficit) at end of period",
        "periodStartLabel": "Total stockholders\u2019 equity (deficit) at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r304",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/BasisofPresentationDetails",
      "http://www.recursion.com/role/CommonStockNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CommonStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Temporary Equity [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r230",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240"
     ],
     "calculation": {
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, carrying amount attributable to parent at end of period",
        "periodStartLabel": "Temporary equity, carrying amount attributable to parent at beginning of period",
        "terseLabel": "Carrying Value",
        "verboseLabel": "Convertible preferred stock (series A, A-1, B, C and D), $0.00001 par value; 200,000,000 and 121,434,713 shares authorized as of September\u00a030, 2021 and December\u00a031, 2020, respectively; 0 and 112,088,065 shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020, respectively; liquidation preference of $0 and $450,850 as of September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation Preferences",
        "verboseLabel": "Convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred shares authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)",
        "verboseLabel": "Preferred shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, shares outstanding at end of period (in shares)",
        "periodStartLabel": "Temporary equity, shares outstanding at beginning of period (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred shares outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://www.recursion.com/role/ConvertiblePreferredStockNarrativeDetails",
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesSubscribedButUnissued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a new issue of securities classified as temporary equity that are allocated to investors for them to buy.  When securities are sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the securities to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Subscribed but Unissued",
        "terseLabel": "Shares of common stock issuable upon conversion (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series D convertible preferred stock inclusive of the convertible notes, net of issuance costs of $228"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r9",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/ConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r180",
      "r181",
      "r182",
      "r267",
      "r295",
      "r410",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
      "http://www.recursion.com/role/InvestmentsTypeofSecurityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CollaborativeDevelopmentContractsBayerAGDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarnings": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed.",
        "label": "Undistributed Earnings, Basic",
        "terseLabel": "Undistributed earnings, basic"
       }
      }
     },
     "localname": "UndistributedEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsDiluted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.",
        "label": "Undistributed Earnings, Diluted",
        "terseLabel": "Undistributed earnings, diluted"
       }
      }
     },
     "localname": "UndistributedEarningsDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossPerShareDetails",
      "http://www.recursion.com/role/StockBasedCompensationSummaryOfChangesInCompanysWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, vesting period"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r123",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.recursion.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
      "http://www.recursion.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498357-110258"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40019-112707"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386226&loc=d3e41614-112719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386226&loc=d3e41620-112719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5.02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.7(e))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r573": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r574": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r575": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r577": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r578": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r579": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r580": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r581": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r582": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r583": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r584": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r585": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001601830-21-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001601830-21-000023-xbrl.zip
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M0:G:5)"Y8>_Y^)_JE#:[AJKS*5CL(- <'E<>-F%$D)?RRCZ>A; G ;1[O5-
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ME61C?OV-S*K2X %,(]N240]@JZJR4AG3$Y$1D;_]W\_]7N<TE%4Q'/SS$=Y
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MZJW0AR$L63 *7$#"!)6:>6J9QXXQ$JU^0&)T_Q[@@DA&P=U#C** @%H:>Q6
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M*^D(I+)>N)/AG!>]*.C_=1::Y9M\B&'S\RUW1$F>X4V#"FIA005A15 >@^/
M#+-.&2&B098BJP#[Z% '%=:\LWR\,Q=36%CBL4$^%?S'5*/L(@/M$ICU7 4B
M+#4KD-ZPA/19:%Z0U9)P2[10+ 1E&*9@R2FW.$625R#FLXST6>0YSA&#,Z]
M;#"36FNI-!52X "*5H1,'UA4M7STJ2OZDJ;<3 ?<'.8P^J[ISQ;\_<^P;VY7
MDXDN4@NBA#0VG7  J^^8LL[Z5"]K%9(1]%F=%;*<FFPI*+% G14Y=10H$8R.
M3$=OO$F)]P80AU%*U_L6<E5E8H(R;E4NY(_(Q20!"SZKOUI]_]5Y6).;WN:;
MVC%OG(X5M(\>"? Q%6)&4V6M37'/X&W@S=')B=RU6[*F^S>\@DSYFWD%%YCD
M1T) E 2-@L,N$.;3::.12401<O '-;X6V66$&<LDLHL"%5PBB\%4>6XPB\39
M""X:YD:J:((P2YS2NC346&2]GT08K!BQX">!7HO:,FZ<%$JF4B.V KVOV]*Q
M]V-['-QH?[A7;IZ:HI> ]JMAN0<7@22#PYIP=RTWB^OA&V,D*/K B<9, P+G
MG'H+SBVQS)&V3_LR&J ?I=1.T4M=06^[V?(B,$GU[SBZ!$3&H_)INO#=X /\
MX2BTY(%[SPA!6D0MJ>-1.RH"UQ<+//'#HWTCI5PL594G7@PP(1B,8<!8D,!8
MZK)C20Q2."RE"IZJQA2NR?KWS21>$&AA@%&"P5%KS0A/9YE9%9!5F*0^$V1Y
M*?4=H&5EJ,&8!2AON=-$,"NE 4?, T;AT1GF:M"RG!!R9>1F4=72("68 +17
M'C''0<$9 A22"&@G%=6KU)-W;*O"%Z8\?V]ZX<JFU]MO]V[?3-U]'U[0=U%(
M[7PZL!%\!9,2=J62 $*58(BLT';[5SJ7-]7ODPWW^H3TEP^R>_D%QT(3&HVR
M7*ATK)T1RGD/=@XSHGE0*Y0AL_SDO?MDF6"T,2KJP&CJTYQZS6D,3J0'X&D5
M7Z43#)>&JK=R$%O # 7O@C 6,\RQ <=>:QI,U)R!$5W^W=#O)M3FG1)J8:==
M(>>ME<X(1!B1QFB/46J-#FZZB ^34'@E*<69$"R(J#12#/2?)4)I(H,/+G""
MW0.DU/.5))0CB <)/AVQBJ73WYV2D4KA*1+<1?$ "?5B)0DE8-EB"GL@SAE5
M..544VRE=2QB2U:@@>V2HXD?(-0D"GTZ'(6KM\/3E>\.0XM(F3 AY-TA[0!"
M!DZE4ZD13< NMDX\S+[]86F)OS1./)E\KV\Z\601;H +R :/G3)*L6"UU>G4
MWTB=<"I:UV80K6GW-?&\0(X?P9"&$!X<<Y8&)B,"PT>UM-+KZ%0P>!(8T]WV
MAV4KYZEC4?K&;#R]]4>"%9:)0"4G'FL&_ N,S#7VRC@I#3-Q^4._[T(/OKM_
M"ZN5FP]5)O><K9Z?SUZ9-4A'95&-AB='H7Q=V&HXV!SXS1B+7I%Z :Y(()C8
M8$E0PEK #1AAZ[B4(D7K13!"MS%$U0:9EG@;.^7Y[L69W92+-3N]7GV41'$Z
MN^?RHRG[53F"L<>PIN5)XI +>SC/S7DH-U_??@3KAOE;]:U_=YMTVF6M'*8-
MDFN:K-47OQO0< E AL: L O,<6$TIN#(,Q^"5]KIB\V/EEB;_,S,^'V]CQ84
M3E4R.,"^-ITOR3P)VN)HK'; +9128E:HZ?9/SCMWW]6;4&%3VTX<)&$&(1VL
MBP&\*,TB&,(5 "\_&<O<SIDE&/M@D9&*>L8]4PI^P$9:@KDULN6")=X*3UWZ
M+Y!@,\VY/JUV>^#2*TY#NNWVW;'%]-G%&$5A# @B \D$!XSC*"/VF(*7K%<A
MHV1Y:+*HINXF)8QX<!,B90XSC3@7V&&DI$J-*U<(I<'R#_MA$GF\N@_RNU %
M4[K4K/IE. V]83[=8NOS"8QVVR7_]P*EH@C!L!@X]XAIXJW4E"/)>6#**JM7
M*/%@Z0E\+ZD'"'$KJ-!1F]2PG%@JO4J=9C65SOE5.J!FZ0E\+X!6."4"(!AL
M'&)"1(5!G)VSV"(/B):M4&;8TA/X7G+#C).YHP[6/K!HI644$\\\IY(2Z?Q#
ML\&OPR"4II<BK+Y?#(IJ5/LR#]@**\T$E225,5N&";BD ?S3:'TZY])@]-"L
M\/V2^%[LL 6(!:C9:H8DDUII9Y0$$$VYH<@:\M#L\+U+\3U88H-,BB@0!>I9
MZV!L -*"<8[@O:KXX"SQO4OQW=MB%SUW2"!CN6;.!!T%8=)$0A@&N*562(HW
MSTSI+_?+V>J?](;G(=Q%+O:]2"ES@8/+RX1B OZ5*E""C8C<&QZ95A>D]"[2
MJ&Z5]1?5UTUJ[*D4UJ:<:!^TQ@0+3Y4BQE@4T -C_;V3VSF%]OX%@')-#<$6
M>TN8]U8;K)$DB"HJE7*KU+ES:0AY+\8HY7XZ*BV*C#*/B292",:5%Y%2HV@C
MD:252$+4BA'R;2CCL.S7A]>9\IN9-C=^W^O2P$)F@#.N+AZ%!R]Z;JJ4!'2>
MM]>F>V@M8]V^6B W5PND2]0BP@S@GVB-M%58 #=130AF0JL VL%;*I:_G?Q/
MST2WTL@>$[ -BJ?V@Y$ASBQ.N9$"60KPUV&Q0N&GGYY!EB#2!5X3TY%R(AEH
M&:33J65"RP0])--X]5'DS\M-=P]E30 %) 0.5G&&E%:<IM8&-B5U!V'=ZD/9
MGY2;[@5/>X\M<!'!BD<6H[*:&Z.=<SSDS(<5BL*ON>G> _["((MI< 2!Q5.>
M*^$(,!87GA-CHERAMBO7<-.[4(W*PHV:HKP/@V)4O7O_X2XJM^ZZ_4H0'A$9
MJ06'B"&?.M""5R25X%ZE%IK+7W)Y,QHN;V'E?/$ ELK$5( 4*&.66&8M"H)&
MBIQTX0&@R%NGR_V#-T*-51A;9)QE$0OEN+:<($!O7AI)EC_?<PED:H%=:)WR
M4C*/P#EC/D8#)BE: 5 :/#0<^?*G1"]@1^O&[[HVU7?V96_'I3L"Y+-"2=B&
MZP!H%Z *LXS[:'FJ-3<&#&!DJCG6:Z51RT-EA_L'20)\;V\0=R(R1@)3A*3\
M-&<%!RU?'Q^VVI'".]X<O_OP'')**J00"TZS=)P&-]SI: B-PCJWQ&><W"_E
M;L<B1X^02.GY0 H>H@D65BLZ)'D$7\,OO]/1M'?YTR27?[17OBL.CT;S.A*+
MYNJJ',A$D(Z44I /:D'+26V,U4P0XWWP>!7Z6=V$*G+%J$*I,5IYS , 5DFX
M$=(:SK2VSEI'],.@BEHQJL!"<0I"$@Q@2J.IQ<B%"# !&1DL0A?C\TO8N_NF
MY&DILUU5X^"W!_\R@[$IS]/76A3(7+[V9C\0LU]0^WZ'@_&$<V0C>"U(I=0F
MH@2E(/=$\<9&KAEKQ1AK/I-A02WKP:=5D2K&I8N,@F^K(S9*&"*P=C2XY0>W
M:UZY*^Q-K*< YX1SU##DM66((DTP!V[QQ-/E/Y/IE2G*/TQO')Z?ORF,+7HP
MN4RS><>H89G;),L"#V"R5 @4*<-<>,; -76,"X8L!ZE5@"M6:,/_ONES__OM
MP0I)(I'8>0?.E$GMG,&<.RJL1%J%Y>^*?M\TO)4>Z,))8QS#WA'$P*TU/$H9
M/3:&6A1M6'Y7:JG(LK"SYP#?"AXD(>D$$!TUU8@K*T$C6@8?K]">YWW3Y_[W
M/@/'!D5'<%"1>8:5LQSS$)T3)ITVL/Q0]+YI>"NHCV*GD?1*<H&9DE(S(S4B
MQ.O4:4[)%=K!^ I.GW8*Z_>'@YIH#W$S ZCHI =P*+AE1!@@:ZK]\R8RPH0W
M#Y::SQ\B-<%C%\IS+@*@1:&C\M9&AY!%UGF%5ZGIX]+)YMT;0 W44^D@51L)
M4-9;89"+D3F, Q:$/UAJWH%LWCTU;:36$TLC]H$Y0XS54@;I'0] .X%72--N
MP@B^Z(U3(X/WP8W+8E2$:NNSZXU]\*_*81^(>3*NSX#<BUNF'!2#P^IM*.M$
MY_.K![C(#Y,@V7=%QU97P]R]O2 <,VVUX1(QAH("+$<1\8 )*,-ZI5H7_HP\
M^2 Q#,6(!.ZH$IJR@)0UD4;.C=81 Z*)*V3U?D:>?)!(C-,@.-AMH8EA-/4;
MBU$I'@/V!(GHUSRYU#SY(/&D1!',=-2(HL"$BII1XQ22)#C#':-KVWVAQBZQ
M2!H'WIX'ND&*\>KJR'N()*54 2Z!*1UFBBH;$%/(6>]UC%JH-3\N+3\^2!PI
M1 2/6SF*?626664(<U8R+56(:QRYS/SX(#&DI08[2@-R"+$0I$UI,QA3&[T-
M&H4U/RXM/SY(_$A$L)PHJ["+S/@(!ELP&C2P9/18N[6]_CN[M*NK$>_>0G-!
ME(_<, 7_<F!'&IQ.N31$4(?P.B*^3!SX(#$BMP9% (A>^I3&8 P)J>,X)=PA
M:U<J7^CA<^"#1(6&$.(I\S%XRXC12@?!'5;>2,J(77/@,G'@@\2!P3/D. &7
MF$A&I5')8=8J6A^)TRN% Q>K3Y:+\1]\6;T+R@K$G<1*,NF)26DOCGJ+41#!
MH0?+A]_2*FL^O%N++$UT&C&+@ ^M=@I%Q%B(6$0K'%ZE'OYK?;C"=IEHSX*7
M,2(#R) 9'; 0S&+)F/+._[S9?VL^O%,^9-0ISR45T1CFL%94<X490YI%SK1;
MI8ZORYS[\*/,<2\-7#%#TC@I&(^.R6A2NC+1)ACJ.$7FXD%!:^:X/^:X^]I5
MD3J9*"\"("=F(C'!<V$\]0%%;'1<:XXE.)+G[G5&L $;;(,27(/.8";M@GH%
ML :A8+A>ZXPE8(N[UQ8V@,F(/NH(;,%0M&!28CK$E_A(/5VE4]:7*!*ZDAK"
M@,>CF26""L886 ]#F0F4&$VYCPZO-<1/T_\":^0\\U9X)IB76 45)-#;:V<P
M4G2EBL!W@JG&9?:$7Y7AW^,P<.?SE)S</'-K]2Z1O02V6)1C_,)4Z6CX]-?6
MO\?%J>FEU\S/9&<X".<[IOP41J_& W^[W?065YWN*,', \ZT4; 04OTK(SH$
M:K"06*HUO_P-?IF9TN3'_X8O:4IW=/XFG(;>-;/:'H!JJ_(=>,V\WV1>CA%5
M3%.C !8SJ@PA/*8,A6"IQV;-O/?%O&3-O-]F7H,PY<0ZZQ%+"0S<,*^HHQIC
M9RE?,^]R\,N="@Y=$>8UQA&'/$W!"!:952)8':U0X%QP<#O6S'M+S)OV?4+I
M"M-[:X!>*\(ND5@4C#-&(\04,UIZRCF67 5-T)I=EH1=E@K@+@WOBAB<$ *<
M),FL]TH@3Y1S,1U;C!U>\^[/ #)74^\JSY -W@O%"9->JD@(%H$CKTVJZEOS
M[E*PRQIB7L&[@2)KM'&,(<H<E\H X)14*,:Y(DZO>7?Y:.:H#U1S)D.D3 >M
MB3,$>RPI(E+1-<Y;@ZUO,% J]25::<) [KE13*K@O./*8:_I"ARG\$ 9Z%M@
M:UD82!!DF9,26XF8%]:Z=,Z9LQX[[AV1:P9:PXZO,I WA#"1F@4)PYS'%MP]
MK+$C@2CL7%@ST-]AH&)@!@D-;P-ARG%ZR46\7)X,2S,*+X,=3;?M5X1G0M3<
M&V2=<)%)''1DZ<P)I*TE7DB[YIGEX9DU[+I*Z47BD:=$NJC >C*%&?*($FY9
ML%ZL8US+"KON6YJ6A8&Y8%@ABA!!X'VJJ(-7FD>M;2H51VO'<XEX9@T[KV!@
M!HC!1N!;P3RSQBD![&H<B30&Z>P:=MX. Z?:DE@X8.%J+[X,)\.J'6_I.280
M)! 2A*:3O)6CJ8FI9%Z'X)S&@JPY9DE!WYI]\S'.2I*H$38:I1,ZC'74<:L4
M8E&FHK@U^SY\R+G"[.M"8(E?M9*.@296E!&PVH UHT)2KMEW60'?FGVS]L74
M>R.)%SPP1;F.2@3$@C0$61W6_M(M^4MS60&[P]'VH"YL^K,8'5V=5[ B#(6)
M%H8K)8R(3")G$:&(:T*9MD&'=0AT51AJJ:#RLG"W"\*BX#EE1J3N;YJFPTV8
ME=IP0OAZ6_HG *L/5W<SE(Z<0"A2I!D7V&IMK/?.6H>Q%FON7A6&6BJ@O2S<
MK3PH;8*<QP0QI9$QE 5'%%+2*\+Q2AT]O]1YA(L[EYX[%(PA#BOC&>;<$+"U
M-DI% \52AC7-'B1@6QP#*8NYTRBDRC066#1.IQ)+98-23HFX9J E!6S+PD#8
M2$PM6 SB+..166,"0^F\+J()^ %K!GJ0L&-Q#!0=1B1:;)TB#%-CA(X 0E3
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M7X^"\7D^OCA]]AO\T:206HL$\M[*$!E2S**@ YA$$1VGV.*_$FB9/E.-SGM
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M2N0-<EQ;#()Q!%"L(^,FGX@64@5K+.V7):J3V5LGYZ.0I=-N,NK*1-U(G*-
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M;R'HL^182(M1ROG6$N(464F I%0#(F# 5$;]DJ9:[K"H)?ED/<E"4YALS\U
M[GG/+?F>.X''/NXL9#$##J=H7FL,D"@* ,8DCLNN*)-R;0-A5*>$UL43301J
M_6U5TW>K6=/=%*#RQ5_T?-/X3M_90F"]ENBKK\UZ._H1*CZ*?Q!O=.%M.MD]
MOWX_X4Y^+4VWOUEWNMW+O%$7M%$_W.R='&,;G*$I*I1 "6AP 6BK(>#($1P\
MA8B^I-\N8,_L7_:ZO;C=H_&9-\[B-H[31DB*&%#(:4 A9T"F4JK8>>&CU(MB
MCD6M=@Q]=JG$:]Y]"]]]</?'L40B,E<TRPU*P>R$1[,<*P(,5= 2D[K3PTEI
M:X&[*LO!16\HPPSBDGL0C7'9+PJME$H!W#X(C V#A*2(;5R'4M8CVXU!; ,=
MKE$L;K]GVI ]2M/GSAMQ([DBC'G@^/0MZ].]7_1LOE+6SH/M_??PY3[>O5L.
M#UC(/M^YB?N<2PVIHQ)8GC(3J)) !X8 T0[C(%DT7/!38KO8D)-LJ+G$G.3=
M5MW=!E.Q"^<<-S9U\2(B-?7RH$B+"1SA:/8&IKE;VZ ,UB5[:L^50I%WX0BN
M\3WGE94;K1D:5]Z!&]]I_P2:6[K3N8YSN-E,#7,W>[U.PUSV4ICY0?NCSD'F
MT^!T)+4#.RN%P\ BDX+,K0"*2@D$5M9I1J76=&WC__U_)$;X?842SC(.%R(G
M,QC+!^-(UPOCF!=2 01I!*.6'$C/,8A<ZSQ3\3.,HM"CLDY062&<.?OSIYD=
M7U(HR&G[W/E.MV!"\;[F"SC4?G$^-&RC-UWD8H[PF5>$3[/9;MV&]&R=ZVZW
MMEEH@;\O.HRG_VK%#LOQ%Z4PZJ?GS9#FIVAB?(CO^D?SZ"".X>P3W=W>8;MQ
M-'M?_\'[!R<WAV>6[7T]:OSW9A=%DS=0H@0&G$;3@UK'@#8(@8 MMH8%"Q5;
M; A/WCX5WC[><V(11  '1P$E*  5S5>@B98:\DB2=LKPG?D=Q4Y4[.MN+^:
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MZ5@$S:PD#&"9ZM;Y5$=3"I]:]T5UT'GCO9R4U1:THS*K+7HS::186GK =4"
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M42L#FNIFGIJ(ISZ,VMPTVMR&2PQ8<8 M$09*Z !D"(2E:J]$B;4-*NN*E'6
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M,GCG#M[[/@9B#<-<&N!@<%'U=A H0QE !BG!,9;2N2J"=]H(@ZFRT"KB?2A
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MK=/G=B\L1U3N3RK'2Q656\OQ N1X)L"!6Q8!?)$4R2&NM4,V2(X2=L)&!3)
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MWGF+O+<6<0MLP7!LD4B21AEE8IJMK!':5,O2F;26NT<@"+5H+4JTIKK=8T8
M"3$R*??7I DCQXE'BAK/K0. C+E2WI*(U4_E1O!3+UI)%ZH]",MP)#'CVZRQ
M9V[L\;-J'92Z"E$'%)W,F0H<U+HF!C$L!8"25%JG93PUK47O&<\;:OE[H/S-
M=/E+*GA**;(Q:L2Q$<B!3"'%D]5*2=#_<F5--OD-Q41>GF7_\G.%3L;AZ0UW
M-E_$ZL^19["T+H%;L@O>39:PSBZX)YH=7 J&I!HT339=+#:(:VJ0D3HB4$>4
M62JD-WIEC0O>5#<44+S?T6B=*O23,)!:A!]/A&?*]N. RQD#35F$!0BSD9&@
M(*@GUE!M/%U9HTPVR<,I29TGM 1Y0@LF9:']=?+(\?4H__@W0B=W:'=#[ Y_
M0_F3IV)Q](+%'=KN0<SIWIG/-2M6EZ-%O@)B=(>#4GZ^'P?#?ML/@>?E[R_V
M,[Q;K1>6C=IEI9#__^UT$3]<K%\I?-D-ES^8^>4_,!F]<+U3W?CX^NVW:K]\
ML,/X%A2;KXW=N73+^:4J-)$9;WVRB'A!@!XR#F:O-;!+78RYMS1V>&6-,-54
M>E%][6MZ^)/0PQH&EAL&9GQ>B@.-S-6GF,Y6HLIE\JA#GA+E@E2&Z%RJ4JFF
M4=>ST)<1!EY\WZ2;9?W-G1E2L^'B0;O;':<&GQ1QJL_*+N-AT+!S<3#:$,()
MPXXSRD3@G#H2%0G[FQD&"67DN6"P1K6Y4.U2A1Q/C-7!I2K]EW-ND6%1(V<D
M9D%&+J@%PUFJ&POPUB=ISRB8(A(BA')$,\4%3\8P[P16F!$MA1=9,(FI!?,E
M">9,AVS!K+=<HF3 X.!66^2P(<AK3*DQ2<0<.JM$DZAE2M!?$G?.TQ:$N2O;
MB/#AK3SC$:VPF^;I&;#M?Q[IE5\XCE.JI#;1<Z!3/%N<R0L7@M8Z$BDP+P3K
M6=U--8[/A>.;LP2+&&]\B@G9R(%@.161D42AB"-305/E<Z@2Q[QIQ(LY7*RQ
MZB?%*I:8)C8QY9CF&DM-)6Q0RX6QGEAI*V.PQJJ7A%53SLFT=LHZC)RDP#DQ
M SM010 L!HLL6'1"$3 &!6L2\=.=HLX,E,%H0F^4PZLOC?0AAZ-+=OM76K[Q
MX^CDI!-S)HCM-$)[X#N]P:A?BOO 5AX'#!<R/U-6&UC[-&BNW:V0#'9\7>?Q
M&9R[)8AW,.ZL>J4@4V/8NU3?\2$&\.L@)S>]V NG($]\3'^QW[93R0I?/X;Y
M'8YCR6,@-=^8BV]<JN @A<=*18,\SFD<.@7DG.%@(!DK8>M2:0/81EPW&:%+
MY.2JH>250,E3E=*L463A*#+C*6> (\HR1&6N R,X0\Y$C60PT2N2,\+P,B:#
MO?)"$Y>9VK64U,S5JG)7/T79B65,3LU9<--5N@"CS>Y@V!]E&ZE"J1J<Y@&G
MUL:,^W=G5VR=O]^GV'A'J4?&.)Q]P P9GQ0*5@3!9'2&+*[(;UV+8HDIP@^L
MC5HB'TLBVY<E,FD:)*$,10?$@:?<ZDZ*A+S"5((U8JDC*VNZB1]^N%X7L;BK
M6&Y,G#F7ZVGG9K?9>UFZW3V ,KSB4* %4(8*B/K?^M]^*Q;*I([>F[P$K5XW
M.T5KV)G+2KE4B4H" > A122=R-4JHT)6*8H<)@YS"CJ&AI4UP>L@N^62K,=V
M$=02MUB)F_H%A'61,>\0QAPDSO.('+<2"84=T<11:?@K]@L\+.]1/EJ2X\TB
MN>Y]?P0J_J3?.X%QGI53MZSL3S+M?7@JXZO$ID5I_6G@Q4E[:#MOOYW$;F@/
M1_V82^*.,B?[8S1L]8:[<?B/;8<:E>9"I4NEJY(F21L=D%9*(4ZQ1YK /P6L
M&I/:I1)CP0E;(KNCEK7%EZ2L9>VQ9&VFH3U/&"M@ %Y&C[@5 CG#-)(L4!9
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M 88&FW?8[ES:_8.1]T"UTBA+>]84G9B-H-F+RP@"W*'3*R%2>6KB8-C+>%V
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M"]+"<@1NC=71B*O^T+(J&;QFUV7AGM ?C^KR6VCB(I,L>"43)XG;&"SV@J=
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M;&^\YUOGZ_O<".V,Q8@Y!L:R$@Z9R#E2+'H6@Y. GRMK=%7^( /Q! A_9B^
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MWW_;V_C$6T<?CK<_OSO>.FH!4+T[W-K895?+4FS#6+9V_CC:RZSYZ-U1:P-
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M,VAW(XP@D[1#\,&N[KSV6I\ZQ_ZN:3CW2A[[ U#I0K(+)Z6W#%"]RHIX]<G
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M9YUA*I3#/#KD 7*  A"/C'8D5_=)5$27+)-  0Q99URO4&BNTL=[Z&/E#:^
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M0SRXA+1.%!DM=7#<)J[#VF:C,V?4YZU\\W(-AE#4C3Y[Q>$^*'0M((Z,.7+
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M:0S&*<1=2,@EZI&WEF$6J:*&KBAQKQ;YMHOLC(E2L02KR@(LL@9>+GE 0J<
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MG3O_^E3K_:%:Z^O66@3BJ8:9]+"TB%L7D=98P\0:1Z5W%B<YN]8&!R:!,L=
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M87:\E^.B=AQL(DHA]R!V(B&C:$ 6V"784*(LMI6/7$'=*X2ZZAC :X2V\3&
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M*3^2K&^VFL4-;/_2$2P1"][.QB&/M-^%(>>AI:4B4$%00&C+-.8Z2[$CG+)
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MA3[3*$^GQLCT(]UR:9>MAOM0V*-O]73_*L)_)9_O_3:3C_FR%R[;R%<B@SD
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M[C?9H'4@Y'^>[!^WX'[[%]^/@==\_' T2^J_G_QSO+M]*/;WX)HG.[G?)#@
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MW*ZR*.>01VJ&$Q@' " !-H0X;CTC3CG/$W$45S'*E8.;R4*IR;.(8U((,^N
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MHC1ARV+>@>.$,^>C42Y2KSAE2KAK)*62AJOQ=F^?'G!+DHS1(BQ)1 !2%.D
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MR#<G'_N_#A)-RN843G#5<S%@K9&Q(B&EHF.$)<D]7=ODDF[,%^:L@;EJP2]
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M+B+-(@'WCP6BF'+!^ZTW?/'XZ]YF UP;FP.4L\YP1@[/VX#Q#JQ%=B#!91P
MF!7=&-UAD:=(G;/<^U@XEI7\E:7V^>)%\J)(NMJB-/]3/F'(D<Y,IB&7^_O.
M61A](G:J@YKJ]A?+Q_Y;7CGTQD7\()O=4(;Y<)-+\WK9"R[:2 IO%[ZRU\\-
M7L/1H:&[Z-ASN'3^\_R-YZ<[B?VCV-_.VE0E&HH3Z@$(;_$66*<, &<NKVW6
MA9PYZ<RW)(SO)\>BPT'A99;'E2?V._QY=%>PV)-*@B6]  _3"J"?LA6@1$-"
M'KP?X(]>IV-=L??_QMU^/\-WEIW-ZPC8_V,$21XW#S[2P\M#<?C] V]=?J0M
M^NFX>?#G<?,[0,SEKH#/ 30UV3PDP7M_MO8 R+YWVG!]UMH[9%_?O_W9/'E[
MT?KR]K*YUX%[!+BZ#*EY^?9GZ^,W*:-DN1D@24?SU *-K!4"T:B(M!%CF?A\
M43T-C&(7<A]3X%I+9Q7LD1-4&07>KESL")C:A,9>_#=V>J=Y%W(F;YAQ;;#V
M1H&;[W&N48 ''T%?1+"2$YS/?+R-AH<$U_&:/DBCP,K=<A< 'KOO-S)2)Z)*
MWIT=G0V&50'O=*EHX16/3M0M&(A!M'U_W)B2C@J>]TNLWSWJQT)9&[\4IWSE
MTX]>_+5,M(W6I/%+\:=?RTSNM;!"770T@D@X(6"KB?-"*6FY!V_)2D,+6,%8
ME[ "?\C=Q?-=$>&LO[PK8AIO1O=Z$/LGKQ%>CKX%ZWB,1*$8?$#<FX"T<P%)
M(P%A!$_8\*TW"18+78 XS*-  T3FI'$*GL09&-IL[\^/V^7QRDSC7RD%9?2;
MRZR'\;:.,[SI.W@:6VL0D>LRH,ND8E1Y_%=Y"X.#8SMLVHO?XX?J&<)KE)GS
M;U'X0 -8(\D"S>6$"=G()-*>!\IAS6E1E+$D,=H?84JUJX-&D5@H$]^I[?J]
M08ZS//QWT#@!_[=]FCVZ_E'&QPN(^DX6/-3.6?=HN]%IYUQ*$:C!%PQW&I^[
M1:M-]AU'VSE7&)\M6V9(BD6YXFEN31\T4K]W4N0C\R%@OQV'MG\!%W>9?&!*
MD*_Y<+LX(%O^X<*!GWP6HJUV#M7 $X;0]30[Q44W;[]W=G0,@4'533N%OD]\
MV'6M:9FL>,:$\4G-%<L_/H&W#9 0U(\)EK (;,Y.81T!2T[+2KQ5:P7OB0RK
MU I>@1JY!'GT-)_+AZFJ"D>ER1M31?C8 -*Z?'O^S4=,/!4))1T,@A ;3(X7
M!C$6K8-_I$MRZPW#.TL 9%R,7)J9W-U=%GID2<KGY*#]W9A;S/^-X#JNTD]?
M'C..Y#/$+,7M;G'L;X>@UHWCG#'J%J=[A83D3_9<IWUD*YE<@CCE;;:+2+CZ
MW 0$B[/\*6<;%._?MJ^J% J@V9D*TV?N:"8DK3HSX"M<67M0Z\L+T9?]@Q]B
M'?JR *H3^.T6Y28]7UKAXU&5QRAU,P [V[E*YF=5IEWJXE&W?3DRSF,U')]T
MG V*,[2B#ARYHJRFW3T%6W<2A\>]L-TH7X-;+D2EJA<'DW]6%'Q-J5%Y_1M4
MJ3J#*2\^*@L;W>'H[BH^BL&,@8)O.K$_(D3*P\)''1NT844B/RCS6SDQE1D^
MBL4:*7!UQ3 %"E>MX.YT&F]40#2NJ9E\NR]3SIG/P^8^TY@M=B.6)4 5S,%[
M1Y4,U2X63SQZRO+)BQ5OI+/A63^.RFDVV:]XUZN\BF, C.+9NO">Q@E\\#A7
M3F3H'V?Q&VQI%^34LZ^"C4(9QUG*^A>Y%](:PCA5/,08M/&C0G$UD]^Z<R_*
MIW*CWH$7.4J[?($(^@^(UGL0;7T8N;V[N7(&E.3 _GRUP-@\^"Q:N]^\24)R
M)Q VB2$>@D1&RX2(=MY)$R@E$(G0906!TSTJJ\B$5M$KKUVBQD"X$XTCR3KC
M00H88]0NS7G6,O$H,G%XWOSXC?C@C,WS"BC6B&OB(#K%%!D6; P<1R?8UAMU
MC4QLCZK#P$)V+K9G032?RF20+8*])0$:6$3 U>R8KN2%,>FL%(I$17D>NQ:=
M3Y$R87@"3^R*D\ 5A6F9!/VO;5V[D^F#LX&=X@A^A=+# %&8ME)C)9"+2N5!
MI1YI8PC\\%$"^@OK?,YM7.=LK0HI3[_YX(/[>O\YH ?#B;+$&,(*?G#A<.XU
M,B@1X[!UPFL.SK;9661Y'F]_KFDM%[/T5GI=-/K[?'PZCS3]>&+;W<*'NZXZ
MH?2[*[>]^LJ%T-?%X7FNF;CJ7L M'OO:XRAS?"0ZX_:>'\?N[%'!S],B>P?^
M;^&:5\YXF<HK7.-YCW)CV0$+'_.*&I4;CYS*G%?14#"?VIQU0(O,WWFO_V/Z
M4"2O7E&=G"X:IZ.JC8;/U0"A6/J<!YB*:J[(:I87R]F)HGB^W1^ WU^>T.0+
M=" BR:VK1;"RY%M&-<J9-;!Z;Q5LC-_=N:@,7XX<JDN/*F\:*8Z:(*;BKU$3
M>'X/?!ML% A4D3RI^FOS'T9U#%,+M5VN#^R[/8(G/,H'!44712'BIP6=SLRY
MP;-*=8R.U*H#A::%QS@[>0<+N-L-S=$:#48]R&7Z(Z\2Q$"[W?+4;;^[^[]H
MP]\@Z!O4COSH:/V]>;Z_^\T0$3C-='G2.O#_(T?&$XY"PN"C6R8)CME:7VNN
M?RE.),>"G0UXHP-+G,-Y6.-?<UE(+7JEZ$W5!OPQ0I#7+(2T=?Z-<VN9]AY1
MF<!EQ. R."W!;Z0J.$X\528?A]&5A7 :4,=X_6O!]G4>P9YDQ&\71_;]WH7M
MY&[Q28/;-)Z#8V&[1^.HI=,[1T5^JQU0E=\+[:/<^38N%"R)9&%7!]MP&Z>Q
M+%#K=:=!';[!0]#Y:.2HDCPM.2I]\&*H2=%3)@,XR903%:5-X5D5K"1%:\[O
MV7$;Z>J&%$C1YJAF\^0CJ->G@F[\D((J'7SJ@,KQ%JADZ^3#1>L[J.;!\8_F
MWBZ?5[^OH%Y?W^?O^?-[OG;K/=S/WA$!-:2@RA14\WC__<?SYMYQVM_[R%L?
MOW%*'"8AH3RN*@]HB4@K0A%3RL3@'7:+E*E1*ZVI48S0Q),D5OA@B"(Z4 G[
MR.8+I(K>*%2L>F-Z8]9>%77SC<T^"*>1IZ2T4BKRS"*J= R.<<8D5BD7J&Y
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M-B+X8/>\^?%;Q)HJA@UB/(!,$/CA, 81P190BD4A.<@$%TLJ(D<R,3OXM1@
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M*VI/9I.DPU/P8Z0&U\5*B;BT%%F6ISX9E13%(8G<8D4(V2:LCI%J@_.@!L>
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MN.K)8(8CESH9SJS76-'HK?"<K95QJT:.QT:.F9EPP7#BI4W(^Q00#]8C&VE
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MZO+4;)Z'F,UC]GPVSQIVS,.:U4!M/)JE_#QN#.PCH?8>9=%O+2U4ME]TGGU
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M/C@907(+?(\1D(&^32S0/6-LPF%XGI)[_2*\9NQR37@A,[DEVA29EDZH0_6
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M1+AM;?1AN$IVF N^T;F?1C1]LR,?."M^4/_ <PF:/Q+C[>9S6QYSP/P/=,
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MP 7@]P[;20,OQ2SNS2S:'!_/LBWF!40W?&;KA.-@>#^P=!J&)&2$!";#V-'
M\'8U#'[7K9,WT)X6]3G%<YX SW$#$[#4C@FS D(<XKN4&"'U+<!K-PZ^,\A8
ML94=LY4V)!VSD#G487KH1%0GKAOJU*"A[G%J$^*&,8TLI8,H?O  _,"+?->R
MJ.=:@&I1Z :4Q8X;628QJ$_CW3015<SBWLS";.O?B.L#0Z"Z;^ ,E<!W=2R*
MU6W#9#SDH$<2WC\=Y.EV)CKK^FT&6L9%!@>;=_!L-5]MW9KA V0[#^$*.<LS
MIIC+QLQE;E!:2!W7C C7H\@C.@$]$0V<2 \\![1#WW%=!YB+Z[@]*JY5Y/3X
MG@1%:]O26J=@* XB9G)79X2!(#==1Z>N%>J<4)N%L6E%) 9!;@Z(27I*;AL(
M\)71H6=*L@]AB"NJW)8J.[9X3 T+M&C=8-A\)@X"W><.URV'V!@H "8;*@G8
M.W)Z=#M6T=JVM-::L@X%2S9T(]T-71NTS=#1 \.(@> LCX1>[#,:]E "JFXN
MJIN+JJ1[>)X>H')$8B>*@?Y)P'SJ.K87AQYS8SMBUC8J4E-%HKCV)ER[.T/-
MB0TG#,Q8)P$!#8F9H1[R"(=7&M2./6[$1O#B)X_<FV7WH(!.L2[%NK921ST2
M1*')3-^SB.G%@6M%..+<X*%%+</8N3JJ^-J6?*WUQT2,N+%ANKK'/ =KZCP]
M# Q?=P/7C$/.. G0'V,-B.\]#=;VF,KKIMDDBJTJMGJ+K48!B[TP\@/?,$@0
M<NH$D<W Y+<H)\P(E$;XB)RS]9E9#HUX[-AZA.R3Q"[3J4FI[INA%Y" AD[(
ME4:H6-=S9EVF3RFUG8@&%K"JF-'0M1GQ'09_PB>[#]$IOK8E7^NDVC#']#P&
MC"P@1"=>[.E^%%EZ:(3$#NS(-DWVA#3"-;K%X+\1K9-L1L4I[^RT(%'."$/#
M-:(H]'A,#)^$!@]X8/ENS!S;#,U_//?%@S>=N5759]7Y.YKI#K4';GGR@:?8
M>^9W6DQO+@K8L,23LNV TI>>)F=)3:?PW<]_.F?'9\G9+^^O3K]]N#K_Z]?1
MV><_''C^V^GGL\] A]\^79Q8MWJ:6/])SK %DW5B_/W7']_.?OG# 7JVSHY3
MV-OIS:D%:QZ?I:>?/\6GGYGS#Z.69SHATYGMFJ!#1)%.+=?3(^I%@6L0WPX]
MR5(!][ ?#,90K9A2PPHCR_&(;=+0XFX41)9G,Y?'AK/8 :6Z DW<@=:]!.TV
MIF_63N3QVJK\SP()2ERY&Q3SH+,B)R*V8]A1%!###FA,38 Q#TD(0LH!:CS/
MM+K05[(R!XM]36^^6Y*H20:0)MDTUZB6Y@ &>EEPCJU;M.MD.M*2::F]?7>.
M/8LF1?XEB7C]8!YK/VSF5.'<"H%M> YQJ$'AJ"Z)0AH&GAE8PJEB>@ EYUXB
M%.X&FQ!Q6O+R T @^8(<L4.^"2][(U,?G58O_KC^AX8D!@9HZ;X3@ERDD:_[
MONOJOD%M:@<>!Q1\\9,3W&ZAUG2*D*VO!!:,: 0(\3WN2\V 4F(0R@!)&7,I
MBV@<V+8?Q=CJR$'N*R]>;S&@<^= :NQU-"NN07R6/%N\<M263II^0Z@_/;=+
M_7SY]1_&(C<,G$#W+4S]B[P0Q_(2W8FLB#!*8\,"9:?D7WBFWW!:+'),#1C!
M>*@=E4C635<$R3KJU@@:W+SH&##0-DF5\0,[-BD3O I;Q1-B.H'IN:'C<HM2
MJ3HO6OW&V@UC-Z-XX[DAQ\75]3^.[W""D]M"#T0T89ZIAY%-P,+WN N8P9G%
M-^MR'C-B@L9+"<@AE]D4\,V/@7G89AR[3KC<DZ/N=(=WBCWDW, P]#BVJ$Y"
M9. !"_4@]MT@]K@?A^&+G[+\%A._S=6KSH4%'U/05R(M;P<=U9T8I690BI_#
MJOWB-?P[GJ7IC3:A8,@ AQ:=XN")#);1QH PHQ)4C B6O-5GQ1AJ2\R1C=2V
M6F&K]"N"K=PF>2D:4+XN$%62+[SMX/:O%W/?JFPTH_T*#<$BFTU7?^56-Y<7
M:^UOQU]['#W5LN8WUOUS5+1]@BZY'A:<7NDTABV^INDUO2E?_#AWDG&2Z=U+
M6H3O:G#T2$6_6^5&E8BR_\X2B4\H2/^3S,:"3JA65-;+1%@OT]9Z <+A3;]4
M^)5LF-A^,XZ3-!%?%?IXW=PTR;[P<IH79=4XM-;IAT!K7!-FL3W0L#>C9;PY
M:K=5BE^9;Y 5-_U::0IL&I9-RYK@.P<9KDVHCW,_MYM%*D[PD)S 7LT)UO<0
M^=:+)\<^EGND3D#0:=90.Z49' ]MDJ9!*CJ+9F6)1(^J]!'0W8UH+QQK[YO>
MJ=CT6#(0?.8#+V?I5#QR/N&%(+]RN!)5JN:FPL5HB8CM3@\NUGF=3 $9V<8]
M9!-D@]$\"&@'!/,-HUD#!O@(5,!9(;[T^XB"!LGX3#A"RX%VDK&A]K)Y8,Z_
M,="N^4";E=C-.9\5KU"#N<.\F7>:U"W2Q$>X<-%>1]Y<1U?UF8X*8+_X^!I*
M4&M1H4$-4&#Y&!&&%C=:":9V&LD^T10]- B1S[-,R@PA"O!]LXS. $ZR1?:R
M9MDM8GV<PB^J?M0(>L8DE'#KLGT5G4S -!1WE6D"C\U&A"Q;IQ8E-706&P+7
M6V/=#;577-Z](?CUBY:0_N_N2 A,AHRELT@XOQK42]''54XXFP+2Q!)KX'-8
M"S^:A8#VL$S,!8Q>GOQ^_@I0;)2PD52&D[26TKC@1\1)D4\KMO'N*QO1[%)
M:9S(([S\^.XM+#$!W)U14,%!#?@P2[E&+/(R?/62O$)Q?#0IDE0SW0IE7N+:
M[\5F?V\V^ZI"H):\!D+32-@LI06HZ$DF3:\&>0"3\:OX2CQD/)O.BE7X#8!8
M0I@#+9R5@.1E"3<)C_++&W'0"9@'\LAY^!E> ;)7+#AN[E& MGIC^YI!?24"
M]->TB/0TSZ\0U!U,$=H1*#]Y^@6VFY17\E5 &%(QDO &2/"2%4G(\:-(-&_G
MV@@H"9=[(=2CHQ ,'>U]]:K?JE>UV/U"8@9 ]8\9@)(C&#]P+ G&6X'O 7D8
M^A]#[>]\5I-KP;\D_%J\+&HB \MV\ %VKKT'=0\TN#5?)#6V+@<%H"9C? YQ
M)Y:+20 QL1M&9R47UPN?S>#NZNN%2X\2Q&,-N\PCZX=7QD4^1@]?B?P+,">9
M"'J5Y%'R[US*DM;TZZH%SHL[I)B_>RGV7?%]_H47X@[[&T/XBXM^ZE1C\)F(
M!\)5 &,)$T!K-LK@Y4"*%3-%_TLN< X^%A^$R V 6I'L4&K57\&5X),L_U*1
M/67 7\KZ>P.-C3@PKFD!/](9J,Q4<@%@ZU0K6<*!! >"&'D&U\<%EQRT_/ R
MA_4!90L@ 28P#I 70PJ5Z$QK1@%XES12(<FB&;P3@)9\PR>C8G8I:""'BP)K
MYRT\6<#"%1^K.6LB?16MXE"Q?J3PFQ+P=H!<;>&1CX.:>L8A,C8-G1[1%_1V
MX$;B@J*;F0F^E=(;I.E<N^09KLQ!$,!7K^$:>)IP8$XHE;)ZKH-VG1=IU$A&
M8,J78+Z)$\:P*ORL7Q923P*8 ,?G0@N0L!<W@X^*&\!_(,Q+,?RBEKWM,4[I
M!'ZME3.0O;*9 =B)8ZW,XRG0+UY1>IF#8!J-JZ^#/C5"924%X9^)V\CSM&(D
M<![D(7!._G4"2(UL -@9K:S&&J> _>;H@Y<.),"PT0S8/7Q,Y2UF]$MRB4""
MA3(@KLZYDJQ$W"XK03JF-Z@)\%0"%>\4  +(.@8V\U<+7;$[/+B\+%JKBM=\
MJJ<T;':&;Z^I=9^Z,+#1$@QYEC_(9KYO,,O[A!T@-%$H<<'%)UHI2*&2!4!(
MZ&<H46$6LD!,/2D% 5<Z4D6,Z&1(8'NH60S$HI5/$%"1TS%>0YK$7#*%*; ,
MB03(D6;3&G4$XB+O$5@ V 7R&S1@T':EY@=<Y$M2Y)D,1<).N,;'DZ1H\'\@
M)!"L+GY3)(#4$I_%&HG D203H@K995CD,X")'+Y""Q2MN'-T3Y?"J-(N<ER7
MH]6@C>@7) C@,<!9(_'D/*.0V(HJ%Y\D# 4E8&9^/<#UY2$J6T!.M(D*V%!1
MOM:25S5+$0=#14OHF""&,V2*>@0O34$KBAJ\KQ4C/$DLKW".[]-2LH(X!U+'
MS69X8&GK &UE20P/P[MF ,LID!^/ '3B:((?RY.( X/@O<(.*!-4*M#_C\H4
MW#W_RE#-PXBO.32D;10F:2HX+6K9&6H7)4TY;A:.6"F$H"ZC%@H,LAPE$XE*
MR&9J>329L^8JD97PBB\EN-()H)RT>7ZC(7Z@(9^$9:20J6 ==3D4,AC^=0K&
MD-1>XUM\7@L!MVO$QE>%_":7C+2@$[&=4L8XLYDPV% J5;>!V"'$K[C%REC"
M03ZT ##B8M4-BOO%>41CW)08'B2S@2*X%72@6X89#+6C%*.JER-<%ZX)IZ0T
M@780WY>@$L+E<=[PXVL O(8L&]E@*>E0FR9CG@J9)6!<*=>P$$(/UXV$^54.
MNA*J7@R,3#%/!5&WRC-H>7 MGB=P3QTX-+[#LC&@Q#M%#+&<L=&@ =0*Q02C
M-[BX $^:7.&3MQ^[[>M008&]N0))SX("R1C,D(+][XOB:_&UR=WZY](<?IY<
MO@!%9[KJHWDT<8@]^;K-9"#7)Y.O>+)]NK\?Z>VF\R],PJJY: PRJ!SQJ')[
M)46D_5>:K\@EA*M"L"(JNFC%.0@+_( TTDN3TJN5<@1^YLVG[>\]#4,GK=+?
M^0C9+3$U+GP<MQ\ 9M1$.%!5:7??Y%,U;$@<0U1"MSR??X4OB*C-B&<YJ-Y2
M3TDJ5T3>G=4&&P@<L#^$5)1N2 2L,-+AX:Y6+RPF$*^H$0BNB[O63%.;P.?A
MS91W]/IV,W,ZL]#70"C?WH1E&%HEFX?:,;Y)B/:0\ZRQ5:(ZS#,G%"M[S_8K
M[1T$ -A5-Q.Y'0T)-D=CH+%"TB0L\#RHQ. )/--K4H0$_T93H3H+++!G-5S@
M[W[4</'J+KA,J[XCK1P#;H(03.$JA/X$UI-4<J1U+O7I5H>P;:.]-K##:Y=8
MV2KA(9]>XW5OJ80/M0V='TKH/J30=0Y$Z%JKA:ZU3.C:*#OO)73WZ9I;[CW\
M* 8D"A+_N7:._QL^3X6+8Z\NQ96,<OE)WM9R^/=*EF['$JK*!AV+GU[;;ET1
ME6"L:OI:WZ%[UUR+FD3(RGWSD-Q_&3S?S,'!)$/3P8.?\5F1QR 6T)F:8QP+
MQ:UF:2_/WENOM)<?WKW5+<NW7KU^&.%YUSQ?J5>=LVD..H@PZ J1C(=Q15I.
M,0F?76G''+T,T@.',8IZUW5$@6OOCX_$)\*.!%LP$P&U*9KNM1<$#JS!SP"C
M!( A?7T824(%1T;@IF@@3L :3E.>HH"<34#-NLZE'CG T# H)]:/]D #BSD"
M=>T;>CK&LQ38B>#;\.0LNA$.#7$P8%#6ZECZXZ'N>OK#/E 77GP+=07FO@7]
M,T0'$@/ELLA Y]- CVECC"_?OCVM$#@(R*O7>U"WEB-0A26#RA>CA_!-P!)X
MDO$PU]$N*/)4.&EHS*<WZ-!#/XB<:2S#&\+/! 0+C)['Z%QC-Q5J"5\3!O)K
MATO_D.U./MDK9)-\\CVNCRR#1FB' >@!WR9Y>C,13//E^Z/?*V0COF_N!=N
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M1(5V"NUV7X+G67<4"/0OK>%Y92]L9I4I,GV*9&K[ ^+?D5JGQ(/"NYUKP][
M]95:LO=[>&YX9QD#+[BC38322U16Y7?2?WZYVZ.SD ?G+Z;!6<;0WV\:W!IN
MJ6XB'"YW6>37TQ%^&:&%J6SXV[?XTNRFR77*)[P0R91EE4,J\D:SN9>7-*5%
M4J4]7F/<'U?[P5X$DVD,W=V#B?]WELB4/Y%/-]!&LS$5B8'YK&"PE^K7,65)
MFDR3^C?BA3EVTUJ$6)V75^8L$?E[UPD JH($'K^"G5YBDH.\I^QF9<K>&FA\
MD8QA6V?\6ON0P^97(?1:^+S #!?SSZIG"2:+3?(RP;M]+9):X>AMCMB_YMW0
M%:\RVJ_0$#C3;+KZ*ZL\URM(_H&^]C@\Q#86'.6=/T=%:XI=<CT$LKG2:0Q;
M?$W3:WI3OOAQ/D$PR?3N)2W"=S4X#B%55+2OT]*\!(K,^/0II87.I^3G\P=]
MHAFA]M UO ?(!O3)MCF/C[WJP^08;K_J/C)"U6U9MJ\R0AOE0^6%JIQ E1>J
M<$#EA3[-,ZK4,)4:IO)"%?$_0[Q7Q+]M7NBJ%K0[ ],C#V(X0:CSLJDTW[3;
M[].--=[SQ#V,:UG;MG3>7T,BA64'AV5DVYG-"LL4EJU]U)>F;][RO^T=PQJ-
M88U1 /? MK[< 7&&5G\NX='._2 33Q1S>CK,R1H$GA*""L\>/%]U8&X[LDOA
MF<*S309^DK[RLP=WTO3D#G8Z0>A ?%))QO+Q+9?46DKV@8W4?>D8ZRO2:D+Q
MW9:)J\"Y2W J:.ZP"'6XY>"#IVT?WS$YY"EBPLM $=8NP6D%2HKN4NT/MARF
MIV"Z&D==;^@\-I+NB?-O&TOOMW7R6UZ6V%<]XB%&S;&6:I:4(ZS=VLI2.;#)
MP+ZUGWGF3QJFOJU@NG.+>@,34('S;KDUM!\;GCTW6.X(Z#U%+%#,7S'_0X"I
M8OZ*^3^2S7(0$95C^-87V18BIDF!0YUF7*/1YUDYW=IP.3#+6U2X6V^41V/7
M7B)WRR&H"J;?R6YT-\AN5/"\&Y[8'>*9N-U4P$7)@,?.^;^K:Z*"Z19!=U]%
M!Y4,4*&7]HRB[=9S"+)LF]6K?!@[%OT*KH>"JO=C;CT!9O;C6(4BUL0[%8E0
M+/(PX-H75'V2+');A_TC37C;AX;<]FO=U-AYKG,%'A0>/20B<V#<-0?I@>EF
MYV6%"H.?&0;;P99E% J#%0;W ! O;6^#I(I^X.XF?N$'P^.^W)_E#KU#N<##
M#D4JEJE8IAA0,O#L+9--E-!7&-P#0%@#RU"&E\+@P\5@<^!86R9[*.6U-[?H
M!L/#$J3[S*/8P]3'Q0[6RX=[93^.M?_5SO*I-N8T ^C&L[2_H\@6AZ9%O#N.
M$JSA9MK.[;&*=TQ3O'/*9/TN'/1X:Q^;OFQA!.72C'JL$)Z*%S>9]VE"0YS=
M>*/%L#?\D.69P'<DGRR?\G+3O1AR5.;<\9*%CM[=K4[HC=@<//;K++V1QZEF
M9H8TI1F3CU>;/TTB1B< *IH-X>4<48UKWD##2*%EO#D3>_Z=WB!]B-^9;^I7
MO<UARQG>+OPD^( 80OD^R> M@$O:QRG\8BP&S2$\D#W@2$;X).)3FJ3EDETT
M!\!CSX-W>#B(/S^'U1PZR\:)KC-$=*/AJM]!^[7>A5@/Z^/D0,"<"JD69J@N
MD$.%61^YF*MZ)&[M9UBH*"A<>P>E3*O!J8_3G%WI/U.).6-$83&Y]<'0J]W.
MQ2AIA^3*\U*@3IK">?,X+@%H<&$[)OD]$E:'>#:<8*DET?^^2(PP-%PCBD*/
MQ\3P26CP@ >6[\;,L<W0_"<@+QZ<Y);/=O@M^>\LB1#PB'-OZ01'>VH?FFFZ
M>V468IWUAXU^K/8,U-0>J[_<[J*=OZR-@(8 RX$CX5SC\9@7B*&P& @M^'A2
MY-&,54.,HYS+AU%NL2FBNYP'#911\"\\ V*+BWPL4+>DJ81(9QF-P3*"&BK$
MGVHI4#)HH?!M'"N-?!'H[2TM1^*-#'_ P<M R8)<ICG<">SM!SL@W;'/XDT-
M2Y1Z<\,7Y>QLUQJ:"U\XYJS[O"DE]J:DML^K UXX*U"\M%.C47Y4,[+QGH"Q
M@\X0@4"YE!RO?5) -T[SZVJB-L[&!M4^F>"%3D=P.YU)W=HU@ Z9(WQ52A;Q
M[OIU<]<I&' .*@[G8L)L/)O."F!AY_ \"C;\CN#>/Q!O2!:&=ULKQ.U]IG=+
M6;LX<WQ^*Y8]#.:WXII#Z]X[,19W<G0GKBY'RT$["ABN'LE3HXS-QK-42)>(
MQW!U4SD1W7:ZN"[0W[3;H>B+6^HOOG>/#$@F)"@<-IG.38R'"\EGEZ-:P?J"
M^#M)*:MD+(!D4O"8"T(I47N12GFFG?Q^?L>%#.9H .%>P.T W")D:HSS2 ZA
M)\3OH,\<%\3/<<,+>YC#R7951,KYE8%QD=LKBZVWZIG1:":P(F"D)K2T!U-,
M\.W]Q9H3T*79-$<JE)0S709I"H1B#(T&M+,) !>4Q-J":4"]R#?**8J\RX0)
M[1,$8#E*)L ?IR/M9WK#BXUUM0HHW6GLD[P4H']=\%3P[5OSV1L_D/3S&.U7
M: AW.YNN_LJJH5YW[&_'7WL<7+#-^8UU_QPU$T,G])+K(9@55SJ-88NO:7I-
M;\H7/\Y/4$\RO7M)B_!=#8Z>**J5H?X6F% B3?2/R&!173VZ!*$F\+[7=-W*
M5\LP@WG*%LB%TB%#N_>.4PIRK>#1,L"+ DQ%[:7\_:O&B9%+RQQ%?"%M3F%E
M%AQ>]'+1 T+K=[R2+'[I9\CCOR2H,0A&J\'.Q_*1F#)ID H-#)2L=!8);1Q^
M3M#6U8#]9&PDY,H/IMF*G:%VTO$:S<-F0I-HE1-)O#:?3<LIJN>@Y'1@LP?C
M=ZCA_P[)_A/VRGM4I'NVL550?#QC)<Y3@(O0G(4ID("MH96S\9@6-[7W:07*
M=! %'FQA+-"&4S:JOX]&3AX)!:M$'A!I(8<'7V^,0W*+C5P5@1( 44HG)7]=
M__ F2DI0+F]>)YDXLOC2&SC/)4B'2ABC<%A,,T<I*#]NY<;0D+*CRHZOWEQ]
M/!0?+41]Y&>>/22NN?)C8[CZL^\M"\S$-8,'6=9:_7%WV3MJ!>XLGSKLJ>[:
MZHGN:P)F#]'Y.\\J<_&$[UD&C\I;.7G+4M .?'SQ\QO1O/?!O+N$P=TBSF@D
M_ZP42F?'LT;1M0)J#2\7L6 WP-A+&LZ:('D24Y?6/.O+P!N0+3H9JME>"LTV
M03/''@1>CP9Y/F8CQGUS]23[PLL[N/IA=>-9%^LL,Q@XAFISMU.@DH%)@KV
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M6)8S A NHGG3?E.>=\;-WS?>T5XIJ'<Y<"M:<[J%/]MQTSO?U))"2WOS>?A
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M@64HU3"R6+9,_$9+DRM4EH5*O_#\8+/3]],&K5V*W:(188R=_^?D6#<#T*\
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MUH"1Z5R='4UV2P([08H1$A;<GH5QUO61;L<5P3(MPX-IYT(<]=WMUBBKQ78
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M7!-&? HYY)^.,/#-KZ_>GKY__>:7=__QXLW//[]Z^^+UZ3]>_W_XU8$'V:?
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MLZL'2@!SPH*"Z=UL%T83,R1)B+J8EIPRZI:C4(5%R<*']8SU"A*0MO /D7/
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MO2%9$I:"S^QO:NZ8X.&QM7JA=&N_3F$X738[OK0D4'2>8.2&NI!P+2'G;5.
MNH2HK-Y> SO**&RQU)N)"G>R+]6>$ R!P?P$WFBF'1U;Z=U]#X]F5?RE1!2"
MEH-G+Q'XK&BZO:$I,]4)#76N%$DS-N&6CLCFH4#7H7(B'C5U,=<TPJXSOA>D
MIBWJ^7.&GL47GE./6?],E#!T27D"-U,R+9VF4H[!XD)H61G$FXPSR \FB8N@
M0.QD2SR<@?UBS1V",B7S>O]-_<<FSB1[0;LQV0\.\U;(N$KAJ-XP^F@TZR//
MHGY+<MULV8I:I*;K\-3U,LRV2V1<>OTDXTNP":9"?KEU^&K$%E?"U!17?D/
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MY=00YH4Y#ZPKJT"!Q7S>4+BZK5:$_@9(:2DM;OP,9>N]0;NL'A2PIVM*ZBZ
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M#/"!VH7"9Y*R 1'5R[(,KJE#T^VX3Q>)JLZP^>V')^5R'E_6</5]DY;Z+9H
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MXNY,M$H]?I[&J2=9%0R!N".J/<=7P'.E/I#HYC,RS!5$8EB_8:47H<XG#C5
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ME_,Z$X9%+((;A340D<3M*^%5U 1" 8 3T@8D1\_'\S<B*E_PY0#:$5_=470
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MZ76BFRT @X#B81B@6Y].;] (AAX7"<EO(?3P"".7.X*'!-5K!5*W TC'*'B
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M;R)C>33@4;X&J^_PSK7%@T_[KUGM.2>VF7U05^$YL2+2=80JL>O$RH"4-N]
MI,\[D&AT=*5*A+Y!&JV^1/9C/T,OC![!9BR<RFN']RH-)=0.=FJ;V:>%=W P
MH=B[>.X<Z_8.++4#*_6.WI9#]-/S3X>*3#G0:L\XL\W,DGU%S^!U':.*?H?^
M^#P8Y'3D?64T.]:N]I9SVZP^)RF-(^^20"*4RH\?Q\QG9= O8K:PQ<9Y-30E
M\;VN;68VAQ3$)^!']C:G&H^CZXE(SM@=$7<A6;#86/<8#K&WOS%!NSZU!QBV
ME=G,J#"[>1R!6 %P1T"LPE]9XB%@J44C7>6.<!;1"YQKO2%C):-<V.N91O9$
M?20-I'@S#:W_('Y&5-U3+-O*;&&DS=Y(3W] @?@EDP&B,A&H?K1Y0T[M\>)5
M9IDSS"B(?D2%8T192'/-KOLT8ZZT<MFZU[.R9[2R%#1QP7K#FJM,7;SYV('$
MO<%>&" W+C>+RVD_#+!;->K8=F);V4?KLNRNI_ZR8GF>,JYZ)3);.<0Q**ZH
MZI, N\)6^!7%+T?"B'V<.U[H(E?\ZKC(I,*HW?YH V=O'K,?-=0>=6I;V<?^
MRCPJK1A8:082U:(?9D\I)X3RHE #G>X68BJFVN@S@L+>>F_#RY=6C\IG1O;!
M,($C9_P(I)&:SH/F *W"4 _3YU;V;%H!)TT<JW,-&[U^A(]CR:15/'H0W7=]
M\B3HH9B,Y0\9Z,;@O56HC+8G7=O*),A%M+>3]ZV(D3NE05+*!3RN+I6(?[_A
M&%'3W*6H6SSX06(X&"Q%]N<GU>M2NXAA6U6C=>(B:QZR$$^-KGP$!FGI)KK'
M$_)@] -[P>*%0L*@(Y>V*W->"* <=D],(_M ;PP%)!9(@QT)T8[993CJ?F;9
ME@8]?_2>\V-GSB[@;(;)R!=7HN^$^)'N\A*_@J+W6TL:Z9S.?[U'/ "A^)>2
MR?B>AQU4_'Z*%H!#)D^:7K9&T&/\ H%3=-G2A2'BI6<\*;IL!33DW^=#ZN$+
M+HY]5S3JLH4)XR$Y2&X-HW>D7K8<'A0QO\Q"K@D.0M&Z3]0/9Y>MJ"0.T+0%
M @D279GZA'-/%W?\C@!O=0K-(:<UF;V U(&0J\6J2'I?<!!29\(O#F03"NVT
M-_QR [HAC0^_:I@J$:IBJK)W[<<62-LBTC4V167Y [65PW-7K=#2ZPG%+/!G
M$T0_X2'CJA&W/QKQP9H'&YY03H>(%K6RFNS>6^@&M"T^L0O7GT)<A<]DSS'E
MC(S'("1$65'S2H2^.7/I$_/],47R_D,HK/XX&E#_/\CA$[X)##[#Q16Z$Y$7
MRI]Z+>B_VP,>R!28!&B,: 5;_(S#Z1UQU.ZZ4:BN?OD2O<:QND_& GMHCQM<
M3'A)ZH1#Z>5;>F;?[!HGB:9J3G*+UH&9S]B;X0"6J+]9J@Z:/T=9D6VH5<\4
MJX/N>:E6$H">$$%OT(N/%&IE:T40WSQN2>U2??F!-Z$_QX5#4G'Y_?1^%W-4
M%N=(6_;^Z(67]SXDRS'D!=&IN' +';D*("8OS@0]$A0Y7UDGVQJP#CZ]_I;*
M>Q0$PA6O9:JO;G@5R3JT,/4,^3.O&+&;]8?42[+(BM*U;&G?V*FI1>)U:*N,
M-3Q?XA=Y/KA\VV/R;CY% "Z1J^O\^ 5-9SS[I8N/OX4\IMPQ%HIJKWT6% \W
M:B$='C?:ZJ+AX9J:G^H_(88@GXK'J?YG.!<O-+I%W$^)RU,='H=X%2R>NK,G
MY"#\*IIWZ],^B4;51])//Q\,B8M=/DG0G'0<5).ZDK+A2G)1/(H88D3F@3\=
M/9)M[:J.616MKL:1OQST.(JG"H_T"8\G@>AMJ@FM2N90TW>QPL6J3)*2A1+W
M'[[G<E8&?B!")D]/WPC_.L&S 9^)B26D,?HR0>0Q#$14='D6%E$JU\[8S[PO
M%%I@OY5H!&X-B\U"BK8:>G<;>>L[\*ZG?5>0?!6IKDZJN"E3AU;=1U'>CP*2
MC,GJ)BD$ZM">W.#R27R^X?UMN:^J%YSRY/?=ZU9M38[WZ2PJR.RNXLK"6MDZ
M<!9KUCNIU(!5L3KH?M!$B3/E1G'QVR1JZ?KKFH&(I<K3ZJN:F:+U<*+E:[)^
MYIG ZL1](>D%Y0^3"E1?.),JK4VVQ P3LDGQ[F2Q1%T][E^<UA)/6RM2!P_C
MKF\:\5QXN0;@E:4O95)U:!E7C(H![09%_^^B7UQ';FJ6&;^3H] )M3#JZI9Q
M LT#?/3IJEI0+!6K \E;GV&(]Q32\R>NX%1,O9:Y7%_F=^Z-:CWD]U-@^V6X
M@WH7SR@"BAVN]C4/SMQ;Q#\1&EZA)U*(U8G%Y>&H0F-NA553N\2!XB.DWD*H
MZ_/Y[")Y!]!UR9IL->&Z+LPFV>/C:&T03_0O;'6IW X1]K M3D)CM%AU1_X)
M2<@E^2C950?9"H)U"+/944]F9!7=N%"LK@Z\:U#_%'%*H@-RY6L+!ZNOKBG)
MQF*W;!S;V]IY9;AOO::<=_;A&?\7/8[D1U<>R-<Z.9$C?<#XP9L)*\UBJ: G
M0%<^<<O.*.:6K4,,+#AN)Y[=&87$%>K]-!M1GP1Q#XT63_0/\%5!K&O'SFQ@
MY.Q;5-_]R!7^QKL:>92)XRV:+$<BW_[D]$;H?$'SX,J3K]"O%FM3 @?LI$%2
M2X46Q:^V5H>9C4+UB"\;6U[7.VV8%4C7H:7W/AD+_[]!P^ S#,1PO.B/ D3_
MC2"]]4-:/.252]8VI^13V'AB$W/%4SD^V2U?U*T@68\]I]1#%%>149\G" 5\
M'A^],D?LT\C[J2<KR@/.KK U"4MBC^&L^G9$IF@=.F[N'NB66Z?;[9C^KETV
M$U.O=HK(!=)U(#;GR*[V&=\ZM6=S0I@L)R'W)A3'HJ.)<C1/?$!O\E;UZ65%
MM&\]NXQ77^ZX&S+Y.XC)<WM5UVU4DG7MLWDG[F^DV^B<T4\DZN#+T5[;=.;Y
M"X2D[RV?OZRX3U<F^[NV4CX,S)P)FL(/W_T/4$L#!!0    ( #4_:E-"]["4
M.AX  .PL 0 5    <GAR>"TR,#(Q,#DS,%]C86PN>&UL[5U;<ULY<G[?7^%X
M7]-CW"]3.YOR>.R-JSQCE\>3W3RQ<&E8S%*D0E*^Y->G08FR)5$2*0+BL9.:
M*8F2:)ZOT1\:W8U&XR__]NEX\N@#SA?CV?2GQ_P']O@13M,LCZ?O?WK\Q[L7
MX![_VU__]*>__ O /WY^^^K1+[-T>HS3Y:-G<PQ+S(\^CI='C_Z><?'/1V4^
M.W[T]]G\G^,/ >"OJW_T;';R>3Y^?[1\))C@5_\Z_S%&+JRP$J2.$I2V&4(4
M'&(.RBGIO<CI7]__J)R-UBD$G6VBMVF$:&2&Y(/VO"3,3JX^=#*>_O/'^B6&
M!3XBX::+U8\_/3Y:+D]^?/+DX\>//WR*\\D/L_G[)X(Q^63][L?G;_]T[?T?
MY>K=W'O_9/77B[<NQIO>2!_+G_SCUU>_IR,\#C">+I9AFNH#%N,?%ZM?OIJE
ML%R-^9VX'MWXCOH3K-\&]5? !4C^PZ=%?OS7/SUZ=#8<\]D$WV)Y5+__\?;E
MI4?.,9VNE/]#FAT_J>]X\FPVS3A=8*87B]EDG*N>?PZ3*L+O1XC+Q>DTG.8Q
M_98D6CUA^?D$?WJ\&!^?3'#]NZ,YEI\>SS_-/T%5/?.255Q_WN7CGWP1(H5)
M.IVLQNP5_7S^D JXFSSX:8GT3\^&<HUC,DN7WC2IBIS-U_]R$B).5K\=G2[@
M?0@GHZ>+!3UCI%@RUML"+@8!*D4#3@L'6>@LHQ0:1;@\=E6L!<FU4GH)B[C2
M_/G'/JF#^@0GR\7Z-ZMA!L;/"?#GR\\_&\M]I7AV.I_3[!^A\YIFI(?($@>5
M:0)[8R-HI[5T/D4LHJ,PYS NR_050Y[.TZ/9/..<3-KC1Q^Q&J!SZW:&*<S3
M->I<GEOG[WBR.#T^7GTF$$&.U_^^FKJ]M;R<M1KB,R42Y'VU_&8^.\'Y\O,;
MFAW+I]/\_+]/QR?5WO^&RU'460=I' 2%BHRP)&R($9A, 65!H6/JHO3;4&W#
M ?'M<*"9 II1XN64%J_WXSC!,_$(R,MIFIQ6%^%OLUG^.)Y,1CEY93)G$$30
MH%C,X% FD%$DH:V@06!=J+$-NFTH(K\=BC172#.JO%X>X?P<U&R:S@V9S-[Q
M0JQE4090+DMR\9"!S!)5R 6+BEVXL1'.-F10WPX9]A_R9MI_-0YQ/!DOQ[@@
MP_7[<I;^>32;T( NJA%;?AZ9F$4*/((C *"\4A E,Y!HE4LE&!.E[T*$NY U
ME'R$,2>= @..QH/BAL1-- ]%8-(E&[TU?=R\KT ,R2]JRHJK[+_OP#?C_+/9
M\?%X6=?G*AT%&$LRPA1 5T \2ILX>6SDJI$#IW,D8YPH9BV.1^>4"%%W8<(M
MH(;D+75E1BO%-&/*.SP^F<W#_/.9<,_"?/Z9(#T]GIV2H[=<SL?Q=!EH47\W
M>Q-61MQ;QP)C!:Q!6L(30PB%8&9;E#9>:\M-%_[L#'5(#E975O558C.N;9"Z
MI*(Y-Q(*SXFD)L/HJHGT/'-42I"IS%W(=-=J>U@/K"M;]E1#,SI<SBM((;/P
MF@-90/(V-2=O,V0'W+OB$Y/"ZO+0J9M[++QA<50-.WVK0_LA3%:F?KF>DO\1
M)J<X(B>XH,%$VI.&HJ#"R2>("4K.@B:?XRQU6H*W@3<D-^W^'+FV\C;73+.)
M\!879*+3$E?HUL(ZPI*==2!]0E!99XC*%\A,&\.\8,KU26MMA#,D#ZT=*?8?
M^7;6,*6Z6B_>8D)B)RW6O^'R0D:,MC"7P6I'0021$6*6"K1,S#-4V,MGOPW5
MD-RK=I1HIH<>Z:LUCF1TT!HE62ATA$-F")Q><69\<CZI)'GOW-4.+'C8Q%4+
M%NPYYFUU_X6*BZ^X&+THD=D"R1ORV6IVP<5@Z975T6O!>,)^'-B(:1LNZ&^3
M"_OKH%T8=32;+]_A_/CE] .M7ZMDPBAYCH'B "#K1.P4QA [R7')UIM8O+ N
M]XG*-Z'9A@?FF^/!WN/>(Z6]%DPKCXE+#I:<%,(A2#"N**!+V@D6= WD>N=W
M&\50ZQ7X3?A<Y]M:PFRX%76#,>H80$6I(=JZZ:A1I!+)95-]UKS->(84)>W)
MAYM<H#T4T-(MGI]BWB AMS()0@'9J%AKKW)-K!O@+GMC?#0D:2\^;(8TI!BI
M/24:J*'A_L9T.0]I^??QDJ*VQ7)VC/,UML\7R(*QOG +3G%:G&W@$*7(D)Q"
MS-(K$?IL_F^#;DC!4V.N-%=.,]K\-EOB5:M&*[]SQA5:P"WQUS('SF&BB%\6
M%UD*9/:ZL&0#F"'%4HU)L>_0M_.=,"SPY301@/$'O((H!"U<C J\K@4*(B($
MD34X[9-&BORYEGV\J%M0#2FJ:LR*9LKHN4=E(R(+P4#TIOH]B0245@'FJ$JR
M(;C0)_G6OB*D;C_/IJO//<MWEVR1,1*+ENE:XU-<K7-G)*I/CN7LBNU3^W(5
MR9#<Z3TYL&G/_]Z#WLZ1SGE<90^3-V&<7TZ?A9/Q,DQ&*A2I!9E>+%*"<HQP
M:!*42X/,<IY8Z<. &P -R8EN3(06*FBXZ;0,XRGFYV$^'4_?+\C#/SVN0XWY
M%RSC-%Z.DC;&!'+/I*VG6[S)%/ Q3\NUYJ@*$\SWJ1F[&]N0W.?&+&FLF):1
M^!K'*B-*9NUDCD<X7=#236LXN?FO9HN:'7U=WH5/HR)8/2B5P7I!5HXE!&>S
MA^P(NLTZ!M;I+,9N0(?D=+<V.!U5UB.9.:+(SR:?"@2,&A0)!Z'&!MP)E!:Y
M)10/6Z7:)#DKDT-1G("4/(E%#BP$DR(('7V2ND25[4&2LX-)6^ZD^5O*;>\S
MXLV83.89Z?'Y+2%X1M_'RZ]JW[F7/'N*9O*JLB1+6N298^"9Q1B+E\ST2=#?
MAFI(SE8K-C33PL-D*[\"YT6R4N52^4K@HK$0I8EDB!7WOA!K39\2N"T!#LGI
M:L66'KIIMS3.IN_KAN/7R;,1R\5DIP,DHC*H$@*XH!1%"XS+:#UFWJ<N;!.:
M(3E/S9:3?4=];_W7T^F;<V-?FS(3F(M9@W7DL2F1)#CO.'#%F-=:,<.O.!77
M#[UO\Z"!IA_OI>+F WM%U7]Y<G607M'/;5L>_+ZDKZOB@UEY?8+SU6,Z]#ZX
MZSG]FB#L)&&C;@CGSYF^?_[II ):C(I23KAL(>0:>*6<(=C,@7XRPD3Z2Z=C
M@=>@-*@O1J)H+7_^!3_@9+8ZN7W^Z2/&4C"8+##!]!G=HZ7E#;5)Q3,IHNVS
MYW$KK"'%*?MQ8T/-<2-M-/,S_H93DG!"B)[FX_%TO%A6>3_@&A1!284)!499
MLHC(*)KR+ !RC"JBLRGU"<OO #:D\*4M25IJI-WV^>I$_WG2:*0%LE1/"F4F
M/2A5L]:9P#"5>78&<RE]*@XOP=B[P':MMJ\E<R&C9!*4L:0XGS0$%A)P5I*4
MA,J*SI;_)OD.:P?OK_]K);5[CGK#BI#I[#*6]0RC2<JM)1LL;''D7L8 7G,%
M.@H2L\28;"=ZWP1I2-:N'17::*!=P?T&9B9, 2FH@.)# <53C30P0486G8A>
M,]:ITOXN>W ?7_ #3D_Q!6ET4^KC^:?SCBVU;)K^SW5;0"/CGJM8@UU2KQ&T
MD 7M0>B@4:54HNY3(G4/L$.RE_MRZ;KGV%=W[2?1A2\D4RP*789D4PW6:R\9
MFL%0%)E]J9/CK,\.R!W!U)U6%+XIANPW\ =.9ES:G:Q#T3>G<<OC'B:UL:V\
MK3(<6^P OYG-5U-A4\N(HJ+Q(FHP)5#(H8L CR6!-UXYK4)2N4\9W)[ FQS!
MV_#X/Z9S#)/Q_V#^]]EDU>0LC*<5T^OI[Y4-9]T;YN,%_>D7^G'Z_@W.Q[-\
ML=NNLO'960,^<)J:DIP<'[($J8*(T@<I61\/LY=$@UI['Y#M&P\,'IHQ;8^@
MWC"2;S%-PF(Q+N.SML%/\W^=GIV,JT[*T]?/7KZ8S7\/$WQ=ODCX19R"ALM2
M0*2XBO@"D' 21 F>&:XP6/7@%F4OD8;E7 QP"CPL:5KV4[LJR04@>F#P7 =
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M4[NT)T6CP:N'Y!5/$=&8V.=\V(Y =W1#OD^V-=1ERVOT$F)>G%4032;D.-$
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M )V:*NK0Z:/1E5NS6B60Z',?*(5T58)V!2UW+_PY"4E$,N!-HM79T3KM73+
M>4@90PBJTZU?#Q&IW",5P6M__1*J:XMD. L+]>9K!\58S#;G:*[6:?]_0JD+
MV1JDE7;1Y4-[GF2'G$ KP0I+YCN86&\%(:\[9Y,"K=YH>L7$NWN>PUH0FU.K
M@\KZ+HJ_S9:XN%S07.\2.7NUQZ[*5I_;9%'<78)&B^*E:UP]1Q8E1;VU1PJH
M) (X0?:"!T2GF--<]FG >//%NOM)M*Y8)L-F;<@%C*GU%HE;"+XV@V'6!2<%
MHW"_NV #/(IX;^U?-1G[#GJSY>9K(%]FT$BE$I57%F2AF$ A 0HV9;#,<)DP
MBM3IKI[->(:TG'3AP#V'ON%]I@7I\?FL>!Y7)R)7^R^HBS/1@"NH0(E0]]CJ
M-60E9EU+C(OL8PAN +1C64=?G[49$UJ,_L-Y#&_FXVD:GX3)E^O-&_D,MWQR
M<Z]A6REZ^ TTBZ/)VD!VC#Q!D14$9@I8PX07(:'!/KL.O?R&7\/RO,#HZROO
MOQKBXS"F09R_+B_&"]+??V*8CX(H4:L<0=#Z1BZWXA 5)M A&>=YH<G4)X39
M%_E@/9)=>'7;:M1=G5W<ESM0OYS^1G/YW4><?,!?9]/ET6)$1C05F21(67/;
M7&!MF1NAH,Z$MU 8V*?'T%ZP!^L,/1#]]E3D8;A7I\B[C[,1K7Q2>_+I1/7T
M5<P.HC2I]H3G):EDA3^XT;M .Z0BVL,P[3YJ.R#!B#$X$D%:DW, +^H-]H$<
MQFA]/7AL3"@I9'OU&K"#4:SB'5*KB0.2;&?5'8YF+V:G\Y'T)EK-!9$!-2BM
M-3A)KW@J0D6AI.O4;_I><(?4J^)P)-M9<6T:VVS ^?EI6>+\ I-W0>>8!$AD
M#A2C,-K9F("AU491])7C%3+=T-CFSD<-J1G%WD3H,+I]TPC/9L?'X[,CM&&:
MZY6MX^E[)(KBXM?Q='Q\>MP@H[#[0YHD%_:4K5&>X>(VPE?U[L#%BU,B!)X_
M_\WZ^:=8+\1ES"8&3A@$I6JZ*A'[&!JGA;$I7^TEUZI7S'8 ]VZ5L\5C-L>Q
M.D15?(G M:0U.*<,06H&V3KM&>,!0Q_WZ=Z0AY2/Z,&_:^UV'D2W[;HV;3<D
MZVT@+#9F81%"0%_OE#,0C0U0;$YHT11,?9*#N^$<4A9B**2[IQ8?FFDOIQ32
MUOFP& GI>,I<$AVBH!$A_Z#>?@.9H<RY$$S6)QVQ,]0AY2(&Q+=[ZO( E*L!
M[AE0G9,K2 YH8JN-;N.@WF0,/JABC4:I>9\J\7N '5)V8EBTNY\^'YYX-00Z
MPRE+E#'6S0E>9)T@":*E69(M\R;3S"FJ3Y>RW;$.*5\Q*-K=3YL/S;IW1SC'
M4(/P$1-,6FX,!*QQO:[EI(:1(R!C\J4$1Z-U2-)]@3JDU,B .'=/7?9-I+P(
MX_E_A,DI_DK8"?8*[%GU:;AT8=7YW_/JLBOR34G<58^1/?(KS9[=).W29R1:
M57U\>?P%SMIQ?#*K4$;2Z&1D3H":<U">%V*O1$"'29>$.G8ZV'P[KGV-Y-_#
M?!ZJ%J;Y;;45B]>GR\62M%$[$0I6,HH80=N:?L[52RW90<BH@L@H;>[3I/@V
M5$/*H#3DS%6+UTPQ[5I5K2;J)CF]M)J,;0*7DP)EE2(;7PQ8G00:R5*2?7AR
M(Z2]N[N'Q1&-?/U6KSWZ$";55&V2W2:;@T.$J&/=8U82R-'QP&)@AEF%PO=)
MSFX-<4@3I@V'KO5^[Z*M-AMJ;W&QG(_3$O/V*+EV.7)>S^57E!XY>3%% 7.^
M\*A822+?M?+?]^%#RA6V9<N#J*-#V^:-F%"YP$7F4%2M/I"*EA8I!6B*X3WF
MD%CWQLWW9<^#M?+K8FL:ZF7+L./\]_5+I.#GKW_Z7U!+ P04    "  U/VI3
M-^(&C==J  #MQP0 %0   ')X<G@M,C R,3 Y,S!?9&5F+GAM;.R]6W=;1Y(N
M^-Z_PN/S.E'.^Z575Y]%R7:-UE%9&DE5=<Z\8.4E4D(7":@!4);JUT\D (HD
M")  ]DX @ERN1?,"[_UEQ)>9$9$1D?_Q/S]?7?[P"2?3X7CTYQ_YG]B//^ H
MC?-P]/[//_[MW:_@?OR?__EO__8?_Q? _W[VYN4//X_3]16.9C\\GV"88?[A
M]^'LPP__R#C]YP]E,K[ZX1_CR3^'GP+ ?\[_H^?CCU\FP_<?9C\()OCJ7R?_
M'B,75E@)4D<)2ML,(0H.,0?EE/1>Y/1_O_]WY6RT3B'H;!-]3"-$(S,D'[3G
M)6%V<O[0R^'HG_]>O\0PQ1]H<*/I_,<___AA-OOX[S_]]/OOO__I<YQ<_FD\
M>?^38$S^=//I'Y<?__S@\[_+^:>Y]_ZG^5^_?G0Z7/=!>BS_Z7__]>7;] &O
M @Q'TUD8I=L7T.OS[.M_>!>-_FGQ1_KH=/COT_E__W*<PFRNGB>'\,/&3]2?
MX.9C4'\%7(#D?_H\S3_^Y[_]\,-"<F&2)N-+?(/EA^6W?WOSXB'2X6CV4QY>
M_;3\S$_A\I(0SY\P^_(1__SC='CU\1)O?O=A@F4C^ILA5U"ZPOD?]6D_=<;T
M@8!,TG5$H-_BJ!*\1XSKGMX=\]=G0<82KB]G/2)^^.Q>\8ZOPK!/ 3]X= ]H
MYP^"*[R*..D3ZKWGWL%Y W(587WD!-/U?-7]4QI?_33']WQ,"_'K\!Z?QC;Y
M//D,=45E7K(YB-O_^ X TO1P-*R+QTOZ<?F$^JX]H>#G&8XRYA]_&.8__SCT
M7,><(Q;CG;)8H@I&&Z,\SX:5@(/;QU1,-Z@NQ^G>4R_K C?^JI'+$/%R_MM!
MQN'@9L=Y,2KCR558#@9?S/!J.A#*I1R\!56L Q54I)U#%U"8K6$V*\[80ZU.
M;U@RQ?2G]^-//]%[?JK2K-_,Q;K0ZQ-O7TBZVZC>T6<'-ALC;&:0,](F**6
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MR:RM7>1[((?X(BW*3FIY50=/>-UC^G"!GX2WXOLRY-P'9Z**4CE7,Z*\=H&
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MJ^B$)LLHN'TG_?DHMA_YM0@,C4?OB6M7=<A?>Z5J)T3*,H!7G$S=S OYK;9
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MV6"K-[0Y"M.A)"N26O0+5*&:G";6\]^<4W(,I6F3VMNJ-=B= Y>E* >>ULN
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MN73T@CM\II]6N;P)P?'3B8Y#B'&/BNDQ#EKQO,&/U[0IA.GM1K$*\>8ZWRU
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M*=Z7@""+),,W)@:H508A2W$&1=)6[>/'_H^9<)=)QXK.KF9<1Q% .6, 95+
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M!WW0;M>F&(TS#5RT8X7:(=/?2,V_7BW)@HB7UZD^6/V,BSG]M>4%&9Z<.6N
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MT-=BH61KHK"%H@AJ24X6U^9TZ@1S>$*UU?J1%.NNLN'XM3E4GV&^D%R;[(P
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MF>/&+GA %?=]  \LXA9QN%1PI0_X  ]\Q /P]Y\.^$80*A6F!R\A]U<@.WC
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M+J^,<;^I[Q5YD8BIN\_4 ^<\5H0&^U )X[I9CELYR9(?RE@G'V8\9.]6OC=
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M'HA\B_+! Y?V0<AY+SS0M@R>SJWG@?2&X $$S2P>B!V"&Q=@"G?@E9Z;!W@
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M1$7:WR=$MQWW7,<R\([I%*D:<+OJQ@O[XB(U;O^\%]9AK/^HK9:*!WS3":1
ME4,Q:EQF447X,-XB-C>DW\)K!EZ]2S)K\:\.HZ4JZO5F55]]Z!!D3B($#YC/
MX8'>V*#O&NW@*]N6!*\^[HX'9B )UZ,%83E@NO_G6^$?5(^WX(&$O=VW2299
M/C[6Q87L+$??WGFTR7):GOE/-BB*EIP$RP;Y,)%;''NZ70U"G'*.XGCB?SN/
MWVM5/NALI-\=;W,+]21D74_W]>_K.'\\H%)N_ U2Z?<(#Y1AC+.<>]LKQ%Q2
M1R]G@6ICYKQ6# D,LO.@KZ)Y&-W*+S.PO1/\R>2ZI+_6Q1\.XY2+<5"LTZ5^
MY=)4)/R[7!/TQR0S*^ZJ"$7*_9V-=JX?<S<AI(LX,DL[U'.#,D1]>)[3ON;;
MB<[Q#>[]T[?20H*,6<5X]@*CTPQ[\CI0QH>FE!?LM-,2='>7XK\4I]\K"&S+
MD?U88.'$)B U?FWG\_+'EZ58W5LP?=%EJ:E\M<LN&K?@)]Y&"Q4Z%,]5)G^8
M-%=S(0UX_F5&OE^^BRE,"B>/'GXGMC:X=?J%.**?16EQ/1D/8#RK(=1I_EGJ
MR+I'\8>H"K2C<WQ9.VX)Q@=ZFL$YEGZC%V40A?@X6KAUTCGY1P T930.ZO%N
MA<U(SN- SJBO7+*]6G98_PK=@TN-E&]:C8NC9@0P+Q@((7A$?Q4/J%=X#:X8
MN+I?0UU3D]&N76ZW'3U\J:?&XB#_>\:[=^0E1TB?*SE40FCN+-5S$;C(940/
M]M%ZU/0"C#DC>J'\S;J3.M0WH7LF&JL>U\T3[2M&UI>K572O0"%B\WY+P[K$
M*V/?H!B'HN!-9$&@H!DV-)CDNM!VJV?..*01+*FLK(@']O" HO NI!5$KR0P
MFTNS\DDF?55RG8WWMHGJ:LO#!;(MV#.<8FB/GR7MZT-3W43S*\V>\I:2EPZ[
M[)59+U.>VJ6/J^6V=2AC>&E0(*HE++50%L?0:E>><2[FQ515)2XGCC"C51#)
MPH/G]>#C_MG9NC4IOMJ+SRA"[HTXFK^[OUQ/N<5;85TUZAN>;VDBZ^'AYG A
M(8T;]/(\MY'4^=A7MUGLY.V4&"W?U9,/EROK-"F&#"7XN(XZ/'M#YRK;EFGC
MN"L<P_B#!3'9/FZJ,51_P3DEE:M=YOFG\ZDG:;1.&4XTQ%%=8%!>[6RV$;A3
M]G[69F.GF*?9SI_3_Y/A0;9HJL]:P#HS]/J+BI4#*/G;HPBU5_*7^PX-A)AV
MH=5GC/!#]9\Z4OUWHE'+NQ_7WX8)F>5T^A<[W+9,JD\:& OI-^LN"378S3S.
MI&\YP;DM-BH.:26SP0-6@GA@]U;%ZF@*NME"[5 =#W0\_/-R.<DBO R,2=ZD
MCP^*QYY+KL=&^,/"\("]Y8$(C@L]!EF6'MS'@+UO'JMQ'#CZPL%_4)7!K2L>
MA9TP21^&3\[=P<;[O'5<-P_?URZV0CR6R-IJ=?=_+%N"G<';[/5XH'@;LJ1>
M'[XE-^F6'8P]^E)MZT-<S6<\\(9S_T-\7&C47#TAA_XTC0<(#OE,.K.>Y?50
M=L)N OX9*\M>U)KE+,-%W4&,C#14I@9;/":Q4A0V%431B*X+AIKC@08(&Y0<
MH_?-C5<W>?@D-G%6@,SVI1GTKF\5AN*CQRUL!8<J6H6W'>*PX.VL#'-8ZBG
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M2K,RLU"OP>Z_=%=T[-_,3C2[@IA=^<XJ?>\V/5,N/%]V%ESB3 J3 ^/9$%1
M7=>R]N]47N4/($I3@79G[.#  A70SD:AIXEY$.!OX^*/0UO_3%\T2"Q9HEDA
MT/ZGCS!;CG_\,I/&PO/WHMT>??-D0%W"7VY#GOBJ>F4/%$<(I2R'TI@<*<+C
MCGK %<*#?^:Y"/OE_[_%^*]MC32'ZD:] &_<) E0@0>1^N23"5/S5."0BOY
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MLB) 5()*$T0],;JHHR2#'IB03^"2,*:ZHJ=0;%C,<>=DQM<(4\;$AQTRFR4
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M^]%X<;C%<"?<K4T0JZ!"!;K,7O=&N9#(GN*E-OHG>*1&KV-S\'SC-(5RP,[
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M2,:YWK TY"WR.5C;0TP@*> @1:^'WA(?<IR9YGJ1P,P;M3_\G%_3_']W>E<
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MEO4+,NHH55^#DZ)X\3PZ[R^')[:-X)9[+11 H[IOHTC8UCJS]&M%9%K"I),
MKTW5B8*,%Z>4KMIW*5N22O'7L-F-R NUG* @V9M;(MD)0UN&$U=4IF-O\YT7
MX)$45#I^^*H$%DQD7D%_2HZ>83J!'VVG.;'_P9,3I]D4I92:ZB!3WK<2/<+L
M@M#@GWE@_-KRF^ETM,V8?I;%0U57Y48G347HA_;?O"1=*CIKSX!)#I_)CJA%
MYGA-17'-FKPV@8O,U&E%RPLU0BUL$,]4D._ 3U. E=C K>2Z&%(>^2+<7]K6
M1_;1YIZ+"U2H/'A+JG7DIZ_;3WZNX)]U*7K3XXJ*,S>J8])K*LA1#BVR?18@
M.0I0_PC*L1=7QX+]67#727A4?3:'-]:Z[XZWSR5-"D#+LK<'*9LJO=7X@7S5
MBQFK')BN$^=9PR/RL?NH4U/D^7U;';IAU$R(@.[%-W>G7#5W$%73JV;E]6I,
M<DO(^D^:7CU:\@O4%WI*E""8O9/5F,W_@'1^>:IO=:3:/2*(CV?\2@1\WUP1
M&L@W8&W/2S_=P9%_?1>(HB&ZP-MK83@5O"64F0KU=?'VK-$Y1@JD5(^"JPT6
M=0Z%ZREYL&^"V:NS6%;RN>QW=0(KQ2KS2QA\".%Z<TGLU;%Z#M^Z'\U39#I(
MTH).]L=9H1F]1DZ^)4^>X%OV"_*N5)5R8:V(1N3^$M7C2ZF'P).1"Q5X+"0%
MAM$!X;?P3K"ES%VRWQ$'&.8A^(T!.-396J]U=*? %6N^RV"5-?:#]M*X]60_
M"T]4WG?6GF*YVSS;PM%7 PS?>S_WYMRK^33(UW',@^L:AH 3PU=A.888QL08
MY#]F/[A>D5#;85FY,SQ5RXV[>,WX%9("'%[!-Z>-?%PK* VS#GPB+ $<'+>:
MQX2ZC%0 FR-'A91(GV19&4M@+T4+W5T%*K[TKXTKO?3.#)^7&O9A-*2+DI1"
M2)(2J;Y#(><L*J3;'R$K)Q90EGO)W9K9A.%#T:&3/VK*+^JV/#Q63S^.]:-2
ML0+VGQY:+9II7Z-6K,@55^=C3']T=W0SXS7T,?)E]AEN?FHUO3LR#H?C4.]+
M;6@6AWEBY=Y]E_/@@-=ST0V1>=S2&AN3+WR1#BCS>J)@/<]KB$N7VOL4JTSO
M$=G_%5H('0,=*44$0P[O?%582^?8#5Q[,?!:M(&XS&.\J1S9IJ?(8ZM>KV%)
M))$"E<"6&H=PI+7?PMCZ;[HGG\7K-BL)/$SP</J*<%0!3VRE90<A32&A)B<Q
MN,PB*RY& E=LMN'7P<%6W*?$/?L4X4[_F"B +H4_N =O33A%U,=_S*S/'5VT
M-T]P6JGC#+-\9CLO]IP':/,;.)-RNB>!Y#J07A[5@K8](R5RPGI!>)JM'7!@
MX[JV KE,=7DQ6AL!'J)?^<+"XXNL;EZM:\PU4#S3S UJ9G.G9:$ ;F(__2#\
M_C.O%RX<5SZIHJKVI5=,+=)=Q1C$0M2BLC8!+[[^A8$=XR.VI2'VU<9W53X8
MM7+,\GU4NO";"6>40C O]&.Z44@TI(:+#EL7A)5I,("]V^9L&A#WO@.^SN[#
MP\.G^E[Y\"D%NM3#>C];UT8PHAW3W<UEU;W6<?V-D]QA"!'K=$ZMXX_?B-^7
M$56]2OMF_JDIR]J<K(HAI_$T-K*4O%;]I%)M]+77A"*SWF)H2EJP ' 0>OX3
M"<UN-O$,DBPOST<2[UYPA:3T>H\2]_[1TE*WEP8%X+&<S-]4EJW@30L6^OGN
M8(E$:/R/&*90UE\R/CZB.YD+*Y"8 Y?:$M_=!./.1E  1363K__@YFTN;\)U
M"M!FBT$-49%-)0N!1!/R(<#?[_/L.;S]7Y2O_>ZMNT:X8G(!22@U,;7(\PD%
MT(7&T#183GFADKPL*4"47A%LC(D$NN A7[C;Z=[:@MCC\U@@43E^+[:'KAO"
M )[+=KM+;CP'VY<3VHZ:6J<GCN'U*0"?3 ,(QU9"?6P)DA%' >P>'4DP4#7X
M+=XE@-BU&$ 12FFB<[S[31QGD)4[?_M;!=NZ*57B/#Z,6@U#,PC'7$VMIA.2
M+G^9L+:-Z+)]-[7YJ)9J09ZI(4CG!_?-:"E [1 %H"=V6JP[EE)-7</K_\_3
MX/]72W)I:7+IT*+R&OS?K AY-H-8:L].?U(YH,5N2(4>V]%K@J/+'DDW-V-X
M?>J-WW"_5[(?X*@G)2#GILCG*<#PH58*<(_/B]IK1Z[+(,U%)$'[K&OU"^3$
M<;VM20:1<*N$@495H[Q-5Y,'"^E<+Z ?W5R;$L AXI4[<@R/BX?$1]0.U_:O
MGW%+\KW[K.>]G9OL/JJ3 E2PKEV<0;Z1/IKX$OV5E[=ZW*$I@5CX5>2\J6#Q
M[-$'-W\*V]>C/]M/PS'JL+"I81.! >CY95?.UV76J&J;+9\*062M GE?5+G6
MC#"(LUWCQSA,S<8WR)DUAO)P!&F46I14@JJK;S\PXT^1N@(;<<DVI-7@[S15
M/E>5FU5GL4,!KN>J.([>)QK75B>3ESWS/V945GWZ\45=B-75L>/&V8%D!T_4
M.J@>R=2,MGU+9NQ+,PZR2!]M?$-"GYDC\_-C$8UC*^S;8RN),CDORJLJ(E/C
MV(]RW=)M%.!*F7N.M$*:P3D49J=\Y1F&K.?T3XP:G>XH*RDW1W5$.JXN-F(0
M);/6=J5\3 $40*3T4B$I;5[V+BZ Y&\K#_9Z4(W5:6UB6LU)GA0R%P9_D:5:
M8'$3/5AR5<>-B@FRK$L!TA>&T7"O.TE\U.-E"FH"K5WNYXT,@^-N1<[GMWS7
M@XURG@>G%IGAQO&=V))I6).D#1$\(_7:BS7W6T!/4:*5X%WI(MYW-4V&8%%L
MY>;YV?7W\G84(& =OP#?XV)"9SXAP/J9J(""0HC1^'9?>W*L0,Z<<+G0^N9R
M^<VDEWP6<DR#H! #6>A%O.$,Z?JS#QOBB3F<_(2>+[O[J"XPYL':.1F0SV@F
M>;S#L_#!C\DV9E6Z?FYX$^H'Z!0%,-\8M?JV;Y*<+#:XX90OY]*96<'*(1?E
MWGOK!%)82K>>73N Y@WW"[-%)/XR:\C%.KSVC ;31YVB;9+>FOR3Y4MQ?/3V
MY&T'/9;7^6?CYP:3LC)9KQ!%">8OM;"A>O!%!ZKI?+QFXU9* 0+W[T?ZE_9-
M&JNP8DHN->5I]-RG +N]B#>E7U5GE0=%)!CT1IRMKAO=:XH.5#J1O<6RST,=
MXK<QZNNYTXCC;@F3E^-0JC4)0PN6T3\+EA/9]D_V'MFO1BUTO_6ZX3VK<7;)
M@#&1H1N6,]YJ=4:I)GR>FS;B-J/& WI".,LGL55GEX)$Y,ZB4_MD)\0*I 5K
M[)(78!XC^://PU"?AF#;65E4.^%HJ5$([9<FIPK;-_)-AKG**!^[>*KLQXD[
MO@^![O,HNRF,ZM#]75#0-P\*T.1' :JM?*B?<BFLBR8\M+JINROD>6CIUON[
M]F')E@58%NLJR7%6R;9F]R_Y,8\[L%;"NE[5BT/Q6U<_?8TN;QVG &45Q,3
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MO1RPDYFQDU[OI/B?( [LGTXLM4!,(@6 P_W*\( I51T<BUJG&J%_VG@@!\S
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M<.EO)<+@\ B8GLS>!'KQ&LB[7A7VYU.EK:G3%$#':$4^*:Y7LI,Z;?=L?IU
M_1>\>N14SW>T2B&L *CS'YGMK)JQRT4T22'D!6E19>)?:^K%WHC7&\[4E0]O
M;_F;6L<=;%'U]TDR[G?]K:L-^K3/\Q^>GWQ(_QE)2S?\?UA5ZQ(0#=45'- C
M^QC]*JK%M_*'<@9- ?]%JVK]HO._*^[$[[\O=<"T[+\^$ZX5^-<'QXLT"\B7
MB,W[->>IRC0*>,"?N*\-V:4+<B7]A<U^\6B/I+#DWR1I3'_2J^V/)WK4@M2M
M83,!3[L(VTBM*KTN<,)PH7+#N$,D  MC'4EZ/%.G0_A E').7HB20@6RD?LO
M(C/!$>=K+KVTJL/=R_<YJKU- J]/@)OG-2%)E0$()KZ6%P>*Z((W\Z;1I1D%
MH=XN3B,$*3(WL)4"V#K(@$WMU1.&!+"=9"D* +'&0Z8 ]"B MH)U).'6&#$4
M3K@%WP7J[ OL-,N2'2D C+!'V32(8$<!<,%ZR51K I9- <P^@#6+$IK)L&T(
M\4". CB+K*J?9@..'_RZKO V!>"QG7'PI ?V+K!YP:&IGCK4%>I0!_\8*I<"
M"#7 A9&H7)G:W8>094%>L"8A6.7^K\MOX\@+2UK[T\D4@#0QY ."D0+XER-E
M4(&T"6Q1 %0@2U0@@4/_^!/I@A81D26P$@HF?5UG]H9*4  G$+,L5-.SKWYC
M>XKD#/_7*(QV3?[^)VR$P'K0:U@Q-W)+ZHO"#RR2) V+!E+M1TT*H'X ALL'
M3B>0'E$ P'VY _)["B#&9 +T]__\[<G)7Q[7=]=A#N$>PCV$>PCW$.XAW$.X
MAW /X1["/81["/<0[B'<0[B'< _A'L(]A'L(]Q#N(=Q#N(=P#^$>PCV$>PCW
M$.[_?;A1%,#"KSM-Z[>H</V#.E6OOL+!,EB(KK\=:%=2 -.G@>,'XHY0<:.P
MSC\ ;C%&E/C$2G'1#I:?,M@M%A4@:E8Q"1!$T2VZ))=A9>D0%?/YA3T_=CP^
M87J 1ZHS<F-;1::+J?7W)_>K7PTCRE*!*Q%L[^E.W%0QL!P6CK6H+!HL%"\)
M96U[^<GTY#>?4ZKX*U<3MA_ /,]^*PESAEN3=S)K)>9P\LE?JDJ19I/WQD/7
M%2,O%AL>QEO\^^(MJ*1QP:WG\8196"][_A#M1X\;O*CAV%*[M<(E9=48$ONP
M3I>2L2L^BSW:1LOXB?Z5$-'::RD?7G$)8&-S=L6 TWP&Z\81..%BV) N!0"%
MXS(I@!?Q:+*?[AX+KJCVI7ZXMPQUTE!;_9KGR["GY<!I(10%D'J/K$YR_$/;
MC!$C\MT2Q-\:P0E:]XF):13 <6$D:?/-IL"L%DDHJ7ZK"]0!B^%O0FZ^C*8
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MG''Z7$C4S_'*;G,==-A@Y>T548U(SC%FU)<;+'ZCVIY>1@+.G)1K39:,+<D
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M!+,LJ#/!K\!7SK*RMKQ_1R/&36C WG1^-+88\-B82_C84T63!0I@C6I TU(
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M*3Q-/:;SS/R\B^:SW9Q'[@>;!PU0KOO]ON3X@^Y+&?W'*Y#C':P72O'MRPN
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MLV,2(1B]&6Y8@8M2:(H3/W%BK:M6=:*)C+3.WI#RUT%=D[&#$U@SVL^/-^+
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M%)(M<=HW"A_#W]3&BX$2VYG(TIA#;O,U^=5Z09E])C26(.-P7T],-T- VV7
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MM,FB14)OZ(*VUW27?7.$^KSG(]?KDHU7#*;3[158G#S,4OZQE#^PZ T2.Y#
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MLU2_7I5,5T:N<P[XS.)%T<"KN+#V4),)-=FO'@B^B4=Q9FZ%-KK>U &1MB\
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M_@>Z=^P4L7:@;X.3B O +GGF)B. +=FQ!?_1F2=&+)_OZ!_)EU@&5?<2)'!
M%!F0$)Q&E!TYO(AWW^..A*P:U#* IP5I[]R45B6,>>A%E]DUV-TO %P:O%X.
MM#,%S8D&4TY6ZUG#4ZY&E96<M.( 39,IHR 6B_2$G#]9G= F3-Y5O!*I!WR)
M^"%PV-(*TS-27;)M$]L\5]=;IW:O5B9NP0(H=0?;&#L2<,K.L:&!0TH_T)V
MAMK<^6'X7M_6:=TX$8EY/!H-8Z_;2?:)4'V"&2D)O)FU#:%?$*)5S4@?YL[O
MI59++Z46$<E9PO'CZ0DB..I2K7+W4+GS[TBJ6Y*.-K ]YIZ\0@ MEX+20C'W
ME:/AL#U6QB*JEAZKVP>J-1NP.9&3FQC=/?F5'09&4)$-]G;F5&;.K/:UC !?
M'E6*EOW_4-&1D#Z*A%/'Z^YL>2R8_<QO5M?8;+S++8+0&+T4>:JF]IU(V1[W
ML?,(>M'B8NW#"HC)_H1;-Z2!?Z\:@]?#&:\R_!_LO7=8D]NV+QQ$! %%I->@
M@#0I*KU%1;J ]$Y4.HB @+1 !$24+@@(*)$N-720%J0$Z;UWD-X"! B0<N.Z
M=ZV[SU[K^Y[G.W>?[YQ]S_YCY)ESYLG[)GGG&./W&W/,,4E\O(W#6A5%AS-3
M5=)Z*;)N301WQXM'&X@LD[QZI#Y]CYNE$(SAM=\ZFKV*4B  6G%68UTC$B@7
M3_@MMX&) DBO G4<D5*31.FHP#5B\!<+4('0MTEXT1%M!%S'WY\7._D\'0*S
MOEV7!+KIGOD^SD=$15H&GO?LF0MZ2EI8F"MZ='16(IS_R=T(5GX2P[MK ,!C
M/R-Q@<ZK":;8ARE)J8_.^$\B\)1">Q$Z&.LSZ4T_36WB?Z''<:-S7*K;^IGO
MCN]9AGSD:6WT2OFOJ"Z0PA7/$MA'NR%;>,GUJT\*:B.".N*-YHOPV-4->L1
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M+[UAPSTA(4Z=,Y7 GD8V7*Z\4 X&VL::6)IK8C)+]5-6?N#!+I?*7>8.MF#
MRS4R1RP9AF%A=V)J 6U%@^H^/C;S]+XZG7PHP.T[\Y/K<QLM_1* )ND+7#DC
MYY9N?)R1JWN7<>!WL!SD!2X83X?U&[,;\PI0/%,:*Z:0DDT,<2M1=X_>Y\Y$
MZA0\F_;IF#<>$#?H_.0$<9I/U51:A0:#2\#-H""S;M;1^*R93;_#;S?F],>*
MR5ICXZ-U&?0DGD0SWUCHI;G1^"9./)F%1]GSL6%"V'G.3/H-P1-]BR('G@\O
M%=7WCK%TY/.YT1+K7IH.$G!*EH_UB2ED/]VGRNGB[FO2IY*?"52J/A8:Q5_
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M0>HX7W%SE=9ENR2/,05'ASX-,^5_!>#^&27SI)\K,Z7..M-R@WD_W04VYYH
M-?NQ-Q8M3XJ*[MOFE-RSC?[8])PQ\+D=]/@IBS>6,5TSQ>*]<9)M 8O#N7&
M3<I0!6H9-TOQ&AF&^7D"5>J!P)?@& '[UVB:VU--@5=K1NQ)SQWKVU9%3 1?
MZFT9_P!/QE\/G)IC"KQ^\A[QCJUE]#:T*R<884>J4-^=3+-XB&:V"!%O<^[8
M&O.%OK<H@N4J<GU#M0>Y*,^%8W5RUDIHWQ_5?5RXA%]_(05\+(24MSSSAM"A
MC-!#68@]RVX(<&OS_B.@]X>,I1D/<%+*FW2O DMU+W\/B>7NW-LZ[M?>S^%6
M9&Y\04L<,@?29%6VCKY #S#\".C[=3ZW2.&//1_CIE%9'^ +%^WUW#Y$$K,.
MCF(LPJ?@:!/3L_C&35Y/W(%-)D2],OJ*8O0]*-:O'D D 1L9C>%O[B4NX"D%
M<;.(9 U)V1A:K-X>+%(*^MRGW&QDI#9[)?UFP0EC4S&8=#!<:#J4U7,DG;[A
M*G.@>,4'H\S+#;[_<\5)X%4@,#8[Z[>'$WN!/)>C[1D&BDR[AOJ49A<&=S(3
M3^[=5MQ1NPR=/V\DP? I;RBE8A$VS3U5?^?,$6*'*FX+01XGE8J:'$IGUDTK
M4*EE(V[ [5#>6 9RI*Q#-.@J1E]]-,."5#BRS$PMH'=[0Z?D7*-0]F[:X>+8
MC[)IU79EOR+0-=,[:*(!FD/ISH5R\NTO[%WXG(_Q\WBUZ^%4+58<P'K;@@"8
M8]A.N[+7U^(:KEN ,6^3?9YYY]*L5O;D20MN[>,N\"T#)E=;U>&GL8K@QE1"
MV"-_]K&>16FI2\)N([SDQ_ #WN_ FFHKJF]1FO=NZ^"[(#FE.Q53!71G9]Y1
MT(;(F+[L0$,,U1$<4X1:SK 41?J%MA7ZM*41X<&S,%+,W:27 _AU!O2O B$8
M05I%0W@TEJ>P7FC.X04=YN0J)W07T=QH3=>2G,-DPJOKZWI,U]E7P%\("R,
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M3G>Q=!%M5V9+!NI-LZS,.&.@]"5JH'E^'O+-][I42/G"%QHZ'_= D; *^\A
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MY5S5I%:"?==19E=N-YFK2+Q]I>F$>ODD3(RA2O^EOR'\YJG^2Z &I,E00$O
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M"$7/T/#>*NH[;\ 4GZ;O917&P\=V4_6.9&C5A<\ATQ<_+*'-%J0Z\P?K0Z:
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MPHLMTLEM[+3OF=^S8*J+WM_;.<&^>(&-#ZD%I5N-8VR4E")<JRK+HV1MN0-
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MZP9PYP W\8-6Y&DV>;:KGG+,[U*?^?N@5\\!'<3U4!0.*OHWMP-6#?OXO\S
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MD>GR(;N3<Z@=CJ:7]+;JMPRKVR4V9SG*#Z=T1H>N,"D,FWN%"U8^A:DK(^]
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M);P6[.(SXWC;!=?ZRD@==-#MDN2FL!OF#GMF Y#"7ULJ;'S7!.@?Z VZ\D<
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M=T=K2GGFHJ(*+^#"C@G6VI8QO%!B0*C#5"'\#O?BTP9FV53*SXDA/UH5#!X
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M*^\1Y(8**-$>I=$B[C1=5B<TKC1L]^'#6S5#&;TXIK=AIF8*3-3R_B$5)C=
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MS[@5'VN,%+EX*E3_KHS8G*U6H;$W21';VK8:>3RM;C!:A!3,J/*M;K^W N-
M:/:+-]A *8?:7K@MIJ@N*]68N#[^TC;1=T'NZ?K_X.Z]@YJ*PGW1("!%%.F=
MH%2EJ?0:4>D"TI&JTD&,()U I".]" @(J(" E- [A%ZEET#HO4-"#9#R\-SS
M9LZ[<^Z=^^^[F=F9G94]>^_U]=\JW]?RZ0)!AQ]O<S\;N<K#OQP^KR( FN!T
MHT=R=U7+\V!/%$%HT>!G_)%588TU[/XMO<1U: 39!U_TT165L>,/[\;K'C^\
M]#_Y5+[+(IW@>VK9W'!2.J?H&-8)L@]X?>8KIC857>4+$K.+E#X][X%\4O;%
MARW_KW,@<&X&JL:SAW=!O\B"V\$W=BQY)B(\JE^5S:),?;ZM2'?[F\3](#F3
MN "M##,X*4JA^7)@3N.X'-T)/L>-@!G^'QQ?J0 *I'[Y^X7H;]CGF B(0OXP
M7&G$XL<%VP.)874K!7+F:<48W,[%.,RR^G*3>AUN\'-_K?DB@!PI<&VS+KM?
MZ>?$Y";H&E0^;@]EX<&!AG?5%.3.83H8I:5#69W]@0*,GM&,B8?T.@%P)WGP
M2PF[@I2,.W$9QF]I$E6:VF"K7S GLIUQE5,1P##]9]S _:PPP?D8.6EK^B&W
MUO:.<F&"(X.3C>E:$I&AD[OI"]-,VO+WI(:%A@Z&A0F"C*T&L7D&/XU^&Q9G
M$#$XV9H::B0;5;@!_B4W,/R/P5#6<L3?Q6K:?73+M8]^<_T.HQ7&$P^3CZGW
M7SY>S93"MPU<6S4;&#3\M*?(T[:G<!Q+@\E9!E-B[BSJ3%;;5#6]SK.F"5.1
M%E(#/4R/6O7J+B&V0(4@^<+=D"&U[W\[-J6\^,(0#&4F27S*3FWI9RR,0IP%
M@.XV"=\IQS6>$?'$9JE.__V&=,ULZ['*\T%$8$%201!#C[S%]EIJ6T46;5U[
M;7)Y]L_]?ISA,(:3D;8E9^L\O2=-*X=@,8'Y9UNGV3/V[:E2BMPM",O[*9(H
MB8K'[/+1*@:^2\39[0U I-A*R5FX*S"LRB^U*GF5SM*\'?.1^H41^S4$6D4V
MI[9ZF6KG+0N+[+X(DG-YXF#01:]!S^?S\.G!':5+XUXXI_PBQDSQWO%-ML$X
MEM7UHW'@MRX?$QE5L4%;V=&*.*5QC'F,U8V 844N]$(X8ZF(L/N5(P$P@?LA
M)O^9_4,KNXC?U$NI 'X,]6JA<%-KZJ-DL:>)=*03+VP\U]4.GG(A7B]?\QSK
MD/%L?%$M\?A*^,=SI_*=NP\OO-D>W4))KL)6!$'F&$&T61=3D=<?1[<=)LI?
MCWD04VO[)/'P7043O'WZ68Z%=O'VBE/;^"3O]%<86^4V-0-$I7(D@*UOI3=U
M*'0_)QTI-60Q!_D<]ZZ#>QK1S\H8O *-S7J29KJYSQ0=]OK@@_G%J^X[C[L_
M/GE*C(TSP=3_V%%DPWV'2/Q>;)]"I"!>]<C[=;A<V':K]<JOYE<K7['GNOBO
M!#V[:!0.VJS[FP:C(V/U%B*%6)!\+QWSVY-$!LGOKDBU64"7M9I_YTM,,!F5
M/%)RM?L;0_]-2.H&$4M;&V?RX6)E7*<9G-/;<@.A_W6X<#NZX)C],$5RJ'W^
M^"C+;Z59K!.]!9H^D%?'9>-2ZS[@)V;6-FNINS\9-+&VW 97$P#M?.[W/\(=
M\-V/KO87KZ6V%9WM>_28I:AGF=YY'-*'U7Q7<O@" ^TH(@"8^%\"3YFBHJ'C
M;ZV@$2BE3<7FW27@G>4 /L?L=E#URB7U8B2.W 'UY".(]40Z$COMWD@"C<)Y
M@13^K57CY>[( 1XSUEPKQH#5,SRBL+;=EQH'E<)'.5T<MX*.].6E03O"X&LE
M26GY@BMG H=4 2_Q8!SCY.XJ:,TZ>-Q=],(;1YV%Y?CA7=0CF>0-50IR;M3E
M:DCG?9,0WOIJ:._IDCT@:X[RG  (RV)%!)!AY= Q^')[VF%F)LF=BN+(3CXB
MZ2UB&D,"P%J93 .M@_.L!88A5EH"I\2=7?PT&L=A[XY+1'(<\N)^K[\-4JR#
M<<L,\I2+WERI%X'-)U'[[$!$EP@ ZET@N[SW% +9,E"?X[C14,?W[.Y=<H/>
M8:%'-V\*YF#2KA1VKH7Q9T7+N"@?@CM1*[RWUB:%J>VA9^&'1Q3S72[>16<6
M:'#HJ6@-1F]OYU7W[ ^'S2N%"4ML?&[@G*2V+V4OB*GE ?9Q0^2BF7,2YYUI
MB2B+ 2XRDB^/6. W85ZS0TVK0E2K ^# +>. GDK\<, #Q"D!0#4WXQV)1(N*
MGQO$KASQJ:9(ZD>ON2GI#]?!TA1%J"#::.EM?+8 *-,_$)6Z$IK=I77#K'<?
MW^/CU"924ON!4N=><GE_EN])%R04[:^!U4,_55#Y*0 ZG_1)4\;#(S;#N6M:
MX>&"8KMP%DP_$(!5]'<RP2+"R#MI'A, K^\!!+ 4PR/&?;Z*"2O9L9:B";?[
M&IN18YJN;CW]M7%'TBQ< %*_VGWY1/YV?_K20]']^&M.P[55H,!M\_.]H+*+
M+#[0@[2 X9B.>'C3*L@TFEJ$FMB,C?3P-V+E@:))SF=,,(K;"@/.*RWA[61*
M<6T(3YQHJ.*7?TQR1RPPWA=1&# $IX?)&[+C@5/\SE&S#AVSYFIN1ZKQ+";G
M#]4VQYK%5DY<8>T$ .W%3]<S%LF#[3K_103S.>P;U)XTH47(\9=\PMKP!K1^
MO=;J_2KZ3_[KC1F7URNT&^&O$M<U7L"KLK')@ME^#CIX.0)@JJB%$R.V0@!\
M:0&631R<J@GO6P>^*X]<_Y9 &Y-#G@.X2S8X<?YGL:I_=26OEP#(=X">T%F]
M@%QWH$:1#72RD;F;0Q==&#SPZ/2!*=XWUHI54:FE<A+/@FG7!$OMI6=E/UG1
M])33 011LY"J[<AR)I^!PSV48-[0EQ-!>TPIZ.':<;?@N+^( 6 55T]7IHU]
M9MDG N"]-2P/SU@:P(9YOXHWOX<W#'.??,_+_B*U67A:W6WXN6M*CFW1^V0Z
M52O&-"T&%B?&N!+S?\/[#KW*DJ:A8Z5/)H2J*][H>Q2\=EKE?;9K^IM4U31P
MZKKYB;#3-_HT)T;3NNU7LE-]@;HI]:(1G+=U&!V%"AC 2Z0E:XK-$U><@N4>
M!19^YZ4-$K8:3JZ>[Q1UTIEJTM5L5&+5IHL$/4C8[_IO)^_ F>79JN&UPG1A
M]T2255^BV*_<R78$^XM.A"3O2Z<[_;JKJ\PP?1,1A'W[!P)"VR6O*#"Z@O]L
MI][Z1%S+[9;=T-$0K\8]DK  MY6G6RVYCNS;YX%=EY+D]<%^S[\W:3=ITOD5
MW5! *3BC55H:"8 @'T@  1!"W#.\Y&*Y:Q>Z(@.H=F1;JVWNIL/C 7<)@"JZ
MA1:Z2+?:R [<A\3S;;P@GHA6=1[:Z3/(4++B(GHEBVD0/;"]0' TJU[L.?/!
M14*^(D"?[OYG=IO_.O)PXSK:S_S6'EGB7X#<_ICVX>!=;5REVNRU ^3P1PLL
MS+/I4)NH_S'/DF_/Y3KO8<&J89T'NNQ,WG,F\QYZFL+K.:8AMR':9:9>V^>9
M X\,>2-T$3QHS*7Q@V*(VMC)3,N@RX:3L7T@1UG_YK@7M)5U\+I?_*_1X@.B
M$1X*-:L)]@X]3E=T(P'Y"PTEP Y9NR#XEJ1KZ_S:U5! L0],;';#Y'#I^8S2
M:4K%A4@XM++M+30*Y"@R &Y:5^Q9.60<P">(GI$&NZ[WX,OB7IYB>SDGJW]B
M%<?$9>27;UG,;2IZ3+$$GC&W8BLM>(7==?NVG@5,57KP+YCB!FS>&C\ID3[2
MK^)&@C;H@V,[CO)^->\*%''WS>\H>SESG!;7'(M@<O6*6WY$&\A:IH%SIKL<
MG8&I5-8 Z!/_OB)W(^VO[+A\T>;%$U&D3L*XCNK(@P<.)1$G7&EBZ=T3[SLC
MYXR.19PH?MY&YD4<^UL_7VR\43>HWY&?G7H"<VP8[\PLNO5JI&-SO<"5(8ZJ
M981\>."U5DX?>R#"K6Q+E>P89MN"FI:Y<.:THLI<="M/EN!UO->-]M+1CQT'
MB]XE^>;3ASL(JUY]7:I&'FIP.86#A]6S:"R,8V69@,*0D[I/PIG08EE3/-#U
MH$?N+[?J])46"-BT<=),E!;\J.^T=%QU3+[)U=3(5+8G+J6F9*_=$Y:;KRV.
M$&)(W(JCU9KPRJB;98,**SO>7\E@]W,R-QI0NO4_XNS_[5ZRNYPR! !(YWA'
M "_DM1N-B J8 =+(/T?EGX'1<9%-@@50VUVDKQF;,YQ/IJGY7)<;DBCXH+_Q
MCM*NU3UH&X@ <%Z,LF)KD5-?AK-ZPZ[LE5F5NT:J\8-5P>=_1D-=1E^4M+Y[
M_/V3B4I%LI7UQ*=SKM]G]MM2%QN1MQGJ_J%2^?\H81E?=FK5.8;82-T?O0)#
M+#&:Z)WS=D7:EK@.5LD,*EINA1"QFI\;+TIMA!]*TM.^>M\S+R.S':K1GZ%A
MH;%^;MX(S*LRSL0/6]VMUHE<),$"5^8_]"O(&4Y6G=37U7[1^+V:4*\TQ%!>
M1Y7%;/S+Z'#>\TET??+UDW,*S<*!.">%AMH?0 ULR[4FM]<LLD"D"0#8+3B.
MA<.?B  @*>_%I9(3  7K"(Z6-54LSCD]U.K].F,-9=Q,OV#]V6UZ70O64\"O
M%C5,# % ^@3S%M73T[ 84JU%UH5@34GPXOU^]'H&626R]5&#L9Y*2:$_.';R
M-":O?<&TXV-@D$;D#O.;I>AC?8J'"1MA!2ZFYC W)X%?Q==0-/?_L"+._X\R
MC/P[[';1\DB^7PD_?3@7E TMU>6T21WU/3=E\GC=1\8K7V)#"(!08K0H/@1(
M2P L_0'C^>(PKX!TH"VEZT;*? )@Q?FTY]5$\8F?S*%HZ=N*REJ]HSESM4)V
M)]G*Q]+$<X@03-'9.L9PN3$UZ+;&N87W$/.V4>@(M'7N3\(!Q<VO[Y/##OD_
M+>G\3S=UN'XL$5KL_WTL%,_7@AHA , ZH;[5[5V?/OUQ:(LE29WB@>&?B5IN
M+\<Q.;2(C^5,G'#H#1N-KRU_$%JG%?%=6OVY&>_#L=-;?R%% % 2K]CCR!7_
M93$Q( "P6N:C 3>P:L$FY8DZ1)@8;O55.[NQ#0"@ ]1Q*@-#4&K]BFB4"YXT
M<3HK?"!YEI=+8?(@>MW/*Q\QF%U+UJTY' :]LS3F'A56,^6QS<J0+HE$/_W!
M\EKGG5M1]EE<WHOU_JAHG\P8J\CL&M$.'<#"W%:ML93E_<:.YY_ .2H50J])
MGE2%3G[:H4]4(/45;<\FP8 Z6AC&P4W\R[-:E(A759&NZ^V_[%2?]O,$O(X@
MJY>X4%J"AEOR8-**,D4[9)6G*KUOGIL8KRL/2<DE59.]+V>1-]ZM_>P^F\G4
M&L ^?IAS)"IT,NO '_?1)3;A85GOTE)P[TK5NFZXV-QP1CJDF0)BM2K,U&IZ
MN[L2MO/(,=V&>+,NK6[8EKCH\=X/6C_*BP&C:P6,@( J6QS>G[CXZ8::W5Q^
M&RGQ-NM/"=\J)A!C_!=:C>AARXZRHH$)"8NP-(GEO#R;^EAXP><A[:-3^$Y:
M(17@(;.*I;N2ARAC8GYF6G<L,#7 QRYFW<>4*5ON4"AQB^"AC5G*]K<&%K:<
M!56U\[>IVX%(_58"@)5EOXKMXLVDKI=D:H'*_3JD;!D@^8W<OG4L!F: 9\6^
M*6]"7 <]#6P14[LO$"=%GU=DDG^EL#!5/ECS"YY@Q;EC+%8C\-P0A1%Y34H2
MUI@_+T=A+R!O$:@W':B2=&WYK>Y]S>1,HT4G4X4'SD_:_T=IXO_KRT:K?@V8
M6&1D6H*U6C%Y%_+16,W.5#%RPIV^7KC2[%9G>"H0G<"ZXP)!  F=V$MPI]RN
M9(8BRXC=9*#5MT'I-WIT/;P3FG$>L#+X4JD58PC"DA;C8J_X@FO7-,0)&G$0
M2ZJXY)./)_G=#,53?$+ER=^[DI_SCCP@.AMF6%!7Y/BH5?RFB_7[&8]&QX2"
MST.@2:&>57]QC-- PGBX_W#:M99_A3*1A0:(.'/>;,ZV3?WB IGUL.Y!_B#]
MS!&V]??[N< O^&L=?:L0$,U)S/,S0UQ1M<!)]>/AY1@?\'L #UGM F\(W=9H
M1?"IQ%7"LBB=B?=X>X-JA'C]"^2'0D>&]:;/FX][?W[%OS#V9,VO_I%MF'_!
M/M>4;"Z:,X$F )!R9P,8_RNQ"T9?[+EL?H2(]?&]4?<JX^_\7.KWWC$P<=?W
M;0*6$ .>! #*)(I_(D4F@'Y.. 'B4[Z[,[8_;!$V377U >N\ECW[;MAT''XM
M%IRUD??2<I,,Q%X4JQT+#<G'A)P=!47'AM @6S90"\U7K! 'C!5_F#L& ER6
M*XH"\K(95<1IPRN__J!LWWA*E7BSVT1MMCQ(K?2AAY-1<$$>S-HW)4;Y3O@(
MO!*^_W8)B+32J0/?LM0!%YG^\,MDTE5BF-#0EOI,8?SR&O*4=ZM\5&,8PSIA
MMJ\![&?.NU :[Q[]*X9"/CD_[]2_=0U)+#2=:6P91P"WSCO.:["92CS%>"F6
M!E.R/,RYO4A;7&TF9V0M49T7?']^MC?TM=07<JXUFGA5P!GLVGX&-9HX#Z"?
MMWE5%I<LIXR9"JJ^@E37TY9_<VU]UZ(S0;1MP5"DG2G=)RBIQ>LEV)CK9;J)
M9>16KYW(%(>&GJ=>>@:H'WKDUGR-\YYB 2A (Q#U^*%KNK[*#@<!/1K!U.+&
M671HA9X!TMC?AK_JH0?/GZ#,9H*2LHA@WZ'O#B,(@(H*"-\81&;5A;O#4U'L
M[Y<"<TR^IOK4>A2[K'EO=,+O^1Q'&RZ8SDIA!IXB(=][O"M5401CC393KT:=
MU YZY8EDTS1=\0'='@XE8KON//*SSM9_E:S6QW>1] 0N;F8J=I+NN%H3NI%N
M$,D\4=F[=^-/8**V'U$6K@'1N<@$7RH"4D-N%\TY9M&.BD*\)!KI_7HW&3U?
MJB@=K=G:?7R,& "<DL0Z]6#ICU=*2U#G9WYC\A+.GOJOT JME2UU48(M"^+S
M3V*7Y'S>7!:^\45T697SAP3<W$G_75D*<4*\%UZJ>MR1[X!(4F?5WN1=AXHF
M_I'\_.2F>J]TL;V>X</^[QR)<TBM]H=7E;O@L&NZ&5.38**,(H>[.>].0.Z!
MQ4+,=LWR)M[&\1^JW5!95KUZV(-LV1SU***F<63T+4WUNO/S]\*S6L9SHR.R
M6)-IV]=FTEQKQFO0_?KEN)D&'?+M],VV0?N7X9V/YTN:%Y)_:SZ(]69A.\^P
M"K6UU3U:O3?TJ5OQR[40:& U)N254?"N+)K&S-]Q'><).C;#!(#02ATM'?/9
M(EOMY*"C2E5N/H7P.]C.<_.*F#-?SOHKU8#%[#MP>W\G,/7+VBP!]$O-!@LI
M323M=$)\97\/N9I,>_@;V0(2NB59T+7,O*R;L-;27_:83PX$B9_Y(LTU;OJ&
M.'"37'V A4EX6%'A1Z5<T*I:#1/6U6@ZS95;7!J:'^$.\X_TU/@_]I%Q<YVR
M# 9$><-4<4D@1UB8ER4[RK-PR8K<.VC94'RWPYHQU0<LS56 '&#KI^8JX&'?
M++UMK9VGKF2@8]G5W_]!SN02N@3>)UW*1@+;!TN]Y?2O-)X]FY\Q%XC=&(SH
M?:TO;T]&0IM/YB@M/8#["7("W0@8-!5BRA)J3M'<+=/*2LC_D7*P=H/H3>[G
M/W*5=Q6>>"MR7W'AVQ6Y<-_PW%HKNJN[_N"73>5^<E&W_)A"-.N*>$+2R/N3
M5V-#CIXXKU)C'@S&-KM<&>P@9!L&<9FNM@Z7^BV>;&_O4MV]TN ;KE>L+KU?
M5=C^4%:2/LDU"6R]> !:*I>\5=!@AA6L2^SQ9/3Q6%?WW"R,-DO(=NG9M=+"
M#P%K>CK@2+WEDT%6YQ*FSH2?"546AH:\":I"(Q7EKP&;TG*?29*)TR\.SP+0
MB#VO5>H07U"8A(5H>SIGF?M:L*X5K4FNE(K+MT0ER&Z0)N/# :XWY,O2Q%++
M4E@Z53U4>"<UM?=Y.Y3AY&J  _0J%C^Z+_3WEX/A\?I%T0,CJL^%7&_6T)%C
MM(4L!;5_&[_5#G+:YBC&X,K@SG$8&QQ_AW%^.Q3UE0!X/R@N!ZH*Z%F[<,J7
M.;*9SUP=_PD302UB&4"M4E:4^6B="'>S&'[+*TB*Y +S^"'MV8:MR2I4OMZD
MTS7I'LO;2;8/>W>EH1@A2= R \9)U6]V(?MTZ.$2:"D=6K'8<1C#R8Z6BFQR
MR24 VI5$LB$UC#5B_=M@YJ/)@60]J?+YSQ1<;]#?63?R]4HTDN\Q5=J=EI"Q
MG99OM3!="WZK=\"5>>RB%>93@2.KON2XG_4?WK7"87TZ96;NK8O59C_5'B!&
M(+R#.OA2)%4Q6WQ!;.+461Q>63XV_3#"PBU./)8LA?KWE.N\,D3I&J,(X;(@
M'"C1;CQ# \HR7=R,PVW,,ULG5L4AQ213R99*W?P+TV?7(Q2I+QQ+EWWV @-&
MRRV[$ "Q\O8YHE]$UR=X*VJK&[Q,A$=IU-_\Z?![_.F\,IH*X*8UGFSZI<WQ
M0Z[FN9OZJ2P!$ Y'&>M0["YP!0UT99&UH*I#2NFN5,9?F9W&\;-ERA=,"QS6
MNJ[^A#6=X%001N/[L.(#[H;*^B]V8=XF3]39 (9M[ Q<P1C$*C667G,)&JI(
MB@57C&,Y;'')N3NF+TT#RVGEOU"%O;9^$_KEGD[*';$V?F9FXD/8]/F*>Q80
M%W@2Q[##6PI?YASSH)"L1?,6)_DX8A[>QS.X.W_2^Y[?]&)58#+:+]-^G^/*
M!2*'2S_0UYSBJY]JTKI/9L&D8>ACK=]?5=PI].:,3$B)Y $[8I#5'LO(KY6A
MIW9*'5KKB0S84^BJJ:GH9U)X84=*<@4&FF)TVKTDK5@4I9$66%6TU)E1=O&.
MUJ?B7?VDK\]3(>SLM#>[ECYKH ,CKQ:[LZAQX1Z+1 M;2*/:'UO(SS5O[?^8
MSLUE1/RF?%8OI/--+#J\5S%MHS[9*99S/&/-8?_!D7!<N2(I?B2+$O=+7@2Y
M&'S*6&>BD;<>TW[A9?1!Y9G:]]--*@K]X*"/KJOP:L3^* % 5;1ZF^T9 1#"
MC:>-V[\%K,'E7)GM!5@=LDCN'_$,SP^YR9[ AJTP_'&=SM<,(P"J^<.$A4M9
MW'$>B^I-H>JS#WOS!WA\BP/)%>I/)7:O&9H4%[5PFSC_C D_IVYF7(K[^O"Y
M9B.=JD_7B;%BR"1\J1!(704*X^1$Y(]]$(48%CT]AH>Y[^9F[)G9V-SP"_K#
MY#G82B(<1&%^5T<"-8NG7%X6I?4.6NCI6J!L025''Q1(")JAH>ROI>?O7^B6
MZ>[\C*NV^X^1!NOLT 5%#%T^9K&K!6A%Y\Q://Y;- _*AY1>=VC_)2C0-ZW.
MSY_U2!J6 EWZ846"%4,!5\>V%>]6N\BI3(CW>M!7/*F*^O#W2*4_[XM+;D\C
M27:3WYL;U:95=M\OD^C7M:I'</*X/W G-9 =+,Q7--K%G1EKY?+'JL>>WM7I
M_@QEDYX&[VL2MYO,3Q^1R55F6W6![F*V=A?IJW68_2-:P=5?/,#E/HV1X&\#
MZX=(L>A53[)2.>,]T-ZG7UM0%K@U+/PZ('H^#M%U<2:)5[Y9:<LQX? VW4$W
MJ)><]-4;H 8V%3V5:NMXI>8=I14TM'!;$L0P-YOW7?=A>\*M;EWFIY*A   ]
ME77D  V%*GWR>753X$ V]=^I3-W+R2L._$S/67D#6KD.Y86]#Y].F*T#[X-J
M+O".\=:XEWZNZU>;"N56+XW%EA9#\;<QO@@];^-V4V"832.E"%!U_&V5&.G0
MR(8$6WE2]$E?:5:S2Y6-/D;_7X+3@O^: 9&-2^$/"]=MHT+). U 7X;.[:R'
MT>D:V<NE$3WICN'(Y,^;2:KF.&3]S2RF:B<?Z7UMFD#ESS"&/S"G3.L>IR07
M^M8'#O^+A:&*V:'TKXAME%,D50T]WH89 8(4'IL;?U&DV6I8E1BLJ$F&UM75
MU?*S-:S!,&\08/6>/-=W'TT@INLE) 0 J&G(8!7TA?.M!"(62\;*%JI#Y^@:
MESD"%!=1<5,=[(']E>F3&/&&KJ2$EO;>\PO.M[1Y$'1.DXE=LY=64&R6WB2&
MG1^>% -I,$S*Z%>#N,2J@6ASU:/>QR,V'D!3-#XGNFTWI&@0N)ZZ];<Y4P-*
M4K4W>)S]XS07)IK1KBB*>L:3Q3EYI\3Z[D;W%E5@[%.2SZHCA2<EMZ563HN]
MVCLZ6?V'0GT!5+9Z?=\3MNN(IY?.-Z.GRH;N4?C)VW \\-D__V)D7#69MB5N
M(%F;<C[RI:3T?A;=F,GW)UEB$P8=H!B_T<3TC> &62]C)65Z0RJ!7Y$D_[GP
MXS,E&H8L6F7&/$?U;VC*-)5 #>?M\^-5UG@@1W'G9*!#AM,N/_Z+2^/UPWU#
MM#.><;C+>=O%[EA<2XCM%D?^NL?M\*_0IAFN2](3V,]>%,BB2\3VH,<8KZQL
MCIZRYF9\9U++D_3]:DRW;^WT%]R^5B2L39G^!^.2VSS@_.37V<1M.)FWG0Z#
M<\+K4CV U#"?M$G;&DX'X.^\-2 G7;R_&D1/H\P:HFP92?;26!BUVI[384K+
M\NK6[G=-J8*](@Q4=B_!>?F871^FGP 1<' 3K=:.>JE<..K<8<T>I=]=-6&:
M)5',1M1;+5LB8?1;N=CLWRFO!&.^X?6IH9/-OQETHXHDP'_.H#M3/"+52--+
MULLS+,Y@CJP^.M_7@Z,MMJ%GMW5P;+S^+\LG.?3;93F;/R;M^(ID%PQ%5=LT
M5L<:$8\PDC%LK==M+3U^V)0\F14J3 W"I5L3 %'&=A_%SKZ4$P#^F]B5^FQD
MZC(!,"L^ *9']J2Y (*.B;,%:GOQ^<[LP',<J5]I<L[T5DT00KNRMJR&I"P,
MR1M#I* ]\CB]TO7MS9]@WNJ_-'-FO9)-8@(V'B=<*&6!#>U8A=4')6RS ^5W
MSPW3CHWW8*O'SOZNRX((W'R?V R9=.=GR#56; WGWO)W!I_%8^3\87/\7T[,
M/)OJ3#J]4D9_VUQ'R+U1V!=WR'>CWS5G]2POAI[L%ARXR$OEFIFK>/&,3'>6
MYD\\,H]K;S"(8X^E+@&;2>EV%]LQRL/^^#^3-<=D+Q_NDZZ(AOLZ;=]VN9F7
MWZX6RU;2MK+)^_S&(['IR$D"('0&3;=B'.G>ZRX0VE1S3&%=6?[LU=G?OST'
M2]_7 H=<QUI@$TUTRS@WL)3N2-7L!70S;S+736JC-7UTS%WS]AUJ;JWRVO'E
M(4BC20KO<"D]4?I>X?>EW'G#,,O1TRVM[.??T#V!BRM,'5<EC-CGSOZ?;M1L
M]=G$VK:1<%)8S/VKVWP0#/,N6F**X1.U/_-K#7NP_^'KMU)N_N!XE>5X\K<X
MYT./N&AKXK&B'=,[V:5F4?XJ[5-XJLW^AE ;<QPY3$YT$)_/,E9TQ\EMRQ#&
M)G;-PR] -LAS=("< M>,LO-[/B--3:XQ=:&Z]DU^X8DEHD4X. =J#PR5@E++
M\\LC<RVU87^>] GQ%PL0D8?C2DVR"V!:HTU,/[T#C)(T1\7W)568A1V=V5_$
MO2Q@J+A7U+UYMR3\\C=C-H^HIU:&8TOXYF)7]LT=J]OX>PM%RCPT"N,6)A8N
M<A:WP'H*&BCR4CP(F=&CR%,=ISI65216; Y+3&4L;^PW0=<SN;*UU'-H^?L4
M.J3(3A:9.3$:G9_M3[$5I!B 7K4&&YY8D6UEL=N[\*N4C;/@T975:I7;F3_L
M&BW]PTM4;M$]3W>=+=<)L GPP]Q8T+2*Y&0/>EOC<.KG,*].1L7_2D6I!VQZ
M*77VUZ*%>H3Z^=G&;@^V4AH&CENN#;W7HCF-%<W)6U'C,PL=7Z$E(Y,+=AGZ
M-.2L:HKJ3EJ1MHXR&ML[5<MQV4JMV7Y2>$H4R%*,9EF7G?[#''JS7LIJC1*+
M4'3%12$\DU:R5"]WH3KJH#P_J2X=XK[5PQL[ON)/+ICT?OCY4!/9ZK$H*01V
M4Y>79BBC?L<MUVUH<:M7C"6^HXJR_A ?WNV:^<.^L 0HX O]OM$$^:#PSA7&
MI&4V\4U$?RF.Q/NX$PK 6OEP_LQK;/JR-F]BD1)=1Z5F"W%=I"(B81W'-%\]
M-8>8C+F(1XCSCJ]HAG[/EAX6[*7_?)/&];SQAC:I?U$1QD\+\?/NCJ]':0ZY
M#,U\>T4!EIDU)Q?#UH&D6O!,^['=X%[7D^9HSZYU47"S>3+KK:V>=-H(;F>G
M1@ -G[%?;LE?6J3>,<TJ(IX9_B,>8%@5?*?\]QXCV4^Y.,Y@OA873 <!P*O9
MQ7-#]2QD,0>:57W)/+HI[[%K/G_> :7<,7:;M\#8J]8W)$?UR4_=;8KM*6(4
M3 RH'@X95L@2*7U8]6&MY.<#4Q&%OZ*L&$9@!/".S2B/*WV26<YS,:J0>**J
M[/<H_R^PN"I_LRXK(JPMM[K3>QC#2[?9N9^/S56S"^:>$)$ 4;"6$$'64&7*
M/X\85 !G7;J3XIH<[^;:H+9@/S(KD17>!.A]0:J;'\K^Y#TLV\CG+S<Z?P\Q
M1-.M;D8H\CA:JTK&;Y_I5:2]JUD8%KOS.6E6>I48#3/&9030+GH;L6"5BV<S
MS'8+.HVFCJCD=1,I[,CB34)7R\@4G&?%ATF\H<\RAL;%.<2T,ZI24EP[%],+
M) I&XU[&AM5VV=.OAWN;\RJJ*?0Y9ZB6H[WV9:ZII;>+G*+;G4:,PLD0H%M8
M"0+ 4CW+.6\22W-M9?;FG4P9,PKFXND'O>S92Y]N23U)BFQT?GLSTYFA.I=F
MUNQ%HW48/7F$ H"=:/_UNTJU=Q_=R_J%W7P9A"V&HT$.@;4K&]59 ^#LJZ/L
M&'\)5(D.5M#J-@& "'F.GC5#Y@=B%8HMFB?QP;^MS.N(-NHJ8U7?4U&5DYP4
M39T],IGM KM0>4ZA!0PB&2@C<WX /I*5E3Q.RWULHF'BW95_-[59,+[B7^V6
ME&\#EJQO=&T+TIQ6\Y[MFO&1JIB&CI543(A45]F02II^F2IY8B D:--:L/NJ
M8K+6-'"JYJF!1P&'TVJ)TOVI DHWX:>[1O-.9*;SCP0L355]P$)T]_OH"W1'
M&YXD! EN4K-@G'1N.8_/Q'?3';=O8N(W@1%; <DG'9&KBKS>.GA:+8H%^L']
M@B?/5(WP1WAI8#SLDW"7O((R(VZ*>W-Q*I*-&S$;^SNE97?DF4'\,&_5Z"!5
M#/UHF7O"'183]C"R<O8 0P[Z=!T5LCW@WC#:$>H #O0-R/ET7RKB/72DFH%#
MN9WH>'7LQ<-%(^YJ=WMNKFB@+_8(%Q0@ 6TOP?3=C/$'I?[TSK -:8NEE8O.
MOJ]SM?65?^QY=J-5+EYH/*#+?_,';FZ5&[=W!!HN":!)7X)6/C[^U4+A##RZ
M8)8HC%(F._[5A/XW1?B?,V$AH>9)GV7XQV)JJ>\Y[$#[2JTM,>&Y6S]^:9Y=
M%2\]?^_U:<OLQZ5'L2,/VBN: 5* >%KV86^QF1MQM1C/L&0\)/ LH#_(@Q\I
MBSNTGLI+F?KJGV?TD_.( ! >*C)%JZ0MG]P\V^;^=/[.*FUX23 UM9OU_$O:
M.]19!F]U(W1@O3\@1YYZJEH\.YQ5.WW%.=1%XSC(KD$N\'QV_'A(L)"2P3,P
M=$\P>^<B%H0Y/M/=Y[ ]AJZY[)=):SU016HVSAY(9^B$_3I8LW1&'.W4<HPG
MQVWOQOTFJ_9D3/EH\NQ>32A7A+O)!)'^&WOI/)C^K93EC[YC83#/4_#&QY7'
MT]':22F9*8L?/7Y%"HY+/_N?A]J37(3IB>BZ%1XVU?QL-$1J_?K\.'_\.93\
M#S@7EN=N]\@Q#.1D1'Q3@=?[PNE$UK=4NH2&_"2??*OLKBK \K%^Q/9$5>O3
MQYK_9^E/R"^&\90L! "?'YH,7S]# &R_9T Q86GS\=I!5E> >0)@R]5X$8YZ
M-7PAMA@!.AT:)@ TW\ ^PY>2@4?N3Z#3-P\)@.>13750N/]B@G?<DNKF1;9_
MP/1B#1/VR7M%AB0\C2A& UIKNF9]I;D7H).\3@",/Y"R_WO6O>A[7"**ITQ"
MX0)H9S'YYF/V%6B&P8DI%,9,JTFS[^R''F_BL_*(D8/NUVX?/<.0SH.@I7*H
M<';[$-GEH&9M=<DG @"E%3>CNHSHI@;L+CQ!E\81 !0,\S4%2-OFS+^E-:A?
M'>RA9X5LW]+4+KX0@P&<3MO]):\GHBW_"B+O<#IRP$.@2[ %CHG3Z7VL,NJ
M '@Q-E,&?N\AT>S.TKU*$RE"IA_&/\)Z-=Z.YQO#VB_/RUF.@KDGQ#.?D=37
MU'\^>,W]-EX57FN=8)4(0NG!9E;;X#<@KLMRV:2..<H5"&%^YQA%&8X5]7<>
MI!,RO%X49( EER7*RV,\14ZID^GFWA?A7-HDG]\[3%.>*L\^IADF^YQ0/\ ;
MECRL^,K_MSHPH\FI^TH,?!9&  1%8F4Q-#!+;S?DPG$W)U]5O[GI=G$AV(6K
MYV ]LS+L=!H6??>CLC?\&O0OE2$5NG,3=K.I1*MV;P0X%DN$-'RE=EA@#B0
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MZ+#[!W??U5"6@5:5UVS=)?%82QHN!^JH*1H((OV%B<IW_(CIT,ER=J^-O44
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M9&KL+O&;QQTW6U>YF2\WY<ZR</F;F%,_:^NWMI+)RXV,3Y3!<F$I*WK4ASR
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M+"X*K^#D^R$&5FPZ%.Y=9E[]-:]$5)^H1B.<:#0YS+!>S[N#*LYE_-_D(Y(
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M[&QGA0KFR"Q=8WVGZK;JI=U@.VW/-?1T+B<N;^$I!OZ-12\]QT^>XU.&K9)
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MZP!1NQ1V\!HQXW)U6LECH8_?D]MD(7:,28WKE<'7C'N?V)HV]H?QX^3WU(.
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M;H[6YQS@9$MJ5#D',+U8Q[.EK0SI&_6A_EX!K3\^!_ASG0,B<LX!(22"V3E
M!T&D !(MQ(!J@V#)<T ;#"IT#BA DP!PDG"-C, I!,J'T]PSA3GW9@]P782?
MFDYD1I$)9=[W+/C'U\^\TK:4Y*\M>HCFE$OWTON+R[P1?:4L?]']HNM!83!
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M?DN9_S=$1T6OY,WX+8X^;99A+M.R"&-)RE$'S[$DYD*LZ8HC]4TOAA3LI7-
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M][<1_"0\)M/*:R ["_$=71<ZL]7)>M5>V:;47NY/6E>^!-,4,Z<WZN^/H.7
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M#&\8+)6*/M"4</S=-T7<-XW-^&+TW/@N.NH@?0M%NRZ9Z:&^=!P#QR<N ],
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MXS3/.D<W27B+5FE$^4^9KPMX#D5%-IASVU HR$O=3P&0) ;\VD!T.U =7,6
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MG@D@#4%P'J9E@J2*Q1S03=! DXK(*9N\B5*?@@%DV<*KK^F<8:K?XFYYBIB
M:Q)#6:'E3\/%;@60&-)TS'W^!T3^"9*:^CL,#51*%BZT7G ?6LU)>9$S.#A?
MRRNV4SL3W5-&DI[Y^'XJY4$5Z/"#)6SV#3RIP8,R9K:?:?H4\#C!Q"^P;T%<
MX>V$<DSL3HH$0LB (M:T,EYSH7&.)/$KGEJ2!2B8X'CR2PRG;%+Q[A;W'8UF
MTQATJXDM)CRN[5^B 6^;'U^ZKFYR[DM,KB[V]<L2/E,# "O.%<>=;S41R!-
MG\5+'_=;[@\6+?>Q5U[S*@;8Y/T2-!.MO>?*<((860%V0;-: %C!+!59P>F2
MSV?Y]J\\]B2J!Y?G*JOY3*K9-,KX["Y:BJDCH=W %VV \VLVCRE[<EU-M-_'
M6AGG(OKR>DNUZ%&0PD&A(\[TJ ] OPG8]^%<"];A5MZ,.99[P"U!D]L8E=ZO
MAGTBDW=<)B9M#I<$;/K'3F:U&=S$+0F@-H5N'&&$*GI3')KDTOW[IC@TWF45
M$/IB#PSNJZ)*F2HOK4#M^%RZ+\RQ&]Z#V:$23/(R/J<MER<]TT)?0JN(_%'
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MO#,DL7ZG95OT6=Q1#(28P/484FBJMP+M.\"]IF+_U)7QF<86PF(*U >*XS@
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M+3.#%'@?9RQ5SNV;=++ZV<D[LE<G3PK:Q=T6D)$JM\,4S_FKCGC5M9+/6Q.
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M2,FJ458G NW>7#>?/VSX4@G6U>N\E?_AYEQ$9W,K0]AXR(^=&.3A\2 1G)O
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M#'Y.'1VD@<)\!TJ?L^*^*-) ??:8&X!L>%9!U@SR#*1DX&,@E4)!^>@@;^)
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M&94L/S;THS&*%_FLJP$"5A2:SN'8'$L[;\!:LKIS\_(C\IP*/YL ?[5\6W.
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MS$0CJO\B#40"TT"#/<QYUV)\%]SXT8"*%/U& V4$2U)/,]) 7)E4?J@;#?2
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M)]+HN8#7D'TD0.A[$J#+$8Y>-6X^@JQ>ZH06$F!9<M4:T[+ K FN'QH8QY,
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M73NA%QF:;S26];[8N5&--Y1W-@,K=A\U<#R-?;X=OV;O(K2?]J894F)A\X#
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M\+,6G]U ,0PW.PAKMYTJ/\=%H&=*.!9?J?UP9?>W=5/S/:5R7*7UBG\?=3S
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MOIRW;:V,4^\.!,86$X>RG![- \2&0E0*B ? K[ 7**LXP22?K%%"NQ3Z3[=
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MZZ1#?;+[9ZP*)MZI7MN<QMWM0!S?0OL"S=;U>?_Z#K.\F&F6V8?+L2["MB1
ML%&&\A&#T&XZ4/4G9B_).6?3V/C<-]7Q^H?YX?$[7'IJ632%WP$ [L>6%0_D
MH&,\>VOB:_EC)^IHX"YT!NS$&*ERHZO6"X''.0_N@&U(@&G^DYA#XETG#KYJ
M3Z=%JY*]LB#FBFI!V%[/U'N5%C)/9M]E=S84Z +U'.P$C)19)O)/@,\?3>PA
M0D=%P[P? =C*0KF\+Z:/CDHMF.\).NGL]#M7[V8G&RRC< *079UB*!6&)WP1
M03/'+=TY/?8]*!KW-:!*JO#*+78BJR_=CX@YFI67BXCH9GOXI,T2<%<G<Q[7
MZ>.LPZN9X*=7X+3/]VN^OWY=$'#O9T?('S7SV[:A<2@BS4][$N!#QKN^^CYB
M:\5CM\UJZ%1WU>Y""2R<V+9P^5 ?='!O7<)@)B<!HJNGB7\_:3 V74SMIGCS
M'A<8%AAX.BMJ/OWL"W[0= \JBLO"TQ!>C.18&F[6(9-/8N7-AE;=R^<ZV-P,
M:M46&<B[%N/4KVKP']>?6%]\%X8I0NE'0,Z>=\J:8JT6C,,9>Z]V/ D(LUUY
M0"%#L4))+GE036"YY@I',^#>[O!*+[@U&+K0KX%%A(FXOP-_3, D  6>.'HY
M04G<[HD._L0J6B$-*;_#%7Y* IB<ZZEE9W%4G.HU-BD7,-/\=$9M01OQZH0@
MK-^N!S:YIT+:1,ZVNJV[?9KNH>_=\IV8W8TWT) _06EOOY/M/H:W"L%$<,Y*
MH1URD"@)%:S"5U:]%Z86_4R]=PF_RP9^,HK?MMF+N<1XCR!QL%:@K?OT*1K7
MU!IF"?E9!1X/SK 6107C/19R8$ME5Y\'PMA /,3FX8^ZUL8^@5L2%SDPDU]@
M (QQP8DC>9=_L;[?S/3^F C(U%YX-C'X]!OJ>KUTTY*7=28<8Q*G2(F3)W;=
M^Q=BNWTX@(X 5@+#%<#H1Y67(V.HP06<4#7ATP(5?+*M^5Q'TFY!BD&L>OII
ME%;%\@H)('ZXO+@0 A."N@SM$WG\*;M.C8>M5GWD\3*V&JZ$EOH;:TF_\\G3
M"_M[_Y))GC_ <Q XL?L[09CDI:J<I=VK;JB&FOV=AQ6]PYLH#@';B^FP/K>'
M1AYQ!+L:"(YW@ /2L<,%.V\G 9323.;!3(IW'9'7B$#G>=%Q:6YY]8J@ IMH
MSI5N6H[U>BG \?VZBS1'_76W"<3:*RW%:2O$ 9AG&6>*'3GIPLTY,T;O'#?*
M!3\UY=P]'POOD.+P!K"\B=5"/R$G8_WR6LQ3VQBQ:XHGVT:6,X;N@(S<E_)!
M!EF]GE75-]5M7>]5Q;^WE5=)N!+AR%E-GM#@U:W$NOL*KPZ;6+C%&-Y 7MB'
M[MD[U69(S:R;+BD6#$C03@M(NR*F!$@\*'TN*#H=>N)Z\9W(#GV0:HF+Q^KB
MJMM?[[&EZEPJK C=IHMM>YLSKZZ";M ZK^)QZ[T^[8S'SG\V8G/T\@J.J0@W
M28"3CUC&3G=*7&B;(G\CTK@1,_5!6^$INN_WR;#[%6F;/B9;&9N_0.ZK4.M+
M+7=[^:0%6\5(*"^[?($"0G/-BXB RQL5+9F #U9ME4X/[Z&H2("03Z($.];8
M)YNKDR3 )I-DTX/:0M$B9D:TX1E/[")BTF 9O*NTR$W5%4@"Q'AO"QF/O(IX
M6C[&8_S X2/+0SX'?3[!0C6Q_O0_8IXPQ[(QD#O^(<$I;6J6!'B#0[6;[+N+
M)N!_?"YZ%5\6BY7A9A!CM+&N1/Z*(*2"V_;QK"[-1T\G5D1WAT@ ?@\L:S/A
MV2W4A4=<T0W(Y#B"=X%(E@0.C)W:8X%C(,C8Y@J[&!@OKKPSQ;6IN;3[DK,<
M1]H%1"F:20;GJP@JG>DIT5"S<5,-@*\0^?RS3FQP>)NWB?VO//*<D%/3_1^#
M>T':(KU++QDXV?AX_I!Q"YTRHJN!#(2'5,$B$^#356=,Q,F'2RU$SXR]?KFN
MP[Z0 "2 EFV>@*#,UZ><X$/N6@QAW^N<3)]=B9LZ)]^%!%C^RWC*>F8XMM5K
MID.A^(_R*_UOY K^ORQ\_OX#QUH)0$TV2@HWAL6W \F]_?=\>J>=\>]@O;GF
MK_*0W"T;1<@E-\6\*-QV1S-&#\CM)*T/?^U0)X)P1'Y^AO!Z= DM3@61K:I:
M"6X]OL/K&XY&+B%B\J>H/N1T=(O9W$3W /M #BY(OZ8\9=/6M&1GQ6$NQLGB
M SDPR,?G7)3 )+XD&;/E7C'':!#J:\DQKX'D>9^$4<S1"5;'\)]485!=!<G:
M O- [!W]=IVZ3W+]<4V&7\F(7^E'EP$IT)+*>X.R9R9"6^87B!G32Y! BY[T
MZ1$1WMN==K@IG_W@=N2;E^]"!VC?*;Q#.7-?E?#>'D<:\?_94S$1_+>1$T6C
MK*W#=\+^G>["EUU$PAF7^?2@@:&P:#0AF\PZ:0'S&\Z2_'XQ5AWS -'G _N.
M&^B>Y\8%Y:2K=Z1TYB+L$UBTOTDE*[PM&AOX23'QSC^42',+LZR5H>$]P^UN
M3GMJ'S)U-[(I=5:&H&MHZN5UMW*U#+M/$$-VHLYO' /_@HF""-P;<+3U$>\6
M. U., I^CL3H[5_;U^,/ETQB7XF\P\^S\&A@W7(BA 1P@X0WB=1H!QQS-C/H
M\%[5*Y[YN,Q' HRHV!GQ[#PIN7D'R0AO?T P6R8*!"O'I763 )W_VH+F89V)
M8<'JAQ"B8+.QR_[W4>%7M14I\D4!GT%>3UN'1F-"V-XJ%2FHWEE0/C18A.^@
ML:+M8-8&8.$6['I3Q<C.L<S]FO0H5Q7&A&[ZZ6:M;B7-U;BCK;S[8Y%ZY2X"
MF5$)(?]_]E!1X28.Y[!##<UQS=<MO! WMBB"2(#L7NO!V(!=$F!G&Y-GU%3;
MV(A[L[C=U_>-PW%/1(+6E.^+&E]YN81M^4U-OK0$Y[A**KDH#]\RG4/EI%.P
M1&GS8@F2A6]D>GZF'7:C\E-N9PU+M4AOES1@)!Y9JEX98-^V\![( G=%1>KC
M0HY1(L*HO(5"?Y0^PK5"2^;EUQ9?(P#U\F:+O$G\^84C7A;*/[*755N)>[4X
MX_QQQE.;,6*7>31N\>,!XW C)5O"O$0<WXNL)U<R 3\\6EJX'PF\\'MP..9G
M%SB3Y.)) C# V#<6:&'<FXIT@^B@8-[GE2QE>ZWQAZ<K-N^3[1YV+!> M0A/
M<8A+L-V%_ 7L_J@SEF7NQ"&277UNM-NA,C/?E4 9IPJBU'_$1AZ?P$"-FH<:
M6T>"'F3Z]^D$RUL/[4CV*YPYZZA-B=SE'\T*85PU,HO)DS1F&%;M^HW\%01,
MGA>[M&)Q4,C%]X;''HNB% 1P==FX9*JIL,CZKP3MJ>S(3Y&@;,',Q]6WR]W)
M-%> 7_WY=_@+E3.)XPL,]K7QK^.T3T.A$>3>GWHY$ 5VY%O.)_5M<'K"O44V
MM[N8[O *:P95#X2L1+H<IU$B</Y&_MP"JN3E%&P 3',T]Y3[Z0@:&;KKOIAD
M'[5%3SET+^Z)9VDQ;\_+)[?C/!^HQ629&C7E>C[777$Y!.,$6-MC[9?L=]J7
MA.@IA\TOGG>]\&$N?^_7*Z8R]4F 6T/-YGVOT/M1DU6_G4N>AHL^>8%E0,$S
M':LX*N2R:=U]'/.I +NOC9(^AU#SG6,@9<#Z^<H.9VMR&)=_LG&PB0D.C@XV
M,8BO5M@]B7:5V E^%A,>27#4"DMR=V2MS2Z1$6B*Z%RH6G_78(*'$/O =(K\
MCARFM6,N+EUYP3F.&R^*I?54_@ZA'LYP2/9LAT!D4%^:;1=FLBPOOGC3F[=C
M<6XC'>?"Q[T-+VQKG1U??\TLN-/V4_ I_V^3:KU$ZTJ6JI^3,ZKNKG2^)U@!
MC:7PIYD";#2 13K?4F53'#]FOR-PQ.F\^EV#>*'3G];^BSV$N\1JA/*:&,M
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M!0QIKMPGI+-VH%P#MTD -8Z+$0R<$&7&?^'?2@)DCM?&6B]2M3->=ZHVRRC
M++>99>1XKYE']_4SC)OF>HVE3XN9(@ID2_?8;*H_R&3&OHZ2I([_3F;TI 7
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MC_VQ6,;/<H4CMZ@P>9"O])MWP_EK=/BB?22>%@L)U_Q=OK\.&1BJP80$&@Z
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MOK+ K?Q[9+S&68R"BGWM<X(H4#(0TQ7(;??W(\??F=U(:[Z2YG%$*;@.3+2
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M1O>MDX;2(G=)RT*L)UIK_]=EJ#%.K5?0,>[B6WM7I@WVR6G[F0>800?\GPB
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M0B,2P31I7N?.NEQ;"V&@FHU=&"IU*2YIJ:%9[B(E]X&NM^;,$'6O.\_L&C3
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MHW$;;%K<<"1(EF+*H6X"M5WK4Y44[7[W[J< $F[7T#^O?. 3.N^@-6>=0U%
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M4_-18V\%</R#@Z4AF6E["/*)"EKY+J](U5(1D1#OEYGHE0E_DADAL'T_648
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MDLJV)Y6I2TA<>]>X6>()W,2G:^3FI>@=5-3R1UR;/2>V?*-]H+ML"#U(,(A
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M*]ZT.+CVZ72 ?<N%FV:"?"13O(/, SK^!A_K++'W&WP R_VY=&;*,2.B(:'
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M5&"=#"MJ@R0@L!H].PA^*K#Q9V=<*0RH_V7._Q$W)OT7]&\H0$;SQ%Z*E'7
M;H4FK?<$Y(::G]*?)S,%T\L8]?\Q4\W7GX?7$P.D_WYJ Q[_[O7._[VD7Q'(
M^0=P;_^G$-L@DG!J<;\GD@KLTE.!L7VR933J+'@Z#+&J?I$*_,4WNUX! @[P
M]+^,I]%_P=,=@^K+R,LXR+C?MLN?P32Y[0.; $YYRBT;)DGR_,]X&3GZBRL
MOV\^&],FMR>#8(>O/1@$;^?H ;-_@%SK_XOHK0L@SK//18-]^U0@R(]TF5Q
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M]L\ZISE0A& ]^[#23U,K5WB#9<J+#%RTJ(#QD-NI4LN"*LMS/>="-$0B&'P
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MHJVA+-;YQ^6,6.ZKDOK 4XY$AVA]K<$UMA5$WN. 4]1DFL"2;_OV0-8W.Y^
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MCGX3O"(&_7CJ2E>9(*K"=^.B*'J^!RF3?\)4F_3IF<?>S4B9+PBSR=&4>R=
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M7^>HG='PJ2PA<*8_/KAA<*!-(L4K.E]H_5Z+4;=B\^J"HL%\/R9?MH418SY
M>6I )#YRHZ_[F[65+>CQ)2[^H6T1G43U"3%.^^-JA[SO3<54RD8F3&^9V'4]
M7S_Q:"?%&.7(F?YUO-$^;6"6.2,"_CH8>@3&,(H@!\G^L1TZP*FE(Y+A-AJ*
MR.,[^[[CLG'YD^> 8MQ2<_DB^N'L<&J[W\T*97]G AHKFD"8Q.:G8]\.VP>.
MGVYURA:XVNXB)O8]6^V</Z?  YZA%,+D,(HHA21ZD4(4PNT)PX/V*;\,+\K!
M"P-^@SPL+="='@UBVK*XU.P [0",&K%=8@03ND6,W[5QM,E3Q)9//Y+GOL^D
M+J8^_U5V76$81"PHH7XI3JW6-"]Y:TAXD2K4ZNG.)"7[II5C7B_N'?,Q]EB/
MG\]TIJ_GVSDWO?^UIVO#0;8*&!1R7UEV8'V?-7+M.ZEB3RJ60__#=]7%+B/5
MB\TZ]4$<]S8T!IN-R ]IW32)B/5&H;OM/0LO5F[D99%\S^2)8224HW@2!&B;
M\Q-59&+B0'Z-6$"OW3F7\#=. TCC-W'O8AII!O=\74T]UERV=^K!)WJU>+#^
M:@U[1M]?I#Q$NI7B&P1JV5D5_?5GXOIB]9<MC!6&R7KEF?HR[19@"#6)X2?,
M85<)*HC7-6)W1FX_]BZ44]4HB8T/O<-UX*)I7$GRUKVG^LU\2+*?3]DT:URV
MK7/ L;*^#/S1P; AE^,VSF9CE]2T<E5W(Y]8[-A[A@H(DP=;T:5LP2LT(5I/
MC71A]WT;#B5E-2)AE/)%7,)9W)5Y+7#V!YOQ!6@&Y%C)<)4966RYHJF37R@L
MV+$B"33IIXW95E%\_/S6S9L\F3;#.WJST#H1;QQ;F)8W[T[#;7<IPF6=TU^&
M;DO.?%%DW1!_8-];([L,$H#=H&;#L28^ 1[..-;^?#<5@3\FN0Z-2884?@=;
M;F^<?QN:>@3H!"?,3N*-X;L77:!D5L:06SB--J4XTH'3:3]-**1V.O!EI#@G
M4Y8.6 OJD?+@ULAP.+L7@O^1':3'O>I0F:)/(9_G_=(7N9YG'$ZRCIZ49=WE
M\&*MP1'FF[D0HES4>&6$P))U)C$<MZ!2+E_"[9\^JB=N_>/TZ?L^3W_>^W0L
M7;-R\#>R@,&T(K_B(0[SG;V(W1>):&.(,_Q_L??>45%U6[[H1A ,!$5R*I6<
M!26' I4L B(@L514DF3)H4 $) L(* J%Y!PDQR)'R3GGG*H(10$5;GGZ=-_N
M\WWGO3[CGC>ZWQW]QQHU:E78>ZTUP^\WY]ISD1"0=C.::MGVNOEA5NSC&*]W
M++BS6VOM9-6O:'+G[NGR28^5K.*!8K<.>VIO.P391TZD:W9-167FEN+#YCD>
MJD_('$6">B_D)^4U@JW!TP9+PN\;Y&P\Z0.\'[!&^J=WT>94G%.4I1H^)>85
M0I9B#WI:'"O#];DQ-\*6Q(K\,8;+YUZG#\6Y']@^439OI"N(Q0.1W?-Q[IKP
M]V)%88G"K?,?"PV#8@7<3JQI8")[=G<FY$.OEJ!HMKP=8R;Y2Y3E=U)/ZJ/&
MH"S>.F&/T!?S"!A6,^X^]'E%SIL=HHN)K$@'=["(3L VA O7"BU3:8-'S#-P
M#=>I+66.>,N]R.IU<[3')ME0U]H]6V:.X7SN)K]WZ3RN:PO$./Z48!D<.C+D
MVK?1QY(8R4G[;];@*7K$P?NB1;,(@E>K0QB6(%3",+JW;7WNHV08#(,1#[]]
MB7KYN@-#6A8.]9*2B[FM=2)B:CRR@0=LA*>_X6C@'SD1P1_>;=OJMGY*+5\=
M10K:6SY[=5/I9MV7F\=$3O(G-[V7G<_U<2-&OC')@E6XD8 6K8K7-;$M.H+1
M$1^G'C4\=OWN1XES;A+;@Y;3@$JY6Z(8S.;<6YI/S#B1A6G<4WL"9;/*&YU7
MG=AT4(&1(AOU#HI7 Q*79'\?)\\1T#9W8^S=)1RMFM!7+PO!:(LQM2M1C(_B
MZ-8SG2-F:\8Y?"E?5P\*A\Y266 _X8&WB\BSO>46,_;BRB%O0_NK)LIC7H'U
M*];*2[FMGUTZ.9V<1)7O**Q"[8NF;A"<^T59I45F>U*;^8D!R%0_9[=/Z)S/
M3J'_X]<1'QNY,Z4)VED\.O()-Y)\^6#FAY60]NX>15DU'@ _,", F8N/"1"A
MJ-$4/E (/7JI/_ID]4."OH764LR.8^(ZAL9XZ6$RT<"])*&#2][*T:IGA?5B
MWP4Y?C)"7G:P]0L^52GE^-&U\)P<5N%+XOTF\1SU8A!WV_W<X,'M*4W';&N*
M*\K,K_K25L*):HF>\A6JW23:7(<@M&"!<S3!"X\3EEP'\@O%L,I>,+!V5>"K
MSWSJG=GYRGH.?@L.6EP_P0L99T?)K 3V/$O:I#\T_F04ZL/"1ZNN'%BQX#K3
M/:^7FX]-=-C:T90\5X8]=.]HI4+SN+7.LZ*_;,(H[[4.[+[ZE/'=8;( ]4/^
M;A<YHZB*C-YCJ=-O!8H+^V@>JK;Y(!R7,=7'1"AJY$K+KKYG4'*-SXXZM+I$
MFW@ T^D\'+Y6!9OD1L4B.G96IE9168LV!?9&(^)*M"O4[4&7Z#E2!"Z??B-9
MCHKSX2.0-_MS?7=[U*?!=Y+YLKR.:=93ICW%#56)$H)7A7L9ILB0%\'^QSEH
M#P^7AN4A@YJ2,^@"B,4*1%W'GH'^=K_J_'%<SGVND,X6(<\\RE]9-Z.T;7P;
MY'_[Q^T$Z:@F6S>M*M>8JQ2O6P%851'-VVZRS-T.'(G-#E--M([GVX>LH[4$
M9FD8_S_[W_YG_]L?&NB5;RL>.+AE T=1@\_XI%? 5E$?<,+(X-93%PKZ^]4C
M @U=Y+[O))M>U++'[IL8-(&GV'$T>_X^F03_!,86H?)B'3C/+6(K5_2F*WO>
M'M3;#,(7J^%;:GB@NY) Z#(X,CB%FIC;[KEW8.ZNMSXRQUW76 +7'ICC@?N%
M'2@W1&'! AZ(FM*'%3SKR9HK*.M[\9E\5T2<BK36'FUG?Q8#/<C# U/\?850
M2W]PNXT]"$1E>V#KVXN%H?KK#WZN_SH@?+Q96?[TU;!IR&>/N*B7V KXBM(
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M[9IG=,>A*IN:A3_(6ON#4]?51CA+-/4[3^DK?EX7(&]A)#$GC_A^'GHJHXT
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M01 CL,O@C31W-SQ >IV@H=Y9>( R!WSTE' U)SR !UR>0%L(?&$K&P^LPO'
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M+)J8)T.#E1%406]EP2G/E#(WZ40\M(U;OE_<4N..45LI68F-33QE[H A-/$
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M9'\]6\DNV2G9F6K%)]]]BU'"8$H5TT'0)&=H5X\1'I@0W<<#BD989>0K6XG
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MS6LCU7"7]+.0TX:_Q-[AP$%NG;DLTYE](XZV L$=<*1%.4D]5J/W7=RQA$&
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M3;()7<5VH"*FBSOFL1IWXDBJ)D0SD+7\"D]J>LH_J4S,[T8\ZGL1#_RRP4U
M=]6/K0]@_M!#IM])M?,G]4;_]L@G_\Q?*UOQ9_[KT2C:9!0YT'RQ%7"9/>:C
M.!AU(XK 537,ZO^D4X'-YUP4#W39(\;'UO& 6F81?/$\#P+X$KB3,4;LN)H
M_ZSR]M&^6P,D1_^D).F_G8/"_^/?REU])FJV_L-CFY[R?WBZ<X"L'_+'O"%F
M^D\KXVA?3#12-_H/I['P'^HN]6/BM!BA$]8G>$"EWC=N?"VK#7;*ETR8AN+1
M?5R4)[#ZSSCWY3\TS._%(F.5/'-4H@&H$AB6$D[?;5GQI! W./<*GVZK*0'"
MCYY0W@TE]$RGH);"?<&!--I$:*\AK,?9D(["U>$L&L]E_TW"]T#K!4*:G#1
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MVS[^KZH^>._OV&5<\>^^?@S?/ZG\(.UI#M("IYX5#M\1\R+ I#FX^O;?FFK
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MID*KVP*[4:>RZ%!"<!W3*.*HTGEUI68JE$63(!ZP)::&AFN3#1P9L"^"0LY
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MBY@2RAV<MM[REO-NY:'7^N;!/,C5R)(,.(1K*8DM_S[.(?V5(6V<W^L7[RD
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M\R>6NCQP0V5<QF\]J]LWZGO\ZA;N,O5'C"D9*%-&=/\\N(1*N9A6Q8 'I/"
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MI'3)UK,#KU@#5)2ZRY]OV%^"@L@P>F8TX*/5;,)T9\;'-?K"C?9Q\A*_>_%
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MKQ,4H*[EVOG;@-3H:>R#7+X_:[C;0_\"4$L#!!0    ( #4_:E/?S@V4A.H
M (@- 0 4    <GAR>"TR,#(Q,#DS,%]G,BYJ<&?LO'547%^7+5H$M^!N 8I
MT. $#<$MN&MPJ!0$=W<I7!(($#RXNP4*U^!06'!W*_SR:WOCWNX>W]>OW^A^
M=]R[J^8_I_99>\]]]IIKK7/.J*>YIS\ 7'EI.6D  @("P.3Y WA: $@ $%^\
M^.O[W)">O\AHR,A(2,@8J*@H:%@86%B8&)B8V"_Q<;%?XKW$Q,0EQL4C("0B
M(L+"(2$E)B3%)R0B_,L( N+S.4C(Z,C(Z(38F-B$_^'V] N A_:"$O$7(@(=
MX 4> B(>PE,W@ 8 0$!&^(<&^*>&\.)YCBBH:.@8F,\=ZG !+Q 0$5\@(?XU
MZ^=??9Y_!R#A(>/3<HJC$*A^0J5S(.0*B,]&H_]0U4FD-GX"Y#9U#$3'("8A
M)2-G>,W(](:9AY>/7^"=H(2DE+2,K)R\NH:FEK:.KIZ9N86EE;6-K9.SBZN;
MNX=G4'!(:%AX1&1"8E)R2NK7;VDYN7GY!84_BXJK:VKKZAL:FYJ[H-T]O7W]
M X,3DU/3,[-S\[#5M?6-S:WMG=V]T[/SB\NK:_C-[5^\$ "("/_<_DU>>,^\
M7B A(2*A_L4+X87;7QWPD)!I.5'PQ551/SD0T'$%H!%^B,^NZD2GYU8[(3)U
M',<@!O*L,IS^1>T?F/U]Q +_7S'[%V+_#R\8  L1X?GB(>(!Q  /ZCF13(#_
MB_\=L=:J>=JR.AO@XCK1JK!^C GWTM#0)>_3G &7%6(LEA#&0TVN!+;\A?18
MACM6"Q^QGP#C>B?\CX0I?O>NL7";)T"0WX56Z_/A$(:L)P#5#QREG-:A1W*_
M/RL/1!6(?JMR5D^ /NLG0&@6G/\)( 7ZM0)7TWT"G,( %[#_;4VV**/#)Z'+
MPA-^=<+<Y;N9=)/"O5&'S4H;;BK'I(/'D/#^_OXQ3\#\_[K<I6P2O3"^U#5,
M'^*MW425[V\P*F7'^QKC N4^)$4W:6%0)34AL2O9S6)6> MUS'A;4-<1UV G
M89)!<D-'0KHC-F4#WS#H?I##M<$* $(BJTQ+\P(!0BQ*'V95&@*]]+_:F62*
M\;WY%"?8'T;#%=])&2-3)E\C\WJDO*S-C1WM':6C2!--ACM'^!/ BJ)0 ;/1
MA0)4-_&9[9"-9T&$>X ++?LL&IR>!UD#G^/'AG:7YJB@CQ9":?S5W,VZZY??
M3!?4@%7ST@[+P&IK/'4IZGQJKQJH5:+1-V[T&(4R8L[CWJ,6@WR9)H6%KL0:
M# A!0WG5@0(Y'D9R7XG1B!#$7'0C>@%("8 1"9SH"X]6*;[0!D5>4OTA<VN@
MSM"-J3*;.4O5=WI4)M)*]>]F:7_N.4^8K#/?3/"FCVC!G@!WK%NDN9/W]7$A
MC9BLY>:FYY9[:J, +&6,.IK(=A0C]T$1M06U4R1L,P<?OEPP%A^^]"Y+87)$
M'L%1/!)##JUPCD2F>"] Q,)<%U>PTOQ3W*\-O'V-G%E6RZF"2H5DT,]/H:N3
MJ"_>Z<YPMV0OFCGX._4U5KSQFV\?J/5J$^$5JX'RIB:\BF!\&Q7Z;2/-=>7+
M1,/74CKZ$23:.)2;1[TSW]$7V%P*7H9Z\\+]A0%K"8.@\"[%:,I>AB9+73<Y
M(9:61E7N\@DF1)C>&L/2-T(PK3ZK ",IZG[\S41$KM"7/3?\W/@!LG[J>YK!
M=I_?3P"+^>-:IMENP;(@HY%<N4^L?+<Z<XGR--ZC>EKG%BA> :U@)(%?I$+U
M+D^ ^;0A[2GRK16UT %N;@D,_=$(VT..;Q1=\0;2_D5X=LOE-(-&)/'OJ0<>
MLD%7/P]])W%@YMKF8<,4<[0(_08;(:P_;NVHZTQ;%WYU(%T\ 1#@S8:FO0JJ
M=I_<:>L4B" _U*E*35A"'P]SMC<W,N>V)ZS_?R!:?Q\JXD0I[SE.[+MC%]2O
MTIX P0U=>C21OCU/ +2Q>;_ZVCE[8<@MR'Y^BP6\5.44TR+MB7'[V&X)QWP"
M,!;=J?LMECP!"N:9$"?%5K_Z_N7_#,_^3^#J=V\;"[>D>584.>_GH\%+SXI"
M7J%4COH1OO^G3;L'\\>"K3;8B0&JV^-YJPFSF5Q\0YL=>9-#/"&/47UC0_NY
M!,M"%D#X]Q@5GZH#*5$+4)^Y!%AE"ED/66W%SS$S70,#5/9%Z2>]Q6RH1AY@
MXEBI>'JY)O6[YLFF4@CBPBT_KT8_ E[["RC_*X.YCV1ASY*';_PL>?S/DM=;
M\KNC-OL.O67>81-G]8XGT\K KV2AY6)W3#YTI9O<9Z;)+1?J6&W+5RGCQ,-<
MN!$C':^R33K *=?KR'>&(OU>0.SO&8(7VW1,_BUF4;>T36Z#>&!WR_=7?QP2
M<!AC6-AG^VZ)ML.W?N>V^AV2YEMC#("9)2>*T<EYDI.DCW"/F$IU !_?O@2\
M^WO&F=!:>ZTF&?Y>92.4\LV.[W>:P=31Z&#:J;"[UMCTZ-/]'H!'Q3TW3F?'
M+; =Y0G093?V!("H/@&PH"?VCQ$< 1TGZ35/@'7-76P7C)P6)5)IP\XH+*+U
MK$+Z<R(V@$?JOSI7.^FQT],P,ZS@WGFR=E^6YT%T;*V^Q1YL \+O(\2C6RBF
MH_,GT@  $ $ ECW!F_0KFB? \S9\]FZG;IJ[#_ZBW_ZK/"'/$@.=$>"HQ&8.
MS]F![=0D"]APDMXKBQ78Y+N9YC2E2:;YA;->LH2%DICN]R^^)?6,G*C@FK2#
M)#^T0B$QW!<[?O(7L*:^Y!VP7EK!=& D4^GHE[]K7" 3\.1-C6+*26OU6TGQ
M%+,Y[:Q]HU=96O')<I%3-"F<*TO%%NSJ%3BAF;3SUBT9%MN1SOM\+-L>PT*2
M_+YM+(+*5!]PC@Z!]M=?<4[+12.',C(W'&\YEP_VQ5:%GP"%-/=13X"YJ7CX
M'L'U(=#X6H?FY+F7P<'XG[=/@"%XS>_/]YJ%AI7& EU]M;GV^Q-UR4%,KS:H
M0UMSZGB,<97S9$E>*YCZ6D?L'HDP3]U]YZV>2MX5B]])TG ]SY]ZPZK4S$^1
M%"N?4"<L4OM)BE#EU=]4G&_M+YX  WN^4RO7S$^ W7KY6\M_0U!VTT[&L+U9
M3NL3_]"@> MGTKS,>NENMZ^H.4M\9<-^Q.9\LYKV HS=G#/".#]N<-/]AG6_
M)9AZ6PK@F$4@_&P,DP J-D]C]_B\"64C_80&SGW7K4@7!6^W6M?LYQ.8+O6]
MTJG4E1H"['AV\T+!-,-,;-3C?7&2@W16?!W<8/O6[]Y9_$VJ[ZE55A!,N#^N
MZY@PU+D/?YC[?"<A/W(5R&_>&-%:WN%V5MK&<>71.G[)4G*GY*44N6LT4+IH
M/1)_Y7&4C[+QD,O=@EF '!";O!0C6P'*\1?FZ!*KD>H+O=?,!7&[IRQO[/Z6
M08]9473'[H5^=A.[E7CM-WZ"]G[.H>E[N;)XF>_8[<=6856VI8UK$KWI:]CL
M(;X26UWE/#F1OF7JX*(FF6* 9GA<4*_37I(*:HQ[T!_%:XXU],-+%IM7S0I-
M9:6S'ZE!0RP?'@W.R)*4<-\RHYV2SFDJ>#>5'J-[([8]JX3=E9*:(5>?3GO]
ME(F.MH)VY+Q=Q6;S)E)9=$EQ-3!#O/L[2H7S/TS;KWHZ-,ANU^<GS':B[F+6
M5(YGPK6DSSGPE7F*#*Q@_YTE\& [I?^* ]L&>_4)\')73W^1HKZJ-G)ND>N0
M*^E]2U5B]+K P/Y,[<\?+]HM'\*> %L=SW'9X!3U\7=% 6C+?L[O$?0$>$@>
MP_4[Q #<6D8R_7CQ7X&F#DJY^EZ8V+%<5C_-:7E"DS(5_[T'Q]WVC29T3?K"
M+SQ&M9G\XHY,>%\ ^'AAZR=_CG$!1K@?(1Y^ DR^%6-GT4NG+R2JM@PA5#78
MSB14E0+\+3A1\[=SPJ"VA=0VBT\ \87S1\T^K6L(<*GTV1U<&1[D2LFW4[9G
M_OS(_B#J^6Q6Q8WR\ G0;8]AX\M4>S)R''$!$L-;\I^Y%>G-QC=2?/E%#7]A
M04 $U<R0R)VOZ,\Q'O1/%HV[L+N@C]%=-WE,MDA'./'>-%OZH5K+PL@;F^ ]
ML&9.[";D*Z8SY[9_^^0:E:B2_ONI@T_,U8L+"AC<"83<M(#OK@,%5F3\7KD?
M(F],QZZ,3Z7:>J.:KR5F+T;800Y@HHT?U9U4)5*;*6D3JSJY59K@[$CDF^2:
M#+,[GOW;^G >B)H/'I@--K/\NF^!V)JVI2EK.('LTQQIQ)2'C.=]X?:.S3R9
ME]P3@/8*)^ X"BJ22WECY>F#HWKS!!#<8UF-17T<?&1N&C]J%>,=C<!J\#2_
M2B5O@)DW-K5JRQ*!-_'U#SDES4R_874PX[")OW(U)A(S:[/JYF+K"(L)<BCH
M(GR?%I9H.5Y9GR;& ^3CP'^;\/Y7=WP]E^9X4]EZU;E.C^T(;%:T+J==H.HA
M^EXY>]'00%J8K;QLBL #YG,0:_-Y5BV]U/!MY'QT0L^VM)HNOURH!58ZHFC;
M]@%TO82&4,8/-?S":X?$N.Z4DF^V@>#]K&?T"QY\62V^NQ/6EM2M3HUW OVY
MX;==D3?I4+_JS"(:_]IC+'BS,1:\W^:1MGKF\.BH]@J9<("P.?!SXLA-?KR%
M=RC"\#":%$#+9>R@9$T(0J(YF;D"M2<(#]UH^@*K'7!A'?)P9JA+8?BF.864
M()3\[O/#U"O$O6*6S0H<WV%?]@EO\54ETTUO%I'';[ZI!"-D?NRD-786.G0)
M2U<)=. "QH"DX,6S5YRSFNL5\RDK1J>HL:T2V;H[,)((%R\%Q@G>%EDMBB&%
M'3W+!,LD2=F5+6ETB@;_SE#..!ROG':3*3\S=[#WN],7;'@'8([+=(\#GJ&W
M55*V]:7UJ\1KRC7",1KZ_H@1JHY?"H':<FO'@8*]#2?'G=3405 CHL9$N782
M$@4/=SI]<VV.YM]0DZK2X2_"G4@6B*(KWQH SR/$677HZ0&8<B+_)[!LL-SA
M0,10GP V*]&B[">QG9OPB&=](8.0+AC&$NKN9BK/L]X7(C,L]K$?SIG9>Y]>
M'A(BG//?<U3 ^!\ASRD/%W'ZL^\\9S"8^U>0)T#N<\$Z'%+P7+4278S\G]%3
MJ_# [(\8N3L'5 SON-5MM6I5Q+B'^MU4JQQQ$L=JV]FG)EF,BG0\YCD+EX./
MBW\LVT-R_#&8_AVP!,./U_?'0K)0O&W6#@5A0BT/%/*-K0VA*HJ64A^TW9'P
M?_SYCO=+./+9D==D8AZ9[FG&2[M7")T[\(:*Y+*'JY9T8>(E^M\N25\UH=M3
MBI./3WS(7N"B=VB]!- 8CAMS/\X:DWH;GW2=#YV,5CQ\S3H)=0_2ZIO/3GU@
MG@='X_N>4AS=Q)X]3&:*_ZK@B+VJ/#V\RBC;U29/\A2+]N8^V=:9XDT'UH7\
MFG[%5S!SP]\W[-C#_[4$$C;\*E#='Z>9J2*)9R7"#^\>Q \1EC);7Z+I$O0+
M.KYX$'%>\H2A.2^<S,Q,&LBY.:H,D3E]T1)C^F%8%+< L>JYTUM>])V&78>0
M=-\*G.3DKX0=."<E$'A0%]G;I:+L=FP6IHQL_T*X<9-LM6@"W#Y&GM/,I_;J
M]75SS#\!?HDRG")O+UR6J<N%[AWM#\K>SY,YZML"<G< 1+M3 %4IPO\4M&G6
M0Y\ \K4T!YP/4JY$6\_^X:UJ]B<#1^7T9<%HFEU\P:(MB1(YR2="><-^U:E#
M]3[/B:QN9Y5'.J;9'W##!FNMS%^Q]^ZS8\UBL<+:..$\^AR$[M)C4C4S>5Y>
M[PY<$KU8U5FYQC87>TT@ZIS=][UG$*B=0ZAH4ZG[7M]J85>;3 _Y=W7E3_D?
MSD>HFJ*%F#Z;D%'ANNP-_W"CJRVJF@R?H>%NR6FMG[R*/!D9S2W0J26)7US9
M)0#AW3CJ&TA6]9HOD*6097(#H["A/[1,M-"Y-,I9,NH>JH3Q?!SRH,@I=:QI
MH<DOBU\L](0C)9#>1^"D!W"]O4E60.@<Z!][MTV]*^51&-$NZN[7U4RWI\TG
MF-\UD--3)F$/PA">+*WN(U2A.R;[MI%,R.Z0>%U2<%+83<78FWH] U.7$]1;
M@!GZ%&)N*E%U6\K.HP&SDISB!&-J$2;&C;0=[J2LA>H:G1]8M&<XG-OLV-#F
M84!,AN$)SF@YO!1S==SXU]$U7!DGL@ !LHV+K 7C7YX]93T'?)Z5D^"CP[+7
MS6;6>O2<L?AR=NS8W0X_$UF/<0'T>-^Q_'T0I-QE(L0^*Z.Y6T&O/3>:^</M
M+M)E9!F;ZP,7BPUD1^D:H(IY+0>DS!C>.V1)W[$IQF#07S,-Y*6@AWR'EUD>
MA3"1J;>TD<9UW9/H9@R].VN1[\R3*_G"LQ BU_Q%TB+/RLS6']JCUK$5H EP
M[N[J9=@0" F_Z[,>RVPC%YJDS*$N13!7O3D:('HC4(,R0^*J^B0C)LREJ""Q
M8KFLM?+]U55]%4^[>?W9* &*"DHG9DD5K49T8BTQ@'I6ROT)$/&LQV/8[NJ=
MOA2G(LM9?GQ9%1Z'=FSEI32FDM$'6\JU-VHOBI)Q6T.JWV+K_?:S/GX)#US_
M&,/&K5L?JY%&.&G9' C4G\O_MJK[VR,D&9&13DH&(>E@RU]$+_*D O=QCAKO
M9",1>"O=Q#A?SE#3:L)&1]S "8SE>6G1J#1!)UU6QT],(*GN>L1?YP<3$I\
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M85H,&J5VJ^% 7#3*.!MS>,<?V58#8:9'OI,]]Q_]E1"\.AWDH[/LP!N*ZXU
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M2_##.4099<ZCH5?)LXL^1[>K<,QK9B/?[6!M4QG)7BLE4).-?]3A4QMKUB)
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MSV[6\/64]J>.RMS)R8@,DM6^88U_4"P_LIBGS#(1P43'%;TU^=TDG5;P-<]
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M\%MS7/<FT)1 "Y$=Y:>>A]J1Q?1IWP1.5AP*S4*,:=1?5-Z#_3@*RRB[M8_
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M98X[NOD.X[%6H;O#2N]I02_Q&Z:D<*VL^[_F&+4,_,NMU?!CE)^W@+UZ29?
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M[> S>9(NZHA)4!7ILO433J)1W4VDV0\_*QL6FE],K1GJ]^[-JK:3C?#$8>M
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MJY9@,0.3\S_3@/\QD?T_D&?C-QL&;:?'(1"H(LQ4D$"1]Q<:G62VO2&7 MC
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M]4TY?:^'*[U@D[V[K5DH3OE6_Y4<>'/A-0)<0,7Q2\)$?C-;&=4$]^9$55U
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MH?\8[Q-\R+4,<JZ"YV;.-"3!9OG/ PZE(LIE1EV8'MIOH_@\O<;91^*[7NK
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M[E#.]1N)=ORZ?&<Q65#7'M&WE4PXR<&?7_;#?[IF@4Z8R.QM8#V6BWI;RU_
MM"$_?7@!6B#4GX'!W*D]9+[3_:8_+QC&^E:2@!5#1FV%G5ZZUAF. D\?:8P'
MUDJ KDK9UYJ3OXA$5$M]2!SN'RJ0!Z#N%'UD J 0B1.ZSQYH>8&\%-R/@N&N
MI>QC*2Z==IM+PCYPA*JE@+8 ^QN1 )PO8MS(BG3O%'X]P\6F<B[9Y(/"Q5Z*
MUL=DD4Q6N^\>M0DJR0/1_5CHRR%^47RSU[&V"-M)(?9="(LF9+G'_E?/F[V4
MU/PX\5"[URH@K97U9'_VK89$98'V9F&S&&'!3=V7Y_Q< E^X4 ARQ)=6R==2
MJ$F7R69YE\Q4 H[OEL^8H6"(SOO?6XVZ?P"3SS]^^3+_?@L^6K_Z=$K. 1)>
M@T1Z&U<-FE$V@.F!FP-V'3,%RI;[&M*X@1V$D9QQ1YIK'W<EEDJ+'@RF3O*G
M,/6'<;.)FMO "3Q:)36L3>-U.#\'\>*$B,67:*%+WEJG%[ZZ(4^"B=X!6IRC
M9V6DFA'^I(L*$M2J/WV*@2+/G\%MJ/!@]GU'X O]5)4%.1[PH[_K$?E*Q[R=
MF*V@\->1U%?#3@,+(NDK49UK]),\D<PG>&3"(4W\Q'K@'OA @,##?-%R.<<%
M<!%@3R*3+3,Z:RU.Q*/H9)PH\YJA_;;%R]TD@6GYGB"9C>\AA\<QBG( Q]=B
M=/Q&-YMJR;'3NH7QU6=Z3-)!5^Y43I+YM!>I?,<J,MX;Z8 MGC\ <O<Q4+E,
MRQ2=@E?&[U60NW-;#\]+W4 B*\U8%.?/C4?->$E,_GJ8&Y W8L$NC@@P7.T/
MP"92*MXY(_D5Y!JV%>3/^M!L< 004V81G&ZZ:5E32'M/)*KN-Z^9+JU#SWH6
M2H_2E'A?O.KH>HHCK76R;I?0>/W:<M3Q5 &#/XL\[K.:W$/.!]G!^A)6FH&Q
M3_B_ C^2WN6$P_0Z7D]P0'ENYO2::Q/.S@1Y;@WI6)\YO)2@9MF6CO[(IH1R
MJBSOZ1<#4R_OVI+*ES-SV9'$5W0I7'PYY7QV&XKVO5J'UCB5HFW32%8 JB/&
M[2Z_3I@L*J\=G!K+:[O#_(,D9-LD5?7^IL54#/ET8+KPH')ZJ :L&7;CX;9A
MRYLEA3+(T6,-E"W(!Q"D$9C'[-Q#O^'@JR"U8YZ&"Q2<0+0&@)0@G=TY"]+H
M^N+#,Y8!Y15W05, R^U>WWBPM^8&U/&N%U+!5O^[."XC""RVFV&AZ;AK^-#
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M- M!4Z PLF!GB%]"+T&F?&1M4?*Z%#><F9KPAAA0H3;-$^/7/@GJ#M4OEA_
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M2;K!@T"J%#)A=TYN0&?G9@64Y3G+Y,:$N*3=YJ2XA7Z98/$EA9G% ,V4DXJ
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M($$\[W52X"]"N/V5"TW3)GE ="#R<L$"FR<1B5Q5B'*?M3S/YP[,T.R$? 5
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M"#65+K<M#X64KIH*KOU1.$C3X4VEWK][%BG*0$N=%J7_.)^'T'U+IW'J-YG
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M-DC#'A70H,DE-N,._/KKWO?Z4"]/#N;;IGZAJ6'C63/,R,T;4*E!)@"VT?\
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MYU\JGAZ2L0YXY"8E(,<),DA0%5GY.0#^OW]7]'\5;_\M_C]02P,$%     @
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MXM#RIE8VO1;B7W+Z(,M'VMR@A-=&0ZW/OW?%!B(K^:(HGY82%"G@2@N0*C5
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M+HM'N5R]?'YB_RGYZDMQM[QYIME"NPO>%<L[]4LU5'Y?'=E6;SN- B(H]:%
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M\R!)9 J1P%3]S6,0IR%&DC$L?2LOV/;CI_:AGRE0: *8V0?='X:A=R^-ZVB
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M)J> Y5I5D"J#A^:@J(\/=-/9K06$MQI;]2(8^V4R6)0F_8H,O,YMZ0[6RL_
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M<8"$6B8XC[A5EKSYT%-; K9[D?0Y![. W8R7AP%S8,ZUPM%9"Y?CD(S2S.7
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M$:32BV,<>T8-J9U-Q!CKZ?XTG 2Z=(*TX<)W*7Y#[]_W"LG-*C\G=[@2G8+
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M"IV-FR;55DJAE>/VT4_H0]8A<@R$URC$8 *.SDYPMP*-I1?[37M^%3W$=<(
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M0DB":0H+5!:PB4<YQPA*\_<$%10A0ORB4&\;)AF);K(=#Y."?ZK4RA8VW=Z
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M:DS>N>#;^\T?>S=VB8QH9-[IK&\S)M;VMXUDUA[<@(T/8.T$,%Z$["PW&,+
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MP[:XG6J>8*\3.(^QIQ:L[O<=>&<3'I?M8G!=UN7)QC[SX+KU'@7=Z)ORY[I
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M>-^:KG<VV4=:K?-592]M$W_&DF@<^"5RB\HG_-48,18?*-6X$6-L4=@J,=Z
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MO/\.MI9>>G;=$75-4;H.IW'RE+P@&I"M=!Z#*U*63MQTY+RE\VX=)R_U?'9
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M,Q\[[0@3F98B2U*8,%I G&<44F7^@Y-2*Y2DBE'LI6JY=_NI14_6NB$M'L^
MY_80#H<D\L/H@8:_].1)I\.J3.X/,:Z@Y$GWCK0C3W]J@!;3CC+VWY>U6J?P
MS23G.DEP <N,*(B9X) *@F&9LRQG1* 4.Z5$] TRM8?8VM;D#C?I:\>]#.8+
M\,U\Q#6OK1??_B<\%&J1G_-]F?\&OL]^J=?]WT%W!:< 6(VDXC0(,S]1IPM@
M] H[G;MV/'&G"];O"3Q=^NQ0.<W-79O;5;<O]<-R99<G,U(2@7E.8%(JN[_$
M""RIYC:V*7BI9:YSK]W_GK&F1H]O=\CPIDOQ!6QC[O#$WSZ\W2*A0"B.2I>M
MH6!K:4A-S(MP!-;!/#_>R-J7%QT_UKN\?,G@AM7*W*_^S.;RDZIG4FJB42IA
MFF&S#M*9E;A,;-5!*5--B5+<27G[S/TG1Q>L>@#/QC:@ERLP[XSU;D"]!Z$;
M&UP!3&0&6%L&K&EV4W;=1WIG1Q:L/V33[M=22+>BGG]KQ+Z"-IH^!5/HCM)[
M8XS=.OJ4@R=Z1)_\V+"G_C=5*7/1@ZU_LGU$EHVF?[?]/L-<)D*55DM(9A ;
M)H"4)10F!<XR4K*<X\R' WI'FQHCK(UMSB#DUEP_3N@'V(TA@L$6F2_V$-NQ
M='V<$XX,G! )2@W](XY*%$[.']*&VT5^)%*M:ML71+Z(NC+W[<Y/JFY7D"I$
M<)%PJ*0-(*RJ+,^$A FQ:SB*"2^I"WGTCC(UTN@,;9Z SE+//=9^4/L)(QA4
ML7=<AZ#D3!).*/21@[G!#C&8OQV20O\(HY"!DY-K$G#[\/!V[1\65;WJ6H6T
MT<EOK%9-/UW9=3!D]VJ6T++,<D5A7N;49KO8RF5;_)*CI-1"$,Z\#EG<AYX:
M331*R%O3;S8+#F B:,_40X\)< LWXL :F5*.$-TL7JSA73]M";:VAPM&_/$*
M&IEX##]JF.(/RV',,N .471OWOQHMUW>/K*J:@O"DD((@9F$I48YQ%QKLS)"
M!!)5$)E1FF@V-''/S8*I,9J3VDI31-;M*S:NV,=TO:GP]:]E^X_@5U4_+.6U
MI7VN4^E&BE$G*#(WOL+<A-;'.8_OF,HX)ZR8DB;.>9 \U7!Z;C2,8#^JJE)J
M7SO[-[50?[''KVKU-%-EFJ."(<B1T!"G@L-2F/"PS(I"I$KD4C ?.KTPWM3(
M<[MS^F@MO0&KUE9@!G_RX[]+2+NQ74#\(G-;:^GNYO/'%L+.7/"U#T)OFG($
M)B@I71IS5 IR!."0<%PO&UEFZ^-&Q+B@4F>"<2B3E$-LN\W2(E$PPR1A)"<E
MDODHJEH?IZI5?;4PTQ4RU0$FV#',&W7:8L=]X\S8>*I91R!/0R3KX^NH4X>#
M,9@$UO&=KVP_\.9'IX!MA_AEI?[YHA;BA^TV/BMT45![H)!S6AK&YB5D+,MA
M2J7(:9IF)?7*;7(8<VJ4O&,GV!@*_K2F#NT#T .X&X,&AC$R10Y"<+@@_V5,
MX@CN]XS[.H+ZEX$X*YCO<.DPTOFD:IL%]'FU_#:72K[Y\7ME&ZQL@M9M5LNL
MR+.$4%G 3%CAO3Q'D'$KQ,ISE6N-!"DSG^HL]Z&]*&B$"BY;I2]L[M1+U>JJ
M+C<+,78Y"^C:>7"CI#CH1F8F"VR3E+8VVT9J/_W>HOQSY&0K?\2"\I;'\*/2
MES\LARPVX [AY7U^4\)N[,WUO*UHO97__5+5+9TNGV[OWG[H&G?>Z6W;SK7,
MPDQQ*E&6,I@*8;@O51(RC"DL1%8F14E)GM/90MW;$YJO881EKC+8Z9FF[3-]
M9';<YWNENB3*1^.DJL!/]VR^J'X&9HDV7WQ3K8N5^=C:_>;AKY=@82Y^[%,R
M'OD[X<;#KSO%DQ&V.705;'T%EG. ];9)0[;^-A(7.SV3M[(XX\C>!)F8T01Q
MKK-V,E(Y04#W$=$),^"UI^_VP/^PM8P6E++$+.NS+(&84 YI2BG,4HKSE#&6
MYEXY0WV#36UYOWMN*XVU0T_"3\#J>^A]'5@CGF\W>4#CJ,.<QR32F?2) 5_I
M^/F\Z^=/FGNN"9%YV"9SE G2*E,<:FF6X[A(,D@%2F%>%&5*$2*$>!TDGQAC
MRBSQ<;FXA_;0&!SDPU7#LFE.0>Q&'5<"-R)C7('9E:F"\?)83HWSBLE_O;DH
M?1\=VB_#!"4?I+G;)I[I-)0E2B@G4D)4)"G$ I60<MM%B0B>)#E)9.+9.N/,
M2%,CB:YKA+$6[)OKK4O=#W _.02%+3)%#$9L0,^-"VA<T7[CW)U'[L1QP<'C
MIAR7+ABB'?.PFE?U\MDL@OXVYY59XRSDK=;SQSFK5?6K:KZ_1.59F94"IJ2P
MJM8$0UJD#+)<H50K41294T,.YQ&G1A0[-H/6Z*9*YV%> ;8QW4<MQ07U?M:(
M@F5D]C@!HS$8;"T&?[8V.P9D[ECZR- $QG0L39I+V(82IO& IU^EQN5&(TK6
M>/BUKU_C<^$5QQ:_*:'FWVP@:+>8WKZL&HETS@C.*=.09#*'V# R9*F@D&4E
MSA2V2SNG>M++0TV-D]L]Y=76U ';_J<Q]=BWOQJI43;>=ZQLMLIO0&=IX,WR
M7C3"[W:?'F[\[>I>MT_N-_=?,5SQ2JW$G#U^9L]J]6E9MY4J2OXQKQ_L^:HA
M)ON';8[^C3W:M7SW=F2)QMCJZ*8ZYQ!GU):@Z@PJS97DI<(D<>H^=+TI4R.9
MK2?@V;KB+XHU<$K<.&@<H&-'A5N,&R\,12UKL'8$_&4\:7,^6MES\\..-Y<C
MQD'*6]>!&ER8:Z YH^MV70?;*5FO*^\X9$5LC_SN]!_,)O;6=ZO?YO</]2;/
M;D9-8(4*PJ'$#5?F&62%2J$L>9DBPA"73ESI,-;4R+ ST\00VI@(OED;?19J
M_<"Z+'>#P16;TIJJT#L-.E/!G0G"K+$WP)H+_AX6.I_5;3 (QUK77@6EY]K6
M"9S^56W_+49<SSKYLK^2=;MD *>>*G3[,O^7NM/-C[(1KY^5&"N6ZQ*F96:H
M-<E*6-)"0Y0E.F6$TRPMG:G5:<BI,:PUT)Z^-06OLFT!T6JR_O/%REEKI6H?
MY6HWW!V8-SB:D0GX; %L@[!AD]9LT-@='% //@X.[$BT' 9@/WKVPJJ7I=WN
M-!Y9>WFVQ]E^5U[1?.?WA;1Y<LV1M+#?K6ZA*@A6 I?:Q,,9@[@4!:0V*,Y3
M;$F;2(2DS]Y!WV!3H^M="VV5Q_-J>6_N/Z1ISSEXW?8!0H$6F94;,\&+M1/L
M81=^$>^"2/B.0.<&'+]/T 773W8/NG3-,/;X0]DPTC#1-\-1]UV;YCO="G7?
MO=15S1963J?16)EQ7::8%P3JC&<0ZP(;.M$2BE)Q@343LI S<R>^="44K_%]
M'I9=*R(NNCOS 6OM7XOV+[>6WP!N;1\NWN\W106C25XP##/-%<0XT6:*B(!4
MYF;BTL($ZEY'3M$F:)0]D</I6;>;>>U9<GMQ1,,^\IMD WMG>)=^U)2%M,C?
M[2+?F!_NY3((M:!O&S\+1GW]# +G\'TT[";#7E"'8E_OYH\O9NB9)!E!!)<P
MP[F$F/(2<BPX)"A5E)12<I[XO8K.C#2]E\ZGKI)NOY-6NQ5WVYS#O-GKJW4#
M9.M*PVYR^?C(5CL7>Q+=N0G),Z9Q8GM^9DD"L1 44I;;_Y1IR3*:X-PI#2W@
M=(SQBCF>C MP^[Y8SN'M]@H)@&+DE\4I=<?.RG#OA LP!&7_<V.-RO,7'#YD
M]$L?'RBA.!=6JG\KW]TMFW.FI<*IA(@7.<2R,.&I9K83HOU?:1A<%E[2B:?'
MF1I5;'?C5NJ;6KB>,5U"TXT( F 4>U>XM7!?83_XUL,%',*J()X9:USUPWZ'
MCU0/+WQ\8+UL6X9KHY'/*W/330?*M-!YQA,*2TT*6_PF89FD5J,A9:E*M5 Z
M\:J5/3/0U+B@,6XG@ L1F9T%V8TA0D 7F2(VX@)M6-N"&+"YIRL488MESPTV
M;J'L!9>/BF0O?7YP2S\SX7/^J-J6Z2:\WO1P^]MR*?^:/S[.<()2(;(,2BR;
MI8:"M$V0+) J<$Z89#Y25BZ#>A'("")66YO;@^CJQBJL>#?_NPRV&WF$AC R
MD>R@=]NA9Q=R/VW[!:Z-/L_!0]H!.F,4ND?@Y8'';ASH#,6);H+NUP[.UCY4
M'-GH!G&!,$MS#3E'AGP0)Y!CQB#1!<$9+PC2VH=\>L::&N?L2P3YBSGUP>I&
M,X' BLPNO5)*6S&D&W!;UZLY?ZD;Z8]Z"3ZSL'4?#G"%SH8^.][8Z<Z7'#^1
MSWSQDF%L\E4]/2]7;/7#9D+7/XXZ<".=) HC!!DJ.,2R*?#()<QD0I.49IDL
MO=H67QAO:DNAM\O%-[6JFY>QF0&M5BLE(S1!OS0-'&&2IDD!2:D3VSX6P5*D
M!%*")$>ITJ0L_$X4 D[$."<+G[?PCX>[&_,'Q#(R^V\L!:VI41O1.\(2E.4O
MC3DJTSL"<,CVKI<-2*=>%V+L:,]7'S<]'3*S>$VR D-BOD@08\%LTXX""IV)
M0I4FM,3N:=2]0TV-Y]?&[K9RJ 8TV'  N9]2PD(7F4U&1,TC,3H8>B,E1)]$
M,5#BLQ,6O0G/_7<8+]'9R9.]!&>W*X)JV_\R7["%V-=4QV62YTQ)J KSQL*&
M2B'56D"4("UR5DKS[P&T[4\,/;4E^D;;_GE'@EVO[0ZM;W]J+MS"N3@(1^;B
M"_KV&^/'U+?O06P,??M3PT]!W[X'%D=]^[X[Q,VUON55O3)/ZBS)TBPI<P6I
M,&2&2U6:%:DL84Z)C15Y@K(L1B[OVH"I19#OU&+Y9*;%/"C_)TYV[@9Z-Q:+
M"6CLN-(O1[=+" )_KET)F)(Q%,57R=G=&#')M-U#B(9F[A[=9QCC_:8>FZ;G
M;%7_^&HBQ(HUE2O;)0<KTHQE(H,9*6U#M"R%3&74EBRDF4092XA7?=JE :?&
M:)V]H#$8[%A\1>/)BZ"[<5M(*"-SV94H>A.6*S1!">KBH*,2DBL$AP3D?-W(
M776;__Q=538]\[-:S9<2S01#::D*#'-)",0*(Q.(R0QRPE)4D@R)3(_27_>$
M<5,CLB81""R?K4?5#?C6&FM3V8RU(S7./36';ESW6C,3F1>O;J9[T_74[3P$
MG_NG<[RNNCVX3Z._[BD#_STZ[?9 &ZSG;M\8 TL-EN9=8H:PF11K[8.,%RD6
M$DK*$<1)GD,J50++5*BDR+ DR$LW\7B(J9%P8R%X;DWT+"XXQL^-.J]#)3(!
MMH!TUL4H)CCK?-@Z@N-AQBTA..OF4?7 ^4\.#.AL7/&AJEZ4?/>RVM!%NV!M
M,T<JPSEW>B>+9-OM:Y9*PJ26YO&71)@0+LUA61 &*=*L+%*:YD7JE]-QG4'3
M2_G8FFRW?@[R;VQ.VFXEZ? DD"OG44HE<XU26)2VN!2I''+*""R18)0E&=;8
M2]5@O%D<)?AN-^SFC3]6ZJ9^4%WH?0->GLWLB>TLO]84.D;BHTU,[-B[>5Y:
M3T#K2A<^K_.!;L#^L[>;![=U*6"P'03:L.'U=2:-&U '@>\HA YSUV$OUS<O
MU7RAJNI6_/-E7LV;X-W^N%+JW?*)S1<SF3#"D"XA*P0V[\]2P#*QV[4"L]S6
M[N72JS?=Q1&G1JUK@\&.Q3=@;3/XL[7:<X?V,NYN9!D4S<A\>"V0WG3G#$Y0
M1KL\ZJBDY0S"(2^Y7W@=];Q=/G%[HFON_YL2R_N%S;Y<M]%BFQJ?;FQYNY ?
MS3_/'QOZ,[][>5+R\VII@IWZQV?SA:O-)VQ*Y[/=:Y@ACI4N,D-:62HA+DH"
M>8$41+2@FA9%F2=>F?6C6#TU"EP;VA3FJ[65PQ@O[G3[L>9D)G$LYMUQN.GH
MWKD,=GWNRB'7Q"R;2=_Q&W2.V^+KUG7SDW7^IOGD^XM?C\$\/LIT17D7Q+7\
M5=XGHTS&N7?2.(,/K1Q=V;J"6MD6L=M O=M214DN.-48(IYKB&F)("=Y"4M>
M$,8S5&"_$\7>T:;V'MD8"_AR(;U+1_MP=2/^8&A%)NPM4$UWYZVE4=KI.& 2
MN$:T;\21JT0=G#^N$W6Y:!A[;-HYO)M7XG%9O9BOU:;U_"S)J>!:"8-L(B"6
MF57?5:GY3TKRM,Q+3+S207M'FQI[;-N)@%\5L[;VUW ,P->-18*A%IE%=@#;
ML13\:6T%C;$!:<0)E* TTC_BJ#3BY/PAC;A=-*#\\->Y%.S9'L3=WIO5NGU*
MNK=DIG&2<4Q@EN8IQ'F>F\ CP="01V85.M/2+=FR?YBI$4=K*'@TE@*V-M6C
M9NX\GOU\$0ZER$31 62-!!LKA_1Z/H^41V5A$,1&JBH\B5R@JL*+./16%)Z_
M>KQJPHL>[%427O[TP/8H0BQ?3*#0)26LNPA36M"L5,0LPG)F8BEAPBB[,%-%
M6I8XS7/.O)*#3@\S-2Y<6SDL1^@,E&YAT_4 1:;!#3:=A1':,/=C$+;AR>FA
MQFUUTNON49.3_D\/>_K?J>>5$O/F/6!^?E3-0<9"WCXM5_7\7^W[2)"$)"82
M@B*WA, XA1QE)4Q5FML624P7N0\7N PZ-6;8M;G9R64[QOK1A!/F;J01&LG(
M%+)K[@W8&-S@>>N"IS>C^  4E%^<!AZ5;7R@..0>KVL')C**!R5?K&;J9N77
M;5/O;4]W>QORSFYM&PKLNFA47RTG;K<J2I'+)"\9Y,3F-6*F(54%,PR6$(H2
M*2GUV@H*:MW4N&WMG$VRVNZ*W*R/N@Y/N-9. O/D;MQLFM1X[C:%G7(WQGRU
MB8Q,K>'F$/S9. FB[(-%@3]LREU0"\?-P(L![E%"7I1!AKTS/J^60BE9_6*@
MV,G_LP</,\53HA1)(>%20<Q9 9E6#.I"Y[)@J# _^+P!>L::&I^O307V*]*E
M-K=ILXME[:MLTX>Q&^4&0BXR@>Z#MIMK; T-QX#_M[IO:W(;Q])\GU_!MZV.
M2.R")$ "\S 1Z5N%=UVVU^6:CMYZ4.!J:UHI.21EEG-^_0*\2-2- BB R>Z8
M<=F9%,\Y'X0/P,&Y.* 1E,_ZY(W*3@Z&'W.-RT<&>[T>'QZK5.M/V^^V;^A)
M<=O6-:LYDE 3D"+#'H@B#0B3.2@4QT4N4UC8TEE>CC WR5-CE8[BR<IJ;C-?
M.F6<YY7NWAXSQV%P=J*%!S>V7^W3Z_<7"EW'Z"SLBU!HKYNC]+$=<7Z@G/'-
M>;Y@:/34C@1WI8BK#(EFEE!",B%I 6!)2W/LS2!@J<I!R5/(%6)8B,(O?JI7
MWM0HJJ=2MF\T53_.;FP4$+W('-0%;E_CND[1BA%3Y81+X*BJ?IDCQU4Y 7 :
M6>7VL<$]/1Y6R^I])^6N9B5"5%%5@IP6$B L"& D)89G4K,-PIP1P?SRA/O$
M^<R,L;* ZR3?;LW]3G?LX4FCO:BS0J8:,P+RLH0 Z2('3"%#[)KDI,QT2K28
MU7FLOV_9>CLN\L>"XZ._O00_VR9<?9LOE_N:.I&&1)<I+DJ"0)G:&,-<%8"G
MYI^0(%0@2B$1>3,D;Y?R)0:D%?NRPZ&6,NY N"[!8:"-OOY6B#9M^]KTYXZN
M05O>7$4D=,^;RP+';GISU?0S76^N?V9@VQM;WLVLXIM=+U'SSD^ZJ:O+%N^7
MF^VZ"M/:?#42-N=_U23$*J(TS\T"S3-B"WD(#F@IS%)MU@I(TB(7J=?./Z1R
M4SLF[#1-.JH.3%4..HANG/920Q.9 P>.BG]'F CPA6T?$U+!<7O-1(#VI#%-
M#!G#"'S7K_R#8ANU>?>X?5RKW^;+^</C0U/-;?-%64'2%A%^-]\(MOB'8C;/
M#7&NH004,VVV\X@!JJ4$A=:09ZPL<^R5=SU8DZE1LYT2?@0\?!#<V'84:"-3
MZ\Z&I#;B+JG-2!H[VJ*6&YOVW)A2!1)4QB36FG#\>S.@0<EVN#:C,NO-H!W3
MZ.TO'-J_6JRMQ#>J_N_[Y5&GL2^KQ>+=:FT+8,X*HC7+, -E9JN:H5(#EK$<
M%(5".-<,(UCZT*2/\*DQ8ZM[\DNK_=]L);/C9GK)G]:&I#'"<S/K-3AN]!D+
M\LB,&1CM :VP_6$+W!+;0X&16V/[0W/:(GO .X:V>'A2RT>UV75.P3)-24HA
M@(5*;<DP0VJELM%)12:1SAF47@$%QP*F1ER-?KX]&HY0<V.;6["(S"BM:E$Z
MQ%RR.W"#A2,A(S=4.&_B:0.%"\_=<BOV>L$VFU=M1!"GG$K,02HT!R@M*" V
M0(B64J>Z* 447A/X5,34IG"E6_)JB/?^ #D?G_U0/,;QU#>(1+D<OV1]!*_\
M@9@7\,6?,_.\!_[LDP-C_Y;;N;3MNN9/G5*A;W^*Q:-4LHXU?/CQ6"='?])O
MV=I>*VX^JW5U _!AUR=((\)1FB- $&0 08$ 12@#I=)<%F6.L/;*BPNEV-3H
MHVM7MUI/:UD;<KNSS?H>6NML4>#Z1NR&ED_!AMR-P5YB("/SWJACZ!_5&!CP
ML$&/H90;-R8R,*0G(9.AWS]R0ZQ/=2NGSG5PUSE2%DA 6T5&9Z4YY)F=(: P
M-5M&)2DL:<%+Z+4TQ%%S:@M%@'Y,G]H.6QV+;_*)1?J"N"TD+S_LD9>5%Q[Q
M\1IR.0W(-%IS]:OZK]&DRPGN8.VZW*0-SG$\7XBU6_=0"(RT CDW?Z TA8!S
M90XCA.I2EX3KW"OVY[K(R2T<G>SG'P'*<3N [D;@8:&,3,9'%:L/"U9'30MW
MARET;N0UL6.G2#K"<"93TO63@^]M5P_J=[,=KYCP@QU26PRDB3[$B)2RA$#G
M&02(I@HPRA$03!6*H$(QOVIAO=*F1CZULLE.VZ15=V!(83_4SM>N80",?\\Z
M%+LA=ZK7,0E]B=HC<>Q;T^O&G[DF=?C0T,IC?+L/R/NJU@\S+2E!%"I D,X
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MHQBUI<*1R!=MK'#>_&OM%2Y\:N3:#'67TGV_J$U5&.OK=[9L-H,?K<=E8[:
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M-\7VC38NY9-^OQ2K!V4VX#8.;JV^J^5F_J2:GS;QGZYKO=];)S15=IK;)?Y
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M^I)24T!S*8!,=<%2#'-=>+5H\E=A<AM9ZP#35;A1%578V<V&=2[V#<M-3L9
M8+^LLW&_L=U;$65O.QS$,?R/?6I,P0_I ).C/]+E30/C)L_F1';2:5\][Q]I
MLFVKWB9U'M+[I='BL2K$^<GV"OIJ3KI-+N5_JLW6ZEZWQCBJ.?ZK+1QL,^)W
M?HH9D92FVB:E:T[-YED+P!$A@&.6,\Y@AC#R"NZ?BF53(_%:_:IM@EPM%FR]
ML?V#ZA8*OGV#IH*Q:XCO5/2=T%H3H,M1DV+:@2>I\$FV!J!]#Z3FB[=K@'27
MG'2<J)"J:I%T'-,!XYFG-OYA@Z<G8]VXD=J3,?M26/CD%!RV5_A5+<V+%_;
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MNBI'BY(?U7:?_(/3E#.8@U2S#" D"T!3@4"ITTSD:<:S(O/95T76=VK,;0,
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M%IECAP/F=0QU06/00;3WQ:,=15W,ZQY&G9X?YJA_H_AV7XNCT^%'RY2A A:
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MU+=UY<CNJ;M[ +&S(#L!P/][&I;TQ-F/#_AUL5Q/-,M9&2\A6DR@8D2(VDE
M[;-*F7$5Q2!8N/7BKFS$<+ X1+R=(.0]+J>+_,L\OR9O?E*2M=5T@HB<-D1#
M>V&@'1<2\T0Z_<^6QX*;[?%QX[5;H4,^.W3L+]I.L/%I&>:K:17*.;ZE%CX7
MIH&%DD'9'" Z+,#(,,J(&E7"8;:26V_>"B'JV2'D( &/#))?YNOI^L>OTQG^
M=KIQIJTW/#'-@4ME0&7BPOE QD\*<M%U9BKJ@\!Q^XU;@4(_&U <)- NP/ !
M/T]K\GF^_BV<X"2J*(M$$H0(%<R>@6,N0XXQ)*ZX3GA8!OZ^MVX%"O/,0'&
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M#Y?MR.!X02+)52R_SL+G"4]>1Y$#D<L%*!UHMQ08P#@LY&MEK@\L;[_QNNW
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MX+Q(J=Z,7GW A+06X@Q_P_4%+\KYK)CA8%&3=+A)$!DS@"[P(H5(GC]V:GW
MUO8(5>/TS&D'H\$TT &:WJV_X/**D=4U3GRP7-1^=-K7+D 8/7AM"[!:W1.,
M30';8.EAFL;IK=,.20-)OP,<??RR6*X_X?+DS?P;6=D:DJPF(KGL@Y8@%*?
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M;KF17=XD8=[C<C- 8^)S8!QM L/)7JN@&40>)$@7BP\R*=7H4LZ6!(Z+MD'
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M"R01*23)651QD?GE7&9C12BE<>"_UT2<H_64'R)B.TCH':#GGJ$,0@7OK9>
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MBI%;[+<* ?9[_[CYA^8 /)9FQK_M<1^GFT&B3S/J(SK!8AU/D4N=+X#@6,K
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MDA"UHY\&A2&##XC %4IK,3A>FDT"WH703FK66J6ZAU-2!QOTHU/,77$\:YG
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MFD>'0P<F]372F]-THV+Z?(8;7<_SBY-:?_B?F^]/O$-6BBY@K"*>@DY0*Q4
M"U=&R<!-:-.X<QOJQC7 XV-HT5BA'8!TDVE]>3O[/Q$\1@H.(VB!-;GOR5G2
M.8$SRD7+8@B\#2SOIV=<V]D=$ =06@?0>[%:D0A/OH;I<M,_G)CZC*L)"DQ6
M:@.\#A50#@UX)%:$CS:DD LMH3:;_KWTC'NWHSOH#:"T#J!7Q\>OJO!P]6[^
MR_<JI]/IZLM9Z/@:XWJB568N(^%$>0:J% .NL%1;)D7RAWC6O,THMB=)&_<N
M1W> '%:5XW<;NG&1Y3<2+\GR3+:_?*^F'B>.9Z^#<, U!8@J::R7[!T4P9)T
MIE!TV"8X?Y"D<>]O= ?)8537#Q3OGM5>2NZ\AN12;,J6X$QDP*2IUZ>2(A>$
M&.1,""M"UD*T.53:GL9Q+WIT!]9&RNU@D[_+V8N4:C.1%<D=I]\V/;>E4<D'
M:T&&8$'YD"#XS,$+%R5BT*51_+T-=;WU/1@&&4\"\$ U=6TXZ]9PM92K,[V:
M^&S0)AE!\'H0FTT$SZHO'3"+S9 ;YXYE-.^AK[<>"4="X<&JZAF'KQ;SC<S^
M,5U_>44;$FT]R[?3$*>S6AUE,!=OB@!K T5S.2J(7"7(42?!E-2^T1SJ'0GM
MK>_"D9 YG/*ZWJ7?AQ\;VX_%!R^%@E)B!,5*@IBMA$C?%Z@S5T?K@76+M-[:
M*AQY?]Y'06,/+KJ7FV6])8+?<+;XNIDX?QZM:65=EMR2JT&>AXJ26/)D]K-/
MS&7&A9&W,I$/5(KM\-+>6B$,"JFF&NC2EFV<B'/^+DQTO<*9&#I4)+/,:HO-
M8A5XE2)8'KF,FG/MVA2";TUB;_T0CNGU':BP#I"X_7'_)#N?I=;DR"+JVFM$
M@S>$':TXQLAL+*9-RF9[&L?U\XY?"-1"=?N#<D&KK24HW\R_X>H!069+?TJ-
MMZ1(H&P=_IK10)9>9A]+5D8>$YR/T-I)"]0CE3X.I;0.;"6YL1<W)-/_.9TN
MD7BEQ;;^\7X6YNL7\US+W#=N"<56,K)(J[E@J,7M@=6I]QRL\RJ:@,+%-MG"
M[6GLLFAR,+0LCJ*Z?C(W=QA\>;J:SK&>=FZZV55AG_\D3YS0(B#Y*"DJ8K$8
M YX5!U$S*6+("EV;G7P7*KLL@SP:/H=27\<(??$M3&<U+_#K8ODQ7&]<LSF-
MMRI:S\DK\DK6-@N2@2.7B+[TZ)50&%.;2QT[$MJESWDTG ZHQ(Z@NEPDQ+SZ
ME<3]:C&;85IONBS]MECC]<,FYXT)1J=Z);@6C.0"H4@"E*NC)#DYU:Z-T[DE
M@>.F'8\-S09*Z\#IW%Z*$Y$B!7H:(6[V!9DBN$S./%/&RN#)@0EMFK=N3^.X
M6<LC([*1ZOH-T'^=SL,\W2](GYQG)$S@<9/[)P?;^Z(!5<[<":5\+L<$YR.T
MCKNC'SM 'TII'=C*ZUO Q67S-[4+49B]/XVS:7I7B*[:)28%'XHJ!6PHO$XV
M)<:X213SI>!TD(G\E>8[]Z,D=AF>#X:51_;NX137*2+?E0^8$4^J-_)@AY )
MXY()6PR@C@84<O*<HQ:T#TD7D[&6ZS;- O<FN<N _9B('5ZQW2+XK._6W^>D
MTS?TC3G)%E_,\_WWC6J.;46_-CNM';JN-U6<&(]<>9W)&2?I*YTS+6?TH)FQ
M DV2Y H=$>4#L=5E2N"X*V$,@'2P6C[@U_,,R;OR=C'__ F7)YM$2"HQ>Y=H
MWV*.]BV-!9QB&H(K.:@BE;!M4JX/4=1E;J 51@=12Z_YJ<N-9L,1C\7G1!+B
MVM5KQ1'!(4D-+4=M$DDLM2G)?(2H+J/^8]C#0Y33@37;7G(3%JS(*B2PDM:0
M\CQ!T.352)&"=ME[H\/(X?VXA4I'1F$CU760>ZILU?_JB>VW,,/-_0^2V#21
MC=V<D\WSS6]<^\VS[L1WJ[G.78]?OJ<O8?X9/Y"]_H5"3E*"Y=S);!QXR4D)
M(I%T2/! 3KSDRAADL<TQU''Y'-<=:);SZA@LSWTI3731HCA48$K=S*H%B0DS
ME$!VR=I:D=OF>O%!9(_KB_0)])U4V<V U\-8CIYK%HV&6&A+55PY^DP$D!BM
ME\4X^NN9HK>9#],I>G=192<MWR\O_5\<!<[SI6NVF4M_52',BM!:<<BND%BC
M\+0TR45C)EC#E=)%-:JZWI;$<6?+M3LN:Z*B#J*ZZW/#-KFV%R?UEM9YK(J9
M3[3PP03F(5A-#*%!\%8A:$G102C,2]OF(MV3I(U\*M8&$G?&6PRIGPX 5U,?
M5TQ=\O%F3L(ZK4OWC$$^X2P&)FIUA0GDAK@B(92$8),0&K/R$=N<RFY+X<A'
M7$>!7Q-MC7V;\W+*UV7_^7-A3DKBLO:]JR<*F42E&)"X:&D9K]!S8^WM8<,/
MW-U\\!4CGP8U!<V PNW 4)W?&-Q<*LW3]2FIBJ+]TTK)R]/U;XOU_\)U'8DU
M298B?<L8.1+&@/*RCMV6'E!XJ7FP//LVV<YM*1SY=.<X^V0+;76 PH^G7[_.
M-BYMF%VXM&_F9;$\.5/@A>QXT3I$\F:UI=A'*9/(_N8$*&..4BFFL='4@^T(
M''=*;[.XH(5Z.D#=FSD]BY9K73&_(:W,3#+R7-'NGA%400E1L@A<) PB:HW8
MIKOJ+4)&'A310MEW[I;O+_EN!^.\QE5:3C=%'(NR_G)YG^DFX=M-OWGP6<.,
MN-F.U('FV+Q;?@[S\Q;@5R-USMJ#O[_&P[MROF.&V=6TG2O[A3$&Z\E^Y>!H
M1\L"8DB%=C3N@PTFZ=BFF'H0\@].GH6ZV;\KYS?=:YF0*\')K IHGQFHC!Y\
M\@I8REH+U$6S-MG<N[2,:[".CZ\[>;/#M//L+-IK7(?I;%##=O'(MO;M7L*[
M,G.Z%.1U1$(BP!%N-(6/,1(6/6KN2O*MSFBZ,',?JG[FF'\)RSD%3JL7*9V>
MG,YJ*=GYJ,@)>1T6:TL;;BB&4C%FB"9GT#KQPD(*4;8) 9ZF[8]@!G?!W]V2
MPT&UUZU9?!E6T]6B7!?J/J;POL<,8_Z>)' @DW?>[(YT_9[0EFYT^;%:ZB0M
M6$^K205:3X2@.G0CD#MOK(FZT:2*!VDZU#AMI/KNAE1K>??T\WQ*X*X]->Z\
M^A,)^N5L<P7"Y-K@*(-BY 4H+R)$X6(=_>F8]*500-Y$'H=0/?*,HV'0==M*
M'4V-S\E^77 ZD!V[?%PS>W8_P>WM6I2<%V$YF"(3*"<=Q"S(PY=,D_)%*J5-
M&-K<KMUZP8^SCU?0SSYSDWD"8RBL44H)6G,E@DW>6:5SY*Q-6\;MZ.O65NV"
MF =LU9"JZ2#O^AO^?HVC)<5HI_-TYH?>SY\MTI.@<IU-0X)SGD-(+$#)'+-P
MH2:V&U7:[T;IR+/8VH"PJ;J>TR9Y0-KCD:<UVR);)CL>@5I!E9G! L:;0 #3
M 1Q&!Q(+-R5D5D*;6]SM=LB/Z0OFTQF>%R>]_/%J%E:K3YO>.DQ)Q%P/TECM
M,XHQ0 S90Z9OZ^QJ4_DVY^*/$-7M7K@+-NX<0@ZDA XVP,N\2RWI7?^H]X(7
M\TT:YOMT-5')Y5AX >NT.@MN(M>V-GUP*+,R"=LX6H^2-?*AY%#*OPVJP331
M :QN\?!Z<1*F\XDR3BIC-:!, I0A004>)406K%:QJ%3:5%/?2\[(,!I.W8NA
M9=\!@(C\D\5\L\+^AB<1EQ-+[B%'(P%C\N3*)?(;,0A ;VQ6UEF3VMBB.Z2,
M"YP!U'NGY/D06?< EFJ!S^TQ.:NXJ7*;%(;H=<Q0E WU8@I)(W)#/#'ER?=W
MR;?)C]Q+SLA]QQMM6H=+O@/X;*C_LIB1"E9GJZMVK=Q\]^/7V?1:/?:'JC ^
M$8*IY!,MCR CJ$*&.1H>(>0DR6]DUH1&M7\[4CJNI1H ''=\I(::ZC;^WS3[
M74W/ZEOVB/AO_/MA8OR'21HHJK\HDZ"]*4[G%T<CF_%^U]Y]U:RAEOJI3-N?
M1@)5]IJB.8]0='1,QZ)3HT$]N]%Y<'[\[MM>3U=IMEB=+O$JZX6,"9,"AX J
MD?=((@F)12@823Z)(_>-3OBVHF]<J]0067=RYL.KZUD8J8U?<;"I.G_*\ ;K
M/O+&,5O!2\,Q!- VY-K\19/K%05Y8BX9\K*MSW\$LW7E?5Z\][HZ7OZX]M75
MJ@C!1$;[-SCA"VW=#B'4[C@2.==%J2!8&R.V#[7/RJ3M@KJ'4Y^-5/DL#-P!
MQR_W/69X$]?RP&5'M)DLG4TUO!2:PLM0)'@O!' N WINE15MKA7W:^,V8;>(
MO-[1+;43K:R+PH KPM12;Q:Y$&ATH]SZCI0^*]NV"]H.L6T[J["#/,<]7&V2
MS=*%7!SM!RGY>GU*(7AR;J$DB87BYFP:U30\0% OYSLM4/! A'"(2CI%UMF$
M(KS(3P=N;"8A):<Y^1Q*@K,V06+"<4.."#9J+O$D:7V8MX, L 6H]M?&V,TC
M_F-Z>O)FGLY/)F32O(CH(,1,BRW:.H% &A).X%;;)&2)3[E@=Q_;'P8.T-=B
M$.%U8%5^G<ZG:WP[_5;[GZS#_'/MY+O9^<D,_RW\[\5RDV'>K)?(4BR1PAFR
MQB0A1_P%4;OI.5XLB2HHW:9IT@Y$]G($=(1]K97J^D;E%6._A9.+M1N++YYX
MJ6U(/2B;!3A%-CUZ6S*/1MC2QKO:D=!Q;6 SP&P/S(.UUP$X/V'Z,E_,%I]_
M;,8\W&'Q;!\H&95TTH-0S(*2)8,+]&52(;(2L]6BC;'<BKQN@7@X0!:MM=4!
M!._97=Y>'OZR$&V)J"@HCQE4-@4"%Q%\-D)IRS%$?JPPX)*JD2?.C1QO[J><
M/H'V'I=UVDWX3-+\CT6M^[UH[[*ZG-\<,\]<DN22L064J3>*R16&K'W*(H5,
MOO&Q(+@%O=V%)GOBY6D@#JV\CB!Z+7E9[\-/\WESCD_+,%^=4<8GUCOM)%I(
MEMA2K%B(]8/TOF H):38YI[R+E2.&\,TA^/@BNH3A!\P+3[/I_])/D<FL4_+
M-%QZ'1=K[:^+1?Y].IN]F.>W]./I[&P\RFIU>H*U4]95NQJ?D8E4@ >D_:A>
MK_*)G!0MM21//9+(VE3#-69L7+?@F% ?#0[/=W7<*X;:<G-.K_LQT60>N(D<
M1)WKH))*$'*==9Y"L0Z=%Z+-S;,F[/3A@W0!V&$6TX#H^8,MH??+Q5=<KG_4
MH91K^HU:Y?NU7I.9!.%+REI!+K4K6BD%HHL&2#M*<\\D]VW:41V%O3[\JC_Z
M$AL&77^P)7>5=EI-9!$J(B-[4X.LLX,FA1I(0X6A0)=2FRO$C1CJPX?[HR^K
M?1'TAUU(9[_\;OT%EY^^A/F%0B<!C<J::S(KG"+'Z#VX.HR<A:0S$S8S?;1:
MN'9LCMO^_K_>HAL";7^PI5@[>3N3==1F<RB32%$1(1A90 1G.7-&%-6_P[AM
M#_9F,Q/_JRRG71'3P0#1RX6NK4E:9PD\U700?83H"9=.68HBG=3<M"DQV,GB
M-QN,V#-$]]+1\S7&3\ET(D3M':#)'Q32@A+6@<^*0YV];F)PV38:;M>(H7''
M+_:,_!X0U(&1?KB>Y.\K+*>SM]."$Z]-*3(Y$-X9VGV8A< " ^=4B<$7+U-N
MLBJVH:X/=W[P<Y#!%=/MS;7K8W0N&ZY?FZ.SSS6V)Y\YS)VVW4@_\(+;V3B]
M)]YX:1LM8RB"U& M?5!9,?!:*9#2)>5(N]%L5XF^[1L/&\%X[24OPZS."OSX
M!;$F0=_,2=QXV8_JVINO-9MF3&?+/+"< RA5S2\W"K1BY+R0$19:[<SL[G2,
M<Q#5#A<W!SD>3T7/UE3MWUE@RR<?QVPUZ$"P&TBSTF;C.CD=:5\CGPFB)M@D
MP;-SOC"O=1?&ZV*W?O#DYFH!2.2*:T2(9G/UL[;Y,<@A65=41*W1M7&BGJ;M
M.=BM72!QVY<:6#L=Q+]75;GG/617[\./3;0RS_2=Y2E>#T\VZ_F*5\>YB[YP
M0%U',V#= AR%35ZB=5;%I$VC_F '4#W."?3Q,'HTC7: WHO"V3._8>- G'UC
M,ZYWA=>Z$-WDDUL?7? !6&V5KG+RX)@K($W):+*JUQF:('=?BL<YX#T>:H^B
MR6?K#KY__\L!K5AV>/IQW,*'V#FJ:RAU*B75L;?1>E &#<1<BYTCFN)=-DSQ
MKES#*\/^L!NRN3CC@E36.0'!%G)!N#,0:N8P!&]1*Y<B;W/Y:%L*GX.;N L\
M'MZ"!]14!]OM@]R\_/&)'K&YM"J<\BBY YXCR8T'#R%I"S8$07M#M,RUJ0C>
M@KA>&JX,B8IM(Y0]5=0SZBI#Y[=3A4I!"Z% )PJ]%)EHBKJ\AUQLRERX+!L-
M<-B"N'%1-S@@M@Z)]]/.V&U8Z F+9?V%'Y><G-]/-IX5)@)",H%B(X&%PB)M
MP$8IO1$EY]O3OQ]P&!Y\1:=(V5>3B\'%VH$U>HMAA;4U]YN3K\O%M[.A7.>L
MH+%1<Z(='8E(9:;!,Y:@.)-"C%S8W"8?\@A1XQ;<M\+4T-KH %CO2IDFO+TZ
MLDQ*Z"! 6!E !6'!ZR#)(?7.6^53X*X)I.XE9]PR\]9@.EP#'<#H[&2?HNAE
MO=B[7IZFJIYS7EP2SN<L($=9QP2R#%Y04(-<,\E22H*U.3IXC*IQZRY:@VHP
M?72 K0=E]?:R4B4PHEQ:"6CK7%2KB2/C:4O/ 4,*1F"TQW7$+VGKI2W9&-'?
M?@KJ&7)_72Y6JXE32D:I"Z!T$92L0U:5B,"1>95RD:E1'O]QNCIUY/=$P;8@
MVUTE'0#L14JG)Z>SL,;\&HF(-#V?Y/IUAA=-F$\6R_7T/\]2UP_>K!2911-R
M!(&._(3D/$3&!07161EGN=6NS36,H3CH-%(8!K2CJ'EW>/LS>,_Q<Z7T4WLS
M6BN-BY2;(2^0F*(5FTPB+\1Q\%QIIVC%RMN)C=9&=-N"\^.'&HU-Z*[JZ*#P
M^_IRHIA;Q*0B ^Y3/0*N)<N(&K0D3Y8%M$&TR8!<IZ+3@&(8Z.PM[@[VV@=%
M\R+GLS: DYBD*#D%D$91J.4]UJ9_!4RTA'^G$T5*Q[5%E[2->S]Q+(NTGVJ>
M;:7%ID(JS Z9?+/K*XY3<_$H8T<MO/ Y99NU!D^;&>%(:G A6T ?<\@R)6;*
M4S(^:N'%+Z3UQ0\DF&W\QVO5<Z].EW7M3K0WK)@2B0?!0)G@P,F0R X'%J4S
MF&[?D1C(:CU)VG,HM=@%$'>&@ ^JF[$/'\_K,U_C-YPM-N;WU6*UOF3%AH#%
MU7'5"LDSM+* 2X9!]%QGYX7BSFZU<AY_SW.HD-T',T.+N!.T_!*6LQ^U/G+Q
M#9<_SNLE+QG*S@:6I*NN@",744N('#,%%TPA6DPNL%TP\^C;GD.5ZJ'(&4[<
MG>"G]N-;K:ODWI\NTY=PC1O/0[W8E2'4_D;*(X6B)M N)$RR!CES,N\"GH=?
M-4[,=ESD#"3H#@*YZT=9Y[<++C@I@842"R%>U?Q8))ZB"AE*]EIR*X/F;0*X
MAVD:)W [G@\TD#8ZP-6FM]/=2RJ7F[/D0@F')!4;JY ,>"L%I$*>').)JT:%
MS8_3-4Y7F./A:T"M=("QAQE)G-9$(+<O\[I89!!0KZT 3Z:8Z+5AMDWI\F'(
M&KSKRO&0-8PN!DN"'SO9='''J6&RZ?8KCI-L>I2QHR:;2K:*6Z> AUJ]52+A
M2"0/!6MRG!5//^TJV73KWMN$&2S2F #<2P4J! /!DK$U.9O,A1&:M6DD=8N0
MYY!(VD79#UU W$?N'>QJ5['%V0W*WQ;SFM /=;S,)*O"10@,F"+#K%@IM;T5
M!S0QR9#)Q,HV&]MC5#V'+--A@!I((_U4$5RLD0_X#>>G>+Y4ZIFU*>B-2!*R
M<^0$<!TAL)Q Y%@T<L>\:^.9/TC2<TA%#6&O#M/%P=AJ[$%=+:*]O*/K_WP8
MS^=!@@[T:NY:C=5KC!<GL>L?'RLI9RT"+V^HQNBL,PYT3*[V; O@E#&@69:V
M5J9;U=JJ/T7C<+O:ZLW\_%U_"\M_DEL99WCGK?/\"I?D<=8Q5IG,[%G'Q6NM
M RZ[!D29/;.^CAUG%+/6(:O110F%<5:B88Z626O9#<K1N!6GC5#[\)8Z(ARZ
M+6VX)IW]VX?=?<C@=K-!4[ ]<%A44*Q6Q]C D'!HR;^/*8!.-F3:)R,V:M![
M/.MYK1/0-PK#J]A_72P_AAE>O:NVJB7_9#:]ZM=VM2Q"$%*JF("Y5 < J@0>
M(X.$4;F@?3&Y377]H90_&VNX"PH?:?347KT=A+A5EM=$>(OG6[Q)]!Q]-N!J
M5UOE<P:OE 8I(D57M,?(U*95_"Y4CEMQ?R28-E/;L]B(B<9%.6?_QP%YWB>?
M.?PV_33I8^S:***- :RMCEHJ!:IO1NM0E((L"FG:7"\\WJZ]Q7J91%&X1.8
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M3 M1^ZUW=Y!\U%LGP^T\^TF] _"\7RX28E[]2@*[:(=S<SK:A 6>?4(/4;H
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MD'_Z0_8#S;U9+,+LC_47;.LPE,A3U+&.*TZZ=AA:( LKP)#L+#J&++8977
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M#'@2.1:-DA+@R 6E%N17/+<:C-"2?$L2=L\W^[.3/G(OV^NWH9/QTFV]],V
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MTKY-//X<58/M&WGPV??CU@P%QB5J3Z%2J2LU?02'SD$.&9W,HK;TGXWE3D9
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M\!2C,FTY?X:ZCH.$0Q"STX4.I9B>SOZWWQY8_\\+_.]KG*5OZ^=/%UF=J*X
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M4$L! A0#%     @ -3]J4Z-Z;0B:!@  )AD  !0              ( !
M &5X:&EB:70S,3$M<3 S,C$N:'1M4$L! A0#%     @ -3]J4^+^[ZZ1!@
M&AD  !0              ( !S 8  &5X:&EB:70S,3(M<3 S,C$N:'1M4$L!
M A0#%     @ -3]J4U=ER=G3 P  Q0P  !0              ( !CPT  &5X
M:&EB:70S,C$M<3 S,C$N:'1M4$L! A0#%     @ -3]J4[@7+4".^@( 5$L;
M !$              ( !E!$  ')X<G@M,C R,3 Y,S N:'1M4$L! A0#%
M  @ -3]J4U-,2H[4$0  P<4  !$              ( !40P# ')X<G@M,C R
M,3 Y,S N>'-D4$L! A0#%     @ -3]J4T+WL)0Z'@  ["P! !4
M     ( !5!X# ')X<G@M,C R,3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( #4_
M:E,WX@:-UVH  .W'!  5              "  <$\ P!R>')X+3(P,C$P.3,P
M7V1E9BYX;6Q02P$"% ,4    "  U/VI30OD^=@,L! "\T08 %
M    @ '+IP, <GAR>"TR,#(Q,#DS,%]G,2YJ<&=02P$"% ,4    "  U/VI3
MW\X-E(3J  "(#0$ %               @ $ U < <GAR>"TR,#(Q,#DS,%]G
M,BYJ<&=02P$"% ,4    "  U/VI3^&1IC5WU  !R9PH %0
M@ &VO@@ <GAR>"TR,#(Q,#DS,%]L86(N>&UL4$L! A0#%     @ -3]J4YER
M;0I-F0  #SX' !4              ( !1K0) ')X<G@M,C R,3 Y,S!?<')E
:+GAM;%!+!08     "P + -0"  #&30H    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
